<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36504035</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1531-7056</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Jan</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in gastroenterology</Title>
          <ISOAbbreviation>Curr Opin Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Check this out: treatment paradigms in immune-checkpoint inhibitor colitis.</ArticleTitle>
        <Pagination>
          <StartPage>43</StartPage>
          <EndPage>49</EndPage>
          <MedlinePgn>43-49</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MOG.0000000000000892</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Immune checkpoint inhibitors (ICI) have become a pillar of cancer therapy for many people around the world. However, up to two-thirds of all patients undergoing ICI therapy will have immune-related adverse events (irAEs), including immune-checkpoint inhibitor colitis (ICIC). This review summarizes the most valuable and currently available information about the mechanism, diagnosis, and management of ICIC.</AbstractText>
          <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Recent findings include several developments on the leading theories for the mechanisms of ICIC such as the role of the gut microbiome. New emerging therapy strategies include tocilizumab, ustekinumab, mycophenolate mofetil, and calcineurin inhibitors.</AbstractText>
          <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">The occurrence of irAEs remains a limiting factor for the use of immunotherapy in cancer treatment. Prompt diagnosis of ICIC with endoscopy and histologic confirmation can lead to early utilization of known effective treatments such as corticosteroids, infliximab, vedolizumab, and other emerging therapy strategies. We summarize the key points of this review article in our abstract video, Supplemental Digital Content 1, http://links.lww.com/COG/A44.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kiparizoska</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Medstar Georgetown University Hospital, Washington DC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murphy</LastName>
            <ForeName>Megan E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Medstar Georgetown University Hospital, Washington DC.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, New York University, New York City, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mattar</LastName>
            <ForeName>Mark C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Medstar Georgetown University Hospital, Washington DC.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Curr Opin Gastroenterol</MedlineTA>
        <NlmUniqueID>8506887</NlmUniqueID>
        <ISSNLinking>0267-1379</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>HU9DX48N0T</RegistryNumber>
          <NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>10</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36504035</ArticleId>
        <ArticleId IdType="doi">10.1097/MOG.0000000000000892</ArticleId>
        <ArticleId IdType="pii">00001574-202301000-00009</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tran T, Tran NGT, Ho V. Checkpoint inhibitors and the gut. J Clin Med 2022; 11:824.</Citation>
        </Reference>
        <Reference>
          <Citation>Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases 2019; 7:405&#x2013;418.</Citation>
        </Reference>
        <Reference>
          <Citation>Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022; 386:24&#x2013;34.</Citation>
        </Reference>
        <Reference>
          <Citation>Dobosz P, Dzieci&#x105;tkowski T. The intriguing history of cancer immunotherapy. Front Immunol 2019; 10:2965.</Citation>
        </Reference>
        <Reference>
          <Citation>Tang L, Wang J, Lin N, et al. Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol 2021; 12:800879.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma C, Pai RK, Schaeffer DF, et al. Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. J Immunother Cancer 2022; 10:</Citation>
        </Reference>
        <Reference>
          <Citation>Fattizzo B, Rampi N, Barcellini W. Hematological and extra-hematological autoimmune complications after checkpoint inhibitors. Pharmaceuticals (Basel) 2022; 15:557.</Citation>
        </Reference>
        <Reference>
          <Citation>Shroff GS, Shroff S, Ahuja J, et al. Imaging spectrum of adverse events of immune checkpoint inhibitors. Clin Radiol 2021; 76:262&#x2013;272.</Citation>
        </Reference>
        <Reference>
          <Citation>Portenkirchner C, Kienle P, Horisberger K. Checkpoint inhibitor-induced colitis-a clinical overview of incidence, prognostic implications and extension of current treatment options. Pharmaceuticals (Basel) 2021; 14:367.</Citation>
        </Reference>
        <Reference>
          <Citation>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. JCO 2021; 39:4073&#x2013;4126.</Citation>
        </Reference>
        <Reference>
          <Citation>Common Terminology Criteria for Adverse Events (CTCAE) Version 5. 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>W&#xf6;lffer M, Battke F, Schulze M, et al. Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma. Cancers (Basel) 2022; 14:302.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakurai T, De Velasco MA, Sakai K, et al. Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. Mol Oncol 2022; 16:1493&#x2013;1507.</Citation>
        </Reference>
        <Reference>
          <Citation>Hayase E, Jenq RR. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med 2021; 13:107.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson NA, Stewart GD, Welsh SJ, et al. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. BMC Cancer 2022; 22:99.</Citation>
        </Reference>
        <Reference>
          <Citation>Li H, Fu Z, Arslan ME, et al. Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Exp Med 2021; 11:79&#x2013;92.</Citation>
        </Reference>
        <Reference>
          <Citation>De Silva S, Trieu H, Rajan A, et al. Flexible sigmoidoscopy may be sufficient for initial evaluation of suspected immunotherapy-mediated colitis: a cross-sectional study. J Gastroenterol Hepatol 2022; 37:284&#x2013;290.</Citation>
        </Reference>
        <Reference>
          <Citation>Herlihy N, Feakins R. Gut inflammation induced by drugs: can pathology help to differentiate from inflammatory bowel disease? United Eur Gastroenterol J 2022; 10:451&#x2013;464.</Citation>
        </Reference>
        <Reference>
          <Citation>Isidro RA, Ruan AB, Gannarapu S, et al. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology 2021; 78:532&#x2013;541.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou F, Wang X, Glitza Oliva IC, et al. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 2021; 9:e002058.</Citation>
        </Reference>
        <Reference>
          <Citation>Pisuchpen N, Durbin SM, Mooradian MJ, et al. Multidetector computed tomography (MDCT)&#x2013;based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. Eur Radiol 2021; 31:8868&#x2013;8878.</Citation>
        </Reference>
        <Reference>
          <Citation>Allouchery M, Beuvon C, P&#xe9;rault-Pochat M, et al. Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review. Cancers (Basel) 2022; 14:955.</Citation>
        </Reference>
        <Reference>
          <Citation>Skribek M, Rounis K, Afshar S, et al. Effect of corticosteroids on the outcome of patients with advanced non&#x2013;small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer 2021; 145:245&#x2013;254.</Citation>
        </Reference>
        <Reference>
          <Citation>Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13:772&#x2013;798.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson LL, Katznelson E, Leet DE, et al. Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor&#x2013;induced gastroenterocolitis. Eur J Cancer 2021; 142:143&#x2013;146.</Citation>
        </Reference>
        <Reference>
          <Citation>Ohwada S, Ishigami K, Akutsu N, Nakase H. Pharmacological treatments available for immune-checkpoint-inhibitor-induced colitis. Biomedicines 2022; 10:1334.</Citation>
        </Reference>
        <Reference>
          <Citation>Klemm N, Trasolini R, Chahal D, Donnellan F. Vedolizumab for steroid and infliximab refractory immune checkpoint inhibitor associated colitis. Clin Res Hepatol Gastroenterol 2021; 45:101604.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaneoka A, Okada E, Sugino H, et al. Vedolizumab attenuates immune-checkpoint-therapy-induced infliximab-refractory colitis. Diagnostics (Basel) 2022; 12:480.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou F, Faleck D, Thomas A, et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 2021; 9:e003277.</Citation>
        </Reference>
        <Reference>
          <Citation>Dougan M, Wang Y, Rubio-Tapia A, Kim J. AGA Clinical Practice Update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 2021; 160:1384&#x2013;1393.</Citation>
        </Reference>
        <Reference>
          <Citation>Sasson SC, Slevin SM, Cheung VTF, et al. Interferon-gamma&#x2013;producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor&#x2013;colitis. Gastroenterology 2021; 161:1229.e9&#x2013;1244.e9.</Citation>
        </Reference>
        <Reference>
          <Citation>Bishu S, Melia J, Sharfman W, et al. Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. Gastroenterology 2021; 160:932.e3&#x2013;934.e3.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen M, Liu M, Li C, et al. Fecal microbiota transplantation effectively cures a patient with severe bleeding immune checkpoint inhibitor-associated colitis and a short review. Front Oncol 2022; 12:913217.</Citation>
        </Reference>
        <Reference>
          <Citation>Dai C, Liu W. Refractory immune checkpoint inhibitor-induced colitis improved by fecal microbiota transplantation: a case report. Inflamm Bowel Dis 2022; 28:e43&#x2013;e44.</Citation>
        </Reference>
        <Reference>
          <Citation>Holmstr&#xf8;m RB, Nielsen OH, Jacobsen S, et al. 1685P COLAR: results from an intervention study investigating IL-6 blockade with tocilizumab for treatment of immune checkpoint inhibitor induced colitis and arthritis. Ann Oncol 2021; 32:S1180.</Citation>
        </Reference>
        <Reference>
          <Citation>Thomas AS, Ma W, Wang Y. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med 2021; 384:581&#x2013;583.</Citation>
        </Reference>
        <Reference>
          <Citation>Mir R, Shaw HM, Nathan PD. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis. Melanoma Res 2019; 29:102&#x2013;106.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang E, Kiely C, Sandanayake N, Tattersal Sl. Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis. JGH open 2021; 5:558&#x2013;562.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma C, MacDonald JK, Nguyen TM, et al. Pharmacological interventions for the prevention and treatment of immune checkpoint inhibitor-associated enterocolitis: a systematic review. Dig Dis Sci 2021; 67:1128&#x2013;1155.</Citation>
        </Reference>
        <Reference>
          <Citation>Grover S, Dougan M, Tyan K, et al. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer 2020; 126:3758&#x2013;3767.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36389768</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>11</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interaction between gut microbiota and immune checkpoint inhibitor-related colitis.</ArticleTitle>
        <Pagination>
          <StartPage>1001623</StartPage>
          <MedlinePgn>1001623</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1001623</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1001623</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) have become a promising therapeutic strategy for malignant tumors, improving patient prognosis, along with a spectrum of immune-related adverse events (irAEs), including gastrointestinal toxicity, ICI-related colitis (IRC), and diarrhea. The gut microbiota has been suggested as an important regulator in the pathogenesis of IRC, and microbiota modulations like probiotics and fecal microbiota transplantation have been explored to treat the disease. This review discusses the interaction between the gut microbiota and IRC, focusing on the potential pathogenic mechanisms and promising interventions.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Zhou, Zhang, Meng and Pan.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Guanzhou</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Nankai University, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Nana</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical School of Chinese PLA, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069467" MajorTopicYN="N">Fecal Microbiota Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">diarrhea</Keyword>
        <Keyword MajorTopicYN="N">gut microbiota</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">microbiome</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>17</Day>
          <Hour>12</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36389768</ArticleId>
        <ArticleId IdType="pmc">PMC9648670</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2022.1001623</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, et al. . Immune checkpoint inhibitor-associated colitis: From mechanism to management. Front Immunol (2021) 12:800879. doi:&#xa0;10.3389/fimmu.2021.800879</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.800879</ArticleId>
            <ArticleId IdType="pmc">PMC8724248</ArticleId>
            <ArticleId IdType="pubmed">34992611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Sci (New York NY) (2018) 359(6382):1350&#x2013;5. doi:&#xa0;10.1126/science.aar4060</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aar4060</ArticleId>
            <ArticleId IdType="pmc">PMC7391259</ArticleId>
            <ArticleId IdType="pubmed">29567705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med (2015) 373(1):23&#x2013;34. doi:&#xa0;10.1056/NEJMoa1504030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504030</ArticleId>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J immunother Cancer (2018) 6(1):95. doi:&#xa0;10.1186/s40425-018-0411-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0411-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, et al. . Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm bowel Dis (2018) 24(8):1695&#x2013;705. doi:&#xa0;10.1093/ibd/izy104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marin-Acevedo JA, Harris DM, Burton MC. Immunotherapy-induced colitis: An emerging problem for the hospitalist. J Hosp Med (2018) 13(6):413&#x2013;8. doi:&#xa0;10.12788/jhm.2925</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12788/jhm.2925</ArticleId>
            <ArticleId IdType="pubmed">29419822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: A systematic review and meta-analysis. J immunother (Hagerstown Md: 1997) (2018) 41(3):101&#x2013;8. doi:&#xa0;10.1097/cji.0000000000000213</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/cji.0000000000000213</ArticleId>
            <ArticleId IdType="pubmed">29401166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev oncol/hematol (2017) 119:1&#x2013;12. doi:&#xa0;10.1016/j.critrevonc.2017.09.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.critrevonc.2017.09.002</ArticleId>
            <ArticleId IdType="pubmed">29065979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. Ann oncol: Off J Eur Soc Med Oncol (2017) 28(10):2377&#x2013;85. doi:&#xa0;10.1093/annonc/mdx286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx286</ArticleId>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New Engl J Med (2018) 378(2):158&#x2013;68. doi:&#xa0;10.1056/NEJMra1703481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang AE, Golob JL, Schmidt TM, Peltier DC, Lao CD, Tewari M. Targeting the gut microbiome to mitigate immunotherapy-induced colitis in cancer. Trends Cancer (2021) 7(7):583&#x2013;93. doi:&#xa0;10.1016/j.trecan.2021.02.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2021.02.005</ArticleId>
            <ArticleId IdType="pubmed">33741313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V&#xe9;tizou M, Pitt JM, Daill&#xe8;re R, Lepage P, Waldschmitt N, Flament C, et al. . Anticancer immunotherapy by ctla-4 blockade relies on the gut microbiota. Sci (New York NY) (2015) 350(6264):1079&#x2013;84. doi:&#xa0;10.1126/science.aad1329</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. . Commensal bifidobacterium promotes antitumor immunity and facilitates anti-Pd-L1 efficacy. Sci (New York NY) (2015) 350(6264):1084&#x2013;9. doi:&#xa0;10.1126/science.aac4255</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aac4255</ArticleId>
            <ArticleId IdType="pmc">PMC4873287</ArticleId>
            <ArticleId IdType="pubmed">26541606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. . Gut microbiome modulates response to anti-Pd-1 immunotherapy in melanoma patients. Sci (New York NY) (2018) 359(6371):97&#x2013;103. doi:&#xa0;10.1126/science.aan4236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan4236</ArticleId>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. . Fecal microbiota transplant overcomes resistance to anti-Pd-1 therapy in melanoma patients. Sci (New York NY) (2021) 371(6529):595&#x2013;602. doi:&#xa0;10.1126/science.abf3363</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abf3363</ArticleId>
            <ArticleId IdType="pmc">PMC8097968</ArticleId>
            <ArticleId IdType="pubmed">33542131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. . Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann oncol: Off J Eur Soc Med Oncol (2019) 30(12):2012. doi:&#xa0;10.1093/annonc/mdz224</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz224</ArticleId>
            <ArticleId IdType="pubmed">31408090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. . Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-Blockade-Induced colitis. Nat Commun (2016) 7:10391. doi:&#xa0;10.1038/ncomms10391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10391</ArticleId>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usyk M, Pandey A, Hayes RB, Moran U, Pavlick A, Osman I, et al. . Bacteroides vulgatus and bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma. Genome Med (2021) 13(1):160. doi:&#xa0;10.1186/s13073-021-00974-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13073-021-00974-z</ArticleId>
            <ArticleId IdType="pmc">PMC8513370</ArticleId>
            <ArticleId IdType="pubmed">34641962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, et al. . Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. J Natl Cancer Instit (2021) 113(2):162&#x2013;70. doi:&#xa0;10.1093/jnci/djaa057</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djaa057</ArticleId>
            <ArticleId IdType="pmc">PMC7850522</ArticleId>
            <ArticleId IdType="pubmed">32294209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao L, Li Y, Jiang N, Song X, Xu J, Zhu X, et al. . Association of blood biochemical indexes and antibiotic exposure with severe immune-related adverse events in patients with advanced cancers receiving pd-1 inhibitors. J immunother (Hagerstown Md: 1997) (2022) 45(4):210&#x2013;6. doi:&#xa0;10.1097/cji.0000000000000415</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/cji.0000000000000415</ArticleId>
            <ArticleId IdType="pmc">PMC8986630</ArticleId>
            <ArticleId IdType="pubmed">35250004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J, et al. . Intestinal microbiome associated with immune-related adverse events for patients treated with anti-Pd-1 inhibitors, a real-world study. Front Immunol (2021) 12:756872. doi:&#xa0;10.3389/fimmu.2021.756872</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.756872</ArticleId>
            <ArticleId IdType="pmc">PMC8716485</ArticleId>
            <ArticleId IdType="pubmed">34975845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao J, Wang D, Long J, Yang X, Lin J, Song Y, et al. . Gut microbiome is associated with the clinical response to anti-Pd-1 based immunotherapy in hepatobiliary cancers. J immunother Cancer (2021) 9(12):e003334. doi:&#xa0;10.1136/jitc-2021-003334</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2021-003334</ArticleId>
            <ArticleId IdType="pmc">PMC8650503</ArticleId>
            <ArticleId IdType="pubmed">34873013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al. . Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J immunother Cancer (2019) 7(1):242. doi:&#xa0;10.1186/s40425-019-0714-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0714-x</ArticleId>
            <ArticleId IdType="pmc">PMC6729015</ArticleId>
            <ArticleId IdType="pubmed">31488205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinato DJ, Gramenitskaya D, Altmann DM, Boyton RJ, Mullish BH, Marchesi JR, et al. . Antibiotic therapy and outcome from immune-checkpoint inhibitors. J immunother Cancer (2019) 7(1):287. doi:&#xa0;10.1186/s40425-019-0775-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0775-x</ArticleId>
            <ArticleId IdType="pmc">PMC6836427</ArticleId>
            <ArticleId IdType="pubmed">31694714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, Maddur MS, et al. . Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell (2019) 178(6):1313&#x2013;28.e13. doi:&#xa0;10.1016/j.cell.2019.08.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2019.08.010</ArticleId>
            <ArticleId IdType="pmc">PMC6750738</ArticleId>
            <ArticleId IdType="pubmed">31491384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can mitigate intestinal immunopathology in the context of ctla-4 blockade. Proc Natl Acad Sci United States America (2018) 115(1):157&#x2013;61. doi:&#xa0;10.1073/pnas.1712901115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1712901115</ArticleId>
            <ArticleId IdType="pmc">PMC5776803</ArticleId>
            <ArticleId IdType="pubmed">29255057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaito S, Sekiya N, Najima Y, Sano N, Horiguchi S, Kakihana K, et al. . Fatal neutropenic enterocolitis caused by stenotrophomonas maltophilia: A rare and underrecognized entity. Internal Med (Tokyo Japan) (2018) 57(24):3667&#x2013;71. doi:&#xa0;10.2169/internalmedicine.1227-18</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.1227-18</ArticleId>
            <ArticleId IdType="pmc">PMC6355424</ArticleId>
            <ArticleId IdType="pubmed">30101922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmig S, Ott S, Musfeldt M, Kosmahl M, Rosenstiel P, St&#xfc;ber E, et al. . Life-threatening chronic enteritis due to colonization of the small bowel with stenotrophomonas maltophilia. Gastroenterology (2005) 129(2):706&#x2013;12. doi:&#xa0;10.1016/j.gastro.2005.01.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gastro.2005.01.011</ArticleId>
            <ArticleId IdType="pubmed">16083723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilhan ZE, &#x141;aniewski P, Tonachio A, Herbst-Kralovetz MM. Members of prevotella genus distinctively modulate innate immune and barrier functions in a human three-dimensional endometrial epithelial cell model. J Infect Dis (2020) 222(12):2082&#x2013;92. doi:&#xa0;10.1093/infdis/jiaa324</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiaa324</ArticleId>
            <ArticleId IdType="pmc">PMC7661762</ArticleId>
            <ArticleId IdType="pubmed">32515473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Teijlingen NH, Helgers LC, Zijlstra-Willems EM, van Hamme JL, Ribeiro CMS, Strijbis K, et al. . Vaginal dysbiosis associated-bacteria megasphaera elsdenii and prevotella timonensis induce immune activation Via dendritic cells. J Reprod Immunol (2020) 138:103085. doi:&#xa0;10.1016/j.jri.2020.103085</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jri.2020.103085</ArticleId>
            <ArticleId IdType="pubmed">32004804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vatanen T, Kostic AD, d&#x2019;Hennezel E, Siljander H, Franzosa EA, Yassour M, et al. . Variation in microbiome lps immunogenicity contributes to autoimmunity in humans. Cell (2016) 165(4):842&#x2013;53. doi:&#xa0;10.1016/j.cell.2016.04.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.04.007</ArticleId>
            <ArticleId IdType="pmc">PMC4950857</ArticleId>
            <ArticleId IdType="pubmed">27133167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>d&#x2019;Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. mSystems (2017) 2(6):e00046&#x2013;17. doi:&#xa0;10.1128/mSystems.00046-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mSystems.00046-17</ArticleId>
            <ArticleId IdType="pmc">PMC5686520</ArticleId>
            <ArticleId IdType="pubmed">29152585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, et al. . Bacteroides vulgatus and bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation (2018) 138(22):2486&#x2013;98. doi:&#xa0;10.1161/circulationaha.118.033714</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/circulationaha.118.033714</ArticleId>
            <ArticleId IdType="pubmed">30571343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breyner NM, Michon C, de Sousa CS, Vilas Boas PB, Chain F, Azevedo VA, et al. . Microbial anti-inflammatory molecule (Mam) from faecalibacterium prausnitzii shows a protective effect on dnbs and dss-induced colitis model in mice through inhibition of nf-&#x3ba;b pathway. Front Microbiol (2017) 8:114. doi:&#xa0;10.3389/fmicb.2017.00114</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2017.00114</ArticleId>
            <ArticleId IdType="pmc">PMC5285381</ArticleId>
            <ArticleId IdType="pubmed">28203226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J, Liang R, Zhang W, Tian K, Li J, Chen X, et al. . Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice Via modulating tight junction protein expression. J Diabetes (2020) 12(3):224&#x2013;36. doi:&#xa0;10.1111/1753-0407.12986</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1753-0407.12986</ArticleId>
            <ArticleId IdType="pmc">PMC7064962</ArticleId>
            <ArticleId IdType="pubmed">31503404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol (2016) 16(6):341&#x2013;52. doi:&#xa0;10.1038/nri.2016.42</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2016.42</ArticleId>
            <ArticleId IdType="pmc">PMC5541232</ArticleId>
            <ArticleId IdType="pubmed">27231050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes (2016) 7(3):189&#x2013;200. doi:&#xa0;10.1080/19490976.2015.1134082</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2015.1134082</ArticleId>
            <ArticleId IdType="pmc">PMC4939913</ArticleId>
            <ArticleId IdType="pubmed">26963409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. . Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature (2013) 504(7480):451&#x2013;5. doi:&#xa0;10.1038/nature12726</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12726</ArticleId>
            <ArticleId IdType="pmc">PMC3869884</ArticleId>
            <ArticleId IdType="pubmed">24226773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J immunother Cancer (2019) 7(1):108. doi:&#xa0;10.1186/s40425-019-0574-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0574-4</ArticleId>
            <ArticleId IdType="pmc">PMC6471869</ArticleId>
            <ArticleId IdType="pubmed">30995949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. . Butyrate: A double-edged sword for health? Adv Nutr (Bethesda Md) (2018) 9(1):21&#x2013;9. doi:&#xa0;10.1093/advances/nmx009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/advances/nmx009</ArticleId>
            <ArticleId IdType="pmc">PMC6333934</ArticleId>
            <ArticleId IdType="pubmed">29438462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iljazovic A, Roy U, G&#xe1;lvez EJC, Lesker TR, Zhao B, Gronow A, et al. . Perturbation of the gut microbiome by prevotella spp. enhances host susceptibility to mucosal inflammation. Mucosal Immunol (2021) 14(1):113&#x2013;24. doi:&#xa0;10.1038/s41385-020-0296-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41385-020-0296-4</ArticleId>
            <ArticleId IdType="pmc">PMC7790746</ArticleId>
            <ArticleId IdType="pubmed">32433514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Putnam EE, Goodman AL. B vitamin acquisition by gut commensal bacteria. PloS Pathog (2020) 16(1):e1008208. doi:&#xa0;10.1371/journal.ppat.1008208</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1008208</ArticleId>
            <ArticleId IdType="pmc">PMC6977713</ArticleId>
            <ArticleId IdType="pubmed">31971969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson CT, Rodionov DA, Osterman AL, Peterson SN. B vitamins and their role in immune regulation and cancer. Nutrients (2020) 12(11):3380. doi:&#xa0;10.3390/nu12113380</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu12113380</ArticleId>
            <ArticleId IdType="pmc">PMC7693142</ArticleId>
            <ArticleId IdType="pubmed">33158037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: Insights into metabolism and lymphocyte function. Sci (New York NY) (2013) 342(6155):1242454. doi:&#xa0;10.1126/science.1242454</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1242454</ArticleId>
            <ArticleId IdType="pmc">PMC4486656</ArticleId>
            <ArticleId IdType="pubmed">24115444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell (2017) 169(4):570&#x2013;86. doi:&#xa0;10.1016/j.cell.2017.04.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.04.004</ArticleId>
            <ArticleId IdType="pmc">PMC5648021</ArticleId>
            <ArticleId IdType="pubmed">28475890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almeida L, Lochner M, Berod L, Sparwasser T. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol (2016) 28(5):514&#x2013;24. doi:&#xa0;10.1016/j.smim.2016.10.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.smim.2016.10.009</ArticleId>
            <ArticleId IdType="pubmed">27825556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schramm M, Wiegmann K, Schramm S, Gluschko A, Herb M, Uterm&#xf6;hlen O, et al. . Riboflavin (Vitamin B2) deficiency impairs nadph oxidase 2 (Nox2) priming and defense against listeria monocytogenes. Eur J Immunol (2014) 44(3):728&#x2013;41. doi:&#xa0;10.1002/eji.201343940</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201343940</ArticleId>
            <ArticleId IdType="pubmed">24272050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao JN, Xiao L, Wang JY. Polyamines in gut epithelial renewal and barrier function. Physiol (Bethesda Md) (2020) 35(5):328&#x2013;37. doi:&#xa0;10.1152/physiol.00011.2020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physiol.00011.2020</ArticleId>
            <ArticleId IdType="pmc">PMC7642847</ArticleId>
            <ArticleId IdType="pubmed">32783609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy M, Thaiss CA, Zeevi D, Dohnalov&#xe1; L, Zilberman-Schapira G, Mahdi JA, et al. . Microbiota-modulated metabolites shape the intestinal microenvironment by regulating Nlrp6 inflammasome signaling. Cell (2015) 163(6):1428&#x2013;43. doi:&#xa0;10.1016/j.cell.2015.10.048</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.10.048</ArticleId>
            <ArticleId IdType="pmc">PMC5665753</ArticleId>
            <ArticleId IdType="pubmed">26638072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S&#xe1;nchez-Jim&#xe9;nez F, Medina M, Villalobos-Rueda L, Urdiales JL. Polyamines in mammalian pathophysiology. Cell Mol Life sci: CMLS (2019) 76(20):3987&#x2013;4008. doi:&#xa0;10.1007/s00018-019-03196-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-019-03196-0</ArticleId>
            <ArticleId IdType="pubmed">31227845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mei Y, Chen H, Yang B, Zhao J, Zhang H, Chen W. Research progress on conjugated linoleic acid bio-conversion in bifidobacterium. Int J Food Microbiol (2022) 369:109593. doi:&#xa0;10.1016/j.ijfoodmicro.2022.109593</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijfoodmicro.2022.109593</ArticleId>
            <ArticleId IdType="pubmed">35287032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wall R, Ross RP, Shanahan F, O&#x2019;Mahony L, O&#x2019;Mahony C, Coakley M, et al. . Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr (2009) 89(5):1393&#x2013;401. doi:&#xa0;10.3945/ajcn.2008.27023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3945/ajcn.2008.27023</ArticleId>
            <ArticleId IdType="pubmed">19357220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Yang B, Ross RP, Jin Y, Stanton C, Zhao J, et al. . Orally administered CLA ameliorates DSS-induced colitis in mice via intestinal barrier improvement, oxidative stress reduction, and inflammatory cytokine and gut microbiota modulation. J Agric Food Chem (2019) 67(48):13282&#x2013;98. doi:&#xa0;10.1021/acs.jafc.9b05744</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jafc.9b05744</ArticleId>
            <ArticleId IdType="pubmed">31690068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Zheng N, Luo Q, Jiang L, He B, Yuan X, et al. . Probiotics lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells. Front Immunol (2019) 10:1235. doi:&#xa0;10.3389/fimmu.2019.01235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01235</ArticleId>
            <ArticleId IdType="pmc">PMC6558076</ArticleId>
            <ArticleId IdType="pubmed">31214189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu N, Bai X, Cao X, Yue W, Jiang W, Yu Z. Changes in intestinal microbiota and correlation with tlrs in ulcerative colitis in the coastal area of northern China. Microb pathogen (2021) 150:104707. doi:&#xa0;10.1016/j.micpath.2020.104707</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micpath.2020.104707</ArticleId>
            <ArticleId IdType="pubmed">33352216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JL, Gao YY, Zhou J, Tang XY, Wang P, Shen LW, et al. . Changes in serum inflammatory cytokine levels and intestinal flora in a self-healing dextran sodium sulfate-induced ulcerative colitis murine model. Life Sci (2020) 263:118587. doi:&#xa0;10.1016/j.lfs.2020.118587</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.118587</ArticleId>
            <ArticleId IdType="pubmed">33065145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomlinson G, Chimalapati S, Pollard T, Lapp T, Cohen J, Camberlein E, et al. . Tlr-mediated inflammatory responses to streptococcus pneumoniae are highly dependent on surface expression of bacterial lipoproteins. J Immunol (Baltimore Md: 1950) (2014) 193(7):3736&#x2013;45. doi:&#xa0;10.4049/jimmunol.1401413</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1401413</ArticleId>
            <ArticleId IdType="pmc">PMC4170674</ArticleId>
            <ArticleId IdType="pubmed">25172490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang ZH, Liu F, Zhu XR, Suo FY, Jia ZJ, Yao SK. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J Gastroenterol (2021) 27(24):3609&#x2013;29. doi:&#xa0;10.3748/wjg.v27.i24.3609</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v27.i24.3609</ArticleId>
            <ArticleId IdType="pmc">PMC8240054</ArticleId>
            <ArticleId IdType="pubmed">34239273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zelov&#xe1; H, Ho&#x161;ek J. Tnf-&#x3b1; signalling and inflammation: Interactions between old acquaintances. Inflammation res: Off J Eur Histam Res Soc [et al] (2013) 62(7):641&#x2013;51. doi:&#xa0;10.1007/s00011-013-0633-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-013-0633-0</ArticleId>
            <ArticleId IdType="pubmed">23685857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, et al. . Randomised clinical trial: The effectiveness of lactobacillus reuteri atcc 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther (2012) 35(3):327&#x2013;34. doi:&#xa0;10.1111/j.1365-2036.2011.04939.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2036.2011.04939.x</ArticleId>
            <ArticleId IdType="pubmed">22150569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas CM, Hong T, van Pijkeren JP, Hemarajata P, Trinh DV, Hu W, et al. . Histamine derived from probiotic lactobacillus reuteri suppresses tnf Via modulation of pka and erk signaling. PloS One (2012) 7(2):e31951. doi:&#xa0;10.1371/journal.pone.0031951</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0031951</ArticleId>
            <ArticleId IdType="pmc">PMC3285189</ArticleId>
            <ArticleId IdType="pubmed">22384111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lukens JR, Gurung P, Vogel P, Johnson GR, Carter RA, McGoldrick DJ, et al. . Dietary modulation of the microbiome affects autoinflammatory disease. Nature (2014) 516(7530):246&#x2013;9. doi:&#xa0;10.1038/nature13788</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13788</ArticleId>
            <ArticleId IdType="pmc">PMC4268032</ArticleId>
            <ArticleId IdType="pubmed">25274309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, et al. . Gut microbiota signatures are associated with toxicity to combined ctla-4 and pd-1 blockade. Nat Med (2021) 27(8):1432&#x2013;41. doi:&#xa0;10.1038/s41591-021-01406-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01406-6</ArticleId>
            <ArticleId IdType="pubmed">34239137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu D, Mu R, Wei X. The roles of il-1 family cytokines in the pathogenesis of systemic sclerosis. Front Immunol (2019) 10:2025. doi:&#xa0;10.3389/fimmu.2019.02025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02025</ArticleId>
            <ArticleId IdType="pmc">PMC6753625</ArticleId>
            <ArticleId IdType="pubmed">31572353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schenk M, Fabri M, Krutzik SR, Lee DJ, Vu DM, Sieling PA, et al. . Interleukin-1&#x3b2; triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to T cells. Immunology (2014) 141(2):174&#x2013;80. doi:&#xa0;10.1111/imm.12167</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imm.12167</ArticleId>
            <ArticleId IdType="pmc">PMC3904238</ArticleId>
            <ArticleId IdType="pubmed">24032597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomosada Y, Villena J, Murata K, Chiba E, Shimazu T, Aso H, et al. . Immunoregulatory effect of bifidobacteria strains in porcine intestinal epithelial cells through modulation of ubiquitin-editing enzyme A20 expression. PloS One (2013) 8(3):e59259. doi:&#xa0;10.1371/journal.pone.0059259</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0059259</ArticleId>
            <ArticleId IdType="pmc">PMC3608626</ArticleId>
            <ArticleId IdType="pubmed">23555642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouyang W, O&#x2019;Garra A. Il-10 family cytokines il-10 and il-22: From basic science to clinical translation. Immunity (2019) 50(4):871&#x2013;91. doi:&#xa0;10.1016/j.immuni.2019.03.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2019.03.020</ArticleId>
            <ArticleId IdType="pubmed">30995504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glocker EO, Kotlarz D, Boztug K, Gertz EM, Sch&#xe4;ffer AA, Noyan F, et al. . Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. New Engl J Med (2009) 361(21):2033&#x2013;45. doi:&#xa0;10.1056/NEJMoa0907206</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0907206</ArticleId>
            <ArticleId IdType="pmc">PMC2787406</ArticleId>
            <ArticleId IdType="pubmed">19890111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heo YJ, Joo YB, Oh HJ, Park MK, Heo YM, Cho ML, et al. . Il-10 suppresses Th17 cells and promotes regulatory T cells in the Cd4+ T cell population of rheumatoid arthritis patients. Immunol Lett (2010) 127(2):150&#x2013;6. doi:&#xa0;10.1016/j.imlet.2009.10.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.imlet.2009.10.006</ArticleId>
            <ArticleId IdType="pubmed">19895848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S, Luo L, Liang W, Yin Q, Guo J, Rush AM, et al. . Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proc Natl Acad Sci United States America (2020) 117(44):27509&#x2013;15. doi:&#xa0;10.1073/pnas.1921223117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1921223117</ArticleId>
            <ArticleId IdType="pmc">PMC7959554</ArticleId>
            <ArticleId IdType="pubmed">33077598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, et al. . Probiotic bifidobacterium breve induces il-10-Producing Tr1 cells in the colon. PloS Pathog (2012) 8(5):e1002714. doi:&#xa0;10.1371/journal.ppat.1002714</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1002714</ArticleId>
            <ArticleId IdType="pmc">PMC3364948</ArticleId>
            <ArticleId IdType="pubmed">22693446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sokol H, Pigneur B, Watterlot L, Lakhdari O, Berm&#xfa;dez-Humar&#xe1;n LG, Gratadoux JJ, et al. . Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of crohn disease patients. Proc Natl Acad Sci United States America (2008) 105(43):16731&#x2013;6. doi:&#xa0;10.1073/pnas.0804812105</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0804812105</ArticleId>
            <ArticleId IdType="pmc">PMC2575488</ArticleId>
            <ArticleId IdType="pubmed">18936492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mart&#xed;n R, Chain F, Miquel S, Lu J, Gratadoux JJ, Sokol H, et al. . The commensal bacterium faecalibacterium prausnitzii is protective in dnbs-induced chronic moderate and severe colitis models. Inflamm bowel Dis (2014) 20(3):417&#x2013;30. doi:&#xa0;10.1097/01.Mib.0000440815.76627.64</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.Mib.0000440815.76627.64</ArticleId>
            <ArticleId IdType="pubmed">24418903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi O, van Berkel LA, Chain F, Tanweer Khan M, Taverne N, Sokol H, et al. . Faecalibacterium prausnitzii A2-165 has a high capacity to induce il-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep (2016) 6:18507. doi:&#xa0;10.1038/srep18507</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep18507</ArticleId>
            <ArticleId IdType="pmc">PMC4698756</ArticleId>
            <ArticleId IdType="pubmed">26725514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheinecker C, G&#xf6;schl L, Bonelli M. Treg cells in health and autoimmune diseases: New insights from single cell analysis. J Autoimmun (2020) 110:102376. doi:&#xa0;10.1016/j.jaut.2019.102376</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2019.102376</ArticleId>
            <ArticleId IdType="pubmed">31862128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freen-van Heeren JJ. Post-transcriptional control of T-cell cytokine production: Implications for cancer therapy. Immunology (2021) 164(1):57&#x2013;72. doi:&#xa0;10.1111/imm.13339</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imm.13339</ArticleId>
            <ArticleId IdType="pmc">PMC8358718</ArticleId>
            <ArticleId IdType="pubmed">33884612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. . Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med (2018) 24(12):1804&#x2013;8. doi:&#xa0;10.1038/s41591-018-0238-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0238-9</ArticleId>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan B, Tang H, Xu Y, Chen MJ, Wang MZ, Qian JM. [Protective effect and mechanism of lactobacillus rhamnosus on immune checkpoint inhibitors related colitis in mice]. Zhonghua yi xue za zhi (2020) 100(42):3332&#x2013;7. doi:&#xa0;10.3760/cma.j.cn112137-20200520-01598</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.cn112137-20200520-01598</ArticleId>
            <ArticleId IdType="pubmed">33202497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasanello MK, Robillard KT, Boland PM, Bain AJ, Kanehira K. Use of fecal microbial transplantation for immune checkpoint inhibitor colitis. ACG Case Rep J (2020) 7(4):e00360. doi:&#xa0;10.14309/crj.0000000000000360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/crj.0000000000000360</ArticleId>
            <ArticleId IdType="pmc">PMC7224717</ArticleId>
            <ArticleId IdType="pubmed">32548190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai C, Liu WX. Refractory immune checkpoint inhibitor-induced colitis improved by fecal microbiota transplantation: A case report. Inflamm bowel Dis (2022) 28(3):e43&#x2013;e4. doi:&#xa0;10.1093/ibd/izab265</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izab265</ArticleId>
            <ArticleId IdType="pubmed">34751747</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36377339</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>02</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-0142</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>129</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2023</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer</Title>
          <ISOAbbreviation>Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.</ArticleTitle>
        <Pagination>
          <StartPage>367</StartPage>
          <EndPage>375</EndPage>
          <MedlinePgn>367-375</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.34543</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Gastrointestinal immune-related adverse events are frequently caused by immune checkpoint inhibitors (ICIs) and often require interruption of cancer treatment. Compared with ICI colitis and enteritis, limited information exists about ICI gastritis. This study characterized clinical features and treatment outcomes of ICI gastritis.</AbstractText>
          <AbstractText Label="METHODS">Consecutive cancer patients who received ICIs and underwent endoscopy with gastric biopsies while on ICIs from 2011 to 2021 were retrospectively assessed. Specific histopathologic features identified ICI gastritis.</AbstractText>
          <AbstractText Label="RESULTS">Of 6450 ICI-treated patients, 162 (2.5%) underwent endoscopy with gastric biopsies. ICI gastritis was identified in 54 (33%) biopsied patients; 38 (70%) had concurrent ICI enteritis/colitis and 16 (30%) had isolated ICI gastritis. Dyspepsia (38%) and bloating (25%) were the most frequent symptoms of isolated ICI gastritis. Compared with patients with concomitant enteritis/colitis, patients with isolated gastritis were less likely to have diarrhea (13% vs 68%; p&#xa0;&lt;&#xa0;.001) or abdominal pain (19% vs 47%; p&#xa0;=&#xa0;.07). Patients with isolated ICI gastritis less frequently required glucocorticoids (69% vs 92%; p&#xa0;=&#xa0;.04) and had lower incidence of ICI hold/withdrawal (13% vs 42%; p&#xa0;=&#xa0;.06). There was no association between severity or extent of luminal inflammation and antitumor response (p&#xa0;=&#xa0;.85 and p&#xa0;=&#xa0;.44, respectively). Endoscopically, gastric mucosa appeared normal in 11 (20%) patients with biopsy-proven ICI gastritis.</AbstractText>
          <AbstractText Label="CONCLUSION">ICI gastritis may present alone or more commonly with concurrent enteritis/colitis, which may differentiate its clinical course. Gastric biopsies are required to diagnose a substantial minority of endoscopically normal, clinically significant cases. Most patients with isolated gastritis can continue ICI therapy uninterrupted, but a notable proportion require glucocorticoids.</AbstractText>
          <AbstractText Label="PLAIN LANGUAGE SUMMARY">Immune checkpoint inhibitors are effective anticancer treatments, but can cause inflammatory toxicities, including of the stomach (gastritis), intestine, and colon. Limited information is available on gastritis triggered by these agents. Adult patients with cancer who were treated with immune checkpoint inhibitors and had an upper gastrointestinal endoscopy with biopsies of the stomach were examined. More than two-thirds (70%) of people with checkpoint inhibitor gastritis also had inflammatory changes of the small intestine and/or colon. Compared with patients with isolated checkpoint gastritis, the subgroup with concomitant enteritis/colitis more frequently had abdominal pain, diarrhea, needed steroids, and/or needed to pause or stop antitumor therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2022 American Cancer Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Haryal</LastName>
            <ForeName>Aneesha</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Townsend</LastName>
            <ForeName>Matthew J</ForeName>
            <Initials>MJ</Initials>
            <Identifier Source="ORCID">0000-0002-7486-961X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Duke University Hospital, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baskaran</LastName>
            <ForeName>Vinitha</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Srivoleti</LastName>
            <ForeName>Padmavathi</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giobbie-Hurder</LastName>
            <ForeName>Anita</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sack</LastName>
            <ForeName>Jordan S</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Isidro</LastName>
            <ForeName>Raymond A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>LeBoeuf</LastName>
            <ForeName>Nicole R</ForeName>
            <Initials>NR</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buchbinder</LastName>
            <ForeName>Elizabeth I</ForeName>
            <Initials>EI</Initials>
            <Identifier Source="ORCID">0000-0002-7979-8953</Identifier>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hodi</LastName>
            <ForeName>F Stephen</ForeName>
            <Initials>FS</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grover</LastName>
            <ForeName>Shilpa</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6268-6843</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer</MedlineTA>
        <NlmUniqueID>0374236</NlmUniqueID>
        <ISSNLinking>0008-543X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="Y">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005756" MajorTopicYN="Y">Gastritis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004760" MajorTopicYN="Y">Enterocolitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">enterocolitis</Keyword>
        <Keyword MajorTopicYN="N">gastritis</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor adverse effects</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor toxicity</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>2</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36377339</ArticleId>
        <ArticleId IdType="doi">10.1002/cncr.34543</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV, et&#xa0;al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721-1728. doi:10.1001/jamaoncol.2018.3923</Citation>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Sykiotis GP, et&#xa0;al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563-580. doi:10.1038/s41571-019-0218-0</Citation>
        </Reference>
        <Reference>
          <Citation>Hayama N, Ihara H, Honma Y, Itoigawa Y, Kaira K, Fujii M. Severe gastritis due to pembrolizumab treatment in a lung cancer patient.&#xa0;Respirol Case Rep. 2020;8(7):e00636. doi:10.1002/rcr2.636</Citation>
        </Reference>
        <Reference>
          <Citation>Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Melanoma Res. 2018;28(6):645-647. doi:10.1097/cmr.0000000000000502</Citation>
        </Reference>
        <Reference>
          <Citation>Vandepapeli&#xe8;re J, Siplet J, Libbrecht L, Dano H, Baurain J-F, Moreels&#xa0;T. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient. Acta Gastro-Enterol Belg. 2020;83:482-484.</Citation>
        </Reference>
        <Reference>
          <Citation>Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by nivolumab: a case report. World J Gastroenterol. 2020;26(16):1971-1978. doi:10.3748/wjg.v26.i16.1971</Citation>
        </Reference>
        <Reference>
          <Citation>Sugiyama Y, Tanabe H, Fujiya M. Immune checkpoint inhibitor-related gastritis in a patient with metastatic melanoma. JGH Open. 2021;5(10):1218-1219. doi:10.1002/jgh3.12657</Citation>
        </Reference>
        <Reference>
          <Citation>Saito K, Ozono D, Nagumo H, Yoshimura M, Masuzawa Y. Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report. Clin J Gastroenterol. 2022;15(2):368-373. doi:10.1007/s12328-021-01582-5</Citation>
        </Reference>
        <Reference>
          <Citation>Rao BB, Robertson S, Philpott J. Checkpoint inhibitor-induced hemorrhagic gastritis with pembrolizumab. Am J Gastroenterol. 2019;114(2):196. doi:10.1038/s41395-018-0366-3</Citation>
        </Reference>
        <Reference>
          <Citation>Okamoto A, Yoshii S, Tsujii Y, Hayashi Y, Shinzaki S, Takehara T. &#x201c;Stardust&#x201d; gastric mucosa in the course of immune checkpoint inhibitor-associated gastritis. Am J Gastroenterol. 2022;117(10):1555. doi:10.14309/ajg.0000000000001835</Citation>
        </Reference>
        <Reference>
          <Citation>Nishimura Y, Yasuda M, Ocho K, et&#xa0;al. Severe gastritis after administration of nivolumab and ipilimumab. Case Rep Oncol. 2018;11(2):549-556. doi:10.1159/000491862</Citation>
        </Reference>
        <Reference>
          <Citation>Nguyen AH, Sagvand BT, Hwang DG, Legesse T, Cross RK. Isolated gastritis secondary to immune checkpoint inhibitors complicated by superimposed cytomegalovirus infection. ACG Case Rep J. 2022;9(2):e00747. doi:10.14309/crj.0000000000000747</Citation>
        </Reference>
        <Reference>
          <Citation>Liu WT, Li YF, Hsieh TY. Unusual severe gastritis and gastric ulcers caused by pembrolizumab. J Postgrad Med. 2022;68:38-40. doi:10.4103/jpgm.jpgm_1132_20</Citation>
        </Reference>
        <Reference>
          <Citation>Ebisutani N, Tozawa K, Matsuda I, et&#xa0;al. A case of severe acute gastritis as an immune-related adverse event after nivolumab treatment: endoscopic and pathological findings in nivolumab-related gastritis. Dig Dis Sci. 2021;66(7):2461-2465. doi:10.1007/s10620-020-06529-3</Citation>
        </Reference>
        <Reference>
          <Citation>Boike J, Dejulio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J. 2017;4(1):e57. doi:10.14309/crj.2017.57</Citation>
        </Reference>
        <Reference>
          <Citation>Bazarbashi AN, Dolan RD, Yang J, Perencevich ML. Combination checkpoint inhibitor-induced hemorrhagic gastritis. ACG Case Rep J.&#xa0;2020;7(6):e00402. doi:10.14309/crj.0000000000000402</Citation>
        </Reference>
        <Reference>
          <Citation>Tang T, Abu-Sbeih H, Luo W, et&#xa0;al. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019;54(5):538-545. doi:10.1080/00365521.2019.1594356</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology. 2020;76(2):233-243. doi:10.1111/his.13963</Citation>
        </Reference>
        <Reference>
          <Citation>Placke JM, Rawitzer J, Reis H, et&#xa0;al. Apoptotic gastritis in melanoma patients treated with PD-1-based immune checkpoint inhibition - clinical and histopathological findings including the diagnostic value of anti-caspase-3 immunohistochemistry. Front&#xa0;Oncol. 2021;11:725549. doi:10.3389/fonc.2021.725549</Citation>
        </Reference>
        <Reference>
          <Citation>Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology. 2020;76(4):531-539. doi:10.1111/his.14029</Citation>
        </Reference>
        <Reference>
          <Citation>Hayashi Y, Hosoe N, Takabayashi K, et&#xa0;al. Clinical, endoscopic, and pathological characteristics of immune checkpoint inhibitor-induced gastroenterocolitis. Dig Dis Sci. 2021;66:2129-2134.</Citation>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et&#xa0;al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10(4):395-401. doi:10.1093/ecco-jcc/jjv227</Citation>
        </Reference>
        <Reference>
          <Citation>Alomari M, Al Ashi S, Chadalavada P, et&#xa0;al. Gastrointestinal toxicities of immune checkpoint inhibitors are associated with enhanced tumor responsiveness and improved survival. Gastroenterol Res. 2022;15(2):56-66. doi:10.14740/gr1491</Citation>
        </Reference>
        <Reference>
          <Citation>de Malet A, Antoni G, Collins M, et&#xa0;al. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:106-114. doi:10.1016/j.ejca.2018.10.006</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, et&#xa0;al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Cancer Netw. 2020;18:230-241.</Citation>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, et&#xa0;al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768. doi:10.1200/jco.2017.77.6385</Citation>
        </Reference>
        <Reference>
          <Citation>Haanen J, Carbonnel F, Robert C, et&#xa0;al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:119-142. doi:10.1093/annonc/mdx225</Citation>
        </Reference>
        <Reference>
          <Citation>Collins M, Soularue E, Marthey L, Carbonnel F. Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review. Clin Gastroenterol Hepatol. 2020;18(6):1393-1403. e1391. doi:10.1016/j.cgh.2020.01.033</Citation>
        </Reference>
        <Reference>
          <Citation>Patil PA, Zhang X. Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy. Arch Pathol Lab Med. 2021;145(5):571-582. doi:10.5858/arpa.2020-0070-ra</Citation>
        </Reference>
        <Reference>
          <Citation>Foster CC, Couey MA, Kochanny SE, et&#xa0;al. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer. 2021;127(24):4565-4573. doi:10.1002/cncr.33780</Citation>
        </Reference>
        <Reference>
          <Citation>Shafqat H, Gourdin T, Sion A. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. Semin Oncol. 2018;45(3):156-163. doi:10.1053/j.seminoncol.2018.07.003</Citation>
        </Reference>
        <Reference>
          <Citation>von Pawel J, Syrigos K, Mazieres J, et&#xa0;al. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Ann Oncol. 2017;28:v469. doi:10.1093/annonc/mdx380.017</Citation>
        </Reference>
        <Reference>
          <Citation>Haratani K, Hayashi H, Chiba Y, et&#xa0;al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4(3):374-378. doi:10.1001/jamaoncol.2017.2925</Citation>
        </Reference>
        <Reference>
          <Citation>Toi Y, Sugawara S, Kawashima Y, et&#xa0;al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncology. 2018;23(11):1358-1365. doi:10.1634/theoncologist.2017-0384</Citation>
        </Reference>
        <Reference>
          <Citation>Das S, Ciombor KK, Haraldsdottir S, et&#xa0;al. Immune-related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with Food and Drug Administration-approved indications for immunotherapy. Oncology. 2020;25(8):669-679. doi:10.1634/theoncologist.2019-0637</Citation>
        </Reference>
        <Reference>
          <Citation>Masuda K, Shoji H, Nagashima K, et&#xa0;al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019;19(1):974. doi:10.1186/s12885-019-6150-y</Citation>
        </Reference>
        <Reference>
          <Citation>Kelly K, Manitz J, Patel MR, et&#xa0;al. Efficacy and immune-related adverse event associations in avelumab-treated patients. J Immunother Cancer. 2020;8(2):e001427. doi:10.1136/jitc-2020-001427</Citation>
        </Reference>
        <Reference>
          <Citation>Fan Y, Xie W, Huang H, et&#xa0;al. Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front Oncol. 2021;11:633032. doi:10.3389/fonc.2021.633032</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36338892</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2219-2840</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>39</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Oct</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>World journal of gastroenterology</Title>
          <ISOAbbreviation>World J Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival.</ArticleTitle>
        <Pagination>
          <StartPage>5750</StartPage>
          <EndPage>5763</EndPage>
          <MedlinePgn>5750-5763</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3748/wjg.v28.i39.5750</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event following immune checkpoint inhibitor (ICI) therapy for cancer. IMC has been associated with improved overall survival (OS) and progression-free survival (PFS), but data are limited to a single site and predominantly for melanoma patients.</AbstractText>
          <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To determine the association of IMC with OS and PFS and identify clinical predictors of IMC.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective case-control study including 64 ICI users who developed IMC matched according to age, sex, ICI class, and malignancy to a cohort of ICI users without IMC, from May 2011 to May 2020. Using univariate and multivariate logistic regression, we determined association of presence of IMC on OS, PFS, and clinical predictors of IMC. Kaplan-Meier curves were generated to compare OS and PFS between ICI users with and without IMC.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">IMC was significantly associated with a higher OS (mean 24.3 mo vs 17.7 mo, P = 0.05) but not PFS (mean 13.7 mo vs 11.9 mo, P = 0.524). IMC was significantly associated with OS greater than 12 mo [Odds ratio (OR) 2.81, 95% confidence interval (CI) 1.17-6.77]. Vitamin D supplementation was significantly associated with increased risk of IMC (OR 2.48, 95%CI 1.01-6.07).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IMC was significantly associated with OS greater than 12 mo. In contrast to prior work, we found that vitamin D use may be a risk factor for IMC.</AbstractText>
          <CopyrightInformation>&#xa9;The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Weingarden</LastName>
            <ForeName>Alexa R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States. aweingar@stanford.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gubatan</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Sundeep</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balabanis</LastName>
            <ForeName>Tatiana Clorice</ForeName>
            <Initials>TC</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Akshar</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Arpita</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Habtezion</LastName>
            <ForeName>Aida</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>World J Gastroenterol</MedlineTA>
        <NlmUniqueID>100883448</NlmUniqueID>
        <ISSNLinking>1007-9327</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1406-16-2</RegistryNumber>
          <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="Y">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitor-mediated colitis</Keyword>
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Immune-related adverse events</Keyword>
      </KeywordList>
      <CoiStatement>Conflict-of-interest statement: None of the authors have any potential conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>4</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36338892</ArticleId>
        <ArticleId IdType="pmc">PMC9627421</ArticleId>
        <ArticleId IdType="doi">10.3748/wjg.v28.i39.5750</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb&#xe9; C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711&#x2013;723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509&#x2013;2520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4481136</ArticleId>
            <ArticleId IdType="pubmed">26028255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlh&#xe4;ufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin&#xf2; L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab vs Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627&#x2013;1639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5705936</ArticleId>
            <ArticleId IdType="pubmed">26412456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376:1015&#x2013;1026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5635424</ArticleId>
            <ArticleId IdType="pubmed">28212060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmid P, Cortes J, Pusztai L, McArthur H, K&#xfc;mmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810&#x2013;821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32101663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158&#x2013;168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:1393&#x2013;1403.e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32007539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377&#x2013;2385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6:37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5946546</ArticleId>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, Wang Y. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother. 2019;68:553&#x2013;561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30666357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020;126:3758&#x2013;3767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7381363</ArticleId>
            <ArticleId IdType="pubmed">32567084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139&#x2013;148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26765102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, van der Hoeven JJM, Hospers GA, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res. 2020;26:2268&#x2013;2274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31988197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available from: https://ctep.cancer.gov/20protocoldevelopment/electronic_applications/%20docs/CTCAE_v5_Quick_Reference_8.5x11.pdf .</Citation>
        </Reference>
        <Reference>
          <Citation>Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28:2860&#x2013;2865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29045560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kok PS, Cho D, Yoon WH, Ritchie G, Marschner I, Lord S, Friedlander M, Simes J, Lee CK. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3:e2011809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7489825</ArticleId>
            <ArticleId IdType="pubmed">32897371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology. 2017;6:e1344805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5665065</ArticleId>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishay K, Tandon P, Bourassa-Blanchette S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Curr Oncol. 2020;27:e486&#x2013;e494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7606037</ArticleId>
            <ArticleId IdType="pubmed">33173388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Velasco G, Je Y, Boss&#xe9; D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017;5:312&#x2013;318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5418853</ArticleId>
            <ArticleId IdType="pubmed">28246107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056&#x2013;2067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. J Immunother. 2018;41:101&#x2013;108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29401166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komaki Y, Komaki F, Yamada A, Micic D, Ido A, Sakuraba A. Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. Clin Pharmacol Ther. 2018;103:318&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28118483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao J, Li M, Zhang H, Ge Y, Weygant N, An G. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. Int Immunopharmacol. 2020;87:106770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32702598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab vs ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Lancet. 2017;390:1853&#x2013;1862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28822576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. Pembrolizumab vs ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239&#x2013;1251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31345627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, M&#xe1;rquez-Rodas I, Haanen J, Guidoboni M, Maio M, Sch&#xf6;ffski P, Carlino MS, Lebb&#xe9; C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381:1535&#x2013;1546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31562797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honor&#xe9; C, Sargos P, Sunyach MP, Le P&#xe9;choux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15:78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5385590</ArticleId>
            <ArticleId IdType="pubmed">28391775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yadav K, Lewis RJ. Immortal Time Bias in Observational Studies. JAMA. 2021;325:686&#x2013;687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33591334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizzo A, Mollica V, Santoni M, Ricci AD, Rosellini M, Marchetti A, Montironi R, Ardizzoni A, Massari F. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. Eur Urol Focus. 2022;8:514&#x2013;521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33714725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Target Oncol. 2022;17:61&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34894318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs. 2022;31:415&#x2013;423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34429006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill&#xe8;re R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondrag&#xf3;n L, Jacquelot N, Qu B, Ferrere G, Cl&#xe9;menson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91&#x2013;97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104&#x2013;108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6707353</ArticleId>
            <ArticleId IdType="pubmed">29302014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97&#x2013;103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36189293</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.</ArticleTitle>
        <Pagination>
          <StartPage>988849</StartPage>
          <MedlinePgn>988849</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">988849</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.988849</ELocationID>
        <Abstract>
          <AbstractText>With the arrival of the era of tumor immunotherapy, Immune Checkpoint Inhibitors have benefited countless tumor patients. However, the emergence of Immune-Related Adverse Events, especially Immune Checkpoint Inhibitor-Mediated Colitis (IMC), has become an important obstacle to immunotherapy. Therefore, it is very important to clarify the mechanism and influencing factors of IMC. The effect of gut microbiota on IMC is gradually becoming a research hotspot. Gut microbiota from different phyla can affect IMC by regulating innate and acquired immunity of tumor patients in various ways. In this review, we make a systematic and comprehensive introduction of the effect of gut microbiota on IMC. Through understanding the specific effects of gut microbiota on IMC, and then exploring the possibility of reducing IMC by regulating gut microbiota.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Han, Zang, Liu and Chen.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Xu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Medical Research Center of Lung Cancer in Liaoning Province, Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zang</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Medical Research Center of Lung Cancer in Liaoning Province, Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Medical Research Center of Lung Cancer in Liaoning Province, Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Medical Research Center of Lung Cancer in Liaoning Province, Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>09</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">clinical application</Keyword>
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">gut microbiota</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">immunity</Keyword>
        <Keyword MajorTopicYN="N">mechanism</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36189293</ArticleId>
        <ArticleId IdType="pmc">PMC9515466</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2022.988849</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of fda-approved immune checkpoint inhibitors. Int Immunopharmacol (2018) 62:29&#x2013;39. doi:&#xa0;10.1016/j.intimp.2018.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.06.001</ArticleId>
            <ArticleId IdType="pubmed">29990692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. . Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol (2018) 4(12):1721&#x2013;28. doi:&#xa0;10.1001/jamaoncol</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol</ArticleId>
            <ArticleId IdType="pmc">PMC6440712</ArticleId>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. . Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer (2016) 54:139&#x2013;48. doi:&#xa0;10.1016/j.ejca.2015.11.016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2015.11.016</ArticleId>
            <ArticleId IdType="pubmed">26765102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, et al. . Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori (2017) 103(5):405&#x2013;21. doi:&#xa0;10.5301/tj.5000625</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5301/tj.5000625</ArticleId>
            <ArticleId IdType="pubmed">28497847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. Ann Oncol (2017) 28(10):2377&#x2013;85. doi:&#xa0;10.1093/annonc/mdx286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx286</ArticleId>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Fs A, Luo W, Qiao W, Raju GS, Wang Y, et al. . Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer (2018) 6(1):018&#x2013;0411. doi:&#xa0;10.1186/s40425-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al. . Enterocolitis due to immune checkpoint inhibitors: A systematic review. Gut (2018) 67(11):2056&#x2013;67. doi:&#xa0;10.1136/gutjnl-2018-316948</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-316948</ArticleId>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, et al. . Immune checkpoint inhibitor-associated colitis: From mechanism to management. Front Immunol (2021) 12:800879. doi:&#xa0;10.3389/fimmu.2021.800879</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.800879</ArticleId>
            <ArticleId IdType="pmc">PMC8724248</ArticleId>
            <ArticleId IdType="pubmed">34992611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, Mccurdy JD. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: A systematic review and meta-analysis. J Immunother (2018) 41(3):101&#x2013;08. doi:&#xa0;10.1097/CJI.0000000000000213</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000213</ArticleId>
            <ArticleId IdType="pubmed">29401166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, Van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, et al. . Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management. ESMO Open (2018) 3(1):2017&#x2013;000278. doi:&#xa0;10.1136/esmoopen-2017-000278</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: A systematic literature review. Clin Ther (2017) 39(11):2216&#x2013;29. doi:&#xa0;10.1016/j.clinthera.2017.09.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2017.09.011</ArticleId>
            <ArticleId IdType="pubmed">29055500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S&#xf8;rup S, Darvalics B, Russo L, Oksen D, Lamy FX, Verpillat P, et al. . High-dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors&#x2013;a nationwide register-based cohort study. Cancer Med (2021) 10(14):4957&#x2013;63. doi:&#xa0;10.1002/cam4.4040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.4040</ArticleId>
            <ArticleId IdType="pmc">PMC8290247</ArticleId>
            <ArticleId IdType="pubmed">34105315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aldea M, Orillard E, Mansi L, Marabelle A, Scotte F, Lambotte O, et al. . How to manage patients with corticosteroids in oncology in the era of immunotherapy? Eur J Cancer (2020) 141:239&#x2013;51. doi:&#xa0;10.1016/j.ejca.2020.09.032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2020.09.032</ArticleId>
            <ArticleId IdType="pubmed">33212339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verheijden RJ, May AM, Blank CU, Aarts MJB, Van Den Berkmortel FWPJ, van den Eertwegh AJM, et al. . Association of anti-tnf with decreased survival in steroid refractory ipilimumab and anti-Pd1-Treated patients in the Dutch melanoma treatment registry. Clin Cancer Res (2020) 26(9):2268&#x2013;74. doi:&#xa0;10.1158/1078-0432.CCR-19-3322</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3322</ArticleId>
            <ArticleId IdType="pubmed">31988197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amoroso C, Perillo F, Strati F, Fantini MC, Caprioli F, Facciotti F, et al. . The role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation. Cells (2020) 9(5):1234. doi:&#xa0;10.3760/cma.j.cn112137-20200520-01598</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.cn112137-20200520-01598</ArticleId>
            <ArticleId IdType="pmc">PMC7291275</ArticleId>
            <ArticleId IdType="pubmed">32429359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agus A, Cl&#xe9;ment K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut (2021) 70(6):1174&#x2013;82. doi:&#xa0;10.1136/gutjnl-2020-323071</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2020-323071</ArticleId>
            <ArticleId IdType="pmc">PMC8108286</ArticleId>
            <ArticleId IdType="pubmed">33272977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi N, Li N, Duan X, Niu H. Interaction between the gut microbiome and mucosal immune system. Mil Med Res (2017) 4(14):017&#x2013;0122. doi:&#xa0;10.1186/s40779-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40779-9</ArticleId>
            <ArticleId IdType="pmc">PMC5408367</ArticleId>
            <ArticleId IdType="pubmed">28465831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. . A human gut microbial gene catalogue established by metagenomic sequencing. Nature (2010) 464(7285):59&#x2013;65. doi:&#xa0;10.1038/nature08821</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08821</ArticleId>
            <ArticleId IdType="pmc">PMC3779803</ArticleId>
            <ArticleId IdType="pubmed">20203603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miele L, Giorgio V, Alberelli MA, De Candia E, Gasbarrini A, Grieco A. Impact of gut microbiota on obesity, diabetes, and cardiovascular disease risk. Curr Cardiol Rep (2015) 17(12):015&#x2013;0671. doi:&#xa0;10.1007/s11886-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11886-z</ArticleId>
            <ArticleId IdType="pubmed">26497040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Cheng Y, Zang D, Zhang M, Li X, Liu D, et al. . The role of gut microbiota in lung cancer: From carcinogenesis to immunotherapy. Front Oncol (2021) 11:720842(720842). doi:&#xa0;10.3389/fonc.2021.720842</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2021.720842</ArticleId>
            <ArticleId IdType="pmc">PMC8417127</ArticleId>
            <ArticleId IdType="pubmed">34490119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Zhou H, Xu S, Liu D, Cheng Y, Gao B, et al. . The gut microbiome can be used to predict the gastrointestinal response and efficacy of lung cancer patients undergoing chemotherapy. Ann Palliat Med (2020) 9(6):4211&#x2013;27. doi:&#xa0;10.21037/apm-20-2183</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/apm-20-2183</ArticleId>
            <ArticleId IdType="pubmed">33302682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Liu D, Zhou H, Liu X, Li X, Cheng YE, et al. . Intestinal flora characteristics of advanced non-small cell lung cancer in China and their role in chemotherapy based on metagenomics: A prospective exploratory cohort study. Thorac Cancer (2021) 12(24):3293&#x2013;303. doi:&#xa0;10.1111/1759-7714.14199</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1759-7714.14199</ArticleId>
            <ArticleId IdType="pmc">PMC8671906</ArticleId>
            <ArticleId IdType="pubmed">34693651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, et al. . Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-Pd-1 immune checkpoint inhibitors. Eur Urol (2020) 78(4):498&#x2013;502. doi:&#xa0;10.1016/j.eururo.2020.07.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2020.07.011</ArticleId>
            <ArticleId IdType="pubmed">32828600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. . The commensal microbiome is associated with anti-Pd-1 efficacy in metastatic melanoma patients. Science (2018) 359(6371):104&#x2013;08. doi:&#xa0;10.1126/science.aao3290</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aao3290</ArticleId>
            <ArticleId IdType="pmc">PMC6707353</ArticleId>
            <ArticleId IdType="pubmed">29302014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. . Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science (2021) 371(6529):602&#x2013;09. doi:&#xa0;10.1126/science.abb5920</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abb5920</ArticleId>
            <ArticleId IdType="pubmed">33303685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. . Ctla-4 control over Foxp3+ regulatory T cell function. Science (2008) 322(5899):271&#x2013;5. doi:&#xa0;10.1126/science.1160062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1160062</ArticleId>
            <ArticleId IdType="pubmed">18845758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller PL, Carson TL. Mechanisms and microbial influences on ctla-4 and pd-1-Based immunotherapy in the treatment of cancer: A narrative review. Gut Pathog (2020) 12(43):020&#x2013;00381. doi:&#xa0;10.1186/s13099-020-00381-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13099-020-00381-6</ArticleId>
            <ArticleId IdType="pmc">PMC7488430</ArticleId>
            <ArticleId IdType="pubmed">32944086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. . Trans-endocytosis of Cd80 and Cd86: A molecular basis for the cell-extrinsic function of ctla-4. Science (2011) 332(6029):600&#x2013;3. doi:&#xa0;10.1126/science.1202947</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1202947</ArticleId>
            <ArticleId IdType="pmc">PMC3198051</ArticleId>
            <ArticleId IdType="pubmed">21474713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, et al. . A mini-review for cancer immunotherapy: Molecular understanding of pd-1/Pd-L1 pathway &amp; translational blockade of immune checkpoints. Int J Mol Sci (2016) 17(7):1151. doi:&#xa0;10.3390/ijms17071151</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17071151</ArticleId>
            <ArticleId IdType="pmc">PMC4964524</ArticleId>
            <ArticleId IdType="pubmed">27438833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V&#xe9;tizou M, Pitt JM, Daill&#xe8;re R, Lepage P, Waldschmitt N, Flament C, et al. . Anticancer immunotherapy by ctla-4 blockade relies on the gut microbiota. Science (2015) 350(6264):1079&#x2013;84. doi:&#xa0;10.1126/science.aad1329</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. . Gut microbiome modulates response to anti-Pd-1 immunotherapy in melanoma patients. Science (2018) 359(6371):97&#x2013;103. doi:&#xa0;10.1126/science.aan4236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan4236</ArticleId>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill&#xe8;re R, et al. . Gut microbiome influences efficacy of pd-1-Based immunotherapy against epithelial tumors. Science (2018) 359(6371):91&#x2013;7. doi:&#xa0;10.1126/science.aan3706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan3706</ArticleId>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. . Commensal bifidobacterium promotes antitumor immunity and facilitates anti-Pd-L1 efficacy. Science (2015) 350(6264):1084&#x2013;9. doi:&#xa0;10.1126/science.aac4255</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aac4255</ArticleId>
            <ArticleId IdType="pmc">PMC4873287</ArticleId>
            <ArticleId IdType="pubmed">26541606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, et al. . Immune checkpoint inhibitor-associated diarrhea and colitis: A systematic review and meta-analysis of observational studies. J Immunother (2021) 44(8):325&#x2013;34. doi:&#xa0;10.1097/CJI.0000000000000383</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000383</ArticleId>
            <ArticleId IdType="pubmed">34380976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch&#xe1;vez A, Keegan N, Khamashta MA, et al. . Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers (2020) 6(1):020&#x2013;0160. doi:&#xa0;10.1038/s41572-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-6</ArticleId>
            <ArticleId IdType="pubmed">32382051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A, et al. . Management of immune checkpoint inhibitor toxicities. Cancer Manag Res (2020) 12:9139&#x2013;58. doi:&#xa0;10.2147/CMAR.S218756</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S218756</ArticleId>
            <ArticleId IdType="pmc">PMC7533913</ArticleId>
            <ArticleId IdType="pubmed">33061607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, et al. . Clinical characterization of colitis arising from anti-Pd-1 based therapy. Oncoimmunology (2018) 8(1):1524695. doi:&#xa0;10.1080/2162402X.2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018</ArticleId>
            <ArticleId IdType="pmc">PMC6287774</ArticleId>
            <ArticleId IdType="pubmed">30546965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Gp S, Lamine F, Maillard M, Fraga M, et al. . Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol (2019) 16(9):563&#x2013;80. doi:&#xa0;10.1007/s00432-019-03002-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-019-03002-1</ArticleId>
            <ArticleId IdType="pubmed">31092901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, De Felice KM, Loftus EV, Jr., Khanna S. Systematic review: Colitis associated with anti-Ctla-4 therapy. Aliment Pharmacol Ther (2015) 42(4):406&#x2013;17. doi:&#xa0;10.1111/apt.13281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.13281</ArticleId>
            <ArticleId IdType="pubmed">26079306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced Diarrhea/Colitis: Endoscopic and pathologic findings. World J Gastrointest Pathophysiol (2019) 10(2):17&#x2013;28. doi:&#xa0;10.4291/wjgp.v10.i2.17</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4291/wjgp.v10.i2.17</ArticleId>
            <ArticleId IdType="pmc">PMC6751508</ArticleId>
            <ArticleId IdType="pubmed">31559106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, et al. . Alpha-Ctla-4 mab-associated panenteritis: A histologic and immunohistochemical analysis. Am J Surg Pathol (2008) 32(8):1130&#x2013;7. doi:&#xa0;10.1097/PAS.0b013e31817150e3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e31817150e3</ArticleId>
            <ArticleId IdType="pubmed">18545145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, et al. . Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med (2013) 11(75):1479&#x2013;5876. doi:&#xa0;10.1186/11-75</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/11-75</ArticleId>
            <ArticleId IdType="pmc">PMC3637501</ArticleId>
            <ArticleId IdType="pubmed">23521917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saez A, Gomez-Bris R, Herrero-Fernandez B, Mingorance C, Rius C, Gonzalez-Granado JM. Innate lymphoid cells in intestinal homeostasis and inflammatory bowel disease. Int J Mol Sci (2021) 22(14):7618. doi:&#xa0;10.3390/ijms22147618</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22147618</ArticleId>
            <ArticleId IdType="pmc">PMC8307624</ArticleId>
            <ArticleId IdType="pubmed">34299236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Zheng N, Luo Q, Jiang L, He B, Yuan X, et al. . Probiotics lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells. Front Immunol (2019) 10:1235(1235). doi:&#xa0;10.3389/fimmu.2019.01235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01235</ArticleId>
            <ArticleId IdType="pmc">PMC6558076</ArticleId>
            <ArticleId IdType="pubmed">31214189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasson SC, Zaunders JJ, Nahar K, Munier CML, Fairfax BP, Olsson-Brown A, et al. . Mucosal-associated invariant T (Mait) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. Clin Exp Immunol (2020) 202(3):335&#x2013;52. doi:&#xa0;10.1111/cei.13502</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.13502</ArticleId>
            <ArticleId IdType="pmc">PMC7670140</ArticleId>
            <ArticleId IdType="pubmed">32734627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. . Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell (2020) 182(3):655&#x2013;71. doi:&#xa0;10.1016/j.cell.2020.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.06.001</ArticleId>
            <ArticleId IdType="pmc">PMC7415717</ArticleId>
            <ArticleId IdType="pubmed">32603654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao G, Wang X, Wang J, Zu L, Cheng G, Hao M, et al. . Cxcl16/Cxcr6 chemokine signaling mediates breast cancer progression by Perk1/2-dependent mechanisms. Oncotarget (2015) 6(16):14165&#x2013;78. doi:&#xa0;10.18632/oncotarget.3690</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.3690</ArticleId>
            <ArticleId IdType="pmc">PMC4546458</ArticleId>
            <ArticleId IdType="pubmed">25909173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chami B, Yeung AW, Van Vreden C, King NJ, Bao S. The role of Cxcr3 in dss-induced colitis. PloS One (2014) 9(7):e101622. doi:&#xa0;10.1371/journal.pone.0101622</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0101622</ArticleId>
            <ArticleId IdType="pmc">PMC4081590</ArticleId>
            <ArticleId IdType="pubmed">24992040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, et al. . Colon immune-related adverse events: Anti-Ctla-4 and anti-Pd-1 blockade induce distinct immunopathological entities. J Crohns Colitis (2017) 11(10):1238&#x2013;46. doi:&#xa0;10.1093/ecco-jcc/jjx081</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjx081</ArticleId>
            <ArticleId IdType="pubmed">28967957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hone Lopez S, Kats-Ugurlu G, Renken RJ, Buikema HJ, de Groot MR, Visschedijk MC, et al. . Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of Cd8 + T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Arch (2021) 479(6):1119&#x2013;29. doi:&#xa0;10.1007/s00428-021-03170-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-021-03170-x</ArticleId>
            <ArticleId IdType="pmc">PMC8724151</ArticleId>
            <ArticleId IdType="pubmed">34338882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasson SC, Slevin SM, Cheung VTF, Nassiri I, Olsson-Brown A, Fryer E, et al. . Interferon-Gamma-Producing Cd8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology (2021) 161(4):1229&#x2013;44. doi:&#xa0;10.1053/j.gastro.2021.06.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2021.06.025</ArticleId>
            <ArticleId IdType="pmc">PMC8527886</ArticleId>
            <ArticleId IdType="pubmed">34147519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson-Lindbom B, Agace WW. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev (2007) 215:226&#x2013;42. doi:&#xa0;10.1111/j.1600-065X.2006.00482.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065X.2006.00482.x</ArticleId>
            <ArticleId IdType="pubmed">17291292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, et al. . Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: A multi-center study. J Immunother Cancer (2018) 6(1):018&#x2013;0461. doi:&#xa0;10.1186/s40425-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-4</ArticleId>
            <ArticleId IdType="pmc">PMC6280383</ArticleId>
            <ArticleId IdType="pubmed">30518410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, et al. . Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U.S.A. (2015) 112(19):6140&#x2013;5. doi:&#xa0;10.1073/pnas.1417320112</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1417320112</ArticleId>
            <ArticleId IdType="pmc">PMC4434760</ArticleId>
            <ArticleId IdType="pubmed">25918390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. . Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol (2017) 28(6):1368&#x2013;79. doi:&#xa0;10.1093/annonc/mdx108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx108</ArticleId>
            <ArticleId IdType="pubmed">28368458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK. A whole-blood rna transcript-based gene signature is associated with the development of ctla-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. J Immunother Cancer (2018) 6(1):018&#x2013;0408. doi:&#xa0;10.1186/s40425-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-9</ArticleId>
            <ArticleId IdType="pmc">PMC6145108</ArticleId>
            <ArticleId IdType="pubmed">30227886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nardinocchi L, Sonego G, Passarelli F, Avitabile S, Scarponi C, Failla CM, et al. . Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol (2015) 45(3):922&#x2013;31. doi:&#xa0;10.1002/eji.201445052</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201445052</ArticleId>
            <ArticleId IdType="pubmed">25487261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. . Baseline circulating il-17 predicts toxicity while tgf-B1 and il-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer (2015) 3(39):015&#x2013;0081. doi:&#xa0;10.1186/s40425-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-1</ArticleId>
            <ArticleId IdType="pmc">PMC4570556</ArticleId>
            <ArticleId IdType="pubmed">26380086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. . Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity (2011) 34(4):566&#x2013;78. doi:&#xa0;10.1016/j.immuni.2011.03.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2011.03.018</ArticleId>
            <ArticleId IdType="pmc">PMC3088485</ArticleId>
            <ArticleId IdType="pubmed">21511185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaschitz C, Raffatellu M. Th17 cytokines and the gut mucosal barrier. J Clin Immunol (2010) 30(2):196&#x2013;203. doi:&#xa0;10.1007/s10875-010-9368-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-010-9368-7</ArticleId>
            <ArticleId IdType="pmc">PMC2842875</ArticleId>
            <ArticleId IdType="pubmed">20127275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffin GK, Newton G, Tarrio ML, Bu DX, Maganto-Garcia E, Azcutia V, et al. . Il-17 and tnf-A sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol (2012) 188(12):6287&#x2013;99. doi:&#xa0;10.4049/jimmunol.1200385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1200385</ArticleId>
            <ArticleId IdType="pmc">PMC3370121</ArticleId>
            <ArticleId IdType="pubmed">22566565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metzemaekers M, Vandendriessche S, Berghmans N, Gouwy M, Proost P. Truncation of Cxcl8 to Cxcl8(9-77) enhances actin polymerization and in vivo migration of neutrophils. J Leukoc Biol (2020) 107(6):1167&#x2013;73. doi:&#xa0;10.1002/JLB.3AB0220-470R</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/JLB.3AB0220-470R</ArticleId>
            <ArticleId IdType="pubmed">32272490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veldhoen M. Interleukin 17 is a Chief orchestrator of immunity. Nat Immunol (2017) 18(6):612&#x2013;21. doi:&#xa0;10.1038/ni.3742</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3742</ArticleId>
            <ArticleId IdType="pubmed">28518156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. . Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-Blockade-Induced colitis. Nat Commun (2016) 7:10391. doi:&#xa0;10.1038/ncomms10391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10391</ArticleId>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usyk M, Pandey A, Hayes RB, Moran U, Pavlick A, Osman I, et al. . Bacteroides vulgatus and bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma. Genome Med (2021) 13(1):021&#x2013;00974. doi:&#xa0;10.1186/s13073-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13073-z</ArticleId>
            <ArticleId IdType="pmc">PMC8513370</ArticleId>
            <ArticleId IdType="pubmed">34641962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hakozaki T, Richard C, Elkrief A, Hosomi Y, Benla&#xef;faoui M, Mimpen I, et al. . The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer. Cancer Immunol Res (2020) 8(10):1243&#x2013;50. doi:&#xa0;10.1158/2326-6066.CIR-20-0196</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-20-0196</ArticleId>
            <ArticleId IdType="pubmed">32847937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao J, Wang D, Long J, Yang X, Lin J, Song Y, et al. . Gut microbiome is associated with the clinical response to anti-Pd-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer (2021) 9(12):2021&#x2013;003334. doi:&#xa0;10.1136/jitc</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc</ArticleId>
            <ArticleId IdType="pmc">PMC8650503</ArticleId>
            <ArticleId IdType="pubmed">34873013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, et al. . Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer (2021) 21(1):021&#x2013;08530. doi:&#xa0;10.1186/s12885-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-z</ArticleId>
            <ArticleId IdType="pmc">PMC8278634</ArticleId>
            <ArticleId IdType="pubmed">34256732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakurai T, De Velasco MA, Sakai K, Nagai T, Nishiyama H, Hashimoto K, et al. . Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. Mol Oncol (2022) 16(7):1493&#x2013;507. doi:&#xa0;10.1002/1878-0261.13062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.13062</ArticleId>
            <ArticleId IdType="pmc">PMC8978521</ArticleId>
            <ArticleId IdType="pubmed">34270845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can mitigate intestinal immunopathology in the context of ctla-4 blockade. Proc Natl Acad Sci U.S.A. (2018) 115(1):157&#x2013;61. doi:&#xa0;10.1073/pnas</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas</ArticleId>
            <ArticleId IdType="pmc">PMC5776803</ArticleId>
            <ArticleId IdType="pubmed">29255057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, et al. . Gut microbiota signatures are associated with toxicity to combined ctla-4 and PD-1 blockade. Nat Med (2021) 27(8):1432&#x2013;41. doi:&#xa0;10.1038/s41591-021-01406-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01406-6</ArticleId>
            <ArticleId IdType="pubmed">34239137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L. C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol (2019) 145(10):2625&#x2013;31. doi:&#xa0;10.1007/s00432-019-03002-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-019-03002-1</ArticleId>
            <ArticleId IdType="pubmed">31492984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S, et al. . Higher serum c-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin Genitourin Cancer (2018) 16(6):e1151&#x2013;e58. doi:&#xa0;10.1016/j.clgc.2018.07.027</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clgc.2018.07.027</ArticleId>
            <ArticleId IdType="pubmed">30213543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, et al. . Vitamin d intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer (2020) 126(16):3758&#x2013;67. doi:&#xa0;10.1002/cncr.32966</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.32966</ArticleId>
            <ArticleId IdType="pmc">PMC7381363</ArticleId>
            <ArticleId IdType="pubmed">32567084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletcher J, Cooper SC, Ghosh S, Hewison M. The role of vitamin d in inflammatory bowel disease: Mechanism to management. Nutrients (2019) 11(5):1019. doi:&#xa0;10.3390/nu11051019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu11051019</ArticleId>
            <ArticleId IdType="pmc">PMC6566188</ArticleId>
            <ArticleId IdType="pubmed">31067701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, et al. . Soluble ctla-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study. Cancer Immunol Immunother (2019) 68(1):97&#x2013;107. doi:&#xa0;10.1007/s00262-018-2258-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2258-1</ArticleId>
            <ArticleId IdType="pubmed">30311027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasan Ali O, Berner F, Bomze D, F&#xe4;ssler M, Diem S, Cozzio A, et al. . Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer (2019) 107:8&#x2013;14. doi:&#xa0;10.1016/j.ejca.2018.11.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.11.009</ArticleId>
            <ArticleId IdType="pubmed">30529903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S, Luo L, Liang W, Yin Q, Guo J, Rush AM, et al. . Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proc Natl Acad Sci U.S.A. (2020) 117(44):27509&#x2013;15. doi:&#xa0;10.1073/pnas.1921223117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1921223117</ArticleId>
            <ArticleId IdType="pmc">PMC7959554</ArticleId>
            <ArticleId IdType="pubmed">33077598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan L, Qi Y, Qu S, Chen X, Li A, Hendi M, et al. . B. adolescentis ameliorates chronic colitis by regulating Treg/Th2 response and gut microbiota remodeling. Gut Microbes (2021) 13(1):1&#x2013;17. doi:&#xa0;10.1080/19490976.2020.1826746</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2020.1826746</ArticleId>
            <ArticleId IdType="pmc">PMC7889144</ArticleId>
            <ArticleId IdType="pubmed">33557671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhn KA, Schulz HM, Regner EH, Severs EL, Hendrickson JD, Mehta G, et al. . Bacteroidales recruit il-6-Producing intraepithelial lymphocytes in the colon to promote barrier integrity. Mucosal Immunol (2018) 11(2):357&#x2013;68. doi:&#xa0;10.1038/mi.2017.55</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2017.55</ArticleId>
            <ArticleId IdType="pmc">PMC5815964</ArticleId>
            <ArticleId IdType="pubmed">28812548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wegorzewska MM, Glowacki RWP, Hsieh SA, Donermeyer DL, Hickey CA, Horvath SC, et al. . Diet modulates colonic T cell responses by regulating the expression of a bacteroides thetaiotaomicron antigen. Sci Immunol (2019) 4(32):eaau9079. doi:&#xa0;10.1126/sciimmunol.aau9079</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.aau9079</ArticleId>
            <ArticleId IdType="pmc">PMC6550999</ArticleId>
            <ArticleId IdType="pubmed">30737355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K, Hao Z, Du J, Gao Y, Yang S, Zhou Y. Bacteroides thetaiotaomicron relieves colon inflammation by activating aryl hydrocarbon receptor and modulating Cd4 + T cell homeostasis. Int Immunopharmacol (2021) 90:107183. doi:&#xa0;10.1016/j.intimp.2020.107183</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2020.107183</ArticleId>
            <ArticleId IdType="pubmed">33229197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U.S.A. (2010) 107(27):12204&#x2013;9. doi:&#xa0;10.1073/pnas.0909122107</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0909122107</ArticleId>
            <ArticleId IdType="pmc">PMC2901479</ArticleId>
            <ArticleId IdType="pubmed">20566854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiu CC, Ching YH, Wang YC, Liu JY, Li YP, Huang YT, et al. . Monocolonization of germ-free mice with bacteroides fragilis protects against dextran sulfate sodium-induced acute colitis. BioMed Res Int (2014) 675786(10):29. doi:&#xa0;10.1155/2014/675786</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/675786</ArticleId>
            <ArticleId IdType="pmc">PMC4058166</ArticleId>
            <ArticleId IdType="pubmed">24971344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Troy EB, Kasper DL. Beneficial effects of bacteroides fragilis polysaccharides on the immune system. Front Biosci (2010) 15(1):25&#x2013;34. doi:&#xa0;10.2741/3603</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2741/3603</ArticleId>
            <ArticleId IdType="pmc">PMC2995369</ArticleId>
            <ArticleId IdType="pubmed">20036803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, Reinecker HC, Kasper DL. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule Via both innate and adaptive mechanisms. Cell Host Microbe (2014) 15(4):413&#x2013;23. doi:&#xa0;10.1016/j.chom.2014.03.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2014.03.006</ArticleId>
            <ArticleId IdType="pmc">PMC4020153</ArticleId>
            <ArticleId IdType="pubmed">24721570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuffaro B, Assohoun ALW, Boutillier D, S&#xfa;ken&#xed;kov&#xe1; L, Desramaut J, Boudebbouze S, et al. . In vitro characterization of gut microbiota-derived commensal strains: Selection of parabacteroides distasonis strains alleviating tnbs-induced colitis in mice. Cells (2020) 9(9):2104. doi:&#xa0;10.3390/cells9092104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9092104</ArticleId>
            <ArticleId IdType="pmc">PMC7565435</ArticleId>
            <ArticleId IdType="pubmed">32947881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan JL, Wu S, Geis AL, Chan GV, Gomes TAM, Beck SE, et al. . Non-toxigenic bacteroides fragilis (Ntbf) administration reduces bacteria-driven chronic colitis and tumor development independent of polysaccharide a. Mucosal Immunol (2019) 12(1):164&#x2013;77. doi:&#xa0;10.1038/s41385-018-0085-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41385-018-0085-5</ArticleId>
            <ArticleId IdType="pmc">PMC6510666</ArticleId>
            <ArticleId IdType="pubmed">30279518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, et al. . Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome (2020) 8(1):020&#x2013;00811. doi:&#xa0;10.1186/s40168-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40168-2</ArticleId>
            <ArticleId IdType="pmc">PMC7059390</ArticleId>
            <ArticleId IdType="pubmed">32138779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Tang J, Cai Z, Zhou K, Chang L, Bai Y, et al. . Prevotella induces the production of Th17 cells in the colon of mice. J Immunol Res (2020) 1:9607328. doi:&#xa0;10.1155/2020/9607328</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/9607328</ArticleId>
            <ArticleId IdType="pmc">PMC7657696</ArticleId>
            <ArticleId IdType="pubmed">33204736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kehrmann J, Effenberg L, Wilk C, Schoemer D, Ngo Thi Phuong N, Adamczyk A, et al. . Depletion of Foxp3 + regulatory T cells is accompanied by an increase in the relative abundance of firmicutes in the murine gut microbiome. Immunology (2020) 159(3):344&#x2013;53. doi:&#xa0;10.1111/imm.13158</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imm.13158</ArticleId>
            <ArticleId IdType="pmc">PMC7011623</ArticleId>
            <ArticleId IdType="pubmed">31755554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang SL, Han B, Mao YQ, Zhang ZY, Li ZM, Kong CY, et al. . Lacticaseibacillus paracasei Sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes (2022) 14(1):2046246. doi:&#xa0;10.1080/19490976.2022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2022</ArticleId>
            <ArticleId IdType="pmc">PMC8920197</ArticleId>
            <ArticleId IdType="pubmed">35259052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan B, Tang H, Xu Y, Chen MJ, Wang MZ, Qian JM. Protective effect and mechanism of lactobacillus rhamnosus on immune checkpoint inhibitors related colitis in mice. Zhonghua Yi Xue Za Zhi (2020) 100(42):3332&#x2013;37. doi:&#xa0;10.3760/cma.j.cn112137-20200520-01598</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.cn112137-20200520-01598</ArticleId>
            <ArticleId IdType="pubmed">33202497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han SK, Shin YJ, Lee DY, Kim KM, Yang SJ, Kim DS, et al. . Lactobacillus rhamnosus Hdb1258 modulates gut microbiota-mediated immune response in mice with or without lipopolysaccharide-induced systemic inflammation. BMC Microbiol (2021) 21(1):021&#x2013;02192. doi:&#xa0;10.1186/s12866-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12866-4</ArticleId>
            <ArticleId IdType="pmc">PMC8120827</ArticleId>
            <ArticleId IdType="pubmed">33985438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mann ER, Bernardo D, Ng SC, Rigby RJ, Al-Hassi HO, Landy J, et al. . Human gut dendritic cells drive aberrant gut-specific T-cell responses in ulcerative colitis, characterized by increased il-4 production and loss of il-22 and ifn&#x3b3;. Inflammation Bowel Dis (2014) 20(12):2299&#x2013;307. doi:&#xa0;10.1097/MIB.0000000000000223</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000000223</ArticleId>
            <ArticleId IdType="pubmed">25397892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Gu Y, Fang K, Mao K, Dou J, Fan H, et al. . Lactobacillus acidophilus and clostridium butyricum ameliorate colitis in murine by strengthening the gut barrier function and decreasing inflammatory factors. Benef Microbes (2018) 9(5):775&#x2013;87. doi:&#xa0;10.3920/BM2017.0035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3920/BM2017.0035</ArticleId>
            <ArticleId IdType="pubmed">30014710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang YJ, Kim WK, Han DH, Lee K, Ko G. Lactobacillus fermentum species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota. Gut Microbes (2019) 10(6):696&#x2013;711. doi:&#xa0;10.1080/19490976.2019.1589281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2019.1589281</ArticleId>
            <ArticleId IdType="pmc">PMC6866707</ArticleId>
            <ArticleId IdType="pubmed">30939976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JS, Choi JW, Jhun J, Kwon JY, Lee BI, Yang CW, et al. . Lactobacillus acidophilus improves intestinal inflammation in an acute colitis mouse model by regulation of Th17 and treg cell balance and fibrosis development. J Med Food (2018) 21(3):215&#x2013;24. doi:&#xa0;10.1089/jmf.2017.3990</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jmf.2017.3990</ArticleId>
            <ArticleId IdType="pubmed">29336663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mcculloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, et al. . Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-Pd-1. Nat Med (2022) 28(3):545&#x2013;56. doi:&#xa0;10.1038/s41591-022-01698-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-022-01698-2</ArticleId>
            <ArticleId IdType="pubmed">35228752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma QY, Huang DY, Zhang HJ, Wang S, Chen XF. Upregulation of bacterial-specific Th1 and Th17 responses that are enriched in Cxcr5 + Cd4 + T cells in non-small cell lung cancer. Int Immunopharmacol (2017) 52:305&#x2013;09. doi:&#xa0;10.1016/j.intimp.2017.09.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2017.09.024</ArticleId>
            <ArticleId IdType="pubmed">28982050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen X, Wang HG, Zhang MN, Zhang MH, Wang H, Yang XZ. Fecal microbiota transplantation ameliorates experimental colitis Via gut microbiota and T-cell modulation. World J Gastroenterol (2021) 27(21):2834&#x2013;49. doi:&#xa0;10.3748/wjg.v27.i21.2834</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v27.i21.2834</ArticleId>
            <ArticleId IdType="pmc">PMC8173381</ArticleId>
            <ArticleId IdType="pubmed">34135557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, et al. . A defined commensal consortium elicits Cd8 T cells and anti-cancer immunity. Nature (2019) 565(7741):600&#x2013;05. doi:&#xa0;10.1038/s41586-019-0878-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-0878-z</ArticleId>
            <ArticleId IdType="pubmed">30675064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ioannidis M, Cerundolo V, Salio M. The immune modulating properties of mucosal-associated invariant T cells. Front Immunol (2020) 11:1556. doi:&#xa0;10.3389/fimmu.2020.01556</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01556</ArticleId>
            <ArticleId IdType="pmc">PMC7438542</ArticleId>
            <ArticleId IdType="pubmed">32903532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maifeld A, Bartolomaeus H, L&#xf6;ber U, Avery EG, Steckhan N, Mark&#xf3; L, et al. . Fasting alters the gut microbiome reducing blood pressure and body weight in metabolic syndrome patients. Nat Commun (2021) 12(1):021&#x2013;22097. doi:&#xa0;10.1038/s41467-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-0</ArticleId>
            <ArticleId IdType="pmc">PMC8010079</ArticleId>
            <ArticleId IdType="pubmed">33785752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, et al. . A purified membrane protein from akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of Cd8 + T cells in mice. Gut (2020) 69(11):1988&#x2013;97. doi:&#xa0;10.1136/gutjnl-2019-320105</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2019-320105</ArticleId>
            <ArticleId IdType="pmc">PMC7569398</ArticleId>
            <ArticleId IdType="pubmed">32169907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong JM, De Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: Fermentation and short chain fatty acids. J Clin Gastroenterol (2006) 40(3):235&#x2013;43. doi:&#xa0;10.1097/00004836-200603000-00015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004836-200603000-00015</ArticleId>
            <ArticleId IdType="pubmed">16633129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahlstr&#xf6;m A, Sayin SI, Marschall HU, B&#xe4;ckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab (2016) 24(1):41&#x2013;50. doi:&#xa0;10.1016/j.cmet.2016.05.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2016.05.005</ArticleId>
            <ArticleId IdType="pubmed">27320064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun (2018) 9(1):018&#x2013;05470. doi:&#xa0;10.1038/s41467-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-4</ArticleId>
            <ArticleId IdType="pmc">PMC6098093</ArticleId>
            <ArticleId IdType="pubmed">30120222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. . The microbial metabolites, short-chain fatty acids, regulate colonic treg cell homeostasis. Science (2013) 341(6145):569&#x2013;73. doi:&#xa0;10.1126/science.1241165</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1241165</ArticleId>
            <ArticleId IdType="pmc">PMC3807819</ArticleId>
            <ArticleId IdType="pubmed">23828891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function Via histone deacetylase inhibition. Proc Natl Acad Sci U.S.A. (2014) 111(6):2247&#x2013;52. doi:&#xa0;10.1073/pnas.1322269111</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1322269111</ArticleId>
            <ArticleId IdType="pmc">PMC3926023</ArticleId>
            <ArticleId IdType="pubmed">24390544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. . Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity (2014) 40(1):128&#x2013;39. doi:&#xa0;10.1016/j.immuni.2013.12.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.12.007</ArticleId>
            <ArticleId IdType="pmc">PMC4305274</ArticleId>
            <ArticleId IdType="pubmed">24412617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. . Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature (2013) 504(7480):446&#x2013;50. doi:&#xa0;10.1038/nature12721</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12721</ArticleId>
            <ArticleId IdType="pubmed">24226770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Zhou Q, Dorfman RG, Huang X, Fan T, Zhang H, et al. . Butyrate inhibits interleukin-17 and generates tregs to ameliorate colorectal colitis in rats. BMC Gastroenterol (2016) 16(1):016&#x2013;0500. doi:&#xa0;10.1186/s12876-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12876-x</ArticleId>
            <ArticleId IdType="pmc">PMC4967301</ArticleId>
            <ArticleId IdType="pubmed">27473867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Yu T, Huang X, Bilotta AJ, Xu L, Lu Y, et al. . Intestinal microbiota-derived short-chain fatty acids regulation of immune cell il-22 production and gut immunity. Nat Commun (2020) 11(1):020&#x2013;18262. doi:&#xa0;10.1038/s41467-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-6</ArticleId>
            <ArticleId IdType="pmc">PMC7478978</ArticleId>
            <ArticleId IdType="pubmed">32901017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. . Regulation of inflammatory responses by gut microbiota and chemoattractant receptor Gpr43. Nature (2009) 461(7268):1282&#x2013;6. doi:&#xa0;10.1038/nature08530</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08530</ArticleId>
            <ArticleId IdType="pmc">PMC3256734</ArticleId>
            <ArticleId IdType="pubmed">19865172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun M, Wu W, Chen L, Yang W, Huang X, Ma C, et al. . Microbiota-derived short-chain fatty acids promote Th1 cell il-10 production to maintain intestinal homeostasis. Nat Commun (2018) 9(1):018&#x2013;05901. doi:&#xa0;10.1038/s41467-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-2</ArticleId>
            <ArticleId IdType="pmc">PMC6120873</ArticleId>
            <ArticleId IdType="pubmed">30177845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupraz L, Magniez A, Rolhion N, Richard ML, Da Costa G, Touch S, et al. . Gut microbiota-derived short-chain fatty acids regulate il-17 production by mouse and human intestinal &#x393;&#x3b4; T cells. Cell Rep (2021) 36(1):109332. doi:&#xa0;10.1016/j.celrep.2021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021</ArticleId>
            <ArticleId IdType="pubmed">34233192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nastasi C, Candela M, Bonefeld CM, Geisler C, Hansen M, Krejsgaard T, et al. . The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci Rep (2015) 5:16148. doi:&#xa0;10.1038/srep16148</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep16148</ArticleId>
            <ArticleId IdType="pmc">PMC4635422</ArticleId>
            <ArticleId IdType="pubmed">26541096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorrentino G, Perino A, Yildiz E, El Alam G, Bou Sleiman M, Gioiello A, et al. . Bile acids signal Via Tgr5 to activate intestinal stem cells and epithelial regeneration. Gastroenterology (2020) 159(3):956&#x2013;68. doi:&#xa0;10.1053/j.gastro.2020.05.067</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.05.067</ArticleId>
            <ArticleId IdType="pubmed">32485177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paik D, Yao L, Zhang Y, Bae S, D&#x2019;Agostino GD, Zhang M, et al. . Human gut bacteria produce T(H)17-modulating bile acid metabolites. Nature (2022) 603(7903):907&#x2013;12. doi:&#xa0;10.1038/s41586-022-04480-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-022-04480-z</ArticleId>
            <ArticleId IdType="pmc">PMC9132548</ArticleId>
            <ArticleId IdType="pubmed">35296854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell C, Mckenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, et al. . Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature (2020) 581(7809):475&#x2013;79. doi:&#xa0;10.1038/s41586-020-2193-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2193-0</ArticleId>
            <ArticleId IdType="pmc">PMC7540721</ArticleId>
            <ArticleId IdType="pubmed">32461639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jennis M, Cavanaugh CR, Leo GC, Mabus JR, Lenhard J, Hornby PJ, et al. . Microbiota-derived tryptophan indoles increase after gastric bypass surgery and reduce intestinal permeability in vitro and in vivo. Neurogastroenterol Motil (2018) 30(2):e13178. doi:&#xa0;10.1111/nmo.13178</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nmo.13178</ArticleId>
            <ArticleId IdType="pubmed">28782205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Zhu S, Ma N, Johnston LJ, Wu C, Ma X. Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammationophan and intestinal mucosal immunity. Med Res Rev (2021) 41(2):1061&#x2013;88. doi:&#xa0;10.1002/med.21752</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/med.21752</ArticleId>
            <ArticleId IdType="pubmed">33174230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function Via the aryl hydrocarbon receptor. Proc Natl Acad Sci U.S.A. (2020) 117(32):19376&#x2013;87. doi:&#xa0;10.1073/pnas.2000047117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2000047117</ArticleId>
            <ArticleId IdType="pmc">PMC7431026</ArticleId>
            <ArticleId IdType="pubmed">32719140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ihekweazu FD, Engevik MA, Ruan W, Shi Z, Fultz R, Engevik KA, et al. . Bacteroides ovatus promotes il-22 production and reduces trinitrobenzene sulfonic acid-driven colonic inflammation. Am J Pathol (2021) 191(4):704&#x2013;19. doi:&#xa0;10.1016/j.ajpath.2021.01.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2021.01.009</ArticleId>
            <ArticleId IdType="pmc">PMC8027925</ArticleId>
            <ArticleId IdType="pubmed">33516788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busbee PB, Menzel L, Alrafas HR, Dopkins N, Becker W, Miranda K, et al. . Indole-3-Carbinol prevents colitis and associated microbial dysbiosis in an il-22-Dependent manner. JCI Insight (2020) 5(1):127551. doi:&#xa0;10.1172/jci.insight</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight</ArticleId>
            <ArticleId IdType="pmc">PMC7030851</ArticleId>
            <ArticleId IdType="pubmed">31941837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powell DN, Swimm A, Sonowal R, Bretin A, Gewirtz AT, Jones RM, et al. . Indoles from the commensal microbiota act Via the ahr and il-10 to tune the cellular composition of the colonic epithelium during aging. Proc Natl Acad Sci U.S.A. (2020) 117(35):21519&#x2013;26. doi:&#xa0;10.1073/pnas.2003004117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2003004117</ArticleId>
            <ArticleId IdType="pmc">PMC7474656</ArticleId>
            <ArticleId IdType="pubmed">32817517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishnan S, Ding Y, Saedi N, Choi M, Sridharan GV, Sherr DH, et al. . Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. Cell Rep (2018) 23(4):1099&#x2013;111. doi:&#xa0;10.1016/j.celrep.2018.03.109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.03.109</ArticleId>
            <ArticleId IdType="pmc">PMC6392449</ArticleId>
            <ArticleId IdType="pubmed">29694888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, et al. . Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy and toxicity in patients with. J Natl Cancer Inst (2021) 113(2):162&#x2013;70. doi:&#xa0;10.1093/jnci/djaa057</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djaa057</ArticleId>
            <ArticleId IdType="pmc">PMC7850522</ArticleId>
            <ArticleId IdType="pubmed">32294209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al. . Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer (2019) 7(1):019&#x2013;0714. doi:&#xa0;10.1186/s40425-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-x</ArticleId>
            <ArticleId IdType="pmc">PMC6729015</ArticleId>
            <ArticleId IdType="pubmed">31488205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanna S, Vazquez-Baeza Y, Gonz&#xe1;lez A, Weiss S, Schmidt B, Mu&#xf1;iz-Pedrogo DA, et al. . Changes in microbial ecology after fecal microbiota transplantation for recurrent c. difficile infection affected by underlying inflammatory bowel disease. Microbiome (2017) 5(1):017&#x2013;0269. doi:&#xa0;10.1186/s40168-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40168-3</ArticleId>
            <ArticleId IdType="pmc">PMC5433077</ArticleId>
            <ArticleId IdType="pubmed">28506317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasanello MK, Robillard KT, Boland PM, Bain AJ, Kanehira K. Use of fecal microbial transplantation for immune checkpoint inhibitor colitis. ACG Case Rep J (2020) 7(4):0000000000000360. doi:&#xa0;10.14309/crj</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/crj</ArticleId>
            <ArticleId IdType="pmc">PMC7224717</ArticleId>
            <ArticleId IdType="pubmed">32548190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. . Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med (2018) 24(12):1804&#x2013;08. doi:&#xa0;10.1038/s41591-018-0238-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0238-9</ArticleId>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunkara T, Rawla P, Ofosu A, Gaduputi V. Fecal microbiota transplant - a new frontier in inflammatory bowel disease. J Inflammation Res (2018) 11:321&#x2013;28. doi:&#xa0;10.2147/JIR.S176190</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JIR.S176190</ArticleId>
            <ArticleId IdType="pmc">PMC6124474</ArticleId>
            <ArticleId IdType="pubmed">30214266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Le Leu RK, Christophersen CT, Somashekar R, Conlon MA, Meng XQ, et al. . Manipulation of the gut microbiota using resistant starch is associated with protection against colitis-associated colorectal cancer in rats. Carcinogenesis (2016) 37(4):366&#x2013;75. doi:&#xa0;10.1093/carcin/bgw019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgw019</ArticleId>
            <ArticleId IdType="pubmed">26905582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grabinger T, Glaus Garzon JF, Hausmann M, Geirnaert A, Lacroix C, Hennet T. Alleviation of intestinal inflammation by oral supplementation with 2-fucosyllactose in mice. Front Microbiol (2019) 10:1385. doi:&#xa0;10.3389/fmicb.2019.01385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2019.01385</ArticleId>
            <ArticleId IdType="pmc">PMC6593069</ArticleId>
            <ArticleId IdType="pubmed">31275292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Cheng X, Bai L, Gao M, Kang G, Cao X, et al. . Positive interventional effect of engineered butyrate-producing bacteria on metabolic disorders and intestinal flora disruption in obese mice. Microbiol Spectr (2022) 10(2):01147&#x2013;21. doi:&#xa0;10.1128/spectrum</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/spectrum</ArticleId>
            <ArticleId IdType="pmc">PMC9045090</ArticleId>
            <ArticleId IdType="pubmed">35293806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan X, Liu XY, Zhang D, Zhang YD, Li ZH, Liu X, et al. . Construction of a sustainable 3-Hydroxybutyrate-Producing probiotic escherichia coli for treatment of colitis. Cell Mol Immunol (2021) 18(10):2344&#x2013;57. doi:&#xa0;10.1038/s41423-021-00760-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41423-021-00760-2</ArticleId>
            <ArticleId IdType="pmc">PMC8484604</ArticleId>
            <ArticleId IdType="pubmed">34480146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Liao Y, Yang R, Zhu Z, Zhang L, Wu Z, et al. . An engineered probiotic secreting Sj16 ameliorates colitis Via Ruminococcaceae/Butyrate/Retinoic acid axis. Bioeng Transl Med (2021) 6(3):e10219. doi:&#xa0;10.1002/btm2.10219</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/btm2.10219</ArticleId>
            <ArticleId IdType="pmc">PMC8459592</ArticleId>
            <ArticleId IdType="pubmed">34589596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui M, Pang G, Zhang T, Sun T, Zhang L, Kang R, et al. . Optotheranostic nanosystem with phone visual diagnosis and optogenetic microbial therapy for ulcerative colitis at-home care. ACS Nano (2021) 15(4):7040&#x2013;52. doi:&#xa0;10.1021/acsnano.1c00135</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.1c00135</ArticleId>
            <ArticleId IdType="pubmed">33819424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Praveschotinunt P, Duraj-Thatte AM, Gelfat I, Bahl F, Chou DB, Joshi NS, et al. . Engineered e. coli nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut. Nat Commun (2019) 10(1):019&#x2013;13336. doi:&#xa0;10.1038/s41467-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-6</ArticleId>
            <ArticleId IdType="pmc">PMC6898321</ArticleId>
            <ArticleId IdType="pubmed">31811125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E. Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist (2020) 25(4):e679&#x2013;e83. doi:&#xa0;10.1634/theoncologist.2019-0299</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2019-0299</ArticleId>
            <ArticleId IdType="pmc">PMC7160399</ArticleId>
            <ArticleId IdType="pubmed">32297443</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">36159840</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>09</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.</ArticleTitle>
        <Pagination>
          <StartPage>987568</StartPage>
          <MedlinePgn>987568</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">987568</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.987568</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune checkpoint inhibitors (ICIs) have dramatically improved survival in advanced gastrointestinal (GI) cancer patients, but also resulted in immune-related adverse events (irAEs). This study aimed to evaluate serological biomarkers of irAEs and treatment response in GI cancer patients.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS">Metastatic GI cancer patients were enrolled between August 1, 2015, and July 31, 2017. Serum samples were collected at baseline, and a panel of 59 serum biomarkers was tested. The occurrence of irAEs was analyzed, and serological biomarker expression was correlated with irAE incidence and prognosis.</AbstractText>
          <AbstractText Label="RESULTS">Fifty-one patients were enrolled, of whom 47.1% (24/51) were diagnosed with irAEs, including 4 patients (7.8%) with grade 3-5 irAEs. The most common irAE was thyroiditis (9/51, 17.6%), followed by colitis (7/51, 13.7%). The expression of CD28 (P = 0.042), IL-4 (P = 0.033), IL-15 (P = 0.024) and PD-L1 (P = 0.018) was significantly elevated in patients with grade 3-5 irAEs. For organ-specific irAEs, IL-6 levels were higher in patients with thyroiditis and colitis, while IL-22 and SCF levels were higher in patients with colitis. Increased IL-1&#x3b1;, IL-21, LIF, and PIGF-1 levels were significantly associated with myositis incidence, while the serum levels of six cytokines (BTLA, GM-CSF, IL-4, PD-1, PD-L1 and TIM-3) were higher in patients with rash. Prognostic analysis showed that patients with irAEs had better tumor response (P = 0.029), improved PFS (median survival: undefined vs. 2.1 months, P = 0.002), and extended OS (median survival: undefined vs. 4.3 months, P = 0.003). The prognostic value of irAEs was only significant in patients who received anti-PD-1 inhibitors, but not in those who received anti-PD-L1 inhibitors. Besides, elevated BTLA (median OS: not reached vs. 7 months; P = 0.0168) and PD-1 (median OS: not reached vs. 7 months; P = 0.0223) concentrations were associated with longer OS.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Serological proteins are promising markers for predicting immune-related toxicity and prognosis in GI cancer patients. Organ-specific irAEs have various cytokine profiles. Although further validation is needed before clinical application, this study provided a direction for identifying patients at risk for irAEs, and guiding patient selection for ICI therapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Wang, Zou, Li, Jiao, Wang, Zhuo, Gao, Gong, Li, Zhang, Wang, Peng, Qi, Wang, Li, Li, Shen, Zhang and Lu.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yanni</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Jianling</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Affairs, Genecast Precision Medicine Technology Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiao</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yujiao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhuo</LastName>
            <ForeName>Na</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Mengting</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Jifang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xiaotian</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xicheng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Zhi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Changsong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhenghang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Henghui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Zhihao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>09</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018106">CD28 Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072597">Hepatitis A Virus Cellular Receptor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019409">Interleukin-15</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C098069">PIGF protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>207137-56-2</RegistryNumber>
          <NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>83869-56-1</RegistryNumber>
          <NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="Y">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018106" MajorTopicYN="N">CD28 Antigens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005770" MajorTopicYN="Y">Gastrointestinal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072597" MajorTopicYN="N">Hepatitis A Virus Cellular Receptor 2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007154" MajorTopicYN="Y">Immune System Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019409" MajorTopicYN="N">Interleukin-15</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">biomarker</Keyword>
        <Keyword MajorTopicYN="N">cytokines</Keyword>
        <Keyword MajorTopicYN="N">gastrointestinal cancers</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>17</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36159840</ArticleId>
        <ArticleId IdType="pmc">PMC9492966</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2022.987568</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2021) 71(3):209&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33538338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, et al. . Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol Off J Eur Soc Med Oncol (2019) 30(2):250&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6386029</ArticleId>
            <ArticleId IdType="pubmed">30566590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol (2017) 18(9):1182&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6207072</ArticleId>
            <ArticleId IdType="pubmed">28734759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Itzstein MS, Khan S, Gerber DE. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem (2020) 66(6):779&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7259479</ArticleId>
            <ArticleId IdType="pubmed">32363387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA: Cancer J Clin (2020) 70(2):86&#x2013;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31944278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch&#xe1;vez A, Keegan N, Khamashta MA, et al. . Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis primers (2020) 6(1):38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32382051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol Off J Eur Soc Med Oncol (2017) 28(10):2377&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. . Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ (Clinical Res ed) (2018) 360:k793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5851471</ArticleId>
            <ArticleId IdType="pubmed">29540345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, et al. . Serum interleukin-6 and c-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J immunotherapy Cancer (2020) 8(1):e000842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7312339</ArticleId>
            <ArticleId IdType="pubmed">32581042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. . Baseline circulating IL-17 predicts toxicity while TGF-&#x3b2;1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J immunotherapy cancer (2015) 3:39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4570556</ArticleId>
            <ArticleId IdType="pubmed">26380086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, et al. . Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-Based immunotherapy. Clin Cancer Res an Off J Am Assoc Cancer Res (2019) 25(5):1557&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30409824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Z, Zou J, Hu Y, Li S, Zhou T, Gong J, et al. . Serological markers associated with response to immune checkpoint blockade in metastatic gastrointestinal tract cancer. JAMA network Open (2019) 2(7):e197621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6659353</ArticleId>
            <ArticleId IdType="pubmed">31339548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Medical Association . Declaration of Helsinki: Ethical principles for medical research involving human subjects. Jama (2013) 310(20):2191&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24141714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford Engl 1990) (2009) 45(2):228&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19097774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, et al. . Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. oncologist (2019) 24(8):1128&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6693718</ArticleId>
            <ArticleId IdType="pubmed">31015312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. . First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London England) (2021) 398(10294):27&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8436782</ArticleId>
            <ArticleId IdType="pubmed">34102137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. . Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet (London England) (2021) 398(10302):759&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34454674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA network Open (2020) 3(3):e200423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7063495</ArticleId>
            <ArticleId IdType="pubmed">32150268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. . Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol (2017) 18(5):631&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28314688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol (2016) 17(6):717&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27157491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Nie J, Dai L, Hu W, Zhang J, Han J, et al. . Immune-related adverse events and their association with the effectiveness of PD-1/PD-L1 inhibitors in non-small cell lung cancer: A real-world study from China. Front Oncol (2021) 11:607531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7973369</ArticleId>
            <ArticleId IdType="pubmed">33747922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med (2015) 373(1):23&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New Engl J Med (2018) 378(2):158&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. . Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol (2018) 4(12):1721&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6440712</ArticleId>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, Okazaki IM. Stimulatory and inhibitory Co-signals in autoimmunity. Adv Exp Med Biol (2019) 1189:213&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31758536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remember. J Immunol (Baltimore Md 1950) (2012) 189(9):4213&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3481177</ArticleId>
            <ArticleId IdType="pubmed">23087426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci (2012) 33(1):35&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3327885</ArticleId>
            <ArticleId IdType="pubmed">22032984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, et al. . Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med (2019) 7(4):347&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30876831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. . Nivolumab plus ipilimumab in advanced non-Small-Cell lung cancer. New Engl J Med (2019) 381(21):2020&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31562796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia XH, Geng LY, Jiang PP, Xu H, Nan KJ, Yao Y, et al. . The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res CR (2020) 39(1):284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7734811</ArticleId>
            <ArticleId IdType="pubmed">33317597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. . Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol Off J Am Soc Clin Oncol (2019) 37(30):2746&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7001790</ArticleId>
            <ArticleId IdType="pubmed">31216228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, et al. . Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci United States America (2019) 116(44):22246&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6825284</ArticleId>
            <ArticleId IdType="pubmed">31611368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, et al. . Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer immunology immunotherapy CII (2020) 69(9):1813&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7413896</ArticleId>
            <ArticleId IdType="pubmed">32350592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst AM, Chan YH, et al. . Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature. Front Immunol (2022) 13:807050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8831742</ArticleId>
            <ArticleId IdType="pubmed">35154124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyan K, Baginska J, Brainard M, Giobbie-Hurder A, Severgnini M, Manos M, et al. . Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer immunology immunotherapy CII (2021) 70(8):2209&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33481042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol (Baltimore Md 1950) (2009) 183(5):3170&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2903207</ArticleId>
            <ArticleId IdType="pubmed">19648274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev (2013) 252(1):116&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23405899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M&#xf6;ller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin immunopathology (2006) 27(4):391&#x2013;408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16738952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gavriilidis GI, Ntoufa S, Papakonstantinou N, Kotta K, Koletsa T, Chartomatsidou E, et al. . Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia. Haematologica (2021) 106(3):692&#x2013;700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7927890</ArticleId>
            <ArticleId IdType="pubmed">32336682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee WC, Hsu PY, Hsu HY. Stem cell factor produced by tumor cells expands myeloid-derived suppressor cells in mice. Sci Rep (2020) 10(1):11257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7347545</ArticleId>
            <ArticleId IdType="pubmed">32647215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welc SS, Flores I, Wehling-Henricks M, Ramos J, Wang Y, Bertoni C, et al. . Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy. Nat Commun (2019) 10(1):2788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6594976</ArticleId>
            <ArticleId IdType="pubmed">31243277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. . Association of immune-related adverse events with nivolumab efficacy in non-Small-Cell lung cancer. JAMA Oncol (2018) 4(3):374&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6583041</ArticleId>
            <ArticleId IdType="pubmed">28975219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada N, Kawazoe H, Takechi K, Matsudate Y, Utsunomiya R, Zamami Y, et al. . Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: A multicenter retrospective study. Clin Ther (2019) 41(1):59&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30528047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogado J, S&#xe1;nchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Lev&#xed; A, et al. . Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer (Oxford Engl 1990) (2019) 109:21&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30682533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z, et al. . Efficacy of nivolumab and pembrolizumab in patients with advanced non-Small-Cell lung cancer needing treatment interruption because of adverse events: A retrospective multicenter analysis. Clin Lung cancer (2019) 20(1):e97&#x2013;e106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30337270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui J, Bystryn JC. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol (1995) 131(3):314&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7887661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 156(6):1755&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2186870</ArticleId>
            <ArticleId IdType="pubmed">7175440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>L&#xe4;ubli H, Koelzer VH, Matter MS, Herzig P, Dolder Schlienger B, Wiese MN, et al. . The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology (2018) 7(2):e1386362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5749666</ArticleId>
            <ArticleId IdType="pubmed">29308309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? a systematic review and meta-analysis. BMC Med (2020) 18(1):87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7169020</ArticleId>
            <ArticleId IdType="pubmed">32306958</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">36113896</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e005490</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2022-005490</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION">Systemic corticosteroids are the mainstay of treatment for immune checkpoint inhibitor induced (CPI) colitis but are associated with complications including life-threatening infection. The topically acting oral corticosteroid beclomethasone dipropionate (BD) is an effective treatment for mild to moderate flares of ulcerative colitis, and has fewer side effects than systemic corticosteroids. We hypothesized that BD would be an effective treatment for CPI-induced colitis.</AbstractText>
          <AbstractText Label="METHODS">We performed a retrospective analysis of all patients who started BD for CPI-induced colitis at three UK cancer centers between November 2017 and October 2020. All patients underwent endoscopic assessment and biopsy. The initial regimen of BD was 5 mg once daily for 28 days. Data were collected from electronic patient records. Clinical outcomes were assessed at 28 days after initiation of treatment.</AbstractText>
          <AbstractText Label="RESULTS">Twenty-two patients (14 male) with a median age of 64 (range 45-84) with CPI-induced colitis were treated with BD. At baseline, the median number of loose stools in a 24-hour period was six (common terminology criteria for adverse events, CTCAE grade diarrhea=2). Thirteen patients (59%) were dependent on systemic corticosteroids prior to starting BD. Baseline sigmoidoscopy showed moderate inflammation (Mayo Endoscopic Score (MES) = 2) in two patients (9%), mild inflammation (MES=1) in nine patients (41%) and normal findings (MES=0) in eleven patients (50%). Twenty patients (91%) had histopathological features of inflammation. All 22 patients (100%) had a clinical response to BD and 21 (95%) achieved clinical remission with a return to baseline stool frequency (CTCAE diarrhea=0). Ten patients (45%) had symptomatic relapse on cessation of BD, half within 7 days of stopping. All patients recaptured response on restarting BD. No adverse events were reported in patients treated with BD.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Topical BD represents an appealing alternative option to systemic immunosuppressive treatments to treat colonic inflammation. In this study, BD was effective and safe at inducing remission in CPI-induced colitis, which was refractory to systemic corticosteroids. Further randomized studies are needed to confirm these findings and determine the optimum dosing regimen.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Alexander</LastName>
            <ForeName>James L</ForeName>
            <Initials>JL</Initials>
            <Identifier Source="ORCID">0000-0001-8542-327X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ibraheim</LastName>
            <ForeName>Hajir</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Richards</LastName>
            <ForeName>Camellia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shum</LastName>
            <ForeName>Ben</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Renal &amp; Skin Units, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pavlidis</LastName>
            <ForeName>Polychronis</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental Immunobiology, King's College London, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, King's College Hospital NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hunter</LastName>
            <ForeName>Nikki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Renal &amp; Skin Units, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teare</LastName>
            <ForeName>Julian P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wotherspoon</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histopathology, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Furness</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Renal &amp; Skin Units, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turajlic</LastName>
            <ForeName>Samra</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Renal &amp; Skin Units, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pickering</LastName>
            <ForeName>Lisa</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Renal &amp; Skin Units, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Larkin</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Renal &amp; Skin Units, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Speight</LastName>
            <ForeName>Ally</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papa</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Powell</LastName>
            <ForeName>Nick</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Royal Marsden NHS Foundation Trust, London, UK nicholas.powell@imperial.ac.uk.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MR/S000828/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>KGZ1SLC28Z</RegistryNumber>
          <NameOfSubstance UI="D001507">Beclomethasone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001507" MajorTopicYN="Y">Beclomethasone</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: JLA reports meeting travel support from Vifor Pharma. NP reports he has served as a speaker for Allergan, Bristol Myers Squibb, Falk, Ferring, Janssen, Pfizer, Tillotts, and Takeda, and as a consultant and/or an advisory board member for AbbVie, Allergan, Celgene, Bristol Myers Squibb, Ferring, and Vifor Pharma. JL reports institution grants from Achilles therapeutics, BMS, Merck Sorono, Nektar, Novartis, Pfizer, Roche, Immunocore, Aveo and Pharmacyclics, consulting fees from Iovance, Boston Biomedical, Pfizer, BMS, GSK, Novartis, Incyte, Immunocore, YKT Global, iOnctura and Apple Tree, honoraria from Roche, Novartis, iOnctura, BMS, Pfizer, Incyte, Dynavax, CRUK, GSK, Eisai, Merck, TouchIME and Touch Experts and support for meeting attendance and/or travel from BMS, iOnctura, Roche, Pfizer, Incyte, Merck, Novartis, Pierre Fabre, BUG, ESMO, AIM, AstraZeneca, NCRI, Syneos Health, EUSA, KCA, Bioevents, MedConcept, GSK and RVMais. ST reports grants or contracts from Cancer Research UK (grant reference number C50947/A18176), The National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (grant reference number A109), The Kidney and Melanoma Cancer Fund of the Royal Marsden Cancer Charity, The Rosetrees Trust (grant reference number A2204) and Ventana Medical Systems Inc (grant reference numbers 10467 and 10530), honoraria from Jules Bordet Institute, Erasmus, Open Health and MD Anderson, support for attending meetings and/or travel from Jules Bordet Institute, ESMO, SMR, Broad, KCA, IFOM, EORTC, ASCO, Ventana, Roche, Institute of Molecular medicine, KTH Sweden, Pfizer, Erasmus, Systems biology, MD Anderson, WK Weiser, AACR, Research degrees Team, Melanoma Focus and SITC, patents Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 and PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>20</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36113896</ArticleId>
        <ArticleId IdType="pmc">PMC9486376</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2022-005490</ArticleId>
        <ArticleId IdType="pii">jitc-2022-005490</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734&#x2013;6. 10.1126/science.271.5256.1734</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.271.5256.1734</ArticleId>
            <ArticleId IdType="pubmed">8596936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwai Y, Ishida M, Tanaka Y, et al. . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293&#x2013;7. 10.1073/pnas.192461099</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.192461099</ArticleId>
            <ArticleId IdType="pmc">PMC129438</ArticleId>
            <ArticleId IdType="pubmed">12218188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tawbi HA, Schadendorf D, Lipson EJ, et al. . Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386:24&#x2013;34. 10.1056/NEJMoa2109970</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2109970</ArticleId>
            <ArticleId IdType="pubmed">34986285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst RS, Soria J-C, Kowanetz M, et al. . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563&#x2013;7. 10.1038/nature14011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14011</ArticleId>
            <ArticleId IdType="pmc">PMC4836193</ArticleId>
            <ArticleId IdType="pubmed">25428504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. . Five-Year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535&#x2013;46. 10.1056/NEJMoa1910836</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910836</ArticleId>
            <ArticleId IdType="pubmed">31562797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158&#x2013;68. 10.1056/NEJMra1703481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samaan MA, Pavlidis P, Papa S, et al. . Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol 2018;15:222&#x2013;34. 10.1038/nrgastro.2018.14</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2018.14</ArticleId>
            <ArticleId IdType="pubmed">29512649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powell N, Ibraheim H, Raine T, et al. . British Society of gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679&#x2013;97. 10.1016/S2468-1253(20)30014-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2468-1253(20)30014-5</ArticleId>
            <ArticleId IdType="pubmed">32553146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C, et al. . Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv264&#x2013;6. 10.1093/annonc/mdy162</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy162</ArticleId>
            <ArticleId IdType="pubmed">29917046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtis JR, Westfall AO, Allison J, et al. . Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55:420&#x2013;6. 10.1002/art.21984</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.21984</ArticleId>
            <ArticleId IdType="pubmed">16739208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Castillo M, Romero FA, Arg&#xfc;ello E, et al. . The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 2016;63:1490&#x2013;3. 10.1093/cid/ciw539</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciw539</ArticleId>
            <ArticleId IdType="pmc">PMC5106605</ArticleId>
            <ArticleId IdType="pubmed">27501841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. . Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 2018;6:37. 10.1186/s40425-018-0346-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0346-6</ArticleId>
            <ArticleId IdType="pmc">PMC5946546</ArticleId>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, et al. . High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 2018;124:3706&#x2013;14. 10.1002/cncr.31629</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31629</ArticleId>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arbour KC, Mezquita L, Long N, et al. . Impact of baseline steroids on efficacy of programmed cell death-1 and programmed Death-Ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018;36:2872&#x2013;8. 10.1200/JCO.2018.79.0006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.79.0006</ArticleId>
            <ArticleId IdType="pubmed">30125216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Castillo M, Romero FA, Arg&#xfc;ello E, et al. . The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 2016;63:1490&#x2013;3. 10.1093/cid/ciw539</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciw539</ArticleId>
            <ArticleId IdType="pmc">PMC5106605</ArticleId>
            <ArticleId IdType="pubmed">27501841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibraheim H, Baillie S, Samaan MA, et al. . Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020;52:1432&#x2013;52. 10.1111/apt.15998</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.15998</ArticleId>
            <ArticleId IdType="pubmed">32920854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander JL, Ibraheim H, Sheth B, et al. . Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. J Immunother Cancer 2021;9:e002742. 10.1136/jitc-2021-002742</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2021-002742</ArticleId>
            <ArticleId IdType="pmc">PMC8264884</ArticleId>
            <ArticleId IdType="pubmed">34233964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. . Endoscopic and histologic features of immune checkpoint Inhibitor-Related colitis. Inflamm Bowel Dis 2018;24:1695&#x2013;705. 10.1093/ibd/izy104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. . Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018;3:e000278. 10.1136/esmoopen-2017-000278</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ, et al. . Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283&#x2013;9. 10.1200/JCO.2005.04.5716</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.04.5716</ArticleId>
            <ArticleId IdType="pmc">PMC2140223</ArticleId>
            <ArticleId IdType="pubmed">16710025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. . Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018;3:e000278. 10.1136/esmoopen-2017-000278</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. . Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016;10:395&#x2013;401. 10.1093/ecco-jcc/jjv227</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv227</ArticleId>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spain L, Diem S, Khabra K, et al. . Patterns of steroid use in diarrhoea and/or colitis (D/C) from immune checkpoint inhibitors (ICPI). Annals of Oncology 2016;27:vi374. 10.1093/annonc/mdw378.46</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw378.46</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibraheim H, Spain L, Samani A. Microscopic colonic inflammation in immune check point inhibitor-induced Diarrhoea/Colitis. Gut 2018;67:A80.</Citation>
        </Reference>
        <Reference>
          <Citation>Ibraheim H, Green M, Papa S, et al. . Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis. BMJ Case Rep 2019;12. doi:10.1136/bcr-2018-226481. [Epub ahead of print: 03 Apr 2019].</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2018-226481</ArticleId>
            <ArticleId IdType="pmc">PMC6453372</ArticleId>
            <ArticleId IdType="pubmed">30948391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K, Abu-Sbeih H, Samdani R, et al. . Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 2019;25:385&#x2013;93. 10.1093/ibd/izy240</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy240</ArticleId>
            <ArticleId IdType="pmc">PMC7534361</ArticleId>
            <ArticleId IdType="pubmed">30169584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daley-Yates PT, Price AC, Sisson JR, et al. . Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001;51:400&#x2013;9. 10.1046/j.0306-5251.2001.01374.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.0306-5251.2001.01374.x</ArticleId>
            <ArticleId IdType="pmc">PMC2014471</ArticleId>
            <ArticleId IdType="pubmed">11421996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Assche G, Manguso F, Zibellini M, et al. . Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. Am J Gastroenterol 2015;110:708&#x2013;15. 10.1038/ajg.2015.114</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2015.114</ArticleId>
            <ArticleId IdType="pubmed">25869389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamb CA, Kennedy NA, Raine T, et al. . British Society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1&#x2013;106. 10.1136/gutjnl-2019-318484</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2019-318484</ArticleId>
            <ArticleId IdType="pmc">PMC6872448</ArticleId>
            <ArticleId IdType="pubmed">31562236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Felice KM, Gupta A, Rakshit S, et al. . Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res 2015;25:321&#x2013;7. 10.1097/CMR.0000000000000165</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CMR.0000000000000165</ArticleId>
            <ArticleId IdType="pubmed">25933207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Molina GE, Chen ST, et al. . Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292. 10.1186/s40425-019-0756-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0756-0</ArticleId>
            <ArticleId IdType="pmc">PMC6839080</ArticleId>
            <ArticleId IdType="pubmed">31699151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steed KP, Hooper G, Ventura P, et al. . The in vivo behaviour of a colonic delivery system: a pilot study in man. Int J Pharm 1994;112:199&#x2013;206. 10.1016/0378-5173(94)90355-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0378-5173(94)90355-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol 2015;80:372&#x2013;80. 10.1111/bcp.12637</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.12637</ArticleId>
            <ArticleId IdType="pmc">PMC4574823</ArticleId>
            <ArticleId IdType="pubmed">25808113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chalabi M, Cardona A, Nagarkar DR, et al. . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the oak and poplar trials. Ann Oncol 2020;31:525&#x2013;31. 10.1016/j.annonc.2020.01.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.annonc.2020.01.006</ArticleId>
            <ArticleId IdType="pubmed">32115349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortellini A, Di Maio M, Nigro O, et al. . Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer 2021;9:e002421. 10.1136/jitc-2021-002421</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2021-002421</ArticleId>
            <ArticleId IdType="pmc">PMC8031700</ArticleId>
            <ArticleId IdType="pubmed">33827906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuderer NM, Choueiri TK, Shah DP, et al. . Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395:1907&#x2013;18. 10.1016/S0140-6736(20)31187-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)31187-9</ArticleId>
            <ArticleId IdType="pmc">PMC7255743</ArticleId>
            <ArticleId IdType="pubmed">32473681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kennedy NA, Jones G-R, Lamb CA, et al. . British Society of gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020;69:984&#x2013;90. 10.1136/gutjnl-2020-321244</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2020-321244</ArticleId>
            <ArticleId IdType="pmc">PMC7211081</ArticleId>
            <ArticleId IdType="pubmed">32303607</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">36096534</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>09</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e005111</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2022-005111</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies of alternatives to glucocorticoids are lacking. We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis and arthritis.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS">Patients with solid cancer experiencing Common Terminology Criteria for Adverse Events (CTCAE v5.0) grade &gt;1 ICI-induced colitis/diarrhea (n=9), arthritis (n=9), or both (n=2) were recruited and treated with tocilizumab (8&#x2009;mg/kg) every 4&#x2009;weeks until worsening or unacceptable toxicity. Patients were not allowed to receive systemic glucocorticoids and other immunosuppressive drugs within the 14-day screening period. The primary endpoint was clinical improvement of colitis and arthritis, defined as &#x2265;1 grade CTCAE reduction within 8&#x2009;weeks. Secondary endpoints were improvements and glucocorticoid-free remission at week 24; safety; radiologic, endoscopic, and histological changes; and changes in plasma concentrations of C reactive protein, cytokines (IL-6, IL-8, and IL-17), and YKL-40.</AbstractText>
          <AbstractText Label="RESULTS">Nineteen patients were available for efficacy analysis; one patient was excluded due to pancreatic insufficiency-induced diarrhea. Patients received treatment with pembrolizumab (n=10) or nivolumab (n=4) as monotherapy or ipilimumab and nivolumab (n=5) combined. Seven patients had been initially treated with glucocorticoids, and two of them also received infliximab. Ten patients continued ICI therapy during tocilizumab treatment. The primary endpoint was achieved in 15 of 19 (79%) patients. Additional one patient had &#x2265;1 grade reduction at week 10, and another patient had stabilized symptoms. At week 24, ongoing improvement without glucocorticoids (n=12), including complete remission (n=10), was noted. Five patients had grades 3-4 treatment-related adverse events, which were manageable and reversible.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Tocilizumab showed promising clinical efficacy and a manageable safety profile in the treatment of ICI-induced colitis and arthritis. Our findings support the feasibility of randomized trials of immune-related adverse events.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION NUMBER">NCT03601611.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Holmstroem</LastName>
            <ForeName>Rikke Boedker</ForeName>
            <Initials>RB</Initials>
            <Identifier Source="ORCID">0000-0002-5476-9937</Identifier>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Immunotherapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nielsen</LastName>
            <ForeName>Ole Haagen</ForeName>
            <Initials>OH</Initials>
            <Identifier Source="ORCID">0000-0003-4612-8635</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacobsen</LastName>
            <ForeName>Sren</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-5654-4993</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Copenhagen Lupus and Vasculitis Clinic, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riis</LastName>
            <ForeName>Lene Buhl</ForeName>
            <Initials>LB</Initials>
            <Identifier Source="ORCID">0000-0003-4669-3159</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Theile</LastName>
            <ForeName>Susann</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-9804-7744</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bjerrum</LastName>
            <ForeName>Jacob Tveiten</ForeName>
            <Initials>JT</Initials>
            <Identifier Source="ORCID">0000-0002-6249-3889</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vilmann</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0001-7889-1104</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Gastrounit - Division of Surgery, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johansen</LastName>
            <ForeName>Julia Sidenius</ForeName>
            <Initials>JS</Initials>
            <Identifier Source="ORCID">0000-0002-4217-6560</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boisen</LastName>
            <ForeName>Mogens Karsbl</ForeName>
            <Initials>MK</Initials>
            <Identifier Source="ORCID">0000-0002-9891-5449</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eefsen</LastName>
            <ForeName>Rikke Helene Lvendahl</ForeName>
            <Initials>RHL</Initials>
            <Identifier Source="ORCID">0000-0003-1421-1792</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marie Svane</LastName>
            <ForeName>Inge</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-9451-6037</Identifier>
            <AffiliationInfo>
              <Affiliation>National Center for Cancer Immunotherapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nielsen</LastName>
            <ForeName>Dorte Lisbet</ForeName>
            <Initials>DL</Initials>
            <Identifier Source="ORCID">0000-0002-8766-8729</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Inna Markovna</ForeName>
            <Initials>IM</Initials>
            <Identifier Source="ORCID">0000-0003-2891-0762</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Copenhagen University Hospital, Herlev, Denmark inna.chen@regionh.dk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT03601611</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I031V2H011</RegistryNumber>
          <NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001168" MajorTopicYN="Y">Arthritis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CTLA-4 Antigen</Keyword>
        <Keyword MajorTopicYN="N">Cytokines</Keyword>
        <Keyword MajorTopicYN="N">Cytotoxicity, Immunologic</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Programmed Cell Death 1 Receptor</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: All authors completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. RBH received speaking honoraria from BPNO. P. Vilmann reported a consulting relationship with MediGlobe GmbH, Grassau. JJ reported receiving research funding and hotel/airfare reimbursement to attend global health meetings from Roche, BMS, and Celgene. MKB reported receiving hotel/airfare reimbursement to attend global health meetings from Pfizer. RHLE received research funding from BMS and advisory relationship with Amgen. IMS has been principal investigator in BMS-supported trials and received honoraria from BMS for speaking and serving on an advisory board. IMC reported receiving research funding and hotel/airfare reimbursement to attend global health meetings from Roche, BMS, Celgene, Genis, and advisory relationship with Amgen. OHN, LBR, ST, SJ, and DLN had no disclosures.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>12</Day>
          <Hour>20</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36096534</ArticleId>
        <ArticleId IdType="pmc">PMC9472120</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2022-005111</ArticleId>
        <ArticleId IdType="pii">jitc-2022-005111</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158&#x2013;68. 10.1056/NEJMra1703481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Casals M, Brahmer JR, Callahan MK, et al. . Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38. 10.1038/s41572-020-0160-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-020-0160-6</ArticleId>
            <ArticleId IdType="pubmed">32382051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider BJ, Naidoo J, Santomasso BD, et al. . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39:4073&#x2013;126. 10.1200/JCO.21.01440</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.21.01440</ArticleId>
            <ArticleId IdType="pubmed">34724392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussaini S, Chehade R, Boldt RG, et al. . Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev 2021;92:102134. 10.1016/j.ctrv.2020.102134</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2020.102134</ArticleId>
            <ArticleId IdType="pubmed">33302134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eggermont AMM, Kicinski M, Blank CU, et al. . Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 2020;6:519&#x2013;27. 10.1001/jamaoncol.2019.5570</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.5570</ArticleId>
            <ArticleId IdType="pmc">PMC6990933</ArticleId>
            <ArticleId IdType="pubmed">31895407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019;7:306. 10.1186/s40425-019-0805-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0805-8</ArticleId>
            <ArticleId IdType="pmc">PMC6858629</ArticleId>
            <ArticleId IdType="pubmed">31730012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shankar B, Zhang J, Naqash AR, et al. . Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol 2020;6:1952&#x2013;6. 10.1001/jamaoncol.2020.5012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2020.5012</ArticleId>
            <ArticleId IdType="pmc">PMC7596677</ArticleId>
            <ArticleId IdType="pubmed">33119034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reid PD, Cifu AS, Bass AR. Management of Immunotherapy-Related toxicities in patients treated with immune checkpoint inhibitor therapy. JAMA 2021;325:482&#x2013;3. 10.1001/jama.2020.17308</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.17308</ArticleId>
            <ArticleId IdType="pubmed">33528524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. . Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. 10.1136/jitc-2021-002435</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2021-002435</ArticleId>
            <ArticleId IdType="pmc">PMC8237720</ArticleId>
            <ArticleId IdType="pubmed">34172516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Comprehensive Cancer Network . Management of Immunotherapy-Related Toxicities. In: NCCN guidelines. Version 1.2022, 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014;13:668&#x2013;77. 10.1016/j.autrev.2013.12.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2013.12.004</ArticleId>
            <ArticleId IdType="pubmed">24418308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keegan A, Ricciuti B, Garden P, et al. . Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer 2020;8:e000678. 10.1136/jitc-2020-000678</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-000678</ArticleId>
            <ArticleId IdType="pmc">PMC7537334</ArticleId>
            <ArticleId IdType="pubmed">33020238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 2018;18:773&#x2013;89. 10.1038/s41577-018-0066-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-018-0066-7</ArticleId>
            <ArticleId IdType="pubmed">30254251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Zhai X, Li J, et al. . The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. Front Immunol 2021;12:670391. 10.3389/fimmu.2021.670391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.670391</ArticleId>
            <ArticleId IdType="pmc">PMC8339552</ArticleId>
            <ArticleId IdType="pubmed">34367136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le RQ, Li L, Yuan W, et al. . Fda approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23:943&#x2013;7. 10.1634/theoncologist.2018-0028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0028</ArticleId>
            <ArticleId IdType="pmc">PMC6156173</ArticleId>
            <ArticleId IdType="pubmed">29622697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabay C, Emery P, van Vollenhoven R, et al. . Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541&#x2013;50. 10.1016/S0140-6736(13)60250-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)60250-0</ArticleId>
            <ArticleId IdType="pubmed">23515142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Rhee F, Voorhees P, Dispenzieri A, et al. . International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018;132:2115&#x2013;24. 10.1182/blood-2018-07-862334</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-07-862334</ArticleId>
            <ArticleId IdType="pmc">PMC6238190</ArticleId>
            <ArticleId IdType="pubmed">30181172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>, Gordon AC, Mouncey PR, et al. , REMAP-CAP Investigators . Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021;384:1491&#x2013;502. 10.1056/NEJMoa2100433</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2100433</ArticleId>
            <ArticleId IdType="pmc">PMC7953461</ArticleId>
            <ArticleId IdType="pubmed">33631065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjoern J, Iversen TZ, Nitschke NJ, et al. . Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy 2016;18:1043&#x2013;55. 10.1016/j.jcyt.2016.05.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcyt.2016.05.010</ArticleId>
            <ArticleId IdType="pubmed">27378345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 2019;15:813&#x2013;22. 10.1080/1744666X.2019.1629904</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1744666X.2019.1629904</ArticleId>
            <ArticleId IdType="pmc">PMC7936577</ArticleId>
            <ArticleId IdType="pubmed">31219357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stroud CR, Hegde A, Cherry C, et al. . Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 2019;25:551&#x2013;7. 10.1177/1078155217745144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155217745144</ArticleId>
            <ArticleId IdType="pubmed">29207939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim ST, Tayar J, Trinh VA, et al. . Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 2017;76:2061&#x2013;4. 10.1136/annrheumdis-2017-211560</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-211560</ArticleId>
            <ArticleId IdType="pubmed">28830882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimitriou F, Hogan S, Menzies AM, et al. . Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer 2021;157:214&#x2013;24. 10.1016/j.ejca.2021.08.031</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2021.08.031</ArticleId>
            <ArticleId IdType="pubmed">34536945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campochiaro C, Farina N, Tomelleri A. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med 2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34391591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappelli LC, Gutierrez AK, Bingham CO, et al. . Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res 2017;69:1751&#x2013;63. 10.1002/acr.23177</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.23177</ArticleId>
            <ArticleId IdType="pmc">PMC5478477</ArticleId>
            <ArticleId IdType="pubmed">27998041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnaud-Coffin P, Maillet D, Gan HK, et al. . A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer 2019;145:639&#x2013;48. 10.1002/ijc.32132</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32132</ArticleId>
            <ArticleId IdType="pubmed">30653255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Common Terminology Criteria for Adverse Events (CTCAE), v5.0 . National Institutes and health, National cancer Institute 2017, 2017. National Institutes and Health. Available: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50</Citation>
        </Reference>
        <Reference>
          <Citation>2010. EMA Europe . 2010, last update 26/04/2022. Available: https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Hammond S, Olsson-Brown A, Grice S, et al. . Checkpoint inhibition reduces the threshold for drug-specific T-cell priming and increases the incidence of sulfasalazine hypersensitivity. Toxicol Sci 2022;186:58&#x2013;69. 10.1093/toxsci/kfab144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/toxsci/kfab144</ArticleId>
            <ArticleId IdType="pmc">PMC8883351</ArticleId>
            <ArticleId IdType="pubmed">34850240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olivares-Hern&#xe1;ndez A, Figuero-P&#xe9;rez L, Amores Mart&#xed;n MA, et al. . Response to treatment with an anti-interleukin-6 receptor antibody (tocilizumab) in a patient with hemophagocytic syndrome secondary to immune checkpoint inhibitors. Case Rep Oncol Med 2021;2021:1&#x2013;5. 10.1155/2021/6631859</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/6631859</ArticleId>
            <ArticleId IdType="pmc">PMC7895569</ArticleId>
            <ArticleId IdType="pubmed">33628551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neelapu SS, Tummala S, Kebriaei P, et al. . Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47&#x2013;62. 10.1038/nrclinonc.2017.148</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.148</ArticleId>
            <ArticleId IdType="pmc">PMC6733403</ArticleId>
            <ArticleId IdType="pubmed">28925994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Molina GE, Chen ST, et al. . Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292. 10.1186/s40425-019-0756-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0756-0</ArticleId>
            <ArticleId IdType="pmc">PMC6839080</ArticleId>
            <ArticleId IdType="pubmed">31699151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander JL, Ibraheim H, Sheth B, et al. . Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. J Immunother Cancer 2021;9:e002742. 10.1136/jitc-2021-002742</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2021-002742</ArticleId>
            <ArticleId IdType="pmc">PMC8264884</ArticleId>
            <ArticleId IdType="pubmed">34233964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, et al. . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019;7:93. 10.1186/s40425-019-0577-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0577-1</ArticleId>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, et al. . Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017;66:581&#x2013;92. 10.1007/s00262-017-1962-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-1962-6</ArticleId>
            <ArticleId IdType="pmc">PMC5406433</ArticleId>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibraheim H, Baillie S, Samaan MA, et al. . Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020;52:1432&#x2013;52. 10.1111/apt.15998</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.15998</ArticleId>
            <ArticleId IdType="pubmed">32920854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishu S, Melia J, Sharfman W, et al. . Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. Gastroenterology 2021;160:e933:932&#x2013;4. 10.1053/j.gastro.2020.10.029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.10.029</ArticleId>
            <ArticleId IdType="pubmed">33096100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, et al. . Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 2018;24:1804&#x2013;8. 10.1038/s41591-018-0238-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0238-9</ArticleId>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas AS, Ma W, Wang Y. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med 2021;384:581&#x2013;3. 10.1056/NEJMc2031717</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2031717</ArticleId>
            <ArticleId IdType="pubmed">33567198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walley T, Milson D. Loperamide related toxic megacolon in Clostridium difficile colitis. Postgrad Med J 1990;66:582. 10.1136/pgmj.66.777.582-a</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/pgmj.66.777.582-a</ArticleId>
            <ArticleId IdType="pmc">PMC2429653</ArticleId>
            <ArticleId IdType="pubmed">2217023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samaan MA, Pavlidis P, Papa S, et al. . Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol 2018;15:222&#x2013;34. 10.1038/nrgastro.2018.14</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2018.14</ArticleId>
            <ArticleId IdType="pubmed">29512649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franklin C, Rooms I, Fiedler M, et al. . Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer 2017;86:248&#x2013;56. 10.1016/j.ejca.2017.09.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.09.019</ArticleId>
            <ArticleId IdType="pubmed">29055840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kostine M, Finckh A, Bingham CO, et al. . EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021;80:36&#x2013;48. 10.1136/annrheumdis-2020-217139</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-217139</ArticleId>
            <ArticleId IdType="pmc">PMC7788064</ArticleId>
            <ArticleId IdType="pubmed">32327425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montfort A, Filleron T, Virazels M, et al. . Combining nivolumab and ipilimumab with infliximab or Certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin Cancer Res 2021;27:1037&#x2013;47. 10.1158/1078-0432.CCR-20-3449</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-20-3449</ArticleId>
            <ArticleId IdType="pubmed">33272982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brammer JE, Braunstein Z, Katapadi A, et al. . Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J Immunother Cancer 2021;9:e002303. 10.1136/jitc-2020-002303</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-002303</ArticleId>
            <ArticleId IdType="pmc">PMC8386216</ArticleId>
            <ArticleId IdType="pubmed">34429331</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">36043345</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>11</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1759-7714</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Thoracic cancer</Title>
          <ISOAbbreviation>Thorac Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gut microbiota shed new light on the management of immune-related adverse events.</ArticleTitle>
        <Pagination>
          <StartPage>2681</StartPage>
          <EndPage>2691</EndPage>
          <MedlinePgn>2681-2691</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/1759-7714.14626</ELocationID>
        <Abstract>
          <AbstractText>Immunotherapy has dramatically revolutionized the therapeutic landscape for patients with cancer. Although immune checkpoint inhibitors are now accepted as effective anticancer therapies, they introduce a novel class of toxicity, termed immune-related adverse events, which can lead to the temporary or permanent discontinuation of immunotherapy and life-threatening tumor progression. Therefore, the effective prevention and treatment of immune-related adverse events is a clinical imperative to maximize the utility of immunotherapies. Immune-related adverse events are related to the intestinal microbiota, baseline gut microbiota composition is an important determinant of immune checkpoint inhibitor-related colitis, and antibiotics exacerbate these undesirable side-effects. Supplementation with specific probiotics reduces immune checkpoint inhibitor-related colitis in mice, and fecal microbiota transplantation has now been shown to effectively treat refractory immune checkpoint inhibitor-related colitis in the clinic. Hence, modifying the microbiota holds great promise for preventing and treating immune-related adverse events. Microbiomes and their metabolites play important roles in the potential underlying mechanisms through interactions with both innate and adaptive immune cells. Here we review the gut microbiota and immune regulation; the changes occurring in the microbiota during immune checkpoint inhibitor therapy; the relationship between the microbiota and immune-related adverse events, antibiotics, probiotics/prebiotics, and fecal microbiota transplantation in immune checkpoint inhibitor-related colitis; and the protective mechanisms mediated by the microbiome and metabolites in immune-related adverse events.</AbstractText>
          <CopyrightInformation>&#xa9; 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Tan</LastName>
            <ForeName>Bei</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-0053-7399</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liu</LastName>
            <ForeName>Yun-Xin</ForeName>
            <Initials>YX</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Doctor Program, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-2832-2664</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Min-Jiang</ForeName>
            <Initials>MJ</Initials>
            <Identifier Source="ORCID">0000-0002-4040-6115</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Meng-Zhao</ForeName>
            <Initials>MZ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qian</LastName>
            <ForeName>Jia-Ming</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>08</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Singapore</Country>
        <MedlineTA>Thorac Cancer</MedlineTA>
        <NlmUniqueID>101531441</NlmUniqueID>
        <ISSNLinking>1759-7706</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056692" MajorTopicYN="N">Prebiotics</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">fecal microbiota transplantation</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">intestinal microbiota</Keyword>
        <Keyword MajorTopicYN="N">probiotics</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>31</Day>
          <Hour>3</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">36043345</ArticleId>
        <ArticleId IdType="pmc">PMC9527168</ArticleId>
        <ArticleId IdType="doi">10.1111/1759-7714.14626</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA&#x2010;approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12:738. 10.3390/cancers12030738</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12030738</ArticleId>
            <ArticleId IdType="pmc">PMC7140028</ArticleId>
            <ArticleId IdType="pubmed">32245016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:1&#x2013;11. 10.1038/212276-018-0191-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/212276-018-0191-1</ArticleId>
            <ArticleId IdType="pmc">PMC6292890</ArticleId>
            <ArticleId IdType="pubmed">30546008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das S, Johnson DB. Immune&#x2010;related irAE events and anti&#x2010;tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:306. 10.1186/240425-019-0805-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/240425-019-0805-8</ArticleId>
            <ArticleId IdType="pmc">PMC6858629</ArticleId>
            <ArticleId IdType="pubmed">31730012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu&#x2010;Sbeih H, Ali FS, Qiao W, Lu Y, Patal S, Diab A, et al. Immune checkpoint inhibitor&#x2010;induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother. 2019;68:553&#x2013;61. 10.1007/s00262-019-02303-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-019-02303-1</ArticleId>
            <ArticleId IdType="pubmed">30666357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matson V, Fessier J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti&#x2010;PD&#x2010;1 efficacy in metastatic melanoma patients. Science. 2018;359:104&#x2013;8. 10.1126/science.aao3290</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aao3290</ArticleId>
            <ArticleId IdType="pmc">PMC6707353</ArticleId>
            <ArticleId IdType="pubmed">29302014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti&#x2010;PD&#x2010;1 immunotherapy in melanoma patients. Science. 2018;359:97&#x2013;103. 10.1126/science.aan4236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan4236</ArticleId>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou M, Daillere R, et al. Gut microbiome influences efficacy of PD&#x2010;1&#x2010;based immunotherapy against epithelial tumors. Science. 2018;359:91&#x2013;7. 10.1126/science.aan3706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan3706</ArticleId>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davar D, Dzutsev AK, MuCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti&#x2010;PD&#x2010;1 therapy in melanoma patients. Science. 2021;371:595&#x2013;602. 10.1126/science.abf3363</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abf3363</ArticleId>
            <ArticleId IdType="pmc">PMC8097968</ArticleId>
            <ArticleId IdType="pubmed">33542131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baruch EN, Youngster I, Ben&#x2010;Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy&#x2010;refractory melanoma patients. Science. 2021;371:602&#x2013;9. 10.1126/science.abb5920</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abb5920</ArticleId>
            <ArticleId IdType="pubmed">33303685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Liu Z, Chen T. Gut microbiota: a promising milestone in enhancing the efficacy of PD1/PD&#x2010;L1 blockade therapy. Front Oncol. 2022;12:847350. 10.3389/fonc.2022.847350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2022.847350</ArticleId>
            <ArticleId IdType="pmc">PMC8890472</ArticleId>
            <ArticleId IdType="pubmed">35252014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Human Microbiome Project Consortium . Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207&#x2013;14. 10.1038/nature11234</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11234</ArticleId>
            <ArticleId IdType="pmc">PMC3564958</ArticleId>
            <ArticleId IdType="pubmed">22699609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lozupone CA, Stombaugh J, Gordon J, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220&#x2013;30. 10.1038/nature11550</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11550</ArticleId>
            <ArticleId IdType="pmc">PMC3577372</ArticleId>
            <ArticleId IdType="pubmed">22972295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lloyd&#x2010;Price J, Mahurkar A, Rahnavard G, Crabtree J, Orvis J, Hall AB, et al. Strains, functions and dynamics in the expanded human microbiome project. Nature. 2017;550:61&#x2013;6. 10.1038/nature23889</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature23889</ArticleId>
            <ArticleId IdType="pmc">PMC5831082</ArticleId>
            <ArticleId IdType="pubmed">28953883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535:75&#x2013;84. 10.1038/nature18848</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature18848</ArticleId>
            <ArticleId IdType="pubmed">27383982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, et al. Peripheral education of the immune system by colonic commensal microbiota. Nature. 2011;478:250&#x2013;4. 10.1038/nature10434</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10434</ArticleId>
            <ArticleId IdType="pmc">PMC3192908</ArticleId>
            <ArticleId IdType="pubmed">21937990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu HM, Zhou YL, Xu J, Li YF, Zhao C, Huang HL, et al. Inhibition of PD&#x2010;1 protects against TNBS&#x2010;induced colitis via alteration of enteric microbiota. Biomed Res Int. 2021;2021:4192451. 10.1155/2021/4182451</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/4182451</ArticleId>
            <ArticleId IdType="pmc">PMC7810563</ArticleId>
            <ArticleId IdType="pubmed">33506015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA&#x2010;4 blockade relies on the gut microbiota. Science. 2015;350:1079&#x2013;84. 10.1126/science.aad1329</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, Soularue E, Roux KL, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368&#x2013;79. 10.1093/annonc/mdx108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx108</ArticleId>
            <ArticleId IdType="pubmed">28368458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Li M, Liu B, Zhu H, Dai Q, Fan X, et al. Relating gut microbiome and its modulating factors to immunotherapy in solid tumors: a systematic review. Front Oncol. 2021;11:642110. 10.3389/fonc.2021.642110</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2021.642110</ArticleId>
            <ArticleId IdType="pmc">PMC8012896</ArticleId>
            <ArticleId IdType="pubmed">33816289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, et al. Prospective correlation between the patient microbiome with response to and development of immune&#x2010;mediated adverse effects to immunotherapy in lung cancer. BMC Cancer. 2021;21:808. 10.1186/s12885-021-08530-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-021-08530-z</ArticleId>
            <ArticleId IdType="pmc">PMC8278634</ArticleId>
            <ArticleId IdType="pubmed">34256732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierrard J, Seront E. Impact of the gut microbiome on immune checkpoint inhibitor efficacy&#x2010;a systematic review. Curr Oncol. 2019;26:395&#x2013;403. 10.3747/co.26.5177</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3747/co.26.5177</ArticleId>
            <ArticleId IdType="pmc">PMC6927774</ArticleId>
            <ArticleId IdType="pubmed">31896938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, et al. Gut microbiota signatures are associated with toxicity to combined CTLA&#x2010;4 and PD&#x2010;1 blockade. Nat Med. 2021;27:1432&#x2013;41. 10.1038/s41591-021-01406</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01406</ArticleId>
            <ArticleId IdType="pubmed">34239137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint&#x2010;blockade&#x2010;induced colitis. Nat Commun. 2016;7:10391. 10.1038/ncomms10391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10391</ArticleId>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Xiong Q, Li L, Hu Y. Intestinal microbiota predicts lung cancer patients at risk of immune&#x2010;related diarrhea. Immunotherapy. 2019;11:385&#x2013;96. 10.2217/imt-2018-0144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2018-0144</ArticleId>
            <ArticleId IdType="pubmed">30693820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai K, Sakurai T, De Velasco MA, Nagai T, Chikugo T, Ueshima K, et al. Intestinal microbiota and gene expression reveal similarity and dissimilarity between immune&#x2010;mediated colitis and ulcerative colitis. Front Oncol. 2021;11:763468. 10.3389/fonc.2021.763468</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2021.763468</ArticleId>
            <ArticleId IdType="pmc">PMC8578892</ArticleId>
            <ArticleId IdType="pubmed">34778085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, et al. Intestinal microbiota signatures of clinical response and immune&#x2010;related adverse events in melanoma patients treated with anti&#x2010;PD&#x2010;1. Nat Med. 2022;28:545&#x2013;56. 10.1038/s41591-022-01698-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-022-01698-2</ArticleId>
            <ArticleId IdType="pubmed">35228752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu&#x2010;Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AMP, Okhuysen PC, et al. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor&#x2010;mediated diarrhea and colitis. J Immunother Cancer. 2019;7:242. 10.1186/s40425-019-0714-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0714-x</ArticleId>
            <ArticleId IdType="pmc">PMC6729015</ArticleId>
            <ArticleId IdType="pubmed">31488205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Yin Q, Chen L, Davis MM, et al. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA&#x2010;4 blockade. Proc Natl Acad Sci U S A. 2018;115:157&#x2013;61. 10.1073/pnas.1712901115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1712901115</ArticleId>
            <ArticleId IdType="pmc">PMC5776803</ArticleId>
            <ArticleId IdType="pubmed">29255057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Zheng N, Luo Q, Jiang L, He B, Yuan X, et al. Probiotics Lactobacillus reuteri abrogates immune checkpoint blockade&#x2010;associated colitis by inhibiting group 3 innate lymphoid cells. Front Immunol. 2019;10:1235. 10.3389/fimmu.2019.01235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01235</ArticleId>
            <ArticleId IdType="pmc">PMC6558076</ArticleId>
            <ArticleId IdType="pubmed">31214189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kostine M, Mauric E, Tison A, Barnetche T, Barre A, Nikolski M, et al. Baseline co&#x2010;medications may alter the anti&#x2010;tumoural effect of checkpoint inhibitors as well as the risk of immune&#x2010;related adverse events. Eur J Cancer. 2021;157:474&#x2013;84. 10.1016/j.ejca.2021.08.036</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2021.08.036</ArticleId>
            <ArticleId IdType="pubmed">34649118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S, Luo L, Liang W, Yin Q, Cuo J, Rush AM, et al. Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proc Natl Acad Sci U S A. 2020;117:27509&#x2013;15. 10.1073/pnas.1921223117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1921223117</ArticleId>
            <ArticleId IdType="pmc">PMC7959554</ArticleId>
            <ArticleId IdType="pubmed">33077598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374:1632&#x2013;40. 10.1126/science.aaz7015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaz7015</ArticleId>
            <ArticleId IdType="pmc">PMC8970537</ArticleId>
            <ArticleId IdType="pubmed">34941392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobson A, Lam L, Rajendram M, Tamburini F, Honeycutt J, Pham T, et al. A gut commensal&#x2010;produced metabolite mediates colonization resistance to salmonella infection. Cell Host Microbe. 2018;24:296&#x2013;307.e7. 10.1016/j.chom.2018.07.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2018.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC6223613</ArticleId>
            <ArticleId IdType="pubmed">30057174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz DJ, Rebeck ON, Dantas G. Complex interactions between the microbiome and cancer immune therapy. Crit Rev Clin Lab Sci. 2019;56:567&#x2013;85. 10.1080/10408363.2019.1660303</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10408363.2019.1660303</ArticleId>
            <ArticleId IdType="pmc">PMC6776419</ArticleId>
            <ArticleId IdType="pubmed">31526274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly&#x2010;Y M, et al. The microbial metabolites, short&#x2010;chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569&#x2013;73. 10.1126/science.1241165</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1241165</ArticleId>
            <ArticleId IdType="pmc">PMC3807819</ArticleId>
            <ArticleId IdType="pubmed">23828891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arpaia N, Campbell C, Fan X, Dikiy S, Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T&#x2010;cell generation. Nature. 2013;504:451&#x2013;5. 10.1038/nature12726</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12726</ArticleId>
            <ArticleId IdType="pmc">PMC3869884</ArticleId>
            <ArticleId IdType="pubmed">24226773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, Dupont HL, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor&#x2010;associated colitis. Nat Med. 2018;24:1804&#x2013;8. 10.1038/s41591-018-0238-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0238-9</ArticleId>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasanello MK, Robillard KT, Boland PM, Bain AJ, Kanehira K. Use of fecal microbial transplantation for immune checkpoint inhibitor colitis. ACG Case Rep J. 2020;7:e00360. 10.14309/crj.0000000000000360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/crj.0000000000000360</ArticleId>
            <ArticleId IdType="pmc">PMC7224717</ArticleId>
            <ArticleId IdType="pubmed">32548190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN guidelines insights: management of immunotherapy&#x2010;related toxicities, version 1.2020. J Natl Compr Cancer Network. 2020;18:230&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32135517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA&#x2010;4 blockade in melanoma. N Engl J Med. 2014;371:2189&#x2013;99. 10.1056/NEJMoa1406498</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1406498</ArticleId>
            <ArticleId IdType="pmc">PMC4315319</ArticleId>
            <ArticleId IdType="pubmed">25409260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drobni ZD, Zafar A, Zubiri L, Zlotoff DA, Alvi MR, Lee C, et al. Decreased absolute lymphocyte count and increased neutrophil/lymphocyte ratio with immune checkpoint inhibitor&#x2010;associated myocarditis. J Am Heart Assoc. 2020;9:e018306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7763791</ArticleId>
            <ArticleId IdType="pubmed">33190570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, et al. Sustained in vivo signaling by long&#x2010;lived IL&#x2010;2 induces prolonged increases of regulatory T cells. J Autoimmun. 2015;56:66&#x2013;80. 10.1016/j.haut.2014.10.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.haut.2014.10.002</ArticleId>
            <ArticleId IdType="pmc">PMC4298360</ArticleId>
            <ArticleId IdType="pubmed">25457307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Tang L, Feng Y, Zhao SY, Han M, Zhang C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourgenesis by modulation of CD8+ T cells in mice. Gut. 2020;69:1988&#x2013;97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7569398</ArticleId>
            <ArticleId IdType="pubmed">32169907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usami M, Kishimoto K, Ohata A, Miyoshi M, Aoyama M, Fueda Y, et al. Butyrate and trichostatin a attenuate nuclear factor&#x3ba;B activation and tumor necrosis factor &#x3b1; secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res. 2008;28:321&#x2013;8. 10.1016/j.nutres.2008.02.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nutres.2008.02.012</ArticleId>
            <ArticleId IdType="pubmed">19083427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vinolo MA, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short&#x2010;chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. 2011;22:849&#x2013;55. 10.1016/j.jnutbio.2010.07.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jnutbio.2010.07.009</ArticleId>
            <ArticleId IdType="pubmed">21167700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13:1299&#x2013;307. 10.1038/nm1652</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1652</ArticleId>
            <ArticleId IdType="pubmed">17922010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, McLoughlin RM, Cobb BA, Charrel&#x2010;Dennis M, Zaleski KJ, Golenbock D, et al. A bacterial carbohydrate links innate and adaptive responses through Toll&#x2010;like receptor 2. J Exp Med. 2006;203:2853&#x2013;63. 10.1084/jem.20062008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20062008</ArticleId>
            <ArticleId IdType="pmc">PMC2118167</ArticleId>
            <ArticleId IdType="pubmed">17178920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, et al. The Toll&#x2010;like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332:974&#x2013;7. 10.1126/science.1206095</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1206095</ArticleId>
            <ArticleId IdType="pmc">PMC3164325</ArticleId>
            <ArticleId IdType="pubmed">21512004</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35977003</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2326-6074</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Oct</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology research</Title>
          <ISOAbbreviation>Cancer Immunol Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines.</ArticleTitle>
        <Pagination>
          <StartPage>1167</StartPage>
          <EndPage>1174</EndPage>
          <MedlinePgn>1167-1174</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/2326-6066.CIR-22-0362</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint blockade is therapeutically successful for many patients across multiple cancer types. However, immune-related adverse events (irAE) frequently occur and can sometimes be life threatening. It is critical to understand the immunologic mechanisms of irAEs with the goal of finding novel treatment targets. Herein, we report our analysis of tissues from patients with irAE dermatitis using multiparameter immunofluorescence (IF), spatial transcriptomics, and RNA in situ hybridization (RISH). Skin psoriasis cases were studied as a comparison, as a known Th17-driven disease, and colitis was investigated as a comparison. IF analysis revealed that CD4+ and CD8+ tissue-resident memory T (TRM) cells were preferentially expanded in the inflamed portion of skin in cutaneous irAEs compared with healthy skin controls. Spatial transcriptomics allowed us to focus on areas containing TRM cells to discern functional phenotype and revealed expression of Th1-associated genes in irAEs, compared with Th17-asociated genes in psoriasis. Expression of PD-1, CTLA-4, LAG-3, and other inhibitory receptors was observed in irAE cases. RISH technology combined with IF confirmed expression of IFN, CXCL9, CXCL10, and TNF in irAE dermatitis, as well as IFN within TRM cells specifically. The Th1-skewed phenotype was confirmed in irAE colitis cases compared with healthy colon.</AbstractText>
          <CopyrightInformation>&#xa9;2022 The Authors; Published by the American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Reschke</LastName>
            <ForeName>Robin</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-2850-2526</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shapiro</LastName>
            <ForeName>Jason W</ForeName>
            <Initials>JW</Initials>
            <Identifier Source="ORCID">0000-0002-1321-8418</Identifier>
            <AffiliationInfo>
              <Affiliation>Center for Research Informatics, University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Jovian</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-9214-7576</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rouhani</LastName>
            <ForeName>Sherin J</ForeName>
            <Initials>SJ</Initials>
            <Identifier Source="ORCID">0000-0001-7248-847X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olson</LastName>
            <ForeName>Daniel J</ForeName>
            <Initials>DJ</Initials>
            <Identifier Source="ORCID">0000-0001-8902-7661</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zha</LastName>
            <ForeName>Yuanyuan</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-0574-7352</Identifier>
            <AffiliationInfo>
              <Affiliation>Human Immunological Monitoring Facility, University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gajewski</LastName>
            <ForeName>Thomas F</ForeName>
            <Initials>TF</Initials>
            <Identifier Source="ORCID">0000-0001-5727-3972</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R35 CA210098</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA009566</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Immunol Res</MedlineTA>
        <NlmUniqueID>101614637</NlmUniqueID>
        <ISSNLinking>2326-6066</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>63231-63-0</RegistryNumber>
          <NameOfSubstance UI="D012313">RNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003872" MajorTopicYN="Y">Dermatitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091246" MajorTopicYN="N">Memory T Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011565" MajorTopicYN="Y">Psoriasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>14</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35977003</ArticleId>
        <ArticleId IdType="pmc">PMC9530647</ArticleId>
        <ArticleId IdType="doi">10.1158/2326-6066.CIR-22-0362</ArticleId>
        <ArticleId IdType="pii">707917</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:1270&#x2013;1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26398076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institutional, retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 2019;80:990&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6420863</ArticleId>
            <ArticleId IdType="pubmed">30399387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reschke R, Mockenhaupt M, Simon JC, Ziemer M. Severe bullous skin eruptions on checkpoint inhibitor therapy &#x2013; in most cases severe bullous lichenoid drug eruptions. J Dtsch Dermatol Ges 2019;17:942&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31210413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013;23:498&#x2013;501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24113862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Libert C, Dejager L. How steroids steer T cells. Cell Rep 2014;7:938&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24856295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. . High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 2018;124:3706&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lommerts JE, Bekkenk MW, Luiten RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf 2021;20:883&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33896329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schreiner D, King CG. CD4+ memory T cells at home in the tissue: mechanisms for health and disease. Front Immunol 2018;9:2394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6198086</ArticleId>
            <ArticleId IdType="pubmed">30386342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights 2014;5:9&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4389010</ArticleId>
            <ArticleId IdType="pubmed">26000152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reschke R, Yu J, Flood BA, Higgs EF, Hatogai K, Gajewski TF. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer 2021;9:e003521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8487215</ArticleId>
            <ArticleId IdType="pubmed">34593622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreatta M, Carmona SJ. UCell: Robust and scalable single-cell gene signature scoring. Comput Struct Biotechnol J 2021;19:3796&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8271111</ArticleId>
            <ArticleId IdType="pubmed">34285779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan GE, Harris JE, Richmond JM. Resident memory T cells in autoimmune skin diseases. Front Immunol 2021;12:652191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8128248</ArticleId>
            <ArticleId IdType="pubmed">34012438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12461566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasson SC, Slevin SM, Cheung VTF, Nassiri I, Olsson-Brown A, Fryer E, et al. . Interferon-gamma&#x2013;producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor&#x2013;colitis. Gastroenterology 2021;161:1229&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8527886</ArticleId>
            <ArticleId IdType="pubmed">34147519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. . CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation &#x2013; a target for novel cancer therapy. Cancer Treat Rev 2018;63:40&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5801162</ArticleId>
            <ArticleId IdType="pubmed">29207310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, et al. . Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol 2017;137:350&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5258673</ArticleId>
            <ArticleId IdType="pubmed">27686391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glatigny S, Duhen R, Arbelaez C, Kumari S, Bettelli E. Integrin alpha L controls the homing of regulatory T cells during CNS autoimmunity in the absence of integrin alpha 4. Sci Rep 2015;5:7834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4296287</ArticleId>
            <ArticleId IdType="pubmed">25592296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kok L, Masopust D, Schumacher TN. The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues. Nat Rev Immunol 2022;22:283&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8415193</ArticleId>
            <ArticleId IdType="pubmed">34480118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reschke R, Gussek P, Boldt A, Sack U, K&#xf6;hl U, Lordick F, et al. . Distinct immune signatures indicative of treatment response and immune-related adverse events in melanoma patients under immune checkpoint inhibitor therapy. Int J Mol Sci 2021;22:8017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8348898</ArticleId>
            <ArticleId IdType="pubmed">34360781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lozano AX, Chaudhuri AA, Nene A, Bacchiocchi A, Earland N, Vesely MD, et al. . T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med 2022;28:353&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8866214</ArticleId>
            <ArticleId IdType="pubmed">35027754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, et al. . Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor&#x2013;induced colitis: a multi-center study. J Immunother Cancer 2018;6:142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6280383</ArticleId>
            <ArticleId IdType="pubmed">30518410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basin S, Perrin J, Michot JM, Lambotte O, Cauquil C. Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy. Eur J Cancer 2021;145:230&#x2013;3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33517201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu ZI, Link VM, Lima-Junior DS, Delaleu J, Bouladoux N, Han S-J, et al. . Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. Available from: http://www.pnas.org/doi/10.1073/pnas.2200348119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2200348119</ArticleId>
            <ArticleId IdType="pmc">PMC9245641</ArticleId>
            <ArticleId IdType="pubmed">35727974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, et al. . Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009;129:2175&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2892172</ArticleId>
            <ArticleId IdType="pubmed">19295614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butcher MJ, Wu CI, Waseem T, Galkina EV. CXCR6 regulates the recruitment of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortas. Int Immunol 2016;28:255&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4888347</ArticleId>
            <ArticleId IdType="pubmed">26614640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, et al. . IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res 2019;7:860&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30996018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, et al. . Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6839080</ArticleId>
            <ArticleId IdType="pubmed">31699151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skon CN, Lee JY, Anderson KG, Masopust D, Hogquist KA, Jameson SC. Transcriptional downregulation of S1pr1 is required for establishment of resident memory CD8+ T cells. Nat Immunol 2013;14:1285&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3844557</ArticleId>
            <ArticleId IdType="pubmed">24162775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kisuya J, Chemtai A, Raballah E, Keter A, Ouma C. The diagnostic accuracy of Th1 (IFN-&#x3b3;, TNF-&#x3b1;, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB- HIV co-infected patients. Sci Rep 2019;9:2966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6393479</ArticleId>
            <ArticleId IdType="pubmed">30814543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parameswaran N, Patial S. Tumor necrosis factor-&#x3b1; signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010;20:87&#x2013;103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3066460</ArticleId>
            <ArticleId IdType="pubmed">21133840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al. . Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, et al. . Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018;6:103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6180568</ArticleId>
            <ArticleId IdType="pubmed">30305177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariam&#xe9; AF, Touriol C, et al. . Blocking tumor necrosis factor &#x3b1; enhances CD8 T-cell-dependent immunity in experimental melanoma. Cancer Res 2015;75:2619&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25977337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montfort A, Filleron T, Virazels M, Dufau C, Milh&#xe8;s J, Pag&#xe8;s C, et al. . Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin Cancer Res 2021;27:1037&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33272982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elad S, Or R, Resnick I, Shapira MY, Elad S. Topical tacrolimus&#x2014;a novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int 2003;16:665&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12768230</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35917654</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>08</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>08</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-1967</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>109</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer treatment reviews</Title>
          <ISOAbbreviation>Cancer Treat Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>102440</StartPage>
          <MedlinePgn>102440</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctrv.2022.102440</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0305-7372(22)00109-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immune checkpoint inhibitors (ICIs) have improved cancer outcomes. However, immune-related adverse effects are common. The aim was to investigate the incidence of diarrhea and colitis of ICIs alone and in combination with chemotherapy or tyrosine kinase inhibitors (TKIs), histopathological findings, and management.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Two separate studies, including meta-analyses, were performed. Key inclusion criteria were for Study I) phase I-IV trials, and data on diarrhea and/or colitis; for Study II) studies describing histopathologic and endoscopic findings and/or biologic treatment for ICI-induced colitis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of anti-PD-1/PD-L1 antibody-induced diarrhea and colitis was 10% and 2%, respectively, with no clinically relevant differences between the compounds. The CTLA-4 inhibitor, ipilimumab, induced diarrhea and colitis in 33% and 7% of patients, respectively, whereas the incidence of diarrhea and colitis following ipilimumab combined with nivolumab was 21%-37% and 4%-8%, depending on regimen. The incidence of all-grade diarrhea following ICIs combined with chemotherapy or TKIs was high (17%-56%), whereas only 0.5% of patients developed severe (&#x2265;grade 3) colitis. The main patterns of histopathologic presentation after PD-1/CTLA-4 inhibitor mono- or combination therapy were acute and chronic active colitis and microscopic colitis-like. Infliximab and vedolizumab were equally effective against ICI-induced colitis.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Expanding treatment options include combinations of ICIs and chemotherapy/TKI with a high incidence of diarrhea and a low incidence of colitis; thus, a potential risk of overtreatment with corticosteroids exists. We suggest a more tailored approach, particularly for the management of low-grade diarrhea. Prospective clinical trials are needed to refine management.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nielsen</LastName>
            <ForeName>Dorte Lisbet</ForeName>
            <Initials>DL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: dorte.nielsen.01@regionh.dk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Juhl</LastName>
            <ForeName>Carsten Bogh</ForeName>
            <Initials>CB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: carsten.bogh.juhl@regionh.dk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Inna Markovna</ForeName>
            <Initials>IM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: inna.chen@regionh.dk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kellermann</LastName>
            <ForeName>Lauge</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: lauge.kellermann@regionh.dk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nielsen</LastName>
            <ForeName>Ole Haagen</ForeName>
            <Initials>OH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: ole.haagen.nielsen@regionh.dk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>07</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Cancer Treat Rev</MedlineTA>
        <NlmUniqueID>7502030</NlmUniqueID>
        <ISSNLinking>0305-7372</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Diarrhea</Keyword>
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Toxicity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>2</Day>
          <Hour>18</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35917654</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ctrv.2022.102440</ArticleId>
        <ArticleId IdType="pii">S0305-7372(22)00109-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35842365</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>08</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-3562</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver</Title>
          <ISOAbbreviation>Dig Liver Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID.</ArticleTitle>
        <Pagination>
          <StartPage>1162</StartPage>
          <EndPage>1167</EndPage>
          <MedlinePgn>1162-1167</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dld.2022.06.020</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1590-8658(22)00564-3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS">There is no consensus on the management of immune checkpoint inhibitor (ICI) for treating cancer in patients with pre-existing inflammatory bowel disease (IBD). The Groupe d'tude Thrapeutique des Affections Inflammatoires du tube Digestif (GETAID) aimed to provide recommendations on this topic.</AbstractText>
          <AbstractText Label="METHODS">A dedicated working group performed a comprehensive expert-based review of the literature, generated clinical key question and shaped recommendations that were further voted for approval by the educational and scientific committees of the GETAID. Using consensus methods, treatment modalities were defined by vote.</AbstractText>
          <AbstractText Label="RESULTS">Majority of patients with IBD in clinical remission can be treated with ICI after cancer diagnosis. The rate of relapse or immune-related diarrhoea or colitis upon ICI treatment is up to 39.8% and is maximal with ICI combination therapy compared to monotherapies. When starting ICI in a patient with IBD, it is recommended to assess disease activity and pursue ongoing maintenance therapy. In case of relapse or immune-related diarrhoea or colitis upon ICI treatment, treatment depends on grading of diarrhoea or colitis and may include corticosteroid therapy, infliximab and/or vedolizumab.</AbstractText>
          <AbstractText Label="CONCLUSIONS">In the present publication, we provided recommendations, which may assist gastroenterologists, haematologists, and oncologists for a better management of patients with pre-existing IBD before and during cancer treatment with ICI.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Amiot</LastName>
            <ForeName>Aurelien</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hopitaux Universitaires Bictre, AP-HP, Universite Paris Est Creteil, Le Kremlin Bictre, France; INSERM, Centre for Research in Epidemiology and Population Health, Institut Gustave Roussy, Universit Paris Saclay, Villejuif, France. Electronic address: aurelien.amiot@aphp.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laharie</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>CHU de Bordeaux, Hpital Haut-Lvque, Service d'Hpato-gastroentrologie et oncologie digestive - Universit de Bordeaux, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malamut</LastName>
            <ForeName>Georgia</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, AP-HP-Centre, Universit de Paris, Hpital Cochin, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Serrero</LastName>
            <ForeName>Melanie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, University Hospital of Marseille Nord, Aix-Marseille, Marseille University, Marseille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Poullenot</LastName>
            <ForeName>Florian</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>CHU de Bordeaux, Hpital Haut-Lvque, Service d'Hpato-gastroentrologie et oncologie digestive - Universit de Bordeaux, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>educational committee of the GETAID</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>07</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Dig Liver Dis</MedlineTA>
        <NlmUniqueID>100958385</NlmUniqueID>
        <ISSNLinking>1590-8658</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Aliment Pharmacol Ther. 2021 Feb;53(3):374-382</RefSource>
          <PMID Version="1">33314269</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Crohn's disease</Keyword>
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Inflammatory bowel disease</Keyword>
        <Keyword MajorTopicYN="N">Ulcerative colitis</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest Aurelien Amiot has received consulting fees from Abbvie, Hospira, Takeda, Gilead and Biocodex as well as lecture fees and travel accommodations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Takeda and MSD. This author has also received advisory board fees from Gilead, Takeda and Abbvie. David Laharie declares counselling, boards, transports, or personal fees from Abbvie, Biogaran, Biogen, Celgene, Celltrion, Ferring, Galapagos, HAC-pharma, Janssen, MSD, Novartis, Pfizer, Prometheus, Roche, Takeda, Theradiag, Tillots. Georgia Malamut declares consulting fees from Calypso, lecture fees from Janssen and Mayoli Spindler and congress registration fees from Janssen and Amgen Melanie Serrero has received lecture or consulting fees from Abbvie, Ferring, Amgen, Celltrion, Janssen, Ferring, Takeda and Tillotts. Florian Poullenot declares counselling, boards, transports, or personal fees from Abbvie, Biogen, Ferring, Janssen, MSD, Pfizer, Takeda. No conflicts of interest are claimed by the remaining authors.</CoiStatement>
      <InvestigatorList>
        <Investigator ValidYN="Y">
          <LastName>Peyrin-Biroulet</LastName>
          <ForeName>Laurent</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Laharie</LastName>
          <ForeName>David</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bourreille</LastName>
          <ForeName>Arnaud</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Vuitton</LastName>
          <ForeName>Lucine</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bouguen</LastName>
          <ForeName>Guillaume</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Abitbol</LastName>
          <ForeName>Vered</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Amiot</LastName>
          <ForeName>Aurelien</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Biron</LastName>
          <ForeName>Amelie</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bourrier</LastName>
          <ForeName>Anne</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Caillo</LastName>
          <ForeName>Ludovic</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Fumery</LastName>
          <ForeName>Mathurin</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gilletta</LastName>
          <ForeName>Cyrielle</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Plastaras</LastName>
          <ForeName>Laurianne</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Serrero</LastName>
          <ForeName>Melanie</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Simon</LastName>
          <ForeName>Marion</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Viennot</LastName>
          <ForeName>Stephanie</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Seksik</LastName>
          <ForeName>Philippe</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Attar</LastName>
          <ForeName>Alain</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Buisson</LastName>
          <ForeName>Anthony</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Caron</LastName>
          <ForeName>Benedicte</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Charkaoui</LastName>
          <ForeName>Maeva</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gornet</LastName>
          <ForeName>Jean-Marc</ForeName>
          <Initials>JM</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Guillo</LastName>
          <ForeName>Lucas</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Berre</LastName>
          <ForeName>Catherine Le</ForeName>
          <Initials>CL</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Louis</LastName>
          <ForeName>Edouard</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Malamut</LastName>
          <ForeName>Georgia</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mathieu</LastName>
          <ForeName>Nicolas</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Nachury</LastName>
          <ForeName>Maria</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Nancey</LastName>
          <ForeName>Stephane</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Paul</LastName>
          <ForeName>Stephane</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Reenaers</LastName>
          <ForeName>Catherine</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Treton</LastName>
          <ForeName>Xavier</ForeName>
          <Initials>X</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Uzzan</LastName>
          <ForeName>Mathieu</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wils</LastName>
          <ForeName>Pauline</ForeName>
          <Initials>P</Initials>
        </Investigator>
      </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>16</Day>
          <Hour>22</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35842365</ArticleId>
        <ArticleId IdType="doi">10.1016/j.dld.2022.06.020</ArticleId>
        <ArticleId IdType="pii">S1590-8658(22)00564-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35801666</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1447-0756</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>48</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>The journal of obstetrics and gynaecology research</Title>
          <ISOAbbreviation>J Obstet Gynaecol Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A case of recurrent endometrial cancer with long-term complete remission following pembrolizumab-induced severe immune-related adverse event colitis.</ArticleTitle>
        <Pagination>
          <StartPage>2630</StartPage>
          <EndPage>2634</EndPage>
          <MedlinePgn>2630-2634</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jog.15346</ELocationID>
        <Abstract>
          <AbstractText>Endometrial cancer is generally diagnosed at an early stage and has a good prognosis, although once it recurs, the prognosis is poor because of few therapeutic options. Since endometrial cancer has a high frequency of microsatellite instability-high/mismatch repair deficiency, the anti-PD-1 antibody pembrolizumab is expected to be one of the key therapeutic agents for recurrent endometrial cancer. Immune-related adverse events (irAEs) are autoimmune-like unique and occasionally life-threatening side effects of immune checkpoint inhibitors. Here, we report a rare case of recurrent endometrial cancer that showed long-term complete remission after developing relapsing severe irAE colitis following the introduction of pembrolizumab.</AbstractText>
          <CopyrightInformation>&#xa9; 2022 Japan Society of Obstetrics and Gynecology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yamamoto</LastName>
            <ForeName>Akiko</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-1952-7166</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagashima</LastName>
            <ForeName>Takeo</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imai</LastName>
            <ForeName>Yoshinari</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akitsu</LastName>
            <ForeName>Kensuke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamanaka</LastName>
            <ForeName>Zenta</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishi</LastName>
            <ForeName>Hirotaka</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-4110-7704</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>07</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>J Obstet Gynaecol Res</MedlineTA>
        <NlmUniqueID>9612761</NlmUniqueID>
        <ISSNLinking>1341-8076</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DPT0O3T46P</RegistryNumber>
          <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016889" MajorTopicYN="Y">Endometrial Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anti-PD-1 antibody</Keyword>
        <Keyword MajorTopicYN="N">endometrial cancer</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse event</Keyword>
        <Keyword MajorTopicYN="N">pembrolizumab</Keyword>
        <Keyword MajorTopicYN="N">recurrence</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>8</Day>
          <Hour>7</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35801666</ArticleId>
        <ArticleId IdType="doi">10.1111/jog.15346</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Colombo N, Creutzberg C, Amant F, Bosse T, Gonz&#xe1;lez-Mart&#xed;n A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41. https://doi.org/10.1093/annonc/mdv484</Citation>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. https://doi.org/10.3322/caac.21654</Citation>
        </Reference>
        <Reference>
          <Citation>Connor EV, Rose PG. Management strategies for recurrent endometrial cancer. Expert Rev Anticancer Ther. 2018;18(9):873-85. https://doi.org/10.1080/14737140.2018.1491311</Citation>
        </Reference>
        <Reference>
          <Citation>Neri M, Peiretti M, Melis GB, Piras B, Vallerino V, Paoletti AM, et al. Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother. 2019;20(16):2019-32. https://doi.org/10.1080/14656566.2019.1654996</Citation>
        </Reference>
        <Reference>
          <Citation>Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017. PO.17.00073. https://doi.org/10.1200/PO.17.00073</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87. https://doi.org/10.1186/s12916-020-01549-2</Citation>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-68. https://doi.org/10.1056/NEJMra1703481</Citation>
        </Reference>
        <Reference>
          <Citation>Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623-7. https://doi.org/10.1126/science.1255904</Citation>
        </Reference>
        <Reference>
          <Citation>Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49. https://doi.org/10.3389/fphar.2017.00311</Citation>
        </Reference>
        <Reference>
          <Citation>Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60. https://doi.org/10.1016/j.ctrv.2016.02.001 Epub 2016 Feb 6.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6(1):95. https://doi.org/10.1186/s40425-018-0411-1</Citation>
        </Reference>
        <Reference>
          <Citation>Thomas AS, Wang Y. Checkpoint inhibitor-induced colitis. Am J Gastroenterol. 2020;115(8):1301-2. https://doi.org/10.14309/ajg.0000000000000739</Citation>
        </Reference>
        <Reference>
          <Citation>Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1-10. https://doi.org/10.1200/JCO.19.02105</Citation>
        </Reference>
        <Reference>
          <Citation>Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. https://doi.org/10.1186/s40425-019-0805-8</Citation>
        </Reference>
        <Reference>
          <Citation>Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675-84. https://doi.org/10.1200/JCO.2017.77.0412</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35432346</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.</ArticleTitle>
        <Pagination>
          <StartPage>804597</StartPage>
          <MedlinePgn>804597</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">804597</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.804597</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its ligand, programmed cell death protein ligand 1 (PD-L1) and enhance antitumor T-cell activity. ICIs provide clinical benefits in a percentage of patients with advanced cancers, but they are usually associated with a remarkable spectrum of immune-related adverse events (irAEs) (e.g., rash, colitis, hepatitis, pneumonitis, endocrine, cardiac and musculoskeletal dysfunctions). Particularly patients on combination therapy (e.g., anti-CTLA-4 plus anti-PD-1/PD-L1) experience some form of irAEs. Different mechanisms have been postulated to explain these adverse events. Host factors such as genotype, gut microbiome and pre-existing autoimmune disorders may affect the risk of adverse events. Fatal ICI-related irAEs are due to myocarditis, colitis or pneumonitis. irAEs usually occur within the first months after ICI initiation but can develop as early as after the first dose to years after ICI initiation. Most irAEs resolve pharmacologically, but some appear to be persistent. Glucocorticoids represent the mainstay of management of irAEs, but other immunosuppressive drugs can be used to mitigate refractory irAEs. In the absence of specific trials, several guidelines, based on data from retrospective studies and expert consensus, have been published to guide the management of ICI-related irAEs.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Poto, Troiani, Criscuolo, Marone, Ciardiello, Tocchetti and Varricchi.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Poto</LastName>
            <ForeName>Remo</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Troiani</LastName>
            <ForeName>Teresa</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Criscuolo</LastName>
            <ForeName>Gjada</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marone</LastName>
            <ForeName>Giancarlo</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Moscati Hospital Pharmacy, Aversa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ciardiello</LastName>
            <ForeName>Fortunato</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tocchetti</LastName>
            <ForeName>Carlo Gabriele</ForeName>
            <Initials>CG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Varricchi</LastName>
            <ForeName>Gilda</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>World Allergy Organization (WAO) Center of Excellence, Naples, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council, Naples, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">PD-L1</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">cytotoxic T lymphocyte-associated protein (CTLA-4)</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor (ICI)</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse event (irAE)</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">programmed cell death protein -1 (PD-1)</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35432346</ArticleId>
        <ArticleId IdType="pmc">PMC9005797</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2022.804597</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov (2018) 8:1069&#x2013;86. doi:&#xa0;10.1158/2159-8290.CD-18-0367</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-18-0367</ArticleId>
            <ArticleId IdType="pubmed">30115704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Allison JP. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies With Curative Potential. Cell (2015) 161:205&#x2013;14. doi:&#xa0;10.1016/j.cell.2015.03.030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.03.030</ArticleId>
            <ArticleId IdType="pmc">PMC5905674</ArticleId>
            <ArticleId IdType="pubmed">25860605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lebbe C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, et al. . Survival Follow-Up and Ipilimumab Retreatment of Patients With Advanced Melanoma Who Received Ipilimumab in Prior Phase II Studies. Ann Oncol (2014) 25:2277&#x2013;84. doi:&#xa0;10.1093/annonc/mdu441</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdu441</ArticleId>
            <ArticleId IdType="pmc">PMC4990834</ArticleId>
            <ArticleId IdType="pubmed">25210016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. . Overall Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med (2017) 377:1345&#x2013;56. doi:&#xa0;10.1056/Nejmoa1709684</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/Nejmoa1709684</ArticleId>
            <ArticleId IdType="pmc">PMC5706778</ArticleId>
            <ArticleId IdType="pubmed">28889792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. . Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol (2019) 5:1411&#x2013;20. doi:&#xa0;10.1001/jamaoncol.2019.2187</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.2187</ArticleId>
            <ArticleId IdType="pmc">PMC6659167</ArticleId>
            <ArticleId IdType="pubmed">31343665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Wolchok JD. Cancer Immunotherapy Using Checkpoint Blockade. Science (2018) 359:1350&#x2013;5. doi:&#xa0;10.1126/science.aar4060</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aar4060</ArticleId>
            <ArticleId IdType="pmc">PMC7391259</ArticleId>
            <ArticleId IdType="pubmed">29567705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fritz JM, Lenardo MJ. Development of Immune Checkpoint Therapy for Cancer. J Exp Med (2019) 216:1244&#x2013;54. doi:&#xa0;10.1084/jem.20182395</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20182395</ArticleId>
            <ArticleId IdType="pmc">PMC6547853</ArticleId>
            <ArticleId IdType="pubmed">31068379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Sharpe AH. Balance and Imbalance in the Immune System: Life on the Edge. Immunity (2014) 41:682&#x2013;4. doi:&#xa0;10.1016/j.immuni.2014.11.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.11.005</ArticleId>
            <ArticleId IdType="pmc">PMC4710093</ArticleId>
            <ArticleId IdType="pubmed">25517610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ise W, Kohyama M, Nutsch KM, Lee HM, Suri A, Unanue ER, et al. . CTLA-4 Suppresses the Pathogenicity of Self Antigen-Specific T Cells by Cell-Intrinsic and Cell-Extrinsic Mechanisms. Nat Immunol (2010) 11:129&#x2013;35. doi:&#xa0;10.1038/ni.1835ni.1835</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1835ni.1835</ArticleId>
            <ArticleId IdType="pmc">PMC3235641</ArticleId>
            <ArticleId IdType="pubmed">20037585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. . Anti-PD-1 Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders or Major Toxicity With Ipilimumab. Ann Oncol (2017) 28:368&#x2013;76. doi:&#xa0;10.1093/annonc/mdw443</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw443</ArticleId>
            <ArticleId IdType="pubmed">27687304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management. J Cutan Med Surg (2021) 25:59&#x2013;76. doi:&#xa0;10.1177/1203475420943260</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1203475420943260</ArticleId>
            <ArticleId IdType="pubmed">32746624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. . Treatment Outcomes of Immune-Related Cutaneous Adverse Events. J Clin Oncol (2019) 37:2746&#x2013;58. doi:&#xa0;10.1200/JCO.18.02141</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.18.02141</ArticleId>
            <ArticleId IdType="pmc">PMC7001790</ArticleId>
            <ArticleId IdType="pubmed">31216228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol (2018) 19:345&#x2013;61. doi:&#xa0;10.1007/s40257-017-0336-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40257-017-0336-3</ArticleId>
            <ArticleId IdType="pubmed">29256113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al. . Enterocolitis Due to Immune Checkpoint Inhibitors: A Systematic Review. Gut (2018) 67:2056&#x2013;67. doi:&#xa0;10.1136/gutjnl-2018-316948</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-316948</ArticleId>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siakavellas SI, Bamias G. Checkpoint Inhibitor Colitis: A New Model of Inflammatory Bowel Disease? Curr Opin Gastroenterol (2018) 34:377&#x2013;83. doi:&#xa0;10.1097/MOG.0000000000000482</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MOG.0000000000000482</ArticleId>
            <ArticleId IdType="pubmed">30157044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, et al. . Immune-Checkpoint Inhibitor-Induced Diarrhea and Colitis in Patients With Advanced Malignancies: Retrospective Review at MD Anderson. J Immunother Cancer (2018) 6:37. doi:&#xa0;10.1186/s40425-018-0346-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0346-6</ArticleId>
            <ArticleId IdType="pmc">PMC5946546</ArticleId>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herrmann J. Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia. Nat Rev Cardiol (2020) 17:474&#x2013;502. doi:&#xa0;10.1038/s41569-020-0348-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41569-020-0348-1</ArticleId>
            <ArticleId IdType="pmc">PMC8782611</ArticleId>
            <ArticleId IdType="pubmed">32231332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, et al. . Myocarditis Associated With Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. Oncologist (2018) 23:874&#x2013;8. doi:&#xa0;10.1634/theoncologist.2018-0157</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0157</ArticleId>
            <ArticleId IdType="pmc">PMC6156187</ArticleId>
            <ArticleId IdType="pubmed">29802220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, et al. . Cardiotoxicity of Immune Checkpoint Inhibitors. ESMO Open (2017) 2:e000247. doi:&#xa0;10.1136/esmoopen-2017-000247</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000247</ArticleId>
            <ArticleId IdType="pmc">PMC5663252</ArticleId>
            <ArticleId IdType="pubmed">29104763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. . Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. JAMA Oncol (2018) 4:1721&#x2013;8. doi:&#xa0;10.1001/jamaoncol.2018.3923</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.3923</ArticleId>
            <ArticleId IdType="pmc">PMC6440712</ArticleId>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varricchi G, Galdiero MR, Tocchetti CG. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology. Circulation (2017) 136:1989&#x2013;92. doi:&#xa0;10.1161/CIRCULATIONAHA.117.029626</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.029626</ArticleId>
            <ArticleId IdType="pubmed">29158212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tocchetti CG, Galdiero MR, Varricchi G. Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology. J Am Coll Cardiol (2018) 71:1765&#x2013;7. doi:&#xa0;10.1016/j.jacc.2018.02.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2018.02.038</ArticleId>
            <ArticleId IdType="pubmed">29567211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. . Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation (2017) 136:2085&#x2013;7. doi:&#xa0;10.1161/CIRCULATIONAHA.117.030571</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.030571</ArticleId>
            <ArticleId IdType="pubmed">29158217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune Checkpoint Inhibitor-Associated Myocarditis: Manifestations and Mechanisms. J Clin Invest (2021) 131:e145186. doi:&#xa0;10.1172/JCI145186145186</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI145186145186</ArticleId>
            <ArticleId IdType="pmc">PMC7919710</ArticleId>
            <ArticleId IdType="pubmed">33645548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reuss JE, Suresh K, Naidoo J. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. Curr Oncol Rep (2020) 22:56. doi:&#xa0;10.1007/s11912-020-00920-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11912-020-00920-z</ArticleId>
            <ArticleId IdType="pubmed">32415399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Q, Zhu EC, Wu JB, Li T, Hou YL, Wang DY, et al. . Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. Front Immunol (2019) 10:108. doi:&#xa0;10.3389/fimmu.2019.00108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00108</ArticleId>
            <ArticleId IdType="pmc">PMC6369169</ArticleId>
            <ArticleId IdType="pubmed">30778352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer Immunotherapy - Immune Checkpoint Blockade and Associated Endocrinopathies. Nat Rev Endocrinol (2017) 13:195&#x2013;207. doi:&#xa0;10.1038/nrendo.2016.205</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrendo.2016.205</ArticleId>
            <ArticleId IdType="pmc">PMC5629093</ArticleId>
            <ArticleId IdType="pubmed">28106152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev (2019) 40:17&#x2013;65. doi:&#xa0;10.1210/er.2018-00006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/er.2018-00006</ArticleId>
            <ArticleId IdType="pmc">PMC6270990</ArticleId>
            <ArticleId IdType="pubmed">30184160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Patrizio A, et al. . Autoimmune Endocrine Dysfunctions Associated With Cancer Immunotherapies. Int J Mol Sci (2019) 20:2560. doi:&#xa0;10.3390/ijms20102560</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20102560</ArticleId>
            <ArticleId IdType="pmc">PMC6566424</ArticleId>
            <ArticleId IdType="pubmed">31137683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calabrese LH, Calabrese C, Cappelli LC. Rheumatic Immune-Related Adverse Events From Cancer Immunotherapy. Nat Rev Rheumatol (2018) 14:569&#x2013;79. doi:&#xa0;10.1038/s41584-018-0074-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-018-0074-9</ArticleId>
            <ArticleId IdType="pubmed">30171203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. . EULAR Points to Consider for the Diagnosis and Management of Rheumatic Immune-Related Adverse Events Due to Cancer Immunotherapy With Checkpoint Inhibitors. Ann Rheum Dis (2021) 80:36&#x2013;48. doi:&#xa0;10.1136/annrheumdis-2020-217139</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-217139</ArticleId>
            <ArticleId IdType="pmc">PMC7788064</ArticleId>
            <ArticleId IdType="pubmed">32327425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S. How We Treat Neurological Toxicity From Immune Checkpoint Inhibitors. ESMO Open (2019) 4:e000540. doi:&#xa0;10.1136/esmoopen-2019-000540</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2019-000540</ArticleId>
            <ArticleId IdType="pmc">PMC6678012</ArticleId>
            <ArticleId IdType="pubmed">31423344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, et al. . Haematological Immune-Related Adverse Events With Immune Checkpoint Inhibitors, How to Manage? Eur J Cancer (2019) 122:72&#x2013;90. doi:&#xa0;10.1016/j.ejca.2019.07.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.07.014</ArticleId>
            <ArticleId IdType="pubmed">31634647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, et al. . Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell (2017) 170:1120&#x2013;1133 e1117. doi:&#xa0;10.1016/j.cell.2017.07.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.07.024</ArticleId>
            <ArticleId IdType="pmc">PMC5591072</ArticleId>
            <ArticleId IdType="pubmed">28803728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, et al. . A Systematic Review of Adverse Events in Randomized Trials Assessing Immune Checkpoint Inhibitors. Int J Cancer (2019) 145:639&#x2013;48. doi:&#xa0;10.1002/ijc.32132</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32132</ArticleId>
            <ArticleId IdType="pubmed">30653255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu L, Khadaroo PA, Su H, Kong L, Chen L, Wang X, et al. . The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-PD-1/PD-L1 Plus Anti-CTLA-4): A Systematic Review and Meta-Analysis. BMC Cancer (2019) 19:559. doi:&#xa0;10.1186/s12885-019-5785-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-5785-z</ArticleId>
            <ArticleId IdType="pmc">PMC6558837</ArticleId>
            <ArticleId IdType="pubmed">31182049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. . Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. JAMA Oncol (2019) 5:1008&#x2013;19. doi:&#xa0;10.1001/jamaoncol.2019.0393</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.0393</ArticleId>
            <ArticleId IdType="pmc">PMC6487913</ArticleId>
            <ArticleId IdType="pubmed">31021376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Kahler KC, Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. J Clin Oncol (2012) 30:2691&#x2013;7. doi:&#xa0;10.1200/JCO.2012.41.6750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.41.6750</ArticleId>
            <ArticleId IdType="pubmed">22614989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. . Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol (2017) 35:3815&#x2013;22. doi:&#xa0;10.1200/JCO.2016.72.1167</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.72.1167</ArticleId>
            <ArticleId IdType="pubmed">28915085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, et al. . Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation. Ann Rheum Dis (2020) 79:332&#x2013;8. doi:&#xa0;10.1136/annrheumdis-2019-216109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-216109</ArticleId>
            <ArticleId IdType="pmc">PMC7031780</ArticleId>
            <ArticleId IdType="pubmed">31540935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan KK, Bass AR. Autoimmune Complications of Immunotherapy: Pathophysiology and Management. BMJ (2020) 369:m736. doi:&#xa0;10.1136/bmj.m736</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m736</ArticleId>
            <ArticleId IdType="pubmed">32253223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. . Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes (2018) 67:1471&#x2013;80. doi:&#xa0;10.2337/dbi18-0002dbi18-0002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dbi18-0002dbi18-0002</ArticleId>
            <ArticleId IdType="pmc">PMC6054443</ArticleId>
            <ArticleId IdType="pubmed">29937434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, van der Auwera BJ, et al. . Immune Checkpoint Inhibitors and Type 1 Diabetes Mellitus: A Case Report and Systematic Review. Eur J Endocrinol (2019) 181:363&#x2013;74. doi:&#xa0;10.1530/EJE-19-0291EJE-19-0291</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-19-0291EJE-19-0291</ArticleId>
            <ArticleId IdType="pmc">PMC6709545</ArticleId>
            <ArticleId IdType="pubmed">31330498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, et al. . Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab (2016) 101:4431&#x2013;9. doi:&#xa0;10.1210/jc.2016-2300</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2016-2300</ArticleId>
            <ArticleId IdType="pmc">PMC5095250</ArticleId>
            <ArticleId IdType="pubmed">27571185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, et al. . New Insight in Endocrine-Related Adverse Events Associated to Immune Checkpoint Blockade. Best Pract Res Clin Endocrinol Metab (2020) 34:101370. doi:&#xa0;10.1016/j.beem.2019.101370</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.beem.2019.101370</ArticleId>
            <ArticleId IdType="pubmed">31983543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, et al. . Delayed Immune-Related Adverse Events With Anti-PD-1-Based Immunotherapy in Melanoma. Ann Oncol (2021) 32:917&#x2013;25. doi:&#xa0;10.1016/j.annonc.2021.03.204</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.annonc.2021.03.204</ArticleId>
            <ArticleId IdType="pubmed">33798657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patrinely JR, Jr., Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, et al. . Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma. JAMA Oncol (2021) 7:744&#x2013;8. doi:&#xa0;10.1001/jamaoncol.2021.0051</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2021.0051</ArticleId>
            <ArticleId IdType="pmc">PMC7995124</ArticleId>
            <ArticleId IdType="pubmed">33764387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappelli LC, Bingham CO, 3rd. Spectrum and Impact of Checkpoint Inhibitor-Induced irAEs. Nat Rev Rheumatol (2021) 17:69&#x2013;70. doi:&#xa0;10.1038/s41584-020-00546-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-020-00546-2</ArticleId>
            <ArticleId IdType="pubmed">33235330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity. Nat Rev Clin Oncol (2022) 1&#x2013;14. doi:&#xa0;10.1038/s41571-022-00600-w</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-022-00600-w</ArticleId>
            <ArticleId IdType="pmc">PMC8790946</ArticleId>
            <ArticleId IdType="pubmed">35082367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated With Immune Checkpoint Inhibitors. Horm Metab Res (2019) 51:145&#x2013;56. doi:&#xa0;10.1055/a-0843-3366</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/a-0843-3366</ArticleId>
            <ArticleId IdType="pubmed">30861560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh N, Tiongson MD, Stewart C, Chan KK, Jivanelli B, Cappelli L, et al. . Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series. J Clin Rheumatol (2020) 27:e317-22. doi:&#xa0;10.1097/RHU.0000000000001370</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RHU.0000000000001370</ArticleId>
            <ArticleId IdType="pmc">PMC7606361</ArticleId>
            <ArticleId IdType="pubmed">32345841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, et al. . Single-Cell Immune Landscape of Human Atherosclerotic Plaques. Nat Med (2019) 25:1576&#x2013;88. doi:&#xa0;10.1038/s41591-019-0590-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0590-4</ArticleId>
            <ArticleId IdType="pmc">PMC7318784</ArticleId>
            <ArticleId IdType="pubmed">31591603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strauss L, Mahmoud MAA, Weaver JD, Tijaro-Ovalle NM, Christofides A, Wang Q, et al. . Targeted Deletion of PD-1 in Myeloid Cells Induces Antitumor Immunity. Sci Immunol (2020) 5:eaay1863. doi:&#xa0;10.1126/sciimmunol.aay18635/43/eaay1863</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.aay18635/43/eaay1863</ArticleId>
            <ArticleId IdType="pmc">PMC7183328</ArticleId>
            <ArticleId IdType="pubmed">31901074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic Immune Responses Are Regulated by the PD-1/PD-L Pathway in Mice. J Clin Invest (2007) 117:2974&#x2013;82. doi:&#xa0;10.1172/JCI31344</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI31344</ArticleId>
            <ArticleId IdType="pmc">PMC1974866</ArticleId>
            <ArticleId IdType="pubmed">17853943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poels K, van Leent MMT, Boutros C, Tissot H, Roy S, Meerwaldt AE, et al. . Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. JACC CardioOncol (2020) 2:599&#x2013;610. doi:&#xa0;10.1016/j.jaccao.2020.08.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaccao.2020.08.007</ArticleId>
            <ArticleId IdType="pmc">PMC8352210</ArticleId>
            <ArticleId IdType="pubmed">34396271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. . Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation (2020) 142:2299&#x2013;311. doi:&#xa0;10.1161/CIRCULATIONAHA.120.049981</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049981</ArticleId>
            <ArticleId IdType="pmc">PMC7736526</ArticleId>
            <ArticleId IdType="pubmed">33003973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calabretta R, Hoeller C, Pichler V, Mitterhauser M, Karanikas G, Haug A, et al. . Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries. Circulation (2020) 142:2396&#x2013;8. doi:&#xa0;10.1161/CIRCULATIONAHA.120.048708</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048708</ArticleId>
            <ArticleId IdType="pubmed">32894978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minasian L, Dimond E, Davis M, Adhikari B, Fagerstrom R, Fabian C, et al. . The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. JACC CardioOncol (2019) 1:105&#x2013;13. doi:&#xa0;10.1016/j.jaccao.2019.08.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaccao.2019.08.007</ArticleId>
            <ArticleId IdType="pmc">PMC7288847</ArticleId>
            <ArticleId IdType="pubmed">32529192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazarico I, Capel I, Gimenez-Palop O, Albert L, Berges I, Luchtenberg F, et al. . Low Frequency of Positive Antithyroid Antibodies is Observed in Patients With Thyroid Dysfunction Related to Immune Check Point Inhibitors. J Endocrinol Invest (2019) 42:1443&#x2013;50. doi:&#xa0;10.1007/s40618-019-01058-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-019-01058-x</ArticleId>
            <ArticleId IdType="pubmed">31093955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, et al. . Incidence, Features, and Prognosis of Immune-Related Adverse Events Involving the Thyroid Gland Induced by Nivolumab. PloS One (2019) 14:e0216954. doi:&#xa0;10.1371/journal.pone.0216954</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0216954</ArticleId>
            <ArticleId IdType="pmc">PMC6516638</ArticleId>
            <ArticleId IdType="pubmed">31086392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Jr., Sznol M, et al. . Bullous Disorders Associated With Anti-PD-1 and Anti-PD-L1 Therapy: A Retrospective Analysis Evaluating the Clinical and Histopathologic Features, Frequency, and Impact on Cancer Therapy. J Am Acad Dermatol (2018) 79:1081&#x2013;8. doi:&#xa0;10.1016/j.jaad.2018.07.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2018.07.008</ArticleId>
            <ArticleId IdType="pubmed">30025829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Sci Transl Med (2014) 6:230ra245. doi:&#xa0;10.1126/scitranslmed.3008002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3008002</ArticleId>
            <ArticleId IdType="pubmed">24695685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, et al. . Autoimmune Antibodies Correlate With Immune Checkpoint Therapy-Induced Toxicities. Proc Natl Acad Sci USA (2019) 116:22246&#x2013;51. doi:&#xa0;10.1073/pnas.1908079116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1908079116</ArticleId>
            <ArticleId IdType="pmc">PMC6825284</ArticleId>
            <ArticleId IdType="pubmed">31611368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansen A, Christensen SJ, Scheie D, Hojgaard JLS, Kondziella D. Neuromuscular Adverse Events Associated With Anti-PD-1 Monoclonal Antibodies: Systematic Review. Neurology (2019) 92:663&#x2013;74. doi:&#xa0;10.1212/WNL.0000000000007235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000007235</ArticleId>
            <ArticleId IdType="pubmed">30850443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. . Baseline Circulating IL-17 Predicts Toxicity While TGF-Beta1 and IL-10 are Prognostic of Relapse in Ipilimumab Neoadjuvant Therapy of Melanoma. J Immunother Cancer (2015) 3:39. doi:&#xa0;10.1186/s40425-015-0081-181</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-015-0081-181</ArticleId>
            <ArticleId IdType="pmc">PMC4570556</ArticleId>
            <ArticleId IdType="pubmed">26380086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, et al. . Predictive and Sensitive Biomarkers for Thyroid Dysfunctions During Treatment With Immune-Checkpoint Inhibitors. Cancer Sci (2020) 111:1468&#x2013;77. doi:&#xa0;10.1111/cas.14363</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.14363</ArticleId>
            <ArticleId IdType="pmc">PMC7226278</ArticleId>
            <ArticleId IdType="pubmed">32086984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4. Immunity (1995) 3:541&#x2013;7. doi:&#xa0;10.1016/1074-7613(95)90125-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/1074-7613(95)90125-6</ArticleId>
            <ArticleId IdType="pubmed">7584144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. . Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice. Science (2001) 291:319&#x2013;22. doi:&#xa0;10.1126/science.291.5502.319</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.291.5502.319</ArticleId>
            <ArticleId IdType="pubmed">11209085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 Shared Epitope Alleles and Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. Rheumatology (Oxford) (2019) 58:476&#x2013;80. doi:&#xa0;10.1093/rheumatology/key358</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/key358</ArticleId>
            <ArticleId IdType="pmc">PMC6821338</ArticleId>
            <ArticleId IdType="pubmed">30508191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Med (2019) 36:1075&#x2013;81. doi:&#xa0;10.1111/dme.14050</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dme.14050</ArticleId>
            <ArticleId IdType="pmc">PMC6698212</ArticleId>
            <ArticleId IdType="pubmed">31199005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasan Ali O, Berner F, Bomze D, Fassler M, Diem S, Cozzio A, et al. . Human Leukocyte Antigen Variation is Associated With Adverse Events of Checkpoint Inhibitors. Eur J Cancer (2019) 107:8&#x2013;14. doi:&#xa0;10.1016/j.ejca.2018.11.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.11.009</ArticleId>
            <ArticleId IdType="pubmed">30529903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. . Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. Science (2015) 350:1079&#x2013;84. doi:&#xa0;10.1126/science.aad1329</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gil-Cruz C, Perez-Shibayama C, De Martin A, Ronchi F, van der Borght K, Niederer R, et al. . Microbiota-Derived Peptide Mimics Drive Lethal Inflammatory Cardiomyopathy. Science (2019) 366:881&#x2013;6. doi:&#xa0;10.1126/science.aav3487</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aav3487</ArticleId>
            <ArticleId IdType="pubmed">31727837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. . Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab. Ann Oncol (2017) 28:1368&#x2013;79. doi:&#xa0;10.1093/annonc/mdx108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx108</ArticleId>
            <ArticleId IdType="pubmed">28368458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. . Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis. Nat Commun (2016) 7:10391. doi:&#xa0;10.1038/ncomms10391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10391</ArticleId>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. . Fulminant Myocarditis With Combination Immune Checkpoint Blockade. N Engl J Med (2016) 375:1749&#x2013;55. doi:&#xa0;10.1056/NEJMoa1609214</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1609214</ArticleId>
            <ArticleId IdType="pmc">PMC5247797</ArticleId>
            <ArticleId IdType="pubmed">27806233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berner F, Bomze D, Diem S, Ali OH, Fassler M, Ring S, et al. . Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol (2019) 5:1043&#x2013;7. doi:&#xa0;10.1001/jamaoncol.2019.0402</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.0402</ArticleId>
            <ArticleId IdType="pmc">PMC6487908</ArticleId>
            <ArticleId IdType="pubmed">31021392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. . Immune-Related Adverse Events With Immune Checkpoint Blockade: A Comprehensive Review. Eur J Cancer (2016) 54:139&#x2013;48. doi:&#xa0;10.1016/j.ejca.2015.11.016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2015.11.016</ArticleId>
            <ArticleId IdType="pubmed">26765102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lozano AX, Chaudhuri AA, Nene A, Bacchiocchi A, Earland N, Vesely MD, et al. . T Cell Characteristics Associated With Toxicity to Immune Checkpoint Blockade in Patients With Melanoma. Nat Med (2022) 28:353&#x2013;62. doi:&#xa0;10.1038/s41591-021-01623-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01623-z</ArticleId>
            <ArticleId IdType="pmc">PMC8866214</ArticleId>
            <ArticleId IdType="pubmed">35027754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. . CTLA-4 Control Over Foxp3+ Regulatory T Cell Function. Science (2008) 322:271&#x2013;5. doi:&#xa0;10.1126/science.1160062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1160062</ArticleId>
            <ArticleId IdType="pubmed">18845758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zheng P. How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity? Trends Immunol (2018) 39:953&#x2013;6. doi:&#xa0;10.1016/j.it.2018.10.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2018.10.009</ArticleId>
            <ArticleId IdType="pmc">PMC6589807</ArticleId>
            <ArticleId IdType="pubmed">30497614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanc C, Hans S, Tran T, Granier C, Saldman A, Anson M, et al. . Targeting Resident Memory T Cells for Cancer Immunotherapy. Front Immunol (2018) 9:1722. doi:&#xa0;10.3389/fimmu.2018.01722</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01722</ArticleId>
            <ArticleId IdType="pmc">PMC6072845</ArticleId>
            <ArticleId IdType="pubmed">30100906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. . Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell (2020) 182:655&#x2013;71.e622. doi:&#xa0;10.1016/j.cell.2020.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.06.001</ArticleId>
            <ArticleId IdType="pmc">PMC7415717</ArticleId>
            <ArticleId IdType="pubmed">32603654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, et al. . Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes With PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res (2021) 27:5131&#x2013;40. doi:&#xa0;10.1158/1078-0432.CCR-21-0921</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-21-0921</ArticleId>
            <ArticleId IdType="pmc">PMC8815444</ArticleId>
            <ArticleId IdType="pubmed">34244291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maekura T, Naito M, Tahara M, Ikegami N, Kimura Y, Sonobe S, et al. . Predictive Factors of Nivolumab-Induced Hypothyroidism in Patients With Non-Small Cell Lung Cancer. In Vivo (2017) 31:1035&#x2013;9. doi:&#xa0;10.21873/invivo.11166</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21873/invivo.11166</ArticleId>
            <ArticleId IdType="pmc">PMC5656848</ArticleId>
            <ArticleId IdType="pubmed">28882978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, et al. . Association of Antithyroglobulin Antibodies With the Development of Thyroid Dysfunction Induced by Nivolumab. Cancer Sci (2018) 109:3583&#x2013;90. doi:&#xa0;10.1111/cas.13800</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13800</ArticleId>
            <ArticleId IdType="pmc">PMC6215874</ArticleId>
            <ArticleId IdType="pubmed">30230649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al. . Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol (2019) 5:376&#x2013;83. doi:&#xa0;10.1001/jamaoncol.2018.5860</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.5860</ArticleId>
            <ArticleId IdType="pmc">PMC6439838</ArticleId>
            <ArticleId IdType="pubmed">30589930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bingley PJ. Clinical Applications of Diabetes Antibody Testing. J Clin Endocrinol Metab (2010) 95:25&#x2013;33. doi:&#xa0;10.1210/jc.2009-1365</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-1365</ArticleId>
            <ArticleId IdType="pubmed">19875480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin HH, Gutenberg A, Chen TY, Tsai NM, Lee CJ, Cheng YC, et al. . In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis. Sci Rep (2017) 7:43492. doi:&#xa0;10.1038/srep43492</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep43492</ArticleId>
            <ArticleId IdType="pmc">PMC5337949</ArticleId>
            <ArticleId IdType="pubmed">28262761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, et al. . Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights Into Pathogenesis From an Autopsy Series. Am J Pathol (2016) 186:3225&#x2013;35. doi:&#xa0;10.1016/j.ajpath.2016.08.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2016.08.020</ArticleId>
            <ArticleId IdType="pmc">PMC5225294</ArticleId>
            <ArticleId IdType="pubmed">27750046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. . Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer. N Engl J Med (2012) 366:2455&#x2013;65. doi:&#xa0;10.1056/NEJMoa1200694</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200694</ArticleId>
            <ArticleId IdType="pmc">PMC3563263</ArticleId>
            <ArticleId IdType="pubmed">22658128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. . Anti-Programmed-Death-Receptor-1 Treatment With Pembrolizumab in Ipilimumab-Refractory Advanced Melanoma: A Randomised Dose-Comparison Cohort of a Phase 1 Trial. Lancet (2014) 384:1109&#x2013;17. doi:&#xa0;10.1016/S0140-6736(14)60958-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(14)60958-2</ArticleId>
            <ArticleId IdType="pubmed">25034862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godel P, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Understanding Cytokine Release Syndrome. Intensive Care Med (2018) 44:371&#x2013;3. doi:&#xa0;10.1007/s00134-017-4943-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00134-017-4943-5</ArticleId>
            <ArticleId IdType="pubmed">28956093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ceschi A, Noseda R, Palin K, Verhamme K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Front Pharmacol (2020) 11:557. doi:&#xa0;10.3389/fphar.2020.00557</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.00557</ArticleId>
            <ArticleId IdType="pmc">PMC7212758</ArticleId>
            <ArticleId IdType="pubmed">32425791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, et al. . Immune Dysregulation in Cancer Patients Developing Immune-Related Adverse Events. Br J Cancer (2019) 120:63&#x2013;8. doi:&#xa0;10.1038/s41416-018-0155-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-018-0155-1</ArticleId>
            <ArticleId IdType="pmc">PMC6325132</ArticleId>
            <ArticleId IdType="pubmed">30377338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, et al. . Gut Microbiota Signatures are Associated With Toxicity to Combined CTLA-4 and PD-1 Blockade. Nat Med (2021) 27:1432&#x2013;41. doi:&#xa0;10.1038/s41591-021-01406-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01406-6</ArticleId>
            <ArticleId IdType="pubmed">34239137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice. J Immunol (2008) 181:2513&#x2013;21. doi:&#xa0;10.4049/jimmunol.181.4.2513</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.181.4.2513</ArticleId>
            <ArticleId IdType="pmc">PMC2587295</ArticleId>
            <ArticleId IdType="pubmed">18684942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. . Autoantibodies Against Cardiac Troponin I are Responsible for Dilated Cardiomyopathy in PD-1-Deficient Mice. Nat Med (2003) 9:1477&#x2013;83. doi:&#xa0;10.1038/nm955nm955</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm955nm955</ArticleId>
            <ArticleId IdType="pubmed">14595408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 Protects Against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis. J Immunol (2012) 188:4876&#x2013;84. doi:&#xa0;10.4049/jimmunol.1200389</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1200389</ArticleId>
            <ArticleId IdType="pmc">PMC3345066</ArticleId>
            <ArticleId IdType="pubmed">22491251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, et al. . Polygenic Risk for Skin Autoimmunity Impacts Immune Checkpoint Blockade in Bladder Cancer. Proc Natl Acad Sci USA (2020) 117:12288&#x2013;94. doi:&#xa0;10.1073/pnas.1922867117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1922867117</ArticleId>
            <ArticleId IdType="pmc">PMC7275757</ArticleId>
            <ArticleId IdType="pubmed">32430334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson R, Theron AJ, Rapoport BL. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Front Immunol (2019) 10:2254. doi:&#xa0;10.3389/fimmu.2019.02254</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02254</ArticleId>
            <ArticleId IdType="pmc">PMC6775220</ArticleId>
            <ArticleId IdType="pubmed">31616428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. . Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science (2015) 350:1084&#x2013;9. doi:&#xa0;10.1126/science.aac4255science.aac4255[pii</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aac4255science.aac4255[pii</ArticleId>
            <ArticleId IdType="pmc">PMC4873287</ArticleId>
            <ArticleId IdType="pubmed">26541606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. . Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors. Science (2018) 359:91&#x2013;7. doi:&#xa0;10.1126/science.aan3706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan3706</ArticleId>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. . The Commensal Microbiome is Associated With Anti-PD-1 Efficacy in Metastatic Melanoma Patients. Science (2018) 359:104&#x2013;8. doi:&#xa0;10.1126/science.aao3290</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aao3290</ArticleId>
            <ArticleId IdType="pmc">PMC6707353</ArticleId>
            <ArticleId IdType="pubmed">29302014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. . Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Science (2018) 359:97&#x2013;103. doi:&#xa0;10.1126/science.aan4236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan4236</ArticleId>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, et al. . Autoimmune Diseases and Immune-Checkpoint Inhibitors for Cancer Therapy: Review of the Literature and Personalized Risk-Based Prevention Strategy. Ann Oncol (2020) 31:724&#x2013;44. doi:&#xa0;10.1016/j.annonc.2020.03.285</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.annonc.2020.03.285</ArticleId>
            <ArticleId IdType="pubmed">32194150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, et al. . Safety and Efficacy of Anti-Programmed Death 1 Antibodies in Patients With Cancer and Pre-Existing Autoimmune or Inflammatory Disease. Eur J Cancer (2018) 91:21&#x2013;9. doi:&#xa0;10.1016/j.ejca.2017.12.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.12.008</ArticleId>
            <ArticleId IdType="pubmed">29331748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Pre-Existing Autoimmune Disease and the Risk of Immune-Related Adverse Events Among Patients Receiving Checkpoint Inhibitors for Cancer. Cancer Immunol Immunother (2019) 68:917&#x2013;26. doi:&#xa0;10.1007/s00262-019-02321-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-019-02321-z</ArticleId>
            <ArticleId IdType="pubmed">30877325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, et al. . Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. J Endocr Soc (2018) 2:241&#x2013;51. doi:&#xa0;10.1210/js.2017-00432</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/js.2017-00432</ArticleId>
            <ArticleId IdType="pmc">PMC5836529</ArticleId>
            <ArticleId IdType="pubmed">29600292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gowen MF, Giles KM, Simpson D, Tchack J, Zhou H, Moran U, et al. . Baseline Antibody Profiles Predict Toxicity in Melanoma Patients Treated With Immune Checkpoint Inhibitors. J Transl Med (2018) 16:82. doi:&#xa0;10.1186/s12967-018-1452-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-018-1452-4</ArticleId>
            <ArticleId IdType="pmc">PMC5880088</ArticleId>
            <ArticleId IdType="pubmed">29606147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valpione S, Pasquali S, Campana LG, Piccin L, Mocellin S, Pigozzo J, et al. . Sex and Interleukin-6 are Prognostic Factors for Autoimmune Toxicity Following Treatment With Anti-CTLA4 Blockade. J Transl Med (2018) 16:94. doi:&#xa0;10.1186/s12967-018-1467-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-018-1467-x</ArticleId>
            <ArticleId IdType="pmc">PMC5896157</ArticleId>
            <ArticleId IdType="pubmed">29642948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, et al. . Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. Clin Cancer Res (2019) 25:1557&#x2013;63. doi:&#xa0;10.1158/1078-0432.CCR-18-2795</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-2795</ArticleId>
            <ArticleId IdType="pubmed">30409824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. . Early B Cell Changes Predict Autoimmunity Following Combination Immune Checkpoint Blockade. J Clin Invest (2018) 128:715&#x2013;20. doi:&#xa0;10.1172/JCI9679896798[pii</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI9679896798[pii</ArticleId>
            <ArticleId IdType="pmc">PMC5785243</ArticleId>
            <ArticleId IdType="pubmed">29309048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, et al. . Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated With Immune-Checkpoint Inhibitors. Oncologist (2019) 24:1128&#x2013;36. doi:&#xa0;10.1634/theoncologist.2018-</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-</ArticleId>
            <ArticleId IdType="pmc">PMC6693718</ArticleId>
            <ArticleId IdType="pubmed">31015312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giommoni E, Giorgione R, Paderi A, Pellegrini E, Gambale E, Marini A, et al. . Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. Immuno (2021) 1:253. doi:&#xa0;10.3390/immuno1030017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/immuno1030017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schindler K, Harmankaya K, Kuk D, Mangana J, Michielin O, HoellerReinhard Dummer C, et al. . Abstract: Correlation of Absolute and Relative Eosinophil Counts With Immune-Related Adverse Events in Melanoma Patients Treated With Ipilimumab. J Clin Oncol (2014) 32:9096. doi:&#xa0;10.1200/jco.2014.32.15_suppl.9096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2014.32.15_suppl.9096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, et al. . The Association Between Tumor Burden and Severe Immune-Related Adverse Events in non-Small Cell Lung Cancer Patients Responding to Immune-Checkpoint Inhibitor Treatment. Lung Cancer (2019) 130:159&#x2013;61. doi:&#xa0;10.1016/j.lungcan.2019.02.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2019.02.011</ArticleId>
            <ArticleId IdType="pubmed">30885338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, et al. . Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Diabetes Care (2018) 41:e150&#x2013;1. doi:&#xa0;10.2337/dc18-1465dc18-1465</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc18-1465dc18-1465</ArticleId>
            <ArticleId IdType="pmc">PMC7301161</ArticleId>
            <ArticleId IdType="pubmed">30305348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen JV, Sullivan RJ, et al. . Hypophysitis Secondary to Nivolumab and Pembrolizumab is a Clinical Entity Distinct From Ipilimumab-Associated Hypophysitis. Eur J Endocrinol (2019) 181:211&#x2013;9. doi:&#xa0;10.1530/EJE-19-0238EJE-19-0238</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-19-0238EJE-19-0238</ArticleId>
            <ArticleId IdType="pubmed">31176301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M, Pietropaolo M. Time to Dissect the Autoimmune Etiology of Cancer Antibody Immunotherapy. J Clin Invest (2020) 130:51&#x2013;61. doi:&#xa0;10.1172/JCI131194131194</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI131194131194</ArticleId>
            <ArticleId IdType="pmc">PMC6934191</ArticleId>
            <ArticleId IdType="pubmed">31895048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Hodi FS, Giobbie-Hurder A, Wang X, Zhou J, Zhang A, et al. . The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. Cancer Immunol Res (2019) 7:1214&#x2013;20. doi:&#xa0;10.1158/2326-6066.CIR-18-0613</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0613</ArticleId>
            <ArticleId IdType="pmc">PMC6606328</ArticleId>
            <ArticleId IdType="pubmed">31088848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. . High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis is Associated With Reduced Survival in Patients With Melanoma. Cancer (2018) 124:3706&#x2013;14. doi:&#xa0;10.1002/cncr.31629</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31629</ArticleId>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis. Lancet (2018) 391:933. doi:&#xa0;10.1016/S0140-6736(18)30533-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)30533-6</ArticleId>
            <ArticleId IdType="pmc">PMC6668330</ArticleId>
            <ArticleId IdType="pubmed">29536852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V, et al. . Diagnosis, Monitoring and Management of Immune-Related Adverse Drug Reactions of Anti-PD-1 Antibody Therapy. Cancer Treat Rev (2016) 45:7&#x2013;18. doi:&#xa0;10.1016/j.ctrv.2016.02.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2016.02.003</ArticleId>
            <ArticleId IdType="pubmed">26922661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory Eruptions Associated With Immune Checkpoint Inhibitor Therapy: A Single-Institution Retrospective Analysis With Stratification of Reactions by Toxicity and Implications for Management. J Am Acad Dermatol (2019) 80:990&#x2013;7. doi:&#xa0;10.1016/j.jaad.2018.10.062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2018.10.062</ArticleId>
            <ArticleId IdType="pmc">PMC6420863</ArticleId>
            <ArticleId IdType="pubmed">30399387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, et al. . Vitiligo-Like Lesions Occurring in Patients Receiving Anti-Programmed Cell Death-1 Therapies are Clinically and Biologically Distinct From Vitiligo. J Am Acad Dermatol (2017) 76:863&#x2013;70. doi:&#xa0;10.1016/j.jaad.2016.10.044</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2016.10.044</ArticleId>
            <ArticleId IdType="pubmed">28094061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aggarwal P. Disproportionality Analysis of Bullous Pemphigoid Adverse Events With PD-1 Inhibitors in the FDA Adverse Event Reporting System. Expert Opin Drug Saf (2019) 18:623&#x2013;33. doi:&#xa0;10.1080/14740338.2019.1619693</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14740338.2019.1619693</ArticleId>
            <ArticleId IdType="pubmed">31088310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol (2018) 19:31&#x2013;9. doi:&#xa0;10.1007/s40257-018-0384-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40257-018-0384-3</ArticleId>
            <ArticleId IdType="pmc">PMC6244569</ArticleId>
            <ArticleId IdType="pubmed">30374901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soldatos TG, Dimitrakopoulou-Strauss A, Larribere L, Hassel JC, Sachpekidis C. Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. Diagnostics (Basel) (2018) 8:76. doi:&#xa0;10.3390/diagnostics8040076</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/diagnostics8040076</ArticleId>
            <ArticleId IdType="pmc">PMC6316083</ArticleId>
            <ArticleId IdType="pubmed">30384507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, et al. . Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. Ann Emerg Med (2019) 73:79&#x2013;87. doi:&#xa0;10.1016/j.annemergmed.2018.04.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.annemergmed.2018.04.019</ArticleId>
            <ArticleId IdType="pubmed">29880440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. . Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4. J Clin Oncol (2006) 24:2283&#x2013;9. doi:&#xa0;10.1200/JCO.2005.04.5716</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.04.5716</ArticleId>
            <ArticleId IdType="pmc">PMC2140223</ArticleId>
            <ArticleId IdType="pubmed">16710025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of Immune Checkpoint Inhibitor-Related Colitis in Solid Tumor Patients: A Systematic Review and Meta-Analysis. Oncoimmunology (2017) 6:e1344805. doi:&#xa0;10.1080/2162402X.2017.1344805</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1344805</ArticleId>
            <ArticleId IdType="pmc">PMC5665065</ArticleId>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, et al. . Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflamm Bowel Dis (2018) 24:1695&#x2013;705. doi:&#xa0;10.1093/ibd/izy1044989161</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy1044989161</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, et al. . Cancer Immunotherapy With Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis (2016) 10:395&#x2013;401. doi:&#xa0;10.1093/ecco-jcc/jjv227</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv227</ArticleId>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. . A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered With or Without Prophylactic Budesonide in Patients With Unresectable Stage III or IV Melanoma. Clin Cancer Res (2009) 15:5591&#x2013;8. doi:&#xa0;10.1158/1078-0432.CCR-09-1024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-1024</ArticleId>
            <ArticleId IdType="pubmed">19671877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Jr., Abdel-Wahab N, et al. . Infliximab Associated With Faster Symptom Resolution Compared With Corticosteroids Alone for the Management of Immune-Related Enterocolitis. J Immunother Cancer (2018) 6:103. doi:&#xa0;10.1186/s40425-018-0412-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0412-0</ArticleId>
            <ArticleId IdType="pmc">PMC6180568</ArticleId>
            <ArticleId IdType="pubmed">30305177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. . Vedolizumab Treatment for Immune Checkpoint Inhibitor-Induced Enterocolitis. Cancer Immunol Immunother (2017) 66:581&#x2013;92. doi:&#xa0;10.1007/s00262-017-1962-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-1962-6</ArticleId>
            <ArticleId IdType="pmc">PMC5406433</ArticleId>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, et al. . Early Introduction of Selective Immunosuppressive Therapy Associated With Favorable Clinical Outcomes in Patients With Immune Checkpoint Inhibitor-Induced Colitis. J Immunother Cancer (2019) 7:93. doi:&#xa0;10.1186/s40425-019-0577-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0577-1</ArticleId>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of Immune Checkpoint Inhibitors: An Evolving Picture of Risk Associated With a Vital Class of Immunotherapy Agents. Liver Int (2018) 38:976&#x2013;87. doi:&#xa0;10.1111/liv.13746</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/liv.13746</ArticleId>
            <ArticleId IdType="pubmed">29603856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. . Characterization of Liver Injury Induced by Cancer Immunotherapy Using Immune Checkpoint Inhibitors. J Hepatol (2018) 68:1181&#x2013;90. doi:&#xa0;10.1016/j.jhep.2018.01.033</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2018.01.033</ArticleId>
            <ArticleId IdType="pubmed">29427729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, et al. . Clinical Characteristics and Outcomes of Immune Checkpoint Inhibitor-Induced Pancreatic Injury. J Immunother Cancer (2019) 7:31. doi:&#xa0;10.1186/s40425-019-0502-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0502-7</ArticleId>
            <ArticleId IdType="pmc">PMC6364483</ArticleId>
            <ArticleId IdType="pubmed">30728076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. . Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination. Nat Rev Clin Oncol (2016) 13:473&#x2013;86. doi:&#xa0;10.1038/nrclinonc.2016.58</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2016.58</ArticleId>
            <ArticleId IdType="pubmed">27141885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varricchi G, Loffredo S, Marone G, Modestino L, Fallahi P, Ferrari SM, et al. . The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. Int J Mol Sci (2019) 20:3934. doi:&#xa0;10.3390/ijms20163934ijms20163934</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20163934ijms20163934</ArticleId>
            <ArticleId IdType="pmc">PMC6720642</ArticleId>
            <ArticleId IdType="pubmed">31412566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, et al. . Immune-Related Thyroiditis With Immune Checkpoint Inhibitors. Thyroid (2018) 28:1243&#x2013;51. doi:&#xa0;10.1089/thy.2018.0116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2018.0116</ArticleId>
            <ArticleId IdType="pmc">PMC6157359</ArticleId>
            <ArticleId IdType="pubmed">30132401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlov S, Salari F, Kashat L, Walfish PG. Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies. J Clin Endocrinol Metab (2015) 100:1738&#x2013;41. doi:&#xa0;10.1210/jc.2014-4560</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-4560</ArticleId>
            <ArticleId IdType="pubmed">25751110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, et al. . Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab (2017) 102:2770&#x2013;80. doi:&#xa0;10.1210/jc.2017-004483805504</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2017-004483805504</ArticleId>
            <ArticleId IdType="pmc">PMC5546861</ArticleId>
            <ArticleId IdType="pubmed">28609832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. . Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma. J Clin Endocrinol Metab (2014) 99:4078&#x2013;85. doi:&#xa0;10.1210/jc.2014-2306</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-2306</ArticleId>
            <ArticleId IdType="pubmed">25078147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albarel F, Gaudy C, Castinetti F, Carre T, Morange I, Conte-Devolx B, et al. . Long-Term Follow-Up of Ipilimumab-Induced Hypophysitis, a Common Adverse Event of the Anti-CTLA-4 Antibody in Melanoma. Eur J Endocrinol (2015) 172:195&#x2013;204. doi:&#xa0;10.1530/EJE-14-0845</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-14-0845</ArticleId>
            <ArticleId IdType="pubmed">25416723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, et al. . Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study. Clin Cancer Res (2015) 21:749&#x2013;55. doi:&#xa0;10.1158/1078-0432.CCR-14-2353</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2353</ArticleId>
            <ArticleId IdType="pmc">PMC4334697</ArticleId>
            <ArticleId IdType="pubmed">25538262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-Induced Hypophysitis: MR Imaging Findings. AJNR Am J Neuroradiol (2009) 30:1751&#x2013;3. doi:&#xa0;10.3174/ajnr.A1623</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A1623</ArticleId>
            <ArticleId IdType="pmc">PMC7051497</ArticleId>
            <ArticleId IdType="pubmed">19474123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Ipilimumab: A Novel Immunomodulating Therapy Causing Autoimmune Hypophysitis: A Case Report and Review. Eur J Endocrinol (2012) 167:1&#x2013;5. doi:&#xa0;10.1530/EJE-12-0167</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-12-0167</ArticleId>
            <ArticleId IdType="pubmed">22495490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. . The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma From the Ipilimumab Network. PloS One (2013) 8:e53745. doi:&#xa0;10.1371/journal.pone.0053745</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0053745</ArticleId>
            <ArticleId IdType="pmc">PMC3544906</ArticleId>
            <ArticleId IdType="pubmed">23341990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotwal A, Haddox C, Block M, Kudva YC. Immune Checkpoint Inhibitors: An Emerging Cause of Insulin-Dependent Diabetes. BMJ Open Diabetes Res Care (2019) 7:e000591. doi:&#xa0;10.1136/bmjdrc-2018-000591</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjdrc-2018-000591</ArticleId>
            <ArticleId IdType="pmc">PMC6398813</ArticleId>
            <ArticleId IdType="pubmed">30899528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaudy C, Clevy C, Monestier S, Dubois N, Preau Y, Mallet S, et al. . Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes. Diabetes Care (2015) 38:e182&#x2013;183. doi:&#xa0;10.2337/dc15-1331dc15-1331</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc15-1331dc15-1331</ArticleId>
            <ArticleId IdType="pubmed">26310693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, et al. . Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. Diabetes Care (2015) 38:e137&#x2013;138. doi:&#xa0;10.2337/dc15-0889dc15-0889</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc15-0889dc15-0889</ArticleId>
            <ArticleId IdType="pubmed">26116720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, et al. . Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy. Diabetes Care (2015) 38:e55&#x2013;57. doi:&#xa0;10.2337/dc14-234938/4/e55</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc14-234938/4/e55</ArticleId>
            <ArticleId IdType="pmc">PMC4370325</ArticleId>
            <ArticleId IdType="pubmed">25805871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James EA, Mallone R, Kent SC, DiLorenzo TP. T-Cell Epitopes and Neo-Epitopes in Type 1 Diabetes: A Comprehensive Update and Reappraisal. Diabetes (2020) 69:1311&#x2013;35. doi:&#xa0;10.2337/dbi19-002269/7/1311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dbi19-002269/7/1311</ArticleId>
            <ArticleId IdType="pmc">PMC7306130</ArticleId>
            <ArticleId IdType="pubmed">32561620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, et al. . Autoimmune Diabetes Induced by PD-1 Inhibitor-Retrospective Analysis and Pathogenesis: A Case Report and Literature Review. Cancer Immunol Immunother (2017) 66:1399&#x2013;410. doi:&#xa0;10.1007/s00262-017-2033-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-2033-8</ArticleId>
            <ArticleId IdType="pubmed">28634815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. . Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol (2017) 35:709&#x2013;17. doi:&#xa0;10.1200/JCO.2016.68.2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.68.2005</ArticleId>
            <ArticleId IdType="pmc">PMC5559901</ArticleId>
            <ArticleId IdType="pubmed">27646942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. . Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med (2012) 366:2443&#x2013;54. doi:&#xa0;10.1056/NEJMoa1200690</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId>
            <ArticleId IdType="pmc">PMC3544539</ArticleId>
            <ArticleId IdType="pubmed">22658127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. . Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373:1627&#x2013;39. doi:&#xa0;10.1056/NEJMoa1507643</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1507643</ArticleId>
            <ArticleId IdType="pmc">PMC5705936</ArticleId>
            <ArticleId IdType="pubmed">26412456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. . Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373:123&#x2013;35. doi:&#xa0;10.1056/NEJMoa1504627</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504627</ArticleId>
            <ArticleId IdType="pmc">PMC4681400</ArticleId>
            <ArticleId IdType="pubmed">26028407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-Analysis. JAMA Oncol (2016) 2:1607&#x2013;16. doi:&#xa0;10.1001/jamaoncol.2016.24532544610</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.24532544610</ArticleId>
            <ArticleId IdType="pubmed">27540850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, et al. . Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Clin Lung Cancer (2019) 20:442&#x2013;450 e444. doi:&#xa0;10.1016/j.cllc.2019.07.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2019.07.006</ArticleId>
            <ArticleId IdType="pubmed">31446020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, et al. . Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. J Thorac Oncol (2018) 13:1930&#x2013;9. doi:&#xa0;10.1016/j.jtho.2018.08.2035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.08.2035</ArticleId>
            <ArticleId IdType="pubmed">30267842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho JY, Kim J, Lee JS, Kim YJ, Kim SH, Lee YJ, et al. . Characteristics, Incidence, and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With non-Small Cell Lung Cancer. Lung Cancer (2018) 125:150&#x2013;6. doi:&#xa0;10.1016/j.lungcan.2018.09.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2018.09.015</ArticleId>
            <ArticleId IdType="pubmed">30429014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khunger M, Jain P, Rakshit S, Pasupuleti V, Hernandez AV, Stevenson J, et al. . Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clin Lung Cancer (2018) 19:e335&#x2013;48. doi:&#xa0;10.1016/j.cllc.2018.01.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2018.01.002</ArticleId>
            <ArticleId IdType="pubmed">29433902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Ann Oncol (2017) 28:2377&#x2013;85. doi:&#xa0;10.1093/annonc/mdx286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx286</ArticleId>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Hong D, Zhang X, Lu X, Miao J. PD-1 Inhibitors Increase the Incidence and Risk of Pneumonitis in Cancer Patients in a Dose-Independent Manner: A Meta-Analysis. Sci Rep (2017) 7:44173. doi:&#xa0;10.1038/srep44173</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep44173</ArticleId>
            <ArticleId IdType="pmc">PMC5341153</ArticleId>
            <ArticleId IdType="pubmed">28272463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsen BT, Chae JM, Dixit AS, Hartman TE, Peikert T, Roden AC. Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-Related Pneumonitis. Am J Surg Pathol (2019) 43:1331&#x2013;40. doi:&#xa0;10.1097/PAS.0000000000001298</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0000000000001298</ArticleId>
            <ArticleId IdType="pubmed">31162288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui P, Liu Z, Wang G, Ma J, Qian Y, Zhang F, et al. . Risk Factors for Pneumonitis in Patients Treated With Anti-Programmed Death-1 Therapy: A Case-Control Study. Cancer Med (2018) 7:4115&#x2013;20. doi:&#xa0;10.1002/cam4.1579</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1579</ArticleId>
            <ArticleId IdType="pmc">PMC6089164</ArticleId>
            <ArticleId IdType="pubmed">29797416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, et al. . Pre-Existing Pulmonary Fibrosis is a Risk Factor for Anti-PD-1-Related Pneumonitis in Patients With non-Small Cell Lung Cancer: A Retrospective Analysis. Lung Cancer (2018) 125:212&#x2013;7. doi:&#xa0;10.1016/j.lungcan.2018.10.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2018.10.001</ArticleId>
            <ArticleId IdType="pubmed">30429022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi E, Schinzari G, Tortora G. Pneumonitis From Immune Checkpoint Inhibitors and COVID-19: Current Concern in Cancer Treatment. J Immunother Cancer (2020) 8:e000952. doi:&#xa0;10.1136/jitc-2020-000952</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-000952</ArticleId>
            <ArticleId IdType="pmc">PMC7387312</ArticleId>
            <ArticleId IdType="pubmed">32699182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. . Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2017) 28:iv119&#x2013;42. doi:&#xa0;10.1093/annonc/mdx2253958159</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx2253958159</ArticleId>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2018) 36:1714&#x2013;68. doi:&#xa0;10.1200/JCO.2017.77.6385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.6385</ArticleId>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomatou G, Tzilas V, Kotteas E, Syrigos K, Bouros D. Immune Checkpoint Inhibitor-Related Pneumonitis. Respiration (2020) 99:932&#x2013;42. doi:&#xa0;10.1159/000509941</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000509941</ArticleId>
            <ArticleId IdType="pubmed">33260191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. . Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw (2019) 17:255&#x2013;89. doi:&#xa0;10.6004/jnccn.2019.0013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2019.0013</ArticleId>
            <ArticleId IdType="pubmed">30865922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. . Rheumatic Disorders Associated With Immune Checkpoint Inhibitors in Patients With Cancer-Clinical Aspects and Relationship With Tumour Response: A Single-Centre Prospective Cohort Study. Ann Rheum Dis (2018) 77:393&#x2013;8. doi:&#xa0;10.1136/annrheumdis-2017-212257</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-212257</ArticleId>
            <ArticleId IdType="pubmed">29146737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappelli LC, Gutierrez AK, Bingham CO, 3rd, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken) (2017) 69:1751&#x2013;63. doi:&#xa0;10.1002/acr.23177</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.23177</ArticleId>
            <ArticleId IdType="pmc">PMC5478477</ArticleId>
            <ArticleId IdType="pubmed">27998041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith MH, Bass AR. Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response. Arthritis Care Res (Hoboken) (2019) 71:362&#x2013;6. doi:&#xa0;10.1002/acr.23467</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.23467</ArticleId>
            <ArticleId IdType="pubmed">29125905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calabrese C, Cappelli LC, Kostine M, Kirchner E, Braaten T, Calabrese L. Polymyalgia Rheumatica-Like Syndrome From Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature. RMD Open (2019) 5:e000906. doi:&#xa0;10.1136/rmdopen-2019-000906</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/rmdopen-2019-000906</ArticleId>
            <ArticleId IdType="pmc">PMC6525600</ArticleId>
            <ArticleId IdType="pubmed">31168414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, et al. . Clinical Presentation of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Differs by Immunotherapy Regimen. Semin Arthritis Rheum (2018) 48:553&#x2013;7. doi:&#xa0;10.1016/j.semarthrit.2018.02.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2018.02.011</ArticleId>
            <ArticleId IdType="pmc">PMC6150859</ArticleId>
            <ArticleId IdType="pubmed">29573850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappelli LC, Bingham CO, 3rd. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. Arthritis Rheumatol (2021) 73:553&#x2013;65. doi:&#xa0;10.1002/art.41587</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41587</ArticleId>
            <ArticleId IdType="pmc">PMC8005424</ArticleId>
            <ArticleId IdType="pubmed">33186490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Aure K, et al. . Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients With Cancer. Neurology (2018) 91:e985&#x2013;94. doi:&#xa0;10.1212/WNL.0000000000006124</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006124</ArticleId>
            <ArticleId IdType="pubmed">30089619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al. . Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. Circulation (2018) 138:743&#x2013;5. doi:&#xa0;10.1161/CIRCULATIONAHA.118.035898</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035898</ArticleId>
            <ArticleId IdType="pubmed">30359135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreira A, Loquai C, Pfohler C, Kahler KC, Knauss S, Heppt MV, et al. . Myositis and Neuromuscular Side-Effects Induced by Immune Checkpoint Inhibitors. Eur J Cancer (2019) 106:12&#x2013;23. doi:&#xa0;10.1016/j.ejca.2018.09.033</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.09.033</ArticleId>
            <ArticleId IdType="pubmed">30453170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liewluck T, Kao JC, Mauermann ML. PD-1 Inhibitor-Associated Myopathies: Emerging Immune-Mediated Myopathies. J Immunother (2018) 41:208&#x2013;11. doi:&#xa0;10.1097/CJI.0000000000000196</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000196</ArticleId>
            <ArticleId IdType="pubmed">29200081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an Adverse Event of Immune Checkpoint Blockade for Cancer Therapy. Semin Arthritis Rheum (2019) 48:736&#x2013;40. doi:&#xa0;10.1016/j.semarthrit.2018.05.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2018.05.006</ArticleId>
            <ArticleId IdType="pubmed">29909921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groarke JD, Cheng S, Moslehi J. Cancer-Drug Discovery and Cardiovascular Surveillance. N Engl J Med (2013) 369:1779&#x2013;81. doi:&#xa0;10.1056/NEJMp1313140</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMp1313140</ArticleId>
            <ArticleId IdType="pubmed">24180496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. . Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol (2018) 71:1755&#x2013;64. doi:&#xa0;10.1016/j.jacc.2018.02.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2018.02.037</ArticleId>
            <ArticleId IdType="pmc">PMC6196725</ArticleId>
            <ArticleId IdType="pubmed">29567210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. . Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitors. Cardiovasc Res (2019) 115:854&#x2013;68. doi:&#xa0;10.1093/cvr/cvz0265304411[pii</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvz0265304411[pii</ArticleId>
            <ArticleId IdType="pmc">PMC6452314</ArticleId>
            <ArticleId IdType="pubmed">30715219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. . Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study. Lancet Oncol (2018) 19:1579&#x2013;89. doi:&#xa0;10.1016/S1470-2045(18)30608-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30608-9</ArticleId>
            <ArticleId IdType="pmc">PMC6287923</ArticleId>
            <ArticleId IdType="pubmed">30442497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B, et al. . Immune Checkpoint Inhibitor-Induced Myositis, the Earliest and Most Lethal Complication Among Rheumatic and Musculoskeletal Toxicities. Autoimmun Rev (2020) 19:102586. doi:&#xa0;10.1016/j.autrev.2020.102586</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2020.102586</ArticleId>
            <ArticleId IdType="pubmed">32535094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, et al. . Smoldering Myocarditis Following Immune Checkpoint Blockade. J Immunother Cancer (2017) 5:91. doi:&#xa0;10.1186/s40425-017-0296-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0296-4</ArticleId>
            <ArticleId IdType="pmc">PMC5697345</ArticleId>
            <ArticleId IdType="pubmed">29157297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. . Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation (2019) 140:80&#x2013;91. doi:&#xa0;10.1161/CIRCULATIONAHA.118.034497</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.034497</ArticleId>
            <ArticleId IdType="pmc">PMC6779326</ArticleId>
            <ArticleId IdType="pubmed">31390169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, et al. . Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. Can J Cardiol (2018) 34:1059&#x2013;68. doi:&#xa0;10.1016/j.cjca.2018.03.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cjca.2018.03.012</ArticleId>
            <ArticleId IdType="pubmed">29980467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puzanov I, Diab A, Abdallah K, Bingham CO, 3rd, Brogdon C, Dadu R, et al. . Managing Toxicities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations From the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer (2017) 5:95. doi:&#xa0;10.1186/s40425-017-0300-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0300-z</ArticleId>
            <ArticleId IdType="pmc">PMC5697162</ArticleId>
            <ArticleId IdType="pubmed">29162153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Buhlaiga N, Thebault P, Lapointe R, Johnson NA, Miller WH., Jr. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. N Engl J Med (2019) 380:2375&#x2013;6. doi:&#xa0;10.1056/NEJMc1903064</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1903064</ArticleId>
            <ArticleId IdType="pubmed">31189042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thackeray JT, Pietzsch S, Stapel B, Ricke-Hoch M, Lee CW, Bankstahl JP, et al. . Insulin Supplementation Attenuates Cancer-Induced Cardiomyopathy and Slows Tumor Disease Progression. JCI Insight (2017) 2 e93098. doi:&#xa0;10.1172/jci.insight.9309893098</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.9309893098</ArticleId>
            <ArticleId IdType="pmc">PMC5436547</ArticleId>
            <ArticleId IdType="pubmed">28515362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, et al. . Targeting Early Stages of Cardiotoxicity From Anti-PD1 Immune Checkpoint Inhibitor Therapy. Eur Heart J (2022) 43:316&#x2013;29. doi:&#xa0;10.1093/eurheartj/ehab4306352226</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehab4306352226</ArticleId>
            <ArticleId IdType="pubmed">34389849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varricchi G, Galdiero MR, Tocchetti CG. Novel Actors on the Stage of Cardiac Dysfunction Induced by Anti-PD1 Oncological Treatments. Eur Heart J (2021) 43:330&#x2013;2. doi:&#xa0;10.1093/eurheartj/ehab5846359545[pii</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehab5846359545[pii</ArticleId>
            <ArticleId IdType="pubmed">34459886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. . Neurological Adverse Events Associated With Immune Checkpoint Inhibitors: Review of the Literature. Eur J Cancer (2017) 73:1&#x2013;8. doi:&#xa0;10.1016/j.ejca.2016.12.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2016.12.001</ArticleId>
            <ArticleId IdType="pubmed">28064139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, et al. . Neurologic Toxicity Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Study. J Immunother Cancer (2019) 7:134. doi:&#xa0;10.1186/s40425-019-0617-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0617-x</ArticleId>
            <ArticleId IdType="pmc">PMC6530194</ArticleId>
            <ArticleId IdType="pubmed">31118078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, et al. . Haematological Immune-Related Adverse Events Induced by Anti-PD-1 or Anti-PD-L1 Immunotherapy: A Descriptive Observational Study. Lancet Haematol (2019) 6:e48&#x2013;57. doi:&#xa0;10.1016/S2352-3026(18)30175-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2352-3026(18)30175-3</ArticleId>
            <ArticleId IdType="pubmed">30528137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, et al. . Hematological Immune Related Adverse Events After Treatment With Immune Checkpoint Inhibitors. Eur J Cancer (2021) 147:170&#x2013;81. doi:&#xa0;10.1016/j.ejca.2021.01.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2021.01.013</ArticleId>
            <ArticleId IdType="pubmed">33706206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, et al. . Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated With Immune Checkpoint Inhibitors. Am J Hematol (2019) 94:563&#x2013;74. doi:&#xa0;10.1002/ajh.25448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.25448</ArticleId>
            <ArticleId IdType="pmc">PMC9552038</ArticleId>
            <ArticleId IdType="pubmed">30790338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. . Cutaneous, Gastrointestinal, Hepatic, Endocrine, and Renal Side-Effects of Anti-PD-1 Therapy. Eur J Cancer (2016) 60:190&#x2013;209. doi:&#xa0;10.1016/j.ejca.2016.02.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2016.02.025</ArticleId>
            <ArticleId IdType="pubmed">27085692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami N, Motwani S, Riella LV. Renal Complications of Immune Checkpoint Blockade. Curr Probl Cancer (2017) 41:100&#x2013;10. doi:&#xa0;10.1016/j.currproblcancer.2016.12.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.currproblcancer.2016.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC5440194</ArticleId>
            <ArticleId IdType="pubmed">28189263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. . Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance. Nat Rev Clin Oncol (2019) 16:563&#x2013;80. doi:&#xa0;10.1038/s41571-019-0218-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-019-0218-0</ArticleId>
            <ArticleId IdType="pubmed">31092901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. . Clinicopathological Features of Acute Kidney Injury Associated With Immune Checkpoint Inhibitors. Kidney Int (2016) 90:638&#x2013;47. doi:&#xa0;10.1016/j.kint.2016.04.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2016.04.008</ArticleId>
            <ArticleId IdType="pmc">PMC4983464</ArticleId>
            <ArticleId IdType="pubmed">27282937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, et al. . Nephrotoxicity of Immune Checkpoint Inhibitors Beyond Tubulointerstitial Nephritis: Single-Center Experience. J Immunother Cancer (2019) 7:2. doi:&#xa0;10.1186/s40425-018-0478-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0478-8</ArticleId>
            <ArticleId IdType="pmc">PMC6322290</ArticleId>
            <ArticleId IdType="pubmed">30612580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoun J, Titah C, Cochereau I. Ocular and Orbital Side-Effects of Checkpoint Inhibitors: A Review Article. Curr Opin Oncol (2016) 28:288&#x2013;94. doi:&#xa0;10.1097/CCO.0000000000000296</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0000000000000296</ArticleId>
            <ArticleId IdType="pubmed">27136135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, Wei X. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. Front Immunol (2021) 12:701951. doi:&#xa0;10.3389/fimmu.2021.701951</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.701951</ArticleId>
            <ArticleId IdType="pmc">PMC8421677</ArticleId>
            <ArticleId IdType="pubmed">34504488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, et al. . Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. Am J Ophthalmol (2019) 202:109&#x2013;17. doi:&#xa0;10.1016/j.ajo.2019.02.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajo.2019.02.012</ArticleId>
            <ArticleId IdType="pubmed">30772350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, et al. . Ocular Adverse Events Following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. Ocul Immunol Inflamm (2020) 28:854&#x2013;9. doi:&#xa0;10.1080/09273948.2019.1583347</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2019.1583347</ArticleId>
            <ArticleId IdType="pmc">PMC8130843</ArticleId>
            <ArticleId IdType="pubmed">31013173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, et al. . Sicca Syndrome Associated With Immune Checkpoint Inhibitor Therapy. Oncologist (2019) 24:1259&#x2013;69. doi:&#xa0;10.1634/theoncologist.2018-0823</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0823</ArticleId>
            <ArticleId IdType="pmc">PMC6738284</ArticleId>
            <ArticleId IdType="pubmed">30996010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. . Pembrolizumab Versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 372:2521&#x2013;32. doi:&#xa0;10.1056/NEJMoa1503093</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1503093</ArticleId>
            <ArticleId IdType="pubmed">25891173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med (2016) 375:1856&#x2013;67. doi:&#xa0;10.1056/NEJMoa1602252</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1602252</ArticleId>
            <ArticleId IdType="pmc">PMC5564292</ArticleId>
            <ArticleId IdType="pubmed">27718784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. . Nivolumab and Ipilimumab Versus Ipilimumab in Untreated Melanoma. N Engl J Med (2015) 372:2006&#x2013;17. doi:&#xa0;10.1056/NEJMoa1414428</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1414428</ArticleId>
            <ArticleId IdType="pmc">PMC5744258</ArticleId>
            <ArticleId IdType="pubmed">25891304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan SA, Pruitt SL, Xuan L, Gerber DE. Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options. JAMA Oncol (2016) 2:1507&#x2013;8. doi:&#xa0;10.1001/jamaoncol.2016.2238</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5656433</ArticleId>
            <ArticleId IdType="pubmed">27262099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. Ann Intern Med (2018) 168:121&#x2013;30. doi:&#xa0;10.7326/M17-20732667695</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M17-20732667695</ArticleId>
            <ArticleId IdType="pubmed">29297009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tison A, Quere G, Misery L, Funck-Brentano E, Danlos FX, Routier E, et al. . Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol (2019) 71:2100&#x2013;11. doi:&#xa0;10.1002/art.41068</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41068</ArticleId>
            <ArticleId IdType="pubmed">31379105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. . Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol (2015) 33:3193&#x2013;8. doi:&#xa0;10.1200/JCO.2015.60.8448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.60.8448</ArticleId>
            <ArticleId IdType="pmc">PMC5087335</ArticleId>
            <ArticleId IdType="pubmed">26282644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. . Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol (2017) 35:785&#x2013;92. doi:&#xa0;10.1200/JCO.2015.66.1389</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.66.1389</ArticleId>
            <ArticleId IdType="pubmed">28068177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotwal A, Kottschade L, Ryder M. PD-L1 Inhibitor-Induced Thyroiditis Is Associated With Better Overall Survival in Cancer Patients. Thyroid (2020) 30:177&#x2013;84. doi:&#xa0;10.1089/thy.2019.0250</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2019.0250</ArticleId>
            <ArticleId IdType="pmc">PMC7047075</ArticleId>
            <ArticleId IdType="pubmed">31813343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. . Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol (2016) 152:45&#x2013;51. doi:&#xa0;10.1001/jamadermatol.2015.2707</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2015.2707</ArticleId>
            <ArticleId IdType="pubmed">26501224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 373:1270&#x2013;1. doi:&#xa0;10.1056/NEJMc1509660</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1509660</ArticleId>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, et al. . Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association. Circulation (2020) 141:e69&#x2013;92. doi:&#xa0;10.1161/CIR.0000000000000745</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIR.0000000000000745</ArticleId>
            <ArticleId IdType="pubmed">31902242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. . Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ Heart Fail (2020) 13:e007405. doi:&#xa0;10.1161/CIRCHEARTFAILURE.120.007405</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.120.007405</ArticleId>
            <ArticleId IdType="pmc">PMC7673642</ArticleId>
            <ArticleId IdType="pubmed">33176455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, et al. . Association of Steroids Use With Survival in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) (2020) 12:546. doi:&#xa0;10.3390/cancers12030546</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12030546</ArticleId>
            <ArticleId IdType="pmc">PMC7139305</ArticleId>
            <ArticleId IdType="pubmed">32120803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. . Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol (2018) 36:2872&#x2013;8. doi:&#xa0;10.1200/JCO.2018.79.0006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.79.0006</ArticleId>
            <ArticleId IdType="pubmed">30125216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott SC, Pennell NA. Early Use of Systemic Corticosteroids in Patients With Advanced NSCLC Treated With Nivolumab. J Thorac Oncol (2018) 13:1771&#x2013;5. doi:&#xa0;10.1016/j.jtho.2018.06.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.06.004</ArticleId>
            <ArticleId IdType="pubmed">29935305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuca G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, et al. . Modulation of Peripheral Blood Immune Cells by Early Use of Steroids and its Association With Clinical Outcomes in Patients With Metastatic non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. ESMO Open (2019) 4:e000457. doi:&#xa0;10.1136/esmoopen-2018-000457</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2018-000457</ArticleId>
            <ArticleId IdType="pmc">PMC6435242</ArticleId>
            <ArticleId IdType="pubmed">30964126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chasset F, Pages C, Biard L, Roux J, Sidina I, Madelaine I, et al. . Single-Center Study Under a French Temporary Authorization for Use (TAU) Protocol for Ipilimumab in Metastatic Melanoma: Negative Impact of Baseline Corticosteroids. Eur J Dermatol (2015) 25:36&#x2013;44. doi:&#xa0;10.1684/ejd.2014.2471</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1684/ejd.2014.2471</ArticleId>
            <ArticleId IdType="pubmed">25500362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol (2019) 37:1927&#x2013;34. doi:&#xa0;10.1200/JCO.19.00189</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.00189</ArticleId>
            <ArticleId IdType="pubmed">31206316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Draghi A, Borch TH, Radic HD, Chamberlain CA, Gokuldass A, Svane IM, et al. . Differential Effects of Corticosteroids and Anti-TNF on Tumor-Specific Immune Responses: Implications for the Management of irAEs. Int J Cancer (2019) 145:1408&#x2013;13. doi:&#xa0;10.1002/ijc.32080</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32080</ArticleId>
            <ArticleId IdType="pubmed">30575963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel F, van den Eertwegh AJM, et al. . Association of Anti-TNF With Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res (2020) 26:2268&#x2013;74. doi:&#xa0;10.1158/1078-0432.CCR-19-3322</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3322</ArticleId>
            <ArticleId IdType="pubmed">31988197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesage C, Longvert C, Prey S, Maanaoui S, Dreno B, Machet L, et al. . Incidence and Clinical Impact of Anti-TNFalpha Treatment of Severe Immune Checkpoint Inhibitor-Induced Colitis in Advanced Melanoma: The Mecolit Survey. J Immunother (2019) 42:175&#x2013;9. doi:&#xa0;10.1097/CJI.0000000000000268</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000268</ArticleId>
            <ArticleId IdType="pubmed">31090656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen AY, Wolchok JD, Bass AR. TNF in the Era of Immune Checkpoint Inhibitors: Friend or Foe? Nat Rev Rheumatol (2021) 17:213&#x2013;23. doi:&#xa0;10.1038/s41584-021-00584-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-021-00584-4</ArticleId>
            <ArticleId IdType="pmc">PMC8366509</ArticleId>
            <ArticleId IdType="pubmed">33686279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suijkerbuijk KPM, Verheijden RJ. TNF Inhibition for Immune Checkpoint Inhibitor-Induced irAEs: The Jury is Still Out. Nat Rev Rheumatol (2021) 17:505. doi:&#xa0;10.1038/s41584-021-00640-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-021-00640-z</ArticleId>
            <ArticleId IdType="pubmed">34103723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, et al. . Prophylactic TNF Blockade Uncouples Efficacy and Toxicity in Dual CTLA-4 and PD-1 Immunotherapy. Nature (2019) 569:428&#x2013;32. doi:&#xa0;10.1038/s41586-019-1162-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1162-y</ArticleId>
            <ArticleId IdType="pubmed">31043740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. . Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation (2020) 141:2031&#x2013;4. doi:&#xa0;10.1161/CIRCULATIONAHA.119.044703</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.044703</ArticleId>
            <ArticleId IdType="pmc">PMC7301778</ArticleId>
            <ArticleId IdType="pubmed">32539614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galdiero MR, Morelli E, Triggianese P, Carucci L, Punziano A, Pinto A, et al. . First Report of De Novo Nivolumab-Induced Oligoarthritis in a Young Man With Relapsing Classic Hodgkin Lymphoma. J Clin Rheumatol (2020) 27:S877&#x2013;8. doi:&#xa0;10.1097/RHU.0000000000001459</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RHU.0000000000001459</ArticleId>
            <ArticleId IdType="pmc">PMC8746895</ArticleId>
            <ArticleId IdType="pubmed">32511147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimba A, Ikuta K. Control of Immunity by Glucocorticoids in Health and Disease. Semin Immunopathol (2020) 42:669&#x2013;80. doi:&#xa0;10.1007/s00281-020-00827-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-020-00827-8</ArticleId>
            <ArticleId IdType="pubmed">33219395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent Therapy With Immune Checkpoint Inhibitors and TNFalpha Blockade in Patients With Gastrointestinal Immune-Related Adverse Events. J Immunother Cancer (2019) 7:226. doi:&#xa0;10.1186/s40425-019-0711-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0711-0</ArticleId>
            <ArticleId IdType="pmc">PMC6704680</ArticleId>
            <ArticleId IdType="pubmed">31439050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalisz KR, Ramaiya NH, Laukamp KR, Gupta A. Immune Checkpoint Inhibitor Therapy-Related Pneumonitis: Patterns and Management. Radiographics (2019) 39:1923&#x2013;37. doi:&#xa0;10.1148/rg.2019190036</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/rg.2019190036</ArticleId>
            <ArticleId IdType="pubmed">31584861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang JH, Bluestone JA, Young A. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends Immunol (2021) 42:293&#x2013;311. doi:&#xa0;10.1016/j.it.2021.02.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2021.02.006</ArticleId>
            <ArticleId IdType="pubmed">33714688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, et al. . Outcomes of Vedolizumab Therapy in Patients With Immune Checkpoint Inhibitor-Induced Colitis: A Multi-Center Study. J Immunother Cancer (2018) 6:142. doi:&#xa0;10.1186/s40425-018-0461-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0461-4</ArticleId>
            <ArticleId IdType="pmc">PMC6280383</ArticleId>
            <ArticleId IdType="pubmed">30518410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frohne CC, Llano EM, Perkovic A, Cohen RD, Luke JJ. Complete Response of Metastatic Melanoma in a Patient With Crohn&#x2019;s Disease Simultaneously Receiving Anti-Alpha4beta7 and Anti-PD1 Antibodies. J Immunother Cancer (2019) 7:1. doi:&#xa0;10.1186/s40425-018-0484-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0484-x</ArticleId>
            <ArticleId IdType="pmc">PMC6322234</ArticleId>
            <ArticleId IdType="pubmed">30612589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. . Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. N Engl J Med (2019) 380:2377&#x2013;9. doi:&#xa0;10.1056/NEJMc1901677</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1901677</ArticleId>
            <ArticleId IdType="pubmed">31189043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, et al. . Rituximab for Nivolumab Plus Ipilimumab-Induced Encephalitis in a Small-Cell Lung Cancer Patient. Ann Oncol (2017) 28:2318&#x2013;9. doi:&#xa0;10.1093/annonc/mdx252</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx252</ArticleId>
            <ArticleId IdType="pubmed">28911080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, et al. . Rituximab in the Treatment of Pembrolizumab-Induced Myasthenia Gravis. Eur J Cancer (2018) 102:49&#x2013;51. doi:&#xa0;10.1016/j.ejca.2018.07.125</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.07.125</ArticleId>
            <ArticleId IdType="pubmed">30138772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mamlouk O, Lin JS, Abdelrahim M, Tchakarov AS, Glass WF, Selamet U, et al. . Checkpoint Inhibitor-Related Renal Vasculitis and Use of Rituximab. J Immunother Cancer (2020) 8:e000750. doi:&#xa0;10.1136/jitc-2020-000750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-000750</ArticleId>
            <ArticleId IdType="pmc">PMC7380836</ArticleId>
            <ArticleId IdType="pubmed">32718987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. . Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade. J Oncol Pharm Pract (2019) 25:551&#x2013;7. doi:&#xa0;10.1177/1078155217745144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155217745144</ArticleId>
            <ArticleId IdType="pubmed">29207939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, et al. . Successful Treatment of Arthritis Induced by Checkpoint Inhibitors With Tocilizumab: A Case Series. Ann Rheum Dis (2017) 76:2061&#x2013;4. doi:&#xa0;10.1136/annrheumdis-2017-211560</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-211560</ArticleId>
            <ArticleId IdType="pubmed">28830882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Miller WH., Jr. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. N Engl J Med (2017) 376:1989&#x2013;91. doi:&#xa0;10.1056/NEJMc1703047</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1703047</ArticleId>
            <ArticleId IdType="pubmed">28514612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, et al. . IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity From Immunotherapy. Cancer Immunol Res (2019) 7:860&#x2013;5. doi:&#xa0;10.1158/2326-6066.CIR-18-0682</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0682</ArticleId>
            <ArticleId IdType="pubmed">30996018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. . Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated Colitis. Nat Med (2018) 24:1804&#x2013;8. doi:&#xa0;10.1038/s41591-018-0238-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0238-9</ArticleId>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang RS, Padegimas A, Murphy KM, Evans PT, Peters CJ, Domenico CM, et al. . Treatment of Corticosteroid Refractory Immune Checkpoint Inhibitor Myocarditis With Infliximab: A Case Series. Cardiooncology (2021) 7:13. doi:&#xa0;10.1186/s40959-021-00095-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40959-021-00095-x</ArticleId>
            <ArticleId IdType="pmc">PMC8008661</ArticleId>
            <ArticleId IdType="pubmed">33785062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. . Intensified Immunosuppressive Therapy in Patients With Immune Checkpoint Inhibitor-Induced Myocarditis. J Immunother Cancer (2020) 8:e001887. doi:&#xa0;10.1136/jitc-2020-001887</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001887</ArticleId>
            <ArticleId IdType="pmc">PMC7725077</ArticleId>
            <ArticleId IdType="pubmed">33298621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar B, Ballas Z. Adverse Events Associated With Immune Checkpoint Blockade. N Engl J Med (2018) 378:1164. doi:&#xa0;10.1056/NEJMc1801663</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1801663</ArticleId>
            <ArticleId IdType="pmc">PMC6433406</ArticleId>
            <ArticleId IdType="pubmed">29565520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mann DL. Innate Immunity and the Failing Heart: The Cytokine Hypothesis Revisited. Circ Res (2015) 116:1254&#x2013;68. doi:&#xa0;10.1161/CIRCRESAHA.116.302317</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.116.302317</ArticleId>
            <ArticleId IdType="pmc">PMC4380242</ArticleId>
            <ArticleId IdType="pubmed">25814686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frantz S, Falcao-Pires I, Balligand JL, Bauersachs J, Brutsaert D, Ciccarelli M, et al. . The Innate Immune System in Chronic Cardiomyopathy: A European Society of Cardiology (ESC) Scientific Statement From the Working Group on Myocardial Function of the ESC. Eur J Heart Fail (2018) 20:445&#x2013;59. doi:&#xa0;10.1002/ejhf.1138</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejhf.1138</ArticleId>
            <ArticleId IdType="pmc">PMC5993315</ArticleId>
            <ArticleId IdType="pubmed">29333691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. . Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med (2013) 369:699&#x2013;710. doi:&#xa0;10.1056/NEJMoa1215734</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1215734</ArticleId>
            <ArticleId IdType="pubmed">23964932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. . Vedolizumab as Induction and Maintenance Therapy for Crohn&#x2019;s Disease. N Engl J Med (2013) 369:711&#x2013;21. doi:&#xa0;10.1056/NEJMoa1215739</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1215739</ArticleId>
            <ArticleId IdType="pubmed">23964933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sands BE, Peyrin-Biroulet L, Loftus EV, Jr., Danese S, Colombel JF, Toruner M, et al. . Vedolizumab Versus Adalimumab for Moderate-To-Severe Ulcerative Colitis. N Engl J Med (2019) 381:1215&#x2013;26. doi:&#xa0;10.1056/NEJMoa1905725</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1905725</ArticleId>
            <ArticleId IdType="pubmed">31553834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varricchi G, Poto R, Ianiro G, Punziano A, Marone G, Gasbarrini A, et al. . Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions. Front Immunol (2021) 12:712915. doi:&#xa0;10.3389/fimmu.2021.712915</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.712915</ArticleId>
            <ArticleId IdType="pmc">PMC8366412</ArticleId>
            <ArticleId IdType="pubmed">34408753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness of Fecal-Derived Microbiota Transfer Using Orally Administered Capsules for Recurrent Clostridium Difficile Infection. BMC Infect Dis (2015) 15:191. doi:&#xa0;10.1186/s12879-015-0930-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-015-0930-z</ArticleId>
            <ArticleId IdType="pmc">PMC4506624</ArticleId>
            <ArticleId IdType="pubmed">25885020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. . Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium Difficile Infection: A Randomized Clinical Trial. JAMA (2017) 318:1985&#x2013;93. doi:&#xa0;10.1001/jama.2017.17077</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2017.17077</ArticleId>
            <ArticleId IdType="pmc">PMC5820695</ArticleId>
            <ArticleId IdType="pubmed">29183074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection. JAMA (2014) 312:1772&#x2013;8. doi:&#xa0;10.1001/jama.2014.13875</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2014.13875</ArticleId>
            <ArticleId IdType="pubmed">25322359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allegretti JR, Korzenik JR, Hamilton MJ. Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. Difficile Infection. J Vis Exp (2014) 52154. doi:&#xa0;10.3791/52154</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3791/52154</ArticleId>
            <ArticleId IdType="pmc">PMC4396937</ArticleId>
            <ArticleId IdType="pubmed">25549239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silverman MS, Davis I, Pillai DR. Success of Self-Administered Home Fecal Transplantation for Chronic Clostridium Difficile Infection. Clin Gastroenterol Hepatol (2010) 8:471&#x2013;3. doi:&#xa0;10.1016/j.cgh.2010.01.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2010.01.007</ArticleId>
            <ArticleId IdType="pubmed">20117243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tariq R, Pardi DS, Bartlett MG, Khanna S. Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection: A Systematic Review and Meta-Analysis. Clin Infect Dis (2019) 68:1351&#x2013;8. doi:&#xa0;10.1093/cid/ciy7215078604</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciy7215078604</ArticleId>
            <ArticleId IdType="pubmed">30957161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Groot P, Scheithauer T, Bakker GJ, Prodan A, Levin E, Khan MT, et al. . Donor Metabolic Characteristics Drive Effects of Faecal Microbiota Transplantation on Recipient Insulin Sensitivity, Energy Expenditure and Intestinal Transit Time. Gut (2020) 69:502&#x2013;12. doi:&#xa0;10.1136/gutjnl-2019-318320</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2019-318320</ArticleId>
            <ArticleId IdType="pmc">PMC7034343</ArticleId>
            <ArticleId IdType="pubmed">31147381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson BC, Vatanen T, Cutfield WS, O&#x2019;Sullivan JM. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front Cell Infect Microbiol (2019) 9:2. doi:&#xa0;10.3389/fcimb.2019.00002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2019.00002</ArticleId>
            <ArticleId IdType="pmc">PMC6348388</ArticleId>
            <ArticleId IdType="pubmed">30719428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic Review: The Global Incidence of Faecal Microbiota Transplantation-Related Adverse Events From 2000 to 2020. Aliment Pharmacol Ther (2021) 53:33&#x2013;42. doi:&#xa0;10.1111/apt.16148</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.16148</ArticleId>
            <ArticleId IdType="pubmed">33159374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, et al. . Reorganisation of Faecal Microbiota Transplant Services During the COVID-19 Pandemic. Gut (2020) 69:1555&#x2013;63. doi:&#xa0;10.1136/gutjnl-2020-321829</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2020-321829</ArticleId>
            <ArticleId IdType="pmc">PMC7456726</ArticleId>
            <ArticleId IdType="pubmed">32620549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. . Moving Towards Personalized Treatments of Immune-Related Adverse Events. Nat Rev Clin Oncol (2020) 17:504&#x2013;15. doi:&#xa0;10.1038/s41571-020-0352-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-020-0352-8</ArticleId>
            <ArticleId IdType="pubmed">32246128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-Angiogenic Agents - Overcoming Tumour Endothelial Cell Anergy and Improving Immunotherapy Outcomes. Nat Rev Clin Oncol (2021) 18:527&#x2013;40. doi:&#xa0;10.1038/s41571-021-00496-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-021-00496-y</ArticleId>
            <ArticleId IdType="pubmed">33833434</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35307927</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1445-5994</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>52</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Internal medicine journal</Title>
          <ISOAbbreviation>Intern Med J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint inhibitor colitis with concurrent cytomegalovirus reactivation.</ArticleTitle>
        <Pagination>
          <StartPage>504</StartPage>
          <EndPage>505</EndPage>
          <MedlinePgn>504-505</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/imj.15714</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Au</LastName>
            <ForeName>Minnie</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-3740-4725</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rajagopalan</LastName>
            <ForeName>Arvind</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tee</LastName>
            <ForeName>Derrick</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Philpott</LastName>
            <ForeName>Hamish</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Intern Med J</MedlineTA>
        <NlmUniqueID>101092952</NlmUniqueID>
        <ISSNLinking>1444-0903</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003586" MajorTopicYN="Y">Cytomegalovirus Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>5</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35307927</ArticleId>
        <ArticleId IdType="doi">10.1111/imj.15714</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35296560</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>07</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e004560</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2022-004560</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitor-associated colitis (ICIC) affects approximately 15% of cancer patients treated with immunotherapy. Although histological evaluation is potentially valuable for both the diagnosis of ICIC and evaluation of disease activity, use in clinical practice is heterogeneous. We aimed to develop expert recommendations to standardize histological assessment of disease activity in patients with ICIC. Using the modified Research and Development/University of California Los Angeles (RAND/UCLA) appropriateness methodology, an international panel of 11 pathologists rated the appropriateness of 99 statements on a 9-point Likert scale during two rounds of anonymous voting. Results were discussed between rounds using moderated videoconferences. There are currently no disease-specific instruments for assessing histological features of ICIC. The panel considered that colonoscopy with at least three biopsies per segment from a total of at least five segments, including both endoscopically normal and inflamed areas, was appropriate for tissue acquisition. They agreed that biopsies should be oriented such that the long axis of the colonic crypts is visualized and should be stained with hematoxylin and eosin. Histological items that the panel voted were appropriate to evaluate in ICIC included the degree of structural/architectural change, chronic inflammatory infiltrate, lamina propria and intraepithelial neutrophils, crypt abscesses and destruction, erosions/ulcerations, apoptosis, surface intraepithelial lymphocytosis, and subepithelial collagen thickness. The appropriateness of routine immunohistochemistry was uncertain. These expert recommendations will help standardize assessment of histological activity in patients with ICIC. The panel also identified the development and validation of an ICIC-specific histological index as a research priority.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-4698-9948</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology &amp; Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada christopher.ma@ucalgary.ca.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pai</LastName>
            <ForeName>Rish K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schaeffer</LastName>
            <ForeName>David F</ForeName>
            <Initials>DF</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Anatomic Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krell</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guizzetti</LastName>
            <ForeName>Leonardo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McFarlane</LastName>
            <ForeName>Stefanie C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>MacDonald</LastName>
            <ForeName>John K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Won-Tak</ForeName>
            <Initials>WT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of California San Francisco, San Francisco, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feakins</LastName>
            <ForeName>Roger M</ForeName>
            <Initials>RM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histopathology, Royal Free Hospital, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kirsch</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine and Pathobiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lauwers</LastName>
            <ForeName>Gregory Y</ForeName>
            <Initials>GY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departments of Pathology and Oncologic Sciences, University of South Florida, Tampa, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pai</LastName>
            <ForeName>Reetesh K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosty</LastName>
            <ForeName>Christophe</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Envoi Specialist Pathologists, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Srivastava</LastName>
            <ForeName>Amitabh</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walsh</LastName>
            <ForeName>Joanna C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feagan</LastName>
            <ForeName>Brian G</ForeName>
            <Initials>BG</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Schulich School of Medicine, Western University, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jairath</LastName>
            <ForeName>Vipul</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Schulich School of Medicine, Western University, London, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA008748</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CTLA-4 Antigen</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
        <Keyword MajorTopicYN="N">neutrophil infiltration</Keyword>
        <Keyword MajorTopicYN="N">programmed cell death 1 receptor</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: CM has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pfizer, Roche; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Ferring, Janssen, Takeda, and Pfizer; research support from Pfizer. RiKP has received consulting fees from AbbVie, Eli Lilly, Allergan, Genentech, and Alimentiv. DFS has received consulting fees from Merck, Diaceutics, Pfizer, Allakos, and Alimentiv; stock ownership in Satisfai Health. JK has received advisory fees from Clovis Oncology, AstraZeneca, and Tesaro. LG is an employee of Alimentiv. SCM is an employee of Alimentiv. JKM is an employee of Alimentiv. RMF receives consulting fees from Alimentiv and has received fees from Bristol Myers Squibb, Janssen, and Takeda. RK has received consulting fees from Alimentiv. GYL has received consulting fees from Alimentiv. ReKP has received consulting fees from Alimentiv. CR has received consulting fees from Alimentiv. BGF is a scientific advisory board member for AbbVie, Allergan, Amgen, AstraZeneca, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Elan, Biogen, Ferring, Genentech&#x2013;Roche, Janssen&#x2013;Johnson &amp; Johnson, Merck, Millennium, Nestl&#xe9;, Novo Nordisk, Novartis, Pfizer, Prometheus, Protagonist, Receptos, Salix, Sigmoid Pharma, Takeda, Teva, TiGenix, Tillotts Pharma, and UCB Pharma; consulting fees from AbbVie, Actogenix, Akros, Albireo Pharma, Allergan, Amgen, AstraZeneca, Avaxia Biologics, Avir Pharma, Axcan, Baxter Healthcare, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan&#x2013;Biogen, EnGene, Ferring, Genentech&#x2013;Roche, GiCare Pharma, Gilead Sciences, Given Imaging, GlaxoSmithKline, Ironwood, Janssen Biotech&#x2013;Centocor, Janssen&#x2013;Johnson &amp; Johnson, Kyowa Hakko Kirin, Eli Lilly, Merck, Mesoblast Pharma, Millennium, Nestl&#xe9;, Novo Nordisk, Novartis, Pfizer, Prometheus, Protagonist, Receptos Salix, Sanofi, Shire, Sigmoid Pharma, Synergy Pharma, Takeda, Teva, TiGenix, Tillotts Pharma, UCB Pharma, Vertex, VHsquared, Wyeth, Zealand, and Zygenia; lecture fees from AbbVie, Janssen&#x2013;Johnson &amp; Johnson, Takeda, and UCB Pharma, and grant support from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech&#x2013;Centocor, Janssen&#x2013;Johnson &amp; Johnson, Pfizer, Receptos, Sanofi, and Takeda, and is the Senior Scientific Officer of Alimentiv Inc. VJ has received has received consulting/advisory board fees from AbbVie, Alimentiv (formerly Robarts Clinical Trials), Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert; speaker&#x2019;s fees from, Abbvie, Ferring, Galapagos, Janssen Pfizer Shire, Takeda.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35296560</ArticleId>
        <ArticleId IdType="pmc">PMC8928359</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2022-004560</ArticleId>
        <ArticleId IdType="pii">jitc-2022-004560</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pasquali S, Chiarion-Sileni V, Rossi CR, et al. . Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: a network meta-analysis. Cancer Treat Rev 2017;54:34&#x2013;42. 10.1016/j.ctrv.2017.01.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2017.01.006</ArticleId>
            <ArticleId IdType="pubmed">28189914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, et al. . Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2018;2:Cd011123. 10.1002/14651858.CD011123.pub2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD011123.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6491081</ArticleId>
            <ArticleId IdType="pubmed">29405038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aoun F, Kourie HR, Sideris S, et al. . Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Immunotherapy 2015;7:1259&#x2013;71. 10.2217/imt.15.91</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt.15.91</ArticleId>
            <ArticleId IdType="pubmed">26595284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raju S, Joseph R, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther 2018;7:63&#x2013;75. 10.2147/ITT.S125070</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/ITT.S125070</ArticleId>
            <ArticleId IdType="pmc">PMC6074780</ArticleId>
            <ArticleId IdType="pubmed">30105218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallis CJD, Lawson K, Butaney M, et al. . Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. Jpn J Clin Oncol 2020;50:800&#x2013;9. 10.1093/jjco/hyaa021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jjco/hyaa021</ArticleId>
            <ArticleId IdType="pubmed">32083295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 2020;36:25&#x2013;32. 10.1097/MOG.0000000000000593</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MOG.0000000000000593</ArticleId>
            <ArticleId IdType="pubmed">31609734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Meti N, Miller WH, et al. . Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ 2019;191:E40&#x2013;6. 10.1503/cmaj.180870</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.180870</ArticleId>
            <ArticleId IdType="pmc">PMC6333545</ArticleId>
            <ArticleId IdType="pubmed">30642824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakakida T, Ishikawa T, Chihara Y, et al. . Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol 2020;22:919&#x2013;27. 10.1007/s12094-019-02214-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-019-02214-8</ArticleId>
            <ArticleId IdType="pubmed">31576495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Cancer Institute . Common terminology criteria for adverse events (CTCAE) v5.0. cancer therapy evaluation program, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Choi K, Abu-Sbeih H, Samdani R, et al. . Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 2019;25:385&#x2013;93. 10.1093/ibd/izy240</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy240</ArticleId>
            <ArticleId IdType="pmc">PMC7534361</ArticleId>
            <ArticleId IdType="pubmed">30169584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. . Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 2018;24:1695&#x2013;705. 10.1093/ibd/izy104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, et al. . Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018;6:95. 10.1186/s40425-018-0411-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0411-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M, Wang Y, Rubio-Tapia A, et al. . AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 2021;160:1384&#x2013;93. 10.1053/j.gastro.2020.08.063</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.08.063</ArticleId>
            <ArticleId IdType="pubmed">33080231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, MacDonald JK, Nguyen TM, et al. . Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. Aliment Pharmacol Ther 2022;55:178&#x2013;90. 10.1111/apt.16718</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.16718</ArticleId>
            <ArticleId IdType="pubmed">34821404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geboes K, Riddell R, Ost A, et al. . A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404&#x2013;9. 10.1136/gut.47.3.404</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.47.3.404</ArticleId>
            <ArticleId IdType="pmc">PMC1728046</ArticleId>
            <ArticleId IdType="pubmed">10940279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosli MH, Feagan BG, Zou G, et al. . Development and validation of a histological index for UC. Gut 2017;66:50&#x2013;8. 10.1136/gutjnl-2015-310393</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-310393</ArticleId>
            <ArticleId IdType="pubmed">26475633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. . Development and validation of the Nancy histological index for UC. Gut 2017;66:43&#x2013;9. 10.1136/gutjnl-2015-310187</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-310187</ArticleId>
            <ArticleId IdType="pubmed">26464414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitch K, Bernstein S, Aguilar M. The RAND/UCLA Appropriateness Method User&#x2019;s Manual. Santa Monica, CA: RAND Corporation, 2001.</Citation>
        </Reference>
        <Reference>
          <Citation>Pai RK, Pai RK, Brown I, et al. . The significance of histological activity measurements in immune checkpoint inhibitor colitis. Aliment Pharmacol Ther 2021;53:150&#x2013;9. 10.1111/apt.16142</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.16142</ArticleId>
            <ArticleId IdType="pubmed">33146440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. . Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018;3:e000278. 10.1136/esmoopen-2017-000278</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burla J, Bluemel S, Biedermann L, et al. . Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course. Inflamm Intest Dis 2020;5:109&#x2013;16. 10.1159/000507579</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000507579</ArticleId>
            <ArticleId IdType="pmc">PMC7506225</ArticleId>
            <ArticleId IdType="pubmed">32999883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung VTF, Gupta T, Olsson-Brown A, et al. . Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer 2020;123:207&#x2013;15. 10.1038/s41416-020-0882-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-020-0882-y</ArticleId>
            <ArticleId IdType="pmc">PMC7374736</ArticleId>
            <ArticleId IdType="pubmed">32418993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mooradian MJ, Wang DY, Coromilas A, et al. . Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 2020;8:e000451. 10.1136/jitc-2019-000451</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2019-000451</ArticleId>
            <ArticleId IdType="pmc">PMC7239692</ArticleId>
            <ArticleId IdType="pubmed">32414860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright AP, Piper MS, Bishu S, et al. . Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 2019;49:1474&#x2013;83. 10.1111/apt.15263</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.15263</ArticleId>
            <ArticleId IdType="pmc">PMC6637018</ArticleId>
            <ArticleId IdType="pubmed">31035308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology 2019;58:vii17&#x2013;28. 10.1093/rheumatology/kez465</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kez465</ArticleId>
            <ArticleId IdType="pmc">PMC6900915</ArticleId>
            <ArticleId IdType="pubmed">31816081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. . Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016;10:395&#x2013;401. 10.1093/ecco-jcc/jjv227</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv227</ArticleId>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Sedano R, Almradi A, et al. . An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials. Gastroenterology 2021;160:2291&#x2013;302. 10.1053/j.gastro.2021.02.035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2021.02.035</ArticleId>
            <ArticleId IdType="pmc">PMC8851891</ArticleId>
            <ArticleId IdType="pubmed">33610533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patil PA, Zhang X. Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy. Arch Pathol Lab Med 2021;145:571&#x2013;82. 10.5858/arpa.2020-0070-RA</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/arpa.2020-0070-RA</ArticleId>
            <ArticleId IdType="pubmed">32338534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JH, Pezhouh MK, Lauwers GY, et al. . Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol 2017;41:643&#x2013;54. 10.1097/PAS.0000000000000829</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0000000000000829</ArticleId>
            <ArticleId IdType="pubmed">28296676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen J, Ernstoff M, Wang Y, et al. . Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 2020;8:e000604. 10.1136/jitc-2020-000604</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-000604</ArticleId>
            <ArticleId IdType="pmc">PMC7295425</ArticleId>
            <ArticleId IdType="pubmed">32532839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo Y-C, Price C, Blenman K, et al. . Checkpoint inhibitor colitis shows drug-specific differences in immune cell reaction that overlap with inflammatory bowel disease and predict response to colitis therapy. Am J Clin Pathol 2021;156:214&#x2013;28. 10.1093/ajcp/aqaa217</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ajcp/aqaa217</ArticleId>
            <ArticleId IdType="pubmed">33555016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adam K, Iuga A, Tocheva AS, et al. . A novel mouse model for checkpoint inhibitor-induced adverse events. PLoS One 2021;16:e0246168. 10.1371/journal.pone.0246168</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0246168</ArticleId>
            <ArticleId IdType="pmc">PMC7877613</ArticleId>
            <ArticleId IdType="pubmed">33571254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pivetta E, Capuano A, Scanziani E, et al. . Multiplex staining depicts the immune infiltrate in colitis-induced colon cancer model. Sci Rep 2019;9:12645. 10.1038/s41598-019-49164-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-49164-3</ArticleId>
            <ArticleId IdType="pmc">PMC6718623</ArticleId>
            <ArticleId IdType="pubmed">31477791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Battat R, Parker CE, et al. . Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease? Expert Rev Gastroenterol Hepatol 2019;13:319&#x2013;30. 10.1080/17474124.2019.1563481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17474124.2019.1563481</ArticleId>
            <ArticleId IdType="pubmed">30791776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kane SV, Sandborn WJ, Rufo PA, et al. . Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309&#x2013;14. 10.1111/j.1572-0241.2003.07458.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1572-0241.2003.07458.x</ArticleId>
            <ArticleId IdType="pubmed">12818275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou F, Wang X, Glitza Oliva IC, et al. . Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 2021;9:e002058. 10.1136/jitc-2020-002058</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-002058</ArticleId>
            <ArticleId IdType="pmc">PMC7805368</ArticleId>
            <ArticleId IdType="pubmed">33436487</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35277350</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1938-0682</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical genitourinary cancer</Title>
          <ISOAbbreviation>Clin Genitourin Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>260</StartPage>
          <EndPage>269</EndPage>
          <MedlinePgn>260-269</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clgc.2022.01.017</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1558-7673(22)00035-0</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION">Immune checkpoint inhibitors (ICIs) have become a standard of care in metastatic renal cell carcinoma (mRCC) but are associated with immune-related adverse events (irAEs) including colitis. Growing evidence suggests proton pump inhibitors (PPIs) increase the risk of inflammatory bowel disease (IBD). Given the pathophysiological overlap between IBD and ICI colitis, we sought to evaluate the relationship between PPI use and ICI colitis in mRCC patients.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS">We performed a retrospective study of adult patients who received ICI therapy for mRCC between 2015 and 2018 at University of Texas Southwestern Medical Center affiliated hospitals. Clinical characteristics, oncological outcomes, ICI colitis details, and PPI use details were collected by manual chart review. The diagnosis of ICI colitis was made via biopsy when available, or by clinical criteria (symptoms and response to immunosuppressive therapy) when biopsy specimens were unavailable or inconclusive. Univariable and multivariable logistic regression analyses were conducted to assess the potential contribution of PPIs to ICI colitis.</AbstractText>
          <AbstractText Label="RESULTS">A total of 176 patients received ICI therapy for mRCC, of which 16 (9.1%) were diagnosed with ICI colitis. Patients with ICI colitis presented with elevated stool lactoferritin and calprotectin and a wide range of endoscopic and histologic findings. There were no significant differences between patients with and without ICI colitis in age, gender, medical comorbidities, RCC history, and overall survival. However, exposure to ipilimumab and PPI use were more frequently observed in patients with ICI colitis than those without. In univariable and multivariable logistic regression analyses, exposure to ipilimumab and chronic use of PPIs &gt; 8 weeks were significantly associated with ICI colitis.</AbstractText>
          <AbstractText Label="CONCLUSION">In addition to ipilimumab use, chronic use of PPIs may be associated with ICI colitis in patients with mRCC.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Jianyi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elias</LastName>
            <ForeName>Roy</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Lan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Levonyak</LastName>
            <ForeName>Nicholas</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Asokan</LastName>
            <ForeName>Annapoorani</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>University of Texas Southwestern Medical School, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Christie</LastName>
            <ForeName>Alana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kubiliun</LastName>
            <ForeName>Nisa</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brugarolas</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hammers</LastName>
            <ForeName>Hans J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: hans.hammers@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P50 CA196516</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 DK007745</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Genitourin Cancer</MedlineTA>
        <NlmUniqueID>101260955</NlmUniqueID>
        <ISSNLinking>1558-7673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002292" MajorTopicYN="Y">Carcinoma, Renal Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="Y">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Kidney Cancer</Keyword>
        <Keyword MajorTopicYN="N">Proton Pump Inhibitor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35277350</ArticleId>
        <ArticleId IdType="mid">NIHMS1850387</ArticleId>
        <ArticleId IdType="pmc">PMC9701615</ArticleId>
        <ArticleId IdType="doi">10.1016/j.clgc.2022.01.017</ArticleId>
        <ArticleId IdType="pii">S1558-7673(22)00035-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine 2018;378:1277&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5972549</ArticleId>
            <ArticleId IdType="pubmed">29562145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine 2019;380:1103&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6716603</ArticleId>
            <ArticleId IdType="pubmed">30779531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine 2019;380:1116&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30779529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine 2019;380:1103&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6716603</ArticleId>
            <ArticleId IdType="pubmed">30779531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Annals of oncology : official journal of the European Society for Medical Oncology 2017;28:2377&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33080231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. Journal of immunotherapy 2018;41:101&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29401166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology 2017;18:611&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28359784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017;35:3851&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7587408</ArticleId>
            <ArticleId IdType="pubmed">28678668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. Journal for immunotherapy of cancer 2018;6:37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5946546</ArticleId>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA oncology 2016;2:234&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26633184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahler KC, Eigentler TK, Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer immunology, immunotherapy : CII 2018;67:825&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29487980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. Journal of Crohn&#x2019;s &amp; colitis 2016;10:395&#x2013;401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 2017;6:e1344805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5665065</ArticleId>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature communications 2016;7:10391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proceedings of the National Academy of Sciences of the United States of America 2018;115:157&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5776803</ArticleId>
            <ArticleId IdType="pubmed">29255057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature medicine 2018;24:1804&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Wang Y. Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis. Digestive Diseases and Sciences 2020;65:797&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32040664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals of oncology : official journal of the European Society for Medical Oncology 2017;28:1368&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28368458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson MA, Verdi S, Maxan M-E, et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nature communications 2018;9:2655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6037668</ArticleId>
            <ArticleId IdType="pubmed">29985401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Bastard Q, Al-Ghalith GA, Gr&#xe9;goire M, et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Alimentary Pharmacology &amp; Therapeutics 2018;47:332&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29205415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012;5:219&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3388523</ArticleId>
            <ArticleId IdType="pubmed">22778788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonderup OK, Nielsen GL, Dall M, Pottegard A, Hallas J. Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. Alimentary pharmacology &amp; therapeutics 2018;48:618&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30039564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Law EH, Badowski M, Hung YT, Weems K, Sanchez A, Lee TA. Association Between Proton Pump Inhibitors and Microscopic Colitis. The Annals of pharmacotherapy 2017;51:253&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27733667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz NRM, Hutfless S, Herrinton LJ, et al. Proton Pump Inhibitors, H2 Blocker Use, and Risk of Inflammatory Bowel Disease in Children. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2019;24:489&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6836698</ArticleId>
            <ArticleId IdType="pubmed">31719810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juillerat P, Schneeweiss S, Cook EF, Ananthakrishnan AN, Mogun H, Korzenik JR. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Alimentary pharmacology &amp; therapeutics 2012;36:239&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22670722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R, Richardson P, Yu H, Kramer J, Hou JK. Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease. Digestion 2017;95:188&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28288458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K, Abu-Sbeih H, Samdani R, et al. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflammatory bowel diseases 2019;25:385&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7534361</ArticleId>
            <ArticleId IdType="pubmed">30169584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siakavellas SI, Bamias G. Checkpoint inhibitor colitis: a new model of inflammatory bowel disease? Current opinion in gastroenterology 2018;34:377&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30157044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflammatory bowel diseases 2018;24:1695&#x2013;705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. The American journal of gastroenterology 2013;108:308&#x2013;28; quiz 29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23419381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology 2017;152:706&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28257716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016;14:836&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26748223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou F, Abu-Sbeih H, Ma W, et al. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. Journal of the National Comprehensive Cancer Network : JNCCN 2020:1&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33316767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verhaegh BP, de Vries F, Masclee AA, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Alimentary pharmacology &amp; therapeutics 2016;43:1004&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26956016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: a Systematic Review. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32007539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut 2016;65:740&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4853569</ArticleId>
            <ArticleId IdType="pubmed">26657899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruno G, Zaccari P, Rocco G, et al. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World journal of gastroenterology 2019;25:2706&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6580352</ArticleId>
            <ArticleId IdType="pubmed">31235994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Dougan M, Tyan K, et al. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer 2020;126:3758&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7381363</ArticleId>
            <ArticleId IdType="pubmed">32567084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonnenberg A, Turner KO, Genta RM. Decreased risk for microscopic colitis and inflammatory bowel disease among patients with reflux disease. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2018;20:813&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29603881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World journal of gastroenterology 2017;23:6500&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5643276</ArticleId>
            <ArticleId IdType="pubmed">29085200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clinic proceedings 2018;93:240&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29406201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diao X. Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer. Thoracic cancer 2020;11:1763&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7327691</ArticleId>
            <ArticleId IdType="pubmed">32374445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Clinical Cancer Research 2020;26:5487&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32933995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin BD, Jiao XD, Zhou XC, et al. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncoimmunology 2021;10:1929727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8296970</ArticleId>
            <ArticleId IdType="pubmed">34350061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Canadian family physician Medecin de famille canadien 2017;63:354&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5429051</ArticleId>
            <ArticleId IdType="pubmed">28500192</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35236743</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e003725</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2021-003725</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Despite the great success, the therapeutic benefits of immune checkpoint inhibitors (ICIs) in cancer immunotherapy are limited by either various resistance mechanisms or ICI-associated toxic effects including gastrointestinal toxicity. Thus, novel therapeutic strategies that provide manageable side effects to existing ICIs would enhance and expand their therapeutic efficacy and application. Due to its proven role in cancer development and immune regulation, gut microbiome has gained increasing expectation as a potential armamentarium to optimize immunotherapy with ICI. However, much has to be learned to fully harness gut microbiome for clinical applicability. Here we have assessed whether microbial metabolites working at the interface between microbes and the host immune system may optimize ICI therapy.</AbstractText>
          <AbstractText Label="METHODS">To this purpose, we have tested indole-3-carboxaldehyde (3-IAld), a microbial tryptophan catabolite known to contribute to epithelial barrier function and immune homeostasis in the gut via the aryl hydrocarbon receptor (AhR), in different murine models of ICI-induced colitis. Epithelial barrier integrity, inflammation and changes in gut microbiome composition and function were analyzed. AhR, indoleamine 2,3-dioxygenase 1, interleukin (IL)-10 and IL-22 knockout mice were used to investigate the mechanism of 3-IAld activity. The function of the microbiome changes induced by 3-IAld was evaluated on fecal microbiome transplantation (FMT). Finally, murine tumor models were used to assess the effect of 3-IAld treatment on the antitumor activity of ICI.</AbstractText>
          <AbstractText Label="RESULTS">On administration to mice with ICI-induced colitis, 3-IAld protected mice from intestinal damage via a dual action on both the host and the microbes. Indeed, paralleling the activation of the host AhR/IL-22-dependent pathway, 3-IAld also affected the composition and function of the microbiota such that FMT from 3-IAld-treated mice protected against ICI-induced colitis with the contribution of butyrate-producing bacteria. Importantly, while preventing intestinal damage, 3-IAld did not impair the antitumor activity of ICI.</AbstractText>
          <AbstractText Label="CONCLUSIONS">This study provides a proof-of-concept demonstration that moving past bacterial phylogeny and focusing on bacterial metabolome may lead to a new class of discrete molecules, and that working at the interface between microbes and the host immune system may optimize ICI therapy.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Renga</LastName>
            <ForeName>Giorgia</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-9762-6493</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy rengagiorgia@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nunzi</LastName>
            <ForeName>Emilia</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pariano</LastName>
            <ForeName>Marilena</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Puccetti</LastName>
            <ForeName>Matteo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bellet</LastName>
            <ForeName>Marina Maria</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pieraccini</LastName>
            <ForeName>Giuseppe</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0003-3103-3924</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Health Sciences, University of Florence, Firenze, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Onofrio</LastName>
            <ForeName>Fiorella</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santarelli</LastName>
            <ForeName>Ilaria</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stincardini</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aversa</LastName>
            <ForeName>Franco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riuzzi</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Antognelli</LastName>
            <ForeName>Cinzia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gargaro</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bereshchenko</LastName>
            <ForeName>Oxana</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Philosophy, Social Sciences and Education, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ricci</LastName>
            <ForeName>Maurizio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giovagnoli</LastName>
            <ForeName>Stefano</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Romani</LastName>
            <ForeName>Luigina</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Costantini</LastName>
            <ForeName>Claudio</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8DUH1N11BX</RegistryNumber>
          <NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cytotoxicity</Keyword>
        <Keyword MajorTopicYN="N">immune tolerance</Keyword>
        <Keyword MajorTopicYN="N">immunologic</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35236743</ArticleId>
        <ArticleId IdType="pmc">PMC8896050</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2021-003725</ArticleId>
        <ArticleId IdType="pii">jitc-2021-003725</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 2020;37:443&#x2013;55. 10.1016/j.ccell.2020.03.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2020.03.017</ArticleId>
            <ArticleId IdType="pmc">PMC7182070</ArticleId>
            <ArticleId IdType="pubmed">32289269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw 2020;20:e9. 10.4110/in.2020.20.e9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4110/in.2020.20.e9</ArticleId>
            <ArticleId IdType="pmc">PMC7049586</ArticleId>
            <ArticleId IdType="pubmed">32158597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauch&#xe9; D, Mauze S, Kochel C, et al. . Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of Fc&#x3b3;R interactions. J Immunother Cancer 2020;8. 10.1136/jitc-2020-001584</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001584</ArticleId>
            <ArticleId IdType="pmc">PMC7604872</ArticleId>
            <ArticleId IdType="pubmed">33127658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitt JM, V&#xe9;tizou M, Daill&#xe8;re R, et al. . Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -Extrinsic factors. Immunity 2016;44:1255&#x2013;69. 10.1016/j.immuni.2016.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.06.001</ArticleId>
            <ArticleId IdType="pubmed">27332730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 2017;17:271&#x2013;85. 10.1038/nrc.2017.13</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2017.13</ArticleId>
            <ArticleId IdType="pubmed">28303904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iida N, Dzutsev A, Stewart CA, et al. . Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967&#x2013;70. 10.1126/science.1240527</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1240527</ArticleId>
            <ArticleId IdType="pmc">PMC6709532</ArticleId>
            <ArticleId IdType="pubmed">24264989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viaud S, Saccheri F, Mignot G, et al. . The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971&#x2013;6. 10.1126/science.1240537</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1240537</ArticleId>
            <ArticleId IdType="pmc">PMC4048947</ArticleId>
            <ArticleId IdType="pubmed">24264990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V&#xe9;tizou M, Pitt JM, Daill&#xe8;re R, et al. . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079&#x2013;84. 10.1126/science.aad1329</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V, Spencer CN, Nezi L, et al. . Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97&#x2013;103. 10.1126/science.aan4236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan4236</ArticleId>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews MC, Duong CPM, Gopalakrishnan V, et al. . Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 2021;27:1432&#x2013;41. 10.1038/s41591-021-01406-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01406-6</ArticleId>
            <ArticleId IdType="pubmed">34239137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almonte AA, Rangarajan H, Yip D, et al. . How does the gut microbiome influence immune checkpoint blockade therapy? Immunol Cell Biol 2021;99:361&#x2013;72. 10.1111/imcb.12423</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imcb.12423</ArticleId>
            <ArticleId IdType="pubmed">33147357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi M, Jiao D, Qin S, et al. . Manipulating gut microbiota composition to enhance the therapeutic effect of cancer immunotherapy. Integr Cancer Ther 2019;18:1534735419876351. 10.1177/1534735419876351</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1534735419876351</ArticleId>
            <ArticleId IdType="pmc">PMC7242797</ArticleId>
            <ArticleId IdType="pubmed">31517538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malczewski AB, Navarro S, Coward JI, et al. . Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy. J Immunother Cancer 2020;8. 10.1136/jitc-2020-001383</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001383</ArticleId>
            <ArticleId IdType="pmc">PMC7604862</ArticleId>
            <ArticleId IdType="pubmed">33127655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 2018;23:716&#x2013;24. 10.1016/j.chom.2018.05.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2018.05.003</ArticleId>
            <ArticleId IdType="pubmed">29902437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockinger B, Shah K, Wincent E. AHR in the intestinal microenvironment: safeguarding barrier function. Nat Rev Gastroenterol Hepatol 2021;18:559&#x2013;70. 10.1038/s41575-021-00430-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41575-021-00430-8</ArticleId>
            <ArticleId IdType="pmc">PMC7611426</ArticleId>
            <ArticleId IdType="pubmed">33742166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zelante T, Iannitti RG, Cunha C, et al. . Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013;39:372&#x2013;85. 10.1016/j.immuni.2013.08.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.08.003</ArticleId>
            <ArticleId IdType="pubmed">23973224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong F, Hao F, Murray IA, et al. . Intestinal microbiota-derived tryptophan metabolites are predictive of Ah receptor activity. Gut Microbes 2020;12:1&#x2013;24. 10.1080/19490976.2020.1788899</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2020.1788899</ArticleId>
            <ArticleId IdType="pmc">PMC7524359</ArticleId>
            <ArticleId IdType="pubmed">32783770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubbard TD, Murray IA, Perdew GH. Indole and tryptophan metabolism: endogenous and dietary routes to Ah receptor activation. Drug Metab Dispos 2015;43:1522&#x2013;35. 10.1124/dmd.115.064246</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.115.064246</ArticleId>
            <ArticleId IdType="pmc">PMC4576673</ArticleId>
            <ArticleId IdType="pubmed">26041783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anesi A, Rubert J, Oluwagbemigun K, et al. . Metabolic profiling of human plasma and urine, targeting tryptophan, tyrosine and branched chain amino acid pathways. Metabolites 2019;9:metabo9110261. 10.3390/metabo9110261</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/metabo9110261</ArticleId>
            <ArticleId IdType="pmc">PMC6918267</ArticleId>
            <ArticleId IdType="pubmed">31683910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vyhl&#xed;dalov&#xe1; B, Krasulov&#xe1; K, Pe&#x10d;inkov&#xe1; P, et al. . Gut microbial catabolites of tryptophan are ligands and agonists of the aryl hydrocarbon receptor: a detailed characterization. Int J Mol Sci 2020;21 10.3390/ijms21072614</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21072614</ArticleId>
            <ArticleId IdType="pmc">PMC7177849</ArticleId>
            <ArticleId IdType="pubmed">32283770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costantini C, Nunzi E, Spolzino A, et al. . Pharyngeal microbial signatures are predictive of the risk of fungal pneumonia in hematologic patients. Infect Immun 2021;89:e0010521. 10.1128/IAI.00105-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00105-21</ArticleId>
            <ArticleId IdType="pmc">PMC8281212</ArticleId>
            <ArticleId IdType="pubmed">33782152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang KY, Lee SH, Jung SM, et al. . Downregulation of Tryptophan-related metabolomic profile in rheumatoid arthritis synovial fluid. J Rheumatol 2015;42:2003&#x2013;11. 10.3899/jrheum.141505</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.141505</ArticleId>
            <ArticleId IdType="pubmed">26329338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Luo Y, Zhu Z, et al. . A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor. J Allergy Clin Immunol 2019;143:e12:2108&#x2013;19. 10.1016/j.jaci.2018.11.036</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2018.11.036</ArticleId>
            <ArticleId IdType="pubmed">30578876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothhammer V, Mascanfroni ID, Bunse L, et al. . Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 2016;22:586&#x2013;97. 10.1038/nm.4106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4106</ArticleId>
            <ArticleId IdType="pmc">PMC4899206</ArticleId>
            <ArticleId IdType="pubmed">27158906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexeev EE, Lanis JM, Kao DJ, et al. . Microbiota-Derived indole metabolites promote human and murine intestinal homeostasis through regulation of interleukin-10 receptor. Am J Pathol 2018;188:1183&#x2013;94. 10.1016/j.ajpath.2018.01.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2018.01.011</ArticleId>
            <ArticleId IdType="pmc">PMC5906738</ArticleId>
            <ArticleId IdType="pubmed">29454749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zelante T, Puccetti M, Giovagnoli S, et al. . Regulation of host physiology and immunity by microbial indole-3-aldehyde. Curr Opin Immunol 2021;70:27&#x2013;32. 10.1016/j.coi.2020.12.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2020.12.004</ArticleId>
            <ArticleId IdType="pubmed">33454521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puccetti M, Pariano M, Borghi M, et al. . Enteric formulated indole-3-carboxaldehyde targets the aryl hydrocarbon receptor for protection in a murine model of metabolic syndrome. Int J Pharm 2021;15:120610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33865951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renga G, Bellet MM, Pariano M, et al. . Thymosin &#x3b1;1 protects from CTLA-4 intestinal immunopathology. Life Sci Alliance 2020;3:e202000662. 10.26508/lsa.202000662</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26508/lsa.202000662</ArticleId>
            <ArticleId IdType="pmc">PMC7441522</ArticleId>
            <ArticleId IdType="pubmed">32817121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powrie F, Leach MW, Mauze S, et al. . Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553&#x2013;62. 10.1016/1074-7613(94)90045-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/1074-7613(94)90045-0</ArticleId>
            <ArticleId IdType="pubmed">7600284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puccetti M, Giovagnoli S, Zelante T, et al. . Development of novel indole-3-aldehyde-loaded gastro-resistant spray-dried microparticles for postbiotic small intestine local delivery. J Pharm Sci 2018;107:2341&#x2013;53. 10.1016/j.xphs.2018.04.023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xphs.2018.04.023</ArticleId>
            <ArticleId IdType="pubmed">29715478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh NP, Singh UP, Singh B, et al. . Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FOXP3 and IL-17 expression and amelioration of experimental colitis. PLoS One 2011;6:e23522. 10.1371/journal.pone.0023522</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0023522</ArticleId>
            <ArticleId IdType="pmc">PMC3156147</ArticleId>
            <ArticleId IdType="pubmed">21858153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Li X, Yu H, et al. . The functional role of fecal microbiota transplantation on dextran sulfate sodium-induced colitis in mice. Front Cell Infect Microbiol 2019;9:393. 10.3389/fcimb.2019.00393</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2019.00393</ArticleId>
            <ArticleId IdType="pmc">PMC6873233</ArticleId>
            <ArticleId IdType="pubmed">31803633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Yin Q, Chen L, et al. . Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci U S A 2018;115:157&#x2013;61. 10.1073/pnas.1712901115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1712901115</ArticleId>
            <ArticleId IdType="pmc">PMC5776803</ArticleId>
            <ArticleId IdType="pubmed">29255057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Ruiz E, Minute L, Otano I, et al. . Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 2019;569:428&#x2013;32. 10.1038/s41586-019-1162-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1162-y</ArticleId>
            <ArticleId IdType="pubmed">31043740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu X, Wang Y, Deng M, et al. . The basic leucine zipper transcription factor NFIL3 directs the development of a common innate lymphoid cell precursor. Elife 2014;3 10.7554/eLife.04406</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.04406</ArticleId>
            <ArticleId IdType="pmc">PMC4356142</ArticleId>
            <ArticleId IdType="pubmed">25310240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulz-Kuhnt A, Neurath MF, Wirtz S, et al. . Innate lymphoid cells as regulators of epithelial integrity: therapeutic implications for inflammatory bowel diseases. Front Med 2021;8:656745. 10.3389/fmed.2021.656745</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2021.656745</ArticleId>
            <ArticleId IdType="pmc">PMC8044918</ArticleId>
            <ArticleId IdType="pubmed">33869257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhar P, McAuley J. The role of the cell surface mucin MUC1 as a barrier to infection and regulator of inflammation. Front Cell Infect Microbiol 2019;9:117. 10.3389/fcimb.2019.00117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2019.00117</ArticleId>
            <ArticleId IdType="pmc">PMC6491460</ArticleId>
            <ArticleId IdType="pubmed">31069176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabung FK, Birmann BM, Epstein MM, et al. . Influence of dietary patterns on plasma soluble CD14, a surrogate marker of gut barrier dysfunction. Curr Dev Nutr 2017;1:e001396. 10.3945/cdn.117.001396</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3945/cdn.117.001396</ArticleId>
            <ArticleId IdType="pmc">PMC5867900</ArticleId>
            <ArticleId IdType="pubmed">29595830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003;24:242&#x2013;8. 10.1016/S1471-4906(03)00072-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1471-4906(03)00072-3</ArticleId>
            <ArticleId IdType="pubmed">12738417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K&#xfc;hn R, L&#xf6;hler J, Rennick D, et al. . Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263&#x2013;74. 10.1016/0092-8674(93)80068-p</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(93)80068-p</ArticleId>
            <ArticleId IdType="pubmed">8402911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busbee PB, Menzel L, Alrafas HR, et al. . Indole-3-carbinol prevents colitis and associated microbial dysbiosis in an IL-22-dependent manner. JCI Insight 2020;5:127551. 10.1172/jci.insight.127551</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.127551</ArticleId>
            <ArticleId IdType="pmc">PMC7030851</ArticleId>
            <ArticleId IdType="pubmed">31941837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu J, Heller JJ, Guo X, et al. . The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 2012;36:92&#x2013;104. 10.1016/j.immuni.2011.11.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2011.11.011</ArticleId>
            <ArticleId IdType="pmc">PMC3268875</ArticleId>
            <ArticleId IdType="pubmed">22177117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei H-X, Wang B, Li B. IL-10 and IL-22 in mucosal immunity: driving protection and pathology. Front Immunol 2020;11:1315. 10.3389/fimmu.2020.01315</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01315</ArticleId>
            <ArticleId IdType="pmc">PMC7332769</ArticleId>
            <ArticleId IdType="pubmed">32670290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong F, Perdew GH. The aryl hydrocarbon receptor as a mediator of host-microbiota interplay. Gut Microbes 2020;12:1859812. 10.1080/19490976.2020.1859812</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2020.1859812</ArticleId>
            <ArticleId IdType="pmc">PMC7781536</ArticleId>
            <ArticleId IdType="pubmed">33382356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zenewicz LA, Yin X, Wang G, et al. . IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J Immunol 2013;190:5306&#x2013;12. 10.4049/jimmunol.1300016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1300016</ArticleId>
            <ArticleId IdType="pmc">PMC3646987</ArticleId>
            <ArticleId IdType="pubmed">23585682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dongowski G, Lorenz A, Anger H. Degradation of pectins with different degrees of esterification by Bacteroides thetaiotaomicron isolated from human gut flora. Appl Environ Microbiol 2000;66:1321&#x2013;7. 10.1128/AEM.66.4.1321-1327.2000</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AEM.66.4.1321-1327.2000</ArticleId>
            <ArticleId IdType="pmc">PMC91987</ArticleId>
            <ArticleId IdType="pubmed">10742206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamanai-Shacoori Z, Smida I, Bousarghin L, et al. . Roseburia spp.: a marker of health? Future Microbiol 2017;12:157&#x2013;70. 10.2217/fmb-2016-0130</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fmb-2016-0130</ArticleId>
            <ArticleId IdType="pubmed">28139139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi FS, O'Day SJ, McDermott DF, et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711&#x2013;23. 10.1056/NEJMoa1003466</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, et al. . Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056&#x2013;67. 10.1136/gutjnl-2018-316948</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-316948</ArticleId>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puccetti M, Pariano M, Borghi M, et al. . Enteric formulated indole-3-carboxaldehyde targets the aryl hydrocarbon receptor for protection in a murine model of metabolic syndrome. Int J Pharm 2021;602:120610. 10.1016/j.ijpharm.2021.120610</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2021.120610</ArticleId>
            <ArticleId IdType="pubmed">33865951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paris A, Tardif N, Galibert M-D, et al. . AhR and cancer: from gene profiling to targeted therapy. Int J Mol Sci 2021;22 10.3390/ijms22020752</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22020752</ArticleId>
            <ArticleId IdType="pmc">PMC7828536</ArticleId>
            <ArticleId IdType="pubmed">33451095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Yu T, Huang X, et al. . Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun 2020;11:4457. 10.1038/s41467-020-18262-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-18262-6</ArticleId>
            <ArticleId IdType="pmc">PMC7478978</ArticleId>
            <ArticleId IdType="pubmed">32901017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Gallausiaux C, Larraufie P, Jarry A, et al. . Butyrate Produced by Commensal Bacteria Down-Regulates Indolamine 2,3-Dioxygenase 1 (IDO-1) Expression via a Dual Mechanism in Human Intestinal Epithelial Cells. Front Immunol 2018;9:2838. 10.3389/fimmu.2018.02838</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02838</ArticleId>
            <ArticleId IdType="pmc">PMC6297836</ArticleId>
            <ArticleId IdType="pubmed">30619249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Jouniaux J-M, Paci A, et al. . Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun 2020;11:2168. 10.1038/s41467-020-16079-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-16079-x</ArticleId>
            <ArticleId IdType="pmc">PMC7195489</ArticleId>
            <ArticleId IdType="pubmed">32358520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han R, Nusbaum O, Chen X, et al. . Valeric acid suppresses liver cancer development by acting as a novel HDAC inhibitor. Mol Ther Oncolytics 2020;19:8&#x2013;18. 10.1016/j.omto.2020.08.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omto.2020.08.017</ArticleId>
            <ArticleId IdType="pmc">PMC7520432</ArticleId>
            <ArticleId IdType="pubmed">33024815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J-H, Wood TK, Lee J. Roles of indole as an interspecies and interkingdom signaling molecule. Trends Microbiol 2015;23:707&#x2013;18. 10.1016/j.tim.2015.08.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tim.2015.08.001</ArticleId>
            <ArticleId IdType="pubmed">26439294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puccetti M, Xiroudaki S, Ricci M, et al. . Postbiotic-enabled targeting of the host-microbiota-pathogen interface: hints of antibiotic decline? Pharmaceutics 2020;12:1. 10.3390/pharmaceutics12070624</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics12070624</ArticleId>
            <ArticleId IdType="pmc">PMC7408102</ArticleId>
            <ArticleId IdType="pubmed">32635461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puccetti M, Pariano M, Renga G, et al. . Targeted drug delivery technologies potentiate the overall therapeutic efficacy of an indole derivative in a mouse cystic fibrosis setting. Cells 2021;10:1601. 10.3390/cells10071601</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells10071601</ArticleId>
            <ArticleId IdType="pmc">PMC8305708</ArticleId>
            <ArticleId IdType="pubmed">34202407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saier MH. The bacterial phosphotransferase system: new frontiers 50 years after its discovery. J Mol Microbiol Biotechnol 2015;25:73&#x2013;8. 10.1159/000381215</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000381215</ArticleId>
            <ArticleId IdType="pmc">PMC4512285</ArticleId>
            <ArticleId IdType="pubmed">26159069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanca A, Abbondio M, Palomba A, et al. . Potential and active functions in the gut microbiota of a healthy human cohort. Microbiome 2017;5:79. 10.1186/s40168-017-0293-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40168-017-0293-3</ArticleId>
            <ArticleId IdType="pmc">PMC5513205</ArticleId>
            <ArticleId IdType="pubmed">28709472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canani RB, Costanzo MD, Leone L, et al. . Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011;17:1519&#x2013;28. 10.3748/wjg.v17.i12.1519</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v17.i12.1519</ArticleId>
            <ArticleId IdType="pmc">PMC3070119</ArticleId>
            <ArticleId IdType="pubmed">21472114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnusson MK, Isaksson S, &#xd6;hman L. The anti-inflammatory immune regulation induced by butyrate is impaired in inflamed intestinal mucosa from patients with ulcerative colitis. Inflammation 2020;43:507&#x2013;17. 10.1007/s10753-019-01133-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10753-019-01133-8</ArticleId>
            <ArticleId IdType="pmc">PMC7170981</ArticleId>
            <ArticleId IdType="pubmed">31797122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y-R, Zhou L-Z, Fang S-T, et al. . Isolation of Desulfovibrio spp. from human gut microbiota using a next-generation sequencing directed culture method. Lett Appl Microbiol 2019;68:553&#x2013;61. 10.1111/lam.13149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/lam.13149</ArticleId>
            <ArticleId IdType="pubmed">30835854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton LL, Ritz NL, Fauque GD, et al. . Sulfur cycling and the intestinal microbiome. Dig Dis Sci 2017;62:2241&#x2013;57. 10.1007/s10620-017-4689-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-017-4689-5</ArticleId>
            <ArticleId IdType="pubmed">28766244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, et al. . Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol 2012;3:448. 10.3389/fphys.2012.00448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2012.00448</ArticleId>
            <ArticleId IdType="pmc">PMC3508456</ArticleId>
            <ArticleId IdType="pubmed">23226130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol 2021;21:739&#x2013;51. 10.1038/s41577-021-00538-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-021-00538-7</ArticleId>
            <ArticleId IdType="pubmed">33846604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A 2020;117:19376&#x2013;87. 10.1073/pnas.2000047117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2000047117</ArticleId>
            <ArticleId IdType="pmc">PMC7431026</ArticleId>
            <ArticleId IdType="pubmed">32719140</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35191192</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>06</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>09</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1752-8062</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical and translational science</Title>
          <ISOAbbreviation>Clin Transl Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>1430</StartPage>
          <EndPage>1438</EndPage>
          <MedlinePgn>1430-1438</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cts.13254</ELocationID>
        <Abstract>
          <AbstractText>Immunotherapy became a key pillar of cancer therapeutics with the approvals of ipilimumab, nivolumab, and pembrolizumab, which inhibit either cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1) that are negative regulators of T-cell activation. However, boosting T-cell activation is often accompanied by autoimmunity, leading to adverse drug reactions (ADRs), including high grade 3-4 colitis and its severe complications whose prevalence may reach 14% for combination checkpoint inhibitors. In this research, we investigated how mechanistic differences between anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab and pembrolizumab) affect colitis, a general class toxicity. The data analytical platform Molecular Health Effect was utilized to map population ADR data from the US Food and Drug Administration (FDA) Adverse Event Reporting System to chemical and biological databases for hypothesis generation regarding the underlying molecular mechanisms causing colitis. Disproportionality analysis was used to assess the statistical relevance between adverse events of interest and molecular causation. We verified that the anti-CTLA-4 drug is associated with an approximately three-fold higher proportional reporting ratio associated with colitis than those of the anti-PD-1 drugs. The signal of the molecular mechanisms, including signaling pathways of inflammatory cytokines, was statistically insignificant to test the hypothesis that the severer rate of colitis associated with ipilimumab would be due to a greater magnitude of T-cell activation as a result of earlier response of the anti-CTLA-4 drug in the immune response. This patient-centered systems-based approach provides an exploratory process to better understand drug pair adverse events at pathway and target levels through reverse translation from postmarket surveillance safety reports.</AbstractText>
          <CopyrightInformation>&#xa9; 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-9179-0735</Identifier>
            <AffiliationInfo>
              <Affiliation>Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lahu</LastName>
            <ForeName>Gezim</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>thinkQ2, Baar, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vakilynejad</LastName>
            <ForeName>Majid</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Takeda Oncology, Cambridge, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soldatos</LastName>
            <ForeName>Theodoros G</ForeName>
            <Initials>TG</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Health GmbH, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jackson</LastName>
            <ForeName>David B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Health GmbH, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lesko</LastName>
            <ForeName>Lawrence J</ForeName>
            <Initials>LJ</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trame</LastName>
            <ForeName>Mirjam N</ForeName>
            <Initials>MN</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Transl Sci</MedlineTA>
        <NlmUniqueID>101474067</NlmUniqueID>
        <ISSNLinking>1752-8054</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018802" MajorTopicYN="N">Patient-Centered Care</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declared no competing interests for this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35191192</ArticleId>
        <ArticleId IdType="pmc">PMC9199880</ArticleId>
        <ArticleId IdType="doi">10.1111/cts.13254</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>YERVOY (ipilimumab) injection label from FDA website. U.S. Food and Drug Administration, 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s094lbl.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>OPDIVO (nivolumab) label from FDA website. U.S. Food and Drug Administration, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>KEYTRUDA (pembrolizumab) label from FDA website. U.S. Food and Drug Administration, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s040lbl.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci. 2016;9:89&#x2010;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5351311</ArticleId>
            <ArticleId IdType="pubmed">26924066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stroh M, Carlile DJ, Li C&#x2010;C, et al. Challenges and opportunities for quantitative clinical pharmacology in cancer immunotherapy: something old, something new, something borrowed, and something blue. CPT Pharmacometrics Syst Pharmacol. 2015;4:495&#x2010;497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4592528</ArticleId>
            <ArticleId IdType="pubmed">26451328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heeren AM, Punt S, Bleeker MCG, et al. Prognostic effect of different PD&#x2010;L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016;29:753&#x2010;763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4931542</ArticleId>
            <ArticleId IdType="pubmed">27056074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Lahu G, Vakilynejad M, et al. A case study of a patient&#x2010;centered reverse translational systems&#x2010;based approach to understand adverse event profiles in drug development [published online ahead of print January 11, 2022]. Clin Transl Sci. 10.1111/cts.13219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cts.13219</ArticleId>
            <ArticleId IdType="pmc">PMC9010262</ArticleId>
            <ArticleId IdType="pubmed">35014203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FDA Adverse Event Reporting System (FAERS) Public Dashboard. U.S. Food &amp; Drug Administration, 2019. https://www.fda.gov/drugs/questions&#x2010;and&#x2010;answers&#x2010;fdas&#x2010;adverse&#x2010;event&#x2010;reporting&#x2010;system&#x2010;faers/fda&#x2010;adverse&#x2010;event&#x2010;reporting&#x2010;system&#x2010;faers&#x2010;public&#x2010;dashboard. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Annals Translational Med. 2016;4:272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4971373</ArticleId>
            <ArticleId IdType="pubmed">27563659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint&#x2010;blockade&#x2010;induced colitis. Nat Commun. 2016;7:10391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prieux&#x2010;Klotz C, Dior M, Damotte D, et al. Immune checkpoint inhibitor&#x2010;induced colitis: diagnosis and management. Targeted Oncol. 2017;12:301&#x2010;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28540478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Questions and Answers on FDA's Adverse Event Reporting System (FAERS). U.S. Food &amp; Drug Administration, 2018. https://www.fda.gov/drugs/surveillance/questions&#x2010;and&#x2010;answers&#x2010;fdas&#x2010;adverse&#x2010;event&#x2010;reporting&#x2010;system&#x2010;faers. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Soldatos TG, Taglang G, Jackson DB. In silico profiling of clinical phenotypes for human targets using adverse event data. High&#x2010;Throughput. 2018;7(4):37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6306940</ArticleId>
            <ArticleId IdType="pubmed">30477159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soldatos TG, Jackson DB. Adverse event circumstances and the case of drug interactions. Healthcare. 2019;7(1):45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6473808</ArticleId>
            <ArticleId IdType="pubmed">30893930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017;46:D1074&#x2010;D1082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5753335</ArticleId>
            <ArticleId IdType="pubmed">29126136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PubChem
. http://pubchem.ncbi.nlm.nih.gov/. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>UniProt
. Accessed August 3, 2020, at https://www.uniprot.org/.</Citation>
        </Reference>
        <Reference>
          <Citation>NCI
. Nature NCI Pathway Interaction Dabase. http://www.ndexbio.org/#/.</Citation>
        </Reference>
        <Reference>
          <Citation>Reactome Inc
. https://reactome.org/. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>BioCarta
. www.biocarta.com.</Citation>
        </Reference>
        <Reference>
          <Citation>Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483&#x2010;486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11828828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427&#x2010;436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19358225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochem Biophys Acta. 2014;1843:2563&#x2010;2582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24892271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koorts AM, Levay PF, Becker PJ, Viljoen M. Pro&#x2010; and anti&#x2010;inflammatory cytokines during immune stimulation: modulation of iron status and red blood cell profile. Mediators Inflamm. 2011;2011:716301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3086355</ArticleId>
            <ArticleId IdType="pubmed">21547258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta&#x2010;1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut. 2003;52:1286&#x2010;1290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1773804</ArticleId>
            <ArticleId IdType="pubmed">12912859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon&#x2010;&#x3b2;&#x2010;1a is accompanied by inhibition of IL&#x2010;13 production. Gut. 2011;60:449&#x2010;455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3430969</ArticleId>
            <ArticleId IdType="pubmed">20971977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabay C. Interleukin&#x2010;6 and chronic inflammation. Arthritis Res Ther. 2006;8(Suppl 2):S3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3226076</ArticleId>
            <ArticleId IdType="pubmed">16899107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baggiolini M, Clark&#x2010;Lewis I. Interleukin&#x2010;8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307:97&#x2010;101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1639201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viennois E, Chen F, Merlin D. NF&#x2010;&#x3ba;B pathway in colitis&#x2010;associated cancers. Transl Gastrointestinal Cancer. 2013;2:21&#x2010;29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3636557</ArticleId>
            <ArticleId IdType="pubmed">23626930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo P&#x2010;C, Scofield BA, Yu I&#x2010;C, Chang F&#x2010;L, Ganea D, Yen J&#x2010;H. Interferon&#x2010;&#x3b2; modulates inflammatory response in cerebral ischemia. J Am Heart Assoc. 2016;5(1): e002610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4859377</ArticleId>
            <ArticleId IdType="pubmed">26747000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skapenko A, Leipe J, Lipsky PE, Schulze&#x2010;Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Ther. 2005;7(Suppl 2):S4&#x2010;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2833981</ArticleId>
            <ArticleId IdType="pubmed">15833146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin&#x2010;2 in the development and control of inflammatory disease. Immunol Rev. 2008;226:19&#x2010;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19161413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC. Interleukin&#x2010;23: a key cytokine in inflammatory diseases. Ann Med. 2011;43:503&#x2010;511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21585245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosmann M, Ward PA. Modulation of inflammation by interleukin&#x2010;27. J Leukoc Biol. 2013;94:1159&#x2010;1165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3828601</ArticleId>
            <ArticleId IdType="pubmed">23904441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winkler D, Faia K, DiNitto J, et al. PI3K&#x2010;&#x3b4; and PI3K&#x2010;&#x3b3; inhibition by IPI&#x2010;145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20:1364&#x2010;1374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24211136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3&#x2010;kinase gamma/delta inhibitor TG100&#x2010;115 [3&#x2010;[2,4&#x2010;diamino&#x2010;6&#x2010;(3&#x2010;hydroxyphenyl)pteridin&#x2010;7&#x2010;yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Therapeut. 2009;328:758&#x2010;765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19056934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3&#x2010;kinase mutant mice. Science (New York, NY). 2002;297:1031&#x2010;1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12130661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol. 2015;23:82&#x2010;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4518027</ArticleId>
            <ArticleId IdType="pubmed">26093105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weichhart T, Hengstschl&#xe4;ger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15:599&#x2010;614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6095456</ArticleId>
            <ArticleId IdType="pubmed">26403194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor&#x2010;induced colitis: A comprehensive review. World J Clin Cases. 2019;7:405&#x2010;418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6397821</ArticleId>
            <ArticleId IdType="pubmed">30842952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16:359&#x2010;365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17019675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schotland P, Bojunga N, Zien A, Trame MN, Lesko LJ. Improving drug safety with a systems pharmacology approach. Eur J Pharm Sci. 2016;94:84&#x2010;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27287422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schotland P, Racz R, Jackson D, Levin R, Strauss DG, Burkhart K. Target&#x2010;adverse event profiles to augment pharmacovigilance: a pilot study with six new molecular entities. CPT Pharmacometrics Syst Pharmacol. 2018;7:809&#x2010;817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6310867</ArticleId>
            <ArticleId IdType="pubmed">30354029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sachpekidis C, Jackson DB, Soldatos TG. Radioimmunotherapy in Non&#x2010;Hodgkin's lymphoma: retrospective adverse event profiling of Zevalin and Bexxar. Pharmaceuticals (Basel, Switzerland) 2019;12(4):141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6958320</ArticleId>
            <ArticleId IdType="pubmed">31546999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soldatos TG, Iakovou I, Sachpekidis C. Retrospective toxicological profiling of radium&#x2010;223 dichloride for the treatment of bone metastases in prostate cancer using adverse event data. Medicina. 2019;55(5):149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6572036</ArticleId>
            <ArticleId IdType="pubmed">31100964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchbinder EI, Desai A. CTLA&#x2010;4 and PD&#x2010;1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98&#x2010;106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4892769</ArticleId>
            <ArticleId IdType="pubmed">26558876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schotland P, Racz R, Jackson DB, et al. Target adverse event profiles for predictive safety in the postmarket setting. Clin Pharmacol Ther. 2021;109:1232&#x2010;1243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8246740</ArticleId>
            <ArticleId IdType="pubmed">33090463</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35124713</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>08</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>08</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0851</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>71</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology, immunotherapy : CII</Title>
          <ISOAbbreviation>Cancer Immunol Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.</ArticleTitle>
        <Pagination>
          <StartPage>2239</StartPage>
          <EndPage>2254</EndPage>
          <MedlinePgn>2239-2254</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-022-03140-5</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non-small cell lung cancer (NSCLC) will be provided in this network meta-analysis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We searched 14 randomized clinical trials (RCTs) including 9572 NSCLC patients by PubMed, EMBASE, Cochrane, and ClinicalTrials.gov. Randomized pairwise and network meta-analyses were used to compare the incidence of severe immune-related adverse events (irAEs) across different ICIs-based treatments using risk ratios (RRs) and 95% confidence intervals (CI).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">For severe dermatologic irAEs, the corresponding ranking of incidences of the nine groups from high to low was: nivolumab&#x2009;+&#x2009;ipilimumab&#x2009;+&#x2009;platinum (79.1%), pembrolizumab (75.2%), nivolumab&#x2009;+&#x2009;ipilimumab (72.9%), camrelizumab&#x2009;+&#x2009;platinum (64.9%), atezolizumab&#x2009;+&#x2009;platinum (47.4%), nivolumab (44.2%), durvalumab (40.5%), pembrolizumab&#x2009;+&#x2009;platinum (15.5%), platinum-based chemotherapy (10.3%). For severe colitis, the corresponding ranking of incidences of the seven groups from high to low was: nivolumab&#x2009;+&#x2009;ipilimumab&#x2009;+&#x2009;platinum (72.4%), nivolumab (63.1%), atezolizumab&#x2009;+&#x2009;platinum (56.9%), durvalumab (56.6%), pembrolizumab (54.9%), pembrolizumab&#x2009;+&#x2009;platinum (38.6%), platinum-based chemotherapy (7.4%). For severe endocrine irAEs, the corresponding ranking of incidences of the nine groups from high to low was: durvalumab (74.3%), atezolizumab&#x2009;+&#x2009;platinum (54.5%), nivolumab&#x2009;+&#x2009;ipilimumab (54.0%), camrelizumab&#x2009;+&#x2009;platinum (51.7%), nivolumab&#x2009;+&#x2009;ipilimumab&#x2009;+&#x2009;platinum (51.6%), pembrolizumab&#x2009;+&#x2009;platinum (49.8%), pembrolizumab (49.2%), nivolumab (46.3%), platinum-based chemotherapy (18.6%). For severe pneumonitis, the corresponding ranking of incidences of the nine groups from high to low was: nivolumab (84.3%), pembrolizumab (84.1%), durvalumab (66.1%), camrelizumab&#x2009;+&#x2009;platinum (61.4%), atezolizumab&#x2009;+&#x2009;platinum (50%), pembrolizumab&#x2009;+&#x2009;platinum (43.4%), platinum-based chemotherapy (16.2%), atezolizumab (6.2%). For severe hepatitis, the corresponding ranking of incidences of the eight groups from high to low was: pembrolizumab (68.8%), nivolumab&#x2009;+&#x2009;ipilimumab&#x2009;+&#x2009;platinum (65%), pembrolizumab&#x2009;+&#x2009;platinum (64.6%), durvalumab (57.9%), nivolumab (47.1%), atezolizumab&#x2009;+&#x2009;platinum (43.4%), camrelizumab&#x2009;+&#x2009;platinum (42%), platinum-based chemotherapy (11.2%).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In addition to platinum-based chemotherapy, pembrolizumab&#x2009;+&#x2009;platinum for severe dermatologic irAEs and colitis, nivolumab for severe endocrine irAEs, atezolizumab for severe pneumonitis, camrelizumab&#x2009;+&#x2009;platinum for severe hepatitis may be associated with lower rates of irAEs than other immune-based regimens.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Jingjing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Medical and Health Group Hangzhou Hospital, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Xiaowen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Medical and Health Group Hangzhou Hospital, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Jianhua</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Medical and Health Group Hangzhou Hospital, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xiaoming</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Medical and Health Group Hangzhou Hospital, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Hu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Weidong</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0003-4333-3000</Identifier>
            <AffiliationInfo>
              <Affiliation>Center of General Surgery, The Xixi Hospital of Hangzhou, 2 Hengbu Street, Liuxia Town, Xihu District, Hangzhou, Zhejiang, China. 625570626@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Cancer Immunol Immunother</MedlineTA>
        <NlmUniqueID>8605732</NlmUniqueID>
        <ISSNLinking>0340-7004</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071076" MajorTopicYN="N">Network Meta-Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Network meta-analysis</Keyword>
        <Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword>
        <Keyword MajorTopicYN="N">Randomized clinical trial</Keyword>
        <Keyword MajorTopicYN="N">Severe immune-related adverse events</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>6</Day>
          <Hour>20</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35124713</ArticleId>
        <ArticleId IdType="doi">10.1007/s00262-022-03140-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s00262-022-03140-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>World Health Organization (2018) Cancer fact sheet. https://www.who.int/news-room/fact-sheets/detail/cancer</Citation>
        </Reference>
        <Reference>
          <Citation>Goldstraw P, Chansky K, Crowley J (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1):39&#x2013;51</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2015.09.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torre L, Siegel R, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1&#x2013;19</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-319-24223-1_1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molina J, Yang R, Cassivi P et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin 83:584&#x2013;594</Citation>
        </Reference>
        <Reference>
          <Citation>Bironzo P, Di M (2018) A review of guidelines for lung cancer. J Thorac Dis 10(Suppl. 13):S1556&#x2013;S1663</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jtd.2018.03.54</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindeman NI et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8:823&#x2013;859</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0b013e318290868f</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khozin S et al (2014) U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist 19:774&#x2013;779</Citation>
        </Reference>
        <Reference>
          <Citation>Boumahdi S, de Sauvage FJ (2020) The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov 19:39&#x2013;56</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41573-019-0044-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandler A, Gray R, Perry MC et al (2006) Paclitaxel&#x2013;carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542&#x2013;2550</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa061884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scagliotti, Parikh, Pawel et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543&#x2013;3551</Citation>
        </Reference>
        <Reference>
          <Citation>Ettinger, Wood, Aisner et al (2017) Non-small cell lung cancer, Version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:504&#x2013;535</Citation>
        </Reference>
        <Reference>
          <Citation>Pedoeem A, Azoulay AI, Strazza M et al (2014) Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 153(1):145&#x2013;152</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2014.04.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone DP, Reck M, Paz-Ares L (2017) First-line Nivolumab in stage IV or recurrent non&#x2013;small-cell lung cancer. N Engl J Med 376:2415&#x2013;2426</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1613493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naiyer A, Byoung C, Niels R (2020) Durvalumab with or without tremelimumab versus standard chemotherapy in first-line treatment of metastatic non&#x2013;small cell lung cancer. JAMA Oncol 6(5):237&#x2013;251</Citation>
        </Reference>
        <Reference>
          <Citation>Paz-Ares L, Luft A, Vicente D (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040&#x2013;2051</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1810865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandhi L, Rodr&#xed;guez-Abreu D, Gadgeel S (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078&#x2013;2092</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1801005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tony SK, Yi-Long W, Iveta K (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet 6736:32409&#x2013;32421</Citation>
        </Reference>
        <Reference>
          <Citation>Reck M, Rodr&#xed;guez-Abreu D (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823&#x2013;1833</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1606774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corey JL, Shirish MG, Hossein B (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet 17(11):30498&#x2013;30510</Citation>
        </Reference>
        <Reference>
          <Citation>Barlesi F, Nishio M, Cobo M (2018) Efficacy of atezolizumab (atezo) 1 carboplatin (carbo)/cisplatin (cis) 1 pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Ann Oncol 29:743&#x2013;744</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy424.066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert J, Federico C, Ihor V (2020) Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol 3:28&#x2013;38</Citation>
        </Reference>
        <Reference>
          <Citation>Howard W, Michael M, Maen H (2019) Atezolizumab in combination with carboplatin plusnab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924&#x2013;937</Citation>
        </Reference>
        <Reference>
          <Citation>Roy SH, Giuseppe G, Filippo DM (2020) Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 383:1328&#x2013;1339</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1917346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmann MD, Paz-Ares L, Bernabe R (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381:2020&#x2013;2031</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou C, Chen G, Huang Y (2020) Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med 12:18</Citation>
        </Reference>
        <Reference>
          <Citation>Paz-Ares L, Ciuleanu T-E, Cobo M (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198&#x2013;211</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30641-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158&#x2013;168</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greten TF, Sangro B (2017) Targets for immunotherapy of liver cancer. J Hepatol 68:157&#x2013;166</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.09.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang P-F, Chen Y, Song S-Y, Wang T-J, Ji W-J, Li S-W et al (2017) Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 8</Citation>
        </Reference>
        <Reference>
          <Citation>Remon J, Passiglia F, Ahn M-J et al (2020) Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol 15:914&#x2013;947</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2020.03.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721&#x2013;1728</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.3923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Cancer Institute (2019) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Updated May27, 2017. Accessed 12 July 2019</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhou S, Yang F et al (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta analysis. JAMA Oncol 5:1008e1019</Citation>
        </Reference>
        <Reference>
          <Citation>Chen TW, Razak AR, Bedard PL et al (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 00:1&#x2013;6</Citation>
        </Reference>
        <Reference>
          <Citation>Weber J, Thompson JA, Hamid O (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable Stage III or IV melanoma. Clin Cancer Res 15(17):5591&#x2013;5598</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-1024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberati A, Altman DG, Tetzlaff J (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700</Citation>
        </Reference>
        <Reference>
          <Citation>Hutton B, Salanti G, Caldwell DM (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777&#x2013;784</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M14-2385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence intervals</Citation>
        </Reference>
        <Reference>
          <Citation>Basch, Iasonos, McDonough (2016) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903&#x2013;909</Citation>
        </Reference>
        <Reference>
          <Citation>Salanti G, Higgins JPT, Ades AE et al (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17:279&#x2013;301</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0962280207080643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutton A, Ades AE, Cooper N, Abrams K (2008) Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 26:753&#x2013;767</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00019053-200826090-00006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mills EJ, Thorlund K, Ioannidis JP (2013) Demystifying trial networks and network meta-analysis. BMJ 346:f2914</Citation>
        </Reference>
        <Reference>
          <Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557&#x2013;560</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163&#x2013;171</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jclinepi.2010.03.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98&#x2013;110</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jrsm.1044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29:932&#x2013;944</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sim.3767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furukawa TA, Salanti G, Atkinson LZ et al (2016) Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open 6:e010919</Citation>
        </Reference>
        <Reference>
          <Citation>Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol 54:1046&#x2013;1055</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0895-4356(01)00377-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He J, Hu Y, Hu M et al (2015) Development of PD-1/PD-L1&#xb7;pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 5:13100</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep13100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhou S, Yang F et al (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5:1008&#x2013;1019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.0393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kazandjian D, Suzman DL, Blumenthal G (2016) FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 21:634&#x2013;642</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2015-0507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pai-Scherf L, Blumenthal GM, Li H (2017) FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist 22:1392&#x2013;1399</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2017-0078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinstock C, Khozin S, Suzman DUS (2017) Food and Drug Administration approval summary: atezolizumab for metastatic non-small cell lung cancer. Clin Cancer Res 23:4534&#x2013;4539</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-0540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonia SJ, Villegas A, Daniel D (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919&#x2013;1929</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1709937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slater LM, Stupecky M, Sweet P, Osann KE (2002) Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16. Leuk Res 26:205&#x2013;208</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0145-2126(01)00105-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Hou X, Chen J et al (2021) Comparing organ-specific immune-related adverse events for immune checkpoint inhibitors: a Bayesian network meta-analysis. Clin Transl Med 11:e291</Citation>
        </Reference>
        <Reference>
          <Citation>Xu C, Chen Y-P, Du X-J (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226</Citation>
        </Reference>
        <Reference>
          <Citation>Huang Y-F, Xie W-J, Fan H-y et al (2019) Comparative safety of PD-1/PD-L1 inhibitors for cancer patients: systematic review and network meta-analysis. Front Oncol 9:972</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.00972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong Li, Qing Wu, Chen F et al (2021) Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother 70(4):2559&#x2013;2576</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-020-02803-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schindler K et al (2014) Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. ASCO Meet Abstr 32</Citation>
        </Reference>
        <Reference>
          <Citation>Callahan MK et al (2011) Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. ASCO Meet Abstr 29</Citation>
        </Reference>
        <Reference>
          <Citation>Shahabi V et al (2013) Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med 11:75</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-11-75</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34992611</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.</ArticleTitle>
        <Pagination>
          <StartPage>800879</StartPage>
          <MedlinePgn>800879</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">800879</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2021.800879</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies, including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors, have obtained unprecedented benefit in multiple malignancies. However, the immune response activation in the body organs could arise immune-related adverse events (irAEs). Checkpoint inhibitor colitis (CIC) is the most widely reported irAEs. However, some obscure problems, such as the mechanism concerning gut microbiota, the confusing differential diagnosis with inflammatory bowel disease (IBD), the optimal steroid schedule, the reintroduction of ICIs, and the controversial prognosis features, influence the deep understanding and precise diagnosis and management of CIC. Herein, we based on these problems and comprehensively summarized the relevant studies of CIC in patients with NSCLC, further discussing the future research direction of this specific pattern of irAEs.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Tang, Wang, Lin, Zhou, He, Liu and Ma.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Liansha</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jialing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Nan</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yuwen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Wenbo</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jiyan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Xuelei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">diagnosis</Keyword>
        <Keyword MajorTopicYN="N">diarrhoea</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">management</Keyword>
        <Keyword MajorTopicYN="N">mechanism</Keyword>
        <Keyword MajorTopicYN="N">prognosis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34992611</ArticleId>
        <ArticleId IdType="pmc">PMC8724248</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2021.800879</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021 (Vol 71, Pg 7, 2021). CA Cancer J Clin (2021) 71(4):359&#x2013;9. doi: 10.3322/caac.21654</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21654</ArticleId>
            <ArticleId IdType="pubmed">33433946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabezon-Gutierrez L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, Khosravi-Shahi P. Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1. Clin Lung Cancer (2021) 22(5):381&#x2013;9. doi: 10.1016/j.cllc.2021.03.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2021.03.006</ArticleId>
            <ArticleId IdType="pubmed">33875382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, et al. . Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines. J Natl Compr Cancer Netw (2019) 17(12):1464&#x2013;72. doi: doi: 10.6004/jnccn.2019.0059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2019.0059</ArticleId>
            <ArticleId IdType="pubmed">31805526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bei Y, Chen X, Raturi VP, Liu K, Ye S, Xu Q, et al. . Treatment Patterns and Outcomes Change in Early-Stage Non-Small Cell Lung Cancer in Octogenarians and Older: A SEER Database Analysis. Aging Clin Exp Res (2021) 33(1):147&#x2013;56. doi: 10.1007/s40520-020-01517-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40520-020-01517-z</ArticleId>
            <ArticleId IdType="pubmed">32246386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamberti G, Andrini E, Sisi M, Rizzo A, Parisi C, Di Federico A, et al. . Beyond EGFR, ALK and ROS1: Current Evidence and Future Perspectives on Newly Targetable Oncogenic Drivers in Lung Adenocarcinoma. Crit Rev Oncol Hematol (2020) 156:103119. doi: 10.1016/j.critrevonc.2020.103119</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.critrevonc.2020.103119</ArticleId>
            <ArticleId IdType="pubmed">33053439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Shao C, Shi Y, Han W. Lessons Learned From the Blockade of Immune Checkpoints in Cancer Immunotherapy. J Hematol Oncol (2018) 11:31. doi: 10.1186/s13045-018-0578-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-018-0578-4</ArticleId>
            <ArticleId IdType="pmc">PMC6389077</ArticleId>
            <ArticleId IdType="pubmed">29482595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, et al. . A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway &amp; Translational Blockade of Immune Checkpoints. Int J Mol Sci (2016) 17(7):1151. doi: 10.3390/ijms17071151</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17071151</ArticleId>
            <ArticleId IdType="pmc">PMC4964524</ArticleId>
            <ArticleId IdType="pubmed">27438833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy HG, Schneider BJ, Tai AW. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. Clin Trans Gastroenterol (2018) 9(11):206. doi: 10.1038/s41424-018-0049-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41424-018-0049-9</ArticleId>
            <ArticleId IdType="pmc">PMC6143593</ArticleId>
            <ArticleId IdType="pubmed">30228268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Lu X, Luo G, Xiang H. Progress in PD-1/PD-L1 Pathway Inhibitors: From Biomacromolecules to Small Molecules. Eur J Med Chem (2020) 186:111876. doi: 10.1016/j.ejmech.2019.111876</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2019.111876</ArticleId>
            <ArticleId IdType="pubmed">31761384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi H, Nakagawa K. Combination Therapy With PD-1 or PD-L1 Inhibitors for Cancer. Int J Clin Oncol (2020) 25(5):818&#x2013;30. doi: 10.1007/s10147-019-01548-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10147-019-01548-1</ArticleId>
            <ArticleId IdType="pubmed">31549270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated With Immune Checkpoint Blockade. N Engl J Med (2018) 378(2):158&#x2013;68. doi: 10.1056/NEJMra1703481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shannon VR. Pneumonitis Associated With Immune Checkpoint Inhibitors Among Patients With Non-Small Cell Lung Cancer. Curr Opin Pulm Med (2020) 26(4):326&#x2013;40. doi: 10.1097/MCP.0000000000000689</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCP.0000000000000689</ArticleId>
            <ArticleId IdType="pubmed">32452900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naidoo J, Nishino M, Patel SP, Shankar B, Rekhtman N, Illei P, et al. . Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer (2020) 21(5):E435&#x2013;44. doi: 10.1016/j.cllc.2020.02.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2020.02.025</ArticleId>
            <ArticleId IdType="pubmed">32576443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Remon J, Passiglia F, Ahn M-J, Barlesi F, Forde PM, Garon EB, et al. . Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol (2020) 15(6):914&#x2013;47. doi: 10.1016/j.jtho.2020.03.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2020.03.006</ArticleId>
            <ArticleId IdType="pubmed">32179179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. . Nivolumab Plus Ipilimumab in Lung Cancer With a High Tumor Mutational Burden. N Engl J Med (2018) 378(22):2093&#x2013;104. doi: 10.1056/NEJMoa1801946</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1801946</ArticleId>
            <ArticleId IdType="pmc">PMC7193684</ArticleId>
            <ArticleId IdType="pubmed">29658845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reck M, Borghaei H, O'Byrne KJ. Nivolumab Plus Ipilimumab in Non-Small-Cell Lung Cancer. Future Oncol (2019) 15(19):2287&#x2013;302. doi: 10.2217/fon-2019-0031</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fon-2019-0031</ArticleId>
            <ArticleId IdType="pubmed">31066582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reck M, Ciuleanu T-E, Dols MC, Schenker M, Zurawski B, Menezes J, et al. . Nivolumab (NIVO) Plus Ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs 4 Cycles Chemo as First-Line (1L) Treatment (Tx) for Stage IV/recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9la. J Clin Oncol (2020) 38(15):9501&#x2013;9501. doi: 10.1200/JCO.2020.38.15_suppl.9501</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2020.38.15_suppl.9501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizzo A, Brandi G. Biochemical Predictors of Response to Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. Cancer Treat Res Commun (2021) 27:100328. doi: 10.1016/j.ctarc.2021.100328</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctarc.2021.100328</ArticleId>
            <ArticleId IdType="pubmed">33549983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puzanov I, Diab A, Abdallah K, Bingham CO, III, Brogdon C, Dadu R, et al. . Managing Toxicities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations From the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer (2017) 5:95. doi: 10.1186/s40425-017-0300-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0300-z</ArticleId>
            <ArticleId IdType="pmc">PMC5697162</ArticleId>
            <ArticleId IdType="pubmed">29162153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. . Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up (Vol 28, Pg 119, 2017). Ann Oncol (2018) 29:264&#x2013;6. doi: 10.1093/annonc/mdy162</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy162</ArticleId>
            <ArticleId IdType="pubmed">29917046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Raju G, Wang Y. The Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol (2018) 113:S112&#x2013;3. doi: 10.14309/00000434-201810001-00197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/00000434-201810001-00197</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Van Anh T, et al. . Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflamm Bowel Dis (2018) 24(8):1695&#x2013;705. doi: 10.1093/ibd/izy104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marin-Acevedo JA, Harris DM, Burton MC. Immunotherapy-Induced Colitis: An Emerging Problem for the Hospitalist. J Hosp Med (2018) 13(6):413&#x2013;8. doi: 10.12788/jhm.2925</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12788/jhm.2925</ArticleId>
            <ArticleId IdType="pubmed">29419822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroner PT, Mody K, Farraye FA. Immune Checkpoint Inhibitor-Related Luminal GI Adverse Events. Gastrointest Endosc (2019) 90(6):881&#x2013;92. doi: 10.1016/j.gie.2019.09.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gie.2019.09.009</ArticleId>
            <ArticleId IdType="pubmed">31526811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, et al. . Immune Checkpoint Inhibitor-Induced Colitis: A Comprehensive Review. World J Clin Cases (2019) 7(4):405&#x2013;18. doi: 10.12998/wjcc.v7.i4.405</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12998/wjcc.v7.i4.405</ArticleId>
            <ArticleId IdType="pmc">PMC6397821</ArticleId>
            <ArticleId IdType="pubmed">30842952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon T, Afzali A. Immune-Mediated Colitis. Curr Treat Options Gastroenterol (2019) 17(4):506&#x2013;23. doi: 10.1007/s11938-019-00263-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11938-019-00263-0</ArticleId>
            <ArticleId IdType="pubmed">31741212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sehgal K, Khanna S. Gut Microbiome and Checkpoint Inhibitor Colitis. Intest Res (2020) 19(4):360&#x2013;4. doi: 10.5217/ir.2020.00116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5217/ir.2020.00116</ArticleId>
            <ArticleId IdType="pmc">PMC8566823</ArticleId>
            <ArticleId IdType="pubmed">33249800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology (2021) 160(4):1384&#x2013;93. doi: 10.1053/j.gastro.2020.08.063</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.08.063</ArticleId>
            <ArticleId IdType="pubmed">33080231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portenkirchner C, Kienle P, Horisberger K. Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. Pharmaceuticals (2021) 14(4):e1344805. doi: 10.3390/ph14040367</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph14040367</ArticleId>
            <ArticleId IdType="pmc">PMC8074139</ArticleId>
            <ArticleId IdType="pubmed">33923423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of Immune Checkpoint Inhibitor-Related Colitis in Solid Tumor Patients: A Systematic Review and Meta-Analysis. Oncoimmunology (2017) 6(10). doi: 10.1080/2162402X.2017.1344805</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1344805</ArticleId>
            <ArticleId IdType="pmc">PMC5665065</ArticleId>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al. . Enterocolitis Due to Immune Checkpoint Inhibitors: A Systematic Review. Gut (2018) 67(11):2056&#x2013;67. doi: 10.1136/gutjnl-2018-316948</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-316948</ArticleId>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 Inhibitor Gastroenterocolitis: Case Series and Appraisal of 'Immunomodulatory Gastroenterocolitis'. Histopathology (2017) 70(4):558&#x2013;67. doi: 10.1111/his.13118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13118</ArticleId>
            <ArticleId IdType="pubmed">28000302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Chen TW-W, Siu LL, Hansen AR. Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Ann Oncol (2017) 28(10):2377&#x2013;85. doi: 10.1093/annonc/mdx286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx286</ArticleId>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. J Immunother (2018) 41(3):101&#x2013;8. doi: 10.1097/CJI.0000000000000213</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000213</ArticleId>
            <ArticleId IdType="pubmed">29401166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunogi Y, Tominaga K, Abe K, Kanazawa M, Tanaka T, Watanabe S, et al. . Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. Healthcare (2021) 9(4):418. doi: 10.3390/healthcare9040418</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/healthcare9040418</ArticleId>
            <ArticleId IdType="pmc">PMC8066945</ArticleId>
            <ArticleId IdType="pubmed">33916353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mourad AP, De Robles MS. Chemoimmunotherapy-Related Enteritis Resulting in a Mechanical Small Bowel Obstruction - A Case Report. Int J Surg Case Rep (2021) 79:131&#x2013;4. doi: 10.1016/j.ijscr.2020.12.096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijscr.2020.12.096</ArticleId>
            <ArticleId IdType="pmc">PMC7815460</ArticleId>
            <ArticleId IdType="pubmed">33454633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naito T, Nosaka T, Takahashi K, Ofuji K, Matsuda H, Ohtani M, et al. . A Case of Immune Checkpoint Inhibitor-Related Colitis With a Distinctive Endoscopic Finding of Colonic Pseudolipomatosis. Clin J Gastroenterol (2021) 14(5):1431&#x2013;6. doi: 10.1007/s12328-021-01459-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12328-021-01459-7</ArticleId>
            <ArticleId IdType="pubmed">34106395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omotehara S, Nishida M, Yamanashi K, Sakurai K, Katsurada T, Komatsu Y, et al. . A Case of Immune Checkpoint Inhibitor-Associated Gastroenteritis Detected by Ultrasonography. J Clin Ultrasound (2021) 49(6):605&#x2013;9. doi: 10.1002/jcu.22975</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcu.22975</ArticleId>
            <ArticleId IdType="pubmed">33580597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirabae A, Ichihara E, Sunami R, Ota M, Iwamoto Y, Maeda Y, et al. . Rapid Disease Progression of Advanced Non-Small Cell Lung Cancer Five Months After Cessation of Pembrolizumab. Acta Med Okayama (2020) 74(5):423&#x2013;5. doi: 10.18926/AMO/60802</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18926/AMO/60802</ArticleId>
            <ArticleId IdType="pubmed">33106698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Bond SA, Mansour MK, Friedman S. Management of Immunotherapy Colitis: Special Considerations in the COVID-19 Era. Cancer (2020) 126(21):4630&#x2013;3. doi: 10.1002/cncr.33125</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.33125</ArticleId>
            <ArticleId IdType="pmc">PMC7461305</ArticleId>
            <ArticleId IdType="pubmed">32797685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallo A, Talerico R, Novello L, Giustiniani MC, D'Argento E, Bria E, et al. . Collagenous Colitis and Atezolizumab Therapy: An Atypical Case. Clin J Gastroenterol (2021) 14(1):165&#x2013;9. doi: 10.1007/s12328-020-01276-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12328-020-01276-4</ArticleId>
            <ArticleId IdType="pmc">PMC7886711</ArticleId>
            <ArticleId IdType="pubmed">33151423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimura K, Saku A, Karayama M, Inui N, Sugimura H, Suda T. Leucine-Rich &#x3b1;(2)-Glycoprotein as a Potential Biomarker for Immune-Related Colitis After Anti-PD-L1 Therapy: A Report of a Case Series. Clin Lung Cancer (2020) 21(6):e516&#x2013;22. doi: 10.1016/j.cllc.2020.04.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2020.04.005</ArticleId>
            <ArticleId IdType="pubmed">32389505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babacan NA, Tanvetyanon T. Superimposed Clostridium Difficile Infection During Checkpoint Inhibitor Immunotherapy-Induced Colitis. J Immunother (2019) 42(9):350&#x2013;3. doi: 10.1097/CJI.0000000000000270</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000270</ArticleId>
            <ArticleId IdType="pubmed">31107370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou C, Klionsky Y, Treasure ME, Bruno DS. Pembrolizumab-Induced Immune-Mediated Colitis in a Patient With Concurrent Clostridium Difficile Infection. Case Rep Oncol (2019) 12(1):164&#x2013;70. doi: 10.1159/000497155</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000497155</ArticleId>
            <ArticleId IdType="pmc">PMC6477466</ArticleId>
            <ArticleId IdType="pubmed">31043955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deligiorgi MV, Panayiotidis MI, Trafalis DT. Parathyroid Hormone Related Protein (PTHrP)-Mediated Hypercalcemia in Malignancy Associated With Anti-PD-1 Immune Checkpoint Inhibitor Treatment and Related Inflammatory Reactions. Int Immunopharmacol (2019) 77:105942. doi: 10.1016/j.intimp.2019.105942</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2019.105942</ArticleId>
            <ArticleId IdType="pubmed">31699669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni J, Zhang X, Zhang L. Opportunistic Bowel Infection After Corticosteroid Dosage Tapering in a Stage IV Lung Cancer Patient With Tislelizumab-Related Colitis. Thorac Cancer (2020) 11(6):1699&#x2013;702. doi: 10.1111/1759-7714.13401</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1759-7714.13401</ArticleId>
            <ArticleId IdType="pmc">PMC7262879</ArticleId>
            <ArticleId IdType="pubmed">32239681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alhatem A, Patel K, Eriksen B, Bukhari S, Liu C. Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects. ACG Case Rep J (2019) 6(11):e00249. doi: 10.14309/crj.0000000000000249</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/crj.0000000000000249</ArticleId>
            <ArticleId IdType="pmc">PMC7145206</ArticleId>
            <ArticleId IdType="pubmed">32309466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancela-D&#xed;ez B, G&#xf3;mez-De Rueda F, Antolinos P&#xe9;rez MJ, Jim&#xe9;nez-Morales A, L&#xf3;pez-Hidalgo JL. Acute Coronary Syndrome and Recurrent Colitis as Immune-Related Adverse Events in a Lung Cancer Patient. J Oncol Pharm Pract (2020) 26(1):252&#x2013;5. doi: 10.1177/1078155219865596</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155219865596</ArticleId>
            <ArticleId IdType="pubmed">31382863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhenin A, Samartzi V, Lejeune S, Seront E. Cascade of Immunologic Adverse Events Related to Pembrolizumab Treatment. BMJ Case Rep (2019) 12(6):e229149. doi: 10.1136/bcr-2018-229149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2018-229149</ArticleId>
            <ArticleId IdType="pmc">PMC6557364</ArticleId>
            <ArticleId IdType="pubmed">31167767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case Report: Reinitiating Pembrolizumab Treatment After Small Bowel Perforation. BMC Cancer (2019) 19:379. doi: 10.1186/s12885-019-5577-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-5577-5</ArticleId>
            <ArticleId IdType="pmc">PMC6482547</ArticleId>
            <ArticleId IdType="pubmed">31018834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibraheim H, Green M, Papa S, Powell N. Topical Beclometasone Dipropionate in the Management of Immune Checkpoint Inhibitor-Induced Microscopic Colitis. BMJ Case Rep (2019) 12(4):e226481. doi: 10.1136/bcr-2018-226481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2018-226481</ArticleId>
            <ArticleId IdType="pmc">PMC6453372</ArticleId>
            <ArticleId IdType="pubmed">30948391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasuda Y, Urata Y, Tohnai R, Ito S, Kawa Y, Kono Y, et al. . Immune-Related Colitis Induced by the Long-Term Use of Nivolumab in a Patient With Non-Small Cell Lung Cancer. Internal Med (2018) 57(9):1269&#x2013;72. doi: 10.2169/internalmedicine.9230-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.9230-17</ArticleId>
            <ArticleId IdType="pmc">PMC5980808</ArticleId>
            <ArticleId IdType="pubmed">29279482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, et al. . The Characteristics of Nivolumab-Induced Colitis: An Evaluation of Three Cases and a Literature Review. BMC Gastroenterol (2018) 18(1):135. doi: 10.1186/s12876-018-0864-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12876-018-0864-1</ArticleId>
            <ArticleId IdType="pmc">PMC6119262</ArticleId>
            <ArticleId IdType="pubmed">30170560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iyoda T, Kurita N, Takada A, Watanabe H, Ando M. Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient With Non-Small Cell Lung Cancer. Am J Case Rep (2018) 19:360&#x2013;4. doi: 10.12659/AJCR.908570</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/AJCR.908570</ArticleId>
            <ArticleId IdType="pmc">PMC5884314</ArticleId>
            <ArticleId IdType="pubmed">29581417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callens R, Tamsin A, van Zandweghe L. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC. J Thorac Oncol (2019) 14(3):e49&#x2013;50. doi: 10.1016/j.jtho.2018.11.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.11.014</ArticleId>
            <ArticleId IdType="pubmed">30782382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Vazquez S, de-la-Riva-Onandia S, Ignacio Echeveste J, Munoz-Navas M. Immune Mediated Colitis Caused by Lung Cancer Treatment With Atezolizumab. Rev Esp Enferm Dig (2017) 109(12):863&#x2013;4. doi: 10.17235/reed.2017.5060/2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.17235/reed.2017.5060/2017</ArticleId>
            <ArticleId IdType="pubmed">29019253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takenaka T, Yamazaki K, Miura N, Harada N, Takeo S. Osimertinib Reactivated Immune-Related Colitis After Treatment With Anti-PD1 Antibody for Non-Small Cell Lung Cancer. Invest New Drugs (2017) 35(6):848&#x2013;50. doi: 10.1007/s10637-017-0481-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10637-017-0481-9</ArticleId>
            <ArticleId IdType="pubmed">28601918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubo K, Kato M, Mabe K. Nivolumab-Associated Colitis Mimicking Ulcerative Colitis. Clin Gastroenterol Hepatol (2017) 15(9):XXXV&#x2013;XXXVI. doi: 10.1016/j.cgh.2017.03.026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2017.03.026</ArticleId>
            <ArticleId IdType="pubmed">28351793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A, et al. . Management of Immune Checkpoint Inhibitor Toxicities. Cancer Manage Res (2020) 12:9139&#x2013;57. doi: 10.2147/CMAR.S218756</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S218756</ArticleId>
            <ArticleId IdType="pmc">PMC7533913</ArticleId>
            <ArticleId IdType="pubmed">33061607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, et al. . Immune-Checkpoint Inhibitor-Induced Diarrhea and Colitis in Patients With Advanced Malignancies: Retrospective Review at MD Anderson. J Immunother Cancer (2018) 6. doi: 10.1186/s40425-018-0346-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0346-6</ArticleId>
            <ArticleId IdType="pmc">PMC5946546</ArticleId>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foppen MHG, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, et al. . Immune Checkpoint Inhibition-Related Colitis: Symptoms, Endoscopic Features, Histology and Response to Management. ESMO Open (2018) 3(1):e000278. doi: 10.1136/esmoopen-2017-000278</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi Y, Hosoe N, Takabayashi K, Limpias Kamiya KJL, Tsugaru K, Shimozaki K, et al. . Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. Dig Dis Sci (2021) 66(6):2129&#x2013;34. doi: 10.1007/s10620-020-06441-w</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-020-06441-w</ArticleId>
            <ArticleId IdType="pubmed">32621258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assarzadegan N, Montgomery E, Anders RA. Immune Checkpoint Inhibitor Colitis: The Flip Side of the Wonder Drugs. Virchows Arch (2018) 472(1):125&#x2013;33. doi: 10.1007/s00428-017-2267-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-017-2267-z</ArticleId>
            <ArticleId IdType="pubmed">29143108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai S, Nakamura S, Matsumoto T. Nivolumab-Induced Colitis Treated by Infliximab. Clin Gastroenterol Hepatol (2017) 15(4):E80&#x2013;1. doi: 10.1016/j.cgh.2016.09.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2016.09.017</ArticleId>
            <ArticleId IdType="pubmed">27664866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gondal B, Patel P, Gallan A, Hart J, Bissonnette M. Gastrointestinal Adverse Effects of Immunomodulation: Acute Colitis With Immune Check Point Inhibitor Nivolumab. Inflamm Bowel Dis (2016) 22:S12&#x2013;3. doi: 10.1097/01.MIB.0000480057.88945.e3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.MIB.0000480057.88945.e3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baroudjian B, Lourenco N, Pages C, Chami I, Maillet M, Bertheau P, et al. . Anti-PD1-Induced Collagenous Colitis in a Melanoma Patient. Melanoma Res (2016) 26(3):308&#x2013;11. doi: 10.1097/CMR.0000000000000252</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CMR.0000000000000252</ArticleId>
            <ArticleId IdType="pubmed">26990271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Kaehler KC, Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. J Clin Oncol (2012) 30(21):2691&#x2013;7. doi: 10.1200/JCO.2012.41.6750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.41.6750</ArticleId>
            <ArticleId IdType="pubmed">22614989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hillock NT, Heard S, Kichenadasse G, Hill CL, Andrews J. Infliximab for Ipilimumab-Induced Colitis: A Series of 13 Patients. Asia Pac J Clin Oncol (2017) 13(5):E284&#x2013;90. doi: 10.1111/ajco.12651</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajco.12651</ArticleId>
            <ArticleId IdType="pubmed">27981760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. . Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination. Nat Rev Clin Oncol (2016) 13(8):473&#x2013;86. doi: 10.1038/nrclinonc.2016.58</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2016.58</ArticleId>
            <ArticleId IdType="pubmed">27141885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, et al. . Clinical Characterization of Colitis Arising From Anti-PD-1 Based Therapy. Oncoimmunology (2019) 8(1):e1524695. doi: 10.1080/2162402X.2018.1524695</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1524695</ArticleId>
            <ArticleId IdType="pmc">PMC6287774</ArticleId>
            <ArticleId IdType="pubmed">30546965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. . Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2017) 28(suppl_4):iv119&#x2013;42. doi: 10.1093/annonc/mdx225</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx225</ArticleId>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida T, Iijima H, Adachi S. Immune Checkpoint Inhibitor-Induced Diarrhea/Colitis: Endoscopic and Pathologic Findings. World J Gastrointest Pathophysiol (2019) 10(2):17&#x2013;28. doi: 10.4291/wjgp.v10.i2.17</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4291/wjgp.v10.i2.17</ArticleId>
            <ArticleId IdType="pmc">PMC6751508</ArticleId>
            <ArticleId IdType="pubmed">31559106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. . Blockade of Cytotoxic T-Lymphocyte Antigen-4 by Ipilimumab Results in Dysregulation of Gastrointestinal Immunity in Patients With Advanced Melanoma. Cancer Immun (2010) 10:11&#x2013;1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2999944</ArticleId>
            <ArticleId IdType="pubmed">21090563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, et al. . Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3(+) T Cells. Dig Dis Sci (2010) 55(5):1396&#x2013;405. doi: 10.1007/s10620-009-0839-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-009-0839-8</ArticleId>
            <ArticleId IdType="pmc">PMC2904314</ArticleId>
            <ArticleId IdType="pubmed">19507029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y-H, Zang X-Y, Wang J-C, Huang S-S, Xu J, Zhang P. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomed Pharmacother (2019) 120:109437. doi: 10.1016/j.biopha.2019.109437</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2019.109437</ArticleId>
            <ArticleId IdType="pubmed">31590992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes MJ, Griseri T, Johnson AMF, Young W, Powrie F, Izcue A. CTLA-4 Promotes Foxp3 Induction and Regulatory T Cell Accumulation in the Intestinal Lamina Propria. Mucosal Immunol (2013) 6(2):324&#x2013;34. doi: 10.1038/mi.2012.75</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2012.75</ArticleId>
            <ArticleId IdType="pmc">PMC3574974</ArticleId>
            <ArticleId IdType="pubmed">22910217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, et al. . Cancer Immunotherapy With Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis (2016) 10(4):395&#x2013;401. doi: 10.1093/ecco-jcc/jjv227</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv227</ArticleId>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siakavellas SI, Bamias G. Checkpoint Inhibitor Colitis: A New Model of Inflammatory Bowel Disease? Curr Opin Gastroenterol (2018) 34(6):377&#x2013;83. doi: 10.1097/MOG.0000000000000482</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MOG.0000000000000482</ArticleId>
            <ArticleId IdType="pubmed">30157044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol (2020) 115(2):202&#x2013;10. doi: 10.14309/ajg.0000000000000497</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/ajg.0000000000000497</ArticleId>
            <ArticleId IdType="pubmed">31922959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tadano H, Torigoe T. Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Nihon Rinsho Meneki Gakkai Kaishi (2017) 40(2):102&#x2013;8. doi: 10.2177/jsci.40.102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2177/jsci.40.102</ArticleId>
            <ArticleId IdType="pubmed">28603200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller PL, Carson TL. Mechanisms and Microbial Influences on CTLA-4 and PD-1-Based Immunotherapy in the Treatment of Cancer: A Narrative Review. Gut Pathog (2020) 12(1):43. doi: 10.1186/s13099-020-00381-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13099-020-00381-6</ArticleId>
            <ArticleId IdType="pmc">PMC7488430</ArticleId>
            <ArticleId IdType="pubmed">32944086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharpe AH, Abbas AK. Focus on Research: T-Cell Costimulation - Biology, Therapeutic Potential, and Challenges. N Engl J Med (2006) 355(10):973&#x2013;5. doi: 10.1056/NEJMp068087</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMp068087</ArticleId>
            <ArticleId IdType="pubmed">16908487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T Cell Immunity Against Cancer. Clin Cancer Res (2003) 9(12):4296&#x2013;303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14555498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. . Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science (2011) 332(6029):600&#x2013;3. doi: 10.1126/science.1202947</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1202947</ArticleId>
            <ArticleId IdType="pmc">PMC3198051</ArticleId>
            <ArticleId IdType="pubmed">21474713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. . CTLA-4 Control Over Foxp3(+) Regulatory T Cell Function. Science (2008) 322(5899):271&#x2013;5. doi: 10.1126/science.1160062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1160062</ArticleId>
            <ArticleId IdType="pubmed">18845758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. . PD-1 Alters T-Cell Metabolic Reprogramming by Inhibiting Glycolysis and Promoting Lipolysis and Fatty Acid Oxidation. Nat Commun (2015) 6:6692. doi: 10.1038/ncomms7692</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms7692</ArticleId>
            <ArticleId IdType="pmc">PMC4389235</ArticleId>
            <ArticleId IdType="pubmed">25809635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2. Mol Cell Biol (2013) 33(16):3091&#x2013;8. doi: 10.1128/MCB.00319-13</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00319-13</ArticleId>
            <ArticleId IdType="pmc">PMC3753920</ArticleId>
            <ArticleId IdType="pubmed">23732914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, et al. . Immune-Related Adverse Events of Checkpoint Inhibitors. Nat Rev Dis Primers (2020) 6(1):31. doi: 10.1038/s41572-020-0160-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-020-0160-6</ArticleId>
            <ArticleId IdType="pubmed">32382051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4. Immunity (1995) 3(5):541&#x2013;7. doi: 10.1016/1074-7613(95)90125-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/1074-7613(95)90125-6</ArticleId>
            <ArticleId IdType="pubmed">7584144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of Autoimmune Disease by Deletion of CTLA-4 in Mice in Adulthood. Proc Natl Acad Sci U S A (2016) 113(17):E2383&#x2013;92. doi: 10.1073/pnas.1603892113</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1603892113</ArticleId>
            <ArticleId IdType="pmc">PMC4855592</ArticleId>
            <ArticleId IdType="pubmed">27071130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. . Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4. J Clin Oncol (2006) 24(15):2283&#x2013;9. doi: 10.1200/JCO.2005.04.5716</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.04.5716</ArticleId>
            <ArticleId IdType="pmc">PMC2140223</ArticleId>
            <ArticleId IdType="pubmed">16710025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guthery SL, Heubi JE, Filipovich A. Enteral Metronidazole for the Prevention of Graft Versus Host Disease in Pediatric Marrow Transplant Recipients: Results of a Pilot Study. Bone Marrow Transplant (2004) 33(12):1235&#x2013;9. doi: 10.1038/sj.bmt.1704474</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bmt.1704474</ArticleId>
            <ArticleId IdType="pubmed">15077127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on Immunologic Therapy With Anti-CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management. Semin Oncol (2010) 37(5):485&#x2013;98. doi: 10.1053/j.seminoncol.2010.09.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.seminoncol.2010.09.003</ArticleId>
            <ArticleId IdType="pubmed">21074064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Zheng N, Luo Q, Jiang L, He B, Yuan X, et al. . Probiotics Lactobacillus Reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. Front Immunol (2019) 10. doi: 10.3389/fimmu.2019.01235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01235</ArticleId>
            <ArticleId IdType="pmc">PMC6558076</ArticleId>
            <ArticleId IdType="pubmed">31214189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, et al. . Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. J Crohns Colitis (2017) 11(10):1238&#x2013;46. doi: 10.1093/ecco-jcc/jjx081</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjx081</ArticleId>
            <ArticleId IdType="pubmed">28967957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshino K, Nakayama T, Ito A, Sato E, Kitano S. Severe Colitis After PD-1 Blockade With Nivolumab in Advanced Melanoma Patients: Potential Role of Th1-Dominant Immune Response in Immune-Related Adverse Events: Two Case Reports. BMC Cancer (2019) 19(1):1019. doi: 10.1186/s12885-019-6138-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-6138-7</ArticleId>
            <ArticleId IdType="pmc">PMC6819390</ArticleId>
            <ArticleId IdType="pubmed">31664934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. . Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell (2020) 182(3):655&#x2013;+. doi: 10.1016/j.cell.2020.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.06.001</ArticleId>
            <ArticleId IdType="pmc">PMC7415717</ArticleId>
            <ArticleId IdType="pubmed">32603654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song M-Y, Hong C-P, Park SJ, Kim J-H, Yang B-G, Park Y, et al. . Protective Effects of Fc-Fused PD-L1 on Two Different Animal Models of Colitis. Gut (2015) 64(2):260&#x2013;71. doi: 10.1136/gutjnl-2014-307311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2014-307311</ArticleId>
            <ArticleId IdType="pubmed">24902766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent Therapy With Immune Checkpoint Inhibitors and TNF Alpha Blockade in Patients With Gastrointestinal Immune-Related Adverse Events. J Immunother Cancer (2019) 7(1):226. doi: 10.1186/s40425-019-0711-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0711-0</ArticleId>
            <ArticleId IdType="pmc">PMC6704680</ArticleId>
            <ArticleId IdType="pubmed">31439050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bamias G, Delladetsima I, Perdiki M, Siakavellas SI, Goukos D, Papatheodoridis GV, et al. . Immunological Characteristics of Colitis Associated With Anti-CTLA-4 Antibody Therapy. Cancer Invest (2017) 35(7):443&#x2013;55. doi: 10.1080/07357907.2017.1324032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/07357907.2017.1324032</ArticleId>
            <ArticleId IdType="pubmed">28548891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. . CXCL9, CXCL10, CXCL11/CXCR3 Axis for Immune Activation - A Target for Novel Cancer Therapy. Cancer Treat Rev (2018) 63:40&#x2013;7. doi: 10.1016/j.ctrv.2017.11.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2017.11.007</ArticleId>
            <ArticleId IdType="pmc">PMC5801162</ArticleId>
            <ArticleId IdType="pubmed">29207310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurath MF. Targeting Immune Cell Circuits and Trafficking in Inflammatory Bowel Disease. Nat Immunol (2019) 20(8):970&#x2013;9. doi: 10.1038/s41590-019-0415-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-019-0415-0</ArticleId>
            <ArticleId IdType="pubmed">31235952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitt JM, Vetizou M, Waldschmitt N, Kroemer G, Chamaillard M, Boneca IG, et al. . Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. Cancer Res (2016) 76(16):4602&#x2013;7. doi: 10.1158/0008-5472.CAN-16-0448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-0448</ArticleId>
            <ArticleId IdType="pubmed">27474734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan Z, Hammer C, Guardino E, Chandler GS, Albert ML. Mechanisms of Immune-Related Adverse Events Associated With Immune Checkpoint Blockade: Using Germline Genetics to Develop a Personalized Approach. Genome Med (2019) 11(1):39. doi: 10.1186/s13073-019-0652-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13073-019-0652-8</ArticleId>
            <ArticleId IdType="pmc">PMC6585053</ArticleId>
            <ArticleId IdType="pubmed">31221204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belkaid Y, Hand TW. Role of the Microbiota in Immunity and Inflammation. Cell (2014) 157(1):121&#x2013;41. doi: 10.1016/j.cell.2014.03.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.03.011</ArticleId>
            <ArticleId IdType="pmc">PMC4056765</ArticleId>
            <ArticleId IdType="pubmed">24679531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Torchinsky MB, Gobert M, Xiong H, Xu M, Linehan JL, et al. . Focused Specificity of Intestinal T(H)17 Cells Towards Commensal Bacterial Antigens. Nature (2014) 510(7503):152&#x2013;+. doi: 10.1038/nature13279</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13279</ArticleId>
            <ArticleId IdType="pmc">PMC4128479</ArticleId>
            <ArticleId IdType="pubmed">24739972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson R, Theron AJ, Rapoport BL. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Front Immunol (2019) 10. doi: 10.3389/fimmu.2019.02254</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02254</ArticleId>
            <ArticleId IdType="pmc">PMC6775220</ArticleId>
            <ArticleId IdType="pubmed">31616428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. . Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis. Nat Commun (2016) 7:10391. doi: 10.1038/ncomms10391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10391</ArticleId>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derosa L, Routy B, Kroemer G, Zitvogel L. The Intestinal Microbiota Determines the Clinical Efficacy of Immune Checkpoint Blockers Targeting PD-1/PD-L1. Oncoimmunology (2018) 7(6):e1434468. doi: 10.1080/2162402X.2018.1434468</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1434468</ArticleId>
            <ArticleId IdType="pmc">PMC5980343</ArticleId>
            <ArticleId IdType="pubmed">29872574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goubet A-G, Daillere R, Routy B, Derosa L, Roberti PM, Zitvogel L. The Impact of the Intestinal Microbiota in Therapeutic Responses Against Cancer. C R Biol (2018) 341(5):284&#x2013;9. doi: 10.1016/j.crvi.2018.03.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.crvi.2018.03.004</ArticleId>
            <ArticleId IdType="pubmed">29631891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. . Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors. Science (2018) 359(6371):91&#x2013;+. doi: 10.1126/science.aan3706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan3706</ArticleId>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. . Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab. Ann Oncol (2019) 30(12):2012&#x2013;2. doi: 10.1093/annonc/mdz224</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz224</ArticleId>
            <ArticleId IdType="pubmed">31408090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. . Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Science (2018) 359(6371):97&#x2013;103. doi: 10.1126/science.aan4236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan4236</ArticleId>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang JY, Lee SM, Mazmanian SK. The Human Commensal Bacteroides Fragilis Binds Intestinal Mucin. Anaerobe (2011) 17(4):137&#x2013;41. doi: 10.1016/j.anaerobe.2011.05.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anaerobe.2011.05.017</ArticleId>
            <ArticleId IdType="pmc">PMC3163789</ArticleId>
            <ArticleId IdType="pubmed">21664470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazmanian SK, Round JL, Kasper DL. A Microbial Symbiosis Factor Prevents Intestinal Inflammatory Disease. Nature (2008) 453(7195):620&#x2013;5. doi: 10.1038/nature07008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07008</ArticleId>
            <ArticleId IdType="pubmed">18509436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. . Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. Science (2015) 350(6264):1079&#x2013;+. doi: 10.1126/science.aad1329</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S, Trinchieri G. Microbiota: A Key Orchestrator of Cancer Therapy. Nat Rev Cancer (2017) 17(5):271&#x2013;+. doi: 10.1038/nrc.2017.13</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2017.13</ArticleId>
            <ArticleId IdType="pubmed">28303904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, Reinecker H-C, Kasper DL. Plasmacytoid Dendritic Cells Mediate Anti-Inflammatory Responses to a Gut Commensal Molecule via Both Innate and Adaptive Mechanisms. Cell Host Microbe (2014) 15(4):413&#x2013;23. doi: 10.1016/j.chom.2014.03.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2014.03.006</ArticleId>
            <ArticleId IdType="pmc">PMC4020153</ArticleId>
            <ArticleId IdType="pubmed">24721570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. . Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science (2015) 350(6264):1084&#x2013;9. doi: 10.1126/science.aac4255</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aac4255</ArticleId>
            <ArticleId IdType="pmc">PMC4873287</ArticleId>
            <ArticleId IdType="pubmed">26541606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can Mitigate Intestinal Immunopathology in the Context of CTLA-4 Blockade. Proc Natl Acad Sci U S A (2018) 115(1):157&#x2013;61. doi: 10.1073/pnas.1712901115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1712901115</ArticleId>
            <ArticleId IdType="pmc">PMC5776803</ArticleId>
            <ArticleId IdType="pubmed">29255057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus Reuteri in Human Health and Diseases. Front Microbiol (2018) 9. doi: 10.3389/fmicb.2018.00757</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2018.00757</ArticleId>
            <ArticleId IdType="pmc">PMC5917019</ArticleId>
            <ArticleId IdType="pubmed">29725324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, Fuchs CS, et al. . Aspirin, Nonsteroidal Anti-Inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis: A Cohort Study. Ann Internal Med (2012) 156(5):350&#x2013;9. doi: 10.7326/0003-4819-156-5-201203060-00007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-156-5-201203060-00007</ArticleId>
            <ArticleId IdType="pmc">PMC3369539</ArticleId>
            <ArticleId IdType="pubmed">22393130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, et al. . Vitamin D Intake is Associated With Decreased Risk of Immune Checkpoint Inhibitor-Induced Colitis. Cancer (2020) 126(16):3758&#x2013;67. doi: 10.1002/cncr.32966</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.32966</ArticleId>
            <ArticleId IdType="pmc">PMC7381363</ArticleId>
            <ArticleId IdType="pubmed">32567084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyan K, Grover S, Dougan M, Sullivan RJ, Giobbie-Hurder A, Blum S, et al. . Association of Vitamin D Intake With Decreased Risk of Immune Checkpoint Inhibitor-Induced Colitis. J Clin Oncol (2020) 38(5):S89. doi: 10.1200/JCO.2020.38.5_suppl.89</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2020.38.5_suppl.89</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, et al. . Efficacy and Toxicity of Treatment With the Anti-CTLA-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-PD-1 Therapy. Br J Cancer (2016) 114(10):1084&#x2013;9. doi: 10.1038/bjc.2016.107</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2016.107</ArticleId>
            <ArticleId IdType="pmc">PMC4865968</ArticleId>
            <ArticleId IdType="pubmed">27124339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. . Anti-PD-1 Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders or Major Toxicity With Ipilimumab. Ann Oncol (2017) 28(2):368&#x2013;76. doi: 10.1093/annonc/mdw443</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw443</ArticleId>
            <ArticleId IdType="pubmed">27687304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. . Ipilimumab Monotherapy in Patients With Pretreated Advanced Melanoma: A Randomised, Double-Blind, Multicentre, Phase 2, Dose-Ranging Study. Lancet Oncol (2010) 11(2):155&#x2013;64. doi: 10.1016/S1470-2045(09)70334-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(09)70334-1</ArticleId>
            <ArticleId IdType="pubmed">20004617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol (2017) 8. doi: 10.3389/fphar.2017.00049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2017.00049</ArticleId>
            <ArticleId IdType="pmc">PMC5296331</ArticleId>
            <ArticleId IdType="pubmed">28228726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. . Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol (2016) 2(2):234&#x2013;40. doi: 10.1001/jamaoncol.2015.4368</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2015.4368</ArticleId>
            <ArticleId IdType="pubmed">26633184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaehler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, et al. . Ipilimumab in Metastatic Melanoma Patients With Pre-Existing Autoimmune Disorders. Cancer Immunol Immunother (2018) 67(5):825&#x2013;34. doi: 10.1007/s00262-018-2134-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2134-z</ArticleId>
            <ArticleId IdType="pubmed">29487980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishay K, Tandon P, Bourassa-Blanchette S, Laurie SA, McCurdy JD. The Risk of Diarrhea and Colitis in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Curr Oncol (Toronto Ont) (2020) 27(5):486&#x2013;94. doi: 10.3747/co.27.6251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3747/co.27.6251</ArticleId>
            <ArticleId IdType="pmc">PMC7606037</ArticleId>
            <ArticleId IdType="pubmed">33173388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paz-Ares L, Ciuleanu T-E, Cobo M, Schenker M, Zurawski B, Menezes J, et al. . First-Line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol (2021) 22(2):198&#x2013;211. doi: 10.1016/S1470-2045(20)30641-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30641-0</ArticleId>
            <ArticleId IdType="pubmed">33476593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. . Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med (2019) 381(21):2020&#x2013;31. doi: 10.1056/NEJMoa1910231</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910231</ArticleId>
            <ArticleId IdType="pubmed">31562796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. . Safety and Antitumour Activity of Durvalumab Plus Tremelimumab in Non-Small-Cell Lung Cancer: A Multicentre, Phase 1b Study. Lancet Oncol (2016) 17(3):299&#x2013;308. doi: 10.1016/S1470-2045(15)00544-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)00544-6</ArticleId>
            <ArticleId IdType="pmc">PMC5500167</ArticleId>
            <ArticleId IdType="pubmed">26858122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rocco D, Gravara LD, Gridelli C. The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives Open Access Plus. Curr Clin Pharmacol (2020) 15(1):11&#x2013;9. doi: 10.2174/1574884714666190809124555</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1574884714666190809124555</ArticleId>
            <ArticleId IdType="pmc">PMC7497556</ArticleId>
            <ArticleId IdType="pubmed">31400270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Jr., Lawrence DP, et al. . Sequential Administration of Nivolumab and Ipilimumab With a Planned Switch in Patients With Advanced Melanoma (CheckMate 064): An Open-Label, Randomised, Phase 2 Trial. Lancet Oncol (2016) 17(7):943&#x2013;55. doi: 10.1016/S1470-2045(16)30126-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)30126-7</ArticleId>
            <ArticleId IdType="pmc">PMC5474305</ArticleId>
            <ArticleId IdType="pubmed">27269740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. . Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol (2017) 35(34):3815&#x2013;+. doi: 10.1200/JCO.2016.72.1167</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.72.1167</ArticleId>
            <ArticleId IdType="pubmed">28915085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, et al. . Safety and Efficacy of Combination Therapy Using Programmed Cell Death Protein-1/Programmed Cell Death Ligand-1 Inhibitors and Radiotherapy in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cancer Med (2021) 10(4):1222&#x2013;39. doi: 10.1002/cam4.3718</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.3718</ArticleId>
            <ArticleId IdType="pmc">PMC7926021</ArticleId>
            <ArticleId IdType="pubmed">33465302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, et al. . Immune-Related Adverse Events of a PD-(L)1 Inhibitor Plus Chemotherapy Versus a PD-(L)1 Inhibitor Alone in First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Control Trials. Cancer (2021) 127(5):777&#x2013;86. doi: 10.1002/cncr.33270</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.33270</ArticleId>
            <ArticleId IdType="pubmed">33119182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, et al. . Fluctuations in Routine Blood Count Might Signal Severe Immune-Related Adverse Events in Melanoma Patients Treated With Nivolumab. J Dermatol Sci (2017) 88(2):225&#x2013;31. doi: 10.1016/j.jdermsci.2017.07.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2017.07.007</ArticleId>
            <ArticleId IdType="pubmed">28736218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manson G, Norwood J, Marabelle A, Kohrt H, Houot R. Biomarkers Associated With Checkpoint Inhibitors. Ann Oncol (2016) 27(7):1199&#x2013;206. doi: 10.1093/annonc/mdw181</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw181</ArticleId>
            <ArticleId IdType="pubmed">27122549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. . Baseline Circulating IL-17 Predicts Toxicity While TGF-Beta 1 and IL-10 are Prognostic of Relapse in Ipilimumab Neoadjuvant Therapy of Melanoma. J Immunother Cancer (2015) 3:39. doi: 10.1186/s40425-015-0081-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-015-0081-1</ArticleId>
            <ArticleId IdType="pmc">PMC4570556</ArticleId>
            <ArticleId IdType="pubmed">26380086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyan K, Baginska J, Brainard M, Giobbie-Hurder A, Severgnini M, Manos M, et al. . Cytokine Changes During Immune-Related Adverse Events and Corticosteroid Treatment in Melanoma Patients Receiving Immune Checkpoint Inhibitors. Cancer Immunol Immunother (2021) 70(8):2209&#x2013;21. doi: 10.1007/s00262-021-02855-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-021-02855-1</ArticleId>
            <ArticleId IdType="pubmed">33481042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meshkibaf S, Martins AJ, Henry GT, Kim SO. Protective Role of G-CSF in Dextran Sulfate Sodium-Induced Acute Colitis Through Generating Gut-Homing Macrophages. Cytokine (2016) 78:69&#x2013;78. doi: 10.1016/j.cyto.2015.11.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2015.11.025</ArticleId>
            <ArticleId IdType="pubmed">26687628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, et al. . Gene Expression Profiling of Whole Blood in Ipilimumab-Treated Patients for Identification of Potential Biomarkers of Immune-Related Gastrointestinal Adverse Events. J Trans Med (2013) 11:75. doi: 10.1186/1479-5876-11-75</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-11-75</ArticleId>
            <ArticleId IdType="pmc">PMC3637501</ArticleId>
            <ArticleId IdType="pubmed">23521917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Giacomo AM, Biagioli M, Maio M. The Emerging Toxicity Profiles of Anti-CTLA-4 Antibodies Across Clinical Indications. Semin Oncol (2010) 37(5):499&#x2013;507. doi: 10.1053/j.seminoncol.2010.09.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.seminoncol.2010.09.007</ArticleId>
            <ArticleId IdType="pubmed">21074065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NCI Common Terminology Criteria for Adverse Events (CTCAE) Data Files . Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.</Citation>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. . Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance. Nat Rev Clin Oncol (2019) 16(9):563&#x2013;80. doi: 10.1038/s41571-019-0218-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-019-0218-0</ArticleId>
            <ArticleId IdType="pubmed">31092901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, et al. . Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. Cancer Immunol Res (2017) 5(4):286&#x2013;91. doi: 10.1158/2326-6066.CIR-16-0302</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0302</ArticleId>
            <ArticleId IdType="pubmed">28373217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA. Isolated Recto-Sigmoid Colitis: A New Imaging Pattern of Ipilimumab-Associated Colitis. Abdom Radiol (2016) 41(2):207&#x2013;14. doi: 10.1007/s00261-015-0560-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00261-015-0560-3</ArticleId>
            <ArticleId IdType="pubmed">26867901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, De Felice KM, Loftus EV, Jr., Khanna S. Systematic Review: Colitis Associated With Anti-CTLA-4 Therapy. Aliment Pharmacol Ther (2015) 42(4):406&#x2013;17. doi: 10.1111/apt.13281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.13281</ArticleId>
            <ArticleId IdType="pubmed">26079306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot J-M, Lambotte O, et al. . Detection of Immune-Related Adverse Events by Medical Imaging in Patients Treated With Anti-Programmed Cell Death 1. Eur J Cancer (2018) 96:91&#x2013;104. doi: 10.1016/j.ejca.2018.03.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.03.006</ArticleId>
            <ArticleId IdType="pubmed">29698933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. . Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated With Ipilimumab. Cancer Immunol Res (2015) 3(10):1185&#x2013;92. doi: 10.1158/2326-6066.CIR-15-0102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0102</ArticleId>
            <ArticleId IdType="pmc">PMC4596761</ArticleId>
            <ArticleId IdType="pubmed">26100356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, et al. . Ipilimumab-Associated Colitis: CT Findings. Am J Roentgenol (2013) 200(5):W468&#x2013;74. doi: 10.2214/AJR.12.9751</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/AJR.12.9751</ArticleId>
            <ArticleId IdType="pubmed">23718569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-Induced Perforating Colitis. J Clin Gastroenterol (2013) 47(9):781&#x2013;5. doi: 10.1097/MCG.0b013e31828f1d51</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCG.0b013e31828f1d51</ArticleId>
            <ArticleId IdType="pmc">PMC6091636</ArticleId>
            <ArticleId IdType="pubmed">23632354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abolhassani A-R, Schuler G, Kirchberger MC, Heinzerling L. C-Reactive Protein as an Early Marker of Immune-Related Adverse Events. J Cancer Res Clin Oncol (2019) 145(10):2625&#x2013;31. doi: 10.1007/s00432-019-03002-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-019-03002-1</ArticleId>
            <ArticleId IdType="pubmed">31492984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schindler K, Harmankaya K, Kuk D, Mangana J, Michielin O, Hoeller C, et al. . Correlation of Absolute and Relative Eosinophil Counts With Immune-Related Adverse Events in Melanoma Patients Treated With Ipilimumab. J&#xa0;Clin Oncol (2014) 32(15):S9096. doi: 10.1200/jco.2014.32.15_suppl.9096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2014.32.15_suppl.9096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura Y, Tanaka R, Maruyama H, Ishitsuka Y, Okiyama N, Watanabe R, et al. . Correlation Between Blood Cell Count and Outcome of Melanoma Patients Treated With Anti-PD-1 Antibodies. Jpn J Clin Oncol (2019) 49(5):431&#x2013;7. doi: 10.1093/jjco/hyy201</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jjco/hyy201</ArticleId>
            <ArticleId IdType="pubmed">30753621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou F, Wang X, Glitza IC, McQuade JL, Wang J, Zhang HC, et al. . Fecal Calprotectin Concentration to Assess Endoscopic and Histologic Remission in Patients With Cancer With Immune-Mediated Diarrhea and Colitis. J&#xa0;Immunother Cancer (2021) 9(1):1. doi: 10.1136/jitc-2020-002058</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-002058</ArticleId>
            <ArticleId IdType="pmc">PMC7805368</ArticleId>
            <ArticleId IdType="pubmed">33436487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright AP, Piper MS, Bishu S, Stidham RW. Systematic Review and Case Series: Flexible Sigmoidoscopy Identifies Most Cases of Checkpoint Inhibitor-Induced Colitis. Aliment Pharmacol Ther (2019) 49(12):1474&#x2013;83. doi: 10.1111/apt.15263</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.15263</ArticleId>
            <ArticleId IdType="pmc">PMC6637018</ArticleId>
            <ArticleId IdType="pubmed">31035308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herlihy JD, Beasley S, Simmelink A, Maddukuri V, Amin A, Kamionek M, et al. . Flexible Sigmoidoscopy Rather Than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis. South Med J (2019) 112(3):154&#x2013;8. doi: 10.14423/SMJ.0000000000000944</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14423/SMJ.0000000000000944</ArticleId>
            <ArticleId IdType="pubmed">30830228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Front Immunol (2017) 8. doi: 10.3389/fimmu.2017.01547</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01547</ArticleId>
            <ArticleId IdType="pmc">PMC5715331</ArticleId>
            <ArticleId IdType="pubmed">29230210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Heide H, van den Brandt-Gradel V, Tytgat GN, Endert E, Wiltink EH, Schipper ME, et al. . Comparison of Beclomethasone Dipropionate and Prednisolone 21-Phosphate Enemas in the Treatment of Ulcerative Proctitis. J Clin Gastroenterol (1988) 10(2):169&#x2013;72. doi: 10.1097/00004836-198804000-00013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004836-198804000-00013</ArticleId>
            <ArticleId IdType="pubmed">3047215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, et al. . Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. Clin Gastroenterol Hepatol (2016) 14(6):836&#x2013;42. doi: 10.1016/j.cgh.2015.12.028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2015.12.028</ArticleId>
            <ArticleId IdType="pubmed">26748223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, et al. . Budesonide Treatment for Microscopic Colitis From Immune Checkpoint Inhibitors. J Immunother Cancer (2019) 7(1):292. doi: 10.1186/s40425-019-0756-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0756-0</ArticleId>
            <ArticleId IdType="pmc">PMC6839080</ArticleId>
            <ArticleId IdType="pubmed">31699151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis. J Immunother Cancer (2018) 6(1):95. doi: 10.1186/s40425-018-0411-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0411-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain A, Lipson EJ, Sharfman WH, Brant SR, Lazarev MG. Colonic Ulcerations may Predict Steroid-Refractory Course in Patients With Ipilimumab-Mediated Enterocolitis. World J Gastroenterol (2017) 23(11):2023&#x2013;8. doi: 10.3748/wjg.v23.i11.2023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v23.i11.2023</ArticleId>
            <ArticleId IdType="pmc">PMC5360643</ArticleId>
            <ArticleId IdType="pubmed">28373768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patil PA, Zhang X. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Arch Pathol Lab Med (2021) 145(5):571&#x2013;82. doi: 10.5858/arpa.2020-0070-RA</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/arpa.2020-0070-RA</ArticleId>
            <ArticleId IdType="pubmed">32338534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-Related Adverse Events in the Gastrointestinal Tract: Diagnostic Utility of Upper Gastrointestinal Biopsies. Histopathology (2020) 76(2):233&#x2013;43. doi: 10.1111/his.13963</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13963</ArticleId>
            <ArticleId IdType="pmc">PMC8386137</ArticleId>
            <ArticleId IdType="pubmed">31361907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shivaj UN, Jeffery L, Gui X, Smith SCL, Ahmad OF, Akbar A, et al. . Immune Checkpoint Inhibitor-Associated Gastrointestinal and Hepatic Adverse Events and Their Management. Ther Adv Gastroenterol (2019) 12:1756284819884196. doi: 10.1177/1756284819884196</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756284819884196</ArticleId>
            <ArticleId IdType="pmc">PMC6831976</ArticleId>
            <ArticleId IdType="pubmed">31723355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karamchandani DM, Chetty R. Immune Checkpoint Inhibitor-Induced Gastrointestinal and Hepatic Injury: Pathologists' Perspective. J Clin Pathol (2018) 71(8):665&#x2013;71. doi: 10.1136/jclinpath-2018-205143</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jclinpath-2018-205143</ArticleId>
            <ArticleId IdType="pubmed">29703758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. Am J Surg Pathol (2017) 41(5):643&#x2013;54. doi: 10.1097/PAS.0000000000000829</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0000000000000829</ArticleId>
            <ArticleId IdType="pubmed">28296676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Star KV, Ho VT, Wang HH, Odze RD. Histologic Features in Colon Biopsies Can Discriminate Mycophenolate From GVHD-Induced Colitis. Am J Surg Pathol (2013) 37(9):1319&#x2013;28. doi: 10.1097/PAS.0b013e31829ab1ef</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e31829ab1ef</ArticleId>
            <ArticleId IdType="pubmed">24076772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakellariou S, Zouki DN, Ziogas DC, Pouloudi D, Gogas H, Delladetsima I. Granulomatous Colitis in a Patient With Metastatic Melanoma Under Immunotherapy: A Case Report and Literature Review. BMC Gastroenterol (2021) 21(1):227. doi: 10.1186/s12876-021-01812-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12876-021-01812-7</ArticleId>
            <ArticleId IdType="pmc">PMC8136206</ArticleId>
            <ArticleId IdType="pubmed">34011268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bavi P, Butler M, Serra S, Chetty R. Immune Modulator-Induced Changes in the Gastrointestinal Tract. Histopathology (2017) 71(3):494&#x2013;6. doi: 10.1111/his.13224</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13224</ArticleId>
            <ArticleId IdType="pubmed">28342232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Varona A, Odze RD, Makrauer F. Lymphocytic Colitis Secondary to Ipilimumab Treatment. Inflamm Bowel Dis (2013) 19(2):E15&#x2013;6. doi: 10.1002/ibd.22846</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ibd.22846</ArticleId>
            <ArticleId IdType="pubmed">22114048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>St Romain PE, Salama AKS, Ferguson NL, Burbridge RA. Ipilimumab-Associated Lymphocytic Colitis: A Case Report. Trans Gastrointest Cancer (2016) 5(1):44&#x2013;6. doi: 10.3978/j.issn.2224-4778</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3978/j.issn.2224-4778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayata G, Ithamukkala S, Sapp H, Shaz BH, Brien TP, Wang HH, et al. . Prevalence and Significance of Inflammatory Bowel Disease-Like Morphologic Features in Collagenous and Lymphocytic Colitis. Am J Surg Pathol (2002) 26(11):1414&#x2013;23. doi: 10.1097/00000478-200211000-00003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-200211000-00003</ArticleId>
            <ArticleId IdType="pubmed">12409717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K, Abu-Sbeih H, Samdani R, Gonzalez GN, Raju GS, Richards DM, et al. . Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflamm Bowel Dis (2019) 25(2):385&#x2013;93. doi: 10.1093/ibd/izy240</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy240</ArticleId>
            <ArticleId IdType="pmc">PMC7534361</ArticleId>
            <ArticleId IdType="pubmed">30169584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du-Thanh A, Pallure V, Girard C, Dereure O, Guillot B. Clostridium Difficile Infection may Loom Behind Ipilimumab-Induced Auto-Immune Colitis. Eur J Dermatol (2015) 25(4):344&#x2013;4. doi: 10.1684/ejd.2015.2561</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1684/ejd.2015.2561</ArticleId>
            <ArticleId IdType="pubmed">25905620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ledezma B, Binder S, Hamid O. Atypical Clinical Response Patterns to Ipilimumab: Four Case Studies of Advanced Melanoma. Clin J Oncol Nurs (2011) 15(4):393&#x2013;403. doi: 10.1188/11.CJON.393-403</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1188/11.CJON.393-403</ArticleId>
            <ArticleId IdType="pubmed">21810572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler BL, Pezhouh MK, Kim A, Luan L, Zhu Q, Gani F, et al. . Histopathological and Immunophenotypic Features of Ipilimumab-Associated Colitis Compared to Ulcerative Colitis. J Internal Med (2018) 283(6):568&#x2013;77. doi: 10.1111/joim.12744</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joim.12744</ArticleId>
            <ArticleId IdType="pmc">PMC5992029</ArticleId>
            <ArticleId IdType="pubmed">29464806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2018) 36(17):1714&#x2013;+. doi: 10.1200/JCO.2017.77.6385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.6385</ArticleId>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol (2016) 2(10):1346&#x2013;53. doi: 10.1001/jamaoncol.2016.1051</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.1051</ArticleId>
            <ArticleId IdType="pubmed">27367787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, et al. . Inflammatory Gastrointestinal Diseases Associated With PD-1 Blockade Antibodies. Ann Oncol (2017) 28(11):2860&#x2013;5. doi: 10.1093/annonc/mdx403</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx403</ArticleId>
            <ArticleId IdType="pubmed">29045560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. . Management of Immunotherapy-Related Toxicities. Version 1.2019. J Natl Compr Cancer Netw (2019) 17(3):255&#x2013;88. doi: 10.6004/jnccn.2019.0013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2019.0013</ArticleId>
            <ArticleId IdType="pubmed">30865922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. Am Soc Clin Oncol Educ Book (2018) 38:13&#x2013;9. doi: 10.1200/EDBK_100013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/EDBK_100013</ArticleId>
            <ArticleId IdType="pubmed">30231401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson LL, Katznelson E, Leet DE, Durbin SM, Yoon J, Reynolds KL, et al. . Impact of Systemic Corticosteroids on Survival Outcomes in Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. Eur J Cancer (Oxford Engl 1990) (2021) 142:143&#x2013;6. doi: 10.1016/j.ejca.2020.09.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2020.09.022</ArticleId>
            <ArticleId IdType="pmc">PMC8300871</ArticleId>
            <ArticleId IdType="pubmed">33268234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. . High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis is Associated With Reduced Survival in Patients With Melanoma. Cancer (2018) 124(18):3706&#x2013;14. doi: 10.1002/cncr.31629</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31629</ArticleId>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horvat TZ, Adel NG, Thu-Oanh D, Momtaz P, Postow MA, Callahan MK, et al. . Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol (2015) 33(28):3193&#x2013;+. doi: 10.1200/JCO.2015.60.8448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.60.8448</ArticleId>
            <ArticleId IdType="pmc">PMC5087335</ArticleId>
            <ArticleId IdType="pubmed">26282644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Favara DM, Spain L, Au L, Clark J, Daniels E, Diem S, et al. . Five-Year Review of Corticosteroid Duration and Complications in the Management of Immune Checkpoint Inhibitor-Related Diarrhoea and Colitis in Advanced Melanoma. ESMO Open (2020) 5(4):e000585. doi: 10.1136/esmoopen-2019-000585</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2019-000585</ArticleId>
            <ArticleId IdType="pmc">PMC7348326</ArticleId>
            <ArticleId IdType="pubmed">32641348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. . Prevention and Treatment of Cancer-Related Infections, Version 2.2016. J Natl Compr Cancer Netw (2016) 14(7):882&#x2013;913. doi: 10.6004/jnccn.2016.0093</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2016.0093</ArticleId>
            <ArticleId IdType="pubmed">27407129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pernot S, Ramtohul T, Taieb J. Checkpoint Inhibitors and Gastrointestinal Immune-Related Adverse Events. Curr Opin Oncol (2016) 28(4):264&#x2013;8. doi: 10.1097/CCO.0000000000000292</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0000000000000292</ArticleId>
            <ArticleId IdType="pubmed">27138569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K&#xe4;hler KC, Hassel JC, Heinzerling L, Loquai C, M&#xf6;ssner R, Ugurel S, et al. . Management of Side Effects of Immune Checkpoint Blockade by Anti-CTLA-4 and Anti-PD-1 Antibodies in Metastatic Melanoma. J Dtsch Dermatol Ges (2016) 14(7):662&#x2013;81. doi: 10.1111/ddg.13047</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ddg.13047</ArticleId>
            <ArticleId IdType="pubmed">27373241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, et al. . Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol (2019) 37(30):2738&#x2013;45. doi: 10.1200/JCO.19.00320</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.00320</ArticleId>
            <ArticleId IdType="pmc">PMC6800279</ArticleId>
            <ArticleId IdType="pubmed">31163011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. Am J Clin Pathol (2021) 156(2):214&#x2013;28. doi: 10.1093/ajcp/aqaa217</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ajcp/aqaa217</ArticleId>
            <ArticleId IdType="pubmed">33555016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Jr., Abdel-Wahab N, et al. . Infliximab Associated With Faster Symptom Resolution Compared With Corticosteroids Alone for the Management of Immune-Related Enterocolitis. J Immunother Cancer (2018) 6(1):103. doi: 10.1186/s40425-018-0412-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0412-0</ArticleId>
            <ArticleId IdType="pmc">PMC6180568</ArticleId>
            <ArticleId IdType="pubmed">30305177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and its Management With Infliximab. Dig Dis Sci (2009) 54(11):2538&#x2013;40. doi: 10.1007/s10620-008-0641-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-008-0641-z</ArticleId>
            <ArticleId IdType="pubmed">19104936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang HC, Luo W, Wang Y. Acute Liver Injury in the Context of Immune Checkpoint Inhibitor-Related Colitis Treated With Infliximab. J Immunother Cancer (2019) 7(1):47. doi: 10.1186/s40425-019-0532-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0532-1</ArticleId>
            <ArticleId IdType="pmc">PMC6380028</ArticleId>
            <ArticleId IdType="pubmed">30777137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. . Nivolumab in Previously Untreated Melanoma Without BRAF Mutation. N Engl J Med (2015) 372(4):320&#x2013;30. doi: 10.1056/NEJMoa1412082</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1412082</ArticleId>
            <ArticleId IdType="pubmed">25399552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rastogi P, Sultan M, Charabaty AJ, Atkins MB, Mattar MC. Ipilimumab Associated Colitis: An IpiColitis Case Series at MedStar Georgetown University Hospital. World J Gastroenterol (2015) 21(14):4373&#x2013;8. doi: 10.3748/wjg.v21.i14.4373</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v21.i14.4373</ArticleId>
            <ArticleId IdType="pmc">PMC4394100</ArticleId>
            <ArticleId IdType="pubmed">25892889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohn HM, Dave M, Loftus EV, Jr. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis (2017) 23(8):301&#x2013;15. doi: 10.1097/MIB.0000000000001199</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000001199</ArticleId>
            <ArticleId IdType="pmc">PMC5731468</ArticleId>
            <ArticleId IdType="pubmed">28708806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, et al. . New Therapeutic Perspectives to Manage Refractory Immune Checkpoint-Related Toxicities. Lancet Oncol (2019) 20(1):e54&#x2013;64. doi: 10.1016/S1470-2045(18)30828-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30828-3</ArticleId>
            <ArticleId IdType="pubmed">30614479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onuki T, Morita E, Sakamoto N, Nagai Y, Sata M, Hagiwara K. Severe Upper Gastrointestinal Disorders in Pembrolizumab-Treated Non-Small Cell Lung Cancer Patient. Respirol Case Rep (2018) 6(6):e00334. doi: 10.1002/rcr2.334</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/rcr2.334</ArticleId>
            <ArticleId IdType="pmc">PMC5980602</ArticleId>
            <ArticleId IdType="pubmed">30065841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, et al. . Outcomes of Vedolizumab Therapy in Patients With Immune Checkpoint Inhibitor-Induced Colitis: A Multi-Center Study. J Immunother Cancer (2018) 6(1):142. doi: 10.1186/s40425-018-0461-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0461-4</ArticleId>
            <ArticleId IdType="pmc">PMC6280383</ArticleId>
            <ArticleId IdType="pubmed">30518410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. . Vedolizumab Treatment for Immune Checkpoint Inhibitor-Induced Enterocolitis. Cancer Immunol Immunother (2017) 66(5):581&#x2013;92. doi: 10.1007/s00262-017-1962-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-1962-6</ArticleId>
            <ArticleId IdType="pmc">PMC5406433</ArticleId>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh AH, Ferman M, Brown MP, Andrews JM. Vedolizumab: A Novel Treatment for Ipilimumab-Induced Colitis. BMJ Case Rep (2016) 2016:bcr2016216641. doi: 10.1136/bcr-2016-216641</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2016-216641</ArticleId>
            <ArticleId IdType="pmc">PMC5015180</ArticleId>
            <ArticleId IdType="pubmed">27539137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, et al. . Early Introduction of Selective Immunosuppressive Therapy Associated With Favorable Clinical Outcomes in Patients With Immune Checkpoint Inhibitor-Induced Colitis. J Immunother Cancer (2019) 7(1):93. doi: 10.1186/s40425-019-0577-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0577-1</ArticleId>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas AS, Ma W, Wang Y. Ustekinumab for Refractory Colitis Associated With Immune Checkpoint Inhibitors. N Engl J Med (2021) 384(6):581&#x2013;3. doi: 10.1056/NEJMc2031717</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2031717</ArticleId>
            <ArticleId IdType="pubmed">33567198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mir R, Shaw HM, Nathan PD. Mycophenolate Mofetil Alongside High-Dose Corticosteroids: Optimizing the Management of Combination Immune Checkpoint Inhibitor-Induced Colitis. Melanoma Res (2019) 29(1):102&#x2013;6. doi: 10.1097/CMR.0000000000000543</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CMR.0000000000000543</ArticleId>
            <ArticleId IdType="pubmed">30395075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alcantar D, Al-Jaashaami L, Giron F. A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated With Mycophenolate and High-Dose Steroids. Cureus (2019) 11(12):e6392. doi: 10.7759/cureus.6392</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7759/cureus.6392</ArticleId>
            <ArticleId IdType="pmc">PMC6957235</ArticleId>
            <ArticleId IdType="pubmed">31938669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishu S, Melia J, Sharfman W, Lao CD, Fecher LA, Higgins PDR. Efficacy and Outcome of Tofacitinib in Immune Checkpoint Inhibitor Colitis. Gastroenterology (2021) 160(3):932&#x2013;4.e933. doi: 10.1053/j.gastro.2020.10.029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.10.029</ArticleId>
            <ArticleId IdType="pubmed">33096100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. . Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated Colitis. Nat Med (2018) 24(12):1804&#x2013;8. doi: 10.1038/s41591-018-0238-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0238-9</ArticleId>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasanello MK, Robillard KT, Boland PM, Bain AJ, Kanehira K. Use of Fecal Microbial Transplantation for Immune Checkpoint Inhibitor Colitis. ACG Case Rep J (2020) 7(4):e00360. doi: 10.14309/crj.0000000000000360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/crj.0000000000000360</ArticleId>
            <ArticleId IdType="pmc">PMC7224717</ArticleId>
            <ArticleId IdType="pubmed">32548190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FO, Goff SL, Klapper JA, Levy C, Allen T, Mavroukakis SA, et al. . Risk of Bowel Perforation in Patients Receiving Interleukin-2 After Therapy With Anti-CTLA 4 Monoclonal Antibody. J Immunother (2007) 30(1):130&#x2013;0. doi: 10.1097/01.cji.0000211334.06762.89</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.cji.0000211334.06762.89</ArticleId>
            <ArticleId IdType="pmc">PMC2151199</ArticleId>
            <ArticleId IdType="pubmed">17198092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, et al. . Immune Checkpoint Inhibitor-Induced Colitis as a Predictor of Survival in Metastatic Melanoma. Cancer Immunol Immunother (2019) 68(4):553&#x2013;61. doi: 10.1007/s00262-019-02303-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-019-02303-1</ArticleId>
            <ArticleId IdType="pubmed">30666357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, et al. . Prognostic Implications of Co-Occurring Dermatologic and Gastrointestinal Toxicity From Immune Checkpoint Inhibition Therapy for Advanced Malignancies: A Retrospective Cohort Study. J Am Acad Dermatol (2020) 82(3):743&#x2013;6. doi: 10.1016/j.jaad.2019.07.049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2019.07.049</ArticleId>
            <ArticleId IdType="pmc">PMC8386139</ArticleId>
            <ArticleId IdType="pubmed">31349048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ezponda Casajus A, Calvo Imirizaldu M, de Torres Tajes JP, Garcia-Baizan A, Castanon Alvarez E, Cano Rafart D, et al. . Immune-Related Adverse Events as Predictors of Response in Cancer Patients Undergoing Immunotherapy. Radiologia (2020) 62(2):131&#x2013;8. doi: 10.1016/j.rxeng.2019.10.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rxeng.2019.10.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, et al. . Correlation Between Immune-Related Adverse Events and Prognosis in Patients With Gastric Cancer Treated With Nivolumab. BMC Cancer (2019) 19(1):974. doi: 10.1186/s12885-019-6150-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-6150-y</ArticleId>
            <ArticleId IdType="pmc">PMC6805586</ArticleId>
            <ArticleId IdType="pubmed">31638948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, et al. . Safety of Resuming Anti-PD-1 in Patients With Immune-Related Adverse Events (irAEs) During Combined Anti-CTLA-4 and Anti-PD1 in Metastatic Melanoma. Ann Oncol (2018) 29(1):250&#x2013;5. doi: 10.1093/annonc/mdx642</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx642</ArticleId>
            <ArticleId IdType="pmc">PMC5834131</ArticleId>
            <ArticleId IdType="pubmed">29045547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association With Outcomes. Clin Cancer Res (2016) 22(4):886&#x2013;94. doi: 10.1158/1078-0432.CCR-15-1136</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1136</ArticleId>
            <ArticleId IdType="pmc">PMC4755809</ArticleId>
            <ArticleId IdType="pubmed">26446948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. . Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol (2017) 35(7):785&#x2013;+. doi: 10.1200/JCO.2015.66.1389</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.66.1389</ArticleId>
            <ArticleId IdType="pubmed">28068177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lauwyck J, Beckwee A, Santens A, Schwarze JK, Awada G, Vandersleyen V, et al. . C-Reactive Protein as a Biomarker for Immune-Related Adverse Events in Melanoma Patients Treated With Immune Checkpoint Inhibitors in the Adjuvant Setting. Melanoma Res (2021) 31(4):371&#x2013;7. doi: 10.1097/CMR.0000000000000748</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CMR.0000000000000748</ArticleId>
            <ArticleId IdType="pubmed">34054056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al. . Impact of Antibiotic Therapy on the Development and Response to Treatment of Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis. J Immunother Cancer (2019) 7(1):242. doi: 10.1186/s40425-019-0714-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0714-x</ArticleId>
            <ArticleId IdType="pmc">PMC6729015</ArticleId>
            <ArticleId IdType="pubmed">31488205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, et al. . Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol (2019) 5(9):1310&#x2013;7. doi: 10.1001/jamaoncol.2019.1022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.1022</ArticleId>
            <ArticleId IdType="pmc">PMC6555478</ArticleId>
            <ArticleId IdType="pubmed">31169866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, et al. . Rechallenge Patients With Immune Checkpoint Inhibitors Following Severe Immune-Related Adverse Events: Review of the Literature and Suggested Prophylactic Strategy. J Immunother Cancer (2020) 8(1):e000604. doi: 10.1136/jitc-2020-000604</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-000604</ArticleId>
            <ArticleId IdType="pmc">PMC7295425</ArticleId>
            <ArticleId IdType="pubmed">32532839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. . Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol (2020) 6(6):865&#x2013;71. doi: 10.1001/jamaoncol.2020.0726</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2020.0726</ArticleId>
            <ArticleId IdType="pmc">PMC7163782</ArticleId>
            <ArticleId IdType="pubmed">32297899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park R, Lopes L, Saeed A. Outcomes Following Immunotherapy Re-Challenge After Immune-Related Adverse Event: Systematic Review and Meta-Analysis. Immunotherapy (2020) 12(16):1183&#x2013;93. doi: 10.2217/imt-2020-0103</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2020-0103</ArticleId>
            <ArticleId IdType="pubmed">32878511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, et al. . Safety and Efficacy of Restarting Immune Checkpoint Inhibitors After Clinically Significant Immune-Related Adverse Events in Metastatic Renal Cell Carcinoma. J Immunother Cancer (2020) 8(1):e000144. doi: 10.1136/jitc-2019-000144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2019-000144</ArticleId>
            <ArticleId IdType="pmc">PMC7057439</ArticleId>
            <ArticleId IdType="pubmed">32066646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching Administration of Anti-PD-1 and Anti-PD-L1 Antibodies as Immune Checkpoint Inhibitor Rechallenge in Individuals With Advanced Non-Small Cell Lung Cancer: Case Series and Literature Review. Thorac Cancer (2020) 11(7):1927&#x2013;33. doi: 10.1111/1759-7714.13483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1759-7714.13483</ArticleId>
            <ArticleId IdType="pmc">PMC7327670</ArticleId>
            <ArticleId IdType="pubmed">32421224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gobbini E, Toffart AC, Perol M, Assie J-B, Duruisseaux M, Coupez D, et al. . Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer (2020) 21(5):E497&#x2013;510. doi: 10.1016/j.cllc.2020.04.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2020.04.013</ArticleId>
            <ArticleId IdType="pubmed">32605892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Baetz T. Safety of Immunotherapy Rechallenge After Immune-Related Adverse Events in Patients With Advanced Cancer. J Immunother (2021) 44(1):41&#x2013;8. doi: 10.1097/CJI.0000000000000337</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000337</ArticleId>
            <ArticleId IdType="pubmed">32815895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, et al. . Safety of Immune Checkpoint Inhibitor Rechallenge After Discontinuation for Grade &gt;= 2 Immune-Related Adverse Events in Patients With Cancer. J&#xa0;Immunother Cancer (2020) 8(2):1. doi: 10.1136/jitc-2020-001622</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001622</ArticleId>
            <ArticleId IdType="pmc">PMC7768965</ArticleId>
            <ArticleId IdType="pubmed">33428586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, et al. . Et Al: Safety and Efficacy of Re-Treating With Immunotherapy After Immune-Related Adverse Events in Patients With NSCLC. Cancer Immunol Res (2018) 6(9):1093&#x2013;9. doi: 10.1158/2326-6066.CIR-17-0755</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-17-0755</ArticleId>
            <ArticleId IdType="pmc">PMC6125223</ArticleId>
            <ArticleId IdType="pubmed">29991499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levra MG, Cotte F-E, Corre R, Calvet C, Gaudin A-F, Penrod JR, et al. . Immunotherapy Rechallenge After Nivolumab Treatment in Advanced Non Small Cell Lung Cancer in the Real-World Setting: A National Data Base Analysis. Lung Cancer (Amsterdam Netherlands) (2020) 140:99&#x2013;106. doi: 10.1016/j.lungcan.2019.12.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2019.12.017</ArticleId>
            <ArticleId IdType="pubmed">31911324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito K, Oguri T, Takeda N, Fukumitsu K, Fukuda S, Kanemitsu Y, et al. . A Case of Non-Small Cell Lung Cancer With Long-Term Response After Re-Challenge With Nivolumab. Respir Med Case Rep (2020) 29:100979. doi: 10.1016/j.rmcr.2019.100979</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmcr.2019.100979</ArticleId>
            <ArticleId IdType="pmc">PMC6926357</ArticleId>
            <ArticleId IdType="pubmed">31890556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaehler KC, Hassel JC, Heinzerling L, Loquai C, Moessner R, Ugurel S, et al. . Management of Side Effects of Immune Checkpoint Blockade by Anti-CTLA-4 and Anti-PD-1 Antibodies in Metastatic Melanoma. J Dtsch Dermatol Ges (2016) 14(7):662&#x2013;81. doi: 10.1111/ddg.13047</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ddg.13047</ArticleId>
            <ArticleId IdType="pubmed">27373241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Front Med (2018) 5. doi: 10.3389/fmed.2018.00351</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2018.00351</ArticleId>
            <ArticleId IdType="pmc">PMC6315146</ArticleId>
            <ArticleId IdType="pubmed">30631766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, et al. . Immune Dysregulation in Cancer Patients Developing Immune-Related Adverse Events. Br J Cancer (2019) 120(1):63&#x2013;8. doi: 10.1038/s41416-018-0155-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-018-0155-1</ArticleId>
            <ArticleId IdType="pmc">PMC6325132</ArticleId>
            <ArticleId IdType="pubmed">30377338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Head L, Gorden N, Van Gulick R, Amato CM, Frazer-Abel A, Robinson W, et al. . Biomarkers to Predict Immune-Related Adverse Events With Checkpoint Inhibitors. J Clin Oncol (2019) 37(8):S131. doi: 10.1200/JCO.2019.37.8_suppl.131</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.8_suppl.131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, et al. . Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. Clin Cancer Res (2019) 25(5):1557&#x2013;63. doi: 10.1158/1078-0432.CCR-18-2795</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-2795</ArticleId>
            <ArticleId IdType="pubmed">30409824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott SC, Pennell NA. Early Use of Systemic Corticosteroids in Patients With Advanced NSCLC Treated With Nivolumab. J Thorac Oncol (2018) 13(11):1771&#x2013;5. doi: 10.1016/j.jtho.2018.06.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.06.004</ArticleId>
            <ArticleId IdType="pubmed">29935305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuca G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, et al. . Modulation of Peripheral Blood Immune Cells by Early Use of Steroids and its Association With Clinical Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. ESMO Open (2019) 4(1):e000457. doi: 10.1136/esmoopen-2018-000457</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2018-000457</ArticleId>
            <ArticleId IdType="pmc">PMC6435242</ArticleId>
            <ArticleId IdType="pubmed">30964126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jove M, Vilarino N, Nadal E. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Advanced Non-Small Cell Lung Cancer. Trans Lung Cancer Res (2019) 8:S364&#x2013;8. doi: 10.21037/tlcr.2019.06.06</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/tlcr.2019.06.06</ArticleId>
            <ArticleId IdType="pmc">PMC6987359</ArticleId>
            <ArticleId IdType="pubmed">32038916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaucher L, Adda L, Sejourne A, Joachim C, Chaby G, Poulet C, et al. . Impact of the Corticosteroid Indication and Administration Route on Overall Survival and the Tumor Response After Immune Checkpoint Inhibitor Initiation. Ther Adv Med Oncol (2021) 13:1758835921996656. doi: 10.1177/1758835921996656</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758835921996656</ArticleId>
            <ArticleId IdType="pmc">PMC7923985</ArticleId>
            <ArticleId IdType="pubmed">33717227</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34987517</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.</ArticleTitle>
        <Pagination>
          <StartPage>793831</StartPage>
          <MedlinePgn>793831</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">793831</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2021.793831</ELocationID>
        <Abstract>
          <AbstractText>During the past decades, immunotherapy, especially the antibody-mediated immune checkpoint blockade (ICB) has shown durable tumor inhibition and changed the paradigm of cancer treatment. However, a growing body of evidence suggests that ICB treatment induces severe immune-related adverse events (irAEs), and the side effect even leads to the discontinuation of lifesaving treatment. Here, we found that ICB treatment induces colitis in melanoma patients and promotes the infiltration of CD8[+] effector T cells into colitic lesions. Further transcriptomic dissection indicated the PI3K-AKT-mTOR pathway was highly activated in CD8[+] effector T cells of colitic lesions. Moreover, we developed a mouse melanoma model to recapitulate the gastrointestinal toxicity of anti-PD-1 treatment in clinical settings. Anti-PD-1 treatment significantly contributed to the infiltration of CD8[+] T cells, and correspondingly induced severe enteritis. Immunohistochemistry experiments showed that the PI3K-AKT-mTOR pathway of T cells was activated by anti-PD-1 treatment. Blockade of the pathway with mTOR inhibitor sirolimus not only inhibits tumor growth but also suppresses the T cell infiltration in colitic lesions. More importantly, combination with sirolimus and anti-PD-1 synergistically inhibits tumor growth via inducing the immunogenic cell death of tumor cells in vivo. In summary, our research demonstrated the principle of mTOR inhibitor and anti-PD-1 combinatorial therapeutic regimen, which provided a novel therapeutic strategy for irAEs in clinics.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Bai, Wang, Ma, Song, Liu, Wu, Zhao, Liu, Liu, Zhang, Zhao, Zheng, Jing and Shi.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xueyan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Guozhen</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Microbial Innovation and Development Department, Chemical Manufacturing and Control (CMC) Center, Hangzhou Zhong Mei Hua Dong Pharmaceutical Co., Ltd., Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Jinen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiaowei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yujie</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Zhihui</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Microbial Innovation and Development Department, Chemical Manufacturing and Control (CMC) Center, Hangzhou Zhong Mei Hua Dong Pharmaceutical Co., Ltd., Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Microbial Innovation and Development Department, Chemical Manufacturing and Control (CMC) Center, Hangzhou Zhong Mei Hua Dong Pharmaceutical Co., Ltd., Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Zirui</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Microbial Innovation and Development Department, Chemical Manufacturing and Control (CMC) Center, Hangzhou Zhong Mei Hua Dong Pharmaceutical Co., Ltd., Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jing</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Hubing</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006131">Growth Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091203">MTOR Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006131" MajorTopicYN="N">Growth Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091203" MajorTopicYN="N">MTOR Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">effector T-cells</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint blockade</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">mTOR inhibitor</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
      </KeywordList>
      <CoiStatement>Author GM, WZ, XZ, and ZZ is employed by Hangzhou Zhong Mei Hua Dong Pharmaceutical Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>5</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34987517</ArticleId>
        <ArticleId IdType="pmc">PMC8721049</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2021.793831</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell (2018) 175(2):313&#x2013;26. doi:&#xa0;10.1016/j.cell.2018.09.035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.09.035</ArticleId>
            <ArticleId IdType="pmc">PMC6538253</ArticleId>
            <ArticleId IdType="pubmed">30290139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Allison JP. The Future of Immune Checkpoint Therapy. Sci (New York NY) (2015) 348(6230):56&#x2013;61. doi:&#xa0;10.1126/science.aaa8172</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaa8172</ArticleId>
            <ArticleId IdType="pubmed">25838373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by CTLA-4 Blockade. Sci (New York NY) (1996) 271(5256):1734&#x2013;6. doi:&#xa0;10.1126/science.271.5256.1734</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.271.5256.1734</ArticleId>
            <ArticleId IdType="pubmed">8596936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations. Sci Trans Med (2016) 8(328):328rv4. doi:&#xa0;10.1126/scitranslmed.aad7118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aad7118</ArticleId>
            <ArticleId IdType="pmc">PMC4859220</ArticleId>
            <ArticleId IdType="pubmed">26936508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. . Safety and Tumor Responses With Lambrolizumab (Anti-PD-1) in Melanoma. New Engl J Med (2013) 369(2):134&#x2013;44. doi:&#xa0;10.1056/NEJMoa1305133</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1305133</ArticleId>
            <ArticleId IdType="pmc">PMC4126516</ArticleId>
            <ArticleId IdType="pubmed">23724846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. . Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New Engl J Med (2012) 366(26):2443&#x2013;54. doi:&#xa0;10.1056/NEJMoa1200690</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId>
            <ArticleId IdType="pmc">PMC3544539</ArticleId>
            <ArticleId IdType="pubmed">22658127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Chandra S, Sosman JA. Immune Checkpoint Inhibitor Toxicity in 2018. Jama (2018) 320(16):1702&#x2013;3. doi:&#xa0;10.1001/jama.2018.13995</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2018.13995</ArticleId>
            <ArticleId IdType="pubmed">30286224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated With Immune Checkpoint Blockade. New Engl J Med (2018) 378(2):158&#x2013;68. doi:&#xa0;10.1056/NEJMra1703481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal Toxicity of Immune Checkpoint Inhibitors: From Mechanisms to Management. Nat Rev Gastroenterol Hepatol (2018) 15(4):222&#x2013;34. doi:&#xa0;10.1038/nrgastro.2018.14</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2018.14</ArticleId>
            <ArticleId IdType="pubmed">29512649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol (2018) 36(17):1714&#x2013;68. doi:&#xa0;10.1200/jco.2017.77.6385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2017.77.6385</ArticleId>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. . Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol Off J Eur Soc Med Oncol (2017) 28(suppl_4):iv119&#x2013;42. doi:&#xa0;10.1093/annonc/mdx225</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx225</ArticleId>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. . Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol Off J Am Soc Clin Oncol (2018) 36(28):2872&#x2013;8. doi:&#xa0;10.1200/jco.2018.79.0006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2018.79.0006</ArticleId>
            <ArticleId IdType="pubmed">30125216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. . High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis is Associated With Reduced Survival in Patients With Melanoma. Cancer (2018) 124(18):3706&#x2013;14. doi:&#xa0;10.1002/cncr.31629</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31629</ArticleId>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, et al. . Autoimmune Bullous Skin Disorders With Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res (2016) 4(5):383&#x2013;9. doi:&#xa0;10.1158/2326-6066.Cir-15-0123</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.Cir-15-0123</ArticleId>
            <ArticleId IdType="pmc">PMC5241697</ArticleId>
            <ArticleId IdType="pubmed">26928461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. . Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell (2020) 182(3):655&#x2013;671.e22. doi:&#xa0;10.1016/j.cell.2020.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.06.001</ArticleId>
            <ArticleId IdType="pmc">PMC7415717</ArticleId>
            <ArticleId IdType="pubmed">32603654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. . Fulminant Myocarditis With Combination Immune Checkpoint Blockade. New Engl J Med (2016) 375(18):1749&#x2013;55. doi:&#xa0;10.1056/NEJMoa1609214</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1609214</ArticleId>
            <ArticleId IdType="pmc">PMC5247797</ArticleId>
            <ArticleId IdType="pubmed">27806233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Feng Y, Xu J, Shi Y, Yang J, Zhang R, et al. . Combination of MAPK Inhibition With Photothermal Therapy Synergistically Augments the Anti-Tumor Efficacy of Immune Checkpoint Blockade. J Controlled Release Off J Controlled Release Society (2021) 332:194&#x2013;209. doi:&#xa0;10.1016/j.jconrel.2021.02.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2021.02.020</ArticleId>
            <ArticleId IdType="pubmed">33631225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Feng Y, Xu G, Chen Y, Luo Y, Song J, et al. . MAPK-Targeted Drug Delivered by a pH-Sensitive MSNP Nanocarrier Synergizes With PD-1 Blockade in Melanoma Without T-Cell Suppression. Adv Funct Mat (2019) 29(12):1806916. doi:&#xa0;10.1002/adfm.201806916</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adfm.201806916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. . Improved Survival With Ipilimumab in Patients With Metastatic Melanoma. New Engl J Med (2010) 363(8):711&#x2013;23. doi:&#xa0;10.1056/NEJMoa1003466</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, et al. . Long Term Survival With Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade Using Tremelimumab. Eur J Cancer (Oxford Engl 1990) (2015) 51(17):2689&#x2013;97. doi:&#xa0;10.1016/j.ejca.2015.08.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2015.08.012</ArticleId>
            <ArticleId IdType="pmc">PMC4821004</ArticleId>
            <ArticleId IdType="pubmed">26364516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. . Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol Off J Am Soc Clin Oncol (2015) 33(17):1889&#x2013;94. doi:&#xa0;10.1200/jco.2014.56.2736</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2014.56.2736</ArticleId>
            <ArticleId IdType="pmc">PMC5089162</ArticleId>
            <ArticleId IdType="pubmed">25667295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Han X. Anti-PD-1/PD-L1 Therapy of Human Cancer: Past, Present, and Future. J Clin Invest (2015) 125(9):3384&#x2013;91. doi:&#xa0;10.1172/jci80011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci80011</ArticleId>
            <ArticleId IdType="pmc">PMC4588282</ArticleId>
            <ArticleId IdType="pubmed">26325035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. . Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nat Med (2002) 8(8):793&#x2013;800. doi:&#xa0;10.1038/nm730</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm730</ArticleId>
            <ArticleId IdType="pubmed">12091876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. . Pembrolizumab for the Treatment of non-Small-Cell Lung Cancer. New Engl J Med (2015) 372(21):2018&#x2013;28. doi:&#xa0;10.1056/NEJMoa1501824</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1501824</ArticleId>
            <ArticleId IdType="pubmed">25891174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. . Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. Jama (2016) 315(15):1600&#x2013;9. doi:&#xa0;10.1001/jama.2016.4059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2016.4059</ArticleId>
            <ArticleId IdType="pubmed">27092830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. . Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Sci (New York NY) (2017) 357(6349):409&#x2013;13. doi:&#xa0;10.1126/science.aan6733</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan6733</ArticleId>
            <ArticleId IdType="pmc">PMC5576142</ArticleId>
            <ArticleId IdType="pubmed">28596308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, et al. . Correlations Between the Immune-Related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clin Lung Cancer (2019) 20(4):237&#x2013;47. doi:&#xa0;10.1016/j.cllc.2019.02.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2019.02.006</ArticleId>
            <ArticleId IdType="pubmed">30885550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, et al. . Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol Off J Am Soc Clin Oncol (2019) 37(30):2730&#x2013;7. doi:&#xa0;10.1200/jco.19.00318</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.19.00318</ArticleId>
            <ArticleId IdType="pubmed">31116675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association With Outcomes. Clin Cancer Res an Off J Am Assoc Cancer Res (2016) 22(4):886&#x2013;94. doi:&#xa0;10.1158/1078-0432.Ccr-15-1136</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.Ccr-15-1136</ArticleId>
            <ArticleId IdType="pmc">PMC4755809</ArticleId>
            <ArticleId IdType="pubmed">26446948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, et al. . Smoldering Myocarditis Following Immune Checkpoint Blockade. J Immunother Cancer (2017) 5(1):91. doi:&#xa0;10.1186/s40425-017-0296-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0296-4</ArticleId>
            <ArticleId IdType="pmc">PMC5697345</ArticleId>
            <ArticleId IdType="pubmed">29157297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. . Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. JAMA Oncol (2018) 4(12):1721&#x2013;8. doi:&#xa0;10.1001/jamaoncol.2018.3923</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.3923</ArticleId>
            <ArticleId IdType="pmc">PMC6440712</ArticleId>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asnani A. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. Curr Oncol Rep (2018) 20(6):44. doi:&#xa0;10.1007/s11912-018-0690-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11912-018-0690-1</ArticleId>
            <ArticleId IdType="pubmed">29644505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol (2019) 40(6):511&#x2013;23. doi:&#xa0;10.1016/j.it.2019.04.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2019.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC6527345</ArticleId>
            <ArticleId IdType="pubmed">31053497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Am J Clin Dermatol (2018) 19(3):345&#x2013;61. doi:&#xa0;10.1007/s40257-017-0336-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40257-017-0336-3</ArticleId>
            <ArticleId IdType="pubmed">29256113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villadolid J, Amin A. Immune Checkpoint Inhibitors in Clinical Practice: Update on Management of Immune-Related Toxicities. Trans Lung Cancer Res (2015) 4(5):560&#x2013;75. doi:&#xa0;10.3978/j.issn.2218-6751.2015.06.06</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3978/j.issn.2218-6751.2015.06.06</ArticleId>
            <ArticleId IdType="pmc">PMC4630514</ArticleId>
            <ArticleId IdType="pubmed">26629425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, Li WP, Meng C, Ivashkiv LB. Inhibition of IFN-Gamma Signaling by Glucocorticoids. J Immunol (Baltimore Md 1950) (2003) 170(9):4833&#x2013;9. doi:&#xa0;10.4049/jimmunol.170.9.4833</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.170.9.4833</ArticleId>
            <ArticleId IdType="pubmed">12707366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianchi M, Meng C, Ivashkiv LB. Inhibition of IL-2-Induced Jak-STAT Signaling by Glucocorticoids. Proc Natl Acad Sci United States America (2000) 97(17):9573&#x2013;8. doi:&#xa0;10.1073/pnas.160099797</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.160099797</ArticleId>
            <ArticleId IdType="pmc">PMC16906</ArticleId>
            <ArticleId IdType="pubmed">10920190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, et al. . Clinical Experience With Ipilimumab 3 Mg/Kg: Real-World Efficacy and Safety Data From an Expanded Access Programme Cohort. J Trans Med (2014) 12:116. doi:&#xa0;10.1186/1479-5876-12-116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-12-116</ArticleId>
            <ArticleId IdType="pmc">PMC4030525</ArticleId>
            <ArticleId IdType="pubmed">24885479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel D, Madani S, Patel S, Guglani L. Review of Pulmonary Adverse Effects of Infliximab Therapy in Crohn's Disease. Expert Opin Drug Safety (2016) 15(6):769&#x2013;75. doi:&#xa0;10.1517/14740338.2016.1160053</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14740338.2016.1160053</ArticleId>
            <ArticleId IdType="pubmed">26923135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon HJ, Cot&#xe9; TR, Cuffe MS, Kramer JM, Braun MM. Case Reports of Heart Failure After Therapy With a Tumor Necrosis Factor Antagonist. Ann Internal Med (2003) 138(10):807&#x2013;11. doi:&#xa0;10.7326/0003-4819-138-10-200305200-00008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-138-10-200305200-00008</ArticleId>
            <ArticleId IdType="pubmed">12755552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell (2017) 168(6):960&#x2013;76. doi:&#xa0;10.1016/j.cell.2017.02.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.02.004</ArticleId>
            <ArticleId IdType="pmc">PMC5394987</ArticleId>
            <ArticleId IdType="pubmed">28283069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR Kinase Structure, Mechanism and Regulation. Nature (2013) 497(7448):217&#x2013;23. doi:&#xa0;10.1038/nature12122</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12122</ArticleId>
            <ArticleId IdType="pmc">PMC4512754</ArticleId>
            <ArticleId IdType="pubmed">23636326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ra&#xef;ch-Regu&#xe9; D, Fabian KP, Watson AR, Fecek RJ, Storkus WJ, Thomson AW. Intratumoral Delivery of Mtorc2-Deficient Dendritic Cells Inhibits B16 Melanoma Growth by Promoting CD8(+) Effector T Cell Responses. Oncoimmunology (2016) 5(6):e1146841. doi:&#xa0;10.1080/2162402x.2016.1146841</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402x.2016.1146841</ArticleId>
            <ArticleId IdType="pmc">PMC4938309</ArticleId>
            <ArticleId IdType="pubmed">27471613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell (2017) 170(4):605&#x2013;35. doi:&#xa0;10.1016/j.cell.2017.07.029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.07.029</ArticleId>
            <ArticleId IdType="pmc">PMC5726441</ArticleId>
            <ArticleId IdType="pubmed">28802037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fugger L, Jensen LT, Rossjohn J. Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. Cell (2020) 181(1):63&#x2013;80. doi:&#xa0;10.1016/j.cell.2020.03.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.03.007</ArticleId>
            <ArticleId IdType="pubmed">32243797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilarinho S, Lifton RP. Liver Transplantation: From Inception to Clinical Practice. Cell (2012) 150(6):1096&#x2013;9. doi:&#xa0;10.1016/j.cell.2012.08.030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.08.030</ArticleId>
            <ArticleId IdType="pubmed">22980971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A, et al. . Distinct Functional Significance of Akt and mTOR Constitutive Activation in Mantle Cell Lymphoma. Blood (2008) 111(10):5142&#x2013;51. doi:&#xa0;10.1182/blood-2007-07-103481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2007-07-103481</ArticleId>
            <ArticleId IdType="pubmed">18339899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dancey J. mTOR Signaling and Drug Development in Cancer. Nat Rev Clin Oncol (2010) 7(4):209&#x2013;19. doi:&#xa0;10.1038/nrclinonc.2010.21</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2010.21</ArticleId>
            <ArticleId IdType="pubmed">20234352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qayed M, Cash T, Tighiouart M, MacDonald TJ, Goldsmith KC, Tanos R, et al. . A Phase I Study of Sirolimus in Combination With Metronomic Therapy (CHOAnome) in Children With Recurrent or Refractory Solid and Brain Tumors. Pediatr Blood Cancer (2020) 67(4):e28134. doi:&#xa0;10.1002/pbc.28134</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.28134</ArticleId>
            <ArticleId IdType="pubmed">31876107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, et al. . Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of Mtorc1 in Tumors. J Clin Oncol Off J Am Soc Clin Oncol (2010) 28(5):835&#x2013;40. doi:&#xa0;10.1200/jco.2009.25.2981</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2009.25.2981</ArticleId>
            <ArticleId IdType="pmc">PMC4810029</ArticleId>
            <ArticleId IdType="pubmed">20048174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, et al. . Targeting the mTOR Pathway Uncouples the Efficacy and Toxicity of PD-1 Blockade in Renal Transplantation. Nat Commun (2019) 10(1):4712. doi:&#xa0;10.1038/s41467-019-12628-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-12628-1</ArticleId>
            <ArticleId IdType="pmc">PMC6797722</ArticleId>
            <ArticleId IdType="pubmed">31624262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of Immune Responses by mTOR. Annu Rev Immunol (2012) 30:39&#x2013;68. doi:&#xa0;10.1146/annurev-immunol-020711-075024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-020711-075024</ArticleId>
            <ArticleId IdType="pmc">PMC3616892</ArticleId>
            <ArticleId IdType="pubmed">22136167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Flies DB. Molecular Mechanisms of T Cell Co-Stimulation and Co-Inhibition. Nat Rev Immunol (2013) 13(4):227&#x2013;42. doi:&#xa0;10.1038/nri3405</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3405</ArticleId>
            <ArticleId IdType="pmc">PMC3786574</ArticleId>
            <ArticleId IdType="pubmed">23470321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation. Sci Signaling (2012) 5(230):ra46. doi:&#xa0;10.1126/scisignal.2002796</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2002796</ArticleId>
            <ArticleId IdType="pmc">PMC5498435</ArticleId>
            <ArticleId IdType="pubmed">22740686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji C, Roy MD, Golas J, Vitsky A, Ram S, Kumpf SW, et al. . Myocarditis in Cynomolgus Monkeys Following Treatment With Immune Checkpoint Inhibitors. Clin Cancer Res an Off J Am Assoc Cancer Res (2019) 25(15):4735&#x2013;48. doi:&#xa0;10.1158/1078-0432.Ccr-18-4083</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.Ccr-18-4083</ArticleId>
            <ArticleId IdType="pubmed">31085720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berner F, Bomze D, Diem S, Ali OH, F&#xe4;ssler M, Ring S, et al. . Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol (2019) 5(7):1043&#x2013;7. doi:&#xa0;10.1001/jamaoncol.2019.0402</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.0402</ArticleId>
            <ArticleId IdType="pmc">PMC6487908</ArticleId>
            <ArticleId IdType="pubmed">31021392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam S, Lee A, Lim J, Lim JS. Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs). Biomolecules Ther (2019) 27(1):63&#x2013;70. doi:&#xa0;10.4062/biomolther.2018.201</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2018.201</ArticleId>
            <ArticleId IdType="pmc">PMC6319546</ArticleId>
            <ArticleId IdType="pubmed">30521746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. . Early B Cell Changes Predict Autoimmunity Following Combination Immune Checkpoint Blockade. J Clin Invest (2018) 128(2):715&#x2013;20. doi:&#xa0;10.1172/jci96798</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci96798</ArticleId>
            <ArticleId IdType="pmc">PMC5785243</ArticleId>
            <ArticleId IdType="pubmed">29309048</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34956219</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.</ArticleTitle>
        <Pagination>
          <StartPage>788499</StartPage>
          <MedlinePgn>788499</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">788499</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2021.788499</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) and radiotherapy (RT) combinations for various metastatic cancers are increasingly utilized, yet the augmentation of anti-cancer immunity including distant tumor responses by RT remains ill-characterized. Immunosuppressive tumor microenvironments and defective anti-tumor immune activation including immune-related adverse events (irAEs) likely limit dramatic immuno-radiotherapy combinations, though it remains unclear which immune characteristics mediate dramatic systemic tumor regression in only a small subset of patients. Moreover, the efficacy of ICI treatment in patients receiving immunosuppressive therapies for autoimmune conditions or irAEs is convoluted, yet clinically valuable. Here, we report a case of a 75-year-old man with myasthenia gravis and metastatic melanoma who experienced complete and durable systemic regression after receiving pembrolizumab and single-lesion RT while on prednisone for myasthenia gravis prophylaxis and vedolizumab for immune-mediated colitis after previously experiencing mixed response on pembrolizumab monotherapy. We discuss the potential paradoxical effects and clinical considerations of immunosuppressive regimens in patients with underlying autoimmune disease or adverse immune reactions while receiving immuno-radiotherapy combinations.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Moradi, Clark, Schneider, Deshane and Dobelbower.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Moradi</LastName>
            <ForeName>Luke A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clark</LastName>
            <ForeName>Curtis A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schneider</LastName>
            <ForeName>Craig S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deshane</LastName>
            <ForeName>Alok S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dobelbower</LastName>
            <ForeName>Michael C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9RV78Q2002</RegistryNumber>
          <NameOfSubstance UI="C543529">vedolizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DPT0O3T46P</RegistryNumber>
          <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VB0R961HZT</RegistryNumber>
          <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059248" MajorTopicYN="Y">Chemoradiotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">abscopal effect</Keyword>
        <Keyword MajorTopicYN="N">autoimmune myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy case report</Keyword>
        <Keyword MajorTopicYN="N">metastatic melanoma</Keyword>
        <Keyword MajorTopicYN="N">radiation therapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34956219</ArticleId>
        <ArticleId IdType="pmc">PMC8692289</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2021.788499</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Johnson DB, Sullivan RJ, Menzies AM. Immune Checkpoint Inhibitors in Challenging Populations. Cancer (2017) 123:1904&#x2013;11. doi: 10.1002/cncr.30642</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.30642</ArticleId>
            <ArticleId IdType="pmc">PMC5445005</ArticleId>
            <ArticleId IdType="pubmed">28241095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. . Immunologic Correlates of the Abscopal Effect in a Patient With Melanoma. N Engl J Med (2012) 366(10):925&#x2013;31. doi: 10.1056/NEJMoa1112824</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1112824</ArticleId>
            <ArticleId IdType="pmc">PMC3345206</ArticleId>
            <ArticleId IdType="pubmed">22397654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. . Five-Year Survival Outcomes for Patients With Advanced Melanoma Treated With Pembrolizumab in KEYNOTE-001. Ann Oncol (2019) 30:582&#x2013;8. doi: 10.1093/annonc/mdz011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz011</ArticleId>
            <ArticleId IdType="pmc">PMC6503622</ArticleId>
            <ArticleId IdType="pubmed">30715153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using Immunotherapy to Boost the Abscopal Effect. Nat Rev Cancer (2018) 18:313&#x2013;22. doi: 10.1038/nrc.2018.6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2018.6</ArticleId>
            <ArticleId IdType="pmc">PMC5912991</ArticleId>
            <ArticleId IdType="pubmed">29449659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition With Radiation Therapy. Int J Radiat Oncol Biol Phys (2020) 108:17&#x2013;26. doi: 10.1016/j.ijrobp.2019.12.033</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2019.12.033</ArticleId>
            <ArticleId IdType="pubmed">32819613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, et al. . Improved Survival Associated With Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res (2020) 26:6437&#x2013;44. doi: 10.1158/1078-0432.CCR-20-1790</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-20-1790</ArticleId>
            <ArticleId IdType="pmc">PMC8561652</ArticleId>
            <ArticleId IdType="pubmed">33028595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of Radiotherapy and Immunotherapy for Treatment of Oligometastases. Lancet Oncol (2019) 20:e434&#x2013;42. doi: 10.1016/S1470-2045(19)30157-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(19)30157-3</ArticleId>
            <ArticleId IdType="pubmed">31364595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frohne CC, Llano EM, Perkovic A, Cohen RD, Luke JJ. Complete Response of Metastatic Melanoma in a Patient With Crohn&#x2019;s Disease Simultaneously Receiving Anti-Alpha4beta7 and Anti-PD1 Antibodies. J Immunother Cancer (2019) 7:1. doi: 10.1186/s40425-018-0484-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0484-x</ArticleId>
            <ArticleId IdType="pmc">PMC6322234</ArticleId>
            <ArticleId IdType="pubmed">30612589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mole RH. Whole Body Irradiation; Radiobiology or Medicine? Br J Radiol (1953) 26:234&#x2013;41. doi: 10.1259/0007-1285-26-305-234</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1259/0007-1285-26-305-234</ArticleId>
            <ArticleId IdType="pubmed">13042090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beyls C, Haustermans K, Deroose CM, Pans S, Vanbeckevoort D, Verslype C, et al. . Could Autoimmune Disease Contribute to the Abscopal Effect in Metastatic Hepatocellular Carcinoma? Hepatology (2020) 72:1152&#x2013;4. doi: 10.1002/hep.31186</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31186</ArticleId>
            <ArticleId IdType="pubmed">32348580</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34821404</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2036</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>55</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Alimentary pharmacology &amp; therapeutics</Title>
          <ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis.</ArticleTitle>
        <Pagination>
          <StartPage>178</StartPage>
          <EndPage>190</EndPage>
          <MedlinePgn>178-190</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.16718</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Although there is interest in developing pharmacotherapies for the treatment of immune checkpoint inhibitor-associated enterocolitis (ICIC), there is currently no consensus on how to optimally measure disease activity in this condition.</AbstractText>
          <AbstractText Label="AIMS">To identify all scoring indices used for the measurement of disease activity in ICIC, assess their operating properties, and explore their potential utility as outcome measures.</AbstractText>
          <AbstractText Label="METHODS">We searched MEDLINE, EMBASE and the Cochrane Library from inception to November 2020 to identify studies that evaluated disease activity and severity in patients with ICI-associated enterocolitis. These scoring tools could be designed specifically for ICIC or adapted from other diseases, and assessed clinical, endoscopic, or histologic disease activity.</AbstractText>
          <AbstractText Label="RESULTS">Sixty-four studies were included. The Common Terminology Criteria for Adverse Events is commonly used to describe symptoms, although has only been partially validated and was not designed as a disease activity index. Endoscopic and histologic indices used in inflammatory bowel disease have been adopted for ICIC including the Mayo Endoscopic Subscore, Ulcerative Colitis Endoscopic Index of Severity, Simple Endoscopic Score for Crohn's Disease, Nancy Histological Index, Robarts Histopathological Index, and Geboes Score, among others. None of these indices has been validated for use in ICIC, and all lacked content validity and responsiveness.</AbstractText>
          <AbstractText Label="CONCLUSIONS">There are no validated clinical, endoscopic, or histologic outcomes to assess disease activity in ICIC. Development and validation of reliable and responsive outcome measures that can be used to measure disease activity will be paramount for both clinical practice and for the development of treatments.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-4698-9948</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology &amp; Hepatology, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>MacDonald</LastName>
            <ForeName>John K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Tran M</ForeName>
            <Initials>TM</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Joshua</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vande Casteele</LastName>
            <ForeName>Niels</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feagan</LastName>
            <ForeName>Brian G</ForeName>
            <Initials>BG</Initials>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jairath</LastName>
            <ForeName>Vipul</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0002-1092-0033</Identifier>
            <AffiliationInfo>
              <Affiliation>Alimentiv Inc (formerly Robarts Clinical Trials), London, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Aliment Pharmacol Ther</MedlineTA>
        <NlmUniqueID>8707234</NlmUniqueID>
        <ISSNLinking>0269-2813</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004760" MajorTopicYN="Y">Enterocolitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>8</Hour>
          <Minute>57</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34821404</ArticleId>
        <ArticleId IdType="doi">10.1111/apt.16718</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Pasquali S, Chiarion-Sileni V, Rossi CR, Mocellin S. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: a network meta-analysis. Cancer Treat Rev. 2017;54:34-42.</Citation>
        </Reference>
        <Reference>
          <Citation>Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2:Cd011123.</Citation>
        </Reference>
        <Reference>
          <Citation>Aoun F, Kourie HR, Sideris S, Roumegu&#xe8;re T, van Velthoven R, Gil T. Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Immunotherapy. 2015;7:1259-1271.</Citation>
        </Reference>
        <Reference>
          <Citation>Atkins MB, Clark JI, Quinn DI. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol. 2017;28:1484-1494.</Citation>
        </Reference>
        <Reference>
          <Citation>Ellis PM, Vella ET, Ung YC. Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017;18:444-459.e441.</Citation>
        </Reference>
        <Reference>
          <Citation>Raju S, Joseph R, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer. ImmunoTargets Ther. 2018;7:63-75.</Citation>
        </Reference>
        <Reference>
          <Citation>Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;76-83.</Citation>
        </Reference>
        <Reference>
          <Citation>Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.</Citation>
        </Reference>
        <Reference>
          <Citation>Shivaji UN, Jeffery L, Gui X, et al. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol. 2019;12:1756284819884196.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol. 2020;36:25-32.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma C, MacDonald JK, Nguyen TM, et al. Pharmacological interventions for the prevention and treatment of immune checkpoint inhibitor-associated enterocolitis: a systematic review. Digest Dis Sci. 2021. https://doi.org/10.1007/s10620-021-06948-w. Online ahead of print.</Citation>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-1768.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18:230-241.</Citation>
        </Reference>
        <Reference>
          <Citation>Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.</Citation>
        </Reference>
        <Reference>
          <Citation>Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95.</Citation>
        </Reference>
        <Reference>
          <Citation>Yutsudo K, Tanaka A, Komaki Y, et al. The efficacy of early treatment in immune checkpoint inhibitor-related colitis: clinical outcomes in a retrospective case series. Am J Gastroenterol. 2019;114(Suppl. 1):S29.</Citation>
        </Reference>
        <Reference>
          <Citation>Hindryckx P, Levesque BG, Holvoet T, et al. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2018;67:61-69.</Citation>
        </Reference>
        <Reference>
          <Citation>Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis. 1985;38:27-36.</Citation>
        </Reference>
        <Reference>
          <Citation>Terwee CB, Bot SDM, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60:34-42.</Citation>
        </Reference>
        <Reference>
          <Citation>United States Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services. 2009.</Citation>
        </Reference>
        <Reference>
          <Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.</Citation>
        </Reference>
        <Reference>
          <Citation>Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126:1763-1768.</Citation>
        </Reference>
        <Reference>
          <Citation>Arriola E, Wheater M, Lopez MA, Thomas G, Ottensmeier C. Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. Oncoimmunology. 2016;5:e1209615.</Citation>
        </Reference>
        <Reference>
          <Citation>Burla J, Bluemel S, Biedermann L, et al. Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course. Inflamm Intest Dis. 2020;5:109-116.</Citation>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Zheng H, Zubiri L, et al. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019;8:4986-4999.</Citation>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24:1804-1808.</Citation>
        </Reference>
        <Reference>
          <Citation>Inoue S, Kono M, Fukuda H, et al. Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitor-associated colitis. J Gastroenterol Hepatol. 2021;36:1180-1186.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142.</Citation>
        </Reference>
        <Reference>
          <Citation>Cheung VTF, Gupta T, Olsson-Brown A, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer. 2020;123:207-215.</Citation>
        </Reference>
        <Reference>
          <Citation>Pai RK, Pai RK, Brown I, et al. The significance of histological activity measurements in immune checkpoint inhibitor colitis. Aliment Pharmacol Ther. 2021;53:150-159.</Citation>
        </Reference>
        <Reference>
          <Citation>Mooradian MJ, Wang DY, Coromilas A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer. 2020;8:e000451.</Citation>
        </Reference>
        <Reference>
          <Citation>Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14:836-842.</Citation>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581-592.</Citation>
        </Reference>
        <Reference>
          <Citation>Sasson SC, Zaunders JJ, Nahar K, et al. Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. Clin Exp Immunol. 2020;202:335-352.</Citation>
        </Reference>
        <Reference>
          <Citation>Arai M, Taida T, Fan MM, Imai C, Tawada A, Takiguchi Y. Evaluation of diarrhea as immune-related adverse event by colonoscopy. Ann Oncol. 2018;29:vii56.</Citation>
        </Reference>
        <Reference>
          <Citation>Isidro RA, Ruan AB, Gannarapu S, et al. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology. 2021;78:532-541.</Citation>
        </Reference>
        <Reference>
          <Citation>Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint inhibitor colitis shows drug-specific differences in immune cell reaction that overlap with inflammatory bowel disease and predict response to colitis therapy. Am J Clin Pathol. 2021;156:214-228.</Citation>
        </Reference>
        <Reference>
          <Citation>Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol. 2016;41:207-214.</Citation>
        </Reference>
        <Reference>
          <Citation>De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015;25:321-327.</Citation>
        </Reference>
        <Reference>
          <Citation>Garcia-Neuer M, Marmarelis ME, Jangi SR, et al. Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients. Cancer Immunol Res. 2017;5:286-291.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. Am J Roentgenol. 2013;200:W468-W474.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Mooradian MJ, Kim DaeWon, et al. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019;8:e1524695.</Citation>
        </Reference>
        <Reference>
          <Citation>Dulai PS, Jairath V, Khanna R, et al. Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2020;51:1047-1066.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Wang X, Lashner B, Bresalier RS, Charabaty A, Wang Y. Early introduction of non-steroidal immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. Gastroenterology. 2019;156(6 Suppl. 1):S-232.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34777387</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.</ArticleTitle>
        <Pagination>
          <StartPage>768957</StartPage>
          <MedlinePgn>768957</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">768957</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2021.768957</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) have provided tremendous clinical benefit in several cancer types. However, systemic activation of the immune system also leads to several immune-related adverse events. Of these, ICI-mediated colitis (IMC) occurs frequently and is the one with the highest absolute fatality. To improve current treatment strategies, it is important to understand the cellular mechanisms that induce this form of colitis. In this review, we discuss important pathways that are altered in IMC in mouse models and in human colon biopsy samples. This reveals a complex interplay between several types of immune cells and the gut microbiome. In addition to a mechanistic understanding, patients at risk should be identifiable before ICI therapy. Here we propose to focus on T-cell subsets that interact with bacteria after inducing epithelial damage. Especially, intestinal resident immune cells are of interest. This may lead to a better understanding of IMC and provides opportunities for prevention and management.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Westdorp, Sweep, Gorris, Hoentjen, Boers-Sonderen, Post, Heuvel, Piet, Boleij, Bloemendal and de Vries.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Westdorp</LastName>
            <ForeName>Harm</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sweep</LastName>
            <ForeName>Mark W D</ForeName>
            <Initials>MWD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gorris</LastName>
            <ForeName>Mark A J</ForeName>
            <Initials>MAJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Oncode Institute, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoentjen</LastName>
            <ForeName>Frank</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boers-Sonderen</LastName>
            <ForeName>Marye J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van der Post</LastName>
            <ForeName>Rachel S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van den Heuvel</LastName>
            <ForeName>Michel M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piet</LastName>
            <ForeName>Berber</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boleij</LastName>
            <ForeName>Annemarie</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bloemendal</LastName>
            <ForeName>Haiko J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Vries</LastName>
            <ForeName>I Jolanda M</ForeName>
            <Initials>IJM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001419" MajorTopicYN="N">Bacteria</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor (ICI)</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">mechanisms</Keyword>
        <Keyword MajorTopicYN="N">treatment</Keyword>
      </KeywordList>
      <CoiStatement>FH has served on advisory boards, as speaker, or consultant for AbbVie, Celgene, Janssen-Cilag, Merck Sharp &amp; Dohme, Takeda, Celltrion, Teva, Sandoz, and Dr Falk, and has received unrestricted grants from Dr Falk, Janssen-Cilag, and AbbVie. MH received research grants from Merck and AstraZeneca. BP received fees from advisory boards of Takeda, Bristol-Myers Squibb, Janssen, and Pfizer. BP received lecturing fees from AstraZeneca and Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>58</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34777387</ArticleId>
        <ArticleId IdType="pmc">PMC8586074</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2021.768957</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pennock GK, Chow LQM. New Drug Development and Clinical Pharmacology the Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 20:812&#x2013;22. doi:&#xa0;10.1634/theoncologist.2014-</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2014-</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, Dronca RS, et al. . Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol (2018) 9:1739. doi:&#xa0;10.3389/fimmu.2018.01739</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01739</ArticleId>
            <ArticleId IdType="pmc">PMC6072836</ArticleId>
            <ArticleId IdType="pubmed">30100909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugiura D, Maruhashi T, Okazaki I, Shimizu K, Maeda TK, Takemoto T, et al. . Restriction of PD-1 Function by Cis -PD-L1/CD80 Interactions Is Required for Optimal T Cell Responses. Science (2019) 364:558&#x2013;66. doi:&#xa0;10.1126/science.aav7062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aav7062</ArticleId>
            <ArticleId IdType="pubmed">31000591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Pul KM, Fransen MF, van de Ven R, de Gruijl TD. Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy. Front Immunol (2021) 12:643291. doi:&#xa0;10.3389/fimmu.2021.643291</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.643291</ArticleId>
            <ArticleId IdType="pmc">PMC7956978</ArticleId>
            <ArticleId IdType="pubmed">33732264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell (2018) 175:313&#x2013;26. doi:&#xa0;10.1016/j.cell.2018.09.035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.09.035</ArticleId>
            <ArticleId IdType="pmc">PMC6538253</ArticleId>
            <ArticleId IdType="pubmed">30290139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakdash G, Simone P, Dijk TV, Figdor CG, De Vries IJM. The Nature of Activatory and Tolerogenic Dendritic Cell-Derived Signal II. Front Immunol (2013) 4:53. doi:&#xa0;10.3389/fimmu.2013.00053</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2013.00053</ArticleId>
            <ArticleId IdType="pmc">PMC3584294</ArticleId>
            <ArticleId IdType="pubmed">23450201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sckisel GD, Bouchlaka MN, Monjazeb AM, Crittenden M, Curti BD, Wilkins DEC, et al. . Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity. Immunity (2015) 43:240&#x2013;50. doi:&#xa0;10.1016/j.immuni.2015.06.023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2015.06.023</ArticleId>
            <ArticleId IdType="pmc">PMC4770886</ArticleId>
            <ArticleId IdType="pubmed">26231116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zenke S, Palm MM, Braun J, Gavrilov A, Meiser P, B&#xf6;ttcher JP, et al. . Quorum Regulation via Nested Antagonistic Feedback Circuits Mediated by the Receptors CD28 and CTLA-4 Confers Robustness to T Cell Population Dynamics. Immunity (2020) 52:313&#x2013;27.e7. doi:&#xa0;10.1016/j.immuni.2020.01.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2020.01.018</ArticleId>
            <ArticleId IdType="pubmed">32049052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jago CB, Yates J, Saraiva C&#xe2;mara NO, Lechler RI, Lombardi G. Differential Expression of CTLA-4 Among T Cell Subsets. Clin Exp Immunol (2004) 136:463&#x2013;71. doi:&#xa0;10.1111/j.1365-2249.2004.02478.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2004.02478.x</ArticleId>
            <ArticleId IdType="pmc">PMC1809051</ArticleId>
            <ArticleId IdType="pubmed">15147348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. . CTLA-4 Control Over Foxp3+ Regulatory T Cell Function. Science (2008) 322:271&#x2013;5. doi:&#xa0;10.1126/science.1160062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1160062</ArticleId>
            <ArticleId IdType="pubmed">18845758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graziani G, Tentori L, Navarra P. Ipilimumab: A Novel Immunostimulatory Monoclonal Antibody for the Treatment of Cancer. Pharmacol Res (2012) 65:9&#x2013;22. doi:&#xa0;10.1016/j.phrs.2011.09.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2011.09.002</ArticleId>
            <ArticleId IdType="pubmed">21930211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, et al. . Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma. J Immunother (2012) 35:89&#x2013;97. doi:&#xa0;10.1097/CJI.0b013e31823aa41c</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0b013e31823aa41c</ArticleId>
            <ArticleId IdType="pubmed">22130166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Allison JP, et al. . Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res (2019) 25:1233&#x2013;8. doi:&#xa0;10.1158/1078-0432.CCR-18-0762.Anti</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-0762.Anti</ArticleId>
            <ArticleId IdType="pmc">PMC6348141</ArticleId>
            <ArticleId IdType="pubmed">30054281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. . Autosomal Dominant Immune Dysregulation Syndrome in Humans With CTLA4 Mutations. Nat Med (2014) 20:1410&#x2013;6. doi:&#xa0;10.1038/nm.3746</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3746</ArticleId>
            <ArticleId IdType="pmc">PMC4668597</ArticleId>
            <ArticleId IdType="pubmed">25329329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. . Tissue Expression of PD-L1 Mediates Peripheral T Cell Tolerance. J Exp Med (2006) 203:883&#x2013;95. doi:&#xa0;10.1084/jem.20051776</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20051776</ArticleId>
            <ArticleId IdType="pmc">PMC2118286</ArticleId>
            <ArticleId IdType="pubmed">16606670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S, Yuan P, Wu H, Chen J, Fu J, Li P, et al. . Dendritic Cells With an Increased PD-L1 by TGF-&#x3b2; Induce T Cell Anergy for the Cytotoxicity of Hepatocellular Carcinoma Cells. Int Immunopharmacol (2014) 20:117&#x2013;23. doi:&#xa0;10.1016/j.intimp.2014.02.027</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2014.02.027</ArticleId>
            <ArticleId IdType="pubmed">24606770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther (2015) 14:847&#x2013;56. doi:&#xa0;10.1158/1535-7163.MCT-14-0983</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0983</ArticleId>
            <ArticleId IdType="pubmed">25695955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, et al. . PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated With Immune Checkpoint Inhibitors. Clin Cancer Res (2017) 23:4270&#x2013;9. doi:&#xa0;10.1158/1078-0432.CCR-16-3146</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-3146</ArticleId>
            <ArticleId IdType="pmc">PMC5540774</ArticleId>
            <ArticleId IdType="pubmed">28223273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. . PD-L2 Is a Second Ligand for PD-1 and Inhibits T Cell Activation. Nat Immunol (2001) 2:261&#x2013;8. doi:&#xa0;10.1038/85330</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/85330</ArticleId>
            <ArticleId IdType="pubmed">11224527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol (2008) 26:677&#x2013;704. doi:&#xa0;10.1146/annurev.immunol.26.021607.090331</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.26.021607.090331</ArticleId>
            <ArticleId IdType="pubmed">18173375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. . PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res (2017) 23:3158&#x2013;67. doi:&#xa0;10.1158/1078-0432.CCR-16-1761</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-1761</ArticleId>
            <ArticleId IdType="pubmed">28619999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Hammers H, Lipson EJ. Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity. Futur Oncol (2015) 11:1307&#x2013;26. doi:&#xa0;10.2217/fon.15.52</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fon.15.52</ArticleId>
            <ArticleId IdType="pubmed">25798726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, et al. . FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist (2017) 22:1392&#x2013;9. doi:&#xa0;10.1634/theoncologist.2017-0078</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2017-0078</ArticleId>
            <ArticleId IdType="pmc">PMC5679831</ArticleId>
            <ArticleId IdType="pubmed">28835513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markham A, Duggan S. Cemiplimab: First Global Approval. Drugs (2018) 78:1841&#x2013;6. doi:&#xa0;10.1007/s40265-018-1012-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-018-1012-5</ArticleId>
            <ArticleId IdType="pubmed">30456447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinstock C, Khozin S, Suzman D, Zhang L, Tang S, Wahby S, et al. . Food and Drug Administration Approval Summary: Atezolizumab for Metastatic non&#x2013;Small Cell Lung Cancer. Clin Cancer Res (2017) 23:4534&#x2013;9. doi:&#xa0;10.1158/1078-0432.CCR-17-0540</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-0540</ArticleId>
            <ArticleId IdType="pubmed">28611199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim ES. Avelumab: First Global Approval. Drugs (2017) 77:929&#x2013;37. doi:&#xa0;10.1007/s40265-017-0749-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-017-0749-6</ArticleId>
            <ArticleId IdType="pubmed">28456944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syed YY. Durvalumab: First Global Approval. Drugs (2017) 77:1369&#x2013;76. doi:&#xa0;10.1007/s40265-017-0782-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-017-0782-5</ArticleId>
            <ArticleId IdType="pmc">PMC5636860</ArticleId>
            <ArticleId IdType="pubmed">28643244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. . PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance. Nature (2014) 515:568&#x2013;71. doi:&#xa0;10.1038/nature13954</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13954</ArticleId>
            <ArticleId IdType="pmc">PMC4246418</ArticleId>
            <ArticleId IdType="pubmed">25428505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated With Immune Checkpoint Blockade. N Engl J Med (2018) 378:158&#x2013;68. doi:&#xa0;10.1056/nejmra1703481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmra1703481</ArticleId>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 373:23&#x2013;34. doi:&#xa0;10.1056/nejmoa1504030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa1504030</ArticleId>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. . Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis. BMJ (2018) 363:k4226. doi:&#xa0;10.1136/bmj.k4226</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.k4226</ArticleId>
            <ArticleId IdType="pmc">PMC6222274</ArticleId>
            <ArticleId IdType="pubmed">30409774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cameron F, Whiteside G, Perry C. Ipilimumab: First Global Approval. Drugs (2011) 71:1093&#x2013;104. doi:&#xa0;10.2165/11595310-000000000-00000</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11595310-000000000-00000</ArticleId>
            <ArticleId IdType="pubmed">21668044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Ann Oncol (2017) 28:2377&#x2013;85. doi:&#xa0;10.1093/annonc/mdx286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx286</ArticleId>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. . Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. JAMA Oncol (2018) 4:1721&#x2013;8. doi:&#xa0;10.1001/jamaoncol.2018.3923</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.3923</ArticleId>
            <ArticleId IdType="pmc">PMC6440712</ArticleId>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, et al. . Cancer Immunotherapy With Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohn&#x2019;s Colitis (2016) 10:395&#x2013;401. doi:&#xa0;10.1093/ecco-jcc/jjv227</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv227</ArticleId>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ, Feldman AL, Marybeth S, Royal RE, et al. . Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4. J Clin Oncol (2006) 24:2283&#x2013;9. doi: 10.1200/JCO.2005.04.5716</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.04.5716</ArticleId>
            <ArticleId IdType="pmc">PMC2140223</ArticleId>
            <ArticleId IdType="pubmed">16710025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. . Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell (2020) 182:655&#x2013;71.e22. doi:&#xa0;10.1016/j.cell.2020.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.06.001</ArticleId>
            <ArticleId IdType="pmc">PMC7415717</ArticleId>
            <ArticleId IdType="pubmed">32603654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mami-Chouaib F, Tartour E. Editorial: Tissue Resident Memory T Cells. Front Immunol (2019) 10:1018. doi:&#xa0;10.3389/fimmu.2019.01018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01018</ArticleId>
            <ArticleId IdType="pmc">PMC6546023</ArticleId>
            <ArticleId IdType="pubmed">31191515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corgnac S, Boutet M, Kfoury M, Naltet C, Mami-Chouaib F. The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin. Front Immunol (2018) 9:1904. doi:&#xa0;10.3389/fimmu.2018.01904</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01904</ArticleId>
            <ArticleId IdType="pmc">PMC6104123</ArticleId>
            <ArticleId IdType="pubmed">30158938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X, Lee A, Huang S, Gao J, Spence JR, Owyang C. Lactobacillus Rhamnosus GG Prevents Epithelial Barrier Dysfunction Induced by Interferon-Gamma and Fecal Supernatants From Irritable Bowel Syndrome Patients in Human Intestinal Enteroids and Colonoids. Gut Microbes (2019) 10:59&#x2013;76. doi:&#xa0;10.1080/19490976.2018.1479625</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2018.1479625</ArticleId>
            <ArticleId IdType="pmc">PMC6363076</ArticleId>
            <ArticleId IdType="pubmed">30040527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deem RL, Shanahan F, Targan SR. Triggered Human Mucosal T Cells Release Tumour Necrosis Factor-Alpha and Interferon-Gamma Which Kill Human Colonic Epithelial Cells. Clin Exp Immunol (1991) 83:79&#x2013;84. doi:&#xa0;10.1111/j.1365-2249.1991.tb05592.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.1991.tb05592.x</ArticleId>
            <ArticleId IdType="pmc">PMC1535451</ArticleId>
            <ArticleId IdType="pubmed">1899066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izcue A, Coombes JL, Powrie F. Regulatory T Cells Suppress Systemic and Mucosal Immune Activation to Control Intestinal Inflammation. Immunol Rev (2006) 212:256&#x2013;71. doi:&#xa0;10.1111/j.0105-2896.2006.00423.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.0105-2896.2006.00423.x</ArticleId>
            <ArticleId IdType="pubmed">16903919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, et al. . Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells. Dig Dis Sci (2010) 55:1396&#x2013;405. doi:&#xa0;10.1007/s10620-009-0839-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-009-0839-8</ArticleId>
            <ArticleId IdType="pmc">PMC2904314</ArticleId>
            <ArticleId IdType="pubmed">19507029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bamias G, Delladetsima I, Perdiki M, Siakavellas SI, Goukos D, Papatheodoridis GV, et al. . Immunological Characteristics of Colitis Associated With Anti-CTLA-4 Antibody Therapy. Cancer Invest (2017) 35:443&#x2013;55. doi:&#xa0;10.1080/07357907.2017.1324032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/07357907.2017.1324032</ArticleId>
            <ArticleId IdType="pubmed">28548891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu L, Yang F, Zhang F, Guo D, Li L, Wang X, et al. . CD69 Enhances Immunosuppressive Function of Regulatory T-Cells and Attenuates Colitis by Prompting IL-10 Production. Cell Death Dis (2018) 9(9):905. doi:&#xa0;10.1038/s41419-018-0927-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0927-9</ArticleId>
            <ArticleId IdType="pmc">PMC6125584</ArticleId>
            <ArticleId IdType="pubmed">30185773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teixeira-Coelho M, Guedes J, Ferreirinha P, Howes A, Pedrosa J, Rodrigues F, et al. . Differential Post-Transcriptional Regulation of IL-10 by TLR2 and TLR4-Activated Macrophages. Eur J Immunol (2014) 44:856&#x2013;66. doi:&#xa0;10.1002/eji.201343734</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201343734</ArticleId>
            <ArticleId IdType="pmc">PMC4623319</ArticleId>
            <ArticleId IdType="pubmed">24227629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma F, Liu X, Li D, Wang P, Li N, Lu L, et al. . Microrna-466l Upregulates IL-10 Expression in TLR-Triggered Macrophages by Antagonizing RNA-Binding Protein Tristetraprolin-Mediated IL-10 Mrna Degradation. J&#xa0;Immunol (2010) 184:6053&#x2013;9. doi:&#xa0;10.4049/jimmunol.0902308</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0902308</ArticleId>
            <ArticleId IdType="pubmed">20410487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. . Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation. Immunity (2011) 34:566&#x2013;78. doi:&#xa0;10.1016/j.immuni.2011.03.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2011.03.018</ArticleId>
            <ArticleId IdType="pmc">PMC3088485</ArticleId>
            <ArticleId IdType="pubmed">21511185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ying H, Yang L, Qiao G, Li Z, Zhang L, Yin F, et al. . Cutting Edge: Ctla-4&#x2013;B7 Interaction Suppresses Th17 Cell Differentiation. J Immunol (2010) 185:1375&#x2013;8. doi:&#xa0;10.4049/jimmunol.0903369</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0903369</ArticleId>
            <ArticleId IdType="pmc">PMC2915549</ArticleId>
            <ArticleId IdType="pubmed">20601598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callahan MK, Yang A, Tandon S, Xu Y, Subudhi SK, Roman RA, et al. . Evaluation of Serum IL-17 Levels During Ipilimumab Therapy: Correlation With Colitis. J Clin Oncol (2011) 29:2505&#x2013;5. doi: 10.1200/jco.2011.29.15_suppl.2505</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2011.29.15_suppl.2505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaschitz C, Raffatellu M. Th17 Cytokines and the Gut Mucosal Barrier. J&#xa0;Clin Immunol (2010) 30:196&#x2013;203. doi:&#xa0;10.1007/s10875-010-9368-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-010-9368-7</ArticleId>
            <ArticleId IdType="pmc">PMC2842875</ArticleId>
            <ArticleId IdType="pubmed">20127275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ina K, Kusugami K, Hosokawa T, Imada A, Shimizu T, Yamaguchi T, et al. . Increased Mucosal Production of Granulocyte Colony-Stimulating Factor Is Related to a Delay in Neutrophil Apoptosis in Inflammatory Bowel Disease. J&#xa0;Gastroenterol Hepatol (1999) 14:46&#x2013;53. doi:&#xa0;10.1046/j.1440-1746.1999.01807.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1440-1746.1999.01807.x</ArticleId>
            <ArticleId IdType="pubmed">10029277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metzemaekers M, Vandendriessche S, Berghmans N, Gouwy M, Proost P. Truncation of CXCL8 to CXCL8(9-77) Enhances Actin Polymerization and In Vivo Migration of Neutrophils. J Leukoc Biol (2020) 107:1167&#x2013;73. doi:&#xa0;10.1002/JLB.3AB0220-470R</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/JLB.3AB0220-470R</ArticleId>
            <ArticleId IdType="pubmed">32272490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, et al. . Evidence for a Cross-Talk Between Human Neutrophils and Th17 Cells. Blood (2010) 115:335&#x2013;43. doi:&#xa0;10.1182/blood-2009-04-216085</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-04-216085</ArticleId>
            <ArticleId IdType="pubmed">19890092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. Am J Surg Pathol (2017) 41:643&#x2013;54. doi:&#xa0;10.1097/PAS.0000000000000829</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0000000000000829</ArticleId>
            <ArticleId IdType="pubmed">28296676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritzman AM, Hughes-Hanks JM, Blaho VA, Wax LE, Mitchell WJ, Brown CR. The Chemokine Receptor CXCR2 Ligand KC (CXCL1) Mediates Neutrophil Recruitment and Is Critical for Development of Experimental Lyme Arthritis and Carditis. Infect Immun (2010) 78:4593&#x2013;600. doi:&#xa0;10.1128/IAI.00798-10</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00798-10</ArticleId>
            <ArticleId IdType="pmc">PMC2976349</ArticleId>
            <ArticleId IdType="pubmed">20823213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Filippo K, Dudeck A, Hasenberg M, Nye E, Van Rooijen N, Hartmann K, et al. . Mast Cell and Macrophage Chemokines CXCL1/CXCL2 Control the Early Stage of Neutrophil Recruitment During Tissue Inflammation. Blood (2013) 121:4930&#x2013;7. doi:&#xa0;10.1182/blood-2013-02-486217</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2013-02-486217</ArticleId>
            <ArticleId IdType="pubmed">23645836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Zheng N, Luo Q, Jiang L, He B, Yuan X, et al. . Probiotics Lactobacillus Reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. Front Immunol (2019) 10:1235. doi:&#xa0;10.3389/fimmu.2019.01235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01235</ArticleId>
            <ArticleId IdType="pmc">PMC6558076</ArticleId>
            <ArticleId IdType="pubmed">31214189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S, Luo L, Liang W, Yin Q, Guo J, Rush AM, et al. . Bifidobacterium Alters the Gut Microbiota and Modulates the Functional Metabolism of T Regulatory Cells in the Context of Immune Checkpoint Blockade. Proc Natl Acad Sci (2020) 117:2&#x2013;8. doi:&#xa0;10.1073/pnas.1921223117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1921223117</ArticleId>
            <ArticleId IdType="pmc">PMC7959554</ArticleId>
            <ArticleId IdType="pubmed">33077598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omenetti S, Pizarro TT. The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome. Front Immunol (2015) 6:639. doi:&#xa0;10.3389/fimmu.2015.00639</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2015.00639</ArticleId>
            <ArticleId IdType="pmc">PMC4681807</ArticleId>
            <ArticleId IdType="pubmed">26734006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 Balance. Eur J Immunol (2010) 40:1830&#x2013;5. doi:&#xa0;10.1002/eji.201040391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201040391</ArticleId>
            <ArticleId IdType="pubmed">20583029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. . Enhanced Secretion of Tumour Necrosis Factor-Alpha, IL-6, and IL-1&#x3b2; by Isolated Lamina Propria Mononuclear Cells From Patients With Ulcerative Colitis and Crohn&#x2019;s Disease. Clin Exp Immunol (1993) 94:174&#x2013;81. doi:&#xa0;10.1111/j.1365-2249.1993.tb05997.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.1993.tb05997.x</ArticleId>
            <ArticleId IdType="pmc">PMC1534387</ArticleId>
            <ArticleId IdType="pubmed">8403503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones GR, Bain CC, Fenton TM, Kelly A, Brown SL, Ivens AC, et al. . Dynamics of Colon Monocyte and Macrophage Activation During Colitis. Front Immunol (2018) 9:2764. doi:&#xa0;10.3389/fimmu.2018.02764</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02764</ArticleId>
            <ArticleId IdType="pmc">PMC6277765</ArticleId>
            <ArticleId IdType="pubmed">30542349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groom JR, Luster AD. CXCR3 in T Cell Function. Exp Cell Res (2011) 317:620&#x2013;31. doi:&#xa0;10.1016/j.yexcr.2010.12.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2010.12.017</ArticleId>
            <ArticleId IdType="pmc">PMC3065205</ArticleId>
            <ArticleId IdType="pubmed">21376175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chami B, Yeung AWS, Van Vreden C, King NJC, Bao S. The Role of CXCR3 in DSS-Induced Colitis. PLoS One (2014) 9(7):e101622. doi:&#xa0;10.1371/journal.pone.0101622</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0101622</ArticleId>
            <ArticleId IdType="pmc">PMC4081590</ArticleId>
            <ArticleId IdType="pubmed">24992040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. . Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer Res (2020) 26:487&#x2013;504. doi:&#xa0;10.1158/1078-0432.CCR-19-1868</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-1868</ArticleId>
            <ArticleId IdType="pubmed">31636098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X, Ding S, Jiang H, Liu G. Roles of Macrophages in the Development and Treatment of Gut Inflammation. Front Cell Dev Biol (2021) 9:625423. doi:&#xa0;10.3389/fcell.2021.625423</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2021.625423</ArticleId>
            <ArticleId IdType="pmc">PMC7960654</ArticleId>
            <ArticleId IdType="pubmed">33738283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bain CC, Mowat AM. Macrophages in Intestinal Homeostasis and Inflammation. Immunol Rev (2014) 260:102&#x2013;17. doi:&#xa0;10.1111/imr.12192</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12192</ArticleId>
            <ArticleId IdType="pmc">PMC4141699</ArticleId>
            <ArticleId IdType="pubmed">24942685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishima Y, Sartor RB. Manipulating Resident Microbiota to Enhance Regulatory Immune Function to Treat Inflammatory Bowel Diseases. J&#xa0;Gastroenterol (2020) 55:4&#x2013;14. doi:&#xa0;10.1007/s00535-019-01618-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-019-01618-1</ArticleId>
            <ArticleId IdType="pmc">PMC6942586</ArticleId>
            <ArticleId IdType="pubmed">31482438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stehr M, Greweling MC, Tischer S, Singh M, Bl&#xf6;cker H, Monner DA, et al. . Charles River Altered Schaedler Flora (CRASF&#xae;) Remained Stable for Four Years in a Mouse Colony Housed in Individually Ventilated Cages. Lab Anim (2009) 43:362&#x2013;70. doi:&#xa0;10.1258/la.2009.0080075</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1258/la.2009.0080075</ArticleId>
            <ArticleId IdType="pubmed">19535393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasson SC, Zaunders JJ, Nahar K, Munier CML, Fairfax BP, Olsson-Brown A, et al. . Mucosal-Associated Invariant T (MAIT) Cells Are Activated in the Gastrointestinal Tissue of Patients With Combination Ipilimumab and Nivolumab Therapy-Related Colitis in a Pathology Distinct From Ulcerative Colitis. Clin Exp Immunol (2020) 202:335&#x2013;52. doi:&#xa0;10.1111/cei.13502</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.13502</ArticleId>
            <ArticleId IdType="pmc">PMC7670140</ArticleId>
            <ArticleId IdType="pubmed">32734627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. . Human Mucosal Associated Invariant T Cells Detect Bacterially Infected Cells. PloS Biol (2010) 8:1&#x2013;14. doi:&#xa0;10.1371/journal.pbio.1000407</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.1000407</ArticleId>
            <ArticleId IdType="pmc">PMC2893946</ArticleId>
            <ArticleId IdType="pubmed">20613858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Bourhis L, Martin E, P&#xe9;guillet I, Guihot A, Froux N, Cor&#xe9; M, et al. . Antimicrobial Activity of Mucosal-Associated Invariant T Cells. Nat Immunol (2010) 11:701&#x2013;8. doi:&#xa0;10.1038/ni.1890</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1890</ArticleId>
            <ArticleId IdType="pubmed">20581831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can Mitigate Intestinal Immunopathology in the Context of CTLA-4 Blockade. Proc Natl Acad Sci USA (2018) 115:157&#x2013;61. doi:&#xa0;10.1073/pnas.1712901115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1712901115</ArticleId>
            <ArticleId IdType="pmc">PMC5776803</ArticleId>
            <ArticleId IdType="pubmed">29255057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AM, Okhuysen PC, et al. . Impact of Antibiotic Therapy on the Development and Response to Treatment of Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis. J Immunother Cancer (2019) 7:1&#x2013;11. doi:&#xa0;10.1186/s40425-019-0832-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0832-5</ArticleId>
            <ArticleId IdType="pmc">PMC6918684</ArticleId>
            <ArticleId IdType="pubmed">31847892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cross ML, Ganner A, Teilab D, Fray LM. Patterns of Cytokine Induction by Gram-Positive and Gram-Negative Probiotic Bacteria. FEMS Immunol Med Microbiol (2004) 42:173&#x2013;80. doi:&#xa0;10.1016/j.femsim.2004.04.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.femsim.2004.04.001</ArticleId>
            <ArticleId IdType="pubmed">15364101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin JC, B&#xe9;riou G, Heslan M, Bossard C, Jarry A, Abidi A, et al. . IL-22BP Is Produced by Eosinophils in Human Gut and Blocks IL-22 Protective Actions During Colitis. Mucosal Immunol (2016) 9:539&#x2013;49. doi:&#xa0;10.1038/mi.2015.83</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2015.83</ArticleId>
            <ArticleId IdType="pubmed">26329427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Victor AR, Nalin AP, Dong W, McClory S, Wei M, Mao C, et al. . IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-&#x3ba;b. J&#xa0;Immunol (2017) 199:2333&#x2013;42. doi:&#xa0;10.4049/jimmunol.1601554</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1601554</ArticleId>
            <ArticleId IdType="pmc">PMC5624342</ArticleId>
            <ArticleId IdType="pubmed">28842466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, Belkaid Y, et al. . Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal Homeostasis. Science (2014) 343(6178):1249288. doi:&#xa0;10.1126/science.1252785</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1252785</ArticleId>
            <ArticleId IdType="pmc">PMC4291125</ArticleId>
            <ArticleId IdType="pubmed">24625929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park HJ, Lee SW, Van Kaer L, Hong S. Cd1d-Dependent Inkt Cells Control Dss-Induced Colitis in a Mouse Model of Ifn&#x3b3;-Mediated Hyperinflammation by Increasing Il22-Secreting Ilc3 Cells. Int J Mol Sci (2021) 22:1&#x2013;11. doi:&#xa0;10.3390/ijms22031250</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22031250</ArticleId>
            <ArticleId IdType="pmc">PMC7866066</ArticleId>
            <ArticleId IdType="pubmed">33513946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov II, et al. . Lymphoid Tissue Inducer-Like Cells Are an Innate Source of IL-17 and IL-22. J Exp Med (2009) 206:35&#x2013;41. doi:&#xa0;10.1084/jem.20072713</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20072713</ArticleId>
            <ArticleId IdType="pmc">PMC2626689</ArticleId>
            <ArticleId IdType="pubmed">19114665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina A, et al. . Type 3 Innate Lymphoid Cells Producing IL-17 and IL-22 Are Expanded in the Gut, in the Peripheral Blood, Synovial Fluid and Bone Marrow of Patients With Ankylosing Spondylitis. Ann Rheum Dis (2015) 74:1739&#x2013;47. doi:&#xa0;10.1136/annrheumdis-2014-206323</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2014-206323</ArticleId>
            <ArticleId IdType="pubmed">25902790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. . Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated Colitis. Nat Med (2018) 24:1804&#x2013;8. doi:&#xa0;10.1038/s41591-018-0238-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0238-9</ArticleId>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasanello MK, Robillard KT, Boland PM, Bain AJ, Kanehira K. Use of Fecal Microbial Transplantation for Immune Checkpoint Inhibitor Colitis. ACG Case Rep J (2020) 7:e00360. doi:&#xa0;10.14309/crj.0000000000000360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/crj.0000000000000360</ArticleId>
            <ArticleId IdType="pmc">PMC7224717</ArticleId>
            <ArticleId IdType="pubmed">32548190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, et al. . Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. J Crohn&#x2019;s Colitis (2017) 11:1238&#x2013;46. doi:&#xa0;10.1093/ecco-jcc/jjx081</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjx081</ArticleId>
            <ArticleId IdType="pubmed">28967957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 Inhibitor Gastroenterocolitis: Case Series and Appraisal of &#x2018;Immunomodulatory Gastroenterocolitis. Histopathology (2017) 70:558&#x2013;67. doi:&#xa0;10.1111/his.13118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13118</ArticleId>
            <ArticleId IdType="pubmed">28000302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Front Immunol (2017) 8:1547. doi:&#xa0;10.3389/fimmu.2017.01547</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01547</ArticleId>
            <ArticleId IdType="pmc">PMC5715331</ArticleId>
            <ArticleId IdType="pubmed">29230210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al. . CTLA4 Blockade Increases Th17 Cells in Patients With Metastatic Melanoma. J Transl Med (2009) 7:1&#x2013;13. doi:&#xa0;10.1186/1479-5876-7-35</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-7-35</ArticleId>
            <ArticleId IdType="pmc">PMC2697137</ArticleId>
            <ArticleId IdType="pubmed">19457253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshino K, Nakayama T, Ito A, Sato E, Kitano S. Severe Colitis After PD-1 Blockade With Nivolumab in Advanced Melanoma Patients: Potential Role of Th1-Dominant Immune Response in Immune-Related Adverse Events: Two Case Reports. BMC Cancer (2019) 19:1&#x2013;7. doi:&#xa0;10.1186/s12885-019-6138-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-6138-7</ArticleId>
            <ArticleId IdType="pmc">PMC6819390</ArticleId>
            <ArticleId IdType="pubmed">31664934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, et al. . Intestinal Tolerance Is Converted to Autoimmune Enteritis Upon PD-1 Ligand Blockade. J Immunol (2009) 182:2102&#x2013;12. doi:&#xa0;10.4049/jimmunol.0802769</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0802769</ArticleId>
            <ArticleId IdType="pmc">PMC3682217</ArticleId>
            <ArticleId IdType="pubmed">19201863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beswick EJ, Johnson JR, Saada JI, Humen M, House J, Dann S, et al. . TLR4 Activation Enhances the PD-L1&#x2013;Mediated Tolerogenic Capacity of Colonic CD90 + Stromal Cells. J Immunol (2014) 193:2218&#x2013;29. doi:&#xa0;10.4049/jimmunol.1203441</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1203441</ArticleId>
            <ArticleId IdType="pmc">PMC4142442</ArticleId>
            <ArticleId IdType="pubmed">25070848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1/PD-L and Autoimmunity: A Growing Relationship. Cell Immunol (2016) 310:27&#x2013;41. doi:&#xa0;10.1016/j.cellimm.2016.09.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2016.09.009</ArticleId>
            <ArticleId IdType="pubmed">27660198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes MJ, Griseri T, Johnson AMF, Young W, Powrie F, Izcue A. CTLA-4 Promotes Foxp3 Induction and Regulatory T Cell Accumulation in the Intestinal Lamina Propria. Mucosal Immunol (2013) 6:324&#x2013;34. doi:&#xa0;10.1038/mi.2012.75</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2012.75</ArticleId>
            <ArticleId IdType="pmc">PMC3574974</ArticleId>
            <ArticleId IdType="pubmed">22910217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. . Baseline Circulating IL-17 Predicts Toxicity While TGF-&#x3b2;1 and IL-10 Are Prognostic of Relapse in Ipilimumab Neoadjuvant Therapy of Melanoma. J&#xa0;Immunother Cancer (2015) 3:15&#x2013;20. doi:&#xa0;10.1186/s40425-015-0081-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-015-0081-1</ArticleId>
            <ArticleId IdType="pmc">PMC4570556</ArticleId>
            <ArticleId IdType="pubmed">26380086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. . Pretreatment Neutrophil-to-Lymphocyte Ratio as a Marker of Outcomes in Nivolumab-Treated Patients With Advanced Non-Small-Cell Lung Cancer. Lung Cancer (2017) 106:1&#x2013;7. doi:&#xa0;10.1016/j.lungcan.2017.01.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2017.01.013</ArticleId>
            <ArticleId IdType="pubmed">28285682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, et al. . Baseline Neutrophil-to-Lymphocyte Ratio Is Associated With Outcome of Ipilimumab-Treated Metastatic Melanoma Patients. Br J Cancer (2015) 112:1904&#x2013;10. doi:&#xa0;10.1038/bjc.2015.180</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2015.180</ArticleId>
            <ArticleId IdType="pmc">PMC4580390</ArticleId>
            <ArticleId IdType="pubmed">26010413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, et al. . Baseline Neutrophils and Derived Neutrophilto-Lymphocyte Ratio: Prognostic Relevance in Metastatic Melanoma Patients Receiving Ipilimumab. Ann Oncol (2016) 27:732&#x2013;8. doi:&#xa0;10.1093/annonc/mdw016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw016</ArticleId>
            <ArticleId IdType="pubmed">26802161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, et al. . Continuous Monitoring of Neutrophils to Lymphocytes Ratio for Estimating the Onset, Severity, and Subsequent Prognosis of Immune Related Adverse Events. Sci Rep (2021) 11:1&#x2013;11. doi:&#xa0;10.1038/s41598-020-79397-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-79397-6</ArticleId>
            <ArticleId IdType="pmc">PMC7809015</ArticleId>
            <ArticleId IdType="pubmed">33446685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ksienski D, Wai ES, Alex D, Croteau NS, Freeman AT, Chan A, et al. . Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Advanced Non-Small Cell Lung Cancer Patients With High PD-L1 Tumor Expression Receiving Pembrolizumab. Transl Lung Cancer Res (2021) 10:355&#x2013;67. doi:&#xa0;10.21037/tlcr-20-541</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/tlcr-20-541</ArticleId>
            <ArticleId IdType="pmc">PMC7867765</ArticleId>
            <ArticleId IdType="pubmed">33569318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, et al. . Vitamin D Intake Is Associated With Decreased Risk of Immune Checkpoint Inhibitor-Induced Colitis. Cancer (2020) 126:3758&#x2013;67. doi:&#xa0;10.1002/cncr.32966</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.32966</ArticleId>
            <ArticleId IdType="pmc">PMC7381363</ArticleId>
            <ArticleId IdType="pubmed">32567084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai M, Grieshaber-Bouyer R, Wang J, Schmider AB, Wilson ZS, Zeng L, et al. . CD177 Modulates Human Neutrophil Migration Through Activation-Mediated Integrin and Chemoreceptor Regulation. Blood (2017) 130:2092&#x2013;100. doi:&#xa0;10.1182/blood-2017-03-768507</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2017-03-768507</ArticleId>
            <ArticleId IdType="pmc">PMC5680608</ArticleId>
            <ArticleId IdType="pubmed">28807980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, et al. . Gene Expression Profiling of Whole Blood in Ipilimumab-Treated Patients for Identification of Potential Biomarkers of Immune-Related Gastrointestinal Adverse Events. J Transl Med (2013) 11:1&#x2013;11. doi:&#xa0;10.1186/1479-5876-11-75</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-11-75</ArticleId>
            <ArticleId IdType="pmc">PMC3637501</ArticleId>
            <ArticleId IdType="pubmed">23521917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sipponen T. Diagnostics and Prognostics of Inflammatory Bowel Disease With Fecal Neutrophil-Derived Biomarkers Calprotectin and Lactoferrin. Dig Dis (2013) 31:336&#x2013;44. doi:&#xa0;10.1159/000354689</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000354689</ArticleId>
            <ArticleId IdType="pubmed">24246984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, Van Zoelen MAD, et al. . Mrp8 and Mrp14 Are Endogenous Activators of Toll-Like Receptor 4, Promoting Lethal, Endotoxin-Induced Shock. Nat Med (2007) 13:1042&#x2013;9. doi:&#xa0;10.1038/nm1638</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1638</ArticleId>
            <ArticleId IdType="pubmed">17767165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voganatsi A, Panyutich A, Miyasaki K, Murthy R. Mechanism of Extracellular Release of Human Neutrophil Calprotectin Complex Abstract : Calprotectin Is an Abundant Cytosolic Protein Complex of Human Neutrophils With In Vitro Extracellular Antimicrobial Activity. Studies Suggest Particulate Stimuli. J Leukoc Biol (2001) 70:130&#x2013;4. doi:&#xa0;10.1189/jlb.70.1.130</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.70.1.130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson MC, Chaze T, Co&#xef;c YM, Injarabian L, Jonsson F, Lombion N, et al. . MUB 40 Binds to Lactoferrin and Stands as a Specific Neutrophil Marker. Cell Chem Biol (2018) 25:483&#x2013;93.e9. doi:&#xa0;10.1016/j.chembiol.2018.01.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2018.01.014</ArticleId>
            <ArticleId IdType="pubmed">29478905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis 11 Medical and Health Sciences 1103 Clinical Sciences. J Immunother Cancer (2018) 6:1&#x2013;11. doi:&#xa0;10.1186/s40425-018-0411-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0411-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. . Vedolizumab Treatment for Immune Checkpoint Inhibitor-Induced Enterocolitis. Cancer Immunol Immunother (2017) 66:581&#x2013;92. doi:&#xa0;10.1007/s00262-017-1962-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-1962-6</ArticleId>
            <ArticleId IdType="pmc">PMC5406433</ArticleId>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou F, Wang X, Glitza IC, Mcquade JL, Wang J, Zhang HC, et al. . Fecal Calprotectin Concentration to Assess Endoscopic and Histologic Remission in Patients With Cancer With Immune-Mediated Diarrhea and Colitis. J&#xa0;Immunother Cancer (2021) 9:1&#x2013;8. doi:&#xa0;10.1136/jitc-2020-002058</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-002058</ArticleId>
            <ArticleId IdType="pmc">PMC7805368</ArticleId>
            <ArticleId IdType="pubmed">33436487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guidelines. J Clin Oncol (2018) 17:3246&#x2013;58. doi:&#xa0;10.1200/JCO.2017.77.6385.Corresponding</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.6385.Corresponding</ArticleId>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theede K, Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. Inflamm Bowel Dis (2016) 22:1042&#x2013;8. doi:&#xa0;10.1097/MIB.0000000000000736</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000000736</ArticleId>
            <ArticleId IdType="pubmed">26919460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, et al. . Lactoferrin in Whole Gut Lavage Fluid as a Marker for Disease Activity in Inflammatory Bowel Disease: Comparison With Other Neutrophil-Derived Proteins. Am J Gastroenterol (2002) 97:360&#x2013;9. doi:&#xa0;10.1016/S0002-9270(01)04032-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9270(01)04032-1</ArticleId>
            <ArticleId IdType="pubmed">11866274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. . Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis. Nat Commun (2016) 7:10391. doi:&#xa0;10.1038/ncomms10391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10391</ArticleId>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. . Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab. Ann Oncol (2017) 28:1368&#x2013;79. doi:&#xa0;10.1093/annonc/mdx108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx108</ArticleId>
            <ArticleId IdType="pubmed">28368458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Xiong Q, Li L, Hu Y. Intestinal Microbiota Predicts Lung Cancer Patients at Risk of Immune-Related Diarrhea. Immunotherapy (2019) 11:385&#x2013;96. doi:&#xa0;10.2217/imt-2018-0144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2018-0144</ArticleId>
            <ArticleId IdType="pubmed">30693820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tastan C, Karhan E, Zhou W, Fleming E, Voigt AY, Yao X, et al. . Tuning of Human MAIT Cell Activation by Commensal Bacteria Species and MR1-Dependent T-Cell Presentation. Mucosal Immunol (2018) 11:1591&#x2013;605. doi:&#xa0;10.1038/s41385-018-0072-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41385-018-0072-x</ArticleId>
            <ArticleId IdType="pmc">PMC6279574</ArticleId>
            <ArticleId IdType="pubmed">30115998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander ET, Minton A, Peters MC, Phanstiel O, Gilmour SK. A Novel Polyamine Blockade Therapy Activates an Anti-Tumor Immune Response. Oncotarget (2017) 8:84140&#x2013;52. doi:&#xa0;10.18632/oncotarget.20493</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.20493</ArticleId>
            <ArticleId IdType="pmc">PMC5663583</ArticleId>
            <ArticleId IdType="pubmed">29137411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes CS, Shicora AC, Keough MP, Snook AE, Burns MR, Gilmour SK. Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment. Cancer Immunol Res (2014) 2:274&#x2013;85. doi:&#xa0;10.1158/2326-6066.CIR-13-0120-T</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0120-T</ArticleId>
            <ArticleId IdType="pmc">PMC4101915</ArticleId>
            <ArticleId IdType="pubmed">24778323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reich KM, Fedorak RN, Madsen K, Kroeker KI. Vitamin D Improves Inflammatory Bowel Disease Outcomes: Basic Science and Clinical Review. World J Gastroenterol (2014) 20:4934&#x2013;47. doi:&#xa0;10.3748/wjg.v20.i17.4934</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i17.4934</ArticleId>
            <ArticleId IdType="pmc">PMC4009525</ArticleId>
            <ArticleId IdType="pubmed">24803805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meeker S, Seamons A, Maggio-Price L, Paik J. Protective Links Between Vitamin D, Inflammatory Bowel Disease and Colon Cancer. World J Gastroenterol (2016) 22:933&#x2013;48. doi:&#xa0;10.3748/wjg.v22.i3.933</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v22.i3.933</ArticleId>
            <ArticleId IdType="pmc">PMC4716046</ArticleId>
            <ArticleId IdType="pubmed">26811638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletcher J, Cooper SC, Ghosh S, Hewison M. The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. Nutrients (2019) 11(5):1019. doi:&#xa0;10.3390/nu11051019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu11051019</ArticleId>
            <ArticleId IdType="pmc">PMC6566188</ArticleId>
            <ArticleId IdType="pubmed">31067701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, et al. . Multi-Omics Prediction of Immune-Related Adverse Events During Checkpoint Immunotherapy. Nat Commun (2020) 11:1&#x2013;7. doi:&#xa0;10.1038/s41467-020-18742-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-18742-9</ArticleId>
            <ArticleId IdType="pmc">PMC7532211</ArticleId>
            <ArticleId IdType="pubmed">33009409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Itzstein MS, Khan S, Gerber DE. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. Clin Chem (2020) 66:779&#x2013;93. doi:&#xa0;10.1093/clinchem/hvaa081</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/clinchem/hvaa081</ArticleId>
            <ArticleId IdType="pmc">PMC7259479</ArticleId>
            <ArticleId IdType="pubmed">32363387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events&#x2014;a Comprehensive Review. Front Oncol (2021) 10:585311. doi:&#xa0;10.3389/fonc.2020.585311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.585311</ArticleId>
            <ArticleId IdType="pmc">PMC7905347</ArticleId>
            <ArticleId IdType="pubmed">33643899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. . Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2017) 28:iv119&#x2013;42. doi:&#xa0;10.1093/annonc/mdx225</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx225</ArticleId>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. . Management of Immunotherapy-Related Toxicities, Version 1.2019. JNCCN J Natl Compr Cancer Netw (2019) 17:255&#x2013;89. doi:&#xa0;10.6004/jnccn.2019.0013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2019.0013</ArticleId>
            <ArticleId IdType="pubmed">30865922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am (2016) 42:157&#x2013;76. doi:&#xa0;10.1016/j.rdc.2015.08.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rdc.2015.08.004</ArticleId>
            <ArticleId IdType="pmc">PMC4751577</ArticleId>
            <ArticleId IdType="pubmed">26611557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and Benefits of Infliximab for the Treatment of Crohn&#x2019;s Disease. Clin Gastroenterol Hepatol (2006) 4:1017&#x2013;24. doi:&#xa0;10.1016/j.cgh.2006.05.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2006.05.020</ArticleId>
            <ArticleId IdType="pubmed">16843733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verheijden RJ, May AM, Blank CU, Aarts MJB, Berkmortel FWPJVD, Eertwegh AJMVD, et al. . Association of Anti-TNF With Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res (2020) 26:2268&#x2013;74. doi:&#xa0;10.1158/1078-0432.CCR-19-3322</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3322</ArticleId>
            <ArticleId IdType="pubmed">31988197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danylesko I, Bukauskas A, Paulson M, Peceliunas V, Gedde-Dahl d.y T, Shimoni A, et al. . Anti-&#x3b1;4&#x3b2;7 Integrin Monoclonal Antibody (Vedolizumab) for the Treatment of Steroid-Resistant Severe Intestinal Acute Graft-Versus-Host Disease. Bone Marrow Transplant (2019) 54:987&#x2013;93. doi:&#xa0;10.1038/s41409-018-0364-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41409-018-0364-5</ArticleId>
            <ArticleId IdType="pubmed">30356163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, et al. . Early Introduction of Selective Immunosuppressive Therapy Associated With Favorable Clinical Outcomes in Patients With Immune Checkpoint Inhibitor-Induced Colitis. J Immunother Cancer (2019) 7:1&#x2013;11. doi:&#xa0;10.1186/s40425-019-0577-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0577-1</ArticleId>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou F, Shah AY, Glitza IC, Richards D, Thomas AS, Wang Y. S0137 Comparative Study of Vedolizumab and Infliximab Treatment in Patients With Immune-Mediated Diarrhea and Colitis. Am J Gastroenterol (2020) 115:S68. doi:&#xa0;10.14309/ajg.0000000000000848</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/ajg.0000000000000848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, et al. . IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity From Immunotherapy. Cancer Immunol Res (2019) 7:860&#x2013;5. doi:&#xa0;10.1158/2326-6066.CIR-18-0682</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0682</ArticleId>
            <ArticleId IdType="pubmed">30996018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, et al. . Secukinumab, a Human Anti-IL-17A Monoclonal Antibody, for Moderate to Severe Crohn&#x2019;s Disease: Unexpected Results of a Randomised, Double-Blindplacebo- Controlled Trial. Gut (2012) 61:1693&#x2013;700. doi:&#xa0;10.1136/gutjnl-2011-301668</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2011-301668</ArticleId>
            <ArticleId IdType="pmc">PMC4902107</ArticleId>
            <ArticleId IdType="pubmed">22595313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sands BE, Sandborn WJ, Panaccione R, O&#x2019;Brien CD, Zhang H, Johanns J, et al. . Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med (2019) 381:1201&#x2013;14. doi:&#xa0;10.1056/nejmoa1900750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa1900750</ArticleId>
            <ArticleId IdType="pubmed">31553833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishu S, Melia J, Sharfman W, Lao CD, Fecher LA, Higgins PDR. Efficacy and Outcome of Tofacitinib in Immune Checkpoint Inhibitor Colitis. Gastroenterology (2021) 160:932&#x2013;34.e3. doi:&#xa0;10.1053/j.gastro.2020.10.029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.10.029</ArticleId>
            <ArticleId IdType="pubmed">33096100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Hudson M, Batist G. Tofacitinib for Refractory Immune-Related Colitis From PD-1 Therapy. N Engl J Med (2020) 382:2374&#x2013;5. doi:&#xa0;10.1056/nejmc2010419</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmc2010419</ArticleId>
            <ArticleId IdType="pubmed">32521140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fern&#xe1;ndez-Clotet A, Castro-Poceiro J, Pan&#xe9;s J. Tofacitinib for the Treatment of Ulcerative Colitis. Expert Rev Clin Immunol (2018) 14:881&#x2013;92. doi:&#xa0;10.1080/1744666X.2018.1532291</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1744666X.2018.1532291</ArticleId>
            <ArticleId IdType="pubmed">30285500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen TT, Ramsay L, Ahanfeshar-Adams M, Lajoie M, Schadendorf D, Alain T, et al. . Mutations in the IFN&#x3b3;-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. Clin Cancer Res (2021) 27(12):3432&#x2013;42. doi:&#xa0;10.1158/1078-0432.ccr-20-3365. clincanres.3365.2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-20-3365</ArticleId>
            <ArticleId IdType="pubmed">33593882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voth E, Khanna S. Fecal Microbiota Transplantation for Treatment of Patients With Recurrent Clostridioides Difficile Infection. Expert Rev Anti Infect Ther (2020) 18:669&#x2013;76. doi:&#xa0;10.1080/14787210.2020.1752192</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14787210.2020.1752192</ArticleId>
            <ArticleId IdType="pubmed">32266848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfaleh K, Anabrees J. Probiotics for Prevention of Necrotizing Enterocolitis in Preterm Infants. Evidence-Based Child Heal (2014) 9:584&#x2013;671. doi:&#xa0;10.1002/ebch.1976</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ebch.1976</ArticleId>
            <ArticleId IdType="pubmed">25236307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V&#xe9;tizou M, Pitt JM, Daill&#xe8;re R, Lepage P, Waldschmitt N, Flament C, et al. . Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. Science (2015) 350:1079&#x2013;84. doi:&#xa0;10.1126/science.aad1329</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill&#xe8;re R, et al. . Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors. Science (2018) 359:91&#x2013;7. doi:&#xa0;10.1126/science.aan3706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan3706</ArticleId>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. . Preoperative Ipilimumab Plus Nivolumab in Locoregionally Advanced Urothelial Cancer: The NABUCCO Trial. Nat Med (2020) 26:1839&#x2013;44. doi:&#xa0;10.1038/s41591-020-1085-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-1085-z</ArticleId>
            <ArticleId IdType="pubmed">33046870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, et al. . Survival and Biomarker Analyses From the Opacin-Neo and Opacin Neoadjuvant Immunotherapy Trials in Stage III Melanoma. Nat Med (2021) 27:256&#x2013;63. doi:&#xa0;10.1038/s41591-020-01211-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-01211-7</ArticleId>
            <ArticleId IdType="pubmed">33558721</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34751747</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-4844</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Inflammatory bowel diseases</Title>
          <ISOAbbreviation>Inflamm Bowel Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Refractory Immune Checkpoint Inhibitor-induced Colitis Improved by Fecal Microbiota Transplantation: A Case Report.</ArticleTitle>
        <Pagination>
          <StartPage>e43</StartPage>
          <EndPage>e44</EndPage>
          <MedlinePgn>e43-e44</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/ibd/izab265</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Cong</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0003-1317-183X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wei-Xin</ForeName>
            <Initials>WX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Inflamm Bowel Dis</MedlineTA>
        <NlmUniqueID>9508162</NlmUniqueID>
        <ISSNLinking>1078-0998</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069467" MajorTopicYN="N">Fecal Microbiota Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34751747</ArticleId>
        <ArticleId IdType="doi">10.1093/ibd/izab265</ArticleId>
        <ArticleId IdType="pii">6424075</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34716545</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1865-7265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical journal of gastroenterology</Title>
          <ISOAbbreviation>Clin J Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nivolumab dose escalation triggered immune checkpoint inhibitor-induced colitis after 147 weeks of prolonged stable use in a patient with lung cancer: a case report.</ArticleTitle>
        <Pagination>
          <StartPage>128</StartPage>
          <EndPage>133</EndPage>
          <MedlinePgn>128-133</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12328-021-01542-z</ELocationID>
        <Abstract>
          <AbstractText>A 56-year-old man with advanced lung adenocarcinoma presented to the emergency department with a 6-day history of diarrhea. He was treated for lung cancer with nivolumab 3 mg/kg (144 mg/body) every 2 weeks (Q2W), followed by an increase to 240 mg Q2W for 147 weeks, for a total of 69 administrations. His dose was then increased to 480 mg/body every four weeks (Q4W) 12 days before his presentation. Clostridioides difficile toxin, cytomegalovirus antigenemia, and stool bacterial cultures were negative. Colonoscopy revealed diffusely edematous granular mucosa with mucosal redness, exudates, loss of vascular pattern, and aphtha throughout the colon but no ulcers. We diagnosed the patient with immune checkpoint inhibitor-induced colitis. We started prednisolone at a dose of 60 mg/day. His symptoms gradually improved, and he recovered without diarrhea on day ten after hospitalization. After prednisolone tapering, his symptoms did not worsen. Colonoscopy showed significant improvement on day 29, and the diffuse redness disappeared. The patient did not experience subsequent recurrence of diarrhea. He had no progression of lung cancer despite the termination of nivolumab for seven months. Here, we report a case of lung cancer in which nivolumab dose escalation after prolonged stable use triggered immune checkpoint inhibitor-induced colitis.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. Japanese Society of Gastroenterology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Soma</LastName>
            <ForeName>Kazumasa</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishida</LastName>
            <ForeName>Tsutomu</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-4037-9003</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan. tnishida.gastro@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Osugi</LastName>
            <ForeName>Naoto</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morimura</LastName>
            <ForeName>Osamu</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adachi</LastName>
            <ForeName>Shiro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujii</LastName>
            <ForeName>Yoshifumi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sugimoto</LastName>
            <ForeName>Aya</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mukai</LastName>
            <ForeName>Kaori</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamatsu</LastName>
            <ForeName>Dai</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumoto</LastName>
            <ForeName>Kengo</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamamoto</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka, 560-8565, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Clin J Gastroenterol</MedlineTA>
        <NlmUniqueID>101477246</NlmUniqueID>
        <ISSNLinking>1865-7265</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
          <NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">Nivolumab</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34716545</ArticleId>
        <ArticleId IdType="doi">10.1007/s12328-021-01542-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s12328-021-01542-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/intimm/dxm057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443&#x2013;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2016.4059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1507643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2014.59.4358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samaan MA, Pavlidis P, Papa S, et al. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol. 2018;15:222&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2018.14</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(09)70334-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shulgin B, Kosinsky Y, Omelchenko A, et al. Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. Oncoimmunology. 2020;9:1748982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2020.1748982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long GV, Tykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018;29:2208&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis. Am J Gastroenterol. 2020;115:202&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/ajg.0000000000000497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10:395&#x2013;401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: endoscopic and pathologic findings. World J Gastrointest Pathophysiol. 2019;10:17&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4291/wjgp.v10.i2.17</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agrawal S, Feng Y, Roy A, et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016;4:72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-016-0177-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Mooradian MJ, Kim D, et al. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019;8:e1524695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1524695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-015-0455-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasuda Y, Urata Y, Tohnai R, et al. Immune-related colitis induced by the long-term use of nivolumab in a patient with non-small cell lung cancer. Intern Med. 2018;57:1269&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.9230-17</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34515105</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1421-9867</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>102</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Digestion</Title>
          <ISOAbbreviation>Digestion</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>965</StartPage>
          <EndPage>973</EndPage>
          <MedlinePgn>965-973</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000518543</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As immune-checkpoint inhibitors (ICI) are becoming standard therapies for malignant tumors, increasing attention has been paid to their associated immune-related adverse events (irAEs). The gastrointestinal tract is the major site of irAEs, and it has recently become evident that the large bowel is the most frequently affected region. The aim of this narrative review was to clarify the endoscopic and histopathologic findings of and treatments for ICI-induced colitis.</AbstractText>
          <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Endoscopic findings of ICI-induced colitis include a reddish, edematous mucosa with increased mucous exudate, loss of normal vascularity, and a granular mucosa with or without mucosal breaks. Histopathologic findings of ICI-induced colitis are expansion of the lamina propria, intraepithelial infiltration of neutrophils, crypt architectural distortion, neutrophilic crypt abscess, and prominent apoptosis. The clinical, endoscopic, and histopathologic severity of ICI-induced colitis is diverse, but colonoscopy together with biopsy is necessary for diagnosis. While a certain proportion of patients with ICI-induced colitis have an intractable clinical course, management guidelines are based on retrospective analyses. Prospective studies are needed to assess the efficacy of various medications, including immunosuppressive regimens. Key Messages: Colonoscopy with biopsy is the gold standard for the diagnosis of ICI-induced colitis. Endoscopists should be aware of the clinical features and pathophysiology of ICI-induced colitis for prompt diagnosis and treatment planning.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yanai</LastName>
            <ForeName>Shunichi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toya</LastName>
            <ForeName>Yosuke</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sugai</LastName>
            <ForeName>Tamotsu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Pathology, Iwate Medical University, Morioka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumoto</LastName>
            <ForeName>Takayuki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Digestion</MedlineTA>
        <NlmUniqueID>0150472</NlmUniqueID>
        <ISSNLinking>0012-2823</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Diarrhea</Keyword>
        <Keyword MajorTopicYN="N">Immune-checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Immune-related adverse event</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>9</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34515105</ArticleId>
        <ArticleId IdType="doi">10.1159/000518543</ArticleId>
        <ArticleId IdType="pii">000518543</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34380976</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1537-4513</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunotherapy (Hagerstown, Md. : 1997)</Title>
          <ISOAbbreviation>J Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.</ArticleTitle>
        <Pagination>
          <StartPage>325</StartPage>
          <EndPage>334</EndPage>
          <MedlinePgn>325-334</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/CJI.0000000000000383</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) have transformed the management of advanced malignancies but are associated with diarrhea and colitis. The objective of our systematic review and meta-analysis was to determine the incidence and outcomes of ICI-associated diarrhea and colitis. Bibliographic databases were searched through August 13, 2019, for observational studies of ICI therapy reporting the incidence and/or treatment of diarrhea or colitis. The primary outcome was ICI-associated diarrhea and colitis. Meta-analyses were performed with random-effects models. Twenty-five studies (N=12,661) were included. All studies had a high risk of bias in at least 1 domain. The overall incidence of diarrhea/colitis was 12.8% [95% confidence interval (CI), 8.8-18.2, I2=96.5]. The incidence was lower in patients treated with anti-programmed cell death 1/programmed death-ligand 1 (4.1%, 95% CI, 2.6-6.5) than in those treated with anti-cytotoxic T-cell lymphocyte-associated antigen 4 (20.1%, 95% CI, 15.9-25.1). The remission of diarrhea and/or colitis was higher in patients treated with corticosteroids plus biologics (88.4%, 95% CI, 79.4-93.8) than in those treated with corticosteroids alone (58.3%, 95% CI, 49.3-66.7, Q=18.7, P&lt;0.001). ICI were permanently discontinued in 48.1% of patients (95% CI, 17.8-79.1). ICI were restarted after temporary interruption in 48.6% of patients (95% CI, 18.2-79.4) of whom 17.0% (95% CI, 6.4-30.0) experienced recurrence. Real-world incidence of ICI-associated diarrhea/colitis exceeds 10%. These events lead to permanent ICI discontinuation in just over 50% of patients, while &lt;20% have recurrence of symptoms if ICI are resumed. Further studies are needed to identify patients who would benefit from early treatment with biologics as well as appropriate patients to resume ICI therapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tran</LastName>
            <ForeName>Ashley N</ForeName>
            <Initials>AN</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Melinda</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hundt</LastName>
            <ForeName>Melanie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chugh</LastName>
            <ForeName>Rishika</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohm</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grimshaw</LastName>
            <ForeName>Alyssa</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ciarleglio</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hung</LastName>
            <ForeName>Kenneth W</ForeName>
            <Initials>KW</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Proctor</LastName>
            <ForeName>Deborah D</ForeName>
            <Initials>DD</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Price</LastName>
            <ForeName>Christina C</ForeName>
            <Initials>CC</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Allergy and Immunology, Yale School of Medicine.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>VA Connecticut Healthcare System, West Haven, CT.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laine</LastName>
            <ForeName>Loren</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>VA Connecticut Healthcare System, West Haven, CT.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Bawardy</LastName>
            <ForeName>Badr</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Digestive Diseases.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>T32 DK007017</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Immunother</MedlineTA>
        <NlmUniqueID>9706083</NlmUniqueID>
        <ISSNLinking>1524-9557</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34380976</ArticleId>
        <ArticleId IdType="doi">10.1097/CJI.0000000000000383</ArticleId>
        <ArticleId IdType="pii">00002371-202110000-00005</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, et al. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother. 2018;41:101&#x2013;108.</Citation>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563&#x2013;580.</Citation>
        </Reference>
        <Reference>
          <Citation>Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29&#x2013;39.</Citation>
        </Reference>
        <Reference>
          <Citation>Grover S, Rahma OE, Hashemi N, et al. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ Book. 2018;38:13&#x2013;19.</Citation>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056&#x2013;2067.</Citation>
        </Reference>
        <Reference>
          <Citation>Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol. 2018;9:180.</Citation>
        </Reference>
        <Reference>
          <Citation>Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases. 2019;7:405&#x2013;418.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6:e1344805.</Citation>
        </Reference>
        <Reference>
          <Citation>Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264&#x2013;269; W264.</Citation>
        </Reference>
        <Reference>
          <Citation>McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40&#x2013;46.</Citation>
        </Reference>
        <Reference>
          <Citation>Wells G, Shea B, O&#x2019;Connell D, et al. The Newcastle&#x2013;Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis; 2000.</Citation>
        </Reference>
        <Reference>
          <Citation>Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers&#x2019; to authors&#x2019; assessments. BMC Med Res Methodol. 2014;14:45.</Citation>
        </Reference>
        <Reference>
          <Citation>US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41&#x2013;48.</Citation>
        </Reference>
        <Reference>
          <Citation>Franklin C, Rooms I, Fiedler M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer. 2017;86:248&#x2013;256.</Citation>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.</Citation>
        </Reference>
        <Reference>
          <Citation>Herlihy J, Beasley S, Simmelink A, et al. Flexible sigmoidoscopy rather than colonoscopy is adequate for the diagnosis of ipilimumab-associated colitis. South Med J. 2019;112:154&#x2013;158.</Citation>
        </Reference>
        <Reference>
          <Citation>Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190&#x2013;209.</Citation>
        </Reference>
        <Reference>
          <Citation>Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193&#x2013;3198.</Citation>
        </Reference>
        <Reference>
          <Citation>Jain A, Lipson EJ, Sharfman WH, et al. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol. 2017;23:2023&#x2013;2028.</Citation>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234&#x2013;240.</Citation>
        </Reference>
        <Reference>
          <Citation>Khoja L, Atenafu EG, Ye Q, et al. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncol Lett. 2016;11:1581&#x2013;1585.</Citation>
        </Reference>
        <Reference>
          <Citation>Leonardi GC, Gainor JF, Altan M, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol. 2018;36:1905&#x2013;1912.</Citation>
        </Reference>
        <Reference>
          <Citation>Mangana J, Dimitriou F, Braun R, et al. Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma. Melanoma Res. 2019;29:648&#x2013;654.</Citation>
        </Reference>
        <Reference>
          <Citation>Manrique MC, Mosquera Martinez J, Garcia Gonzalez J, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician Lung Cancer Group clinical experience. Transl Lung Cancer Res. 2018;7:404&#x2013;415.</Citation>
        </Reference>
        <Reference>
          <Citation>Richter MD, Pinkston O, Kottschade LA, et al. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the mayo clinic experience. Arthritis Rheumatol. 2018;70:356&#x2013;360.</Citation>
        </Reference>
        <Reference>
          <Citation>Wiater K, Switaj T, Mackiewicz J, et al. Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Contemp Oncol (Pozn). 2013;17:257&#x2013;262.</Citation>
        </Reference>
        <Reference>
          <Citation>Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29:250&#x2013;255.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Naqash AR, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol. 2019;37:2738&#x2013;2745.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142.</Citation>
        </Reference>
        <Reference>
          <Citation>Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28:2860&#x2013;2865.</Citation>
        </Reference>
        <Reference>
          <Citation>De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015;25:321&#x2013;327.</Citation>
        </Reference>
        <Reference>
          <Citation>de Malet A, Antoni G, Collins M, et al. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:106&#x2013;114.</Citation>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Zheng H, Zubiri L, et al. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019;8:4986&#x2013;4999.</Citation>
        </Reference>
        <Reference>
          <Citation>Lesage C, Longvert C, Prey S, et al. Incidence and clinical impact of anti-TNFalpha treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit Survey. J Immunother. 2019;42:175&#x2013;179.</Citation>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Connor A, Marples M, Mulatero C, et al. Ipilimumab-induced colitis: experience from a tertiary referral center. Therap Adv Gastroenterol. 2016;9:457&#x2013;462.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Mooradian MJ, Kim D, et al. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019;8:e1524695.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer JR, et al. Management of immunotherapy-related toxicities, version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:255&#x2013;289.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Wang Y Naing A, Hajjar J. Gastrointestinal tract adverse events. Immunotherapy. Cham, Switzerland: Springer International Publishing; 2020:247&#x2013;253.</Citation>
        </Reference>
        <Reference>
          <Citation>Badran YR, Cohen JV, Brastianos PK, et al. Concurrent therapy with immune checkpoint inhibitors and TNF&#x3b1; blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019;7:226.</Citation>
        </Reference>
        <Reference>
          <Citation>Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569:428&#x2013;432.</Citation>
        </Reference>
        <Reference>
          <Citation>Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6:103.</Citation>
        </Reference>
        <Reference>
          <Citation>Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohn Colitis. 2016;10:1437&#x2013;1444.</Citation>
        </Reference>
        <Reference>
          <Citation>Luoma AM, Suo S, Williams HL, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182:655.e22&#x2013;671.e22.</Citation>
        </Reference>
        <Reference>
          <Citation>Schadendorf D, Wolchok JD, Hodi FS. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35:3807&#x2013;3814.</Citation>
        </Reference>
        <Reference>
          <Citation>Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865&#x2013;871.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34338882</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-2307</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>479</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Virchows Archiv : an international journal of pathology</Title>
          <ISOAbbreviation>Virchows Arch</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.</ArticleTitle>
        <Pagination>
          <StartPage>1119</StartPage>
          <EndPage>1129</EndPage>
          <MedlinePgn>1119-1129</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00428-021-03170-x</ELocationID>
        <Abstract>
          <AbstractText>Colitis is a common, but poorly understood, adverse event of immune checkpoint inhibitors that are standard-of-care for an expanding range of cancer types. This explorative study aimed to describe the immune infiltrates in the colon from individuals developing checkpoint inhibitor colitis and compare them to well-known immunophenotypes of acute graft-versus-host disease, ulcerative colitis, and Crohn's disease. Colon biopsies (n = 20 per group) of patients with checkpoint inhibitor colitis, acute graft-versus-host disease, ulcerative colitis and Crohn's disease, all colitis treatment-nave, and of individuals with a normal colon were analyzed using immunohistochemistry: CD8 for cytotoxic T cells, CD4 for T helper cells, and CD68 to identify cells of macrophage lineage. CD8 + T cell, CD4 + T cell, and CD68 + cell counts were performed. Cell infiltration was scored as scattered/patchy or band-like in the superficial and deep gut mucosa. Checkpoint inhibitor colitis was found to be heavily infiltrated by CD8 + T cells. Comparative analysis between groups showed that both CD8 + T cell counts (P &lt; 0.01) and immune cell infiltration patterns in checkpoint inhibitor colitis were most similar to those observed in ulcerative colitis, with a deep band-like CD4 + T cell infiltration pattern and a superficial band-like CD68 + cell infiltration pattern in both. In conclusion, this is the first immunohistopathological study comparing infiltrate characteristics of checkpoint inhibitor colitis, acute graft-versus-host disease, ulcerative colitis, and Crohn's disease. Checkpoint inhibitor colitis samples are heterogeneous, heavily infiltrated by CD8 + T cells, and show an immune cell infiltration pattern that is more similar to ulcerative colitis than to colonic acute graft-versus-host disease or colonic Crohn's disease.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hone Lopez</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-7615-3474</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kats-Ugurlu</LastName>
            <ForeName>Gursah</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-3006-5978</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Renken</LastName>
            <ForeName>Remco J</ForeName>
            <Initials>RJ</Initials>
            <Identifier Source="ORCID">0000-0002-7777-9484</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences of Cells &amp; Systems, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cognitive Neuroscience Centre , University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buikema</LastName>
            <ForeName>Henk J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Groot</LastName>
            <ForeName>Marco R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Visschedijk</LastName>
            <ForeName>Marijn C</ForeName>
            <Initials>MC</Initials>
            <Identifier Source="ORCID">0000-0001-7277-7677</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dijkstra</LastName>
            <ForeName>Gerard</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0003-4563-7462</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jalving</LastName>
            <ForeName>Mathilde</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-9142-9050</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Haan</LastName>
            <ForeName>Jacco J</ForeName>
            <Initials>JJ</Initials>
            <Identifier Source="ORCID">0000-0002-1629-4715</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands. j.j.de.haan@umcg.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Virchows Arch</MedlineTA>
        <NlmUniqueID>9423843</NlmUniqueID>
        <ISSNLinking>0945-6317</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006086" MajorTopicYN="N">Graft vs Host Disease</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acute graft-versus-host disease</Keyword>
        <Keyword MajorTopicYN="N">CD8-positive T-lymphocytes</Keyword>
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Inflammatory bowel disease</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>2</Day>
          <Hour>12</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34338882</ArticleId>
        <ArticleId IdType="pmc">PMC8724151</ArticleId>
        <ArticleId IdType="doi">10.1007/s00428-021-03170-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s00428-021-03170-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Darvin P, Toor S, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:1&#x2013;11. doi: 10.1038/s12276-018-0191-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s12276-018-0191-1</ArticleId>
            <ArticleId IdType="pmc">PMC6292890</ArticleId>
            <ArticleId IdType="pubmed">30546008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018;472:125&#x2013;133. doi: 10.1007/s00428-017-2267-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-017-2267-z</ArticleId>
            <ArticleId IdType="pubmed">29143108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119&#x2013;iv142. doi: 10.1093/annonc/mdx225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx225</ArticleId>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol. 2018;4:1721&#x2013;1728. doi: 10.1001/jamaoncol.2018.3923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.3923</ArticleId>
            <ArticleId IdType="pmc">PMC6440712</ArticleId>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel J, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056&#x2013;2067. doi: 10.1136/gutjnl-2018-316948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-316948</ArticleId>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyashita H, Mikami T, Satoi S, Cruz C, Galsky MD. Incidence and risk of colitis with programmed death 1 versus programmed death ligand 1 inhibitors for the treatment of cancer. J Immunother. 2020;43:291&#x2013;298. doi: 10.1097/CJI.0000000000000339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000339</ArticleId>
            <ArticleId IdType="pubmed">32960847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother. 2018;41:101&#x2013;108. doi: 10.1097/CJI.0000000000000213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000213</ArticleId>
            <ArticleId IdType="pubmed">29401166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GeukesFoppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278. doi: 10.1136/esmoopen-2017-000278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prieux-Klotz C, Dior M, Damotte D, et al. (2017) Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017;12:301&#x2013;308. doi: 10.1007/s11523-017-0495-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11523-017-0495-4</ArticleId>
            <ArticleId IdType="pubmed">28540478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verheijden RJ, May AM, Blank CU, et al. (2020) Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res. 2020;26:2268&#x2013;2274. doi: 10.1158/1078-0432.CCR-19-3322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3322</ArticleId>
            <ArticleId IdType="pubmed">31988197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez RS, Salaria SN, Bohannon CD, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of &#x2018;immunomodulatory gastroenterocolitis&#x2019;. Histopathology. 2016;70:558&#x2013;567. doi: 10.1111/his.13118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13118</ArticleId>
            <ArticleId IdType="pubmed">28000302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 2017;41:643&#x2013;654. doi: 10.1097/PAS.0000000000000829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0000000000000829</ArticleId>
            <ArticleId IdType="pubmed">28296676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karamchandani D, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists&#x2019; perspective. J Clin Pathol. 2018;71:665&#x2013;671. doi: 10.1136/jclinpath-2018-205143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jclinpath-2018-205143</ArticleId>
            <ArticleId IdType="pubmed">29703758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008;32:1130&#x2013;1137. doi: 10.1097/PAS.0b013e31817150e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e31817150e3</ArticleId>
            <ArticleId IdType="pubmed">18545145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smids C, HorjusTalaburHorje CS, Drylewicz J, et al. Intestinal T cell profiling in inflammatory bowel disease: linking T cell subsets to disease activity and disease course. J Crohns Colitis. 2017;12:465&#x2013;475. doi: 10.1093/ecco-jcc/jjx160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjx160</ArticleId>
            <ArticleId IdType="pubmed">29211912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartley CP, Carrillo-Polanco LF, Rowan DJ, et al. Colonic graft-vs.-host disease in autologous versus allogeneic transplant patients: earlier onset, more apoptosis, and lack of regulatory T-cell attenuation. Mod Pathol. 2018;31:1619&#x2013;1626. doi: 10.1038/s41379-018-0078-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41379-018-0078-7</ArticleId>
            <ArticleId IdType="pubmed">29899549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beres AJ, Haribhai D, Chadwick AC, et al. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol. 2012;189:464&#x2013;474. doi: 10.4049/jimmunol.1200886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1200886</ArticleId>
            <ArticleId IdType="pmc">PMC3381996</ArticleId>
            <ArticleId IdType="pubmed">22649199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio CA, Langner C, Schmidt P. Partial to complete abrogation of the subepithelial macrophage barrier against the gut microbiota in patients with ulcerative colitis and Crohn&#x2019;s colitis. Histopathology. 2017;72:580&#x2013;587. doi: 10.1111/his.13417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13417</ArticleId>
            <ArticleId IdType="pubmed">29023984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Xiao X, Demirci G, Madsen J, Li XC. Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms. J Immunol. 2012;188:2703&#x2013;2711. doi: 10.4049/jimmunol.1102997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1102997</ArticleId>
            <ArticleId IdType="pmc">PMC3298083</ArticleId>
            <ArticleId IdType="pubmed">22327074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144&#x2013;164K. doi: 10.1093/ecco-jcc/jjy113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjy113</ArticleId>
            <ArticleId IdType="pubmed">30137275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13:273&#x2013;284. doi: 10.1093/ecco-jcc/jjy114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjy114</ArticleId>
            <ArticleId IdType="pubmed">30137278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mowat A, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14:667&#x2013;685. doi: 10.1038/nri3738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3738</ArticleId>
            <ArticleId IdType="pubmed">25234148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175:998&#x2013;1013.e20. doi: 10.1016/j.cell.2018.10.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.10.038</ArticleId>
            <ArticleId IdType="pmc">PMC6641984</ArticleId>
            <ArticleId IdType="pubmed">30388456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobol I, Chen CL, Mahmood SS, Borczuk AC. Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy. Arch Pathol Lab Med. 2020;144:1392&#x2013;1396. doi: 10.5858/arpa.2019-0447-OA.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/arpa.2019-0447-OA</ArticleId>
            <ArticleId IdType="pmc">PMC8445131</ArticleId>
            <ArticleId IdType="pubmed">32150459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181&#x2013;1190. doi: 10.1016/j.jhep.2018.01.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2018.01.033</ArticleId>
            <ArticleId IdType="pubmed">29427729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patil PA, Zhang X. Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy. Arch Pathol Lab Med. 2020;145(5):571&#x2013;582. doi: 10.5858/arpa.2020-0070-RA.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/arpa.2020-0070-RA</ArticleId>
            <ArticleId IdType="pubmed">32338534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irshaid L, Robert ME, Zhang X. Immune checkpoint inhibitor&#x2013;induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from Helicobacter pylori gastritis and celiac disease therapy. Arch Pathol Lab Med. 2021;145:191&#x2013;200. doi: 10.5858/arpa.2019-0700-OA.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/arpa.2019-0700-OA</ArticleId>
            <ArticleId IdType="pubmed">33501492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beswick EJ, Grim C, Singh A, et al. Expression of programmed death-ligand 1 by human colonic CD90+ stromal cells differs between ulcerative colitis and Crohn&#x2019;s disease and determines their capacity to suppress Th1 cells. Front Immunol. 2018;9:1125. doi: 10.3389/fimmu.2018.01125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01125</ArticleId>
            <ArticleId IdType="pmc">PMC5992387</ArticleId>
            <ArticleId IdType="pubmed">29910803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Ni J, Xu WD, et al. Association of CTLA-4 variants with susceptibility to inflammatory bowel disease: a meta-analysis. Hum Immunol. 2014;75:227&#x2013;233. doi: 10.1016/j.humimm.2013.12.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humimm.2013.12.008</ArticleId>
            <ArticleId IdType="pubmed">24374044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis. 2017;11:1238&#x2013;1246. doi: 10.1093/ecco-jcc/jjx081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjx081</ArticleId>
            <ArticleId IdType="pubmed">28967957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo YC, Price C, Blenman K, Patil Zhang PX, Robert ME. Checkpoint inhibitor colitis shows drug-specific differences in immune cell reaction that overlap with inflammatory bowel disease and predict response to colitis therapy. Am J Clin Pathol. 2021;156(2):214&#x2013;228. doi: 10.1093/ajcp/aqaa217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ajcp/aqaa217</ArticleId>
            <ArticleId IdType="pubmed">33555016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler BL, Pezhouh MK, Kim A, et al. Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med. 2018;283:568&#x2013;577. doi: 10.1111/joim.12744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joim.12744</ArticleId>
            <ArticleId IdType="pmc">PMC5992029</ArticleId>
            <ArticleId IdType="pubmed">29464806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569:428&#x2013;432. doi: 10.1038/s41586-019-1162-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1162-y</ArticleId>
            <ArticleId IdType="pubmed">31043740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581&#x2013;592. doi: 10.1007/s00262-017-1962-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-1962-6</ArticleId>
            <ArticleId IdType="pmc">PMC5406433</ArticleId>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7:93. doi: 10.1186/s40425-019-0577-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0577-1</ArticleId>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuoka K, Saito E, Fujii T, et al. Tacrolimus for the treatment of ulcerative colitis. Intes Res. 2015;13:219&#x2013;226. doi: 10.5217/ir.2015.13.3.219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5217/ir.2015.13.3.219</ArticleId>
            <ArticleId IdType="pmc">PMC4479736</ArticleId>
            <ArticleId IdType="pubmed">26130996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ram R, Storb R. Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leuk Lymphoma. 2013;54:1591&#x2013;1601. doi: 10.3109/10428194.2012.762978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10428194.2012.762978</ArticleId>
            <ArticleId IdType="pmc">PMC3700680</ArticleId>
            <ArticleId IdType="pubmed">23278640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas AS, Ma W, Wang Y. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med. 2021;384:581&#x2013;583. doi: 10.1056/NEJMc2031717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2031717</ArticleId>
            <ArticleId IdType="pubmed">33567198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Hudson M, Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. N Engl J Med. 2020;382:2374&#x2013;2375. doi: 10.1056/NEJMc2002527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2002527</ArticleId>
            <ArticleId IdType="pubmed">32521140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beardslee T, Draper A, Kudchadkar R. Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumour necrosis factor &#x3b1; therapy. J Oncol Pharm Pract. 2019;25:1275&#x2013;1281. doi: 10.1177/1078155218793709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155218793709</ArticleId>
            <ArticleId IdType="pubmed">30124124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins F, Sykiotis GP, Maillard MT, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019;20:e54&#x2013;64. doi: 10.1016/S1470-2045(18)30828-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30828-3</ArticleId>
            <ArticleId IdType="pubmed">30614479</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34332139</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2210-741X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinics and research in hepatology and gastroenterology</Title>
          <ISOAbbreviation>Clin Res Hepatol Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint inhibitor induced colitis: A nationwide population-based study.</ArticleTitle>
        <Pagination>
          <StartPage>101778</StartPage>
          <MedlinePgn>101778</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinre.2021.101778</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2210-7401(21)00157-1</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">ICIs are used in the management of several malignancies. However, they can result in immune-related adverse events, such as colitis. The aim of this study is to obtain an epidemiological survey of patients who develop immune checkpoint inhibitor (ICI)-induced colitis and identify underlying risk factors.</AbstractText>
          <AbstractText Label="METHODS">A cohort study was performed using Explorys, a US-based population database. Our cohort included all patients in a five-year interval on an ICI. We further identified those who developed colitis after initiating an ICI. Demographic data and possible risk factors were assessed. Odds ratios were calculated and multivariable statistical analysis was performed.</AbstractText>
          <AbstractText Label="RESULTS">3.6% of patients developed ICI-induced colitis. Women [OR: 1.2; 95% CI 1.224-1.231, p &lt;0.001], Caucasians [OR: 2.3; 2.284 - 2.299], individuals older than 65 years [OR: 1.3; 1.319 - 1.326], obese patients [OR: 3.3; 3.273 - 3.302], and those with a history of alcohol abuse [OR: 2.5; 2.485 - 2.523] were more likely to develop colitis. Patients who received Nivolumab [OR: 2.8; 2.563 - 3.022], Ipilimumab [OR: 4.9; 3.937 - 6.061], Pembrolizumab [OR 2.7; 2.463 - 2.868], and Atezolizumab [OR 2.9; 2.430 - 3.388] had an increased odds of developing colitis. The majority of cases were diagnosed in the first 6 months of therapy.</AbstractText>
          <AbstractText Label="CONCLUSIONS">This is the largest study to describe the epidemiology of ICI-induced colitis and it is the first to identify underlying risk factors. Ipilimumab poses the greatest risk for ICI-induced colitis. The risk of colitis should be discussed with all patients prior to initiating an ICI, as it may be a factor in choosing among ICIs.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Farha</LastName>
            <ForeName>Natalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alkhayyat</LastName>
            <ForeName>Motasem</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology &amp; Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: alkhaym@ccf.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lindsey</LastName>
            <ForeName>Adrian</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Liver Disease, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mansoor</LastName>
            <ForeName>Emad</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Liver Disease, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saleh</LastName>
            <ForeName>Mohannad Abou</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology &amp; Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Clin Res Hepatol Gastroenterol</MedlineTA>
        <NlmUniqueID>101553659</NlmUniqueID>
        <ISSNLinking>2210-7401</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Immune-related adverse events</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>20</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34332139</ArticleId>
        <ArticleId IdType="doi">10.1016/j.clinre.2021.101778</ArticleId>
        <ArticleId IdType="pii">S2210-7401(21)00157-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34256056</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-0012</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>161</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gastroenterology</Title>
          <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed.</ArticleTitle>
        <Pagination>
          <StartPage>1106</StartPage>
          <EndPage>1108</EndPage>
          <MedlinePgn>1106-1108</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2021.07.007</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(21)03241-8</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dougan</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, and Harvard Medical School, Boston, Massachusetts. Electronic address: mldougan@partners.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016421">Editorial</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Gastroenterology</MedlineTA>
        <NlmUniqueID>0374630</NlmUniqueID>
        <ISSNLinking>0016-5085</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Gastroenterology. 2021 Oct;161(4):1229-1244.e9</RefSource>
          <PMID Version="1">34147519</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>13</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34256056</ArticleId>
        <ArticleId IdType="doi">10.1053/j.gastro.2021.07.007</ArticleId>
        <ArticleId IdType="pii">S0016-5085(21)03241-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34170536</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2036</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Alimentary pharmacology &amp; therapeutics</Title>
          <ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Letter: safety of immune checkpoint inhibitors in patients with pre-established microscopic colitis-a single-centre experience.</ArticleTitle>
        <Pagination>
          <StartPage>217</StartPage>
          <EndPage>218</EndPage>
          <MedlinePgn>217-218</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.16458</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fredrick</LastName>
            <ForeName>Thomas W</ForeName>
            <Initials>TW</Initials>
            <Identifier Source="ORCID">0000-0002-2906-1574</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Braga Neto</LastName>
            <ForeName>Manuel B</ForeName>
            <Initials>MB</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramos</LastName>
            <ForeName>Guilherme P</ForeName>
            <Initials>GP</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kane</LastName>
            <ForeName>Sunanda</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-6410-4242</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pardi</LastName>
            <ForeName>Darrell S</ForeName>
            <Initials>DS</Initials>
            <Identifier Source="ORCID">0000-0003-0420-8784</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raffals</LastName>
            <ForeName>Laura E</ForeName>
            <Initials>LE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Aliment Pharmacol Ther</MedlineTA>
        <NlmUniqueID>8707234</NlmUniqueID>
        <ISSNLinking>0269-2813</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Aliment Pharmacol Ther. 2021 Feb;53(3):374-382</RefSource>
          <PMID Version="1">33314269</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046728" MajorTopicYN="Y">Colitis, Microscopic</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>12</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34170536</ArticleId>
        <ArticleId IdType="doi">10.1111/apt.16458</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021;53:374-382.</Citation>
        </Reference>
        <Reference>
          <Citation>Pardi DS. Diagnosis and management of microscopic colitis. Am J Gastroenterol. 2017;112:78-85.</Citation>
        </Reference>
        <Reference>
          <Citation>Miehlke S, Verhaegh B, Tontini GE, Madisch A, Langner C, M&#xfc;nch A. Microscopic colitis: pathophysiology and clinical management. Lancet Gastroenterol Hepatol. 2019;4:305-314.</Citation>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.</Citation>
        </Reference>
        <Reference>
          <Citation>Kr&#xf6;ner PT, Mody K, Farraye FA. Immune checkpoint inhibitor-related luminal GI adverse events. Gastrointest Endosc. 2019;90:881-892.</Citation>
        </Reference>
        <Reference>
          <Citation>Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis. Am J Gastroenterol. 2020;115:202-210.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6:37.</Citation>
        </Reference>
        <Reference>
          <Citation>Braga Neto MB, Ramos GP, Loftus EV Jr, Faubion WA, Raffals LE. Use of immune checkpoint inhibitors in patients with pre-established inflammatory bowel diseases: retrospective case series. Clin Gastroenterol Hepatol. 2021;19:1285-1287.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34162429</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1756-994X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genome medicine</Title>
          <ISOAbbreviation>Genome Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.</ArticleTitle>
        <Pagination>
          <StartPage>107</StartPage>
          <MedlinePgn>107</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">107</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13073-021-00923-w</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory pathways. Administration of ICIs augments T cell-mediated immune responses against tumor, resulting in improved overall survival in cancer patients. It has emerged that the intestinal microbiome can modulate responses to ICIs via the host immune system and that the use of antibiotics can lead to reduced efficacy of ICIs. Recently, reports that fecal microbiota transplantation can lead to ICI therapy responses in patients previously refractory to therapy suggest that targeting the microbiome may be a viable strategy to reprogram the tumor microenvironment and augment ICI therapy. Intestinal microbial metabolites may also be linked to response rates to ICIs. In addition to response rates, certain toxicities that can arise during ICI therapy have also been found to be associated with the intestinal microbiome, including in particular colitis. A key mechanistic question is how certain microbes can enhance anti-tumor responses or, alternatively, predispose to ICI-associated colitis. Evidence has emerged that the intestinal microbiome can modulate outcomes to ICI therapies via two major mechanisms, including those that are antigen-specific and those that are antigen-independent. Antigen-specific mechanisms occur when epitopes are shared between microbial and tumor antigens that could enhance, or, alternatively, reduce anti-tumor immune responses via cross-reactive adaptive immune cells. Antigen-independent mechanisms include modulation of responses to ICIs by engaging innate and/or adaptive immune cells. To establish microbiome-based biomarkers of outcomes and specifically modulate the intestinal microbiome to enhance efficacy of ICIs in cancer immunotherapy, further prospective interventional studies will be required.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hayase</LastName>
            <ForeName>Eiko</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jenq</LastName>
            <ForeName>Robert R</ForeName>
            <Initials>RR</Initials>
            <Identifier Source="ORCID">0000-0002-5434-439X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. RRJenq@mdanderson.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. RRJenq@mdanderson.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CPRIT Scholar in Cancer Research, Houston, TX, USA. RRJenq@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL124112</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA016672</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Genome Med</MedlineTA>
        <NlmUniqueID>101475844</NlmUniqueID>
        <ISSNLinking>1756-994X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076662" MajorTopicYN="N">Host Microbial Interactions</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Intestinal microbiome</Keyword>
        <Keyword MajorTopicYN="N">Metabolites</Keyword>
      </KeywordList>
      <CoiStatement>R.R.J. has consulted for Karius, Merck, Microbiome DX, and Prolacta, and is on the scientific advisory boards of Kaleido, LISCure Biosciences, Maat Pharma, and Seres, and has received patent royalties licensed to Seres. The remaining authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34162429</ArticleId>
        <ArticleId IdType="pmc">PMC8220726</ArticleId>
        <ArticleId IdType="doi">10.1186/s13073-021-00923-w</ArticleId>
        <ArticleId IdType="pii">10.1186/s13073-021-00923-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hodi FS, O&#x2019;Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711&#x2013;723. doi: 10.1056/NEJMoa1003466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122&#x2013;133. doi: 10.1056/NEJMoa1302369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1302369</ArticleId>
            <ArticleId IdType="pmc">PMC5698004</ArticleId>
            <ArticleId IdType="pubmed">23724867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455&#x2013;2465. doi: 10.1056/NEJMoa1200694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200694</ArticleId>
            <ArticleId IdType="pmc">PMC3563263</ArticleId>
            <ArticleId IdType="pubmed">22658128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11(11):805&#x2013;812. doi: 10.1038/nrc3153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3153</ArticleId>
            <ArticleId IdType="pmc">PMC3426440</ArticleId>
            <ArticleId IdType="pubmed">22020206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&#x2019;s lymphoma. N Engl J Med. 2015;372(4):311&#x2013;319. doi: 10.1056/NEJMoa1411087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1411087</ArticleId>
            <ArticleId IdType="pmc">PMC4348009</ArticleId>
            <ArticleId IdType="pubmed">25482239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23&#x2013;34. doi: 10.1056/NEJMoa1504030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504030</ArticleId>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, Fran&#xe7;ois H, Lazarovici J, le Pavec J, de Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559&#x2013;574. doi: 10.1093/annonc/mdv623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdv623</ArticleId>
            <ArticleId IdType="pubmed">26715621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563&#x2013;580. doi: 10.1038/s41571-019-0218-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-019-0218-0</ArticleId>
            <ArticleId IdType="pubmed">31092901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154&#x2013;173. doi: 10.1016/j.ccell.2020.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2020.10.001</ArticleId>
            <ArticleId IdType="pmc">PMC7878292</ArticleId>
            <ArticleId IdType="pubmed">33125859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8115290</ArticleId>
            <ArticleId IdType="pubmed">33139907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitt JM, Vetizou M, Gomperts Boneca I, Lepage P, Chamaillard M, Zitvogel L. Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. Oncoimmunology. 2017;6(1):e1132137. doi: 10.1080/2162402X.2015.1132137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2015.1132137</ArticleId>
            <ArticleId IdType="pmc">PMC5283646</ArticleId>
            <ArticleId IdType="pubmed">28197360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368&#x2013;1379. doi: 10.1093/annonc/mdx108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx108</ArticleId>
            <ArticleId IdType="pubmed">28368458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sears CL, Pardoll DM. The intestinal microbiome influences checkpoint blockade. Nat Med. 2018;24(3):254&#x2013;255. doi: 10.1038/nm.4511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4511</ArticleId>
            <ArticleId IdType="pmc">PMC6435254</ArticleId>
            <ArticleId IdType="pubmed">29509750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268&#x2013;1273. doi: 10.1126/science.1223490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1223490</ArticleId>
            <ArticleId IdType="pmc">PMC4420145</ArticleId>
            <ArticleId IdType="pubmed">22674334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe. 2012;12(4):496&#x2013;508. doi: 10.1016/j.chom.2012.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2012.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC3516493</ArticleId>
            <ArticleId IdType="pubmed">23084918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Berard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Dore J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971&#x2013;976. doi: 10.1126/science.1240537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1240537</ArticleId>
            <ArticleId IdType="pmc">PMC4048947</ArticleId>
            <ArticleId IdType="pubmed">24264990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, Dai RM, Kiu H, Cardone M, Naik S, Patri AK, Wang E, Marincola FM, Frank KM, Belkaid Y, Trinchieri G, Goldszmid RS. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967&#x2013;970. doi: 10.1126/science.1240527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1240527</ArticleId>
            <ArticleId IdType="pmc">PMC6709532</ArticleId>
            <ArticleId IdType="pubmed">24264989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daillere R, Vetizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity. 2016;45(4):931&#x2013;943. doi: 10.1016/j.immuni.2016.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.09.009</ArticleId>
            <ArticleId IdType="pubmed">27717798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemente CG, Mihm MC, Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):1303&#x2013;1310. doi: 10.1002/(SICI)1097-0142(19960401)77:7&lt;1303::AID-CNCR12&gt;3.0.CO;2-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0142(19960401)77:7&lt;1303::AID-CNCR12&gt;3.0.CO;2-5</ArticleId>
            <ArticleId IdType="pubmed">8608507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203&#x2013;213. doi: 10.1056/NEJMoa020177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa020177</ArticleId>
            <ArticleId IdType="pubmed">12529460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D&#x2019;Angelica M, DeMatteo RP. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16(9):2524&#x2013;2530. doi: 10.1245/s10434-009-0585-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-009-0585-3</ArticleId>
            <ArticleId IdType="pubmed">19568816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jamiyan T, Kuroda H, Yamaguchi R, Nakazato Y, Noda S, Onozaki M, Abe A, Hayashi M. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast. Breast Cancer. 2020;27(5):880&#x2013;892. doi: 10.1007/s12282-020-01084-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12282-020-01084-1</ArticleId>
            <ArticleId IdType="pmc">PMC7438376</ArticleId>
            <ArticleId IdType="pubmed">32222891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271&#x2013;285. doi: 10.1038/nrc.2017.13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2017.13</ArticleId>
            <ArticleId IdType="pubmed">28303904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079&#x2013;1084. doi: 10.1126/science.aad1329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084&#x2013;1089. doi: 10.1126/science.aac4255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aac4255</ArticleId>
            <ArticleId IdType="pmc">PMC4873287</ArticleId>
            <ArticleId IdType="pubmed">26541606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97&#x2013;103. doi: 10.1126/science.aan4236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan4236</ArticleId>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91&#x2013;97. doi: 10.1126/science.aan3706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan3706</ArticleId>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104&#x2013;108. doi: 10.1126/science.aao3290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aao3290</ArticleId>
            <ArticleId IdType="pmc">PMC6707353</ArticleId>
            <ArticleId IdType="pubmed">29302014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, Shiota A, Takeshita K, Yasuma-Mitobe K, Riethmacher D, Kaisho T, Norman JM, Mucida D, Suematsu M, Yaguchi T, Bucci V, Inoue T, Kawakami Y, Olle B, Roberts B, Hattori M, Xavier RJ, Atarashi K, Honda K. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565(7741):600&#x2013;605. doi: 10.1038/s41586-019-0878-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-0878-z</ArticleId>
            <ArticleId IdType="pubmed">30675064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong SF, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Saut&#xe8;s-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549&#x2013;555. doi: 10.1038/s41586-019-1922-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1922-8</ArticleId>
            <ArticleId IdType="pubmed">31942075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costea PI, Zeller G, Sunagawa S, Pelletier E, Alberti A, Levenez F, Tramontano M, Driessen M, Hercog R, Jung FE, Kultima JR, Hayward MR, Coelho LP, Allen-Vercoe E, Bertrand L, Blaut M, Brown JRM, Carton T, Cools-Portier S, Daigneault M, Derrien M, Druesne A, de Vos WM, Finlay BB, Flint HJ, Guarner F, Hattori M, Heilig H, Luna RA, van Hylckama Vlieg J, Junick J, Klymiuk I, Langella P, le Chatelier E, Mai V, Manichanh C, Martin JC, Mery C, Morita H, O'Toole PW, Orvain C, Patil KR, Penders J, Persson S, Pons N, Popova M, Salonen A, Saulnier D, Scott KP, Singh B, Slezak K, Veiga P, Versalovic J, Zhao L, Zoetendal EG, Ehrlich SD, Dore J, Bork P. Towards standards for human fecal sample processing in metagenomic studies. Nat Biotechnol. 2017;35(11):1069&#x2013;1076. doi: 10.1038/nbt.3960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.3960</ArticleId>
            <ArticleId IdType="pubmed">28967887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf J, Song SJ, Kanbar J, Miller-Montgomery S, Heaton R, Mckay R, Patel SP, Swafford AD, Knight R. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579(7800):567&#x2013;574. doi: 10.1038/s41586-020-2095-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2095-1</ArticleId>
            <ArticleId IdType="pmc">PMC7500457</ArticleId>
            <ArticleId IdType="pubmed">32214244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tam V, Patel N, Turcotte M, Bosse Y, Pare G, Meyre D. Benefits and limitations of genome-wide association studies. Nat Rev Genet. 2019;20(8):467&#x2013;484. doi: 10.1038/s41576-019-0127-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41576-019-0127-1</ArticleId>
            <ArticleId IdType="pubmed">31068683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogino S, Nowak JA, Hamada T, Milner DA, Jr, Nishihara R. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol. 2019;14(1):83&#x2013;103. doi: 10.1146/annurev-pathmechdis-012418-012818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pathmechdis-012418-012818</ArticleId>
            <ArticleId IdType="pmc">PMC6345592</ArticleId>
            <ArticleId IdType="pubmed">30125150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DL, Li QY, Tan QY. Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2021;13(1):220&#x2013;231. doi: 10.21037/jtd-20-1953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jtd-20-1953</ArticleId>
            <ArticleId IdType="pmc">PMC7867843</ArticleId>
            <ArticleId IdType="pubmed">33569202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donnelly D, Bajaj S, Yu J, Hsu M, Balar A, Pavlick A, Weber J, Osman I, Zhong J. The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. J Immunother Cancer. 2019;7(1):222. doi: 10.1186/s40425-019-0699-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0699-5</ArticleId>
            <ArticleId IdType="pmc">PMC6700794</ArticleId>
            <ArticleId IdType="pubmed">31426863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamberti G, Andrini E, Sisi M, Federico AD, Ricciuti B. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. Future Oncol. 2020;16(23):1751&#x2013;1766. doi: 10.2217/fon-2020-0215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fon-2020-0215</ArticleId>
            <ArticleId IdType="pubmed">32539551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602&#x2013;609. doi: 10.1126/science.abb5920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abb5920</ArticleId>
            <ArticleId IdType="pubmed">33303685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595&#x2013;602. doi: 10.1126/science.abf3363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abf3363</ArticleId>
            <ArticleId IdType="pmc">PMC8097968</ArticleId>
            <ArticleId IdType="pubmed">33542131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437&#x2013;1444. doi: 10.1093/annonc/mdy103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy103</ArticleId>
            <ArticleId IdType="pmc">PMC6354674</ArticleId>
            <ArticleId IdType="pubmed">29617710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774&#x2013;1778. doi: 10.1001/jamaoncol.2019.2785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.2785</ArticleId>
            <ArticleId IdType="pmc">PMC6743060</ArticleId>
            <ArticleId IdType="pubmed">31513236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, Belanger K, Miller W, Jamal R, Letarte N, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8(4):e1568812. doi: 10.1080/2162402X.2019.1568812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2019.1568812</ArticleId>
            <ArticleId IdType="pmc">PMC6422373</ArticleId>
            <ArticleId IdType="pubmed">30906663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017;279(1):90&#x2013;105. doi: 10.1111/imr.12563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12563</ArticleId>
            <ArticleId IdType="pmc">PMC6026851</ArticleId>
            <ArticleId IdType="pubmed">28856737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, Chun H, Fanucchi M, Lim SH. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7(11):e1507670. doi: 10.1080/2162402X.2018.1507670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1507670</ArticleId>
            <ArticleId IdType="pmc">PMC6205076</ArticleId>
            <ArticleId IdType="pubmed">30377571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsikala-Vafea M, Belani N, Vieira K, Khan H, Farmakiotis D. Antibiotic use is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Int J Infect Dis. 2021;106:142&#x2013;154. doi: 10.1016/j.ijid.2021.03.063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2021.03.063</ArticleId>
            <ArticleId IdType="pubmed">33771672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169(4):570&#x2013;586. doi: 10.1016/j.cell.2017.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.04.004</ArticleId>
            <ArticleId IdType="pmc">PMC5648021</ArticleId>
            <ArticleId IdType="pubmed">28475890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223&#x2013;237. doi: 10.1038/s41575-019-0258-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41575-019-0258-z</ArticleId>
            <ArticleId IdType="pubmed">32076145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nomura M, Nagatomo R, Doi K, Shimizu J, Baba K, Saito T, Matsumoto S, Inoue K, Muto M. Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors. JAMA Netw Open. 2020;3(4):e202895. doi: 10.1001/jamanetworkopen.2020.2895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2020.2895</ArticleId>
            <ArticleId IdType="pmc">PMC7163404</ArticleId>
            <ArticleId IdType="pubmed">32297948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Botticelli A, Vernocchi P, Marini F, Quagliariello A, Cerbelli B, Reddel S, Del Chierico F, Di Pietro F, Giusti R, Tomassini A, et al. Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. J Transl Med. 2020;18(1):49. doi: 10.1186/s12967-020-02231-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-020-02231-0</ArticleId>
            <ArticleId IdType="pmc">PMC6998840</ArticleId>
            <ArticleId IdType="pubmed">32014010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix L, Woerther PL, Vozy A, Naigeon M, Nebot-Bral L, Desbois M, Simeone E, Mateus C, Boselli L, Grivel J, Soularue E, Lepage P, Carbonnel F, Ascierto PA, Robert C, Chaput N. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun. 2020;11(1):2168. doi: 10.1038/s41467-020-16079-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-16079-x</ArticleId>
            <ArticleId IdType="pmc">PMC7195489</ArticleId>
            <ArticleId IdType="pubmed">32358520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun. 2018;9(1):3294. doi: 10.1038/s41467-018-05470-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-05470-4</ArticleId>
            <ArticleId IdType="pmc">PMC6098093</ArticleId>
            <ArticleId IdType="pubmed">30120222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bosse D, Lalani AA, Gopal S, Jin C, Horak C, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019;10(1):4346. doi: 10.1038/s41467-019-12361-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-12361-9</ArticleId>
            <ArticleId IdType="pmc">PMC6761178</ArticleId>
            <ArticleId IdType="pubmed">31554815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karayama M, Masuda J, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suda T, Maekawa M, Sugimura H, Takada A. Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. Clin Transl Oncol. 2021;23(2):418&#x2013;423. doi: 10.1007/s12094-020-02421-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-020-02421-8</ArticleId>
            <ArticleId IdType="pmc">PMC7854397</ArticleId>
            <ArticleId IdType="pubmed">32533317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, Paik S, Stagg J, Groves RA, Gallo M, Lewis IA, Geuking MB, McCoy KD. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020;369(6510):1481&#x2013;1489. doi: 10.1126/science.abc3421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abc3421</ArticleId>
            <ArticleId IdType="pubmed">32792462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kocher F, Amann A, Zimmer K, Geisler S, Fuchs D, Pichler R, Wolf D, Kurz K, Seeber A, Pircher A. High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC) Transl Lung Cancer Res. 2021;10(1):304&#x2013;313. doi: 10.21037/tlcr-20-380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/tlcr-20-380</ArticleId>
            <ArticleId IdType="pmc">PMC7867793</ArticleId>
            <ArticleId IdType="pubmed">33569314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pezo RC, Wong M, Martin A. Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. Ther Adv Gastroenterol. 2019;12:1756284819870911. doi: 10.1177/1756284819870911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756284819870911</ArticleId>
            <ArticleId IdType="pmc">PMC6747860</ArticleId>
            <ArticleId IdType="pubmed">31555343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol. 2019;37(30):2738&#x2013;2745. doi: 10.1200/JCO.19.00320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.00320</ArticleId>
            <ArticleId IdType="pmc">PMC6800279</ArticleId>
            <ArticleId IdType="pubmed">31163011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci U S A. 2018;115(1):157&#x2013;161. doi: 10.1073/pnas.1712901115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1712901115</ArticleId>
            <ArticleId IdType="pmc">PMC5776803</ArticleId>
            <ArticleId IdType="pubmed">29255057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, Pamer EG, Wolchok JD. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7(1):10391. doi: 10.1038/ncomms10391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10391</ArticleId>
            <ArticleId IdType="pmc">PMC4740747</ArticleId>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011;9(2):88&#x2013;96. doi: 10.1038/nrgastro.2011.244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2011.244</ArticleId>
            <ArticleId IdType="pubmed">22183182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407&#x2013;415. doi: 10.1056/NEJMoa1205037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1205037</ArticleId>
            <ArticleId IdType="pubmed">23323867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804&#x2013;1808. doi: 10.1038/s41591-018-0238-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0238-9</ArticleId>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bessell CA, Isser A, Havel JJ, Lee S, Bell DR, Hickey JW, et al. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight. 2020;5(8).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7205429</ArticleId>
            <ArticleId IdType="pubmed">32324171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45&#x2013;56. doi: 10.1038/s41586-019-1593-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1593-5</ArticleId>
            <ArticleId IdType="pubmed">31578484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2(18).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5621908</ArticleId>
            <ArticleId IdType="pubmed">28931759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Si W, Liang H, Bugno J, Xu Q, Ding X, Yang K, et al. Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2021:gutjnl-2020-323426. 10.1136/gutjnl-2020-323426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33685966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SSK, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJM, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577&#x2013;581. doi: 10.1038/nature13988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13988</ArticleId>
            <ArticleId IdType="pmc">PMC4279952</ArticleId>
            <ArticleId IdType="pubmed">25428507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433&#x2013;438. doi: 10.1038/nm.4051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4051</ArticleId>
            <ArticleId IdType="pmc">PMC7446107</ArticleId>
            <ArticleId IdType="pubmed">26901407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fluckiger A, Daillere R, Sassi M, Sixt BS, Liu P, Loos F, Richard C, Rabu C, Alou MT, Goubet AG, et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science. 2020;369(6506):936&#x2013;942. doi: 10.1126/science.aax0701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aax0701</ArticleId>
            <ArticleId IdType="pubmed">32820119</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34159488</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-2568</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>67</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Digestive diseases and sciences</Title>
          <ISOAbbreviation>Dig Dis Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor Colitis.</ArticleTitle>
        <Pagination>
          <StartPage>800</StartPage>
          <EndPage>803</EndPage>
          <MedlinePgn>800-803</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-021-07100-4</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Wendy</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA. wendyzhou16@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frye</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soroudi</LastName>
            <ForeName>Camille</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Triadafilopoulos</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berry</LastName>
            <ForeName>Rani</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Dig Dis Sci</MedlineTA>
        <NlmUniqueID>7902782</NlmUniqueID>
        <ISSNLinking>0163-2116</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="Y">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>7</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34159488</ArticleId>
        <ArticleId IdType="doi">10.1007/s10620-021-07100-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s10620-021-07100-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.&#xa0;Scientifica. 2013;2013:857519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/857519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis.&#xa0;Am J Gastroenterol. 2020;115:202&#x2013;210.</Citation>
        </Reference>
        <Reference>
          <Citation>Pezo RC, Wong M, Martin A. Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities.&#xa0;Ther Adv&#xa0;Gastroenterol. 2019;12:1&#x2013;10.</Citation>
        </Reference>
        <Reference>
          <Citation>Menon T, Afzali A. Immune-mediated colitis. Curr Treat Options Gastroenterol. 2019;17:506&#x2013;523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11938-019-00263-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeRoche TC, Xiao S-Y, Liu X. Histological evaluation in ulcerative colitis. Gastroenterol Rep. 2014;2:178&#x2013;192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/gastro/gou031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain A, Lipson EJ, Sharfman WH, Brant SR, Lazarev MG. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol. 2017;23:2023&#x2013;2028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v23.i11.2023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0461-4</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34158318</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e002567</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2021-002567</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS">The risk of use of immune-mediated diarrhea and colitis (imDC) in patients with preexisting inflammatory bowel disease (IBD) is not fully understood. We report the incidence of imDC in these patients, and compare with a matched cohort of patients with cancer and without IBD.</AbstractText>
          <AbstractText Label="METHODS">Patients with IBD from a tertiary center cancer registry who underwent immune checkpoint inhibitor (ICI) therapy from 2011 to 2019 were identified. A 1:5 matched cohort of patients with and without a history of IBD was created, based on age, ICI therapy, and cancer type. Demographic data, clinical history of IBD, cancer, ICI agent, imDC events after ICI therapy, and overall survival were analyzed. Overall survival and time-to-imDC (TTimDC) were estimated by Kaplan-Meier and multivariate Cox proportional-hazards models.</AbstractText>
          <AbstractText Label="RESULTS">From a retrospective cohort of 3900 patients who received ICI therapy, 30 patients with IBD were matched with 150 patients without a history of IBD. Most patients received PD-1/PD-L1 inhibitor monotherapy (154/180, 85.6%). Individuals with preexisting IBD showed significantly shorter TTimDC than those in the non-IBD group (1-year imDC-free rate 67% vs 93%; HR 7.59, 95%&#x2009;CI 3.00 to 19.15, p&lt;0.0001). Eleven (36%) from the IBD cohort experienced imDC events; none led to life-threatening conditions needing surgical interventions or death. Corticosteroids or biologics were needed in 8/11 (73%) patients, and discontinuation of therapy improved imDC in the remaining three. Half of patients required hospitalization. In contrast, no significant difference in overall survival was observed between IBD and non-IBD cohorts (HR 0.89, 95%&#x2009;CI 0.54 to 1.48). Both groups had overall comparable rates of other non-imDC immune-related adverse events.</AbstractText>
          <AbstractText Label="CONCLUSION">Patients with preexisting IBD had worse time-to-imDC than non-IBD matched controls, yet did not exhibit worse overall survival. While close monitoring of patients with preexisting IBD is warranted while on immunotherapy, this comorbidity should not preclude ICI therapy if clinically required.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sleiman</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-7390-5949</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Ravi</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Faisal</LastName>
            <ForeName>Muhammad Salman</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Philpott</LastName>
            <ForeName>Jessica</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Digestive Diseases &amp; Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Funchain</LastName>
            <ForeName>Pauline</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA FUNCHAP@ccf.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CTLA-4 antigen</Keyword>
        <Keyword MajorTopicYN="N">autoimmunity</Keyword>
        <Keyword MajorTopicYN="N">immunity</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">programmed cell death 1 receptor</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34158318</ArticleId>
        <ArticleId IdType="pmc">PMC8220461</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2021-002567</ArticleId>
        <ArticleId IdType="pii">jitc-2021-002567</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Khan F, Funchain P, Bennett A, et al. . How should we diagnose and manage checkpoint inhibitor-associated colitis? Cleve Clin J Med 2018;85:679&#x2013;83. 10.3949/ccjm.85a.18020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3949/ccjm.85a.18020</ArticleId>
            <ArticleId IdType="pubmed">30192732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins M, Michot JM, Danlos FX, et al. . Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017;28:2860&#x2013;5. 10.1093/annonc/mdx403</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx403</ArticleId>
            <ArticleId IdType="pubmed">29045560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shivaji UN, Jeffery L, Gui X, et al. . Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol 2019;12:175628481988419. 10.1177/1756284819884196</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756284819884196</ArticleId>
            <ArticleId IdType="pmc">PMC6831976</ArticleId>
            <ArticleId IdType="pubmed">31723355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonardi GC, Gainor JF, Altan M, et al. . Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 2018;36:1905&#x2013;12. 10.1200/JCO.2017.77.0305</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.0305</ArticleId>
            <ArticleId IdType="pmc">PMC6553840</ArticleId>
            <ArticleId IdType="pubmed">29746230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi FS, O'Day SJ, McDermott DF, et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711&#x2013;23. 10.1056/NEJMoa1003466</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, et al. . Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017;28:1368&#x2013;79. 10.1093/annonc/mdx108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx108</ArticleId>
            <ArticleId IdType="pubmed">28368458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prieux-Klotz C, Dior M, Damotte D, et al. . Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol 2017;12:301&#x2013;8. 10.1007/s11523-017-0495-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11523-017-0495-4</ArticleId>
            <ArticleId IdType="pubmed">28540478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trac B, Chen HH, Muhlbauer A. IpiColitis: ipilimumab-induced colitis with a wide spectrum of histological features. Am J Dig Dis 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Yanai S, Nakamura S, Kawasaki K, et al. . Immune checkpoint inhibitor-induced diarrhea: clinicopathological study of 11 patients. Dig Endosc 2020;32:616-620. 10.1111/den.13555</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/den.13555</ArticleId>
            <ArticleId IdType="pubmed">31595568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassol CA, Owen D, Kendra K, et al. . Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics. Histopathology 2020;77:240&#x2013;9. 10.1111/his.14115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.14115</ArticleId>
            <ArticleId IdType="pubmed">32298485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al. . Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 2018;168:121&#x2013;30. 10.7326/M17-2073</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M17-2073</ArticleId>
            <ArticleId IdType="pubmed">29297009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tison A, Qu&#xe9;r&#xe9; G, Misery L, et al. . Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol 2019;71:2100&#x2013;11. 10.1002/art.41068</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41068</ArticleId>
            <ArticleId IdType="pubmed">31379105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyi C, Carvajal RD, Wolchok JD, et al. . Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2014;2. 10.1186/s40425-014-0035-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-014-0035-z</ArticleId>
            <ArticleId IdType="pmc">PMC4207313</ArticleId>
            <ArticleId IdType="pubmed">25349698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Faleck DM, Ricciuti B, et al. . Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 2020;38:S450&#x2013;1. 10.14309/01.ajg.0000592636.29532.cc</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/01.ajg.0000592636.29532.cc</ArticleId>
            <ArticleId IdType="pmc">PMC7030892</ArticleId>
            <ArticleId IdType="pubmed">31800340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, et al. . Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017;66:581&#x2013;92. 10.1007/s00262-017-1962-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-1962-6</ArticleId>
            <ArticleId IdType="pmc">PMC5406433</ArticleId>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K&#xe4;hler KC, Eigentler TK, Gesierich A, et al. . Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother 2018;67:825&#x2013;34. 10.1007/s00262-018-2134-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2134-z</ArticleId>
            <ArticleId IdType="pubmed">29487980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Therapy Evaluation Program (CTEP) . Common terminology criteria for adverse events (CTCAE).v.5.0 [5x7], 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Dougan M, Wang Y, Rubio-Tapia A, et al. . AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 2021;160:1384&#x2013;93. 10.1053/j.gastro.2020.08.063</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.08.063</ArticleId>
            <ArticleId IdType="pubmed">33080231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burisch J, Jess T, Martinato M, et al. . The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322&#x2013;37. 10.1016/j.crohns.2013.01.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.crohns.2013.01.010</ArticleId>
            <ArticleId IdType="pubmed">23395397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies AM, Johnson DB, Ramanujam S, et al. . Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017;28:368&#x2013;76. 10.1093/annonc/mdw443</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw443</ArticleId>
            <ArticleId IdType="pubmed">27687304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Ruan AB, Srivoleti P, et al. . Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JCO Oncol Pract 2020;16:e933&#x2013;42. 10.1200/JOP.19.00672</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JOP.19.00672</ArticleId>
            <ArticleId IdType="pubmed">32401685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutzmer R, Koop A, Meier F, et al. . Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017;75:24&#x2013;32. 10.1016/j.ejca.2016.12.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2016.12.038</ArticleId>
            <ArticleId IdType="pubmed">28214654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danlos F-X, Voisin A-L, Dyevre V, et al. . Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 2018;91:21&#x2013;9. 10.1016/j.ejca.2017.12.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.12.008</ArticleId>
            <ArticleId IdType="pubmed">29331748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Naqash AR, et al. . Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 2019;37:2738&#x2013;45. 10.1200/JCO.19.00320</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.00320</ArticleId>
            <ArticleId IdType="pmc">PMC6800279</ArticleId>
            <ArticleId IdType="pubmed">31163011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreatos N, Roopkumar J, Khorana A, et al. . 197&#x2005;Survival outcomes and toxicity among patients treated with concomitant radiotherapy and immunotherapy for advanced melanoma: two faces of the abscopal effect? J Immunother Cancer 2020;8:A212&#x2013;A116. 10.1136/jitc-2020-SITC2020.0197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-SITC2020.0197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arbour KC, Mezquita L, Long N, et al. . Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non&#x2013;small-cell lung cancer. J Clin Oncol 2018;36:2872&#x2013;8. 10.1200/JCO.2018.79.0006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.79.0006</ArticleId>
            <ArticleId IdType="pubmed">30125216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horvat TZ, Adel NG, Dang T-O, et al. . Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193&#x2013;8. 10.1200/JCO.2015.60.8448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.60.8448</ArticleId>
            <ArticleId IdType="pmc">PMC5087335</ArticleId>
            <ArticleId IdType="pubmed">26282644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricciuti B, Dahlberg SE, Adeni A, et al. . Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol 2019;37:1927&#x2013;34. 10.1200/JCO.19.00189</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.00189</ArticleId>
            <ArticleId IdType="pubmed">31206316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, et al. . High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 2018;124:3706&#x2013;14. 10.1002/cncr.31629</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31629</ArticleId>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrelli F, Signorelli D, Ghidini M, et al. . Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers 2020;12. 10.3390/cancers12030546. [Epub ahead of print: 27 Feb 2020].</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12030546</ArticleId>
            <ArticleId IdType="pmc">PMC7139305</ArticleId>
            <ArticleId IdType="pubmed">32120803</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34147519</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-0012</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>161</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gastroenterology</Title>
          <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interferon-Gamma-Producing CD8[+] Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.</ArticleTitle>
        <Pagination>
          <StartPage>1229</StartPage>
          <EndPage>1244.e9</EndPage>
          <MedlinePgn>1229-1244.e9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2021.06.025</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(21)03139-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND &amp; AIMS">The pathogenesis of immune checkpoint inhibitor (ICI)-colitis remains incompletely understood. We sought to identify key cellular drivers of ICI-colitis and their similarities to idiopathic ulcerative colitis, and to determine potential novel therapeutic targets.</AbstractText>
          <AbstractText Label="METHODS">We used a cross-sectional approach to study patients with ICI-colitis, those receiving ICI without the development of colitis, idiopathic ulcerative colitis, and healthy controls. A subset of patients with ICI-colitis were studied longitudinally. We applied a range of methods, including multiparameter and spectral flow cytometry, spectral immunofluorescence microscopy, targeted gene panels, and bulk and single-cell RNA sequencing.</AbstractText>
          <AbstractText Label="RESULTS">We demonstrate CD8[+] tissue resident memory T (TRM) cells are the dominant activated T cell subset in ICI-colitis. The pattern of gastrointestinal immunopathology is distinct from ulcerative colitis at both the immune and epithelial-signaling levels. CD8[+] TRM cell activation correlates with clinical and endoscopic ICI-colitis severity. Single-cell RNA sequencing analysis confirms activated CD8[+] TRM cells express high levels of transcripts for checkpoint inhibitors and interferon-gamma in ICI-colitis. We demonstrate similar findings in both anti-CTLA-4/PD-1 combination therapy and in anti-PD-1 inhibitor-associated colitis. On the basis of our data, we successfully targeted this pathway in a patient with refractory ICI-colitis, using the JAK inhibitor tofacitinib.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Interferon gamma-producing CD8[+] TRM cells are a pathological hallmark of ICI-colitis and a novel target for therapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sasson</LastName>
            <ForeName>Sarah C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Slevin</LastName>
            <ForeName>Stephanie M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheung</LastName>
            <ForeName>Vincent T F</ForeName>
            <Initials>VTF</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nassiri</LastName>
            <ForeName>Isar</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olsson-Brown</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; The Clatterbridge Cancer Centre National Health Service Foundation Trust, Wirral, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fryer</LastName>
            <ForeName>Eve</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cellular Pathology, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferreira</LastName>
            <ForeName>Ricardo C</ForeName>
            <Initials>RC</Initials>
            <AffiliationInfo>
              <Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trzupek</LastName>
            <ForeName>Dominik</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Tarun</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Hillawi</LastName>
            <ForeName>Lulia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Issaias</LastName>
            <ForeName>Mari-Lenna</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Easton</LastName>
            <ForeName>Alistair</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cellular Pathology, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Campo</LastName>
            <ForeName>Leticia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Histopathology Laboratory, Department of Oncology, University of Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>FitzPatrick</LastName>
            <ForeName>Michael E B</ForeName>
            <Initials>MEB</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adams</LastName>
            <ForeName>Joss</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Berkshire Cancer Centre, Royal Berkshire Hospital, Reading, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chitnis</LastName>
            <ForeName>Meenali</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Protheroe</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tuthill</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coupe</LastName>
            <ForeName>Nicholas</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simmons</LastName>
            <ForeName>Alison</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Payne</LastName>
            <ForeName>Miranda</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Middleton</LastName>
            <ForeName>Mark R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Travis</LastName>
            <ForeName>Simon P L</ForeName>
            <Initials>SPL</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>Oxford Inflammatory Bowel Disease Cohort Investigators</CollectiveName>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fairfax</LastName>
            <ForeName>Benjamin P</ForeName>
            <Initials>BP</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; Department of Oncology, University of Oxford and Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klenerman</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brain</LastName>
            <ForeName>Oliver</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom. Electronic address: oliver.brain@ouh.nhs.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MC_UU_00008/7</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MC_UU_12010/7</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>U19 AI082630</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>201488/Z/16/Z</GrantID>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MR/S036377/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>107212/A/15/Z</GrantID>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MC_PC_MR/S025952/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Gastroenterology</MedlineTA>
        <NlmUniqueID>0374630</NlmUniqueID>
        <ISSNLinking>0016-5085</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C556706">CTLA4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573415">IFNG protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>87LA6FU830</RegistryNumber>
          <NameOfSubstance UI="C479163">tofacitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Gastroenterology. 2021 Oct;161(4):1106-1108</RefSource>
          <PMID Version="1">34256056</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091246" MajorTopicYN="N">Memory T Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081246" MajorTopicYN="N">RNA-Seq</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Checkpoint Colitis</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy Colitis</Keyword>
        <Keyword MajorTopicYN="N">Tofacitinib</Keyword>
        <Keyword MajorTopicYN="N">Ulcerative Colitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>20</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34147519</ArticleId>
        <ArticleId IdType="pmc">PMC8527886</ArticleId>
        <ArticleId IdType="doi">10.1053/j.gastro.2021.06.025</ArticleId>
        <ArticleId IdType="pii">S0016-5085(21)03139-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Larkin J., Hodi F.S., Wolchok J.D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N&#xa0;Engl J Med. 2015;373:1270&#x2013;1271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26398076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung V.T.F., Gupta T., Olsson-Brown A. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer. 2020;123:207&#x2013;215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7374736</ArticleId>
            <ArticleId IdType="pubmed">32418993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D.Y., Salem J.E., Cohen J.V. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721&#x2013;1728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6440712</ArticleId>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer J.R., Lacchetti C., Schneider B.J. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J&#xa0;Clin Oncol. 2018;36:1714&#x2013;1768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H., Ali F.S., Wang X. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J&#xa0;Immunother Cancer. 2019;7:93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Wiesnoski D.H., Helmink B.A. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24:1804&#x2013;1808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6322556</ArticleId>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E., Lepage P., Colombel J.F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056&#x2013;2067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arriola E., Wheater M., Lopez M.A. Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. Oncoimmunology. 2016;5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5048766</ArticleId>
            <ArticleId IdType="pubmed">27757302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bamias G., Delladetsima I., Perdiki M. Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy. Cancer Invest. 2017;35:443&#x2013;455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28548891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasson S.C., Zaunders J.J., Nahar K. Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. Clin Exp Immunol. 2020;202:335&#x2013;352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7670140</ArticleId>
            <ArticleId IdType="pubmed">32734627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thome J.J., Yudanin N., Ohmura Y. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014;159:814&#x2013;828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4243051</ArticleId>
            <ArticleId IdType="pubmed">25417158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasson S.C., Gordon C.L., Christo S.N. Local heroes or villains: tissue-resident memory T cells in human health and disease. Cell Mol Immunol. 2020;17:113&#x2013;122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7000672</ArticleId>
            <ArticleId IdType="pubmed">31969685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheuk S., Schlums H., Gallais S&#xe9;r&#xe9;zal I. CD49a Expression defines tissue-resident CD8. Immunity. 2017;46:287&#x2013;300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5337619</ArticleId>
            <ArticleId IdType="pubmed">28214226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malik B.T., Byrne K.T., Vella J.L. Resident memory T cells in the skin mediate durable immunity to melanoma. Sci Immunol. 2017;2(10)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5525335</ArticleId>
            <ArticleId IdType="pubmed">28738020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S.L., Buzzai A., Rautela J. Tissue-resident memory CD8. Nature. 2019;565(7739):366&#x2013;371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30598548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganesan A.P., Clarke J., Wood O. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017;18:940&#x2013;950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6036910</ArticleId>
            <ArticleId IdType="pubmed">28628092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards J., Wilmott J.S., Madore J. CD103. Clin Cancer Res. 2018;24:3036&#x2013;3045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29599411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savas P., Virassamy B., Ye C. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24:986&#x2013;993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29942092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boddupalli C.S., Bar N., Kadaveru K. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight. 2016;1(21)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5161225</ArticleId>
            <ArticleId IdType="pubmed">28018970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke J., Panwar B., Madrigal A. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J&#xa0;Exp Med. 2019;216:2128&#x2013;2149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6719422</ArticleId>
            <ArticleId IdType="pubmed">31227543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luoma A.M., Suo S., Williams H.L. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182:655&#x2013;671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7415717</ArticleId>
            <ArticleId IdType="pubmed">32603654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K., Hudson M., Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. N&#xa0;Engl J Med. 2020;382:2374&#x2013;2375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32521140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishu S., Melia J., Sharfman W. Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. Gastroenterology. 2021;160:932&#x2013;934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33096100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rohart F., Gautier B., Singh A. mixOmics: An R package for 'omics feature selection and multiple data integration. PLoS Comput Biol. 2017;13(11)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5687754</ArticleId>
            <ArticleId IdType="pubmed">29099853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russo P.S.T., Ferreira G.R., Cardozo L.E. CEMiTool: a Bioconductor package for performing comprehensive modular co-expression analyses. BMC Bioinformatics. 2018;19(1):56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5819234</ArticleId>
            <ArticleId IdType="pubmed">29458351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberzon A., Birger C., Thorvaldsd&#xf3;ttir H. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417&#x2013;425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4707969</ArticleId>
            <ArticleId IdType="pubmed">26771021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oughtred R., Stark C., Breitkreutz B.J. The BioGRID interaction database: 2019 update. Nucleic Acids Res. 2019;47(D1):D529&#x2013;D541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6324058</ArticleId>
            <ArticleId IdType="pubmed">30476227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang H.M., Subramaniam M., Targ S. Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. Nat Biotechnol. 2018;36:89&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5784859</ArticleId>
            <ArticleId IdType="pubmed">29227470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy D.J., Campbell K.R., Lun A.T. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics. 2017;33:1179&#x2013;1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5408845</ArticleId>
            <ArticleId IdType="pubmed">28088763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lun A.T., Bach K., Marioni J.C. Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome Biol. 2016;17:75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4848819</ArticleId>
            <ArticleId IdType="pubmed">27122128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber W., Carey V.J., Gentleman R. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015;12:115&#x2013;121. doi: 10.1038/nmeth.3252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.3252</ArticleId>
            <ArticleId IdType="pmc">PMC4509590</ArticleId>
            <ArticleId IdType="pubmed">25633503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lun A.T., McCarthy D.J., Marioni J.C. A&#xa0;step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res. 2016;5:2122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5112579</ArticleId>
            <ArticleId IdType="pubmed">27909575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahlin J.S., Hamey F.K., Pijuan-Sala B. A&#xa0;single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice. Blood. 2018;131(21):e1&#x2013;e11. doi: 10.1182/blood-2017-12-821413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2017-12-821413</ArticleId>
            <ArticleId IdType="pmc">PMC5969381</ArticleId>
            <ArticleId IdType="pubmed">29588278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aibar S., Gonz&#xe1;lez-Blas C.B., Moerman T. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14:1083&#x2013;1086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5937676</ArticleId>
            <ArticleId IdType="pubmed">28991892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mease P., Charles-Schoeman C., Cohen S. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79:1400&#x2013;1413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7569391</ArticleId>
            <ArticleId IdType="pubmed">32759265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dighe A.S., Richards E., Old L.J. Enhanced in&#xa0;vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1:447&#x2013;456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7895156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan D.H., Shankaran V., Dighe A.S. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998;95:7556&#x2013;7561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC22681</ArticleId>
            <ArticleId IdType="pubmed">9636188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards J., Wilmott J.S., Madore J. CD103(+) Tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-na&#xef;ve melanoma patients and expand significantly during anti-PD-1 treatment. Clin Cancer Res. 2018;24:3036&#x2013;3045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29599411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi L.Z., Fu T., Guan B. Interdependent IL-7 and IFN-gamma signalling in T-cell controls tumour eradication by combined alpha-CTLA-4+alpha-PD-1 therapy. Nat Commun. 2016;7:12335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4979067</ArticleId>
            <ArticleId IdType="pubmed">27498556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grasso C.S., Tsoi J., Onyshchenko M. Conserved interferon-gamma signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell. 2020;38:500&#x2013;515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7872287</ArticleId>
            <ArticleId IdType="pubmed">32916126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J., Shi L.Z., Zhao H. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167:397&#x2013;404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5088716</ArticleId>
            <ArticleId IdType="pubmed">27667683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaretsky J.M., Garcia-Diaz A., Shin D.S. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N&#xa0;Engl J Med. 2016;375:819&#x2013;829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5007206</ArticleId>
            <ArticleId IdType="pubmed">27433843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manguso R.T., Pope H.W., Zimmer M.D. In&#xa0;vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413&#x2013;418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5924693</ArticleId>
            <ArticleId IdType="pubmed">28723893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sade-Feldman M., Yizhak K., Bjorgaard S.L. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175:998&#x2013;1013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6641984</ArticleId>
            <ArticleId IdType="pubmed">30388456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalbasi A., Tariveranmoshabad M., Hakimi K. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci Transl Med. 2020;12(565)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8053376</ArticleId>
            <ArticleId IdType="pubmed">33055240</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
      <ReferenceList>
        <Title>Supplementary References</Title>
        <Reference>
          <Citation>Trzupek D., Dunstan M., Cutler A.J. Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. Genome Med. 2020;12:55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7315544</ArticleId>
            <ArticleId IdType="pubmed">32580776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy D.J., Campbell K.R., Lun A.T. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics. 2017;33:1179&#x2013;1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5408845</ArticleId>
            <ArticleId IdType="pubmed">28088763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber W., Carey V.J., Gentleman R. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015;12:115&#x2013;121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509590</ArticleId>
            <ArticleId IdType="pubmed">25633503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lun A.T., McCarthy D.J., Marioni J.C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res. 2016;5:2122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5112579</ArticleId>
            <ArticleId IdType="pubmed">27909575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuart T., Butler A., Hoffman P. Comprehensive integration of single-cell data. Cell. 2019;177:1888&#x2013;1902.e21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6687398</ArticleId>
            <ArticleId IdType="pubmed">31178118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almeida A., Loy A., Hofmann H. ggplot2 Compatible quantile-quantile plots in R. R J. 2018;10:248&#x2013;261.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34107499</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1537-453X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of clinical oncology</Title>
          <ISOAbbreviation>Am J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.</ArticleTitle>
        <Pagination>
          <StartPage>402</StartPage>
          <EndPage>408</EndPage>
          <MedlinePgn>402-408</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/COC.0000000000000841</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND OBJECTIVE">Immune-mediated diarrhea and colitis (IMDC) is a common adverse event in cancer patients receiving immune checkpoint inhibitors (ICIs). Gastrointestinal (GI) infections can co-occur with IMDC, and its impact on the course and outcome of IMDC remains unclear.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS">We retrospectively reviewed cancer patients who received ICIs and developed IMDC between January 2015 and September 2019. GI multiplex panel is used to assess GI infection. The study group included patients with positive infection except those who are only positive for Clostridioides difficile or cytomegalovirus. The control group is IMDC patients with negative infection using frequency matching. Patients' disease course and outcome were compared between groups.</AbstractText>
          <AbstractText Label="RESULTS">A total of 72 patients with IMDC were included: 22 in the study group and 50 as control. Escherichia coli of different pathotypes was observed in 17 patients. Five patients had viral infections, for example, adenovirus, norovirus, and sapovirus. Patients with GI infections more frequently had grade 3 or 4 colitis (43% vs. 18%, P=0.041). Overall, GI infections were not associated with different risks of IMDC recurrence or overall survival. Antibiotics treatment did not affect the requirement for infliximab or vedolizumab but relate to a higher risk of IMDC recurrence (50.0% vs. 0.0%, P=0.015).</AbstractText>
          <AbstractText Label="CONCLUSIONS">In our study, concomitant GI infections are associated with more severe symptoms in IMDC patients. Antimicrobial treatment did not circumvent the need for immunosuppressive therapy for IMDC or improve the clinical outcome. Concomitant GI infection was not associated with a higher risk of IMDC recurrence or poor overall survival.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Weijie</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departments of Gastroenterology, Hepatology, and Nutrition.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Zimu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Saint Joseph Hospital, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abu-Sbeih</LastName>
            <ForeName>Hamzah</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, University of Missouri, Kansas City, MO.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Yuanzun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biosciences, Rice University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Frederick</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Baylor College of Medicine, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Fangwen</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departments of Gastroenterology, Hepatology, and Nutrition.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Charabaty</LastName>
            <ForeName>Aline</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Sibley Memorial Hospital, Johns Hopkins University, Washington, DC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Okhuysen</LastName>
            <ForeName>Pablo C</ForeName>
            <Initials>PC</Initials>
            <AffiliationInfo>
              <Affiliation>Infectious Diseases, Infection Control, and Employee Health.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McQuade</LastName>
            <ForeName>Jennifer L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Melanoma Medical Oncology.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Altan</LastName>
            <ForeName>Mehmet</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Thoracic/Head &amp; Neck Medical Oncology, The University of Texas MD Anderson Cancer Center.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hao Chi</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Gastroenterology, Hepatology, and Nutrition.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>Anusha S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Gastroenterology, Hepatology, and Nutrition.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yinghong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Gastroenterology, Hepatology, and Nutrition.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Clin Oncol</MedlineTA>
        <NlmUniqueID>8207754</NlmUniqueID>
        <ISSNLinking>0277-3732</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003015" MajorTopicYN="N">Clostridium Infections</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004927" MajorTopicYN="N">Escherichia coli Infections</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>9</Day>
          <Hour>20</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34107499</ArticleId>
        <ArticleId IdType="doi">10.1097/COC.0000000000000841</ArticleId>
        <ArticleId IdType="pii">00000421-202108000-00004</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, et al. Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377&#x2013;2385.</Citation>
        </Reference>
        <Reference>
          <Citation>Williams MD, Braun LA, Cooper LM, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004;8:R291&#x2013;R298.</Citation>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714.</Citation>
        </Reference>
        <Reference>
          <Citation>Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.</Citation>
        </Reference>
        <Reference>
          <Citation>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65:e45&#x2013;e80.</Citation>
        </Reference>
        <Reference>
          <Citation>Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775&#x2013;778.</Citation>
        </Reference>
        <Reference>
          <Citation>Khan RR, Lawson AD, Minnich LL, et al. Gastrointestinal norovirus infection associated with exacerbation of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:328&#x2013;333.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang S-L, Wang Z-R, Yang C-Q. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012;4:1051&#x2013;1056.</Citation>
        </Reference>
        <Reference>
          <Citation>Nitzan O, Elias M, Peretz A, et al. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol. 2016;22:1078.</Citation>
        </Reference>
        <Reference>
          <Citation>Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352:544&#x2013;545.</Citation>
        </Reference>
        <Reference>
          <Citation>Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437&#x2013;1444.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Herrera LN, Tang T, et al. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer. 2019;7:242.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24:1804&#x2013;1808.</Citation>
        </Reference>
        <Reference>
          <Citation>Baruch EN, Youngster I, Ortenberg R, et al. Abstract CT042: Fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 therapy in refractory metastatic melanoma patients&#x2014;preliminary results from a phase I clinical trial (NCT03353402). Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Bennett SR, Carbone FR, Karamalis F, et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med. 1997;186:65&#x2013;70.</Citation>
        </Reference>
        <Reference>
          <Citation>June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles&#x2019; heel of cancer immunotherapy? Nat Med. 2017;23:540&#x2013;547.</Citation>
        </Reference>
        <Reference>
          <Citation>Yalamanchili H, Dandachi D, Okhuysen PC. Use and interpretation of enteropathogen multiplex nucleic acid amplification tests in patients with suspected infectious diarrhea. Gastroenterol Hepatol (N Y). 2018;14:646.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34106395</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1865-7265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical journal of gastroenterology</Title>
          <ISOAbbreviation>Clin J Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis.</ArticleTitle>
        <Pagination>
          <StartPage>1431</StartPage>
          <EndPage>1436</EndPage>
          <MedlinePgn>1431-1436</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12328-021-01459-7</ELocationID>
        <Abstract>
          <AbstractText>A man in his 70s received anticancer chemotherapy with the anti-programmed cell death protein-ligand 1 antibody atezolizumab for non-small cell lung cancer. Ten days later, he developed diarrhea and skin rash, which were suspected to be due to immune-related adverse events, and was treated with prednisolone for 2 weeks. Five weeks after atezolizumab administration, he was admitted to our hospital for Common Terminology Criteria for Adverse Events Grade 3 diarrhea and hematochezia. Sigmoidoscopy revealed a dark red color in the mucosa of the transverse colon and multiple whitish mucosal plaques extending from the transverse colon to the rectum. Biopsy specimens revealed empty vacuoles in the lamina propria with infiltration of numerous inflammatory cells, including CD8[+] T cells. Based on the findings of sigmoidoscopy and histology, the diagnosis was immune checkpoint inhibitor-related colitis with colonic pseudolipomatosis. The endoscopic findings and symptoms were markedly improved by prednisolone administration. We herein report the first case of immune checkpoint inhibitor-related colitis with characteristic endoscopic findings of colonic pseudolipomatosis. It is important to perform endoscopy and histological evaluation to determine the differential diagnosis and treatment strategy for patients treated with immune checkpoint inhibitors.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. Japanese Society of Gastroenterology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Naito</LastName>
            <ForeName>Tatsushi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nosaka</LastName>
            <ForeName>Takuto</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Kazuto</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ofuji</LastName>
            <ForeName>Kazuya</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuda</LastName>
            <ForeName>Hidetaka</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohtani</LastName>
            <ForeName>Masahiro</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hiramatsu</LastName>
            <ForeName>Katsushi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imamura</LastName>
            <ForeName>Yoshiaki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Diagnostic Pathology/Surgical Pathology, University of Fukui Hospital, Fukui, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishizuka</LastName>
            <ForeName>Tamotsu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamoto</LastName>
            <ForeName>Yasunari</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-3160-3555</Identifier>
            <AffiliationInfo>
              <Affiliation>Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan. nakamoto-med2@med.u-fukui.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>JP21fk0210077</GrantID>
            <Agency>Japan Agency for Medical Research and Development</Agency>
          </Grant>
          <Grant>
            <GrantID>JP21fk0210047</GrantID>
            <Agency>Japan Agency for Medical Research and Development</Agency>
          </Grant>
          <Grant>
            <GrantID>JP21fk0210058</GrantID>
            <Agency>Japan Agency for Medical Research and Development</Agency>
          </Grant>
          <Grant>
            <GrantID>20K17018</GrantID>
            <Agency>Japan Society for the Promotion of Science</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Clin J Gastroenterol</MedlineTA>
        <NlmUniqueID>101477246</NlmUniqueID>
        <ISSNLinking>1865-7265</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004724" MajorTopicYN="N">Endoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atezolizumab</Keyword>
        <Keyword MajorTopicYN="N">Colonic pseudolipomatosis</Keyword>
        <Keyword MajorTopicYN="N">Immune check point inhibitor-related colitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34106395</ArticleId>
        <ArticleId IdType="doi">10.1007/s12328-021-01459-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s12328-021-01459-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflam Bowel Dis. 2018;24:1695&#x2013;705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foppen MHG, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: endoscopic and pathologic findings. World J Gastrointest Pathophysiol. 2019;10:17&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4291/wjgp.v10.i2.17</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snover DC, Sandstad J, Hutton S. Mucosal pseudolipomatosis of the colon. Am J Clin Pathol. 1985;84:575&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ajcp/84.5.575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ers&#xf6;z F, Toros AB, &#xc7;akar E, et al. Colonic mucosal pseudolipomatosis: are we aware of it? Ulus Cerrahi Derg. 2016;32:90&#x2013;2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27436930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea colitis patients adv malig retrospective review at md anderson. J Immunother Cancer. 2018;6:37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0346-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases. 2019;7:405&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12998/wjcc.v7.i4.405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018;472:125&#x2013;33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-017-2267-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis. 2017;11:1238&#x2013;46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjx081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burla J, Bluemel S, Biedermann L, et al. Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course. Inflamm Intest Dis. 2020;5:109&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000507579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung VTF, Gupta T, Olsson-Brown A, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: Can IBD scoring point the way? Br J Cancer. 2020;123:207&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-020-0882-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright AP, Piper MS, Bishu S, et al. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Systematic Review And Case Series. Aliment Pharmacol Ther. 2019;49:1474&#x2013;83</Citation>
        </Reference>
        <Reference>
          <Citation>Gallo A, Talerico R, Novello L, et al. Collagenous colitis and atezolizumab therapy: an atypical case. Clin J Gastroenterol. 2021;14:165&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12328-020-01276-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magalh&#xe3;es MJ, Coelho A, Salgado M, et al. A rare case of colonic pseudolipomatosis. Ann Gastroenterol. 2015;28:146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25608576</ArticleId>
            <ArticleId IdType="pmc">4289991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwamuro M, Tanaka T, Kawabata T, et al. Pseudolipomatosis of the colon and cecum followed by pneumatosis intestinalis. Intern Med. 2018;57:2501&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.0730-17</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gagliardi G, Thompson IW, Hershman MJ, et al. Pneumatosis coli: a proposed pathogenesis based on study of 25 cases and review of the literature. Int J Colorectal Dis. 1996;11:111&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s003840050031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cammarota G, Cesaro P, Cazzato A, et al. Hydrogen peroxide-related colitis (previously known as &#x201c;pseudolipomatosis&#x201d;): a series of cases occurring in an epidemic pattern. Endoscopy. 2007;39:916&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2007-966652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang T, Abu-Sbeih H, Ma W, et al. Gastrointestinal injury related to antiangiogenesis cancer therapy. Clin Colorectal Cancer. 2020; 19:e117&#x2013;23</Citation>
        </Reference>
        <Reference>
          <Citation>Kunzmann S, Ngyuen T, Stahl A, et al. Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti&#x2014;a case report. BMC Pediatr. 2019;19:353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12887-019-1732-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baandrup L, Hauggaard A, Winberg BH, et al. Neutropenic enterocolitis during first-line chemotherapy with carboplatin and etoposide in small cell lung cancer. Acta Oncol. 2011;50:465&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/0284186X.2010.498430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masciullo V, Mainenti S, Lorusso D, et al. Lethal Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy in ovarian carcinoma: Case report and review of the literature. Obstet Gynecol Int. 2010;2010:749789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20706661</ArticleId>
            <ArticleId IdType="pmc">2913858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinagare AB, Howard SA, Krajewski KM, et al. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol. 2012;199:1259&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/AJR.12.8782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asmis TR, Chung KY, Teitcher JB, et al. Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs. 2008;26:95&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10637-007-9094-z</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34081152</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1084</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>European radiology</Title>
          <ISOAbbreviation>Eur Radiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis.</ArticleTitle>
        <Pagination>
          <StartPage>8868</StartPage>
          <EndPage>8878</EndPage>
          <MedlinePgn>8868-8878</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00330-021-07925-7</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to assess MDCT as a diagnostic and prognostic tool in patients with suspected immune checkpoint inhibitor (ICI)-related colitis.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This retrospective cohort study included patients receiving ICIs at three hospitals between 2015 and 2019 who underwent both abdominopelvic MDCT and endoscopic biopsy to workup suspected ICI-related colitis. Two radiologists independently reviewed MDCT images for signs of colitis based on pre-defined features. Diagnostic performance of MDCT was calculated and categorical variables between treatment subgroups were compared. Logistic regression was used to develop proposed MDCT criteria for diagnosis and MDCT severity score based on a combination of MDCT features of colitis to predict the patient outcomes in ICI-related colitis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 118 MDCT scans from 108 patients were evaluated for suspected colitis, with 72 confirmed ICI-related colitis cases. Sensitivity, specificity, PPV, and NPV of MDCT for diagnosis of ICI-related colitis was 81% (58/72), 52 % (24/46), 73% (58/80), and 63% (24/38), respectively. Small bowel involvement was visualized in 25% of cases with ICI-related colitis (18/72). In melanoma patients presenting with diarrhea grade &#x2265; 2 (n&#xa0;=&#xa0;40), MDCT had the best diagnostic performance for ICI-related colitis (specificity&#xa0;=&#xa0;80% [8/10], PPV&#xa0;=&#xa0;92% [23/25]). MDCT severity scores predicted intravenous steroid use (OR 10.3, p = 0.004), length of stay &gt; 7 days (OR 9.0, p &lt; 0.001), and endoscopic mucosal ulceration (OR 4.7, p = 0.02).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MDCT is a useful diagnostic and prognostic tool for evaluating patients with immune checkpoint inhibitor-related colitis. An MDCT-based severity score enables assessment of disease severity and predicts outcome.</AbstractText>
          <AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">&#x2022; MDCT is useful for the diagnosis of colitis in patients receiving immune checkpoint inhibitor (ICI) therapy, and an MDCT-based severity score allows for prognostication of patient outcomes. &#x2022; MDCT yielded moderate sensitivity (81%) for diagnosis of ICI-related colitis but limited specificity (52%). However, in symptomatic melanoma patients (grade 2-4 diarrhea) with a high pretest probability, MDCT proved useful for diagnosis with a high PPV (92%). &#x2022; For ICI-related colitis, our proposed MDCT severity score has prognostic value in predicting intravenous steroid use, prolonged length of stay during inpatient admission (&gt; 7 days), and endoscopic mucosal ulceration.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. European Society of Radiology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pisuchpen</LastName>
            <ForeName>Nisanard</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durbin</LastName>
            <ForeName>Sienna M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mooradian</LastName>
            <ForeName>Meghan J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fintelmann</LastName>
            <ForeName>Florian J</ForeName>
            <Initials>FJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reynolds</LastName>
            <ForeName>Kerry L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dougan</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kambadakone</LastName>
            <ForeName>Avinash</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-6714-9190</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA. akambadakone@mgh.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 DK114563</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Eur Radiol</MedlineTA>
        <NlmUniqueID>9114774</NlmUniqueID>
        <ISSNLinking>0938-7994</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014054" MajorTopicYN="N">Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Multi-detector computed tomography</Keyword>
        <Keyword MajorTopicYN="N">Prognosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>3</Day>
          <Hour>12</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34081152</ArticleId>
        <ArticleId IdType="doi">10.1007/s00330-021-07925-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s00330-021-07925-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel):12. https://doi.org/10.3390/cancers12030738</Citation>
        </Reference>
        <Reference>
          <Citation>Zubiri L, Allen IM, Taylor MS et al (2020) Immune-related adverse events in the setting of PD-1/L1 inhibitor combination therapy. Oncologist 25:e398&#x2013;e404</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300&#x2013;5309</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158&#x2013;168</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35:424&#x2013;437</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/rg.352140121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishino M, Hatabu H, Hodi FS (2019) Imaging of cancer immunotherapy: current approaches and future directions. Radiology 290:9&#x2013;22</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.2018181349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi FS, O&#x2019;Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711&#x2013;723</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishijima TF, Muss HB, Shachar SS, Moschos SJ (2016) Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev 45:30&#x2013;37</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2016.02.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13:273&#x2013;290</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2016.25</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang GX, Kurra V, Gainor JF et al (2017) Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics 37:2132&#x2013;2144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/rg.2017170085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH (2019) Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol 40:511&#x2013;523</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2019.04.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M (2017) Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol 8:1547. https://doi.org/10.3389/fimmu.2017.01547</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01547</ArticleId>
            <ArticleId IdType="pubmed">29230210</ArticleId>
            <ArticleId IdType="pmc">5715331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M (2020) Gastrointestinal and hepatic complications of immunotherapy: current management and future perspectives. Curr Gastroenterol Rep 22:15. https://doi.org/10.1007/s11894-020-0752-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11894-020-0752-z</ArticleId>
            <ArticleId IdType="pubmed">32185493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida T, Iijima H, Adachi S (2019) Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World J Gastrointest Pathophysiol 10:17&#x2013;28</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4291/wjgp.v10.i2.17</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721&#x2013;1728</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.3923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E et al (2018) Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 24:1695&#x2013;1705</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Neuer M, Marmarelis ME, Jangi SR et al (2017) Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients. Cancer Immunol Res 5:286&#x2013;291</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KW, Ramaiya NH, Krajewski KM et al (2013) Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 200:W468&#x2013;W474</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/AJR.12.9751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA (2016) Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (NY) 41:207&#x2013;214</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00261-015-0560-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mooradian MJ, Wang DY, Coromilas A et al (2020) Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 8. https://doi.org/10.1136/jitc-2019-000451</Citation>
        </Reference>
        <Reference>
          <Citation>Lubner MG, Menias CO, Agrons M et al (2017) Imaging of abdominal and pelvic manifestations of graft-versus-host disease after hematopoietic stem cell transplant. AJR Am J Roentgenol 209:33&#x2013;45</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/AJR.17.17866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahgerefteh SY, Sosna J, Bogot N, Shapira MY, Pappo O, Bloom AI (2011) Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. Radiology 258:660&#x2013;671</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.10100025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoeni RF, Cello JP (2006) CT imaging of colitis. Radiology 240:623&#x2013;638</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.2403050818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philpotts LE, Heiken JP, Westcott MA, Gore RM (1994) Colitis: use of CT findings in differential diagnosis. Radiology 190:445&#x2013;449</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiology.190.2.8284397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balthazar EJ, Yen BC, Gordon RB (1999) Ischemic colitis: CT evaluation of 54 cases. Radiology 211:381&#x2013;388</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiology.211.2.r99ma28381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cruz C, Abujudeh HH, Nazarian RM, Thrall JH (2015) Ischemic colitis: spectrum of CT findings, sites of involvement and severity. Emerg Radiol 22:357&#x2013;365</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10140-015-1304-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel B, Mottola J, Sahni VA et al (2012) MDCT assessment of ulcerative colitis: radiologic analysis with clinical, endoscopic, and pathologic correlation. Abdom Imaging 37:61&#x2013;69</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00261-011-9741-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg HI, Gore RM, Margulis AR, Moss AA, Baker EL (1983) Computed tomography in the evaluation of Crohn disease. AJR Am J Roentgenol 140:277&#x2013;282</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/ajr.140.2.277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gore RM, Balthazar EJ, Ghahremani GG, Miller FH (1996) CT features of ulcerative colitis and Crohn&#x2019;s disease. AJR Am J Roentgenol 167:3&#x2013;15</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/ajr.167.1.8659415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tirumani SH, Ramaiya NH, Keraliya A et al (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3:1185&#x2013;1192</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shieh AC, Guler E, Pfau D et al (2019) Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. Abdom Radiol (NY). https://doi.org/10.1007/s00261-019-02334-3</Citation>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S et al (2018) Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3:e000278. https://doi.org/10.1136/esmoopen-2017-000278</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
            <ArticleId IdType="pmc">5786923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V (2020) Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 76:233&#x2013;243</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714&#x2013;1768</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.6385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y (2018) Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 6:95. https://doi.org/10.1186/s40425-018-0411-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0411-1</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
            <ArticleId IdType="pmc">6156850</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33906378</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1750-7448</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunotherapy</Title>
          <ISOAbbreviation>Immunotherapy</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy.</ArticleTitle>
        <Pagination>
          <StartPage>741</StartPage>
          <EndPage>744</EndPage>
          <MedlinePgn>741-744</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2217/imt-2020-0282</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors have been approved as adjuvant therapy. Adverse immune events occurred during the administration of treatment, and delayed immune-related events have low incidence. A 66-year-old man was treated for hypopharynx cancer in 2012. In 2019, he was treated for a new oropharynx cancer. After undergoing surgery and complete response, the patient received nivolumab as adjuvant treatment. 5 months after the last dose of nivolumab, he presented with grade III diarrhea and abdominal pain for 3 weeks. Rectoscopy showed infiltration of mucous by lymphocytes. Corticosteroid was started resulting in a rapid decrease in symptom severity. With the increasing immune checkpoint inhibitors in adjuvant therapy, strict surveillance and education of patient in remission is necessary.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Domblides</LastName>
            <ForeName>Charlotte</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Hpital Saint-Andr, CHU Bordeaux-University of Bordeaux, Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gross-Goupil</LastName>
            <ForeName>Marine</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Hpital Saint-Andr, CHU Bordeaux-University of Bordeaux, Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ravaud</LastName>
            <ForeName>Alain</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Hpital Saint-Andr, CHU Bordeaux-University of Bordeaux, Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Poullenot</LastName>
            <ForeName>Florian</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hpital Haut-Leveque, CHU Bordeaux-University of Bordeaux, Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daste</LastName>
            <ForeName>Amaury</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Hpital Saint-Andr, CHU Bordeaux-University of Bordeaux, Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Immunotherapy</MedlineTA>
        <NlmUniqueID>101485158</NlmUniqueID>
        <ISSNLinking>1750-743X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009959" MajorTopicYN="N">Oropharyngeal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="plain-language-summary" Language="eng">
        <AbstractText>Lay abstract Immune checkpoint inhibitors have changed the outcomes of several cancers and have been approved after local treatment for melanoma or lung cancer. The toxicities of this treatment were immune-related adverse events and any organ can be involved. Usually, toxicity occurred during the administration of treatment and delayed immune-related events have low incidence. Here, we presented a case report of a patient treated with anti-programmed cell death protein 1 after loco-regional treatment for head and neck cancer and presented with severe diarrhea 5 months after the last dose of treatment. Corticosteroid was started, resulting in a rapid decrease in symptom severity. With the increasing immune checkpoint inhibitors in adjuvant therapy, strict surveillance and education of patient in remission is necessary.</AbstractText>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">adjuvant setting</Keyword>
        <Keyword MajorTopicYN="N">anti PD-1</Keyword>
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">delayed immune-related events</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33906378</ArticleId>
        <ArticleId IdType="doi">10.2217/imt-2020-0282</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33882697</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1750-7448</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunotherapy</Title>
          <ISOAbbreviation>Immunotherapy</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long-term immune-related adverse events after discontinuation of immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>735</StartPage>
          <EndPage>740</EndPage>
          <MedlinePgn>735-740</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2217/imt-2020-0320</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors have revolutionized the treatment of various cancers but are notorious for their potential to cause severe side effects. While most side effects occur during ongoing therapy, an increasing number of reports of late onset have emerged. It is also not yet clear how long side effects can last. Resolution is achieved under symptomatic therapy, but the side effects may persist latently. We present a patient case with recurrence of colitis after closure of an ileostomy over 1 year after discontinuation of immune checkpoint inhibitor therapy with nivolumab and ipilimumab. To the best of our knowledge, no other case with severe colitis still lasting after more than a year of suspension of therapy has yet been reported.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Horisberger</LastName>
            <ForeName>Karoline</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-6143-6607</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery &amp; Transplantation, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Portenkirchner</LastName>
            <ForeName>Carmen</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-0667-8336</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery &amp; Transplantation, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rickenbacher</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery &amp; Transplantation, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Biedermann</LastName>
            <ForeName>Luc</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology &amp; Hepatology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gubler</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology &amp; Hepatology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turina</LastName>
            <ForeName>Matthias</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery &amp; Transplantation, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Immunotherapy</MedlineTA>
        <NlmUniqueID>101485158</NlmUniqueID>
        <ISSNLinking>1750-743X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="plain-language-summary" Language="eng">
        <AbstractText>Lay abstract Checkpoint inhibitors have revolutionized therapy for suitable cancers. However, they can cause side effects that are reminiscent of autoimmune diseases. While most adverse effects occur during ongoing therapy, there are increasing reports of late-onset adverse effects after discontinuation of therapy and of long-lasting adverse effects after discontinuation of treatment, which may remain latent even if symptom relief could be achieved by immunosuppression. We present a patient case with reappearance of a severe inflammation of the large bowel (colitis) after closure of an ostomy over 1 year after withdrawal of immune checkpoint inhibitor therapy. To the best of our knowledge, no other case with severe colitis still lasting after more than a year of suspension of therapy has yet been reported.</AbstractText>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">intestinal perforation</Keyword>
        <Keyword MajorTopicYN="N">irAE</Keyword>
        <Keyword MajorTopicYN="N">long-term adverse event</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33882697</ArticleId>
        <ArticleId IdType="doi">10.2217/imt-2020-0320</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33746162</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1349-7235</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>17</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Internal medicine (Tokyo, Japan)</Title>
          <ISOAbbreviation>Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metachronous Esophageal Ulcers after Immune-mediated Colitis Due to Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review.</ArticleTitle>
        <Pagination>
          <StartPage>2783</StartPage>
          <EndPage>2791</EndPage>
          <MedlinePgn>2783-2791</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.6606-20</ELocationID>
        <Abstract>
          <AbstractText>Although cases of gastrointestinal toxicity of pembrolizumab have been reported, cases of acute immune-mediated colitis accompanied with metachronous esophageal disorders (esophagitis and ulcer) are rare. We herein report a case of acute colitis and metachronous esophageal ulcers due to an immune-related adverse event following concomitant pembrolizumab chemotherapy for lung adenocarcinoma. To our knowledge, there have so far been no reports of cases in which both acute immune-mediated colitis and metachronous esophageal ulcers developed. We therefore report the details of this case along with a review of the pertinent literature.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ogawa</LastName>
            <ForeName>Soichiro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Center for Digestive Disease and Division of Endoscopy, University of Miyazaki Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawakami</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Center for Digestive Disease and Division of Endoscopy, University of Miyazaki Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suzuki</LastName>
            <ForeName>Sho</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuroki</LastName>
            <ForeName>Daisuke</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Center for Digestive Disease and Division of Endoscopy, University of Miyazaki Hospital, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uchiyama</LastName>
            <ForeName>Naomi</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Center for Digestive Disease and Division of Endoscopy, University of Miyazaki Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hatada</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Center for Digestive Disease and Division of Endoscopy, University of Miyazaki Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gi</LastName>
            <ForeName>Toshihiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pathophysiology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Yuichiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pathophysiology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Diagnostic Pathology, University of Miyazaki Hospital, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Intern Med</MedlineTA>
        <NlmUniqueID>9204241</NlmUniqueID>
        <ISSNLinking>0918-2918</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004935" MajorTopicYN="Y">Esophageal Diseases</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004941" MajorTopicYN="Y">Esophagitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014456" MajorTopicYN="N">Ulcer</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ICI</Keyword>
        <Keyword MajorTopicYN="N">immune-mediated colitis</Keyword>
        <Keyword MajorTopicYN="N">metachronous esophageal ulcer</Keyword>
        <Keyword MajorTopicYN="N">pembrolizumab</Keyword>
        <Keyword MajorTopicYN="N">steroid administration</Keyword>
      </KeywordList>
      <CoiStatement>The authors state that they have no Conflict of Interest (COI).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33746162</ArticleId>
        <ArticleId IdType="pmc">PMC8479207</ArticleId>
        <ArticleId IdType="doi">10.2169/internalmedicine.6606-20</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Simonaggio A, Michot JM, Voisin AL, et al. . Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5: 1310-1317, 2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6555478</ArticleId>
            <ArticleId IdType="pubmed">31169866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gettinger SN, Horn L, Gandhi L, et al. . Overall survival and long-term safety of Nivolmab (Anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33: 2004-2012, 2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4672027</ArticleId>
            <ArticleId IdType="pubmed">25897158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shivaji U, Jeffery L, Gui X, et al. . Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Ther Adv Gastoenterol 12: 1-15, 2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6831976</ArticleId>
            <ArticleId IdType="pubmed">31723355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, et al. . Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology 10: e1344805, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5665065</ArticleId>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, et al. . Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 67: 2056-2067, 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World J Gastrointest Pathol 10: 17-28, 2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6751508</ArticleId>
            <ArticleId IdType="pubmed">31559106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Yang JC, Atkins MB, et al. . Toxicities of immunotherapy for the practitioner. J Clin Oncol 33: 2092-2099, 2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4881375</ArticleId>
            <ArticleId IdType="pubmed">25918278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. . Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 24: 1695-1705, 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C, et al. . Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (Suppl): iv119-iv142, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, De Felice KM, Loftus EV Jr, et al. . Systemic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42: 406-417, 2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26079306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright AP, Piper MS, Bishu S, et al. . Systematic review and case series: Flexible sigmoidoscopy identifies most case of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 49: 1474-1483, 2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6637018</ArticleId>
            <ArticleId IdType="pubmed">31035308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E, et al. . Colon immune-related adverse events: anti-CTLA4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Coliti 11: 1238-1246, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28967957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foppen MHG, Rozeman EA, Wilpe SV, et al. . Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3: e000278, 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brand FZA, Suter N, Adam JP, et al. . Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J Immunno Cancer 6: 22, 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5857140</ArticleId>
            <ArticleId IdType="pubmed">29548299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zander T, Aebi S, Rast AC, et al. . Response to pembrolizumab in a patient with relapsing thymoma. J Thorac Oncol 11: e147-e149, 2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27498287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onuki T, Morita E, Sakamoto N, et al. . Severe upper gastrointestinal disorders in Pembrolizumab treated non-small cell lung cancer patient. Respirol Case Rep 6: e00334, 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5980602</ArticleId>
            <ArticleId IdType="pubmed">30065841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida S, Miyamoto S, Naruse H, et al. . Esophagitis in non-small cell lung carcinoma treatment caused by Pembrolizumab. Am J Gastroenterol 115: 13, 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31356230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Justin B, Todd D. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep 4: e57, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5404341</ArticleId>
            <ArticleId IdType="pubmed">28459081</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33741313</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2405-8025</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Trends in cancer</Title>
          <ISOAbbreviation>Trends Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>583</StartPage>
          <EndPage>593</EndPage>
          <MedlinePgn>583-593</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.trecan.2021.02.005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2405-8033(21)00060-1</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) have been a transformational advance in cancer therapy in the past decade. However, ICIs can produce immune-related adverse effects (irAEs), which can lead to both morbidity and premature termination of therapy. Recent studies suggest that the gut microbiota and its metabolites affect ICI efficacy and toxicity. Herein, we review such evidence in the context of ICI-induced colitis. In particular, the short-chain fatty acid butyrate, a microbial metabolite, has known protective effects on the intestine. We discuss how the use of dietary prebiotics, which can be metabolized by bacteria to produce butyrate, can be an intriguing new investigational approach to prevent ICI-associated colitis and lead to improved patient outcomes.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Amy E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Golob</LastName>
            <ForeName>Jonathan L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Infectious Disease, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmidt</LastName>
            <ForeName>Thomas M</ForeName>
            <Initials>TM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Infectious Disease, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA; Department of Ecology and Evolutionary Biology, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peltier</LastName>
            <ForeName>Daniel C</ForeName>
            <Initials>DC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lao</LastName>
            <ForeName>Christopher D</ForeName>
            <Initials>CD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address: clao@med.umich.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tewari</LastName>
            <ForeName>Muneesh</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address: mtewari@med.umich.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Trends Cancer</MedlineTA>
        <NlmUniqueID>101665956</NlmUniqueID>
        <ISSNLinking>2405-8025</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002087">Butyrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002087" MajorTopicYN="N">Butyrates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056692" MajorTopicYN="N">Prebiotics</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">butyrate</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">microbiome</Keyword>
        <Keyword MajorTopicYN="N">prebiotic</Keyword>
        <Keyword MajorTopicYN="N">resistant starch</Keyword>
        <Keyword MajorTopicYN="N">toxicity</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Interests No interests are declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>5</Hour>
          <Minute>56</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33741313</ArticleId>
        <ArticleId IdType="doi">10.1016/j.trecan.2021.02.005</ArticleId>
        <ArticleId IdType="pii">S2405-8033(21)00060-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33567198</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-4406</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>384</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>The New England journal of medicine</Title>
          <ISOAbbreviation>N Engl J Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>581</StartPage>
          <EndPage>583</EndPage>
          <MedlinePgn>581-583</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc2031717</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>Anusha S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>University of Texas M.D. Anderson Cancer Center, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Weijie</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Zhongnan Hospital, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yinghong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-5148-6130</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Texas M.D. Anderson Cancer Center, Houston, TX ywang59@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>N Engl J Med</MedlineTA>
        <NlmUniqueID>0255562</NlmUniqueID>
        <ISSNLinking>0028-4793</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053759">Interleukin-23</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>187348-17-0</RegistryNumber>
          <NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FU77B4U5Z0</RegistryNumber>
          <NameOfSubstance UI="D000069549">Ustekinumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053759" MajorTopicYN="N">Interleukin-23</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069549" MajorTopicYN="N">Ustekinumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>17</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33567198</ArticleId>
        <ArticleId IdType="doi">10.1056/NEJMc2031717</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33566423</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2036</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>53</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Alimentary pharmacology &amp; therapeutics</Title>
          <ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitory colitis. Authors' reply.</ArticleTitle>
        <Pagination>
          <StartPage>638</StartPage>
          <EndPage>639</EndPage>
          <MedlinePgn>638-639</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.16245</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pai</LastName>
            <ForeName>Rish K</ForeName>
            <Initials>RK</Initials>
            <Identifier Source="ORCID">0000-0002-2692-221X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine &amp; Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pai</LastName>
            <ForeName>Reetesh K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schaeffer</LastName>
            <ForeName>David F</ForeName>
            <Initials>DF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Won-Tak</ForeName>
            <Initials>WT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumarasinghe</LastName>
            <ForeName>Priyanthi</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomical Pathology, PathWest Laboratory Medicine and University of Western Australia, Perth, WA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Ian</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Envoi Specialist Pathologists, Brisbane, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lauwers</LastName>
            <ForeName>Gregory Y</ForeName>
            <Initials>GY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Henry L. Moffitt Cancer Center &amp; Research Institute, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016421">Editorial</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Aliment Pharmacol Ther</MedlineTA>
        <NlmUniqueID>8707234</NlmUniqueID>
        <ISSNLinking>0269-2813</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Aliment Pharmacol Ther. 2021 Jan;53(1):150-159</RefSource>
          <PMID Version="1">33146440</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Aliment Pharmacol Ther. 2021 Mar;53(5):636-637</RefSource>
          <PMID Version="1">33566405</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001691" MajorTopicYN="N">Biological Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33566423</ArticleId>
        <ArticleId IdType="doi">10.1111/apt.16245</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Buckle AD, Christensen B. Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitory colitis. Aliment Pharmacol Ther. 2021;53:636-637.</Citation>
        </Reference>
        <Reference>
          <Citation>Pai RK, Pai RK, Brown I, et al. The significance of histological activity measurements in immune checkpoint inhibitor colitis. Aliment Pharmacol Ther. 2021;53:150-159.</Citation>
        </Reference>
        <Reference>
          <Citation>Christensen B, Hanauer SB, Erlich J, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15:1557-1564.</Citation>
        </Reference>
        <Reference>
          <Citation>Pai RK, Hartman DJ, Rivers CR, et al. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18:2510-2517.e5.</Citation>
        </Reference>
        <Reference>
          <Citation>Cheung VTF, Gupta T, Olsson-Brown A, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer. 2020;123:207-215.</Citation>
        </Reference>
        <Reference>
          <Citation>Stahl E, Roda G, Dobbyn A, et al. Collagenous colitis is associated with HLA signature and shares genetic risks with other immune-mediated diseases. Gastroenterology. 2020;159:549-561.e8.</Citation>
        </Reference>
        <Reference>
          <Citation>Grover S, Srivastava A, Friedman S, et al. High prevalence of IBD-associated genetic variants in patients (pts) with immune checkpoint inhibitor (ICI) enteritis/colitis. J Clin Oncol. 2019;37:2582.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33566405</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2036</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>53</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Alimentary pharmacology &amp; therapeutics</Title>
          <ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitor colitis.</ArticleTitle>
        <Pagination>
          <StartPage>636</StartPage>
          <EndPage>637</EndPage>
          <MedlinePgn>636-637</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.16203</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Buckle</LastName>
            <ForeName>Andrew D</ForeName>
            <Initials>AD</Initials>
            <Identifier Source="ORCID">0000-0002-2180-0555</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Christensen</LastName>
            <ForeName>Britt</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-8746-4275</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016421">Editorial</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Aliment Pharmacol Ther</MedlineTA>
        <NlmUniqueID>8707234</NlmUniqueID>
        <ISSNLinking>0269-2813</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Aliment Pharmacol Ther. 2021 Jan;53(1):150-159</RefSource>
          <PMID Version="1">33146440</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Aliment Pharmacol Ther. 2021 Mar;53(5):638-639</RefSource>
          <PMID Version="1">33566423</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33566405</ArticleId>
        <ArticleId IdType="doi">10.1111/apt.16203</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Gong Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract. 2020;16:453-461.</Citation>
        </Reference>
        <Reference>
          <Citation>Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142.</Citation>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.</Citation>
        </Reference>
        <Reference>
          <Citation>Pai RK, Pai RK, Brown I, et al. The significance of histological activity measurements in immune checkpoint inhibitor colitis. Aliment Pharmacol Ther. 2021;53:150-159.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7:93.</Citation>
        </Reference>
        <Reference>
          <Citation>Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut. 2017;66:50-58.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33555016</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1943-7722</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>156</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of clinical pathology</Title>
          <ISOAbbreviation>Am J Clin Pathol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>214</StartPage>
          <EndPage>228</EndPage>
          <MedlinePgn>214-228</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/ajcp/aqaa217</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES">Checkpoint inhibitor (CPI)-associated colitis can limit therapy and has resemblance to inflammatory bowel disease (IBD). Studies exploring mechanistic similarities between these colitides are limited, yet therapeutic targets for either disorder could emerge from shared pathophysiology.</AbstractText>
          <AbstractText Label="METHODS">The morphology and inflammatory content of colonic biopsy specimens from anti-CTLA-4 and anti-PD-1/PD-L1 antibody-treated patients with CPI colitis were compared with initial biopsy specimens from patients with IBD. Predictors of the need for infliximab were sought in CPI patients.</AbstractText>
          <AbstractText Label="RESULTS">Biopsy specimens from CPI patients showed significantly lower chronicity scores and similar activity scores compared with patients with IBD. Anti-CTLA-4 and IBD groups showed equivalent CD8, CD4, PD-1, and PD-L1 expression, while FoxP3 scores were lower and CD68 scores were higher in anti-CTLA-4 compared with IBD biopsy specimens. Anti-PD-1/PD-L1 group had lower scores for CD8, CD4, and PD-1 and equivalent scores for FoxP3, PD-L1, and CD68 compared with IBD. Anti-CTLA-4 biopsy specimens had higher scores for CD8, PD-1, PD-L1, and CD68 than anti-PD-1/PD-L1 biopsy specimens. CD8/FoxP3 ratios and CD68 scores were higher among CPI patients requiring infliximab therapy for colitis compared with those responding to steroids.</AbstractText>
          <AbstractText Label="CONCLUSIONS">The proinflammatory immune phenotype of anti-CTLA-4-associated colitis has significant overlap with IBD. CD8/FoxP3 ratios may predict therapeutic response in CPI-associated colitis.</AbstractText>
          <CopyrightInformation>&#xa9; American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lo</LastName>
            <ForeName>Ying-Chun</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Price</LastName>
            <ForeName>Christina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blenman</LastName>
            <ForeName>Kim</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patil</LastName>
            <ForeName>Pallavi</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xuchen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robert</LastName>
            <ForeName>Marie E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Am J Clin Pathol</MedlineTA>
        <NlmUniqueID>0370470</NlmUniqueID>
        <ISSNLinking>0002-9173</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Immunohistochemistry</Keyword>
        <Keyword MajorTopicYN="N">Inflammatory bowel disease</Keyword>
        <Keyword MajorTopicYN="N">T cells</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>8</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33555016</ArticleId>
        <ArticleId IdType="doi">10.1093/ajcp/aqaa217</ArticleId>
        <ArticleId IdType="pii">6130780</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33506015</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2314-6141</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2021</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>BioMed research international</Title>
          <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of PD-1 Protects against TNBS-Induced Colitis via Alteration of Enteric Microbiota.</ArticleTitle>
        <Pagination>
          <StartPage>4192451</StartPage>
          <MedlinePgn>4192451</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">4192451</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/4192451</ELocationID>
        <Abstract>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Colitis was induced in mice using 2,4,6-trinitrobenzene-sulfonic acid (TNBS), and mice were subsequently treated with either a PD-1 inhibitor or 5-amino-salicylic acid (ASA) as a positive control. Body weight, disease activity index (DAI), colon length, and tissue damage were evaluated, and the enteric microbiota was profiled using high-throughput 16S rRNA sequencing of fecal samples from the experimental mice.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">TNBS caused mice to experience IBD-like symptoms, which were attenuated by the PD-1 inhibitor, as indicated by a decrease in DAI scores (p = 0.0002). Furthermore, in this mouse model of IBD, PD-1 inhibition improved the alpha diversity as well as restored the beta diversity of the enteric microbiome. It also significantly enriched the abundance of short-chain fatty acid- (SCFA-) producing bacteria of the Firmicutes (p &lt; 0.05) and Bacteroidetes (p &lt; 0.05) phyla but depopulated Proteobacteria (p &lt; 0.05).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PD-1 inhibition can partly mitigate TNBS-induced colitis and restore the enteric microbiota by enriching the abundance of SCFA-producing bacteria.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Hao-ming Xu et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Hao-Ming</ForeName>
            <Initials>HM</Initials>
            <Identifier Source="ORCID">0000-0002-8131-7477</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>You-Lian</ForeName>
            <Initials>YL</Initials>
            <Identifier Source="ORCID">0000-0002-7107-3288</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-5371-1899</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ying-Fei</ForeName>
            <Initials>YF</Initials>
            <Identifier Source="ORCID">0000-0002-8437-3191</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Chong</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-9941-8049</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Hong-Li</ForeName>
            <Initials>HL</Initials>
            <Identifier Source="ORCID">0000-0002-5882-1106</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Yan-Lei</ForeName>
            <Initials>YL</Initials>
            <Identifier Source="ORCID">0000-0002-7868-2158</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-5880-8112</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yong-Jian</ForeName>
            <Initials>YJ</Initials>
            <Identifier Source="ORCID">0000-0002-4036-4592</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nie</LastName>
            <ForeName>Yu-Qiang</ForeName>
            <Initials>YQ</Initials>
            <Identifier Source="ORCID">0000-0001-7037-5340</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biomed Res Int</MedlineTA>
        <NlmUniqueID>101600173</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C491383">Pdcd1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4Q81I59GXC</RegistryNumber>
          <NameOfSubstance UI="D019804">Mesalamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8T3HQG2ZC4</RegistryNumber>
          <NameOfSubstance UI="D014302">Trinitrobenzenesulfonic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019804" MajorTopicYN="N">Mesalamine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020011" MajorTopicYN="N">Protective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014302" MajorTopicYN="N">Trinitrobenzenesulfonic Acid</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33506015</ArticleId>
        <ArticleId IdType="pmc">PMC7810563</ArticleId>
        <ArticleId IdType="doi">10.1155/2021/4192451</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lozupone C. A., Stombaugh J. I., Gordon J. I., Jansson J. K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220&#x2013;230. doi: 10.1038/nature11550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11550</ArticleId>
            <ArticleId IdType="pmc">PMC3577372</ArticleId>
            <ArticleId IdType="pubmed">22972295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheehan D., Moran C., Shanahan F. The microbiota in inflammatory bowel disease. Journal of Gastroenterology. 2015;50(5):495&#x2013;507. doi: 10.1007/s00535-015-1064-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-015-1064-1</ArticleId>
            <ArticleId IdType="pubmed">25808229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsen O., Claassen E. The mechanistic link between health and gut microbiota diversity. Scientific reports. 2018;8(1, article 2183)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5794854</ArticleId>
            <ArticleId IdType="pubmed">29391457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuoka K., Kanai T. The gut microbiota and inflammatory bowel disease. Seminars in Immunopathology. 2015;37(1):47&#x2013;55. doi: 10.1007/s00281-014-0454-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-014-0454-4</ArticleId>
            <ArticleId IdType="pmc">PMC4281375</ArticleId>
            <ArticleId IdType="pubmed">25420450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maloy K. J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474(7351):298&#x2013;306. doi: 10.1038/nature10208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10208</ArticleId>
            <ArticleId IdType="pubmed">21677746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagao-Kitamoto H., Kamada N. Host-microbial cross-talk in inflammatory bowel disease. Immune Network. 2017;17(1):1&#x2013;12. doi: 10.4110/in.2017.17.1.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4110/in.2017.17.1.1</ArticleId>
            <ArticleId IdType="pmc">PMC5334117</ArticleId>
            <ArticleId IdType="pubmed">28261015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopalakrishnan V., Spencer C. N., Nezi L., et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97&#x2013;103. doi: 10.1126/science.aan4236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan4236</ArticleId>
            <ArticleId IdType="pmc">PMC5827966</ArticleId>
            <ArticleId IdType="pubmed">29097493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routy B., Le Chatelier E., Derosa L., et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91&#x2013;97. doi: 10.1126/science.aan3706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan3706</ArticleId>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivan A., Corrales L., Hubert N., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084&#x2013;1089. doi: 10.1126/science.aac4255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aac4255</ArticleId>
            <ArticleId IdType="pmc">PMC4873287</ArticleId>
            <ArticleId IdType="pubmed">26541606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matson V., Fessler J., Bao R., et al. The commensal microbiome is associated with anti&#x2013;PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):p. 104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6707353</ArticleId>
            <ArticleId IdType="pubmed">29302014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanai T., Totsuka T., Uraushihara K., et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. Journal of Immunology. 2003;171(8):4156&#x2013;4163. doi: 10.4049/jimmunol.171.8.4156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.171.8.4156</ArticleId>
            <ArticleId IdType="pubmed">14530338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scandiuzzi L., Ghosh K., Hofmeyer K. A., et al. Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Reports. 2014;6(4):625&#x2013;632. doi: 10.1016/j.celrep.2014.01.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.01.020</ArticleId>
            <ArticleId IdType="pmc">PMC3962725</ArticleId>
            <ArticleId IdType="pubmed">24529703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S. J., Kim J., Song M., Sung Y. C., Lee S., Park Y. PD-1 deficiency protects experimental colitis via alteration of gut microbiota. BMB Reports. 2017;50(11):578&#x2013;583. doi: 10.5483/BMBRep.2017.50.11.165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2017.50.11.165</ArticleId>
            <ArticleId IdType="pmc">PMC5720472</ArticleId>
            <ArticleId IdType="pubmed">29065967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris G. P., Beck P. L., Herridge M. S., Depew W. T., Szewczuk M. R., Wallace J. L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96(3):795&#x2013;803. doi: 10.1016/0016-5085(89)90904-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0016-5085(89)90904-9</ArticleId>
            <ArticleId IdType="pubmed">2914642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murthy S. N., Cooper H. S., Shim H., Shah R. S., Ibrahim S. A., Sedergran D. J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Digestive Diseases and Sciences. 1993;38(9):1722&#x2013;1734. doi: 10.1007/BF01303184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01303184</ArticleId>
            <ArticleId IdType="pubmed">8359087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peloquin J. M., Nguyen D. D. The microbiota and inflammatory bowel disease: insights from animal models. Anaerobe. 2013;24:102&#x2013;106. doi: 10.1016/j.anaerobe.2013.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anaerobe.2013.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC3766478</ArticleId>
            <ArticleId IdType="pubmed">23603043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manichanh C., Rigottier-Gois L., Bonnaud E., et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55(2):205&#x2013;211. doi: 10.1136/gut.2005.073817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2005.073817</ArticleId>
            <ArticleId IdType="pmc">PMC1856500</ArticleId>
            <ArticleId IdType="pubmed">16188921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank D. N., Robertson C. E., Hamm C. M., et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflammatory Bowel Diseases. 2011;17(1):179&#x2013;184. doi: 10.1002/ibd.21339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ibd.21339</ArticleId>
            <ArticleId IdType="pmc">PMC3834564</ArticleId>
            <ArticleId IdType="pubmed">20839241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tlaskalov&#xe1;-Hogenov&#xe1; H., &#x160;t&#x11b;p&#xe1;nkov&#xe1; R., Koz&#xe1;kov&#xe1; H., et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cellular &amp; Molecular Immunology. 2011;8(2):110&#x2013;120. doi: 10.1038/cmi.2010.67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cmi.2010.67</ArticleId>
            <ArticleId IdType="pmc">PMC4003137</ArticleId>
            <ArticleId IdType="pubmed">21278760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ince M. N., Blazar B. R., Edmond M. B., Tricot G., Wannemuehler M. J. Understanding luminal microorganisms and their potential effectiveness in treating intestinal inflammation. Inflammatory Bowel Diseases. 2016;22(1):194&#x2013;201. doi: 10.1097/MIB.0000000000000599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000000599</ArticleId>
            <ArticleId IdType="pmc">PMC4679592</ArticleId>
            <ArticleId IdType="pubmed">26457381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lathrop S. K., Bloom S. M., Rao S. M., et al. Peripheral education of the immune system by colonic commensal microbiota. Nature. 2011;478(7368):250&#x2013;254. doi: 10.1038/nature10434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10434</ArticleId>
            <ArticleId IdType="pmc">PMC3192908</ArticleId>
            <ArticleId IdType="pubmed">21937990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X., Song H., Wang Y., Sheng Y., Chen J. Sodium butyrate protects the intestinal barrier function in peritonitic mice. International Journal of Clinical and Experimental Medicine. 2015;8(3):4000&#x2013;4007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4443136</ArticleId>
            <ArticleId IdType="pubmed">26064302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly C. J., Zheng L., Campbell E. L., et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host &amp; Microbe. 2015;17(5):662&#x2013;671. doi: 10.1016/j.chom.2015.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2015.03.005</ArticleId>
            <ArticleId IdType="pmc">PMC4433427</ArticleId>
            <ArticleId IdType="pubmed">25865369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macia L., Tan J., Vieira A. T., et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nature Communications. 2015;6(1):p. 6734. doi: 10.1038/ncomms7734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms7734</ArticleId>
            <ArticleId IdType="pubmed">25828455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velasquez-Manoff M. Gut microbiome: the peacekeepers. Nature. 2015;518(7540):S3&#x2013;S5. doi: 10.1038/518S3a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/518S3a</ArticleId>
            <ArticleId IdType="pubmed">25715278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macia L., Thorburn A. N., Binge L. C., et al. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunological Reviews. 2012;245(1):164&#x2013;176. doi: 10.1111/j.1600-065X.2011.01080.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065X.2011.01080.x</ArticleId>
            <ArticleId IdType="pubmed">22168419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francisco L. M., Sage P. T., Sharpe A. H. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews. 2010;236(1):219&#x2013;242. doi: 10.1111/j.1600-065X.2010.00923.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065X.2010.00923.x</ArticleId>
            <ArticleId IdType="pmc">PMC2919275</ArticleId>
            <ArticleId IdType="pubmed">20636820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wirtz S., Neufert C., Weigmann B., Neurath M. F. Chemically induced mouse models of intestinal inflammation. Nature Protocols. 2007;2(3):541&#x2013;546. doi: 10.1038/nprot.2007.41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2007.41</ArticleId>
            <ArticleId IdType="pubmed">17406617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fichtner-Feigl S., Young C. A., Kitani A., Geissler E. K., Schlitt H. J., Strober W. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology. 2008;135(6):2003&#x2013;2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18938165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawamoto S., Tran T. H., Maruya M., et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science. 2012;336(6080):485&#x2013;489. doi: 10.1126/science.1217718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1217718</ArticleId>
            <ArticleId IdType="pubmed">22539724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetizou M., Pitt J. M., Daillere R., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079&#x2013;1084. doi: 10.1126/science.aad1329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad1329</ArticleId>
            <ArticleId IdType="pmc">PMC4721659</ArticleId>
            <ArticleId IdType="pubmed">26541610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao J. H., Duan J. A., Jiang S., Guo J. M., Qian Y. Y., Qian D. W. Simultaneous determination of six short-chain fatty acids in colonic contents of colitis mice after oral administration of polysaccharides from Chrysanthemum morifolium Ramat by gas chromatography with flame ionization detector. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2016;1029-1030:88&#x2013;94. doi: 10.1016/j.jchromb.2016.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchromb.2016.07.002</ArticleId>
            <ArticleId IdType="pubmed">27428450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eeckhaut V., Machiels K., Perrier C., et al. Butyricicoccus pullicaecorum in inflammatory bowel disease. Gut. 2013;62(12):1745&#x2013;1752. doi: 10.1136/gutjnl-2012-303611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2012-303611</ArticleId>
            <ArticleId IdType="pubmed">23263527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meehan C. J., Beiko R. G. A phylogenomic view of ecological specialization in the Lachnospiraceae, a family of digestive tract-associated bacteria. Genome Biology and Evolution. 2014;6(3):703&#x2013;713. doi: 10.1093/gbe/evu050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/gbe/evu050</ArticleId>
            <ArticleId IdType="pmc">PMC3971600</ArticleId>
            <ArticleId IdType="pubmed">24625961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reeves A. E., Koenigsknecht M. J., Bergin I. L., Young V. B. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infection and Immunity. 2012;80(11):3786&#x2013;3794. doi: 10.1128/IAI.00647-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00647-12</ArticleId>
            <ArticleId IdType="pmc">PMC3486043</ArticleId>
            <ArticleId IdType="pubmed">22890996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louis P., Flint H. J. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiology Letters. 2009;294(1):1&#x2013;8. doi: 10.1111/j.1574-6968.2009.01514.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1574-6968.2009.01514.x</ArticleId>
            <ArticleId IdType="pubmed">19222573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yilmaz B., Juillerat P., &#xd8;y&#xe5;s O., et al. Microbial network disturbances in relapsing refractory Crohn&#x2019;s disease. Nature Medicine. 2019;25(2):323&#x2013;336. doi: 10.1038/s41591-018-0308-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0308-z</ArticleId>
            <ArticleId IdType="pubmed">30664783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machiels K., Joossens M., Sabino J., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275&#x2013;1283. doi: 10.1136/gutjnl-2013-304833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2013-304833</ArticleId>
            <ArticleId IdType="pubmed">24021287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z., Zhu C., Quan Y., et al. Update on intestinal microbiota in Crohn's disease 2017: mechanisms, clinical application, adverse reactions, and outlook. Journal of Gastroenterology and Hepatology. 2017;32(11):1804&#x2013;1812. doi: 10.1111/jgh.13861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jgh.13861</ArticleId>
            <ArticleId IdType="pubmed">28677158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pryde S. E., Duncan S. H., Hold G. L., Stewart C. S., Flint H. J. The microbiology of butyrate formation in the human colon. FEMS Microbiology Letters. 2002;217(2):133&#x2013;139. doi: 10.1111/j.1574-6968.2002.tb11467.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1574-6968.2002.tb11467.x</ArticleId>
            <ArticleId IdType="pubmed">12480096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetizou M., Trinchieri G. Anti-PD1 in the wonder-gut-land. Cell Research. 2018;28(3):263&#x2013;264. doi: 10.1038/cr.2018.12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2018.12</ArticleId>
            <ArticleId IdType="pmc">PMC5835771</ArticleId>
            <ArticleId IdType="pubmed">29336431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sagheddu V., Patrone V., Miragoli F., Puglisi E., Morelli L. Infant early gut colonization by Lachnospiraceae: high frequency of Ruminococcus gnavus. Frontiers in Pediatrics. 2016;4:p. 57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4889575</ArticleId>
            <ArticleId IdType="pubmed">27313996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sch&#xe4;ffler H., Herlemann D. P., Klinitzke P., et al. Vitamin D administration leads to a shift of the intestinal bacterial composition in Crohn's disease patients, but not in healthy controls. Journal of digestive diseases. 2018;19(4):225&#x2013;234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29573237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcelo A., Claustre J., Moro F., Chayvialle J. A., Cuber J. C., Plaisancie P. Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut. 2000;46(2):218&#x2013;224. doi: 10.1136/gut.46.2.218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.46.2.218</ArticleId>
            <ArticleId IdType="pmc">PMC1727811</ArticleId>
            <ArticleId IdType="pubmed">10644316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geirnaert A., Calatayud M., Grootaert C., et al. Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Scientific reports. 2017;7(1, article 11450)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5597586</ArticleId>
            <ArticleId IdType="pubmed">28904372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Gallausiaux C., B&#xe9;guet-Crespel F., Marinelli L., et al. Butyrate produced by gut commensal bacteria activates TGF-beta1 expression through the transcription factor SP1 in human intestinal epithelial cells. Scientific reports. 2018;8(1, article 9742)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6021401</ArticleId>
            <ArticleId IdType="pubmed">29950699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanagibashi T., Hosono A., Oyama A., et al. IgA production in the large intestine is modulated by a different mechanism than in the small intestine: Bacteroides acidifaciens promotes IgA production in the large intestine by inducing germinal center formation and increasing the number of IgA+ B cells. Immunobiology. 2013;218(4):645&#x2013;651. doi: 10.1016/j.imbio.2012.07.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.imbio.2012.07.033</ArticleId>
            <ArticleId IdType="pubmed">22940255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rehman A., Rausch P., Wang J., et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut. 2016;65(2):238&#x2013;248. doi: 10.1136/gutjnl-2014-308341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2014-308341</ArticleId>
            <ArticleId IdType="pubmed">25567118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y. N., Huang F., Cheng H. J., Li S. Y., Liu L., Wang L. Y. Intestine-derived Clostridium leptum induces murine tolerogenic dendritic cells and regulatory T cells in vitro. Human Immunology. 2014;75(12):1232&#x2013;1238. doi: 10.1016/j.humimm.2014.09.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humimm.2014.09.017</ArticleId>
            <ArticleId IdType="pubmed">25300998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y. N., Huang F., Liu L., Qiao H. M., Li Y., Cheng H. J. Effect of oral feeding with Clostridium leptum on regulatory T-cell responses and allergic airway inflammation in mice. Annals of Allergy, Asthma &amp; Immunology. 2012;109(3):201&#x2013;207. doi: 10.1016/j.anai.2012.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anai.2012.06.017</ArticleId>
            <ArticleId IdType="pubmed">22920076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCoy K. D., Ronchi F., Geuking M. B. Host-microbiota interactions and adaptive immunity. Immunological Reviews. 2017;279(1):63&#x2013;69. doi: 10.1111/imr.12575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12575</ArticleId>
            <ArticleId IdType="pubmed">28856735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clavel T., Gomes-Neto J. C., Lagkouvardos I., Ramer-Tait A. E. Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes. Immunological Reviews. 2017;279(1):8&#x2013;22. doi: 10.1111/imr.12578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12578</ArticleId>
            <ArticleId IdType="pmc">PMC5657458</ArticleId>
            <ArticleId IdType="pubmed">28856739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunker J. J., Flynn T. M., Koval J. C., et al. Innate and adaptive humoral responses coat distinct commensal bacteria with immunoglobulin a. Immunity. 2015;43(3):541&#x2013;553. doi: 10.1016/j.immuni.2015.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2015.08.007</ArticleId>
            <ArticleId IdType="pmc">PMC4575282</ArticleId>
            <ArticleId IdType="pubmed">26320660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atarashi K., Tanoue T., Ando M., et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163(2):367&#x2013;380. doi: 10.1016/j.cell.2015.08.058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.08.058</ArticleId>
            <ArticleId IdType="pmc">PMC4765954</ArticleId>
            <ArticleId IdType="pubmed">26411289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin X., Heeney D., Srisengfa Y., Golomb B., Griffey S., Marco M. Bacteriocin biosynthesis contributes to the anti-inflammatory capacities of probiotic Lactobacillus plantarum. Beneficial Microbes. 2018;9(2):333&#x2013;344. doi: 10.3920/BM2017.0096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3920/BM2017.0096</ArticleId>
            <ArticleId IdType="pubmed">29065706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robertson B. R., O'Rourke J. L., Neilan B. A., et al. Mucispirillum schaedleri gen. nov., sp. nov., a spiral-shaped bacterium colonizing the mucus layer of the gastrointestinal tract of laboratory rodents. International Journal of Systematic and Evolutionary Microbiology. 2005;55(3):1199&#x2013;1204. doi: 10.1099/ijs.0.63472-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/ijs.0.63472-0</ArticleId>
            <ArticleId IdType="pubmed">15879255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Botticelli A., Zizzari I., Mazzuca F., et al. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget. 2017;8(5):8890&#x2013;8899. doi: 10.18632/oncotarget.12985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12985</ArticleId>
            <ArticleId IdType="pmc">PMC5352451</ArticleId>
            <ArticleId IdType="pubmed">27806346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder B. O., Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nature Medicine. 2016;22(10):1079&#x2013;1089. doi: 10.1038/nm.4185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4185</ArticleId>
            <ArticleId IdType="pubmed">27711063</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33495297</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e001643</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2020-001643</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions. The benefits of targeting non-DNA repair aspects of PARP with metronomic doses remain unexplored.</AbstractText>
          <AbstractText Label="METHODS">Colon epithelial cells or mouse or human bone marrow (BM)-derived-myeloid-derived suppressor cells (MDSCs) were stimulated to assess the effect of partial PARP-1 inhibition on inflammatory gene expression or immune suppression. Mice treated with azoxymethane/four dextran-sulfate-sodium cycles or APC[Min/+] mice bred into PARP-1[+/-] or treated with olaparib were used to examine the role of PARP-1 in colitis-induced or spontaneous colon cancer, respectively. Syngeneic MC-38 cell-based (microsatellite instability, MSI[high]) or CT-26 cell-based (microsatellite stable, MSS) tumor models were used to assess the effects of PARP inhibition on host responses and synergy with anti-Programmed cell Death protein (PD)-1 immunotherapy.</AbstractText>
          <AbstractText Label="RESULTS">Partial PARP-1 inhibition, via gene heterozygosity or a moderate dose of olaparib, protected against colitis-mediated/APC[Min] -mediated intestinal tumorigenesis and APC[Min] -associated cachexia, while extensive inhibition, via gene knockout or a high dose of olaparib, was ineffective or aggravating. A sub-IC50-olaparib dose or PARP-1 heterozygosity was sufficient to block tumorigenesis in a syngeneic colon cancer model by modulating the suppressive function, but not intratumoral migration or differentiation, of MDSCs, with concomitant increases in intratumoral T cell function and cytotoxicity, as assessed by granzyme-B/interferon-&#x3b3; levels. Adoptive transfer of WT-BM-MDSCs abolished the protective effects of PARP-1 heterozygosity. The mechanism of MDSC modulation involved a reduction in arginase-1/inducible nitric oxide synthase/cyclo-oxygenase-2, but independent of PARP-1 trapping on chromatin. Although a high-concentration olaparib or the high-trapping PARP inhibitor, talazoparib, activated stimulator of interferon gene (STING) in BRCA-proficient cells and induced DNA damage, sub-IC50 concentrations of either drug failed to induce activation of the dsDNA break sensor. STING expression appeared dispensable for MDSC suppressive function and was not strictly required for olaparib-mediated effects. Ironically, STING activation blocked human and mouse MDSC function with no additive effects with olaparib. A metronomic dose of olaparib was highly synergistic with anti-PD-1-based immunotherapy, leading to eradication of MSI[high] or reduction of MSS tumors in mice.</AbstractText>
          <AbstractText Label="CONCLUSIONS">These results support a paradigm-shifting concept that expands the utility of PARP inhibitor and encourage testing metronomic dosing of PARP inhibitor to enhance the efficacy of checkpoint inhibitor-based immunotherapies in cancer.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ghonim</LastName>
            <ForeName>Mohamed A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ibba</LastName>
            <ForeName>Salome V</ForeName>
            <Initials>SV</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Tarhuni</LastName>
            <ForeName>Abdelmetalab F</ForeName>
            <Initials>AF</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Errami</LastName>
            <ForeName>Youssef</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luu</LastName>
            <ForeName>Hanh H</ForeName>
            <Initials>HH</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dean</LastName>
            <ForeName>Matthew J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>El-Bahrawy</LastName>
            <ForeName>Ali H</ForeName>
            <Initials>AH</Initials>
            <Identifier Source="ORCID">0000-0001-6116-0428</Identifier>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wyczechowska</LastName>
            <ForeName>Dorota</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benslimane</LastName>
            <ForeName>Ilyes A</ForeName>
            <Initials>IA</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Del Valle</LastName>
            <ForeName>Luis</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Khami</LastName>
            <ForeName>Amir A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ochoa</LastName>
            <ForeName>Augusto C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boulares</LastName>
            <ForeName>A Hamid</ForeName>
            <Initials>AH</Initials>
            <Identifier Source="ORCID">0000-0001-9916-8126</Identifier>
            <AffiliationInfo>
              <Affiliation>Stanley Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA hboulr@lsuhsc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P20 CA233374</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 GM106392</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 GM114732</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 GM104940</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010793">Phthalazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000067856">Poly(ADP-ribose) Polymerase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9042-14-2</RegistryNumber>
          <NameOfSubstance UI="D016264">Dextran Sulfate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>MO0N1J0SEN</RegistryNumber>
          <NameOfSubstance UI="D001397">Azoxymethane</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WOH1JD9AR8</RegistryNumber>
          <NameOfSubstance UI="C531550">olaparib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>J Immunother Cancer. 2021 Mar;9(3):</RefSource>
          <PMID Version="1">33771894</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D059250" MajorTopicYN="N">Administration, Metronomic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001397" MajorTopicYN="N">Azoxymethane</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016264" MajorTopicYN="N">Dextran Sulfate</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="N">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010793" MajorTopicYN="N">Phthalazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067856" MajorTopicYN="N">Poly(ADP-ribose) Polymerase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">combination</Keyword>
        <Keyword MajorTopicYN="N">drug therapy</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">programmed cell death 1 receptor</Keyword>
        <Keyword MajorTopicYN="N">translational medical research</Keyword>
        <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33495297</ArticleId>
        <ArticleId IdType="pmc">PMC7839867</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2020-001643</ArticleId>
        <ArticleId IdType="pii">jitc-2020-001643</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Veneris JT, Matulonis UA, Liu JF, et al. . Choosing wisely: selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecol Oncol 2020;156:488&#x2013;97. 10.1016/j.ygyno.2019.09.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2019.09.021</ArticleId>
            <ArticleId IdType="pubmed">31630846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gourley C, Balma&#xf1;a J, Ledermann JA, et al. . Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol 2019;37:2257&#x2013;69. 10.1200/JCO.18.02050</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.18.02050</ArticleId>
            <ArticleId IdType="pubmed">31050911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hopkins TA, Ainsworth WB, Ellis PA, et al. . Parp1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol Cancer Res 2019;17:409&#x2013;19. 10.1158/1541-7786.MCR-18-0138</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-18-0138</ArticleId>
            <ArticleId IdType="pubmed">30429212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berger NA, Besson VC, Boulares AH, et al. . Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 2018;175:192-222. 10.1111/bph.13748</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.13748</ArticleId>
            <ArticleId IdType="pmc">PMC5758399</ArticleId>
            <ArticleId IdType="pubmed">28213892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ZQ, Auer B, Stingl L, et al. . Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995;9:509&#x2013;20. 10.1101/gad.9.5.509</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.9.5.509</ArticleId>
            <ArticleId IdType="pubmed">7698643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claybon A, Karia B, Bruce C, et al. . PARP1 suppresses homologous recombination events in mice in vivo. Nucleic Acids Res 2010;38:7538&#x2013;45. 10.1093/nar/gkq624</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkq624</ArticleId>
            <ArticleId IdType="pmc">PMC2995050</ArticleId>
            <ArticleId IdType="pubmed">20660013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pommier Y, O'Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med 2016;8:362ps17. 10.1126/scitranslmed.aaf9246</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaf9246</ArticleId>
            <ArticleId IdType="pubmed">27797957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oumouna-Benachour K, Hans CP, Suzuki Y, et al. . Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Circulation 2007;115:2442&#x2013;50. 10.1161/CIRCULATIONAHA.106.668756</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.668756</ArticleId>
            <ArticleId IdType="pubmed">17438151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghonim MA, Pyakurel K, Ibba SV, et al. . PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. J Transl Med 2015;13:225. 10.1186/s12967-015-0583-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-015-0583-0</ArticleId>
            <ArticleId IdType="pmc">PMC4501284</ArticleId>
            <ArticleId IdType="pubmed">26169874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghonim MA, Pyakurel K, Ibba SV, et al. . PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Clin Sci 2015;129:951&#x2013;62. 10.1042/CS20150122</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/CS20150122</ArticleId>
            <ArticleId IdType="pmc">PMC4613510</ArticleId>
            <ArticleId IdType="pubmed">26205779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI. Myeloid-Derived suppressor cells. Cancer Immunol Res 2017;5:3&#x2013;8. 10.1158/2326-6066.CIR-16-0297</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0297</ArticleId>
            <ArticleId IdType="pmc">PMC5426480</ArticleId>
            <ArticleId IdType="pubmed">28052991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding L, Kim H-J, Wang Q, et al. . Parp inhibition elicits STING-dependent antitumor immunity in BRCA1-deficient ovarian cancer. Cell Rep 2018;25:2972&#x2013;80. 10.1016/j.celrep.2018.11.054</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.11.054</ArticleId>
            <ArticleId IdType="pmc">PMC6366450</ArticleId>
            <ArticleId IdType="pubmed">30540933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. . PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov 2019;9:722&#x2013;37. 10.1158/2159-8290.CD-18-1218</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-18-1218</ArticleId>
            <ArticleId IdType="pmc">PMC6548644</ArticleId>
            <ArticleId IdType="pubmed">31015319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen J, Zhao W, Ju Z, et al. . PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 2019;79:311&#x2013;9. 10.1158/0008-5472.CAN-18-1003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-1003</ArticleId>
            <ArticleId IdType="pmc">PMC6588002</ArticleId>
            <ArticleId IdType="pubmed">30482774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C-X, Ye S-B, Ni J-J, et al. . Sting signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ 2019;26:2314&#x2013;28. 10.1038/s41418-019-0302-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-019-0302-0</ArticleId>
            <ArticleId IdType="pmc">PMC6889506</ArticleId>
            <ArticleId IdType="pubmed">30816302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohamed E, Sierra RA, Trillo-Tinoco J, et al. . The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of sting signaling. Immunity 2020;52:668&#x2013;82. 10.1016/j.immuni.2020.03.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2020.03.004</ArticleId>
            <ArticleId IdType="pmc">PMC7207019</ArticleId>
            <ArticleId IdType="pubmed">32294407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oumouna-Benachour K, Oumouna M, Zerfaoui M, et al. . Intrinsic resistance to apoptosis of colon epithelial cells is a potential determining factor in the susceptibility of the A/J mouse strain to dimethylhydrazine-induced colon tumorigenesis. Mol Carcinog 2007;46:993&#x2013;1002. 10.1002/mc.20351</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.20351</ArticleId>
            <ArticleId IdType="pubmed">17538954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zerfaoui M, Errami Y, Naura AS, et al. . Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. J Immunol 2010;185:1894&#x2013;902. 10.4049/jimmunol.1000646</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1000646</ArticleId>
            <ArticleId IdType="pmc">PMC2910824</ArticleId>
            <ArticleId IdType="pubmed">20610652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zerfaoui M, Naura AS, Errami Y, et al. . Effects of PARP-1 deficiency on airway inflammatory cell recruitment in response to LPS or TNF: differential effects on CXCR2 ligands and Duffy antigen receptor for chemokines. J Leukoc Biol 2009;86:1385&#x2013;92. 10.1189/jlb.0309183</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0309183</ArticleId>
            <ArticleId IdType="pmc">PMC2780916</ArticleId>
            <ArticleId IdType="pubmed">19741160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zerfaoui M, Suzuki Y, Naura AS, et al. . Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: differential requirement for PARP-1 expression and interaction. Cell Signal 2008;20:186&#x2013;94. 10.1016/j.cellsig.2007.10.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2007.10.007</ArticleId>
            <ArticleId IdType="pmc">PMC2278030</ArticleId>
            <ArticleId IdType="pubmed">17993261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Khami AA, Ghonim MA, Del Valle L, et al. . Fuelling the mechanisms of asthma: increased fatty acid oxidation in inflammatory immune cells may represent a novel therapeutic target. Clin Exp Allergy 2017;47:1170&#x2013;84. 10.1111/cea.12947</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cea.12947</ArticleId>
            <ArticleId IdType="pmc">PMC5578913</ArticleId>
            <ArticleId IdType="pubmed">28456994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naura AS, Datta R, Hans CP, et al. . Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia. Eur Respir J 2009;33:252&#x2013;62. 10.1183/09031936.00089008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.00089008</ArticleId>
            <ArticleId IdType="pubmed">18829681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boulares AH, Ferran MC, Lucas-Lenard J. Nf-kappaB activation is delayed in mouse L929 cells infected with interferon suppressing, but not inducing, vesicular stomatitis virus strains. Virology 1996;218:71&#x2013;80. 10.1006/viro.1996.0167</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/viro.1996.0167</ArticleId>
            <ArticleId IdType="pubmed">8615043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D&#xf6;rsam B, Seiwert N, Foersch S, et al. . PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. Proc Natl Acad Sci U S A 2018;115:E4061&#x2013;70. 10.1073/pnas.1712345115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1712345115</ArticleId>
            <ArticleId IdType="pmc">PMC5924876</ArticleId>
            <ArticleId IdType="pubmed">29632181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larmonier CB, Shehab KW, Laubitz D, et al. . Transcriptional Reprogramming and Resistance to Colonic Mucosal Injury in Poly(ADP-ribose) Polymerase 1 (PARP1)-deficient Mice. J Biol Chem 2016;291:8918&#x2013;30. 10.1074/jbc.M116.714386</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M116.714386</ArticleId>
            <ArticleId IdType="pmc">PMC4861461</ArticleId>
            <ArticleId IdType="pubmed">26912654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currey N, Daniel JJ, Mladenova DN, et al. . Microsatellite instability in mouse models of colorectal cancer. Can J Gastroenterol Hepatol 2018;2018:1&#x2013;7. 10.1155/2018/6152928</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/6152928</ArticleId>
            <ArticleId IdType="pmc">PMC5852867</ArticleId>
            <ArticleId IdType="pubmed">29686976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sceneay J, Griessinger CM, Hoffmann SHL, et al. . Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment. PLoS One 2018;13:e0196040. 10.1371/journal.pone.0196040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0196040</ArticleId>
            <ArticleId IdType="pmc">PMC5909918</ArticleId>
            <ArticleId IdType="pubmed">29677215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol 2015;98:913&#x2013;22. 10.1189/jlb.4RI0515-204R</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.4RI0515-204R</ArticleId>
            <ArticleId IdType="pmc">PMC4661041</ArticleId>
            <ArticleId IdType="pubmed">26337512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchetti A, Di Lorito A, Buttitta F. Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle. J Thorac Dis 2017;9:4863&#x2013;6. 10.21037/jtd.2017.11.105</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jtd.2017.11.105</ArticleId>
            <ArticleId IdType="pmc">PMC5756957</ArticleId>
            <ArticleId IdType="pubmed">29312678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arora SP, Mahalingam D. Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 2018;9:170&#x2013;9. 10.21037/jgo.2017.06.10</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jgo.2017.06.10</ArticleId>
            <ArticleId IdType="pmc">PMC5848030</ArticleId>
            <ArticleId IdType="pubmed">29564183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dosset M, Vargas TR, Lagrange A, et al. . PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology 2018;7:e1433981. 10.1080/2162402X.2018.1433981</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1433981</ArticleId>
            <ArticleId IdType="pmc">PMC5980491</ArticleId>
            <ArticleId IdType="pubmed">29872568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 2002;59:1534&#x2013;53. 10.1007/s00018-002-8527-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-002-8527-2</ArticleId>
            <ArticleId IdType="pubmed">12440774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balka KR, Louis C, Saunders TL, et al. . Tbk1 and IKK&#x3b5; act redundantly to mediate STING-Induced NF-&#x3ba;B responses in myeloid cells. Cell Rep 2020;31:107492. 10.1016/j.celrep.2020.03.056</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.03.056</ArticleId>
            <ArticleId IdType="pubmed">32268090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tegtmeyer P-K, Spanier J, Borst K, et al. . Sting induces early IFN-&#x3b2; in the liver and constrains myeloid cell-mediated dissemination of murine cytomegalovirus. Nat Commun 2019;10:2830. 10.1038/s41467-019-10863-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-10863-0</ArticleId>
            <ArticleId IdType="pmc">PMC6597531</ArticleId>
            <ArticleId IdType="pubmed">31249303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss JM, Gu&#xe9;rin MV, Regnier F, et al. . The sting agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. Oncoimmunology 2017;6:e1346765. 10.1080/2162402X.2017.1346765</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1346765</ArticleId>
            <ArticleId IdType="pmc">PMC5665074</ArticleId>
            <ArticleId IdType="pubmed">29123960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaidt MM, Ebert TS, Chauhan D, et al. . The DNA inflammasome in human myeloid cells is initiated by a STING-Cell death program upstream of NLRP3. Cell 2017;171:1110&#x2013;24. e18. 10.1016/j.cell.2017.09.039</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.039</ArticleId>
            <ArticleId IdType="pmc">PMC5901709</ArticleId>
            <ArticleId IdType="pubmed">29033128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang H, Deng L, Hou Y, et al. . Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun 2017;8:8. 10.1038/s41467-017-01566-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-01566-5</ArticleId>
            <ArticleId IdType="pmc">PMC5701019</ArticleId>
            <ArticleId IdType="pubmed">29170400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao S, Xia W, Yamaguchi H, et al. . Parp inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23:3711&#x2013;20. 10.1158/1078-0432.CCR-16-3215</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-3215</ArticleId>
            <ArticleId IdType="pmc">PMC5511572</ArticleId>
            <ArticleId IdType="pubmed">28167507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhuni A, Errami Y, El&#x2010;Bahrawy A, et al. . Paradoxical roles of PARP-1 in colon inflammation and tumorigenesis. Faseb J 2015;29:629.11.</Citation>
        </Reference>
        <Reference>
          <Citation>Chacon-Cabrera A, Mateu-Jimenez M, Langohr K, et al. . Role of PARP activity in lung cancer-induced cachexia: effects on muscle oxidative stress, proteolysis, anabolic markers, and phenotype. J Cell Physiol 2017;232:3744&#x2013;61. 10.1002/jcp.25851</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.25851</ArticleId>
            <ArticleId IdType="pubmed">28177129</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33476895</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0852</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>145</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of cancer (Oxford, England : 1990)</Title>
          <ISOAbbreviation>Eur J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.</ArticleTitle>
        <Pagination>
          <StartPage>155</StartPage>
          <EndPage>157</EndPage>
          <MedlinePgn>155-157</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2020.12.020</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0959-8049(20)31445-3</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Saleh</LastName>
            <ForeName>Khalil</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: khalil_saleh@live.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bellanger</LastName>
            <ForeName>Christophe</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hopital Kremlin Bicetre, Kremlin Bicetre, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garcia</LastName>
            <ForeName>Gabriel</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Classe</LastName>
            <ForeName>Marion</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Even</LastName>
            <ForeName>Caroline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Cancer</MedlineTA>
        <NlmUniqueID>9005373</NlmUniqueID>
        <ISSNLinking>0959-8049</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050031" MajorTopicYN="N">Hashimoto Disease</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016879" MajorTopicYN="Y">Salvage Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014062" MajorTopicYN="N">Tongue Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>21</Day>
          <Hour>20</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33476895</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejca.2020.12.020</ArticleId>
        <ArticleId IdType="pii">S0959-8049(20)31445-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33462141</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e001895</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2020-001895</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A (IL-17A) activity leads to a protumor microenvironment, dependent on its ability to induce the production of inflammatory mediators, mobilize myeloid cells and reshape the tumor environment. In the present study, we aimed to investigate the role of IL-17A in resistance to antitumor immunity and to explore the feasibility of anti-IL-17A combined with anti-PD-1 therapy in MSS CRC murine models.</AbstractText>
          <AbstractText Label="METHODS">The expression of programmed cell death-ligand 1 (PD-L1) and its regulation by miR-15b-5p were investigated in MSS CRC cell lines and tissues. The effects of miR-15b-5p on tumorigenesis and anti-PD-1 treatment sensitivity were verified both in vitro and in colitis-associated cancer (CAC) and APC[min/+] murine models. In vivo efficacy and mechanistic studies were conducted using antibodies targeting IL-17A and PD-1 in mice bearing subcutaneous CT26 and MC38 tumors.</AbstractText>
          <AbstractText Label="RESULTS">Evaluation of clinical pathological specimens confirmed that PD-L1 mRNA levels are associated with CD8+ T&#x2009;cell infiltration and better prognosis. miR-15b-5p was found to downregulate the expression of PD-L1 at the protein level, inhibit tumorigenesis and enhance anti-PD-1 sensitivity in CAC and APC[min/+] CRC models. IL-17A led to high PD-L1 expression in CRC cells through regulating the P65/NRF1/miR-15b-5p axis. Combined IL-17A and PD-1 blockade had efficacy in CT26 and MC38 tumors, with more cytotoxic T lymphocytes cells and fewer myeloid-derived suppressor cells in tumors.</AbstractText>
          <AbstractText Label="CONCLUSIONS">IL-17A increases PD-L1 expression through the p65/NRF1/miR-15b-5p axis and promotes resistance to anti-PD-1 therapy. Blocking IL-17A improved the efficacy of anti-PD-1 therapy in MSS CRC murine models. IL-17A might serve as a therapeutic target to sensitize patients with MSS CRC to ICI therapy.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liu</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liu</LastName>
            <ForeName>Ruiqi</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Bojun</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Lian</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Haoxiu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chunhui</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Jiaqi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Shuling</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhan</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Shengnan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Yuanfei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China yanqiaozhang@ems.hrbmu.edu.cn yaoyuanfei@hrbmu.edu.cn zhengtongsen@hrbmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Tongsen</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China yanqiaozhang@ems.hrbmu.edu.cn yaoyuanfei@hrbmu.edu.cn zhengtongsen@hrbmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Cancer Institute, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yanqiao</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-6206-8364</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China yanqiaozhang@ems.hrbmu.edu.cn yaoyuanfei@hrbmu.edu.cn zhengtongsen@hrbmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508717">IL17A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505361">MIRN15 microRNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>J Immunother Cancer. 2021 Oct;9(10):</RefSource>
          <PMID Version="1">34645677</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019073" MajorTopicYN="N">HT29 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">combination</Keyword>
        <Keyword MajorTopicYN="N">cytokines</Keyword>
        <Keyword MajorTopicYN="N">drug therapy</Keyword>
        <Keyword MajorTopicYN="N">gastrointestinal neoplasms</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33462141</ArticleId>
        <ArticleId IdType="pmc">PMC7813395</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2020-001895</ArticleId>
        <ArticleId IdType="pii">jitc-2020-001895</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7&#x2013;30. 10.3322/caac.21590</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21590</ArticleId>
            <ArticleId IdType="pubmed">31912902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 2018;48:417&#x2013;33. 10.1016/j.immuni.2018.03.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2018.03.007</ArticleId>
            <ArticleId IdType="pmc">PMC6948191</ArticleId>
            <ArticleId IdType="pubmed">29562193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganesh K, Stadler ZK, Cercek A, et al. . Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 2019;16:361&#x2013;75. 10.1038/s41575-019-0126-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41575-019-0126-x</ArticleId>
            <ArticleId IdType="pmc">PMC7295073</ArticleId>
            <ArticleId IdType="pubmed">30886395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overman MJ, McDermott R, Leach JL, et al. . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182&#x2013;91. 10.1016/S1470-2045(17)30422-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(17)30422-9</ArticleId>
            <ArticleId IdType="pmc">PMC6207072</ArticleId>
            <ArticleId IdType="pubmed">28734759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le DT, Durham JN, Smith KN, et al. . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409&#x2013;13. 10.1126/science.aan6733</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan6733</ArticleId>
            <ArticleId IdType="pmc">PMC5576142</ArticleId>
            <ArticleId IdType="pubmed">28596308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuoka S, Hara H, Takahashi N, et al. . Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and Dose-Expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 2020;38:2053&#x2013;61. 10.1200/JCO.19.03296</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.03296</ArticleId>
            <ArticleId IdType="pubmed">32343640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilke CM, Wei S, Wang L, et al. . Dual biological effects of the cytokines interleukin-10 and interferon-&#x3b3;. Cancer Immunol Immunother 2011;60:1529&#x2013;41. 10.1007/s00262-011-1104-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-011-1104-5</ArticleId>
            <ArticleId IdType="pubmed">21918895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hersom M, J&#xf8;rgensen JT. Companion and complementary Diagnostics-Focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in non-small cell lung cancer. Ther Drug Monit 2018;40:9&#x2013;16. 10.1097/FTD.0000000000000460</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/FTD.0000000000000460</ArticleId>
            <ArticleId IdType="pubmed">29084031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le DT, Uram JN, Wang H, et al. . PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509&#x2013;20. 10.1056/NEJMoa1500596</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1500596</ArticleId>
            <ArticleId IdType="pmc">PMC4481136</ArticleId>
            <ArticleId IdType="pubmed">26028255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity 2018;48:434&#x2013;52. 10.1016/j.immuni.2018.03.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2018.03.014</ArticleId>
            <ArticleId IdType="pmc">PMC7116507</ArticleId>
            <ArticleId IdType="pubmed">29562194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu J-M, Li C-W, Lai Y-J, et al. . Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res 2018;78:6349&#x2013;53. 10.1158/0008-5472.CAN-18-1892</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-1892</ArticleId>
            <ArticleId IdType="pmc">PMC6242346</ArticleId>
            <ArticleId IdType="pubmed">30442814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncan DJ, Scott M, Scorer P, et al. . Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry. PLoS One 2019;14:e0215393. 10.1371/journal.pone.0215393</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0215393</ArticleId>
            <ArticleId IdType="pmc">PMC6464208</ArticleId>
            <ArticleId IdType="pubmed">30986253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L-J, Feng F-L, Dong L-Q, et al. . Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics 2018;8:5690&#x2013;702. 10.7150/thno.28742</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.28742</ArticleId>
            <ArticleId IdType="pmc">PMC6276293</ArticleId>
            <ArticleId IdType="pubmed">30555574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conroy JM, Pabla S, Nesline MK, et al. . Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer 2019;7:18. 10.1186/s40425-018-0489-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0489-5</ArticleId>
            <ArticleId IdType="pmc">PMC6346512</ArticleId>
            <ArticleId IdType="pubmed">30678715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tosolini M, Kirilovsky A, Mlecnik B, et al. . Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011;71:1263&#x2013;71. 10.1158/0008-5472.CAN-10-2907</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-2907</ArticleId>
            <ArticleId IdType="pubmed">21303976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Razi S, Baradaran Noveiry B, Keshavarz-Fathi M, et al. . IL-17 and colorectal cancer: from carcinogenesis to treatment. Cytokine 2019;116:7&#x2013;12. 10.1016/j.cyto.2018.12.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2018.12.021</ArticleId>
            <ArticleId IdType="pubmed">30684916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu P, Wu D, Ni C, et al. . &#x3b3;&#x3b4;T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014;40:785&#x2013;800. 10.1016/j.immuni.2014.03.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.03.013</ArticleId>
            <ArticleId IdType="pmc">PMC4716654</ArticleId>
            <ArticleId IdType="pubmed">24816404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Ye X, Pitmon E, et al. . IL-17 inhibits CXCL9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors. J Immunother Cancer 2019;7:324. 10.1186/s40425-019-0757-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0757-z</ArticleId>
            <ArticleId IdType="pmc">PMC6880503</ArticleId>
            <ArticleId IdType="pubmed">31775909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llosa NJ, Luber B, Tam AJ, et al. . Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors. Clin Cancer Res 2019;25:5250&#x2013;9. 10.1158/1078-0432.CCR-19-0114</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-0114</ArticleId>
            <ArticleId IdType="pmc">PMC6726531</ArticleId>
            <ArticleId IdType="pubmed">31061070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis JA, Overman MJ, Vilar E. Mismatch repair-proficient colorectal cancer: finding the right time to respond. Clin Cancer Res 2019;25:5185&#x2013;7. 10.1158/1078-0432.CCR-19-1447</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-1447</ArticleId>
            <ArticleId IdType="pmc">PMC6726523</ArticleId>
            <ArticleId IdType="pubmed">31263028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Gouvello S, Bastuji-Garin S, Aloulou N, et al. . High prevalence of FOXP3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008;57:772&#x2013;9. 10.1136/gut.2007.123794</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2007.123794</ArticleId>
            <ArticleId IdType="pubmed">17965063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Li H, Liu R, et al. . Comprehensive analysis of the relationship between Ras and Raf mutations and MSI status of colorectal cancer in northeastern China. Cell Physiol Biochem 2018;50:1496&#x2013;509. 10.1159/000494649</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000494649</ArticleId>
            <ArticleId IdType="pubmed">30359964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farlow SJ, Jerusalmi A, Sano T. Enhanced transduction of colonic cell lines in vitro and the inflamed colon in mice by viral vectors, derived from adeno-associated virus serotype 2, using virus-microbead conjugates bearing lectin. BMC Biotechnol 2007;7:83. 10.1186/1472-6750-7-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1472-6750-7-83</ArticleId>
            <ArticleId IdType="pmc">PMC2217541</ArticleId>
            <ArticleId IdType="pubmed">18045466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y, Li X, Yang M, et al. . Colitis-accelerated colorectal cancer and metabolic dysregulation in a mouse model. Carcinogenesis 2013;34:1861&#x2013;9. 10.1093/carcin/bgt135</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgt135</ArticleId>
            <ArticleId IdType="pubmed">23615396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kettunen HL, Kettunen ASL, Rautonen NE. Intestinal immune responses in wild-type and ApcMin/+ mouse, a model for colon cancer. Cancer Res 2003;63:5136&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen B, Khodadoust MS, Liu CL, et al. . Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 2018;1711:243&#x2013;59. 10.1007/978-1-4939-7493-1_12</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-7493-1_12</ArticleId>
            <ArticleId IdType="pmc">PMC5895181</ArticleId>
            <ArticleId IdType="pubmed">29344893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennerz JK, van der Sloot KWJ, Le LP, et al. . Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. Int J Colorectal Dis 2016;31:973&#x2013;82. 10.1007/s00384-016-2574-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00384-016-2574-x</ArticleId>
            <ArticleId IdType="pubmed">27026089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker A-M, Cross W, Curtius K, et al. . Evolutionary history of human colitis-associated colorectal cancer. Gut 2019;68:985&#x2013;95. 10.1136/gutjnl-2018-316191</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-316191</ArticleId>
            <ArticleId IdType="pmc">PMC6580738</ArticleId>
            <ArticleId IdType="pubmed">29991641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pekow J, Meckel K, Dougherty U, et al. . miR-193A-3P is a key tumor suppressor in ulcerative colitis-associated colon cancer and promotes carcinogenesis through upregulation of IL17RD. Clin Cancer Res 2017;23:5281&#x2013;91. 10.1158/1078-0432.CCR-17-0171</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-0171</ArticleId>
            <ArticleId IdType="pmc">PMC5581687</ArticleId>
            <ArticleId IdType="pubmed">28600480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim CG, Jang M, Kim Y, et al. . Vegf-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol 2019;4:eaay0555. 10.1126/sciimmunol.aay0555</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.aay0555</ArticleId>
            <ArticleId IdType="pubmed">31704735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knudson KM, Hicks KC, Alter S, et al. . Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. J Immunother Cancer 2019;7:82. 10.1186/s40425-019-0551-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0551-y</ArticleId>
            <ArticleId IdType="pmc">PMC6429734</ArticleId>
            <ArticleId IdType="pubmed">30898149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West NR, McCuaig S, Franchini F, et al. . Emerging cytokine networks in colorectal cancer. Nat Rev Immunol 2015;15:615&#x2013;29. 10.1038/nri3896</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3896</ArticleId>
            <ArticleId IdType="pubmed">26358393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Sun R, Liu J, et al. . Reverse of NK cytolysis resistance of type II cytokine predominant-human tumor cells. Int Immunopharmacol 2006;6:1176&#x2013;80. 10.1016/j.intimp.2006.02.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2006.02.011</ArticleId>
            <ArticleId IdType="pubmed">16714222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blesa JR, Prieto-Ruiz JA, Abraham BA, et al. . NRF-1 is the major transcription factor regulating the expression of the human TOMM34 gene. Biochem Cell Biol 2008;86:46&#x2013;56. 10.1139/O07-151</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1139/O07-151</ArticleId>
            <ArticleId IdType="pubmed">18364745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishino M, Ramaiya NH, Hatabu H, et al. . Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol 2017;14:655&#x2013;68. 10.1038/nrclinonc.2017.88</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.88</ArticleId>
            <ArticleId IdType="pmc">PMC5650537</ArticleId>
            <ArticleId IdType="pubmed">28653677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch M, Beckhove P, Op den Winkel J, et al. . Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg 2006;244:986&#x2013;93. 10.1097/01.sla.0000247058.43243.7b</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.sla.0000247058.43243.7b</ArticleId>
            <ArticleId IdType="pmc">PMC1856622</ArticleId>
            <ArticleId IdType="pubmed">17122624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pag&#xe8;s F, Galon J, Dieu-Nosjean M-C, et al. . Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093&#x2013;102. 10.1038/onc.2009.416</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2009.416</ArticleId>
            <ArticleId IdType="pubmed">19946335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mlecnik B, Van den Eynde M, Bindea G, et al. . Comprehensive Intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst 2018;110:djx123:97&#x2013;108. 10.1093/jnci/djx123</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djx123</ArticleId>
            <ArticleId IdType="pubmed">28922789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chalabi M, Fanchi LF, Dijkstra KK, et al. . Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26:566&#x2013;76. 10.1038/s41591-020-0805-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-0805-8</ArticleId>
            <ArticleId IdType="pubmed">32251400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kao SC, Cheng YY, Williams M, et al. . Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural&#xa0;Mesothelioma. J Thorac Oncol 2017;12:1421&#x2013;33. 10.1016/j.jtho.2017.05.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2017.05.024</ArticleId>
            <ArticleId IdType="pubmed">28629895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji D, Zhan T, Li M, et al. . Enhancement of sensitivity to Chemo/Radiation therapy by using miR-15b against DCLK1 in colorectal cancer. Stem Cell Reports 2018;11:1506&#x2013;22. 10.1016/j.stemcr.2018.10.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stemcr.2018.10.015</ArticleId>
            <ArticleId IdType="pmc">PMC6294114</ArticleId>
            <ArticleId IdType="pubmed">30449704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frampton AE, Krell J, Gall TMH, et al. . miR-15b and miR-17 are tumor-derived plasma microRNAs dysregulated in colorectal neoplasia. Ann Surg 2015;262:e61&#x2013;2. 10.1097/SLA.0000000000000605</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SLA.0000000000000605</ArticleId>
            <ArticleId IdType="pubmed">24646542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L-N, Zhi Z, Chen L-Y, et al. . SIRT1 suppresses colorectal cancer metastasis by transcriptional repression of miR-15b-5p. Cancer Lett 2017;409:104&#x2013;15. 10.1016/j.canlet.2017.09.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2017.09.001</ArticleId>
            <ArticleId IdType="pubmed">28923398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Yao Z, Wang J, et al. . Macrophage-Derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway. Cell Death Differ 2020;27:1765&#x2013;81. 10.1038/s41418-019-0460-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-019-0460-0</ArticleId>
            <ArticleId IdType="pmc">PMC7244707</ArticleId>
            <ArticleId IdType="pubmed">31802034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mezzadra R, Sun C, Jae LT, et al. . Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 2017;549:106&#x2013;10. 10.1038/nature23669</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature23669</ArticleId>
            <ArticleId IdType="pmc">PMC6333292</ArticleId>
            <ArticleId IdType="pubmed">28813410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y, Shi D, Liang Z, et al. . IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells. J Hepatol 2019;71:1206&#x2013;15. 10.1016/j.jhep.2019.08.034</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2019.08.034</ArticleId>
            <ArticleId IdType="pubmed">31499129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aotsuka A, Matsumoto Y, Arimoto T, et al. . Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma. Cancer Sci 2019;110:3068&#x2013;78. 10.1111/cas.14174</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.14174</ArticleId>
            <ArticleId IdType="pmc">PMC6778630</ArticleId>
            <ArticleId IdType="pubmed">31432577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amicarella F, Muraro MG, Hirt C, et al. . Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut 2017;66:692&#x2013;704. 10.1136/gutjnl-2015-310016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-310016</ArticleId>
            <ArticleId IdType="pmc">PMC5529969</ArticleId>
            <ArticleId IdType="pubmed">26719303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blauvelt A. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. Expert Opin Biol Ther 2016;16:255&#x2013;63. 10.1517/14712598.2016.1132695</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14712598.2016.1132695</ArticleId>
            <ArticleId IdType="pubmed">26666707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 2017;376:1989&#x2013;91. 10.1056/NEJMc1703047</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1703047</ArticleId>
            <ArticleId IdType="pubmed">28514612</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33459466</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1349-7006</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>112</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer science</Title>
          <ISOAbbreviation>Cancer Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Identification of characteristic subepithelial surface granulomatosis in immune-related adverse event-associated enterocolitis.</ArticleTitle>
        <Pagination>
          <StartPage>1320</StartPage>
          <EndPage>1325</EndPage>
          <MedlinePgn>1320-1325</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.14773</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) have provided an additional treatment option for various types of human cancers. However, ICIs often induce various immune-related adverse events (irAEs). Enterocolitis is a major irAE with poorly understood histopathological characteristics. In this study, we retrospectively investigated the histopathology of colon tissue samples from 17 patients treated with ICIs. There were two major histological patterns of colitis: an ulcerative colitis-like pattern and a graft vs host disease-like pattern. Although these two patterns of colitis were mutually exclusive, both patterns often showed a characteristic that we call "subepithelial surface granulomatosis" (SSG), which has not been reported in other types of colitis. SSG was found even in colon tissue without symptoms or endoscopic findings of colitis. Given the increasing reports of sarcoid reaction or exacerbation of tuberculosis after treatment with ICIs, granuloma formation could be a histological hallmark of systemic immune activation by ICIs. Although statistical significance was not obtained, probably because of the small sample size, SSG may be a surrogate biomarker of systemic anticancer immune activation. We propose that a prospective study with larger sample size be performed.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kubo</LastName>
            <ForeName>Terufumi</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-9274-2551</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirohashi</LastName>
            <ForeName>Yoshihiko</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-0608-3914</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Keira</LastName>
            <ForeName>Yoshiko</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Hakodate Goryokaku Hospital, Hakodate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akimoto</LastName>
            <ForeName>Mayuko</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Hakodate Goryokaku Hospital, Hakodate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ikeda</LastName>
            <ForeName>Tatsuru</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Hakodate Goryokaku Hospital, Hakodate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kikuchi</LastName>
            <ForeName>Noriaki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgical Pathology, Sunagawa City Medical Center, Sunagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwaki</LastName>
            <ForeName>Hiroyuki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgical Pathology, Sunagawa City Medical Center, Sunagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kikuchi</LastName>
            <ForeName>Tomoki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Asahikawa Red-Cross Hospital, Asahikawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Obata</LastName>
            <ForeName>Masahiko</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Asahikawa Red-Cross Hospital, Asahikawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morita</LastName>
            <ForeName>Rena</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Otaru City General Hospital, Otaru, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kasai</LastName>
            <ForeName>Kiyoshi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Otaru City General Hospital, Otaru, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Segawa</LastName>
            <ForeName>Keiko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Kushiro City General Hospital, Kushiro, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsukahara</LastName>
            <ForeName>Tomohide</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-3678-4359</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanaseki</LastName>
            <ForeName>Takayuki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murata</LastName>
            <ForeName>Kenji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kikuchi</LastName>
            <ForeName>Yasuhiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shinkawa</LastName>
            <ForeName>Tomoyo</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hasegawa</LastName>
            <ForeName>Tadashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgical Pathology, Sapporo Medical University Hospital, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Torigoe</LastName>
            <ForeName>Toshihiko</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>19cm0106309h0004</GrantID>
            <Agency>Japan Agency for Medical Research and Development</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cancer Sci</MedlineTA>
        <NlmUniqueID>101168776</NlmUniqueID>
        <ISSNLinking>1347-9032</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">biomarker</Keyword>
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse event</Keyword>
        <Keyword MajorTopicYN="N">subepithelial surface granulomatosis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>8</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33459466</ArticleId>
        <ArticleId IdType="pmc">PMC7935803</ArticleId>
        <ArticleId IdType="doi">10.1111/cas.14773</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune&#x2010;related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158&#x2010;168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellaguarda E, Hanauer S. Checkpoint inhibitor&#x2010;induced colitis. Am J Gastroenterol. 2020;115:202&#x2010;210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31922959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor&#x2010;induced colitis: a comprehensive review. World J Clin Cases. 2019;7:405&#x2010;418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6397821</ArticleId>
            <ArticleId IdType="pubmed">30842952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD&#x2010;1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology. 2017;70:558&#x2010;567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28000302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti&#x2010;PD&#x2010;1 antibodies. Am J Surg Pathol. 2017;41:643&#x2010;654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28296676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai S, Nakamura S, Kawasaki K, et al. Immune checkpoint inhibitor&#x2010;induced diarrhea: clinicopathological study of 11 patients. Dig Endosc. 2020;32:616&#x2010;620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31595568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barber DL, Sakai S, Kudchadkar RR, et al. Tuberculosis following PD&#x2010;1 blockade for cancer immunotherapy. Sci Transl Med. 2019;11:eaat2702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7372940</ArticleId>
            <ArticleId IdType="pubmed">30651320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chorti E, Kanaki T, Zimmer L, et al. Drug&#x2010;induced sarcoidosis&#x2010;like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis. Eur J Cancer. 2020;131:18&#x2010;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32248071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asano M, Nakane A, Minagawa T. Endogenous gamma interferon is essential in granuloma formation induced by glycolipid&#x2010;containing mycolic acid in mice. Infect Immun. 1993;61:2872&#x2010;2878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC280933</ArticleId>
            <ArticleId IdType="pubmed">8514390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patey&#x2010;Mariaud de Serre N, Canioni D, Ganousse S, et al. Digestive histopathological presentation of IPEX syndrome. Mod Pathol. 2009;22:95&#x2010;102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18820676</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33454238</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2210-741X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinics and research in hepatology and gastroenterology</Title>
          <ISOAbbreviation>Clin Res Hepatol Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Vedolizumab for steroid &amp; infliximab refractory immune checkpoint inhibitor associated colitis.</ArticleTitle>
        <Pagination>
          <StartPage>101604</StartPage>
          <MedlinePgn>101604</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinre.2020.101604</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2210-7401(20)30370-3</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Klemm</LastName>
            <ForeName>Natasha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Internal Medicine Resident, University of British Columbia, 319-630 Broadway East, Vancouver, BC, V5T 0J1, Canada. Electronic address: nklemm@alumni.ubc.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trasolini</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>University of British Columbia, Division of Gastroenterology, Gordon and Leslie Diamond Health Centre, Vancouver General Hospital, 5153-2775 Laurie St., Vancouver, V5Z 1M9, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chahal</LastName>
            <ForeName>Daljeet</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>University of British Columbia, Division of Gastroenterology, Gordon and Leslie Diamond Health Centre, Vancouver General Hospital, 5153-2775 Laurie St., Vancouver, V5Z 1M9, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Donnellan</LastName>
            <ForeName>Fergal</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>University of British Columbia, Division of Gastroenterology, Gordon and Leslie Diamond Health Centre, Vancouver General Hospital, 5153-2775 Laurie St., Vancouver, V5Z 1M9, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Clin Res Hepatol Gastroenterol</MedlineTA>
        <NlmUniqueID>101553659</NlmUniqueID>
        <ISSNLinking>2210-7401</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013256">Steroids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9RV78Q2002</RegistryNumber>
          <NameOfSubstance UI="C543529">vedolizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B72HH48FLU</RegistryNumber>
          <NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>20</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33454238</ArticleId>
        <ArticleId IdType="doi">10.1016/j.clinre.2020.101604</ArticleId>
        <ArticleId IdType="pii">S2210-7401(20)30370-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33436487</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e002058</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2020-002058</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune-mediated diarrhea and colitis (IMDC) is currently diagnosed and monitored by evaluating clinical symptoms. Deep remission is determined by endoscopic and histologic evaluation of the disease process. However, repeating these invasive procedures frequently can become cumbersome. We sought to assess the role of fecal calprotectin (FC) concentration as a non-invasive biomarker of endoscopic or histologic remission.</AbstractText>
          <AbstractText Label="METHODS">We performed a retrospective study of patients with IMDC who were tested for FC at IMDC onset and after IMDC treatment between June 2016 and March 2020. Patient demographics, clinical variables, and FC data were collected and analyzed to determine the optimal cut-off FC concentration to predict endoscopic and histologic remission.</AbstractText>
          <AbstractText Label="RESULTS">Our sample comprised 77 patients with a median age of 62 years; 66% were male and 94% were Caucasian. Sixty-five patients (84%) achieved clinical remission, 46 (60%) achieved endoscopic remission, and 24 (31%) achieved histologic remission after IMDC treatment. FC concentrations decreased from the time of IMDC onset to the end of treatment (p&lt;0.001). High FC concentrations were associated with evident endoscopic inflammation (p=0.003) and acute/chronic active colitis (p=0.025) which positively correlated with the Mayo Endoscopic Subscore (r=0.615, p=0.001) at the time of IMDC onset. In patients who achieved endoscopic remission after treatment, a significantly lower FC concentration was observed at IMDC onset (p=0.006) and after treatment (p&lt;0.001) compared with those without endoscopic remission. The cut-off FC concentration to predict endoscopic remission was &#x2264;116 &#x3bc;g/g and for histologic remission &#x2264;80 &#x3bc;g/g; these cut-offs had optimal specificity (94% and 85%, respectively) and positive predictive value (0.91 and 0.38, respectively).</AbstractText>
          <AbstractText Label="CONCLUSIONS">FC concentration may serve as a non-invasive biomarker to predict endoscopic and histologic remission in patients receiving treatment for IMDC, minimizing the need for frequent invasive endoscopies. Future prospective studies are needed to provide further insight on the role of this marker in disease surveillance.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Fangwen</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xuemei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Glitza Oliva</LastName>
            <ForeName>Isabella C</ForeName>
            <Initials>IC</Initials>
            <Identifier Source="ORCID">0000-0002-4530-7765</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McQuade</LastName>
            <ForeName>Jennifer L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genitourinary Medical Oncology, The University of Texas MD, Anderson Cancer Center, Houston, Texas, USA</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hao Chi</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thompson</LastName>
            <ForeName>John A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>Anusha S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yinghong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-5148-6130</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D039841">Leukocyte L1 Antigen Complex</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>J Immunother Cancer. 2021 Mar;9(3):1</RefSource>
          <PMID Version="1">33741733</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D039841" MajorTopicYN="N">Leukocyte L1 Antigen Complex</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>5</Hour>
          <Minute>57</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33436487</ArticleId>
        <ArticleId IdType="pmc">PMC7805368</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2020-002058</ArticleId>
        <ArticleId IdType="pii">jitc-2020-002058</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem 2019;26:3009&#x2013;25. 10.2174/0929867324666170804143706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/0929867324666170804143706</ArticleId>
            <ArticleId IdType="pubmed">28782469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. . Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018;4:173&#x2013;82. 10.1001/jamaoncol.2017.3064</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2017.3064</ArticleId>
            <ArticleId IdType="pmc">PMC5838579</ArticleId>
            <ArticleId IdType="pubmed">28973656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baxi S, Yang A, Gennarelli RL, et al. . Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793. 10.1136/bmj.k793</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.k793</ArticleId>
            <ArticleId IdType="pmc">PMC5851471</ArticleId>
            <ArticleId IdType="pubmed">29540345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Naqash AR, et al. . Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 2019;37:2738&#x2013;45. 10.1200/JCO.19.00320</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.00320</ArticleId>
            <ArticleId IdType="pmc">PMC6800279</ArticleId>
            <ArticleId IdType="pubmed">31163011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh BP, Marshall JL, He AR. Workup and management of immune-mediated colitis in patients treated with immune checkpoint inhibitors. Oncologist 2020;25:197&#x2013;202. 10.1634/theoncologist.2018-0304</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0304</ArticleId>
            <ArticleId IdType="pmc">PMC7066712</ArticleId>
            <ArticleId IdType="pubmed">32162824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, et al. . Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018;6:95. 10.1186/s40425-018-0411-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0411-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016;44:51&#x2013;60. 10.1016/j.ctrv.2016.02.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2016.02.001</ArticleId>
            <ArticleId IdType="pubmed">26874776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vardhana S, Cicero K, Velez MJ, et al. . Strategies for recognizing and managing immune-mediated adverse events in the treatment of Hodgkin lymphoma with checkpoint inhibitors. Oncologist 2019;24:86&#x2013;95. 10.1634/theoncologist.2018-0045</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0045</ArticleId>
            <ArticleId IdType="pmc">PMC6324643</ArticleId>
            <ArticleId IdType="pubmed">30082490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. . Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 2018;24:1695&#x2013;705. 10.1093/ibd/izy104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 2020;36:25&#x2013;32. 10.1097/MOG.0000000000000593</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MOG.0000000000000593</ArticleId>
            <ArticleId IdType="pubmed">31609734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayling RM, Kok K. Fecal calprotectin. Adv Clin Chem 2018;87:161&#x2013;90. 10.1016/bs.acc.2018.07.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/bs.acc.2018.07.005</ArticleId>
            <ArticleId IdType="pubmed">30342711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manceau H, Chicha-Cattoir V, Puy H, et al. . Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med 2017;55:474&#x2013;83. 10.1515/cclm-2016-0522</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1515/cclm-2016-0522</ArticleId>
            <ArticleId IdType="pubmed">27658156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307&#x2013;20. 10.1080/10408363.2019.1619159</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10408363.2019.1619159</ArticleId>
            <ArticleId IdType="pubmed">31088326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaki-Khatibi F, Qujeq D, Kashifard M, et al. . Calprotectin in inflammatory bowel disease. Clin Chim Acta 2020;510:556&#x2013;65. 10.1016/j.cca.2020.08.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cca.2020.08.025</ArticleId>
            <ArticleId IdType="pmc">PMC7431395</ArticleId>
            <ArticleId IdType="pubmed">32818491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plevris N, Fulforth J, Lyons M, et al. . Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn&#x2019;s disease. Clin Gastroenterol Hepatol 2020:31131&#x2013;9. 10.1016/j.cgh.2020.08.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2020.08.022</ArticleId>
            <ArticleId IdType="pubmed">32798706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevens TW, Gecse K, Turner JR, et al. . Diagnostic accuracy of fecal calprotectin concentration in evaluating therapeutic outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2020;S1542-3565:31128&#x2013;9. 10.1016/j.cgh.2020.08.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2020.08.019</ArticleId>
            <ArticleId IdType="pubmed">32801008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA 2018;320:1702&#x2013;3. 10.1001/jama.2018.13995</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2018.13995</ArticleId>
            <ArticleId IdType="pubmed">30286224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Herrera LN, Tang T, et al. . Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 2019;7:242. 10.1186/s40425-019-0714-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0714-x</ArticleId>
            <ArticleId IdType="pmc">PMC6729015</ArticleId>
            <ArticleId IdType="pubmed">31488205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, et al. . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019;7:93. 10.1186/s40425-019-0577-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0577-1</ArticleId>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shabani F, Farasat A, Mahdavi M, et al. . Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res 2018;67:801&#x2013;12. 10.1007/s00011-018-1173-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-018-1173-4</ArticleId>
            <ArticleId IdType="pubmed">30083975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu Y, Xu W, Han J, et al. . Diagnostic value of fecal calprotectin in necrotizing enterocolitis: a meta-analysis. Early Hum Dev 2020;151:105170. 10.1016/j.earlhumdev.2020.105170</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.earlhumdev.2020.105170</ArticleId>
            <ArticleId IdType="pubmed">32919106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Fan D, Xu S, et al. . Calprotectin in spondyloarthritis: a systematic review and meta-analysis. Int Immunopharmacol 2020;88:106948. 10.1016/j.intimp.2020.106948</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2020.106948</ArticleId>
            <ArticleId IdType="pubmed">32892074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viola A, Fontana A, Belvedere A, et al. . Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach. Scand J Gastroenterol 2020;55:1176&#x2013;84. 10.1080/00365521.2020.1807599</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00365521.2020.1807599</ArticleId>
            <ArticleId IdType="pubmed">32838582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romand X, Paclet M-H, Courtier A, et al. . Serum calprotectin is increased in early axial spondyloarthritis with sacroiliitis and objective signs of inflammation: results from the DESIR cohort. Joint Bone Spine 2020:105068. 10.1016/j.jbspin.2020.08.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbspin.2020.08.003</ArticleId>
            <ArticleId IdType="pubmed">32896670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaki-Khatibi F, Qujeq D, Kashifard M, et al. . Calprotectin in inflammatory bowel disease. Clin Chim Acta 2020;510:556&#x2013;65. 10.1016/j.cca.2020.08.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cca.2020.08.025</ArticleId>
            <ArticleId IdType="pmc">PMC7431395</ArticleId>
            <ArticleId IdType="pubmed">32818491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S-H, Kim M-J, Chang K, et al. . Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol 2017;17:110. 10.1186/s12876-017-0669-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12876-017-0669-7</ArticleId>
            <ArticleId IdType="pmc">PMC5654142</ArticleId>
            <ArticleId IdType="pubmed">29061121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zittan E, Kelly OB, Kirsch R, et al. . Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn's disease. Inflamm Bowel Dis 2016;22:623&#x2013;30. 10.1097/MIB.0000000000000652</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000000652</ArticleId>
            <ArticleId IdType="pubmed">26829408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guardiola J, Lobat&#xf3;n T, Rodr&#xed;guez-Alonso L, et al. . Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol 2014;12:1865&#x2013;70. 10.1016/j.cgh.2014.06.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2014.06.020</ArticleId>
            <ArticleId IdType="pubmed">24993368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theede K, Holck S, Ibsen P, et al. . Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:1929&#x2013;36. 10.1016/j.cgh.2015.05.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2015.05.038</ArticleId>
            <ArticleId IdType="pubmed">26051392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walsh A, Kormilitzin A, Hinds C, et al. . Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis-a prospective analysis. J Crohns Colitis 2019;13:424&#x2013;30. 10.1093/ecco-jcc/jjy184</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjy184</ArticleId>
            <ArticleId IdType="pubmed">30445625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart L, Chavannes M, Kherad O, et al. . Faecal calprotectin predicts endoscopic and histological activity in clinically quiescent ulcerative colitis. J Crohns Colitis 2020;14:46&#x2013;52. 10.1093/ecco-jcc/jjz107</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjz107</ArticleId>
            <ArticleId IdType="pubmed">31314884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricanek P, Brackmann S, Perminow G, et al. . Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 2011;46:1081&#x2013;91. 10.3109/00365521.2011.584897</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00365521.2011.584897</ArticleId>
            <ArticleId IdType="pubmed">21619483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taghvaei T, Maleki I, Nagshvar F, et al. . Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med 2015;10:321&#x2013;8. 10.1007/s11739-014-1144-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11739-014-1144-x</ArticleId>
            <ArticleId IdType="pubmed">25366383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannatelli R, Bazarova A, Zardo D, et al. . Fecal calprotectin thresholds to predict endoscopic remission using advanced optical enhancement techniques and histological remission in IBD patients. Inflamm Bowel Dis 2020:izaa163. 10.1093/ibd/izaa163</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izaa163</ArticleId>
            <ArticleId IdType="pubmed">32592477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lobat&#xf3;n T, Rodr&#xed;guez-Moranta F, Lopez A, et al. . A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013;19:1034&#x2013;42. 10.1097/MIB.0b013e3182802b6e</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0b013e3182802b6e</ArticleId>
            <ArticleId IdType="pubmed">23470502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mak WY, Buisson A, Andersen MJ, et al. . Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig Dis Sci 2018;63:1294&#x2013;301. 10.1007/s10620-018-4980-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-018-4980-0</ArticleId>
            <ArticleId IdType="pubmed">29468374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel A, Panchal H, Dubinsky MC. Fecal calprotectin levels predict histological healing in ulcerative colitis. Inflamm Bowel Dis 2017;23:1600&#x2013;4. 10.1097/MIB.0000000000001157</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000001157</ArticleId>
            <ArticleId IdType="pubmed">28590341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magro F, Lopes J, Borralho P, et al. . Comparing the continuous Geboes score with the Robarts histopathology index: definitions of histological remission and response and their relation to faecal calprotectin levels. J Crohns Colitis 2020;14:169&#x2013;75. 10.1093/ecco-jcc/jjz123</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjz123</ArticleId>
            <ArticleId IdType="pubmed">31504348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lobat&#xf3;n T, Vermeire S, Van Assche G, et al. . Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:579&#x2013;94. 10.1111/apt.12639</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.12639</ArticleId>
            <ArticleId IdType="pubmed">24479980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feagan BG, Rutgeerts P, Sands BE, et al. . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699&#x2013;710. 10.1056/NEJMoa1215734</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1215734</ArticleId>
            <ArticleId IdType="pubmed">23964932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Pei F, Wang X, et al. . Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. Int J Clin Exp Pathol 2015;8:12319&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4680364</ArticleId>
            <ArticleId IdType="pubmed">26722419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The University of Texas MD Anderson Cancer Center . Evaluation and management of suspected immune-mediated colitis/diarrhea. Available: https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/clinical-management/clin-management-immune-mediated-colitis-web-algorithm.pdf [Accessed 04 Nov 2020].</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33375984</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-229X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>76</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical radiology</Title>
          <ISOAbbreviation>Clin Radiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Imaging spectrum of adverse events of immune checkpoint inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>262</StartPage>
          <EndPage>272</EndPage>
          <MedlinePgn>262-272</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.crad.2020.11.117</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0009-9260(20)30625-5</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs), a form of immunotherapy, are increasingly used for a variety of malignancies and have been linked to numerous treatment-related side effects known as immune-related adverse events (irAEs). IrAEs can affect multiple organ systems and are important to recognise in order to avoid misinterpretation as progressive tumour and to ensure appropriate management. In this pictorial review, we will briefly discuss radiological response criteria of immunotherapy and describe the imaging appearances of the wide spectrum of these ICI-associated toxicities.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shroff</LastName>
            <ForeName>G S</ForeName>
            <Initials>GS</Initials>
            <AffiliationInfo>
              <Affiliation>MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 1478, Houston, TX, 77030, USA. Electronic address: gshroff@mdanderson.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shroff</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Houston Methodist, 6560 Fannin St. Ste 802, Houston, TX, 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahuja</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 1478, Houston, TX, 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Truong</LastName>
            <ForeName>M T</ForeName>
            <Initials>MT</Initials>
            <AffiliationInfo>
              <Affiliation>MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 1478, Houston, TX, 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vlahos</LastName>
            <ForeName>I</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 1478, Houston, TX, 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Clin Radiol</MedlineTA>
        <NlmUniqueID>1306016</NlmUniqueID>
        <ISSNLinking>0009-9260</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000307" MajorTopicYN="N">Adrenal Gland Diseases</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006505" MajorTopicYN="N">Hepatitis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010493" MajorTopicYN="N">Pericarditis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013966" MajorTopicYN="N">Thyroiditis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33375984</ArticleId>
        <ArticleId IdType="doi">10.1016/j.crad.2020.11.117</ArticleId>
        <ArticleId IdType="pii">S0009-9260(20)30625-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33314269</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2036</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>53</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Alimentary pharmacology &amp; therapeutics</Title>
          <ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.</ArticleTitle>
        <Pagination>
          <StartPage>374</StartPage>
          <EndPage>382</EndPage>
          <MedlinePgn>374-382</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.16217</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune checkpoint inhibitors may variably impact patients with pre-existing autoimmune diseases.</AbstractText>
          <AbstractText Label="AIMS">To evaluate the risks and outcomes of adverse events in patients with pre-existing inflammatory bowel diseases treated with immune checkpoint inhibitors.</AbstractText>
          <AbstractText Label="METHODS">Through a systematic literature review up until July 31, 2020, we identified 12 studies reporting the impact of immune checkpoint inhibitors in 193 patients with inflammatory bowel disease. Outcomes of interest were relapse of inflammatory bowel disease, need for corticosteroids and/or biologics to manage inflammatory bowel disease relapse, and discontinuation of immune checkpoint inhibitors. We calculated pooled rates (with 95% confidence intervals [CI]) using random effects meta-analysis, and examined risk factors associated with adverse outcomes through qualitative synthesis of individual studies.</AbstractText>
          <AbstractText Label="RESULTS">On meta-analysis, 40% patients (95% CI, 26%-55%) experienced relapse of inflammatory bowel disease with immune checkpoint inhibitors. Among patients who experienced relapse, 76% (95% CI, 65%-85%) required corticosteroids, and 37% (95% CI, 22%-53%) required biologic therapy. Overall, 35% patients (95% CI, 17%-57%) with inflammatory bowel disease discontinued immune checkpoint inhibitors. Gastrointestinal perforation and abdominal surgery due to immune checkpoint inhibitor complications occurred in &lt;5% patients. In a large study, inhibitors of cytotoxic T-lymphocyte antigen-4 (CTLA-4) were associated with a higher risk of relapse than programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Approximately 40% of patients with pre-existing inflammatory bowel diseases experience relapse with immune checkpoint inhibitors, with most relapsing patients requiring corticosteroids and one-third requiring biologics. CTLA-4 inhibitors may be associated with higher risk of relapse.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Meserve</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-1228-3215</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Facciorusso</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-2107-2156</Identifier>
            <AffiliationInfo>
              <Affiliation>Gastroenterology Unit, Ospedali Riuniti di Foggia, Foggia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holmer</LastName>
            <ForeName>Ariela K</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Annese</LastName>
            <ForeName>Vito</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Valiant Clinic &amp; American Hospital, Dubai, United Arab Emirates.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sandborn</LastName>
            <ForeName>William J</ForeName>
            <Initials>WJ</Initials>
            <Identifier Source="ORCID">0000-0002-3314-7960</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Siddharth</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-2640-7269</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Biomedical Informatics, University of California San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K23DK117058</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 DK120515</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 DK007202</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32DK007202</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K23 DK117058</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Aliment Pharmacol Ther</MedlineTA>
        <NlmUniqueID>8707234</NlmUniqueID>
        <ISSNLinking>0269-2813</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Aliment Pharmacol Ther. 2021 Jul;54(2):217-218</RefSource>
          <PMID Version="1">34170536</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Dig Liver Dis. 2022 Sep;54(9):1162-1167</RefSource>
          <PMID Version="1">35842365</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>11</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33314269</ArticleId>
        <ArticleId IdType="mid">NIHMS1683740</ArticleId>
        <ArticleId IdType="pmc">PMC8041067</ArticleId>
        <ArticleId IdType="doi">10.1111/apt.16217</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:1&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6292890</ArticleId>
            <ArticleId IdType="pubmed">30546008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu C, Chen Y-P, Du X-J, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;363:k4226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6222274</ArticleId>
            <ArticleId IdType="pubmed">30409774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018;378:158&#x2013;168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins M, Soularue E, Marthey L, et al. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol 2020;18:1393&#x2013;1403.e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32007539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. Ann Intern Med 2018;168:121&#x2013;130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29297009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19622512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5833365</ArticleId>
            <ArticleId IdType="pubmed">28935701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute of Clinical Excellence (NICE). Quality Assessment of Case Series. Accessed at: https://www.nice.org.uk/guidance/cg3/documents/appendix-4-quality-of-case-series-form2, on July 1, 2020</Citation>
        </Reference>
        <Reference>
          <Citation>Kendall MG, Stuart A, &amp; Ord JK. Kendall&#x2019;s advanced theory of statistics. New York: Oxford University Press. 1987.</Citation>
        </Reference>
        <Reference>
          <Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3802833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Bmj 2003;327:557&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC192859</ArticleId>
            <ArticleId IdType="pubmed">12958120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. Bmj 2001;323:101&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1120714</ArticleId>
            <ArticleId IdType="pubmed">11451790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown LJ, Weppler A, Bhave P, et al. Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD). Journal of Clinical Oncology 2020;38:10026&#x2013;10026.</Citation>
        </Reference>
        <Reference>
          <Citation>Braga Neto MB, Ramos GP, Loftus EV Jr., et al. Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series. Clin Gastroenterol Hepatol 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32565289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Faleck DM, Ricciuti B, et al. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology 2020;38:576&#x2013;583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7030892</ArticleId>
            <ArticleId IdType="pubmed">31800340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tison A, Qu&#xe9;r&#xe9; G, Misery L, et al. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol 2019;71:2100&#x2013;2111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31379105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur A, Doberstein T, Amberker RR, et al. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience. Medicine (Baltimore) 2019;98:e17348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6799752</ArticleId>
            <ArticleId IdType="pubmed">31593084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortellini A, Buti S, Santini D, et al. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist 2019;24:e327&#x2013;e337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6656514</ArticleId>
            <ArticleId IdType="pubmed">30796151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonardi GC, Gainor JF, Altan M, et al. Safety of Programmed Death&#x2013;1 Pathway Inhibitors Among Patients With Non&#x2013;Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. Journal of Clinical Oncology 2018;36:1905&#x2013;1912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6553840</ArticleId>
            <ArticleId IdType="pubmed">29746230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K&#xe4;hler KC, Eigentler TK, Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunology, Immunotherapy 2018;67:825&#x2013;834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29487980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017;28:368&#x2013;376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27687304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol 2016;2:234&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26633184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, Ruan AB, Srivoleti P, et al. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncology Practice;0:JOP.19.00672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32401685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 2017;6:e1344805&#x2013;e1344805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5665065</ArticleId>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. Journal for ImmunoTherapy of Cancer 2018;6:37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5946546</ArticleId>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibraheim H, Baillie S, Samaan MA, et al. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32920854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor&#x2013;induced colitis: a multi-center study. Journal for ImmunoTherapy of Cancer 2018;6:142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6280383</ArticleId>
            <ArticleId IdType="pubmed">30518410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Hudson M, Batist G. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. N Engl J Med 2020;382:2374&#x2013;2375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32521140</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33290513</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1465-3621</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>51</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Japanese journal of clinical oncology</Title>
          <ISOAbbreviation>Jpn J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.</ArticleTitle>
        <Pagination>
          <StartPage>363</StartPage>
          <EndPage>370</EndPage>
          <MedlinePgn>363-370</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/jjco/hyaa203</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Diarrhea is often observed as an immune-related adverse event. In this study, we conducted a retrospective review of the severity of diarrhea, its treatment and the endoscopic findings in patients developing diarrhea as an immune-related adverse event.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">From August 2015 to June 2019, a total of 369 patients received treatment with immune checkpoint inhibitors at our hospital. For this study, development of grade 2 or more diarrhea in these patients was defined as an immune-related adverse event. We analyzed the histopathological severity of the bowel lesions according to the Nancy histological index for ulcerative colitis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 369 patients, 27 (7.3%) developed diarrhea as an immune-related adverse event. Of these 27 patients, 18 received steroid treatment. Colonoscopy was performed in 17 patients and culture of the feces in 18. The tests revealed evidence of bacterial colitis (Aeromonas hydrophila) in two patients. The Nancy histological index was 4, 3, 2, 1 and 0 in two, three, two, two and seven patients, respectively. No findings on colonoscopy were observed in 7 of the 17 patients (41%) who underwent colonoscopy, and most of these patients recovered without steroid treatment. Patients with lower values of the Nancy histological index tended to show better responses to steroid treatment.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">To avoid unnecessary steroid administration, colonoscopic evaluation is essential in patients receiving treatment with immune checkpoint inhibitors who present with diarrhea as an immune-related adverse event. In addition, the endoscopic findings could be useful to predict the response to steroid treatment.</AbstractText>
          <CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yamauchi</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arai</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akizue</LastName>
            <ForeName>Naoki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohta</LastName>
            <ForeName>Yuki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Okimoto</LastName>
            <ForeName>Kenichiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumura</LastName>
            <ForeName>Tomoaki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Meng Meng</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imai</LastName>
            <ForeName>Chiaki</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacy, Chiba University Hospital, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tawada</LastName>
            <ForeName>Akinobu</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kato</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kato</LastName>
            <ForeName>Naoya</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takiguchi</LastName>
            <ForeName>Yuichi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Jpn J Clin Oncol</MedlineTA>
        <NlmUniqueID>0313225</NlmUniqueID>
        <ISSNLinking>0368-2811</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013256">Steroids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003113" MajorTopicYN="Y">Colonoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">colonoscopy</Keyword>
        <Keyword MajorTopicYN="N">diarrhea</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">irAE</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>8</Day>
          <Hour>17</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33290513</ArticleId>
        <ArticleId IdType="doi">10.1093/jjco/hyaa203</ArticleId>
        <ArticleId IdType="pii">6027889</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33268234</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0852</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>142</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of cancer (Oxford, England : 1990)</Title>
          <ISOAbbreviation>Eur J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis.</ArticleTitle>
        <Pagination>
          <StartPage>143</StartPage>
          <EndPage>146</EndPage>
          <MedlinePgn>143-146</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2020.09.022</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0959-8049(20)31031-5</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thompson</LastName>
            <ForeName>Leah L</ForeName>
            <Initials>LL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Katznelson</LastName>
            <ForeName>Ethan</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leet</LastName>
            <ForeName>Donna E</ForeName>
            <Initials>DE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durbin</LastName>
            <ForeName>Sienna M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoon</LastName>
            <ForeName>Jaewon</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reynolds</LastName>
            <ForeName>Kerry L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dougan</LastName>
            <ForeName>Michael L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Steven T</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: stchen@partners.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 DK114563</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Cancer</MedlineTA>
        <NlmUniqueID>9005373</NlmUniqueID>
        <ISSNLinking>0959-8049</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflict of interest statement None of the authors have financial conflicts of interest to report. All listed authors contributed meaningfully to drafting and revisions of the manuscript. No additional individuals were involved in this process.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33268234</ArticleId>
        <ArticleId IdType="mid">NIHMS1724519</ArticleId>
        <ArticleId IdType="pmc">PMC8300871</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejca.2020.09.022</ArticleId>
        <ArticleId IdType="pii">S0959-8049(20)31031-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Collins M, Soularue E, Marthey L, Carbonnel F. Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review. Clin Gastroenterol Hepatol 2020. 10.1016/J.CGH.2020.01.033. Published online January 31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.CGH.2020.01.033</ArticleId>
            <ArticleId IdType="pubmed">32007539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 2018;124(18):3706e14. 10.1002/cncr.31629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31629</ArticleId>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw 2019;17(3):255e89. 10.6004/jnccn.2019.0013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2019.0013</ArticleId>
            <ArticleId IdType="pubmed">30865922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol 2017;17(4):233e47. 10.1038/nri.2017.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.1</ArticleId>
            <ArticleId IdType="pubmed">28192415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das S, Johnson DB. Immune-related adverse events and antitumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019;7(1):306. 10.1186/s40425-019-0805-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0805-8</ArticleId>
            <ArticleId IdType="pmc">PMC6858629</ArticleId>
            <ArticleId IdType="pubmed">31730012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horvat TZ, Adel NG, Dang T-O, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 2015; 33(28):3193e8. 10.1200/JCO.2015.60.8448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.60.8448</ArticleId>
            <ArticleId IdType="pmc">PMC5087335</ArticleId>
            <ArticleId IdType="pubmed">26282644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, Ali N, Shaukat Ali F, Qiao W, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 2018;6(1):37. 10.1186/s40425-018-0346-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0346-6</ArticleId>
            <ArticleId IdType="pmc">PMC5946546</ArticleId>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33173388</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1718-7729</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current oncology (Toronto, Ont.)</Title>
          <ISOAbbreviation>Curr Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>e486</StartPage>
          <EndPage>e494</EndPage>
          <MedlinePgn>e486-e494</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3747/co.27.6251</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune checkpoint inhibitors (icis), including inhibitors of PD-1, PD-L1, and ctla-4, are relatively novel therapies for lung cancer, although their use might be limited by gastrointestinal toxicity. The aim of the present study was to determine the risk of diarrhea and colitis associated with icis in lung cancer and the rates of discontinuation because of those toxicities.</AbstractText>
          <AbstractText Label="METHODS">Electronic databases were searched for prospective trials reporting the risk of diarrhea and colitis in patients with lung cancer treated with PD-1, PD-L1, and ctla-4 inhibitors. The incidences of diarrhea and colitis and their grades were assessed clinically using standardized reporting criteria. Pooled incidence and weighted relative risk estimates for diarrhea and colitis with 95% confidence intervals (cis) were estimated using a random effects model. The incidence of discontinuations for gi toxicity was also calculated.</AbstractText>
          <AbstractText Label="RESULTS">Twenty-seven studies were included: sixteen studies with PD-1 inhibitors, nine studies with PD-L1 inhibitors, and four studies combining PD-based strategies with ctla-4 inhibitors. The incidence of all-grade diarrhea was 9.1% (95% ci: 7.8% to 10.5%) for anti-PD-1 therapy and 11.0% (95% ci: 7.5% to 14.5%) for anti-PD-L1 therapy. The incidence of all-grade colitis was 0.9% (95% ci: 0.4% to 1.3%) for anti-PD-1 therapy and 0.4% (95% ci: 0.0% to 0.8%) for anti-PD-L1 therapy. The relative risk for all-grade diarrhea was higher with combination anti-PD-1 and anti-ctla-4 than with anti-PD-1 monotherapy (relative risk: 1.61; 95% ci: 1.14 to 2.29). Anti-PD-1 therapy was discontinued in 4.1% of patients with diarrhea (95% ci: 0.7% to 7.4%) and in 35.7% of those with colitis (95% ci: 0.0% to 81.1%); combination therapy was discontinued in 10.1% of patients with diarrhea (95% ci: 4.8% to 15.4%) and in 39.9% of those with colitis (95% ci: 3.9% to 75.9%).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Diarrhea is a relatively frequently encountered gi toxicity when ici therapy is used in lung cancer treatment. Colitis is less frequently encountered, although when it does occur, it often results in therapy discontinuation.</AbstractText>
          <CopyrightInformation>2020 Multimed Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bishay</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of Toronto, Toronto, ON.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tandon</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of Toronto, Toronto, ON.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bourassa-Blanchette</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Infectious Diseases, University of Calgary, Calgary, AB.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laurie</LastName>
            <ForeName>S A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medical Oncology, The Ottawa Hospital, Ottawa, ON.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCurdy</LastName>
            <ForeName>J D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, The Ottawa Hospital, Ottawa, ON.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Curr Oncol</MedlineTA>
        <NlmUniqueID>9502503</NlmUniqueID>
        <ISSNLinking>1198-0052</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Lung cancer</Keyword>
        <Keyword MajorTopicYN="N">checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">diarrhea</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology&#x2019;s policy on disclosing conflicts of interest, and we declare that we have none.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>11</Day>
          <Hour>5</Hour>
          <Minute>57</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33173388</ArticleId>
        <ArticleId IdType="pmc">PMC7606037</ArticleId>
        <ArticleId IdType="doi">10.3747/co.27.6251</ArticleId>
        <ArticleId IdType="pii">conc-27-e486</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990&#x2013;2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545&#x2013;602. doi: 10.1016/S0140-6736(16)31678-6. [Erratum in: Lancet 2017;389:e1]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)31678-6</ArticleId>
            <ArticleId IdType="pmc">PMC5055577</ArticleId>
            <ArticleId IdType="pubmed">27733282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136:E359&#x2013;86. doi: 10.1002/ijc.29210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong MCS, Lao XQ, Ho KF, Goggins WB, Tse SLA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7:14300. doi: 10.1038/s41598-017-14513-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-14513-7</ArticleId>
            <ArticleId IdType="pmc">PMC5662733</ArticleId>
            <ArticleId IdType="pubmed">29085026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015;4:327&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4549470</ArticleId>
            <ArticleId IdType="pubmed">26380174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252&#x2013;64. doi: 10.1038/nrc3239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3239</ArticleId>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non&#x2013;small cell lung cancer. Chest. 2017;152:271&#x2013;81. doi: 10.1016/j.chest.2017.04.177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2017.04.177</ArticleId>
            <ArticleId IdType="pubmed">28499515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain P, Jain C, Velcheti V. Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis. 2018;12:1753465817750075. doi: 10.1177/1753465817750075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1753465817750075</ArticleId>
            <ArticleId IdType="pmc">PMC5937156</ArticleId>
            <ArticleId IdType="pubmed">29385894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thungappa S, Ferri J, Caglevic C, Passiglia F, Raez L, Rolfo C. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found&#x2026;. ESMO Open. 2017;2:e000162. doi: 10.1136/esmoopen-2017-000162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000162</ArticleId>
            <ArticleId IdType="pmc">PMC5519814</ArticleId>
            <ArticleId IdType="pubmed">28761734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage iii non-small-cell lung cancer. N Engl J Med. 2017;377:1919&#x2013;29. doi: 10.1056/NEJMoa1709937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1709937</ArticleId>
            <ArticleId IdType="pubmed">28885881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reck M, Rodr&#xed;guez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1&#x2013;positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823&#x2013;33. doi: 10.1056/NEJMoa1606774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1606774</ArticleId>
            <ArticleId IdType="pubmed">27718847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroner PT, Mody K, Farraye FA. Immune checkpoint inhibitor&#x2013;related luminal gi adverse events. Gastrointest Endosc. 2019;90:881&#x2013;92. doi: 10.1016/j.gie.2019.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gie.2019.09.009</ArticleId>
            <ArticleId IdType="pubmed">31526811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D on behalf of the prisma Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the prisma statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId>
            <ArticleId IdType="pmc">PMC2707599</ArticleId>
            <ArticleId IdType="pubmed">19621072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. London, U.K.: The Cochrane Collaboration; 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/9780470712184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121&#x2013;7. doi: 10.1200/JCO.2007.12.4784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.12.4784</ArticleId>
            <ArticleId IdType="pubmed">17991931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49:1&#x2013;15. doi: 10.18637/jss.v049.i05.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18637/jss.v049.i05</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non&#x2013;small-cell lung cancer. N Engl J Med. 2015;373:1627&#x2013;39. doi: 10.1056/NEJMoa1507643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1507643</ArticleId>
            <ArticleId IdType="pmc">PMC5705936</ArticleId>
            <ArticleId IdType="pubmed">26412456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123&#x2013;35. doi: 10.1056/NEJMoa1504627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504627</ArticleId>
            <ArticleId IdType="pmc">PMC4681400</ArticleId>
            <ArticleId IdType="pubmed">26028407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garon EB, Rizvi NA, Hui R, et al. on behalf of the keynote-001 investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018&#x2013;28. doi: 10.1056/NEJMoa1501824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1501824</ArticleId>
            <ArticleId IdType="pubmed">25891174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi NA, Mazi&#xe8;res J, Planchard D, et al. Activity and safety of nivolumab, an anti&#x2013;PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257&#x2013;65. doi: 10.1016/S1470-2045(15)70054-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)70054-9</ArticleId>
            <ArticleId IdType="pmc">PMC5726228</ArticleId>
            <ArticleId IdType="pubmed">25704439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonia SJ, L&#xf3;pez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883&#x2013;95. doi: 10.1016/S1470-2045(16)30098-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)30098-5</ArticleId>
            <ArticleId IdType="pubmed">27269741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non&#x2013;small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299&#x2013;308. doi: 10.1016/S1470-2045(15)00544-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)00544-6</ArticleId>
            <ArticleId IdType="pmc">PMC5500167</ArticleId>
            <ArticleId IdType="pubmed">26858122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (poplar): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837&#x2013;46. doi: 10.1016/S0140-6736(16)00587-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)00587-0</ArticleId>
            <ArticleId IdType="pubmed">26970723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2980&#x2013;7. doi: 10.1200/JCO.2016.66.9929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.66.9929</ArticleId>
            <ArticleId IdType="pmc">PMC5569692</ArticleId>
            <ArticleId IdType="pubmed">27354485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976&#x2013;83. doi: 10.1016/S1470-2045(16)30053-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)30053-5</ArticleId>
            <ArticleId IdType="pmc">PMC5526047</ArticleId>
            <ArticleId IdType="pubmed">27267608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1&#x2013;positive, advanced non-small-cell lung cancer (keynote-010): a randomised controlled trial. Lancet. 2016;387:1540&#x2013;50. doi: 10.1016/S0140-6736(15)01281-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)01281-7</ArticleId>
            <ArticleId IdType="pubmed">26712084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage iv or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415&#x2013;26. doi: 10.1056/NEJMoa1613493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1613493</ArticleId>
            <ArticleId IdType="pmc">PMC6487310</ArticleId>
            <ArticleId IdType="pubmed">28636851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (javelin Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017;18:599&#x2013;610. doi: 10.1016/S1470-2045(17)30240-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(17)30240-1</ArticleId>
            <ArticleId IdType="pmc">PMC5522719</ArticleId>
            <ArticleId IdType="pubmed">28373005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18:31&#x2013;41. doi: 10.1016/S1470-2045(16)30624-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)30624-6</ArticleId>
            <ArticleId IdType="pmc">PMC5476941</ArticleId>
            <ArticleId IdType="pubmed">27932067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hida T, Nishio M, Nogami N, et al. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non&#x2013;small cell lung cancer. Cancer Sci. 2017;108:1000&#x2013;6. doi: 10.1111/cas.13225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13225</ArticleId>
            <ArticleId IdType="pmc">PMC5448646</ArticleId>
            <ArticleId IdType="pubmed">28266091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M, Hida T, Atagi S, et al. Multicentre phase ii study of nivolumab in Japanese patients with advanced or recurrent non-squamous non&#x2013;small cell lung cancer. ESMO Open. 2017;1:e000108. doi: 10.1136/esmoopen-2016-000108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2016-000108</ArticleId>
            <ArticleId IdType="pmc">PMC5566979</ArticleId>
            <ArticleId IdType="pubmed">28861280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase ib keynote-028 study. J Clin Oncol. 2017;35:3823&#x2013;9. doi: 10.1200/JCO.2017.72.5069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.72.5069</ArticleId>
            <ArticleId IdType="pubmed">28813164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (oak): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255&#x2013;65. doi: 10.1016/S0140-6736(16)32517-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)32517-X</ArticleId>
            <ArticleId IdType="pmc">PMC6886121</ArticleId>
            <ArticleId IdType="pubmed">27979383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (atlantic): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19:521&#x2013;36. doi: 10.1016/S1470-2045(18)30144-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30144-X</ArticleId>
            <ArticleId IdType="pmc">PMC7771363</ArticleId>
            <ArticleId IdType="pubmed">29545095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093&#x2013;104. doi: 10.1056/NEJMoa1801946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1801946</ArticleId>
            <ArticleId IdType="pmc">PMC7193684</ArticleId>
            <ArticleId IdType="pubmed">29658845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horn L, Gettinger SN, Gordon MS, et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase i study. Eur J Cancer. 2018;101:201&#x2013;9. doi: 10.1016/j.ejca.2018.06.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.06.031</ArticleId>
            <ArticleId IdType="pubmed">30077125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spigel DR, Chaft JE, Gettinger S, et al. fir: efficacy, safety, and biomarker analysis of a phase ii open-label study of atezolizumab in PD-L1&#x2013;selected patients with non-small-cell lung cancer. J Thorac Oncol. 2018;13:1733&#x2013;42. doi: 10.1016/j.jtho.2018.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.05.004</ArticleId>
            <ArticleId IdType="pmc">PMC7455890</ArticleId>
            <ArticleId IdType="pubmed">29775807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29:959&#x2013;65. doi: 10.1093/annonc/mdy041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy041</ArticleId>
            <ArticleId IdType="pubmed">29408986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato T, Takahashi T, Yoshioka H, et al. keynote-025: phase 1b study of pembrolizumab (pembro) in Japanese patients (pts) with previously treated PD-L1+ non&#x2013;small cell lung cancer (nsclc) [abstract 1120] Ann Oncol. 2016;27:vi422. doi: 10.1093/annonc/mdw383.21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw383.21</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonia SJ, Kim SW, Spira AI, et al. Safety and clinical activity of durvalumab (medi4736), an anti&#x2013;PD-L1 antibody, in treatment-na&#xef;ve patients with advanced non-small-cell lung cancer [abstract 2029] J Clin Oncol. 2016;34 [Available online at: https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.9029; cited 22 August 2020]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.34.15_suppl.9029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balmanoukian AS, Antonia SJ, Hwu WJ, et al. Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage iiib/iv nsclc [abstract 9085] J Clin Oncol. 2017;35 doi: 10.1200/JCO.2017.35.15_suppl.9085. [Available online at: https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9085; cited 22 August 2020]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.35.15_suppl.9085</ArticleId>
            <ArticleId IdType="doi">10.1200/JCO.2017.35.15_suppl.9085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase iii trials (CheckMate 017 and CheckMate 057) J Clin Oncol. 2017;35:3924&#x2013;33. doi: 10.1200/JCO.2017.74.3062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.74.3062</ArticleId>
            <ArticleId IdType="pmc">PMC6075826</ArticleId>
            <ArticleId IdType="pubmed">29023213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor&#x2013;related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6:e1344805. doi: 10.1080/2162402X.2017.1344805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1344805</ArticleId>
            <ArticleId IdType="pmc">PMC5665065</ArticleId>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother. 2018;41:101&#x2013;8. doi: 10.1097/CJI.0000000000000213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000213</ArticleId>
            <ArticleId IdType="pubmed">29401166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage iv non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35:3484&#x2013;515. doi: 10.1200/JCO.2017.74.6065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.74.6065</ArticleId>
            <ArticleId IdType="pubmed">28806116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors. JAMA Oncol. 2016;2:1346&#x2013;53. doi: 10.1001/jamaoncol.2016.1051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.1051</ArticleId>
            <ArticleId IdType="pubmed">27367787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor&#x2013;related colitis. Inflamm Bowel Dis. 2018;24:1695&#x2013;705. doi: 10.1093/ibd/izy104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33146440</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2036</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>53</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Alimentary pharmacology &amp; therapeutics</Title>
          <ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The significance of histological activity measurements in immune checkpoint inhibitor colitis.</ArticleTitle>
        <Pagination>
          <StartPage>150</StartPage>
          <EndPage>159</EndPage>
          <MedlinePgn>150-159</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.16142</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Colitis is a significant complication of immune checkpoint inhibitors (ICI). Currently, clinical and endoscopic severity are used to guide therapy.</AbstractText>
          <AbstractText Label="AIMS">To investigate associations between clinical, endoscopic, and histological features with outcomes METHODS: We identified 149 patients from seven institutions with biopsy-proven ICI colitis. Biopsies were evaluated for histological features including the Geboes score, and the Robarts histopathological index (RHI) was calculated. Clinical, endoscopic, and histological data were tested for associations with biological use and adverse colitis outcomes (biological-refractory colitis, colectomy or death from colitis).</AbstractText>
          <AbstractText Label="RESULTS">Three mutually exclusive histological patterns were identified: acute colitis, chronic active colitis and microscopic colitis. Microscopic colitis was associated with older age (68.5 vs 61&#xa0;years for acute colitis pattern, P&#xa0;=&#xa0;0.02) and longer time to colitis (5.5 vs 3&#xa0;months for the other patterns, P&#xa0;=&#xa0;0.05). Biological use was associated with earlier time to colitis (2 vs 3&#xa0;months, P&#xa0;=&#xa0;0.04) and higher RHI (18 vs 12, P&#xa0;=&#xa0;0.007). On multivariate analysis, RHI &#x2265;14 was associated with biological use with an odds ratio of 4.5 (95% CI 1.4-13.8; P&#xa0;=&#xa0;0.01). Adverse colitis outcomes were associated with shorter time to colitis (2 vs 3&#xa0;months, P&#xa0;=&#xa0;0.008) and higher RHI (24 vs 14, P&#xa0;=&#xa0;0.001). On multivariate analysis, RHI &#x2265;24 was associated with adverse colitis outcomes with an odds ratio 9.5 (95% CI 2.1-42.3 P&#xa0;=&#xa0;0.003).</AbstractText>
          <AbstractText Label="CONCLUSION">Histological activity as measured by RHI is the only factor independently associated with biological use and adverse colitis outcomes. Prospective studies are needed to validate these findings to determine if histological activity should be incorporated into therapeutic algorithms.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pai</LastName>
            <ForeName>Rish K</ForeName>
            <Initials>RK</Initials>
            <Identifier Source="ORCID">0000-0002-2692-221X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pai</LastName>
            <ForeName>Reetesh K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Ian</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Envoi Specialist Pathologists, Brisbane, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Won-Tak</ForeName>
            <Initials>WT</Initials>
            <AffiliationInfo>
              <Affiliation>University of California San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schaeffer</LastName>
            <ForeName>David F</ForeName>
            <Initials>DF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Farnell</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumarasinghe</LastName>
            <ForeName>M Priyanthi</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomical Pathology, PathWest Laboratory Medicine and University of Western Australia, Perth, WA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gunawardena</LastName>
            <ForeName>Dilini</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomical Pathology, PathWest Laboratory Medicine and University of Western Australia, Perth, WA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Baek Hui</ForeName>
            <Initials>BH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Henry L. Moffitt Cancer Center &amp; Research Institute, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Friedman</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Gastrointestinal Oncology Program, Henry L. Moffitt Cancer Center &amp; Research Institute, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghayouri</LastName>
            <ForeName>Masoumeh</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Henry L. Moffitt Cancer Center &amp; Research Institute, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lauwers</LastName>
            <ForeName>Gregory Y</ForeName>
            <Initials>GY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Henry L. Moffitt Cancer Center &amp; Research Institute, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Aliment Pharmacol Ther</MedlineTA>
        <NlmUniqueID>8707234</NlmUniqueID>
        <ISSNLinking>0269-2813</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Aliment Pharmacol Ther. 2021 Mar;53(5):636-637</RefSource>
          <PMID Version="1">33566405</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Aliment Pharmacol Ther. 2021 Mar;53(5):638-639</RefSource>
          <PMID Version="1">33566423</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>4</Day>
          <Hour>8</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33146440</ArticleId>
        <ArticleId IdType="doi">10.1111/apt.16142</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18:230-241.</Citation>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563-580.</Citation>
        </Reference>
        <Reference>
          <Citation>Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis. Am J Gastroenterol. 2020;115:202-210.</Citation>
        </Reference>
        <Reference>
          <Citation>Collins M, Soularue E, Marthey L, et al. Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review. Clin Gastroenterol Hepatol. 2020;18:1393-1403.e1.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Wang Y. Management considerations for immune checkpoint inhibitor-induced enterocolitis based on management of inflammatory bowel disease. Inflamm Bowel Dis. 2020;26:662-668.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol. 2020;36:25-32.</Citation>
        </Reference>
        <Reference>
          <Citation>Wright AP, Piper MS, Bishu S, et al. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2019;49:1474-1483.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24:1695-1705.</Citation>
        </Reference>
        <Reference>
          <Citation>Jairath V, Peyrin-Biroulet L, Zou G, et al. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019;68:1162-1168.</Citation>
        </Reference>
        <Reference>
          <Citation>Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut. 2017;66:50-58.</Citation>
        </Reference>
        <Reference>
          <Citation>Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404-409.</Citation>
        </Reference>
        <Reference>
          <Citation>Scherl EJ, Pruitt R, Gordon GL, et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2009;104:1452-1459.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen J. A power primer. Psychol Bull. 1992;112:155-159.</Citation>
        </Reference>
        <Reference>
          <Citation>Adler BL, Pezhouh MK, Kim A, et al. Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med. 2018;283:568-577.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen JH, Pezhouh MK, Lauwers GY, et al. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 2017;41:643-654.</Citation>
        </Reference>
        <Reference>
          <Citation>Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. J Clin Pathol. 2018;71:665-671.</Citation>
        </Reference>
        <Reference>
          <Citation>Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018;472:125-133.</Citation>
        </Reference>
        <Reference>
          <Citation>Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008;32:1130-1137.</Citation>
        </Reference>
        <Reference>
          <Citation>Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14:836-842.</Citation>
        </Reference>
        <Reference>
          <Citation>Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28:2860-2865.</Citation>
        </Reference>
        <Reference>
          <Citation>Gonzalez RS, Salaria SN, Bohannon CD, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of &#x201c;immunomodulatory gastroenterocolitis&#x201d;. Histopathology. 2017;70:558-567.</Citation>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.</Citation>
        </Reference>
        <Reference>
          <Citation>Bavi P, Butler M, Serra S, et al. Immune modulator-induced changes in the gastrointestinal tract. Histopathology. 2017;71:494-496.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95.</Citation>
        </Reference>
        <Reference>
          <Citation>Mooradian MJ, Wang DY, Coromilas A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer. 2020;8:e000451.</Citation>
        </Reference>
        <Reference>
          <Citation>Cheung VTF, Gupta T, Olsson-Brown A, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer. 2020;123:207-215.</Citation>
        </Reference>
        <Reference>
          <Citation>Pai RK, Jairath V, Vande Casteele N, et al. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest Endosc. 2018;88:887-898.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7:93.</Citation>
        </Reference>
        <Reference>
          <Citation>Pai RK, Hartman DJ, Rivers CR, et al. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18:2510-2517.e5.</Citation>
        </Reference>
        <Reference>
          <Citation>Christensen B, Hanauer SB, Erlich J, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15:1557-1564.</Citation>
        </Reference>
        <Reference>
          <Citation>Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414.</Citation>
        </Reference>
        <Reference>
          <Citation>Choi C-H, Al Bakir I, Ding N-S, et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut. 2019;68:414-422.</Citation>
        </Reference>
        <Reference>
          <Citation>Zenlea T, Yee EU, Rosenberg L, et al. Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study. Am J Gastroenterol. 2016;111:685-690.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33096100</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>08</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-0012</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>160</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gastroenterology</Title>
          <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.</ArticleTitle>
        <Pagination>
          <StartPage>932</StartPage>
          <EndPage>934.e3</EndPage>
          <MedlinePgn>932-934.e3</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2020.10.029</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(20)35316-6</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bishu</LastName>
            <ForeName>Shrinivas</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: bishus@med.umich.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melia</LastName>
            <ForeName>Joanna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, John's Hopkins University, Baltimore, Maryland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharfman</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Oncology, Department of Medicine, John's Hopkins University, Baltimore, Maryland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lao</LastName>
            <ForeName>Christopher D</ForeName>
            <Initials>CD</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fecher</LastName>
            <ForeName>Leslie A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higgins</LastName>
            <ForeName>Peter D R</ForeName>
            <Initials>PDR</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 DK114478</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K08 DK123403</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Gastroenterology</MedlineTA>
        <NlmUniqueID>0374630</NlmUniqueID>
        <ISSNLinking>0016-5085</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>87LA6FU830</RegistryNumber>
          <NameOfSubstance UI="C479163">tofacitinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DPT0O3T46P</RegistryNumber>
          <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer Outcome</Keyword>
        <Keyword MajorTopicYN="N">Checkpoint Inhibitor Colitis</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Refractory</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>23</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33096100</ArticleId>
        <ArticleId IdType="doi">10.1053/j.gastro.2020.10.029</ArticleId>
        <ArticleId IdType="pii">S0016-5085(20)35316-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33080231</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-0012</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>160</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gastroenterology</Title>
          <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review.</ArticleTitle>
        <Pagination>
          <StartPage>1384</StartPage>
          <EndPage>1393</EndPage>
          <MedlinePgn>1384-1393</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2020.08.063</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(20)35282-3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND &amp; AIMS">Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients, but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve the gastrointestinal (GI) tract and liver. The purpose of this expert review was to update gastroenterologists on the gastrointestinal and hepatic toxicities of ICIs and provide best practice advice on their diagnosis and management.</AbstractText>
          <AbstractText Label="METHODS">The evidence reviewed in this work combines the expert clinical opinion of the authors with a comprehensive search of several English-language databases and a manual review of relevant publications.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dougan</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: mldougan@partners.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yinghong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rubio-Tapia</LastName>
            <ForeName>Alberto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lim</LastName>
            <ForeName>Joseph K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Yale Liver Center and Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 DK114563</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017065">Practice Guideline</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Gastroenterology</MedlineTA>
        <NlmUniqueID>0374630</NlmUniqueID>
        <ISSNLinking>0016-5085</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005762" MajorTopicYN="N">Gastroenterology</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
          <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adverse Event</Keyword>
        <Keyword MajorTopicYN="N">Enterocolitis</Keyword>
        <Keyword MajorTopicYN="N">Hepatitis</Keyword>
        <Keyword MajorTopicYN="N">Immune Checkpoint Inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Toxicity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>20</Day>
          <Hour>20</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33080231</ArticleId>
        <ArticleId IdType="doi">10.1053/j.gastro.2020.08.063</ArticleId>
        <ArticleId IdType="pii">S0016-5085(20)35282-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33058056</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1865-7265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical journal of gastroenterology</Title>
          <ISOAbbreviation>Clin J Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis.</ArticleTitle>
        <Pagination>
          <StartPage>152</StartPage>
          <EndPage>158</EndPage>
          <MedlinePgn>152-158</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12328-020-01261-x</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICPI) have been reported to be effective in various carcinomas. They excessively activate the immune system, resulting in frequent immune-related adverse events (irAEs). Colitis induced by ICPI is one of the most common and is known as immune-mediated colitis (IMC). Although IMC and inflammatory bowel disease (IBD) are similar in many respects, there are very few reports of IMC in patients with preexisting IBD such as ulcerative colitis (UC) and Crohn's disease (CD). Whether preexisting IBD is concerned with the development of the colitis is not well known. Here, we reported the case who developed severe ulcerative colitis which started from IMC. It is an important case to follow the time course of the colitis developed. Our conclusion indicated that frequent colonoscopy was important for the management of IMC in a patient who has suffered chronic inflammatory disease, such as UC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kayashima</LastName>
            <ForeName>Atsuto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimozaki</LastName>
            <ForeName>Keitaro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>Kenro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mutaguchi</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takabayashi</LastName>
            <ForeName>Kaoru</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hayashi</LastName>
            <ForeName>Yuichiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, School of Medicine, Keio University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hosoe</LastName>
            <ForeName>Naoki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogata</LastName>
            <ForeName>Haruhiko</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sujino</LastName>
            <ForeName>Tomohisa</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-0699-6577</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. tsujino1224@keio.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanai</LastName>
            <ForeName>Takanori</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Clin J Gastroenterol</MedlineTA>
        <NlmUniqueID>101477246</NlmUniqueID>
        <ISSNLinking>1865-7265</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Immune-mediated colitis</Keyword>
        <Keyword MajorTopicYN="N">PD-1</Keyword>
        <Keyword MajorTopicYN="N">Ulcerative colitis</Keyword>
        <Keyword MajorTopicYN="N">irAE</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>17</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33058056</ArticleId>
        <ArticleId IdType="doi">10.1007/s12328-020-01261-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s12328-020-01261-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Thapa B, Roopkumar J, Kim AS, et al. Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI). J Clin Oncol. 2019;37:e14151&#x2013;e14151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.e14151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2015.4368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K&#xe4;hler KC, Eigentler TK, Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother. 2018;67:825&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2134-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017. https://doi.org/10.1093/annonc/mdw443 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw443</ArticleId>
            <ArticleId IdType="pubmed">28327969</ArticleId>
            <ArticleId IdType="pmc">5834131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hijikata Y, Matsubara Y, Ota Y, et al. Safe use of nivolumab in a patient with epipharyngeal carcinoma and preexisting ulcerative colitis: a histologically proven case report. Intern Med. 2020;59:1105&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.3901-19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright AP, Piper MS, Bishu S, et al. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2019;49:1474&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.15263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler BL, Pezhouh MK, Kim A, et al. Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med. 2018;283:568&#x2013;77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joim.12744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-1962-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai S, Nakamura S, Kawasaki K, et al. Immune checkpoint inhibitor-induced diarrhea: clinicopathological study of 11 patients. Dig Endosc. 2020;32:616&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/den.13555</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32960847</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1537-4513</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2020</Year>
              <Season>Nov/Dec</Season>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunotherapy (Hagerstown, Md. : 1997)</Title>
          <ISOAbbreviation>J Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>291</StartPage>
          <EndPage>298</EndPage>
          <MedlinePgn>291-298</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/CJI.0000000000000339</ELocationID>
        <Abstract>
          <AbstractText>Colitis is a major immune-related adverse event associated with programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, but the risk of colitis with PD-1 versus PD-L1 inhibitors is not well characterized. We performed a meta-analysis for the incidence of all grade and grade 3-4 colitis with PD-1 inhibitor (nivolumab, pembrolizumab, and cemiplimab) or PD-L1 inhibitor (atezolizumab, avelumab, and durvalumab) monotherapy using a fixed effects model. We also conducted subgroup meta-analyses of non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) trials, and a network meta-analysis of randomized trials comparing PD-1 or PD-L1 inhibitors with docetaxel for NSCLC. We also analyzed the Food and Drug Administration Adverse Event Reporting System database to estimate the reporting odds ratio of each medication. PD-1 inhibitors were associated with a higher incidence of all grade and grade 3-4 colitis compared with PD-L1 inhibitors in the analysis of all cancer types [1.49% vs. 0.83%, relative risk; 1.80, 95% confidence interval (CI); 1.22-2.67 for all grade colitis, and 0.85% vs. 0.34%, relative risk; 2.52, 95% CI; 1.46-4.37 for grade 3-4 colitis]. The meta-analyses of NSCLC and UC trials, and the network meta-analysis of NSCLC trials were also suggestive of a higher risk of colitis with PD-1 versus PD-L1 inhibitors. The reporting odds ratio of colitis with PD-1 versus PD-L1 inhibitors was 1.80 (95% CI; 1.53-2.14). In this meta-analysis of clinical trials exploring PD-1 and PD-L1 inhibitors in solid tumors, PD-1 inhibitors were associated with a higher risk of colitis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Miyashita</LastName>
            <ForeName>Hirotaka</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Mount Sinai Beth Israel, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mikami</LastName>
            <ForeName>Takahisa</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Mount Sinai Beth Israel, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Satoi</LastName>
            <ForeName>Sera</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Nippon Medical School Hospital, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cruz</LastName>
            <ForeName>Christina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Mount Sinai Beth Israel, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galsky</LastName>
            <ForeName>Matthew D</ForeName>
            <Initials>MD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Immunother</MedlineTA>
        <NlmUniqueID>9706083</NlmUniqueID>
        <ISSNLinking>1524-9557</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>17</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32960847</ArticleId>
        <ArticleId IdType="doi">10.1097/CJI.0000000000000339</ArticleId>
        <ArticleId IdType="pii">00002371-202011000-00005</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Timeline of Progress in Immunotherapy&#x2014;Cancer Research Institute. Available at: www.cancerresearch.org/immunotherapy/timeline-of-progress. Accessed December 31, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535.</Citation>
        </Reference>
        <Reference>
          <Citation>Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139&#x2013;148.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721&#x2013;1728.</Citation>
        </Reference>
        <Reference>
          <Citation>Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;35:76&#x2013;83.</Citation>
        </Reference>
        <Reference>
          <Citation>Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases. 2019;7:405&#x2013;418.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Cancer Netw. 2019;17:255&#x2013;289.</Citation>
        </Reference>
        <Reference>
          <Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;151:W65&#x2013;W94.</Citation>
        </Reference>
        <Reference>
          <Citation>R&#xfc;cker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3:312&#x2013;324.</Citation>
        </Reference>
        <Reference>
          <Citation>Higgins JPT, Altman DG, G&#xf8;tzsche PC, et al. The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang J, Zhang X, Tong J, et al. Comparing drug safety of hepatitis C therapies using post-market data. BMC Med Inform Decis Mak. 2019;19(suppl 4):147.</Citation>
        </Reference>
        <Reference>
          <Citation>Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733&#x2013;3739.</Citation>
        </Reference>
        <Reference>
          <Citation>Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34:3119&#x2013;3125.</Citation>
        </Reference>
        <Reference>
          <Citation>Powles T, O&#x2019;Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3:e172411.</Citation>
        </Reference>
        <Reference>
          <Citation>Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19:521&#x2013;536.</Citation>
        </Reference>
        <Reference>
          <Citation>Siu LL, Even C, Mesia R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2019;5:195&#x2013;203.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374&#x2013;1385.</Citation>
        </Reference>
        <Reference>
          <Citation>Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35:2117&#x2013;2124.</Citation>
        </Reference>
        <Reference>
          <Citation>Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19:51&#x2013;64.</Citation>
        </Reference>
        <Reference>
          <Citation>Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018;19:1468&#x2013;1479.</Citation>
        </Reference>
        <Reference>
          <Citation>Bang Y-J, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician&#x2019;s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29:2052&#x2013;2060.</Citation>
        </Reference>
        <Reference>
          <Citation>Disis ML, Taylor MH, Kelly K, et al. Efficacy and Safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5:393&#x2013;401.</Citation>
        </Reference>
        <Reference>
          <Citation>Doi T, Iwasa S, Muro K, et al. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer. 2019;22:817&#x2013;827.</Citation>
        </Reference>
        <Reference>
          <Citation>Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5:351&#x2013;357.</Citation>
        </Reference>
        <Reference>
          <Citation>Heery CR, O&#x2019;Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18:587&#x2013;598.</Citation>
        </Reference>
        <Reference>
          <Citation>Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558&#x2013;562.</Citation>
        </Reference>
        <Reference>
          <Citation>McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;34:833&#x2013;842.</Citation>
        </Reference>
        <Reference>
          <Citation>Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909&#x2013;1920.</Citation>
        </Reference>
        <Reference>
          <Citation>Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837&#x2013;1846.</Citation>
        </Reference>
        <Reference>
          <Citation>Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67&#x2013;76.</Citation>
        </Reference>
        <Reference>
          <Citation>Fehrenbacher L, von Pawel J, Park K, et al. Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2018;13:1156&#x2013;1170.</Citation>
        </Reference>
        <Reference>
          <Citation>Petrylak DP, Powles T, Bellmunt J, et al. Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer long-term outcomes from a phase 1 study. JAMA Oncol. 2018;4:537&#x2013;544.</Citation>
        </Reference>
        <Reference>
          <Citation>McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24:749&#x2013;757.</Citation>
        </Reference>
        <Reference>
          <Citation>Horn L, Gettinger SN, Gordon MS, et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018;101:201&#x2013;209.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu JF, Gordon M, Veneris J, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019;154:314&#x2013;322.</Citation>
        </Reference>
        <Reference>
          <Citation>Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with NSCLC. J Thorac Oncol. 2018;13:1733&#x2013;1742.</Citation>
        </Reference>
        <Reference>
          <Citation>Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717&#x2013;726.</Citation>
        </Reference>
        <Reference>
          <Citation>Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35:2781&#x2013;2789.</Citation>
        </Reference>
        <Reference>
          <Citation>Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600&#x2013;1609.</Citation>
        </Reference>
        <Reference>
          <Citation>Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib keynote-012 study. J Clin Oncol. 2016;34:2460&#x2013;2467.</Citation>
        </Reference>
        <Reference>
          <Citation>Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320&#x2013;330.</Citation>
        </Reference>
        <Reference>
          <Citation>Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&#x2019;s lymphoma. N Engl J Med. 2015;372:311&#x2013;319.</Citation>
        </Reference>
        <Reference>
          <Citation>Weber JS, D&#x2019;Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375&#x2013;384.</Citation>
        </Reference>
        <Reference>
          <Citation>Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004&#x2013;2012.</Citation>
        </Reference>
        <Reference>
          <Citation>Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480&#x2013;1492.</Citation>
        </Reference>
        <Reference>
          <Citation>Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123&#x2013;135.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33:4015&#x2013;4022.</Citation>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803&#x2013;1813.</Citation>
        </Reference>
        <Reference>
          <Citation>Weber J, Gibney G, Kudchadkar R, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4:345&#x2013;353.</Citation>
        </Reference>
        <Reference>
          <Citation>Antonia SJ, L&#xf3;pez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883&#x2013;895.</Citation>
        </Reference>
        <Reference>
          <Citation>Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2980&#x2013;2987.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856&#x2013;1867.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17:1590&#x2013;1598.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312&#x2013;322.</Citation>
        </Reference>
        <Reference>
          <Citation>Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:446&#x2013;453.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamazaki N, Kiyohara Y, Uhara H, et al. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study. Cancer Sci. 2017;108:1223&#x2013;1230.</Citation>
        </Reference>
        <Reference>
          <Citation>Ben-Ami E, Barysauskas CM, Solomon S, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer. 2017;123:3285&#x2013;3290.</Citation>
        </Reference>
        <Reference>
          <Citation>Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182&#x2013;1191.</Citation>
        </Reference>
        <Reference>
          <Citation>Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824&#x2013;1835.</Citation>
        </Reference>
        <Reference>
          <Citation>Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461&#x2013;2471.</Citation>
        </Reference>
        <Reference>
          <Citation>Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018;20:674&#x2013;686.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma BBY, Lim W-T, Goh B-C, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018;36:1412&#x2013;1418.</Citation>
        </Reference>
        <Reference>
          <Citation>Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569&#x2013;1576.</Citation>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020&#x2013;1030.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamamoto N, Nokihara H, Yamada Y, et al. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs. 2017;35:207&#x2013;216.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee K-W, Lee DH, Kang JH, et al. Phase I pharmacokinetic study of nivolumab in korean patients with advanced solid tumors. Oncologist. 2018;23:155-e17.</Citation>
        </Reference>
        <Reference>
          <Citation>Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521&#x2013;2532.</Citation>
        </Reference>
        <Reference>
          <Citation>Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908&#x2013;918.</Citation>
        </Reference>
        <Reference>
          <Citation>Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540&#x2013;1550.</Citation>
        </Reference>
        <Reference>
          <Citation>Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153&#x2013;159.</Citation>
        </Reference>
        <Reference>
          <Citation>Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976&#x2013;983.</Citation>
        </Reference>
        <Reference>
          <Citation>Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18:212&#x2013;220.</Citation>
        </Reference>
        <Reference>
          <Citation>Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28:874&#x2013;881.</Citation>
        </Reference>
        <Reference>
          <Citation>Bellmunt J, De Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015&#x2013;1026.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamazaki N, Takenouchi T, Fujimoto M, et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol. 2017;79:651&#x2013;660.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125&#x2013;2132.</Citation>
        </Reference>
        <Reference>
          <Citation>Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28:1036&#x2013;1041.</Citation>
        </Reference>
        <Reference>
          <Citation>Ott PA, Bang Y-J, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study. J Clin Oncol. 2017;35:2535&#x2013;2541.</Citation>
        </Reference>
        <Reference>
          <Citation>Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130:267&#x2013;270.</Citation>
        </Reference>
        <Reference>
          <Citation>Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 Study; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Balar AV, Castellano D, O&#x2019;Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483&#x2013;1492.</Citation>
        </Reference>
        <Reference>
          <Citation>Frenel J-S, Le Tourneau C, O&#x2019;Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017;35:4035&#x2013;4041.</Citation>
        </Reference>
        <Reference>
          <Citation>Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36:61&#x2013;67.</Citation>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12:e0189848.</Citation>
        </Reference>
        <Reference>
          <Citation>Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789&#x2013;1801.</Citation>
        </Reference>
        <Reference>
          <Citation>Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138&#x2013;1145.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940&#x2013;952.</Citation>
        </Reference>
        <Reference>
          <Citation>Shitara K, &#xd6;zg&#xfc;ro&#x11f;lu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123&#x2013;133.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen EEW, Souli&#xe8;res D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156&#x2013;167.</Citation>
        </Reference>
        <Reference>
          <Citation>Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1&#x2013;positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152:243&#x2013;250.</Citation>
        </Reference>
        <Reference>
          <Citation>Nishio M, Takahashi T, Yoshioka H, et al. KEYNOTE-025: phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Cancer Sci. 2019;110:1012&#x2013;1020.</Citation>
        </Reference>
        <Reference>
          <Citation>Mehnert JC, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. BMC Cancer. 2019;19:196.</Citation>
        </Reference>
        <Reference>
          <Citation>Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819&#x2013;1830.</Citation>
        </Reference>
        <Reference>
          <Citation>Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823&#x2013;1833.</Citation>
        </Reference>
        <Reference>
          <Citation>Rugo HS, Delord J-P, Im S-A, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res. 2018;24:2804&#x2013;2811.</Citation>
        </Reference>
        <Reference>
          <Citation>Tahara M, Muro K, Hasegawa Y, et al. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: analyses from KEYNOTE-012. Cancer Sci. 2018;109:771&#x2013;776.</Citation>
        </Reference>
        <Reference>
          <Citation>Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623&#x2013;630.</Citation>
        </Reference>
        <Reference>
          <Citation>Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341&#x2013;351.</Citation>
        </Reference>
        <Reference>
          <Citation>Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:1&#x2013;8.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Chung Y, Bishop C, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci USA. 2006;103:11695&#x2013;11700.</Citation>
        </Reference>
        <Reference>
          <Citation>Pinchuk IV, Saada JI, Beswick EJ, et al. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology. 2008;135:1228.e1&#x2013;1237.e2.</Citation>
        </Reference>
        <Reference>
          <Citation>Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12:92.</Citation>
        </Reference>
        <Reference>
          <Citation>Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152:271&#x2013;281.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32934876</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2162-4011</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>9</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncoimmunology</Title>
          <ISOAbbreviation>Oncoimmunology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>1760676</StartPage>
          <MedlinePgn>1760676</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1760676</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/2162402X.2020.1760676</ELocationID>
        <Abstract>
          <AbstractText>Checkpoint inhibitors have improved the survival of patients with advanced tumors and show a manageable toxicity profile. However, auto-immune colitis remains a relevant side effect, and combinations of anti-PD1/PDL1 and anti-CTLA-4 increase its incidence and severity. Here, we report the case of a 50-year-old patient diagnosed with stage IV cervical cancer that relapsed following radical surgery, external radiation/brachytherapy and standard chemotherapy. She was subsequently treated with Nivolumab and Ipilimumab combination and developed grade 2 colitis presenting a dissociation between endoscopic and pathological findings. At cycle 10 the patient reported grade 3 diarrhea and abdominal discomfort, without blood or mucus in the stools. Immunotherapy was withheld and a colonoscopy was performed, showing normal mucosa in the entire colon. Puzzlingly, histologic evaluation of randomly sampled mucosal biopsy of the distal colon showed an intense intraepithelial lymphocyte infiltration with crypt loss and some regenerating crypts with a few apoptotic bodies set in a chronically inflamed lamina propria, consistent with the microscopic diagnosis of colitis. Treatment with methylprednisolone 2 mg/kg was initiated which led to a decrease in the number of stools to grade 1. Additional investigations to exclude other causes of diarrhea rendered negative results. The patient experienced a major partial response and, following the resolution of diarrhea, she was re-challenged again with immunotherapy, with the reappearance of grade 2 diarrhea, leading to permanent immunotherapy interruption. We conclude and propose that performing random colonic biopsies should be considered in cases of immune checkpoint-associated unexplained diarrhea, even when colonoscopy shows macroscopically normal colonic mucosa inflammatory lesions.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>de Andrea</LastName>
            <ForeName>Carlos Eduardo</ForeName>
            <Initials>CE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Perez-Gracia</LastName>
            <ForeName>Jose Luis</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castanon</LastName>
            <ForeName>Eduardo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ponz-Sarvise</LastName>
            <ForeName>Mariano</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Echeveste</LastName>
            <ForeName>Jose I</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melero</LastName>
            <ForeName>Ignacio</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sanmamed</LastName>
            <ForeName>Miguel F</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodriguez-Ruiz</LastName>
            <ForeName>Maria Esperanza</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncoimmunology</MedlineTA>
        <NlmUniqueID>101570526</NlmUniqueID>
        <ISSNLinking>2162-4011</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004213" MajorTopicYN="N">Dissociative Disorders</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ipilimumab</Keyword>
        <Keyword MajorTopicYN="N">Nivolumab</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse event</Keyword>
        <Keyword MajorTopicYN="N">&#xfeff;colitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32934876</ArticleId>
        <ArticleId IdType="pmc">PMC7466860</ArticleId>
        <ArticleId IdType="doi">10.1080/2162402X.2020.1760676</ArticleId>
        <ArticleId IdType="pii">1760676</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F.. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359&#x2013;5. doi:10.1002/ijc.29210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350&#x2013;1355. doi:10.1126/science.aar4060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aar4060</ArticleId>
            <ArticleId IdType="pmc">PMC7391259</ArticleId>
            <ArticleId IdType="pubmed">29567705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95&#x2013;106. doi:10.1038/nrc2051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2051</ArticleId>
            <ArticleId IdType="pubmed">17251916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borcoman E, Le Tourneau C. Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2017;9(6):431&#x2013;439. doi:10.1177/1758834017708742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758834017708742</ArticleId>
            <ArticleId IdType="pmc">PMC5455883</ArticleId>
            <ArticleId IdType="pubmed">28607581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frenel JS, Le Tourneau C, O&#x2019;Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S,&#xa0;Rangwala R,&#xa0;Varga A. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the Phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035&#x2013;4041. doi:10.1200/JCO.2017.74.5471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.74.5471</ArticleId>
            <ArticleId IdType="pubmed">29095678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scarpignato C, Varga G, Dobronyi I, Papp M. Bombesin-induced pancreatic secretion and growth in rats: effect of proglumide, spantide and ranitidine. Int J Tissue React. 1990;12:299&#x2013;307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1711515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shephard RJ. The need for sport-specific tests. Can J Sport Sci. 1990;15:163&#x2013;164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2257528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Roux PD, Jardine DS, Kanev PM, Loeser JD. Pediatric intracranial pressure monitoring in hypoxic and nonhypoxic brain injury. Childs Nerv Syst. 1991;7(1):34&#x2013;39. doi:10.1007/BF00263831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00263831</ArticleId>
            <ArticleId IdType="pubmed">2054806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10(459):459. doi:10.1126/scitranslmed.aat7807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aat7807</ArticleId>
            <ArticleId IdType="pubmed">30232229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillermo De Velasco, Youjin Je, Dominick Bosse, Mark M. Awad, Patrick A. Ott, Raphael B. Moreira, Fabio Schutz, Joaquim Bellmunt, Guru P. Sonpavde, F. Stephen Hodi, et al. comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2018;6(4):498&#x2013;499. doi:10.1158/2326-6066.CIR-18-0078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0078</ArticleId>
            <ArticleId IdType="pmc">PMC5418853</ArticleId>
            <ArticleId IdType="pubmed">28246107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Velasco G, Je Y, Bosse D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312&#x2013;318. doi:10.1158/2326-6066.CIR-16-0237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0237</ArticleId>
            <ArticleId IdType="pmc">PMC5418853</ArticleId>
            <ArticleId IdType="pubmed">28246107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221. doi:10.1371/journal.pone.0160221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0160221</ArticleId>
            <ArticleId IdType="pmc">PMC4966895</ArticleId>
            <ArticleId IdType="pubmed">27472273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J,&#xa0;Spisek R,&#xa0;Demaria S,&#xa0;Formenti SC, et al. Trial watch: immune checkpoint blockers for cancer therapy. Oncoimmunology. 2017;6(11):e1373237. doi:10.1080/2162402X.2017.1373237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1373237</ArticleId>
            <ArticleId IdType="pmc">PMC5674958</ArticleId>
            <ArticleId IdType="pubmed">29147629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49. doi:10.3389/fphar.2017.00049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2017.00049</ArticleId>
            <ArticleId IdType="pmc">PMC5296331</ArticleId>
            <ArticleId IdType="pubmed">28228726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, et al. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019;8(1):e1524695. doi:10.1080/2162402X.2018.1524695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1524695</ArticleId>
            <ArticleId IdType="pmc">PMC6287774</ArticleId>
            <ArticleId IdType="pubmed">30546965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Varona A, Odze RD, Makrauer F. Lymphocytic colitis secondary to ipilimumab treatment. Inflamm Bowel Dis. 2013;19(2):E15&#x2013;6. doi:10.1002/ibd.22846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ibd.22846</ArticleId>
            <ArticleId IdType="pubmed">22114048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisani LF, Tontini GE, Vecchi M, Pastorelli L. Microscopic colitis: what do we know about pathogenesis? Inflamm Bowel Dis. 2016;22(2):450&#x2013;458. doi:10.1097/MIB.0000000000000628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000000628</ArticleId>
            <ArticleId IdType="pubmed">26529562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol. 2007;38(4):527&#x2013;536. doi:10.1016/j.humpath.2007.01.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2007.01.014</ArticleId>
            <ArticleId IdType="pubmed">17367604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, L&#xf3;pez-Picazo JM, Machiels J-P, Delord J-P, Evans TRJ, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II checkmate 358 trial. J Clin Oncol. 2019;37(31):2825&#x2013;2834. doi:10.1200/JCO.19.00739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.00739</ArticleId>
            <ArticleId IdType="pmc">PMC6823884</ArticleId>
            <ArticleId IdType="pubmed">31487218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I,&#xa0;Ernstoff MS,&#xa0;Gardner JM,&#xa0;Ginex P, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;JCO2017776385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2015;7(11):1213&#x2013;1227. doi:10.2217/imt.15.87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt.15.87</ArticleId>
            <ArticleId IdType="pubmed">26513491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kountouras J, Zavos C. Recent advances in the management of radiation colitis. World J Gastroenterol. 2008;14(48):7289&#x2013;7301. doi:10.3748/wjg.14.7289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.14.7289</ArticleId>
            <ArticleId IdType="pmc">PMC2778112</ArticleId>
            <ArticleId IdType="pubmed">19109862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kennedy GD, Heise CP. Radiation colitis and proctitis. Clin Colon Rectal Surg. 2007;20(1):64&#x2013;72. doi:10.1055/s-2007-970202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2007-970202</ArticleId>
            <ArticleId IdType="pmc">PMC2780150</ArticleId>
            <ArticleId IdType="pubmed">20011363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut. 2005;54(8):1051&#x2013;1054. doi:10.1136/gut.2004.062596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2004.062596</ArticleId>
            <ArticleId IdType="pmc">PMC1774900</ArticleId>
            <ArticleId IdType="pubmed">16009675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis. 2019;25(2):385&#x2013;393. doi:10.1093/ibd/izy240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy240</ArticleId>
            <ArticleId IdType="pmc">PMC7534361</ArticleId>
            <ArticleId IdType="pubmed">30169584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM,&#xa0;et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193&#x2013;3198. doi:10.1200/JCO.2015.60.8448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.60.8448</ArticleId>
            <ArticleId IdType="pmc">PMC5087335</ArticleId>
            <ArticleId IdType="pubmed">26282644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aston WJ, Hope DE, Cook AM, Boon L, Dick I, Nowak AK, Lake RA, Lesterhuis WJ. Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. Oncoimmunology. 2019;8(11):e1641390. doi:10.1080/2162402X.2019.1641390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2019.1641390</ArticleId>
            <ArticleId IdType="pmc">PMC6791454</ArticleId>
            <ArticleId IdType="pubmed">31646089</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32931028</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2559</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>78</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Histopathology</Title>
          <ISOAbbreviation>Histopathology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.</ArticleTitle>
        <Pagination>
          <StartPage>532</StartPage>
          <EndPage>541</EndPage>
          <MedlinePgn>532-541</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/his.14248</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">A varied spectrum of histopathological changes has been associated with immune checkpoint inhibitor (ICI) colitis. This study was performed to evaluate the prevalence of different histopathological patterns of injury in patients with ICI colitis and their association with specific immune check-point inhibitors.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Biopsies from patients with clinically and histologically confirmed ICI colitis were reviewed blindly to determine the predominant pattern of injury and to quantitate discrete histological parameters using the Geboes score. Paneth cell metaplasia, intraepithelial lymphocytes, abnormal subepithelial collagen and degree of crypt epithelial apoptosis was also recorded. A total of 86 patients with ICI colitis (ipilimumab, n&#xa0;=&#xa0;14; ipilimumab&#xa0;+&#xa0;nivolumab, n&#xa0;=&#xa0;29; nivolumab, n&#xa0;=&#xa0;20 and pembrolizumab, n&#xa0;=&#xa0;23) were included. The patterns of injury identified included diffuse active colitis (n&#xa0;=&#xa0;22), chronic active colitis (n&#xa0;=&#xa0;22), lymphocytic colitis (LC, n&#xa0;=&#xa0;16), collagenous colitis (CC, n&#xa0;=&#xa0;14), graft-versus-host disease-like colitis (n&#xa0;=&#xa0;7) and mixed colitis (n&#xa0;=&#xa0;5). Patients on ipilimumab were more likely to have a diffuse active colitis pattern without features of chronicity (P&#xa0;&lt;&#xa0;0.01) and less likely to have LC (P&#xa0;&lt;&#xa0;0.05) compared to other ICIs. LC and CC were more common in patients on nivolumab and pembrolizumab relative to other groups (P&#xa0;&lt;&#xa0;0.05). Chronic active colitis was most frequent in nivolumab patients (P&#xa0;&lt;&#xa0;0.05), and these patients had received more ICI doses and had been on ICI treatment longer compared to other treatment groups.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ICI colitis should be considered in the differential diagnosis of all the common inflammatory patterns of colitis and shows medication specific differences in patterns of injury.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Isidro</LastName>
            <ForeName>Raymond A</ForeName>
            <Initials>RA</Initials>
            <Identifier Source="ORCID">0000-0002-1774-8643</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Alex B</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gannarapu</LastName>
            <ForeName>Swetha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raj</LastName>
            <ForeName>Dhanya</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rahma</LastName>
            <ForeName>Osama</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grover</LastName>
            <ForeName>Shilpa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Srivastava</LastName>
            <ForeName>Amitabh</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Histopathology</MedlineTA>
        <NlmUniqueID>7704136</NlmUniqueID>
        <ISSNLinking>0309-0167</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DPT0O3T46P</RegistryNumber>
          <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword>
        <Keyword MajorTopicYN="N">ipilimumab</Keyword>
        <Keyword MajorTopicYN="N">nivolumab</Keyword>
        <Keyword MajorTopicYN="N">pembrolizumab</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32931028</ArticleId>
        <ArticleId IdType="doi">10.1111/his.14248</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Fritz JM, Lenardo MJ. Development of immune checkpoint therapy for cancer. J. Exp. Med. 2019; 216; 1244-1254.</Citation>
        </Reference>
        <Reference>
          <Citation>Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 2018; 18; 139-147.</Citation>
        </Reference>
        <Reference>
          <Citation>Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell 2018; 33; 547-562.</Citation>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 2019; 16; 563-580.</Citation>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 2018; 378; 158-168.</Citation>
        </Reference>
        <Reference>
          <Citation>Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 2016; 54; 139-148.</Citation>
        </Reference>
        <Reference>
          <Citation>Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat. Rev. Gastroenterol. Hepatol. 2018; 15; 222-234.</Citation>
        </Reference>
        <Reference>
          <Citation>Oble DA, Mino-Kenudson M, Goldsmith J et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am. J. Surg. Pathol. 2008; 32; 1130-1137.</Citation>
        </Reference>
        <Reference>
          <Citation>Baroudjian B, Lourenco N, Pages C et al. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016; 26; 308-311.</Citation>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006; 24; 2283-2289.</Citation>
        </Reference>
        <Reference>
          <Citation>Berman D, Parker SM, Siegel J et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010; 10; 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am. J. Surg. Pathol. 2017; 41; 643-654.</Citation>
        </Reference>
        <Reference>
          <Citation>Choi K, Abu-Sbeih H, Samdani R et al. Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm. Bowel Dis. 2019; 25; 385-393.</Citation>
        </Reference>
        <Reference>
          <Citation>Collins M, Michot JM, Danlos FX et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann. Oncol. 2017; 28; 2860-2865.</Citation>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J. Crohns Colitis 2016; 10; 395-401.</Citation>
        </Reference>
        <Reference>
          <Citation>Verschuren EC, van den Eertwegh AJ, Wonders J et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin. Gastroenterol. Hepatol. 2016; 14; 836-842.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm. Bowel Dis. 2018; 24; 1695-1705.</Citation>
        </Reference>
        <Reference>
          <Citation>Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Lofberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47; 404-409.</Citation>
        </Reference>
        <Reference>
          <Citation>Jauregui-Amezaga A, Geerits A, Das Y et al. A simplified Geboes score for ulcerative colitis. J. Crohns Colitis 2017; 11; 305-313.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee HT, Lee SH, Heo YS. Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules 2019; 24; 1190.</Citation>
        </Reference>
        <Reference>
          <Citation>Na Z, Yeo SP, Bharath SR et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 2017; 27; 147-150.</Citation>
        </Reference>
        <Reference>
          <Citation>Tan S, Zhang H, Chai Y et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat. Commun. 2017; 8; 14369.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 2018; 6; 95.</Citation>
        </Reference>
        <Reference>
          <Citation>Grover S, Srivastava A. Lymphocytic colitis-like pattern of mucosal injury and the challenges in diagnosing cancer immunotherapy-related toxicity. Cancer 2019; 125; 1768-1770.</Citation>
        </Reference>
        <Reference>
          <Citation>Grover S, Ruan AB, Srivoleti P et al. Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JCO Oncol. Pract. 2020; 16; e933-e942.</Citation>
        </Reference>
        <Reference>
          <Citation>Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune checkpoint inhibitor therapy associated gastritis. Histopathology 2020; 76; 531-539.</Citation>
        </Reference>
        <Reference>
          <Citation>Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint inhibitor-induced colitis: a new type of inflammatory bowel disease? ACG Case Rep. J. 2017; 4; e112.</Citation>
        </Reference>
        <Reference>
          <Citation>Khalili H, Burke KE, Roelstraete B, Sachs MC, Olen O, Ludvigsson JF. Microscopic colitis and risk of inflammatory bowel disease in a nationwide cohort study. Gastroenterology 2020; 158; 1574-1583.e2.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32888202</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1440-1746</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of gastroenterology and hepatology</Title>
          <ISOAbbreviation>J Gastroenterol Hepatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitor-associated colitis.</ArticleTitle>
        <Pagination>
          <StartPage>1180</StartPage>
          <EndPage>1186</EndPage>
          <MedlinePgn>1180-1186</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jgh.15246</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">There exists no evidence on the relationship between endoscopic and histologic findings. Furthermore, even after multiple biopsy specimens were obtained, histologic examination usually fails to show the characteristic features of immune checkpoint inhibitor-associated colitis. In this study, we explored the endoscopic and histologic findings of immune checkpoint inhibitor-associated colitis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Patients diagnosed with immune checkpoint inhibitor-associated colitis at our hospital between March 2018 and December 2018 were retrospectively assessed. The degree of mucosal inflammation was evaluated using endoscopic inflammation grade (inactive, mild, moderate, or severe disease) and further observed using magnifying endoscopy with crystal violet staining. Pit structures were classified into three types: regularly arranged pits with circular or elliptical shape (R type), irregularly arranged pits with inhomogeneous size and morphology (IR type), and pits with reduced density or pits that partially disappeared (AD type).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven patients (median age, 71&#xa0;years; range, 44-83&#xa0;years) were diagnosed with immune checkpoint inhibitor-associated colitis. All characteristic histologic findings, including crypt distortion, crypt abscesses, and apoptotic bodies, were observed at sites with moderate-to-severe endoscopic inflammation but not at sites with inactive-to-mild endoscopic inflammation. Characteristic histologic features were observed in 0%, 50%, and 100% of R-type, IR-type, and AD-type mucosa, respectively.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We revealed the possible utility of endoscopic images for selecting suitable target sites for biopsy and showed that endoscopic findings could reduce the time lag associated with tissue diagnosis and sampling errors due to biopsy.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Inoue</LastName>
            <ForeName>Shuntaro</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-9171-9480</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kono</LastName>
            <ForeName>Mitsuhiro</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fukuda</LastName>
            <ForeName>Hiromu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimamoto</LastName>
            <ForeName>Yusaku</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakagawa</LastName>
            <ForeName>Kentaro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohmori</LastName>
            <ForeName>Masayasu</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-5795-2377</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwagami</LastName>
            <ForeName>Hiroyoshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuno</LastName>
            <ForeName>Kenshi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwatsubo</LastName>
            <ForeName>Taro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakahira</LastName>
            <ForeName>Hiroko</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-2264-2963</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuura</LastName>
            <ForeName>Noriko</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shichijo</LastName>
            <ForeName>Satoki</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maekawa</LastName>
            <ForeName>Akira</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanesaka</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamamoto</LastName>
            <ForeName>Sachiko</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takeuchi</LastName>
            <ForeName>Yoji</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higashino</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uedo</LastName>
            <ForeName>Noriya</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kitamura</LastName>
            <ForeName>Masanori</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakatsuka</LastName>
            <ForeName>Shinichi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kunimasa</LastName>
            <ForeName>Kei</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumagai</LastName>
            <ForeName>Toru</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Isei</LastName>
            <ForeName>Taiki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatological Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishihara</LastName>
            <ForeName>Ryu</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>J Gastroenterol Hepatol</MedlineTA>
        <NlmUniqueID>8607909</NlmUniqueID>
        <ISSNLinking>0815-9319</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J4Z741D6O5</RegistryNumber>
          <NameOfSubstance UI="D005840">Gentian Violet</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016099" MajorTopicYN="N">Endoscopy, Gastrointestinal</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005840" MajorTopicYN="Y">Gentian Violet</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Cytotoxic T-lymphocyte-associated protein-4 inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Immune-related adverse event</Keyword>
        <Keyword MajorTopicYN="N">Magnifying endoscopic findings</Keyword>
        <Keyword MajorTopicYN="N">Programmed death-1 inhibitor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32888202</ArticleId>
        <ArticleId IdType="doi">10.1111/jgh.15246</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015; 373: 1803-1813.</Citation>
        </Reference>
        <Reference>
          <Citation>Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer. N. Engl. J. Med. 2015; 373: 1627-1639.</Citation>
        </Reference>
        <Reference>
          <Citation>Ribas A, Hamid O, Daud A et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315: 1600-1609.</Citation>
        </Reference>
        <Reference>
          <Citation>Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 2017; 377: 1345-1356.</Citation>
        </Reference>
        <Reference>
          <Citation>Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567.</Citation>
        </Reference>
        <Reference>
          <Citation>Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015; 372: 311-319.</Citation>
        </Reference>
        <Reference>
          <Citation>Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-562.</Citation>
        </Reference>
        <Reference>
          <Citation>Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 2016; 54: 139-148.</Citation>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017; 28: iv119-iv142.</Citation>
        </Reference>
        <Reference>
          <Citation>Puzanov I, Diab A, Abdallah K et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 2017; 5: 95.</Citation>
        </Reference>
        <Reference>
          <Citation>Oble DA, Mino-Kenudson M, Goldsmith J et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am. J. Surg. Pathol. 2008; 32: 1130-1137.</Citation>
        </Reference>
        <Reference>
          <Citation>Berman D, Parker SM, Siegel J et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010; 10: 11.</Citation>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2018; 36: 1714-1768.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 2018; 6: 95.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm. Bowel Dis. 2018; 24: 1695-1705.</Citation>
        </Reference>
        <Reference>
          <Citation>Nishio Y, Ando T, Maeda O et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006; 55: 1768-1773.</Citation>
        </Reference>
        <Reference>
          <Citation>Watanabe C, Sumioka M, Hiramoto T et al. Magnifying colonoscopy used to predict disease relapse in patients with quiescent ulcerative colitis. Inflamm. Bowel Dis. 2009; 15: 1663-1669.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujiya M, Saitoh Y, Nomura M et al. Minute findings by magnifying colonoscopy are useful for the evaluation of ulcerative colitis. Gastrointest. Endosc. 2002; 56: 535-542.</Citation>
        </Reference>
        <Reference>
          <Citation>Kunihiro M, Tanaka S, Sumii M et al. Magnifying colonoscopic features of ulcerative colitis reflect histologic inflammation. Inflamm. Bowel Dis. 2004; 10: 737-744.</Citation>
        </Reference>
        <Reference>
          <Citation>Isomoto H, Uehara R, Hayashi T et al. Magnifying endoscopic findings can predict clinical outcome during long-term follow-up of more than 12 months in patients with ulcerative colitis. Gastroenterol. Res. Pract. 2013; 2013: 671576.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32780984</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2688-1535</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>JCO oncology practice</Title>
          <ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>462</StartPage>
          <EndPage>463</EndPage>
          <MedlinePgn>462-463</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/OP.20.00573</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Johns Hopkins University, Baltimore, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naidoo</LastName>
            <ForeName>Jarushka</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bloomberg-Kimmel Institute of Cancer Immunotherapy at Johns Hopkins University, Baltimore, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>T32 GM066691</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>JCO Oncol Pract</MedlineTA>
        <NlmUniqueID>101758685</NlmUniqueID>
        <ISSNLinking>2688-1527</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>JCO Oncol Pract. 2020 Aug;16(8):453-461</RefSource>
          <PMID Version="1">32584703</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32780984</ArticleId>
        <ArticleId IdType="doi">10.1200/OP.20.00573</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32780983</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2688-1535</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>JCO oncology practice</Title>
          <ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immunotherapy-Related Colitis: An Emerging Challenge and a Quest for Prospective Data.</ArticleTitle>
        <Pagination>
          <StartPage>464</StartPage>
          <EndPage>465</EndPage>
          <MedlinePgn>464-465</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/OP.20.00620</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kennedy</LastName>
            <ForeName>Laura C</ForeName>
            <Initials>LC</Initials>
            <AffiliationInfo>
              <Affiliation>Vanderbilt University Medical Center, Nashville, TN.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grivas</LastName>
            <ForeName>Petros</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>JCO Oncol Pract</MedlineTA>
        <NlmUniqueID>101758685</NlmUniqueID>
        <ISSNLinking>2688-1527</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>JCO Oncol Pract. 2020 Aug;16(8):453-461</RefSource>
          <PMID Version="1">32584703</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32780983</ArticleId>
        <ArticleId IdType="doi">10.1200/OP.20.00620</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32702598</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1705</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>87</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>International immunopharmacology</Title>
          <ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.</ArticleTitle>
        <Pagination>
          <StartPage>106770</StartPage>
          <MedlinePgn>106770</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2020.106770</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1567-5769(20)31723-9</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Colitis is a life-threatening and common immune-related adverse event in patients receiving immune checkpoint inhibitors (ICIs). Therefore, we performed a meta-analysis to assess the risk of immune-related colitis among various ICI treatment regimens.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We used PubMed, EMBASE, and the Cochrane Library to retrieve phase II or III randomized controlled trials (RCTs) of ICIs that specified the number of all-grade (grade 1-5) colitis and high-grade (grade 3-5) colitis events through January 2020. The pooled relative risk (RR) and 95% confidence intervals (CIs) were calculated to compare the risk of colitis among various therapeutic regimens.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The search strategy identified 40 RCTs involving 26,893 patients. The risk of all-grade and high-grade colitis after PD-1/PD-L1 inhibitor was significantly lower than that of CTLA-4 inhibitor (0.18 and 0.14 relative risk respectively). The risk of all-grade and high-grade colitis was dose-dependent for CTLA-4 inhibitor therapy, but not for PD-1/PD-L1 inhibitor therapy. The relative risk of all-grade and high-grade colitis after combination therapy with PD-1/PD-L1 inhibitor and CTLA-4 inhibitor compared to PD-1/PD-L1 inhibitor alone was 9.25 and 12.00 respectively. No significant difference was found between PD-1/PD-L1 inhibitor combined with chemotherapy or targeted therapy and PD-1/PD-L1 inhibitor alone for either all-grade or high-grade colitis.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our meta-analysis indicates that CTLA-4 inhibitor is associated with a higher risk of colitis compared with PD-1/PD-L1 inhibitor, whether used as a monotherapy or combination immunotherapy. Importantly, the combination of PD-1/PD-L1 inhibitor with chemotherapy or targeted therapy may not increase the risk of colitis significantly compared to PD-1/PD-L1 inhibitor alone.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Jiannan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Manyu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Huiyun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ge</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weygant</LastName>
            <ForeName>Nathaniel</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China; Fujian Key Laboratory of Integrative Medicine in Geriatrics, Fuzhou 350122, China. Electronic address: nweygant@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>An</LastName>
            <ForeName>Guangyu</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. Electronic address: agybjcy@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int Immunopharmacol</MedlineTA>
        <NlmUniqueID>100965259</NlmUniqueID>
        <ISSNLinking>1567-5769</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C556706">CTLA4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Immune-related colitis</Keyword>
        <Keyword MajorTopicYN="N">Meta-analysis</Keyword>
        <Keyword MajorTopicYN="N">PD-1 inhibitor</Keyword>
        <Keyword MajorTopicYN="N">PD-L1 inhibitor</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declared that there is no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32702598</ArticleId>
        <ArticleId IdType="doi">10.1016/j.intimp.2020.106770</ArticleId>
        <ArticleId IdType="pii">S1567-5769(20)31723-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32641348</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2059-7029</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>ESMO open</Title>
          <ISOAbbreviation>ESMO Open</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e000585</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/esmoopen-2019-000585</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune-related diarrhoea/colitis (ir-D/C) is a common adverse event of immune checkpoint inhibitor (ICI) therapy. Guidelines recommend corticosteroid (CS) treatment; however, the average treatment duration for ir-D/C remains poorly defined.</AbstractText>
          <AbstractText Label="METHODS">All advanced melanoma patients treated with ICI therapy at the Royal Marsden Hospital between 2011 and 2016 were reviewed to identify ir-D/C cases alongside clinical variables.</AbstractText>
          <AbstractText Label="RESULTS">117 any-grade ir-D/C episodes occurred in 109 (21%) patients out of a total of 519 patients treated (ipilimumab=77 episodes, anti-PD1=17 (nivolumab or pembrolizumab), ipilimumab and nivolumab=23 (ipi+nivo)) (seven patients had ir-D/C more than once on different lines of treatment) and &gt;/=grade 3 ir-D/C occurred most frequently (63/519 patients (12%) vs 29/519 (5%) grade 1, and 25/519 (5%) grade 2). Median onset (days) of all-grade ir-D/C after starting ICI therapy was 41 for ipilimumab (IQR 24 to 59, n=77), 91 for anti-PD1 (IQR 46 to 355, n=17) and 45 for ipi+nivo (IQR 24 to 67, n=23). In 71/117 (61%) patients, ir-D/C episodes were treated with CS (17% grade 2; 79% grade 3/4): 54 being steroid-responsive; 17 being steroid-refractory and received additional anti-tumor necrosis factor (TNF) treatment. Median grade 3 ir-D/C CS duration was similar across treatments, averaging 58 days. Median overall CS duration (days) was longer in the grade 3/4 D/C steroid-refractory group (94 vs 45 days). Infection developed in 11/71 (15%) CS recipients and in 6/17 (35%) anti-TNF recipients. In 65/117 (55%) patients, ir-D/C episodes were investigated with flexible sigmoidoscopy. Of these patients, 38/65 (58%) had macroscopic colitis and 12/65 (18%) had microscopic colitis. The steroid-refractory group had more macroscopic changes, 13/17 (76%), than the steroid-responsive group, 22/41 (54%).</AbstractText>
          <AbstractText Label="CONCLUSION">Rates of grade 3 ir-D/C were higher than reported in clinical trials. The 58-day median duration of CS therapy for grade 3 ir-D/C places a significant number of patients at risk of complications. We demonstrate that microscopic colitis is an important subgroup, advocating biopsies in ir-D/C even with macroscopically normal bowel.</AbstractText>
          <CopyrightInformation>&#xa9; Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Favara</LastName>
            <ForeName>David M</ForeName>
            <Initials>DM</Initials>
            <Identifier Source="ORCID">0000-0003-3189-6658</Identifier>
            <AffiliationInfo>
              <Affiliation>Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Spain</LastName>
            <ForeName>Lavinia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Au</LastName>
            <ForeName>Lewis</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clark</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daniels</LastName>
            <ForeName>Ella</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diem</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology and Haematology, Kantonsspital St Gallen, Sankt Gallen, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chauhan</LastName>
            <ForeName>Dharmisha</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacy, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turajlic</LastName>
            <ForeName>Samra</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Dynamics Laboratory, Francis Crick Institute, London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Powell</LastName>
            <ForeName>Nick</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Gastroenterology Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation Biology and Cancer Immunology, King's College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Larkin</LastName>
            <ForeName>James M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yousaf</LastName>
            <ForeName>Nadia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Acute Oncology Service and Lung Unit, Royal Marsden NHS Foundation Trust, London, UK nadia.yousaf@rmh.nhs.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>ESMO Open</MedlineTA>
        <NlmUniqueID>101690685</NlmUniqueID>
        <ISSNLinking>2059-7029</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000079424">Tumor Necrosis Factor Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="Y">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079424" MajorTopicYN="N">Tumor Necrosis Factor Inhibitors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">corticosteroids</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy related diarrhoea/colitis</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy toxicity</Keyword>
        <Keyword MajorTopicYN="N">infliximab</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: JL has received research support from Bristol-Myers Squibb, Merck Sharp &amp; Dohme, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics and AVEO Oncology. JL has also consulted for Achilles, AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Merck Sharp &amp; Dohme, Nektar Therapeutics, Novartis, Pierre Fabre, Pfizer, Roche/Genentech, Secarna and Vitaccess. He also declares support from the National Institute of Health Research Biomedical Research Center for Cancer at the Royal Marsden/Institute of Cancer Research.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32641348</ArticleId>
        <ArticleId IdType="pmc">PMC7348326</ArticleId>
        <ArticleId IdType="doi">10.1136/esmoopen-2019-000585</ArticleId>
        <ArticleId IdType="pii">S2059-7029(20)32633-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Michot JM, Bigenwald C, Champiat S, et al. . Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139&#x2013;48. 10.1016/j.ejca.2015.11.016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2015.11.016</ArticleId>
            <ArticleId IdType="pubmed">26765102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, Long GV, Brady B, et al. . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320&#x2013;30. 10.1056/NEJMoa1412082</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1412082</ArticleId>
            <ArticleId IdType="pubmed">25399552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, Schachter J, Long GV, et al. . Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521&#x2013;32. 10.1056/NEJMoa1503093</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1503093</ArticleId>
            <ArticleId IdType="pubmed">25891173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23&#x2013;34. 10.1056/NEJMoa1504030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504030</ArticleId>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, D'Angelo SP, Minor D, et al. . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375&#x2013;84. 10.1016/S1470-2045(15)70076-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)70076-8</ArticleId>
            <ArticleId IdType="pubmed">25795410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. . Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD anderson. J Immunother Cancer 2018;6:37. 10.1186/s40425-018-0346-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0346-6</ArticleId>
            <ArticleId IdType="pmc">PMC5946546</ArticleId>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C, et al. . Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv119&#x2013;42. 10.1093/annonc/mdx225</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx225</ArticleId>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Castillo M, Romero FA, Arg&#xfc;ello E, et al. . The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 2016;63:1490&#x2013;3. 10.1093/cid/ciw539</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciw539</ArticleId>
            <ArticleId IdType="pmc">PMC5106605</ArticleId>
            <ArticleId IdType="pubmed">27501841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Chesney J, Pavlick AC, et al. . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006&#x2013;17. 10.1056/NEJMoa1414428</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1414428</ArticleId>
            <ArticleId IdType="pmc">PMC5744258</ArticleId>
            <ArticleId IdType="pubmed">25891304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez RS, Salaria SN, Bohannon CD, et al. . PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology 2017;70:558&#x2013;67. 10.1111/his.13118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13118</ArticleId>
            <ArticleId IdType="pubmed">28000302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016;44:51&#x2013;60. 10.1016/j.ctrv.2016.02.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2016.02.001</ArticleId>
            <ArticleId IdType="pubmed">26874776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sznol M, Ferrucci PF, Hogg D, et al. . Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 2017;35:JCO2016721167:3815&#x2013;22. 10.1200/JCO.2016.72.1167</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.72.1167</ArticleId>
            <ArticleId IdType="pubmed">28915085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Hodi FS, Wolchok JD, et al. . Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017;35:785&#x2013;92. 10.1200/JCO.2015.66.1389</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.66.1389</ArticleId>
            <ArticleId IdType="pubmed">28068177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merck Sharp &amp; Dohme Corp Keytruda (pembrolizumab) product information; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. . Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol 2018;4:98&#x2013;101. 10.1001/jamaoncol.2017.2391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2017.2391</ArticleId>
            <ArticleId IdType="pmc">PMC5833656</ArticleId>
            <ArticleId IdType="pubmed">28817755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DH, Zobniw CM, Trinh VA, et al. . Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018;6:103. 10.1186/s40425-018-0412-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0412-0</ArticleId>
            <ArticleId IdType="pmc">PMC6180568</ArticleId>
            <ArticleId IdType="pubmed">30305177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain A, Lipson EJ, Sharfman WH, et al. . Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol 2017;23:2023&#x2013;8. 10.3748/wjg.v23.i11.2023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v23.i11.2023</ArticleId>
            <ArticleId IdType="pmc">PMC5360643</ArticleId>
            <ArticleId IdType="pubmed">28373768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins M, Michot JM, Danlos FX, et al. . Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017;28:2860&#x2013;5. 10.1093/annonc/mdx403</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx403</ArticleId>
            <ArticleId IdType="pubmed">29045560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. . Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016;10:395&#x2013;401. 10.1093/ecco-jcc/jjv227</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv227</ArticleId>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K, Abu-Sbeih H, Samdani R, et al. . Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 2019;25:385&#x2013;93. 10.1093/ibd/izy240</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy240</ArticleId>
            <ArticleId IdType="pmc">PMC7534361</ArticleId>
            <ArticleId IdType="pubmed">30169584</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32621258</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-2568</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>66</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Digestive diseases and sciences</Title>
          <ISOAbbreviation>Dig Dis Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis.</ArticleTitle>
        <Pagination>
          <StartPage>2129</StartPage>
          <EndPage>2134</EndPage>
          <MedlinePgn>2129-2134</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-020-06441-w</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hayashi</LastName>
            <ForeName>Yukie</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hosoe</LastName>
            <ForeName>Naoki</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-4516-5648</Identifier>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan. nhosoe@z5.keio.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takabayashi</LastName>
            <ForeName>Kaoru</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Limpias Kamiya</LastName>
            <ForeName>Kenji J L</ForeName>
            <Initials>KJL</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsugaru</LastName>
            <ForeName>Kai</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimozaki</LastName>
            <ForeName>Keitaro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>Kenro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fukuhara</LastName>
            <ForeName>Kayoko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Preventive Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fukuhara</LastName>
            <ForeName>Seiichiro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mutaguchi</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sujino</LastName>
            <ForeName>Tomohisa</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sukawa</LastName>
            <ForeName>Yasutaka</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamamoto</LastName>
            <ForeName>Yasuo</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naganuma</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takaishi</LastName>
            <ForeName>Hiromasa</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Preventive Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimoda</LastName>
            <ForeName>Masayuki</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogata</LastName>
            <ForeName>Haruhiko</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanai</LastName>
            <ForeName>Takanori</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Dig Dis Sci</MedlineTA>
        <NlmUniqueID>7902782</NlmUniqueID>
        <ISSNLinking>0163-2116</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016099" MajorTopicYN="N">Endoscopy, Gastrointestinal</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005756" MajorTopicYN="N">Gastritis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005759" MajorTopicYN="N">Gastroenteritis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Enteritis</Keyword>
        <Keyword MajorTopicYN="N">Gastritis</Keyword>
        <Keyword MajorTopicYN="N">Immune check point inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Immune-rerated adverse events (irAE)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32621258</ArticleId>
        <ArticleId IdType="doi">10.1007/s10620-020-06441-w</ArticleId>
        <ArticleId IdType="pii">10.1007/s10620-020-06441-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100:4712&#x2013;4717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0830997100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443&#x2013;2454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600&#x2013;1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2016.4059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42:406&#x2013;417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.13281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv264-iv6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6:37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0346-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283&#x2013;2289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.04.5716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10:395&#x2013;401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28:2860&#x2013;2865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai S, Nakamura S, Kawasaki K, et al. Immune checkpoint inhibitor-induced diarrhea: clinicopathological study of 11 patients. Dig Endosc. 2020;32:616&#x2013;620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/den.13555</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32603654</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4172</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>182</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell</Title>
          <ISOAbbreviation>Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>655</StartPage>
          <EndPage>671.e22</EndPage>
          <MedlinePgn>655-671.e22</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.06.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)30688-7</ELocationID>
        <Abstract>
          <AbstractText>Checkpoint blockade with antibodies specific for the PD-1 and CTLA-4 inhibitory receptors can induce durable responses in a wide range of human cancers. However, the immunological mechanisms responsible for severe inflammatory side effects remain poorly understood. Here we report a comprehensive single-cell analysis of immune cell populations in colitis, a common and severe side effect of checkpoint blockade. We observed a striking accumulation of CD8 T cells with highly cytotoxic and proliferative states and no evidence of regulatory T cell depletion. T cell receptor (TCR) sequence analysis demonstrated that a substantial fraction of colitis-associated CD8 T cells originated from tissue-resident populations, explaining the frequently early onset of colitis symptoms following treatment initiation. Our analysis also identified cytokines, chemokines, and surface receptors that could serve as therapeutic targets for colitis and potentially other inflammatory side effects of checkpoint blockade.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Luoma</LastName>
            <ForeName>Adrienne M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suo</LastName>
            <ForeName>Shengbao</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Williams</LastName>
            <ForeName>Hannah L</ForeName>
            <Initials>HL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharova</LastName>
            <ForeName>Tatyana</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sullivan</LastName>
            <ForeName>Keri</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manos</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bowling</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hodi</LastName>
            <ForeName>F Stephen</ForeName>
            <Initials>FS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rahma</LastName>
            <ForeName>Osama</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sullivan</LastName>
            <ForeName>Ryan J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boland</LastName>
            <ForeName>Genevieve M</ForeName>
            <Initials>GM</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nowak</LastName>
            <ForeName>Jonathan A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Brigham &amp; Women's Hospital, Boston, MA 02115, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dougan</LastName>
            <ForeName>Stephanie K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dougan</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA. Electronic address: mldougan@partners.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Guo-Cheng</ForeName>
            <Initials>GC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wucherpfennig</LastName>
            <ForeName>Kai W</ForeName>
            <Initials>KW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA; Department of Neurology, Brigham &amp; Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: kai_wucherpfennig@dfci.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 DK114563</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA238039</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA207021</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA163222</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell</MedlineTA>
        <NlmUniqueID>0413066</NlmUniqueID>
        <ISSNLinking>0092-8674</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515187">CXCR3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C106330">CXCR6 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054367">Receptors, CXCR3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000075744">Receptors, CXCR6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005810" MajorTopicYN="N">Multigene Family</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081246" MajorTopicYN="N">RNA-Seq</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011948" MajorTopicYN="N">Receptors, Antigen, T-Cell</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054367" MajorTopicYN="N">Receptors, CXCR3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075744" MajorTopicYN="N">Receptors, CXCR6</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CTLA-4</Keyword>
        <Keyword MajorTopicYN="N">IFN&#x3b3;</Keyword>
        <Keyword MajorTopicYN="N">PD-1</Keyword>
        <Keyword MajorTopicYN="N">TNF&#x3b1;</Keyword>
        <Keyword MajorTopicYN="N">Trm</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">checkpoint blockade</Keyword>
        <Keyword MajorTopicYN="N">cytotoxic T cells</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">inflammatory cytokines</Keyword>
        <Keyword MajorTopicYN="N">irAEs</Keyword>
        <Keyword MajorTopicYN="N">tissue-resident memory T cells</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Interests K.W.W. serves on the scientific advisory board of TCR2 Therapeutics, T-Scan Therapeutics, and Nextechinvest and receives sponsored research funding from Novartis. He is a scientific co-founder of Immunitas Therapeutics. M.D. receives research funding from Novartis and is on the Scientific Advisory Board for Neoleukin Therapeutics. S.K.D. receives research funding from Novartis, Bristol-Myers Squibb, and Eli Lilly. F.S.H. receives research funding from Bristol-Myers Squibb and Novartis; he also consults for Merck, EMD Serono, Novartis, Takeda, Genentech/Roche, Compass Therapeutics, Apricity, Aduro, Sanofi, Pionyr, 7 Hills Pharma, Verastem, Torque, Rheos Kairos, Psioxus Therapeutics, Amgen, and Pieris Pharmaceutical. O.R. receives research support from Merck and is a speaker for activities supported by educational grants from BMS and Merck. He is a consultant for Merck, Celgene, Five Prime, GSK, GFK, Bayer, Roche/Genentech, Puretech, Imvax, and Sobi. In addition, he has patent &#x201c;Methods of using pembrolizumab and trebananib&#x201d; pending. J.A.N. has a provisional patent application for spatial quantification of immune cell infiltration in the tumor microenvironment. R.J.S. has received research funding from Merck and Amgen.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32603654</ArticleId>
        <ArticleId IdType="mid">NIHMS1607269</ArticleId>
        <ArticleId IdType="pmc">PMC7415717</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cell.2020.06.001</ArticleId>
        <ArticleId IdType="pii">S0092-8674(20)30688-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, and Wang Y (2018). Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 6, 142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6280383</ArticleId>
            <ArticleId IdType="pubmed">30518410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aibar S, Gonzalez-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, Rambow F, Marine JC, Geurts P, Aerts J, et al. (2017). SCENIC: single-cell regulatory network inference and clustering. Nat Methods 14, 1083&#x2013;1086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5937676</ArticleId>
            <ArticleId IdType="pubmed">28991892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, Chak S, Naikawadi RP, Wolters PJ, Abate AR, et al. (2019). Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 20, 163&#x2013;172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6340744</ArticleId>
            <ArticleId IdType="pubmed">30643263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martinez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, et al. (2018). Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 36, 2872&#x2013;2878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30125216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, and Dougan M (2019). Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 7, 226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6704680</ArticleId>
            <ArticleId IdType="pubmed">31439050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, Ginhoux F, and Newell EW (2018). Dimensionality reduction for visualizing single-cell data using UMAP. Nature biotechnology.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30531897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blondel VD, Guillaume J-L, L. R, and Lefebvre E (2008). Fast unfolding of communities in large networks. J Stat Mech, P10008.</Citation>
        </Reference>
        <Reference>
          <Citation>Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, and Brenner MB (1994). Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 372, 190&#x2013;193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7969453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, et al. (2017). Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. J Crohns Colitis 11, 1238&#x2013;1246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28967957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curran MA, Montalvo W, Yagita H, and Allison JP (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107, 4275&#x2013;4280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840093</ArticleId>
            <ArticleId IdType="pubmed">20160101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M (2017). Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Front Immunol 8, 1547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5715331</ArticleId>
            <ArticleId IdType="pubmed">29230210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M, and Pietropaolo M (2020). Time to dissect the autoimmune etiology of cancer antibody immunotherapy. J Clin Invest 130, 51&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6934191</ArticleId>
            <ArticleId IdType="pubmed">31895048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. (2007). Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13, 6681&#x2013;6688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2147083</ArticleId>
            <ArticleId IdType="pubmed">17982122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, Cohen J, and Sullivan RJ (2018). High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124, 3706&#x2013;3714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foulds KE, Zenewicz LA, Shedlock DJ, Jiang J, Troy AE, and Shen H (2002). Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol 168, 1528&#x2013;1532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11823476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, et al. (2018). Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3, e000278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groom JR, and Luster AD (2011). CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89, 207&#x2013;215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3863330</ArticleId>
            <ArticleId IdType="pubmed">21221121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grover S, and Srivastava A (2019). Lymphocytic colitis-like pattern of mucosal injury and the challenges in diagnosing cancer immunotherapy-related toxicity. Cancer 125, 1768&#x2013;1770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30892689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu Z, Gu L, Eils R, Schlesner M, and Brors B (2014). circlize Implements and enhances circular visualization in R. Bioinformatics 30, 2811&#x2013;2812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24930139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herold MJ, McPherson KG, and Reichardt HM (2006). Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63, 60&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2792342</ArticleId>
            <ArticleId IdType="pubmed">16314919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi FS, O&#x2019;Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711&#x2013;723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang B, Chen Z, Geng L, Wang J, Liang H, Cao Y, Chen H, Huang W, Su M, Wang H, et al. (2019). Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways. Cell 179, 1160&#x2013;1176 e1124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31730855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, Sullivan RJ, and Dougan M (2019). Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 7, 292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6839080</ArticleId>
            <ArticleId IdType="pubmed">31699151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilicic T, Kim JK, Kolodziejczyk AA, Bagger FO, McCarthy DJ, Marioni JC, and Teichmann SA (2016). Classification of low quality cells from single-cell RNA-seq data. Genome Biol 17, 29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4758103</ArticleId>
            <ArticleId IdType="pubmed">26887813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. (2016). Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 375, 1749&#x2013;1755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5247797</ArticleId>
            <ArticleId IdType="pubmed">27806233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joosse ME, Nederlof I, Walker LSK, and Samsom JN (2019). Tipping the balance: inhibitory checkpoints in intestinal homeostasis. Mucosal Immunol 12, 21&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30498201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, and Campbell DJ (2009). The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 10, 595&#x2013;602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2712126</ArticleId>
            <ArticleId IdType="pubmed">19412181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korotkevich G, Sukhov V, and Sergushichev A (2019). Fast gene set enrichment analysis. bioRxiv, 10.1101/060012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/060012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, et al. (2014). Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345, 1623&#x2013;1627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4371526</ArticleId>
            <ArticleId IdType="pubmed">25213377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, Senda T, Sun X, Ho SH, Lerner H, et al. (2017). Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep 20, 2921&#x2013;2934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5646692</ArticleId>
            <ArticleId IdType="pubmed">28930685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, Lidschreiber K, Kastriti ME, Lonnerberg P, Furlan A, et al. (2018). RNA velocity of single cells. Nature 560, 494&#x2013;498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6130801</ArticleId>
            <ArticleId IdType="pubmed">30089906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langer V, Vivi E, Regensburger D, Winkler TH, Waldner MJ, Rath T, Schmid B, Skottke L, Lee S, Jeon NL, et al. (2019). IFN-gamma drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. J Clin Invest 129, 4691&#x2013;4707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6819119</ArticleId>
            <ArticleId IdType="pubmed">31566580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373, 23&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, and Tamayo P (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 1, 417&#x2013;425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4707969</ArticleId>
            <ArticleId IdType="pubmed">26771021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, and McDonald GB (2010). Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 55, 1396&#x2013;1405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2904314</ArticleId>
            <ArticleId IdType="pubmed">19507029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maloy KJ, and Powrie F (2011). Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298&#x2013;306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21677746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, Gettler K, Chuang LS, Nayar S, Greenstein AJ, et al. (2019). Single-Cell Analysis of Crohn&#x2019;s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell 178, 1493&#x2013;1508 e1420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7060942</ArticleId>
            <ArticleId IdType="pubmed">31474370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masopust D, and Soerens AG (2019). Tissue-Resident T Cells and Other Resident Leukocytes. Annu Rev Immunol 37, 521&#x2013;546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7175802</ArticleId>
            <ArticleId IdType="pubmed">30726153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGinnis CS, Murrow LM, and Gartner ZJ (2019). DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst 8, 329&#x2013;337 e324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6853612</ArticleId>
            <ArticleId IdType="pubmed">30954475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnes L, Healy J, and Melville J (2018). UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. In arXiv e-prints, pp. arXiv:1802.03426.</Citation>
        </Reference>
        <Reference>
          <Citation>McLane LM, Abdel-Hakeem MS, and Wherry EJ (2019). CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol 37, 457&#x2013;495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30676822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al. (2009). Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899&#x2013;911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19464196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurath MF (2014). Cytokines in inflammatory bowel disease. Nat Rev Immunol 14, 329&#x2013;342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24751956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurath MF (2019). Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol 20, 970&#x2013;979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31235952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pijuan-Sala B, Griffiths JA, Guibentif C, Hiscock TW, Jawaid W, Calero-Nieto FJ, Mulas C, Ibarra-Soria X, Tyser RCV, Ho DLL, et al. (2019). A single-cell molecular map of mouse gastrulation and early organogenesis. Nature 566, 490&#x2013;495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6522369</ArticleId>
            <ArticleId IdType="pubmed">30787436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372, 2006&#x2013;2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5744258</ArticleId>
            <ArticleId IdType="pubmed">25891304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, and Hellmann MD (2018). Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378, 158&#x2013;168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, and Group CT (2017). Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833&#x2013;1842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28855077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, and Ideker T (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498&#x2013;2504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC403769</ArticleId>
            <ArticleId IdType="pubmed">14597658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, and Sharma P (2019). Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res 25, 1233&#x2013;1238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6348141</ArticleId>
            <ArticleId IdType="pubmed">30054281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherwood AM, Desmarais C, Livingston RJ, Andriesen J, Haussler M, Carlson CS, and Robins H (2011). Deep sequencing of the human TCRgamma and TCRbeta repertoires suggests that TCRbeta rearranges after alphabeta and gammadelta T cell commitment. Sci Transl Med 3, 90ra61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4179204</ArticleId>
            <ArticleId IdType="pubmed">21734177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210, 1695&#x2013;1710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3754863</ArticleId>
            <ArticleId IdType="pubmed">23897981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smillie CS, Biton M, Ordovas-Montanes J, Sullivan KM, Burgin G, Graham DB, Herbst RH, Rogel N, Slyper M, Waldman J, et al. (2019). Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell 178, 714&#x2013;730 e722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6662628</ArticleId>
            <ArticleId IdType="pubmed">31348891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solomon BL, and Garrido-Laguna I (2018). TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother 67, 1659&#x2013;1667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30232519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, and Satija R (2019). Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902 e1821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6687398</ArticleId>
            <ArticleId IdType="pubmed">31178118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suo S, Zhu Q, Saadatpour A, Fei L, Guo G, and Yuan GC (2018). Revealing the Critical Regulators of Cell Identity in the Mouse Cell Atlas. Cell Rep 25, 1436&#x2013;1445 e1433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6281296</ArticleId>
            <ArticleId IdType="pubmed">30404000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szabo PA, Miron M, and Farber DL (2019). Location, location, location: Tissue resident memory T cells in mice and humans. Sci Immunol 4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6778482</ArticleId>
            <ArticleId IdType="pubmed">30952804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walker MG, Volkmuth W, Sprinzak E, Hodgson D, and Klingler T (1999). Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes. Genome Res 9, 1198&#x2013;1203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC310991</ArticleId>
            <ArticleId IdType="pubmed">10613842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, and Toes RE (2007). Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37, 129&#x2013;138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17154262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Gortz D, This S, Stockenhuber K, et al. (2017). Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 23, 579&#x2013;589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5420447</ArticleId>
            <ArticleId IdType="pubmed">28368383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wickham H (2016). ggplot2 : elegant graphics for data analysis (Springer-Verlag; New York:).</Citation>
        </Reference>
        <Reference>
          <Citation>Xiao G, Wang X, Wang J, Zu L, Cheng G, Hao M, Sun X, Xue Y, Lu J, and Wang J (2015). CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms. Oncotarget 6, 14165&#x2013;14178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4546458</ArticleId>
            <ArticleId IdType="pubmed">25909173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshino K, Nakayama T, Ito A, Sato E, and Kitano S (2019). Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. BMC Cancer 19, 1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6819390</ArticleId>
            <ArticleId IdType="pubmed">31664934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, et al. (2019). Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med 25, 1251&#x2013;1259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6689255</ArticleId>
            <ArticleId IdType="pubmed">31359002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, Laerdahl JK, Stade B, Forster M, Schreiber S, et al. (2015). Early-onset Crohn&#x2019;s disease and autoimmunity associated with a variant in CTLA-4. Gut 64, 1889&#x2013;1897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4512923</ArticleId>
            <ArticleId IdType="pubmed">25367873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, and Deshpande V (2020). Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 76, 233&#x2013;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31361907</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32584703</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2688-1535</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>JCO oncology practice</Title>
          <ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.</ArticleTitle>
        <Pagination>
          <StartPage>453</StartPage>
          <EndPage>461</EndPage>
          <MedlinePgn>453-461</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/OP.20.00002</ELocationID>
        <Abstract>
          <AbstractText>Immune-mediated diarrhea and colitis (IMDC) is among the most common immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors (ICIs). Many factors will affect the risk of IMDC, including the type of ICI used, the type of underlying cancer, and patient characteristics. A recent study showed that preexisting inflammatory bowel disease significantly increases the risk of diarrhea and colitis with ICI treatment. In terms of management, early endoscopic evaluation improves clinical outcome by identifying high-risk patients who will benefit from early add-on immunosuppressants. Inflammatory markers, including fecal lactoferrin and calprotectin, are good screening tools to predict which patients are at risk for colitis. Calprotectin especially is associated with colitis outcome and can be used as a surrogate marker to follow treatment response. Corticosteroids remain the first-line medical treatment of IMDC management, and add-on therapy with vedolizumab or infliximab should be considered in selected patients. Fecal microbiota transplantation may be considered in refractory cases. The decision to resume ICI should be decided by balancing the risk of recurrent IMDC and the likelihood of benefiting from further ICI treatment. There is no clear evidence about whether the use of immunosuppressants will result in a worse cancer outcome. With emerging evidence, our understanding and management strategies are likely to evolve in the future.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Zimu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Saint Joseph Hospital, Chicago, IL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yinghong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>JCO Oncol Pract</MedlineTA>
        <NlmUniqueID>101758685</NlmUniqueID>
        <ISSNLinking>2688-1527</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B72HH48FLU</RegistryNumber>
          <NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>JCO Oncol Pract. 2020 Aug;16(8):464-465</RefSource>
          <PMID Version="1">32780983</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>JCO Oncol Pract. 2020 Aug;16(8):462-463</RefSource>
          <PMID Version="1">32780984</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32584703</ArticleId>
        <ArticleId IdType="doi">10.1200/OP.20.00002</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32567084</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-0142</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>126</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer</Title>
          <ISOAbbreviation>Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.</ArticleTitle>
        <Pagination>
          <StartPage>3758</StartPage>
          <EndPage>3767</EndPage>
          <MedlinePgn>3758-3767</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.32966</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis.</AbstractText>
          <AbstractText Label="METHODS">We performed a retrospective analysis of melanoma patients at Dana-Farber Cancer Institute who received PD-1, CTLA-4, or combination ICIs between May 2011 to October 2017. Clinical and laboratory characteristics associated with pathologically confirmed ICI colitis were evaluated using multivariable logistic regression analyses. External confirmation was performed on an independent cohort from Massachusetts General Hospital.</AbstractText>
          <AbstractText Label="RESULTS">The discovery cohort included 213 patients of whom 37 developed ICI colitis (17%). Vitamin D use was recorded in 66/213 patients (31%) before starting ICIs. In multivariable regression analysis, vitamin D use conferred significantly reduced odds of developing ICI colitis (OR 0.35, 95% CI 0.1-0.9). These results were also demonstrated in the confirmatory cohort (OR 0.46, 95% CI 0.2-0.9) of 169 patients of whom 49 developed ICI colitis (29%). Pre-treatment neutrophil-to-lymphocyte ratio (NLR) &#x2265;5 predicted reduced odds of colitis (OR 0.34, 95% CI 0.1-0.9) only in the discovery cohort.</AbstractText>
          <AbstractText Label="CONCLUSIONS">This is the first study to report that among patients treated with ICIs, vitamin D intake is associated with reduced risk for ICI colitis. This finding is consistent with prior reports of prophylactic use of vitamin D in ulcerative colitis and graft-versus-host-disease. This observation should be validated prospectively in future studies.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 American Cancer Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Grover</LastName>
            <ForeName>Shilpa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dougan</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tyan</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-8585-1802</Identifier>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giobbie-Hurder</LastName>
            <ForeName>Anita</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blum</LastName>
            <ForeName>Steven M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Broad Institute at MIT and Harvard, Cambridge, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Massachusetts General Hospital Cancer Center, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishizuka</LastName>
            <ForeName>Jeffrey</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-4271-7312</Identifier>
            <AffiliationInfo>
              <Affiliation>Departments of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qazi</LastName>
            <ForeName>Taha</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Digestive Disease &amp; Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elias</LastName>
            <ForeName>Rawad</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Hartford HealthCare Cancer Institute, Hartford, Connecticut.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vora</LastName>
            <ForeName>Kruti B</ForeName>
            <Initials>KB</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Alex B</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin-Doyle</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manos</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eastman</LastName>
            <ForeName>Lauren</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davis</LastName>
            <ForeName>Meredith</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gargano</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haq</LastName>
            <ForeName>Rizwan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buchbinder</LastName>
            <ForeName>Elizabeth I</ForeName>
            <Initials>EI</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sullivan</LastName>
            <ForeName>Ryan J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts General Hospital Cancer Center, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ott</LastName>
            <ForeName>Patrick A</ForeName>
            <Initials>PA</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Broad Institute at MIT and Harvard, Cambridge, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hodi</LastName>
            <ForeName>F Stephen</ForeName>
            <Initials>FS</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rahma</LastName>
            <ForeName>Osama E</ForeName>
            <Initials>OE</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2T32CA071345-21A1</GrantID>
            <Agency>Massachusetts General Hospital</Agency>
          </Grant>
          <Grant>
            <GrantID>1K08 DK114563-01</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>5812101</GrantID>
            <Agency>Parker Institute for Cancer Immunotherapy</Agency>
          </Grant>
          <Grant>
            <Agency>American Gastroenterological Association</Agency>
          </Grant>
          <Grant>
            <GrantID>K08 DK114563</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA071345</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer</MedlineTA>
        <NlmUniqueID>0374236</NlmUniqueID>
        <ISSNLinking>0008-543X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C556706">CTLA4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1406-16-2</RegistryNumber>
          <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">irAE</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
        <Keyword MajorTopicYN="N">toxicity</Keyword>
        <Keyword MajorTopicYN="N">vitamin D</Keyword>
      </KeywordList>
      <CoiStatement>Competing Interests: The authors report the following competing interests: SG is employed as Senior Physician Editor, Gastroenterology for UpToDate, a Wolters Kluwer company. MD has grant support from Novartis, is a member of the scientific advisory board for Neoleukin Therapeutics, and has been a consultant for Tillotts Pharma, Genentech, and Partner Therapeutics. SB reports consulting with Two River Consulting and Third Rock Ventures as well as equity in Kronos Bio and Allogene Therapeutics. RH has research grant support from Novartis and BMS as well as a consulting arrangement with Tango Therapeutics. EB has served on advisory boards for Array Biopahrma, Bristol-Myers Squibb (BMS), Trieza Therapeutics and Novartis, and she also receives clinical trial support from Eli Lilly, Novartis, BMS, Genentech and BVD. JI reports consulting for Two River, Trammel Therapeutics, and Tango Therapeutics, and owns equity in Jounce Therapeutics and Kronos Therapeutics. PO reports the following: advisory roles for Alexion, Array, BMS, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, Pfizer, and TRM Oncology; institutional grants from Armo Biosciences, AstraZeneca/MedImmune, BMS, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, and Pfizer; and a speaking engagement from Medscape. SH reports the following: grants from BMS and Novartis; personal fees from BMS, Merck, Serono, Novartis, Takeda, Surface Pharmaceuticals, Genentech/Roche, Compass Therapeutics, Apricity, Bayer, Aduro, Partners Therapeutics, Sanofi, Pfizer, Pionyr Immunotherapeutics, 7 Hills Pharma, Verastem Oncology, Rheos Medicines, and Kairos Therapeutics; equity in Torque Therapeutics; and patents #20100111973 and #7250291 issued as well as #20170248603, #20160340407, #20160046716, #20140004112, #20170022275, #20170008962, and &#x201c;Methods of Using Pembrolizumab and Trebananib&#x201d; pending. OR has research support from Merck; educational grants from BMS and Merck; consulting agreements with Merck, Celgene, Five Prime Therapeutics, GSK, GFK, Defined Health INC, Roche/Genentech, Puretech, Imvax, Leerink and PRMA Consulting; and a patent &#x201c;Methods of Using Pembrolizumab and Trebananib&#x201d; pending.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32567084</ArticleId>
        <ArticleId IdType="mid">NIHMS1601216</ArticleId>
        <ArticleId IdType="pmc">PMC7381363</ArticleId>
        <ArticleId IdType="doi">10.1002/cncr.32966</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Couzin-Frankel J Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432&#x2013;1433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24357284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gentzler R, Hall R, Kunk PR, et al. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy. 2016;8(5):583&#x2013;600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27140411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12):1212&#x2013;1218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24240160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98&#x2013;106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4892769</ArticleId>
            <ArticleId IdType="pubmed">26558876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. The New England journal of medicine. 2018;378(2):158&#x2013;168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691&#x2013;2697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22614989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol. 2019;40(6):511&#x2013;523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6527345</ArticleId>
            <ArticleId IdType="pubmed">31053497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67(11):2056&#x2013;2067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30131322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706&#x2013;3714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. J Immunother. 2018;41(3):101&#x2013;108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29401166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Front Immunol. 2017;8:1547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5715331</ArticleId>
            <ArticleId IdType="pubmed">29230210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(7):785&#x2013;792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28068177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England journal of medicine. 2015;372(21):2006&#x2013;2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5744258</ArticleId>
            <ArticleId IdType="pubmed">25891304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease? ACG Case Rep J. 2017;4:e112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5636906</ArticleId>
            <ArticleId IdType="pubmed">29043290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4):395&#x2013;401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology. 2018;155(4):1079&#x2013;1089 e1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29958857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462&#x2013;1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17120402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology. 2019;157(3):647&#x2013;659 e644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31014995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R, Richardson P, Yu H, Kramer J, Hou JK. Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease. Digestion. 2017;95(3):188&#x2013;193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28288458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med. 2012;156(5):350&#x2013;359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3369539</ArticleId>
            <ArticleId IdType="pubmed">22393130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan SS, Luben R, Bergmann MM, et al. Aspirin in the aetiology of Crohn&#x2019;s disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther. 2011;34(6):649&#x2013;655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21790683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129(3):827&#x2013;836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16143122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017;23(33):6137&#x2013;6146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5597505</ArticleId>
            <ArticleId IdType="pubmed">28970729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgenstern S, Brook E, Rinawi F, Shamir R, Assa A. Tissue and peripheral eosinophilia as predictors for disease outcome in children with ulcerative colitis. Dig Liver Dis. 2017;49(2):170&#x2013;174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27903418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011;17(3):194&#x2013;198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3122090</ArticleId>
            <ArticleId IdType="pubmed">21546723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum S, Ishizuka J, Qazi T, et al. Hypoalbuminemia as a predictor factor for immune related adverse events (irAEs) in advanced melanoma patients treated with immune checkpoint inhibitors (ICIs) Presented at Society for Immunotherapy of Cancer (SITC); November 7&#x2013;11, 2018, Washington D.C.</Citation>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016;2(2):234&#x2013;240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26633184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahler KC, Eigentler TK, Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother. 2018;67(5):825&#x2013;834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29487980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368&#x2013;376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27687304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Faleck DM, Ricciuti B, et al. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology (in press) JCO.19.01674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7030892</ArticleId>
            <ArticleId IdType="pubmed">31800340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368&#x2013;1379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28368458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377&#x2013;2385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28945858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology. 2017;6(10):e1344805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5665065</ArticleId>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4570556</ArticleId>
            <ArticleId IdType="pubmed">26380086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schindler K, Harmankaya K, Kuk D, et al. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. Journal of Clinical Oncology. 2014;32(15_suppl):9096&#x2013;9096.</Citation>
        </Reference>
        <Reference>
          <Citation>Dankers W, Colin EM, van Hamburg JP, Lubberts E. Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. Front Immunol. 2016;7:697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5247472</ArticleId>
            <ArticleId IdType="pubmed">28163705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008;4(8):404&#x2013;412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18594491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2013;45(2):217&#x2013;226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6047889</ArticleId>
            <ArticleId IdType="pubmed">23359064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2017;15(2):240&#x2013;246 e241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5136522</ArticleId>
            <ArticleId IdType="pubmed">27266980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn&#x2019;s disease. Gastroenterology. 2012;142(3):482&#x2013;489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367959</ArticleId>
            <ArticleId IdType="pubmed">22155183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sloka S, Silva C, Wang J, Yong VW. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation. 2011;8:56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3118349</ArticleId>
            <ArticleId IdType="pubmed">21605467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stucci S, Palmirotta R, Passarelli A, et al. Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management. Oncol Lett. 2017;14(5):5671&#x2013;5680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5661371</ArticleId>
            <ArticleId IdType="pubmed">29113194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi S, Pantalena LC, Liu XK, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol. 2011;31(17):3653&#x2013;3669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3165548</ArticleId>
            <ArticleId IdType="pubmed">21746882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients. 2015;7(4):3011&#x2013;3021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4425186</ArticleId>
            <ArticleId IdType="pubmed">25912039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adorini L, Penna G. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb Exp Pharmacol. 2009(188):251&#x2013;273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19031030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Chen Y, Golan MA, et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013;123(9):3983&#x2013;3996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3754241</ArticleId>
            <ArticleId IdType="pubmed">23945234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770&#x2013;1773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16497887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn&#x2019;s disease susceptibility. Gut. 2000;47(2):211&#x2013;214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1728007</ArticleId>
            <ArticleId IdType="pubmed">10896912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eun Y, Kim IY, Sun JM, et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019;9(1):14039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6773778</ArticleId>
            <ArticleId IdType="pubmed">31575933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Celikbilek M, Dogan S, Ozbakir O, et al. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal. 2013;27(1):72&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6807407</ArticleId>
            <ArticleId IdType="pubmed">23292894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acarturk G, Acay A, Demir K, Ulu MS, Ahsen A, Yuksel S. Neutrophil-to-lymphocyte ratio in inflammatory bowel disease - as a new predictor of disease severity. Bratisl Lek Listy. 2015;116(4):213&#x2013;217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25773946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida Y, Hosomi S, Yamagami H, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction. PLoS One. 2019;14(3):e0213505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6405082</ArticleId>
            <ArticleId IdType="pubmed">30845259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Yoon S, Zhang YG, et al. Vitamin D receptor pathway is required for probiotic protection in colitis. Am J Physiol Gastrointest Liver Physiol. 2015;309(5):G341&#x2013;349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4556945</ArticleId>
            <ArticleId IdType="pubmed">26159695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karimi S, Tabataba-Vakili S, Yari Z, et al. The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status. Nutr J. 2019;18(1):16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6419481</ArticleId>
            <ArticleId IdType="pubmed">30871542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahamed ZR, Dutta U, Sharma V, et al. Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial. J Clin Gastroenterol. 2019;53(10):e409&#x2013;e415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31356558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Chen N, Wang D, Zhang J, Gong X. Efficacy of vitamin D in treatment of inflammatory bowel disease: A meta-analysis. Medicine (Baltimore). 2018;97(46):e12662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6257592</ArticleId>
            <ArticleId IdType="pubmed">30431562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Bahr L, Blennow O, Alm J, et al. Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50(9):1217&#x2013;1223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26030049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrillo-Cruz E, Garcia-Lozano JR, Marquez-Malaver FJ, et al. Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. Clin Cancer Res. 2019;25(15):4616&#x2013;4623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31043390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caballero-Velazquez T, Montero I, Sanchez-Guijo F, et al. Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clin Cancer Res. 2016;22(23):5673&#x2013;5681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27358490</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32540858</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e000453</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2019-000453</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational monoclonal antibody with high affinity and binding specificity for PD-1, was engineered to minimize binding to FcR on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The aim of this phase IA/IB study was to investigate the safety/tolerability, antitumor effects and optimal dose and schedule of tislelizumab in patients with advanced solid tumors.</AbstractText>
          <AbstractText Label="METHODS">Patients (aged &#x2265;18 years) enrolled in phase IA received intravenous tislelizumab 0.5, 2, 5 or 10&#x2009;mg/kg every 2&#x2009;weeks; 2 or 5&#x2009;mg/kg administered every 2&#x2009;weeks or every 3&#x2009;weeks; or 200&#x2009;mg every 3&#x2009;weeks; patients in phase IB received 5&#x2009;mg/kg every 3&#x2009;weeks. Primary objectives were to assess tislelizumab's safety/tolerability profile by adverse event (AE) monitoring and antitumor activity using RECIST V.1.1. PD-L1 expression was assessed retrospectively with the VENTANA PD-L1 (SP263) Assay.</AbstractText>
          <AbstractText Label="RESULTS">Between May 2015 and October 2017, 451 patients (n=116, IA; n=335, IB) were enrolled. Fatigue (28%), nausea (25%) and decreased appetite (20%) were the most commonly reported AEs. Most AEs were grade 1-2 severity; anemia (4.9%) was the most common grade 3-4 AE. Treatment-related AEs led to discontinuation in 5.3% of patients. Grade 5 AEs were reported in 14 patients; 2 were considered related to tislelizumab. Pneumonitis (2%) and colitis (1%) were the most common serious tislelizumab-related AEs. As of May 2019, 18% of patients achieved a confirmed objective response in phase IA and 12% in phase IB; median follow-up duration was 13.6 and 7.6 months, respectively. Pharmacokinetics, safety and antitumor activity obtained from both phase IA and IB determined the tislelizumab recommended dose; ultimately, tislelizumab 200&#x2009;mg intravenous every 3&#x2009;weeks was the dose and schedule recommended to be taken into subsequent clinical trials.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Tislelizumab monotherapy demonstrated an acceptable safety/tolerability profile. Durable responses were observed in heavily pretreated patients with advanced solid tumors, supporting the evaluation of tislelizumab 200&#x2009;mg every 3&#x2009;weeks, as monotherapy and in combination therapy, for the treatment of solid tumors and hematological malignancies.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION NUMBER">NCT02407990.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Desai</LastName>
            <ForeName>Jayesh</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia Jayesh.Desai@petermac.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deva</LastName>
            <ForeName>Sanjeev</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Auckland City Hospital, Auckland, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jong Seok</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Seoul National University Bundang Hospital, Seongnam-si, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Chia-Chi</ForeName>
            <Initials>CC</Initials>
            <AffiliationInfo>
              <Affiliation>National Taiwan University Hospital, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yen</LastName>
            <ForeName>Chia-Jui</ForeName>
            <Initials>CJ</Initials>
            <AffiliationInfo>
              <Affiliation>National Cheng Kung University Hospital, Tainan, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chao</LastName>
            <ForeName>Yee</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Keam</LastName>
            <ForeName>Bhumsuk</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Seoul National University Hospital, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jameson</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Waikato Hospital, University of Auckland Waikato Clinical Campus, Hamilton, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Ming-Mo</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Yoon-Koo</ForeName>
            <Initials>YK</Initials>
            <AffiliationInfo>
              <Affiliation>Asan Medical Center, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Markman</LastName>
            <ForeName>Ben</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Monash Health, Monash University, Clayton, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Chang-Hsien</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Chang Gung Memorial Hospital, Chia-yi, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rau</LastName>
            <ForeName>Kun-Ming</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Kyung-Hun</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>Seoul National University Hospital, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Horvath</LastName>
            <ForeName>Lisa</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Friedlander</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Prince of Wales Hospital and Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hill</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Tasman Oncology Research Ltd, Southport, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sandhu</LastName>
            <ForeName>Shahneen</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barlow</LastName>
            <ForeName>Paula</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Auckland City Hospital, Auckland, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Chi-Yuan</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>BeiGene USA, Inc, San Mateo, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>BeiGene (Beijing) Co., Ltd, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>BeiGene (Beijing) Co., Ltd, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>BeiGene USA, Inc, San Mateo, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paton</LastName>
            <ForeName>Virginia</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>BeiGene USA, Inc, San Mateo, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Millward</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Linear Clinical Research, Nedlands, Western Australia, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02407990</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0KVO411B3N</RegistryNumber>
          <NameOfSubstance UI="C000707970">tislelizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020714" MajorTopicYN="N">Maximum Tolerated Dose</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066066" MajorTopicYN="N">Response Evaluation Criteria in Solid Tumors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">oncology</Keyword>
        <Keyword MajorTopicYN="N">programmed cell death 1 receptor</Keyword>
        <Keyword MajorTopicYN="N">tumors</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: JD has served in a consulting or advisory role for Amgen, BeiGene, Bionomics, Eisai, Eli Lilly and Novartis, and their institution has received research funding from Bionomics, GlaxoSmithKline, Novartis and Roche. SD has received personal fees from Roche; C-CL has served in a consulting or advisory role for Novartis and has received travel, accommodations and expenses from BeiGene; BK has received grants and personal fees from AstraZeneca and MSD Oncology, grants from Ono Pharmaceutical and personal fees from Genexin; MJ's institution has received research funding from BeiGene, Merck Sharp &amp; Dohme, Pfizer and Bristol-Myers Squibb; BM has served in a consultancy or advisory role for Novartis; LH has received grants from Astellas; MF has received honoraria from AstraZeneca, Merck Sharp &amp; Dohme, Lilly, Takeda and Novartis, serves in a consulting or advisory role for AstraZeneca, Merck Sharp &amp; Dohme and has received research funding from BeiGene and AstraZeneca. AH is employed by, has a leadership role in and has stock or other ownership in, Tasman Healthcare/Tasman Oncology Research. SS has received grants from Merck, Britsol-Meyers Squibb, Amgen, Endocyte, AstraZeneca and Roche; PB has received personal fees from Roche; LL, C-YW, JW, VP and YZ are employees of BeiGene; MM serves in a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp &amp; Dohme, Novartis and Roche, and has received travel, accommodations and expenses from AstraZeneca, Bristol-Myers Squibb, Merck Sharp &amp; Dohme and Roche.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32540858</ArticleId>
        <ArticleId IdType="pmc">PMC7295442</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2019-000453</ArticleId>
        <ArticleId IdType="pii">jitc-2019-000453</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dahan R, Sega E, Engelhardt J, et al. . Fc&#x3b3;Rs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 2015;28:285&#x2013;95. 10.1016/j.ccell.2015.08.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.08.004</ArticleId>
            <ArticleId IdType="pubmed">26373277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015;37:764&#x2013;82. 10.1016/j.clinthera.2015.02.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2015.02.018</ArticleId>
            <ArticleId IdType="pmc">PMC4497957</ArticleId>
            <ArticleId IdType="pubmed">25823918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847&#x2013;56. 10.1158/1535-7163.MCT-14-0983</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0983</ArticleId>
            <ArticleId IdType="pubmed">25695955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst RS, Soria J-C, Kowanetz M, et al. . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563&#x2013;7. 10.1038/nature14011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14011</ArticleId>
            <ArticleId IdType="pmc">PMC4836193</ArticleId>
            <ArticleId IdType="pubmed">25428504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2:662&#x2013;73. 10.1002/cam4.106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.106</ArticleId>
            <ArticleId IdType="pmc">PMC3892798</ArticleId>
            <ArticleId IdType="pubmed">24403232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konishi J, Yamazaki K, Azuma M, et al. . B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094&#x2013;100. 10.1158/1078-0432.CCR-04-0428</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-0428</ArticleId>
            <ArticleId IdType="pubmed">15297412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi F, Shi M, Zeng Z, et al. . PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887&#x2013;96. 10.1002/ijc.25397</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.25397</ArticleId>
            <ArticleId IdType="pubmed">20473887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu C, Zhu Y, Jiang J, et al. . Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19&#x2013;24. 10.1016/j.acthis.2006.01.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.acthis.2006.01.003</ArticleId>
            <ArticleId IdType="pubmed">16530813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Drake CG, Wollner I, et al. . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167&#x2013;75. 10.1200/JCO.2009.26.7609</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.26.7609</ArticleId>
            <ArticleId IdType="pmc">PMC4834717</ArticleId>
            <ArticleId IdType="pubmed">20516446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, et al. . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443&#x2013;54. 10.1056/NEJMoa1200690</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId>
            <ArticleId IdType="pmc">PMC3544539</ArticleId>
            <ArticleId IdType="pubmed">22658127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamid O, Robert C, Daud A, et al. . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134&#x2013;44. 10.1056/NEJMoa1305133</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1305133</ArticleId>
            <ArticleId IdType="pmc">PMC4126516</ArticleId>
            <ArticleId IdType="pubmed">23724846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Song X, Xu L, et al. . The binding of an anti-PD-1 antibody to Fc&#x3b3;RI has a profound impact on its biological functions. Cancer Immunol Immunother 2018;67:1079&#x2013;90. 10.1007/s00262-018-2160-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2160-x</ArticleId>
            <ArticleId IdType="pmc">PMC6006217</ArticleId>
            <ArticleId IdType="pubmed">29687231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228&#x2013;47. 10.1016/j.ejca.2008.10.026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2008.10.026</ArticleId>
            <ArticleId IdType="pubmed">19097774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuchs CS, Doi T, Jang RW, et al. . Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013. 10.1001/jamaoncol.2018.0013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.0013</ArticleId>
            <ArticleId IdType="pmc">PMC5885175</ArticleId>
            <ArticleId IdType="pubmed">29543932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nanda R, Chow LQM, Dees EC, et al. . Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016;34:2460&#x2013;7. 10.1200/JCO.2015.64.8931</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.64.8931</ArticleId>
            <ArticleId IdType="pmc">PMC6816000</ArticleId>
            <ArticleId IdType="pubmed">27138582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellmunt J, de Wit R, Vaughn DJ, et al. . Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015&#x2013;26. 10.1056/NEJMoa1613683</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1613683</ArticleId>
            <ArticleId IdType="pmc">PMC5635424</ArticleId>
            <ArticleId IdType="pubmed">28212060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg JE, Hoffman-Censits J, Powles T, et al. . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909&#x2013;20. 10.1016/S0140-6736(16)00561-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)00561-4</ArticleId>
            <ArticleId IdType="pmc">PMC5480242</ArticleId>
            <ArticleId IdType="pubmed">26952546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi NA, Mazi&#xe8;res J, Planchard D, et al. . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257&#x2013;65. 10.1016/S1470-2045(15)70054-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)70054-9</ArticleId>
            <ArticleId IdType="pmc">PMC5726228</ArticleId>
            <ArticleId IdType="pubmed">25704439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powles T, O'Donnell PH, Massard C, et al. . Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3:e172411. 10.1001/jamaoncol.2017.2411</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2017.2411</ArticleId>
            <ArticleId IdType="pmc">PMC5824288</ArticleId>
            <ArticleId IdType="pubmed">28817753</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32434876</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1757-790X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMJ case reports</Title>
          <ISOAbbreviation>BMJ Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CMV coinfection in treatment refractory immune checkpoint inhibitor colitis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e233519</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2019-233519</ELocationID>
        <Abstract>
          <AbstractText>As immune checkpoint inhibitors (ICIs) are increasingly used, clinicians are more frequently encountering the side effects of these therapies. ICIs have been implicated in numerous adverse effects against healthy tissues. We present a case of a patient who developed treatment refractory checkpoint inhibitor colitis. Following colonoscopy, it was discovered that this patient had cytomegalovirus (CMV) coinfection. This case report highlights the importance of undertaking an appropriate assessment, including endoscopic and histologic investigation, of patients with presumed ICI colitis. Accurately diagnosing a superimposed CMV colitis changes clinical management and can improve patient outcomes.</AbstractText>
          <CopyrightInformation>&#xa9; BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Harris</LastName>
            <ForeName>Kevin B</ForeName>
            <Initials>KB</Initials>
            <Identifier Source="ORCID">0000-0002-3515-7476</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA harrisk5@ccf.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Funchain</LastName>
            <ForeName>Pauline</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baggott</LastName>
            <ForeName>Brian B</ForeName>
            <Initials>BB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>BMJ Case Rep</MedlineTA>
        <NlmUniqueID>101526291</NlmUniqueID>
        <ISSNLinking>1757-790X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003586" MajorTopicYN="N">Cytomegalovirus Infections</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">gastroenterology</Keyword>
        <Keyword MajorTopicYN="N">hepatitis and other GI infections</Keyword>
        <Keyword MajorTopicYN="N">oncology</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32434876</ArticleId>
        <ArticleId IdType="pmc">PMC7244273</ArticleId>
        <ArticleId IdType="doi">10.1136/bcr-2019-233519</ArticleId>
        <ArticleId IdType="pii">13/5/e233519</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Johnson DB, Chandra S, Sosman JA, et al. . Immune checkpoint inhibitor toxicity in 2018. JAMA 2018;320:1702&#x2013;3. 10.1001/jama.2018.13995</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2018.13995</ArticleId>
            <ArticleId IdType="pubmed">30286224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajwa R, Cheema A, Khan T, et al. . Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-Lymphocyte-Associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res 2019;11:225&#x2013;36. 10.14740/jocmr3750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14740/jocmr3750</ArticleId>
            <ArticleId IdType="pmc">PMC6436564</ArticleId>
            <ArticleId IdType="pubmed">30937112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan F, Funchain P, Bennett A, et al. . How should we diagnose and manage checkpoint inhibitor-associated colitis? Cleve Clin J Med 2018;85:679&#x2013;83. 10.3949/ccjm.85a.18020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3949/ccjm.85a.18020</ArticleId>
            <ArticleId IdType="pubmed">30192732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, K&#xe4;hler KC, Hauschild A, et al. . Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691&#x2013;7. 10.1200/JCO.2012.41.6750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.41.6750</ArticleId>
            <ArticleId IdType="pubmed">22614989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eigentler TK, Hassel JC, Berking C, et al. . Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016;45:7&#x2013;18. 10.1016/j.ctrv.2016.02.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2016.02.003</ArticleId>
            <ArticleId IdType="pubmed">26922661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, et al. . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. JCO 2018;36:1714&#x2013;68. 10.1200/JCO.2017.77.6385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.6385</ArticleId>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DH, Zobniw CM, Trinh VA, et al. . Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018;6:1&#x2013;8. 10.1186/s40425-018-0412-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0412-0</ArticleId>
            <ArticleId IdType="pmc">PMC6180568</ArticleId>
            <ArticleId IdType="pubmed">30305177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mourad FH, Hashash JG, Kariyawasam VC, et al. . Ulcerative colitis and cytomegalovirus infection: from a to Z. J Crohns Colitis 2020;79:1&#x2013;10. 10.1093/ecco-jcc/jjaa036</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjaa036</ArticleId>
            <ArticleId IdType="pubmed">32103246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lankes K, Hundorfean G, Harrer T, et al. . Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology 2016;5:e1128611. 10.1080/2162402X.2015.1128611</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2015.1128611</ArticleId>
            <ArticleId IdType="pmc">PMC4938313</ArticleId>
            <ArticleId IdType="pubmed">27471608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furuta Y, Miyamoto H, Naoe H, et al. . Cytomegalovirus enterocolitis in a patient with refractory immune-related colitis. Case Rep Gastroenterol 2020;14:103&#x2013;9. 10.1159/000506186</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000506186</ArticleId>
            <ArticleId IdType="pmc">PMC7098339</ArticleId>
            <ArticleId IdType="pubmed">32231510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franklin C, Rooms I, Fiedler M, et al. . Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer 2017;86:248&#x2013;56. 10.1016/j.ejca.2017.09.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.09.019</ArticleId>
            <ArticleId IdType="pubmed">29055840</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32422528</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1705</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>84</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>International immunopharmacology</Title>
          <ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.</ArticleTitle>
        <Pagination>
          <StartPage>106601</StartPage>
          <MedlinePgn>106601</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2020.106601</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1567-5769(20)30511-7</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although colitis has been reported in patients treated with immune checkpoint inhibitors (ICIs), associations between colitis and ICIs had not been thoroughly assessed in real-world studies. Here, we identified and characterized significant colitis-associated with ICIs.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Based on the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to December 2019, the disproportionality analysis and Bayesian analysis, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were adopted to data mining of the suspected adverse events of colitis after ICIs administrating. Clinical characteristics of patients with ICIs-associated colitis and the time to onset of colitis following different ICI regimens were collected.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3786 reports of colitis adverse events were identified with ICIs. Seven ICI monotherapies were associated with the reporting of colitis. Statistically significant ROR, PRR, information component (IC), and empirical Bayesian geometric mean (EBGM) emerged for all ICI monotherapies and combination therapies. ICIs-associated colitis affected mostly male (53.51%), with a wide mean age range (60.65 to 72&#xa0;years). Colitis adverse events were commonly reported in patients with melanoma and lung cancer. Adverse outcomes of colitis concerning ICI were mainly outcomes of hospitalization-initiated or prolonged and other serious. Among colitis cases, 17.43% cases of colitis concerning ICI lead to death. The adverse event ofcolitis occurred earliest in ipilimumab monotherapy with a median time to onset of 64.21&#xa0;days (IQR: 27-69&#xa0;days) among all monotherapies.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ICI may lead to severe and disabling ICIs-associated colitis during therapy. Analysis of FAERS data identified signals for adverse events of colitis with ICI regimens. Practitioners should consider the factors that may increase the likelihood of colitis. The findings support a continued surveillance and risk factor identification studies.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Yingying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking Union Medical College Hospital, Beijing 100730, PR China; Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Research Group of Pharmcoepidemiology and Clinical Drug Evaluation, Shenyang Pharmaceutical University, Shenyang 110016, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lifu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Procurement Office, The Fourth Procurement Service Bureau of Joint Logistics Support Army, Shenyang 110000, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiaolin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking Union Medical College Hospital, Beijing 100730, PR China; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xina</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking Union Medical College Hospital, Beijing 100730, PR China. Electronic address: zhaobin@pumch.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hai</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, PR China. Electronic address: hai_xin@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int Immunopharmacol</MedlineTA>
        <NlmUniqueID>100965259</NlmUniqueID>
        <ISSNLinking>1567-5769</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName>
          <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Data mining</Keyword>
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">Spontaneous reporting system</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32422528</ArticleId>
        <ArticleId IdType="doi">10.1016/j.intimp.2020.106601</ArticleId>
        <ArticleId IdType="pii">S1567-5769(20)30511-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32418993</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-1827</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>123</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of cancer</Title>
          <ISOAbbreviation>Br J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?</ArticleTitle>
        <Pagination>
          <StartPage>207</StartPage>
          <EndPage>215</EndPage>
          <MedlinePgn>207-215</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41416-020-0882-y</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes.</AbstractText>
          <AbstractText Label="METHODS">A dual-centre retrospective study was performed on patients receiving ICI for melanoma, NSCLC or urothelial cancer from 2012 to 2018. Demographics, clinical data, endoscopies (reanalysed using Mayo/Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scores), histology (scored with Nancy Index) and treatment outcomes were analysed.</AbstractText>
          <AbstractText Label="RESULTS">In all, 1074 patients were analysed. Twelve percent (134) developed irAE colitis. Median patient age was 66, 59% were male. CTCAE diarrhoea grade does not correlate with steroid/ infliximab use. G3/4 colitis patients are more likely to need infliximab (p&#x2009;&lt;&#x2009;0.0001) but colitis grade does not correlate with steroid duration. CRP, albumin and haemoglobin do not correlate with severity. The UCEIS (p&#x2009;=&#x2009;0.008) and Mayo (p&#x2009;=&#x2009;0.016) scores correlate with severity/infliximab requirement. Patients with higher Nancy indices (3/4) are more likely to require infliximab (p&#x2009;=&#x2009;0.03).</AbstractText>
          <AbstractText Label="CONCLUSIONS">CTCAE assessment does not accurately reflect colitis severity and our data do not support its use in isolation, as this may negatively impact timely management. Our data support utilising endoscopic scoring for patients with &gt;grade 1 CTCAE disease, and demonstrate the potential prognostic utility of objective histologic scoring.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Cheung</LastName>
            <ForeName>Vincent Ting Fung</ForeName>
            <Initials>VTF</Initials>
            <Identifier Source="ORCID">0000-0003-1715-2281</Identifier>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK. vincent.cheung@doctors.org.uk.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK. vincent.cheung@doctors.org.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Gupta</LastName>
            <ForeName>Tarun</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Olsson-Brown</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Birkenhead, Wirral, CH63 4JY, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, L69 3BX, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Subramanian</LastName>
            <ForeName>Sreedhar</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Royal Liverpool University Hospital, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Prescot Street, Liverpool, L7 8XP, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sasson</LastName>
            <ForeName>Sarah Christina</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heseltine</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Birkenhead, Wirral, CH63 4JY, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fryer</LastName>
            <ForeName>Eve</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cellular Pathology, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Collantes</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cellular Pathology, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sacco</LastName>
            <ForeName>Joseph J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Birkenhead, Wirral, CH63 4JY, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, L69 3BX, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pirmohamed</LastName>
            <ForeName>Munir</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, L69 3BX, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simmons</LastName>
            <ForeName>Alison</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klenerman</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tuthill</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford, OX3 7LE, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Protheroe</LastName>
            <ForeName>Andrew S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford, OX3 7LE, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chitnis</LastName>
            <ForeName>Meenali</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford, OX3 7LE, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fairfax</LastName>
            <ForeName>Benjamin Peter</ForeName>
            <Initials>BP</Initials>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford, OX3 7LE, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Payne</LastName>
            <ForeName>Miranda Jane</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford, OX3 7LE, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Middleton</LastName>
            <ForeName>Mark Ross</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford, OX3 7LE, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brain</LastName>
            <ForeName>Oliver</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>NIHR-RP-R3-12-026</GrantID>
            <Acronym>DH_</Acronym>
            <Agency>Department of Health</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MC_UU_00008/7</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MC_UU_12010/7</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MR/N025989/1</GrantID>
            <Agency>RCUK | Medical Research Council (MRC)</Agency>
          </Grant>
          <Grant>
            <GrantID>201488/Z/16/Z</GrantID>
            <Agency>Wellcome</Agency>
          </Grant>
          <Grant>
            <GrantID>MR/S036377/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MR/K021222/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>109965/Z/15/Z</GrantID>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MC_PC_MR/S025952/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Cancer</MedlineTA>
        <NlmUniqueID>0370635</NlmUniqueID>
        <ISSNLinking>0007-0920</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B72HH48FLU</RegistryNumber>
          <NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019459" MajorTopicYN="N">Urothelium</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>V.T.F.C. has received speaker fees from Janssen. A.O.-B. is an MRC Clinical Training Fellow based at the University of Liverpool supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the Medical Research Council, Roche Pharma, Eli Lilly and Company Limited, UCB Pharma, Novartis, the University of Liverpool and the University of Manchester. She has received honoraria for speaking at educational events from Roche Pharma, Bristol-Myers-Squibb (BMS) and MSD. She has received honoraria for attending BMS advisory boards. J.J.S. has received speaker fees from BMS and Pierre Fabre; acted as a consultant for BMS, MSD, Amgen, Delcath and Immunocore; and his institution has received research grants from BMS and AZ. M.P. is the director of the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics. M.R.M. has acted as a consultant for Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Immunocore, Lilly, Merck, Millennium, Novartis, Physiomics, Rigontec, and Roche; his institution has received research grants from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, Eisai, GlaxoSmithKline, Immunocore, Merck, Millennium, Novartis, Pfizer, Rigontec, Roche, and Vertex. O.B. has received speaker fees from BMS and has received a research grant from Celgene. M.T. has performed Advisory/Consultancy work for Pfizer, Novartis, Lilly, Janssen, Roche, Vaccitech, BMS, and has been a paid speaker for and received paid speaking engagements and education support from Novartis, Pfizer, Roche, Janssen, BMS, Genomic Health, Astellas, Esai, Everything Genetics. A.P. has received honoraria from Ipsen, Roche Bayer, Merck and BMC; and has received non-financial support from Ipsen and grants from Merck. The other authors have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32418993</ArticleId>
        <ArticleId IdType="pmc">PMC7374736</ArticleId>
        <ArticleId IdType="doi">10.1038/s41416-020-0882-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41416-020-0882-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A, et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013;369:122&#x2013;133. doi: 10.1056/NEJMoa1302369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1302369</ArticleId>
            <ArticleId IdType="pmc">PMC5698004</ArticleId>
            <ArticleId IdType="pubmed">23724867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi F, O&#x2019;Day S, McDermott D, Weber R, Sosman J, Haanen J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363:711&#x2013;723. doi: 10.1056/NEJMoa1003466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015;372:2018&#x2013;2028. doi: 10.1056/NEJMoa1501824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1501824</ArticleId>
            <ArticleId IdType="pubmed">25891174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer R, Escudier B, McDermott D, George S, Hammers H, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015;373:1803&#x2013;1813. doi: 10.1056/NEJMoa1510665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1510665</ArticleId>
            <ArticleId IdType="pmc">PMC5719487</ArticleId>
            <ArticleId IdType="pubmed">26406148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst R, Soria J-C, Kowanetz M, Fine G, Hamid O, Gordon M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563&#x2013;567. doi: 10.1038/nature14011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14011</ArticleId>
            <ArticleId IdType="pmc">PMC4836193</ArticleId>
            <ArticleId IdType="pubmed">25428504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariotto A, Yabroff K, Shao Y, Feuer E, Brown M. Projections of the cost of cancer care in the United States: 2010&#x2212;2020. J. Natl. Cancer Inst. 2011;103:117&#x2013;128. doi: 10.1093/jnci/djq495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djq495</ArticleId>
            <ArticleId IdType="pmc">PMC3107566</ArticleId>
            <ArticleId IdType="pubmed">21228314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webster R. The immune checkpoint inhibitors: where are we now? Nat. Rev. Drug Discov. 2014;13:883&#x2013;884. doi: 10.1038/nrd4476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd4476</ArticleId>
            <ArticleId IdType="pubmed">25345674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung V, Gupta T, Payne M, Middleton M, Collier J, Simmons A, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol. 2019;10:364&#x2013;371. doi: 10.1136/flgastro-2018-101146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/flgastro-2018-101146</ArticleId>
            <ArticleId IdType="pmc">PMC6788136</ArticleId>
            <ArticleId IdType="pubmed">31656561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michot J, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer. 2016;54:139&#x2013;148. doi: 10.1016/j.ejca.2015.11.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2015.11.016</ArticleId>
            <ArticleId IdType="pubmed">26765102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015;373:23&#x2013;34. doi: 10.1056/NEJMoa1504030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504030</ArticleId>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Version 5.0. (2017). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up&#x2020;. Ann. Oncol. 2017;28(suppl_4):iv119&#x2013;iv142. doi: 10.1093/annonc/mdx225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx225</ArticleId>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer J, Lacchetti C, Schneider B, Atkins M, Brassil K, Caterino J, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 2018;36:1714&#x2013;1768. doi: 10.1200/JCO.2017.77.6385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.6385</ArticleId>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puzanov I, Diab A, Abdallah K, Bingham C, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer. 2017;5:95. doi: 10.1186/s40425-017-0300-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0300-z</ArticleId>
            <ArticleId IdType="pmc">PMC5697162</ArticleId>
            <ArticleId IdType="pubmed">29162153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Truelove S. Cortisone in ulcerative colitis final report on a therapeutic trial. Br. Med. J. 1955;2:1041&#x2013;1048. doi: 10.1136/bmj.2.4947.1041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.2.4947.1041</ArticleId>
            <ArticleId IdType="pmc">PMC1981500</ArticleId>
            <ArticleId IdType="pubmed">13260656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Travis S, Farrant J, Ricketts C, Nolan D, Mortensen N, Kettlewell M, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905&#x2013;910. doi: 10.1136/gut.38.6.905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.38.6.905</ArticleId>
            <ArticleId IdType="pmc">PMC1383200</ArticleId>
            <ArticleId IdType="pubmed">8984031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Travis S, Schnell D, Krzeski P, Abreu M, Altman D, Colombel J, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987&#x2013;995. doi: 10.1053/j.gastro.2013.07.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2013.07.024</ArticleId>
            <ArticleId IdType="pubmed">23891974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corte C, Fernandopulle N, Catuneanu A, Burger D, Cesarini M, White L, et al. Association between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and outcomes in acute severe ulcerative colitis. J. Crohns Colitis. 2015;9:376&#x2013;381. doi: 10.1093/ecco-jcc/jjv047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv047</ArticleId>
            <ArticleId IdType="pubmed">25770163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, et al. Development and validation of the Nancy histological index for UC. Gut. 2017;66:43&#x2013;49. doi: 10.1136/gutjnl-2015-310187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-310187</ArticleId>
            <ArticleId IdType="pubmed">26464414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponte A, Pinho R, Fernandes S, Rodrigues A, Alberto L, Silva J, et al. Impact of histological and endoscopic remissions on clinical recurrence and recurrence-free time in ulcerative colitis. Inflamm. Bowel Dis. 2017;23:2238&#x2013;2244. doi: 10.1097/MIB.0000000000001275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000001275</ArticleId>
            <ArticleId IdType="pubmed">28991857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali F, Luo W, Qiao W, Raju G, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer. 2018;6:95. doi: 10.1186/s40425-018-0411-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0411-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh V, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm. Bowel Dis. 2018;24:1695&#x2013;1705. doi: 10.1093/ibd/izy104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho G, Mowat C, Goddard C, Fennell J, Shah N, Prescott R, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharm. Ther. 2004;19:1079&#x2013;1087. doi: 10.1111/j.1365-2036.2004.01945.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2036.2004.01945.x</ArticleId>
            <ArticleId IdType="pubmed">15142197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Travis S, Schnell D, Krzeski P, Abreu M, Altman D, Colombel J, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Gut. 2012;61:535&#x2013;542. doi: 10.1136/gutjnl-2011-300486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2011-300486</ArticleId>
            <ArticleId IdType="pmc">PMC3292713</ArticleId>
            <ArticleId IdType="pubmed">21997563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder K, Tremaine W, Ilstrup D. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987;317:1625&#x2013;1629. doi: 10.1056/NEJM198712243172603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198712243172603</ArticleId>
            <ArticleId IdType="pubmed">3317057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali F, Wang X, Mallepally N, Chen E, Altan M, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer. 2019;7:93. doi: 10.1186/s40425-019-0577-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0577-1</ArticleId>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol. Immunother. 2017;66:581&#x2013;592. doi: 10.1007/s00262-017-1962-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-1962-6</ArticleId>
            <ArticleId IdType="pmc">PMC5406433</ArticleId>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain A, Lipson E, Sharfman W, Brant S, Lazarev M. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J. Gastroenterol. 2017;23:2023&#x2013;2028. doi: 10.3748/wjg.v23.i11.2023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v23.i11.2023</ArticleId>
            <ArticleId IdType="pmc">PMC5360643</ArticleId>
            <ArticleId IdType="pubmed">28373768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen M, Rozeman E, van Wilpe S, Postma C, Snaebjornsson P, van Thienen J, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278. doi: 10.1136/esmoopen-2017-000278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2017-000278</ArticleId>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung V, Gupta T, Olsson-Brown A, Subramanian S, Sasson S, Heseltine J, et al. P272 Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way? J. Crohns Colitis. 2020;14:S286&#x2013;S288. doi: 10.1093/ecco-jcc/jjz203.401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjz203.401</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32414860</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e000451</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2019-000451</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune-related colitis is a common, often serious complication of immune checkpoint inhibition (ICI). Although endoscopy is not strictly recommended for any grade of diarrhea/colitis, emerging evidence suggests that endoscopic evaluation may have important therapeutic implications. In this retrospective study, we sought to comprehensively characterize the clinical and histologic features of ICI-induced colitis with a specific focus on evaluating the prognostic role of endoscopy.</AbstractText>
          <AbstractText Label="METHODS">Data were collected from the medical records of 130 patients with confirmed ICI-induced colitis. In a subset of patients (n=44) with endoscopic and pathologic data, endoscopic data were scored using the Mayo Endoscopic Score (MES) with scores ranging from 0 (no inflammation) to 3 (colonic ulceration). The impact of infliximab on antitumor outcomes was evaluated using progression-free survival (PFS) and overall survival (OS).</AbstractText>
          <AbstractText Label="RESULTS">We identified 130 patients with ICI-induced colitis across two institutions. All patients were treated with corticosteroids. Additional and/or alternative immunosuppression was employed in 59 cases, with 52 patients (42%) requiring at least one infusion of infliximab 5 mg/kg. Endoscopic assessment with biopsy was performed in 123 cases of suspected colitis (95%), with 44 cases available for MES tabulation. Presence of ulceration (MES 3) was associated with use of infliximab (p=0.008) and MES was significantly higher in patients who received infliximab compared with those who did not (p=0.003) with a median score of 2.5; conversely, those with an MES of zero rarely required secondary immunosuppression. Notably, symptoms of colitis based on Common Terminology Criteria for Adverse Events grade had no association with endoscopic findings based on MES classification. After adjustment for baseline patient and disease characteristics, there was no significant difference in steroid duration or cancer-related outcomes in patients treated with infliximab.</AbstractText>
          <AbstractText Label="CONCLUSIONS">In our study, we demonstrate the association of endoscopic features, specifically the MES, with immunosuppressive needs. Importantly, we also show that MES was not related to severity of patient symptoms. The data suggest that endoscopic features can guide clinical decision-making better than patient symptoms, both identifying high-risk patients who will require infliximab and those who are likely to respond to initial corticosteroids.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mooradian</LastName>
            <ForeName>Meghan J</ForeName>
            <Initials>MJ</Initials>
            <Identifier Source="ORCID">0000-0002-8289-8015</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Daniel Y</ForeName>
            <Initials>DY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coromilas</LastName>
            <ForeName>Alexandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Columbia University, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lumish</LastName>
            <ForeName>Melissa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Tianqi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giobbie-Hurder</LastName>
            <ForeName>Anita</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Douglas B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Sullivan</LastName>
            <ForeName>Ryan J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA rsullivan7@mgh.harvard.edu mldougan@partners.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Dougan</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA rsullivan7@mgh.harvard.edu mldougan@partners.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 DK114563</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K12 CA090625</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B72HH48FLU</RegistryNumber>
          <NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052016" MajorTopicYN="N">Mucositis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">gastroenterology</Keyword>
        <Keyword MajorTopicYN="N">immunology</Keyword>
        <Keyword MajorTopicYN="N">oncology</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32414860</ArticleId>
        <ArticleId IdType="pmc">PMC7239692</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2019-000451</ArticleId>
        <ArticleId IdType="pii">jitc-2019-000451</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hodi FS, O'Day SJ, McDermott DF, et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711&#x2013;23. 10.1056/NEJMoa1003466</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, Schachter J, Long GV, et al. . Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521&#x2013;32. 10.1056/NEJMoa1503093</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1503093</ArticleId>
            <ArticleId IdType="pubmed">25891173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, Long GV, Brady B, et al. . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320&#x2013;30. 10.1056/NEJMoa1412082</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1412082</ArticleId>
            <ArticleId IdType="pubmed">25399552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauken KE, Dougan M, Rose NR, et al. . Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol 2019;40:511&#x2013;23. 10.1016/j.it.2019.04.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2019.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC6527345</ArticleId>
            <ArticleId IdType="pubmed">31053497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol 2017;8:1547. 10.3389/fimmu.2017.01547</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01547</ArticleId>
            <ArticleId IdType="pmc">PMC5715331</ArticleId>
            <ArticleId IdType="pubmed">29230210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Mooradian MJ, Kim D, et al. . Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology 2019;8:e1524695. 10.1080/2162402X.2018.1524695</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1524695</ArticleId>
            <ArticleId IdType="pmc">PMC6287774</ArticleId>
            <ArticleId IdType="pubmed">30546965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23&#x2013;34. 10.1056/NEJMoa1504030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504030</ArticleId>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung V, Gupta T, Olsson-Brown A, et al. . P100 real-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres. 2019;13:S137&#x2013;8. 10.1093/ecco-jcc/jjy222.224</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjy222.224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, K&#xe4;hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691&#x2013;7. 10.1200/JCO.2012.41.6750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.41.6750</ArticleId>
            <ArticleId IdType="pubmed">22614989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Zheng H, Zubiri L, et al. . Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med 2019;8:4986&#x2013;99. 10.1002/cam4.2397</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.2397</ArticleId>
            <ArticleId IdType="pmc">PMC6718531</ArticleId>
            <ArticleId IdType="pubmed">31286682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, et al. . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1714&#x2013;68. 10.1200/JCO.2017.77.6385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.6385</ArticleId>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, et al. . Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018;6:95. 10.1186/s40425-018-0411-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0411-1</ArticleId>
            <ArticleId IdType="pmc">PMC6156850</ArticleId>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Molina GE, Chen ST, et al. . Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292. 10.1186/s40425-019-0756-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0756-0</ArticleId>
            <ArticleId IdType="pmc">PMC6839080</ArticleId>
            <ArticleId IdType="pubmed">31699151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. . Endoscopic and histologic features of immune checkpoint Inhibitor-Related colitis. Inflamm Bowel Dis 2018;24:1695&#x2013;705. 10.1093/ibd/izy104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izy104</ArticleId>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Boogerd W, Blank CU, et al. . Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. Melanoma Res 2018;28:126&#x2013;33. 10.1097/CMR.0000000000000429</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CMR.0000000000000429</ArticleId>
            <ArticleId IdType="pubmed">29356790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber J, Thompson JA, Hamid O, et al. . A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591&#x2013;8. 10.1158/1078-0432.CCR-09-1024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-1024</ArticleId>
            <ArticleId IdType="pubmed">19671877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puzanov I, Diab A, Abdallah K, et al. . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group. J Immunother Cancer 2017;5:95. 10.1186/s40425-017-0300-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0300-z</ArticleId>
            <ArticleId IdType="pmc">PMC5697162</ArticleId>
            <ArticleId IdType="pubmed">29162153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JS, Hodi FS, Wolchok JD, et al. . Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017;35:785&#x2013;92. 10.1200/JCO.2015.66.1389</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.66.1389</ArticleId>
            <ArticleId IdType="pubmed">28068177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje AT, Lawrence D, Flaherty K, et al. . High&#x2010;dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 2018;124:3706&#x2013;14. 10.1002/cncr.31629</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31629</ArticleId>
            <ArticleId IdType="pubmed">29975414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arbour KC, Mezquita L, Long N, et al. . Impact of baseline steroids on efficacy of programmed cell death-1 and programmed Death-Ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018;36:2872&#x2013;8. 10.1200/JCO.2018.79.0006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.79.0006</ArticleId>
            <ArticleId IdType="pubmed">30125216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Common terminology criteria for
adverse events (CTCAE) | Protocol development | CTEP.
Available: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm</Citation>
        </Reference>
        <Reference>
          <Citation>RECIST 1.1 |
RECIST. Available: https://recist.eortc.org/recist-1-1-2/</Citation>
        </Reference>
        <Reference>
          <Citation>Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625&#x2013;9. 10.1056/NEJM198712243172603</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198712243172603</ArticleId>
            <ArticleId IdType="pubmed">3317057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang ML, Neyaz A, Patil D, et al. . Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 2020;76:233&#x2013;243. 10.1111/his.13963</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13963</ArticleId>
            <ArticleId IdType="pubmed">31361907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain A, Lipson EJ, Sharfman WH, et al. . Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol 2017;23:2023&#x2013;8. 10.3748/wjg.v23.i11.2023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v23.i11.2023</ArticleId>
            <ArticleId IdType="pmc">PMC5360643</ArticleId>
            <ArticleId IdType="pubmed">28373768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DH, Zobniw CM, Trinh VA, et al. . Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018;6:103. 10.1186/s40425-018-0412-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-018-0412-0</ArticleId>
            <ArticleId IdType="pmc">PMC6180568</ArticleId>
            <ArticleId IdType="pubmed">30305177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, et al. . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019;7:93. 10.1186/s40425-019-0577-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0577-1</ArticleId>
            <ArticleId IdType="pmc">PMC6444537</ArticleId>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32404733</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1473-5636</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>30</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Melanoma research</Title>
          <ISOAbbreviation>Melanoma Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event.</ArticleTitle>
        <Pagination>
          <StartPage>603</StartPage>
          <EndPage>605</EndPage>
          <MedlinePgn>603-605</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/CMR.0000000000000665</ELocationID>
        <Abstract>
          <AbstractText>Immunotherapy has improved the overall survival of patients with metastatic melanoma. Inflammatory bowel disease-like colitis is the most frequent gastrointestinal serious adverse event in patients treated with immune-checkpoint inhibitors. Collagenous colitis is microscopic colitis. Only two cases of immune-checkpoint inhibitors induced collagenous colitis have been reported. A man in his early 70s was referred for a metastatic melanoma treated with nivolumab as the fourth line of treatment. During the 21st cycle, the patient complained of watery, nonbloody diarrhea (around six times per day). Rectosigmoidoscopy showed no mucosal lesion. A thickened subepithelial collagen band was evidenced by trichrome staining, which was suggestive of collagenous colitis. Nivolumab was stopped and the patient was treated with budesonide 9 mg/day in combination with loperamide and cholestyramine, leading to improvement of diarrhea. However, worsening of digestive symptoms during tapering of corticosteroid dose required the permanent discontinuation of nivolumab. Due to the very low number of cases reported to date and their different evolution under corticosteroids, it is not clear whether or not immune checkpoint inhibitors can be restarted in these patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Janela-Lapert</LastName>
            <ForeName>Raphal</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Dermatology Department, Institute for Research and Innovation in Biomedicine, INSERM 1234, Rouen University Hospital, University of Normandie, Rouen, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bouteiller</LastName>
            <ForeName>Julie</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deschamps-Huvier</LastName>
            <ForeName>Aurlie</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duval-Modeste</LastName>
            <ForeName>Anne-Bndicte</ForeName>
            <Initials>AB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joly</LastName>
            <ForeName>Pascal</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Melanoma Res</MedlineTA>
        <NlmUniqueID>9109623</NlmUniqueID>
        <ISSNLinking>0960-8931</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046729" MajorTopicYN="N">Colitis, Collagenous</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32404733</ArticleId>
        <ArticleId IdType="doi">10.1097/CMR.0000000000000665</ArticleId>
        <ArticleId IdType="pii">00008390-202012000-00011</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>King GT, Sharma P, Davis SL, Jimeno A. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. Drugs Today (Barc). 2018; 54:103&#x2013;122</Citation>
        </Reference>
        <Reference>
          <Citation>Baroudjian B, Lourenco N, Pag&#xe8;s C, Chami I, Maillet M, Bertheau P, et al. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016; 26:308&#x2013;311</Citation>
        </Reference>
        <Reference>
          <Citation>Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer. 2019; 7:292</Citation>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al.; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36:1714&#x2013;1768</Citation>
        </Reference>
        <Reference>
          <Citation>Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017; 35:785&#x2013;792</Citation>
        </Reference>
        <Reference>
          <Citation>Shor J, Churrango G, Hosseini N, Marshall C. Management of microscopic colitis: challenges and solutions. Clin Exp Gastroenterol. 2019; 12:111&#x2013;120</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32401685</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2688-1535</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>JCO oncology practice</Title>
          <ISOAbbreviation>JCO Oncol Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.</ArticleTitle>
        <Pagination>
          <StartPage>e933</StartPage>
          <EndPage>e942</EndPage>
          <MedlinePgn>e933-e942</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JOP.19.00672</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">Enterocolitis is among the leading adverse events associated with immune checkpoint inhibitors (ICIs). There are limited retrospective data regarding the safety of ICIs in patients with inflammatory bowel disease (IBD; ulcerative colitis, Crohn's disease) because they have been generally excluded from clinical trials testing ICIs. Furthermore, there are no outcome data available in patients with microscopic colitis, a leading cause of chronic diarrhea. We aimed to study the safety of ICIs in patients with cancer with pre-existing IBD or microscopic colitis.</AbstractText>
          <AbstractText Label="METHODS">We retrospectively reviewed the records of patients with cancer treated at our institution who received at least 1 dose of either a programmed cell death-1 (PD-1)/ PD-1 ligand inhibitor, cytotoxic T-lymphocyte-associated antigen 4 inhibitor, or both between 2011 and 2018. We identified patients with pre-existing IBD or microscopic colitis.</AbstractText>
          <AbstractText Label="RESULTS">Of 548 patients with solid tumor treated with an ICI, we identified 25 with pre-existing colitis (21 IBD; 4 microscopic colitis). An enterocolitis flare occurred in 7 patients (28%): 3 of 4 patients (75%) with microscopic colitis and 4 of 21 (19%) with IBD. All were treated with systemic corticosteroids, 2 required an anti-tumor necrosis factor agent, and one required an anti-integrin agent and colectomy for treatment of refractory colitis. ICI therapy was discontinued in all patients who experienced an enterocolitis flare.</AbstractText>
          <AbstractText Label="CONCLUSION">In our cohort, exacerbation of enterocolitis occurred in a notable percentage of patients with IBD and a majority of patients with microscopic colitis, leading to discontinuation of ICIs. Although these data suggest that patients with cancer with pre-existing IBD/microscopic colitis may be treated with ICIs, additional studies are needed to validate our results.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Grover</LastName>
            <ForeName>Shilpa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Alex B</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Srivoleti</LastName>
            <ForeName>Padmavathi</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giobbie-Hurder</LastName>
            <ForeName>Anita</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Braschi-Amirfarzan</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Srivastava</LastName>
            <ForeName>Amitabh</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buchbinder</LastName>
            <ForeName>Elizabeth I</ForeName>
            <Initials>EI</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ott</LastName>
            <ForeName>Patrick A</ForeName>
            <Initials>PA</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kehl</LastName>
            <ForeName>Kenneth L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Awad</LastName>
            <ForeName>Mark M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hodi</LastName>
            <ForeName>F Stephen</ForeName>
            <Initials>FS</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rahma</LastName>
            <ForeName>Osama E</ForeName>
            <Initials>OE</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>JCO Oncol Pract</MedlineTA>
        <NlmUniqueID>101758685</NlmUniqueID>
        <ISSNLinking>2688-1527</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046728" MajorTopicYN="Y">Colitis, Microscopic</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32401685</ArticleId>
        <ArticleId IdType="doi">10.1200/JOP.19.00672</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32389505</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1938-0690</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical lung cancer</Title>
          <ISOAbbreviation>Clin Lung Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Leucine-Rich 2-Glycoprotein as a Potential Biomarker for Immune-related Colitis After Anti-PD-L1 Therapy: A Report of a Case Series.</ArticleTitle>
        <Pagination>
          <StartPage>e516</StartPage>
          <EndPage>e522</EndPage>
          <MedlinePgn>e516-e522</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cllc.2020.04.005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1525-7304(20)30104-2</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yoshimura</LastName>
            <ForeName>Katsuhiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan. Electronic address: orihustaky1201@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saku</LastName>
            <ForeName>Aiko</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karayama</LastName>
            <ForeName>Masato</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inui</LastName>
            <ForeName>Naoki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sugimura</LastName>
            <ForeName>Haruhiko</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suda</LastName>
            <ForeName>Takafumi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Lung Cancer</MedlineTA>
        <NlmUniqueID>100893225</NlmUniqueID>
        <ISSNLinking>1525-7304</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C015246">LRG1 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077192" MajorTopicYN="N">Adenocarcinoma of Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Immune checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Immune-related adverse event</Keyword>
        <Keyword MajorTopicYN="N">Infliximab</Keyword>
        <Keyword MajorTopicYN="N">Non&#x2013;small-cell lung cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32389505</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cllc.2020.04.005</ArticleId>
        <ArticleId IdType="pii">S1525-7304(20)30104-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32298485</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2559</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>77</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Histopathology</Title>
          <ISOAbbreviation>Histopathology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.</ArticleTitle>
        <Pagination>
          <StartPage>240</StartPage>
          <EndPage>249</EndPage>
          <MedlinePgn>240-249</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/his.14115</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Immune checkpoint inhibitors (ICIs) have revolutionised the treatment of advanced malignancies by boosting immune-mediated destruction of neoplastic cells, but are associated with side effects stemming from generalised immune system activation against normal tissues. Checkpoint ligand expression in non-tumoral cells of tissues affected by immune-related adverse effects has been described in ICI-associated hypophysitis, myocarditis, and acute interstitial nephritis. We aimed to investigate the tissue expression of the immune checkpoint receptor programmed cell death-1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), in PD-1 inhibitor-associated colitis (PD1i colitis).</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">PD-1 and PD-L1 immunohistochemical expression levels were analysed in 15 cases of PD1i colitis and potential mimics-infectious colitis and inflammatory bowel disease (IBD). Increased epithelial expression of PD-L1 was observed in PD1i colitis as compared with normal colon and infectious colitis, but the expression level was lower than that in IBD. Conversely, PD-1 expression in inflammatory cells was higher in infectious colitis, intermediate in IBD, and minimal or absent in normal colon and in patients receiving PD-1 inhibitors.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although our results do not justify the use of PD-L1 as a discriminatory marker of PD1i colitis against other entities within the differential diagnosis, they support the concept that PD1i colitis and IBD have similar pathogenetic mechanisms. They also highlight the fact that PD-L1 epithelial overexpression is a commonly used mechanism of the gastrointestinal tract mucosa to protect itself from inflammatory-mediated damage resulting from different aetiologies, which probably underpins the high incidence of gastrointestinal immune-related adverse effects in patients receiving ICI therapies, in whom this mechanism is disrupted.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cassol</LastName>
            <ForeName>Clarissa A</ForeName>
            <Initials>CA</Initials>
            <Identifier Source="ORCID">0000-0001-7536-6806</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Division of Medical Oncology, Ohio State University, Columbus, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Owen</LastName>
            <ForeName>Dwight</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Medical Oncology, Ohio State University, Columbus, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kendra</LastName>
            <ForeName>Kari</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Medical Oncology, Ohio State University, Columbus, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Braga</LastName>
            <ForeName>Juarez R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frankel</LastName>
            <ForeName>Wendy L</ForeName>
            <Initials>WL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Division of Medical Oncology, Ohio State University, Columbus, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arnold</LastName>
            <ForeName>Christina A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>The University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Histopathology</MedlineTA>
        <NlmUniqueID>7704136</NlmUniqueID>
        <ISSNLinking>0309-0167</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IBD</Keyword>
        <Keyword MajorTopicYN="N">PD-1</Keyword>
        <Keyword MajorTopicYN="N">PD-L1 checkpoint</Keyword>
        <Keyword MajorTopicYN="N">colitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32298485</ArticleId>
        <ArticleId IdType="doi">10.1111/his.14115</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Hofmann L, Forschner A, Loquai C et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer 2016; 60; 190-209.</Citation>
        </Reference>
        <Reference>
          <Citation>Adler BL, Pezhouh MK, Kim A et al. Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J. Intern. Med. 2018; 283; 568-577.</Citation>
        </Reference>
        <Reference>
          <Citation>Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018; 472; 125-133.</Citation>
        </Reference>
        <Reference>
          <Citation>Bavi P, Butler M, Serra S, Chetty R. Immune modulator-induced changes in the gastrointestinal tract. Histopathology 2017; 71; 494-496.</Citation>
        </Reference>
        <Reference>
          <Citation>Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 inhibitor gastroenterocolitis: case series and appraisal of &#x2018;immunomodulatory gastroenterocolitis&#x2019;. Histopathology 2017; 70; 558-567.</Citation>
        </Reference>
        <Reference>
          <Citation>Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N. Engl. J. Med. 2009; 361; 211-212.</Citation>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Balko JM, Compton ML et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 2016; 375; 1749-1755.</Citation>
        </Reference>
        <Reference>
          <Citation>Champion SN, Stone JR. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod. Pathol. 2020; 33(1); 99-108.</Citation>
        </Reference>
        <Reference>
          <Citation>Caturegli P, Di Dalmazi G, Lombardi M et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 2016; 186; 3225-3235.</Citation>
        </Reference>
        <Reference>
          <Citation>Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 2014; 6; 230ra245.</Citation>
        </Reference>
        <Reference>
          <Citation>Cassol C, Satoskar A, Lozanski G et al. Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int. Rep. 2019; 4; 1152-1160.</Citation>
        </Reference>
        <Reference>
          <Citation>Sury K, Perazella MA, Shirali AC. Cardiorenal complications of immune checkpoint inhibitors. Nat. Rev. Nephrol. 2018; 14; 571-588.</Citation>
        </Reference>
        <Reference>
          <Citation>Coquerelle C, Oldenhove G, Acolty V et al. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut 2009; 58; 1363-1373.</Citation>
        </Reference>
        <Reference>
          <Citation>van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 1999; 190; 355-366.</Citation>
        </Reference>
        <Reference>
          <Citation>Cassol C, Satoskar A, Lozanski Get al.Anti&#x2212;PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int. Rep.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee SJ, Jang BC, Lee SW et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006; 580; 755-762.</Citation>
        </Reference>
        <Reference>
          <Citation>Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002; 8; 793-800.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang X, Yang L, Huang F et al. Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol. Lett. 2017; 184; 7-14.</Citation>
        </Reference>
        <Reference>
          <Citation>Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011; 56; 633-640.</Citation>
        </Reference>
        <Reference>
          <Citation>Scandiuzzi L, Ghosh K, Hofmeyer KA et al. Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Rep. 2014; 6; 625-632.</Citation>
        </Reference>
        <Reference>
          <Citation>Mezache L, Magro C, Hofmeister C, Pichiorri F, Sborov D, Nuovo GJ. Modulation of PD-L1 and CD8 activity in idiopathic and infectious chronic inflammatory conditions. Appl. Immunohistochem. Mol. Morphol. 2017; 25; 100-109.</Citation>
        </Reference>
        <Reference>
          <Citation>Robertson J, Haas CT, Pele LC et al. Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. Sci. Rep. 2016; 6; 26747.</Citation>
        </Reference>
        <Reference>
          <Citation>Gupta R, Neyaz A, Chougule A et al. Autoimmune pancreatitis type 2: diagnostic utility of PD-L1 immunohistochemistry. Am. J. Surg. Pathol. 2019; 43; 898-906.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm. Bowel Dis. 2018; 24; 1695-1705.</Citation>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J. Crohns Colitis 2017; 11; 1238-1246.</Citation>
        </Reference>
        <Reference>
          <Citation>Verschuren EC, van den Eertwegh AJ, Wonders J et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin. Gastroenterol. Hepatol. 2016; 14; 836-842.</Citation>
        </Reference>
        <Reference>
          <Citation>Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. J. Clin. Pathol. 2018; 71; 665-671.</Citation>
        </Reference>
        <Reference>
          <Citation>Atarashi K, Tanoue T, Ando M et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 2015; 163; 367-380.</Citation>
        </Reference>
        <Reference>
          <Citation>Holokai L, Chakrabarti J, Broda T et al. Increased programmed death-ligand 1 is an early epithelial cell response to Helicobacter pylori infection. PLoS Pathog. 2019; 15; e1007468.</Citation>
        </Reference>
        <Reference>
          <Citation>Schonrich G, Raftery MJ. The PD-1/PD-L1 axis and virus infections: a delicate balance. Front. Cell Infect. Microbiol. 2019; 9; 207.</Citation>
        </Reference>
        <Reference>
          <Citation>Song MY, Hong CP, Park SJ et al. Protective effects of Fc-fused PD-L1 on two different animal models of colitis. Gut 2015; 64; 260-271.</Citation>
        </Reference>
        <Reference>
          <Citation>Scandiuzzi L, Ghosh K, Hofmeyer Kimberly A et al. Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Rep. 2014; 6; 625-632.</Citation>
        </Reference>
        <Reference>
          <Citation>Dubin K, Callahan MK, Ren B et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 2016; 7; 10391.</Citation>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 2017; 28; 1368-1379.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 2018; 24; 1804-1808.</Citation>
        </Reference>
        <Reference>
          <Citation>Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin. Immunol. 2005; 115; 184-191.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology 2017; 6; e1344805.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32185493</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1534-312X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current gastroenterology reports</Title>
          <ISOAbbreviation>Curr Gastroenterol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.</ArticleTitle>
        <Pagination>
          <StartPage>15</StartPage>
          <MedlinePgn>15</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11894-020-0752-z</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Checkpoint inhibitor (CPI) immunotherapy has transformed the treatment of multiple cancers over the past decade, leading to durable remissions, but also to severe inflammatory toxicities. These toxicities, termed immune-related adverse events (irAEs), can affect any organ system in the body, but commonly induce inflammation in barrier organs. Gastrointestinal (GI) and hepatic irAEs are among the most frequent and most severe from contemporary immunotherapies, with inflammation in the colon and or small intestines (entero)colitis as the single most common GI irAE. The aim of this review is to describe the evidence supporting our current understanding of CPI enterocolitis and hepatitis, as well as the management of these entities.</AbstractText>
          <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Although most patients who develop enterocolitis recover without long-term GI sequelae, enterocolitis is still an important reason for treatment discontinuation, which, in patients with metastatic cancer, can be a life-threatening outcome. At present, we have almost no prospective, randomized data regarding the management of CPI enterocolitis, and current management algorithms are based on expert opinion and small retrospective studies with a high likelihood of bias. Retrospective studies have defined colonic ulceration as a predictor of colitis responsiveness to corticosteroids, and have defined microscopic colitis as a subtype of CPI enterocolitis with a distinct treatment response. Corticosteroids appear to be effective for 60-70% of patients with CPI enterocolitis, with about a third of patients requiring escalation to a biologic agent such as infliximab or vedolizumab. Yet proper sequencing of these treatments to minimize risk and maximize treatment benefit has not been established, and we do not know how treatment of colitis influences cancer outcomes. CPI enterocolitis and hepatitis are important causes of treatment interruption and discontinue, and significant morbidity in patients undergoing immunotherapy. As guidelines for diagnosis and management rely heavily on expert opinion, we have an urgent need for randomized and prospective trials that use both colitis and cancer outcomes to determine optimal management strategies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dougan</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA. mldougan@partners.org.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Harvard Medical School, Boston, MA, USA. mldougan@partners.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Curr Gastroenterol Rep</MedlineTA>
        <NlmUniqueID>100888896</NlmUniqueID>
        <ISSNLinking>1522-8037</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006505" MajorTopicYN="N">Hepatitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Checkpoint inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Gastrointestinal</Keyword>
        <Keyword MajorTopicYN="N">Immune-related adverse events</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32185493</ArticleId>
        <ArticleId IdType="doi">10.1007/s11894-020-0752-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s11894-020-0752-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>J Immunother Cancer. 2018 Dec 5;6(1):142</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30518410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncologist. 2020 Jan;25(1):6-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31694890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2017 Feb 1;28(2):368-376</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27687304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2018 Oct 11;6(1):103</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30305177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Surg Pathol. 2015 Aug;39(8):1075-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26034866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncoimmunology. 2016 Feb 18;5(6):e1128611</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27471608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melanoma Res. 2018 Oct;28(5):483-484</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30148767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mod Pathol. 2018 Jun;31(6):965-973</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29403081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Rheumatol. 2016 Jan;35(1):1-18</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26573205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2019 Sep 5;7(1):242</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31488205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2018 Jul 1;36(19):1905-1912</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29746230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Crohns Colitis. 2016 Apr;10(4):395-401</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2019 Apr 2;7(1):93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30940209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Surg Pathol. 2017 May;41(5):643-654</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28296676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2018 Nov 29;379(22):2108-2121</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30345906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dig Dis Sci. 2012 Aug;57(8):2233-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22434096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2018 Sep 25;6(1):95</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30253811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2019 May;569(7756):428-432</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31043740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2018 May 11;6(1):37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29747688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2006 May 20;24(15):2283-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16710025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2015 Oct 1;33(28):3193-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26282644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Immunol Res. 2013 Jul;1(1):32-42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24777248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trends Immunol. 2019 Jun;40(6):511-523</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31053497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo Clin Proc. 2013 Apr;88(4):414-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23541015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2010 Aug 19;363(8):711-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Med. 2014 Dec;20(12):1410-1416</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25329329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2016 Jul 29;11(7):e0160221</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27472273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2018 Nov 22;379(21):2040-2051</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30280635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gut. 2015 Dec;64(12):1889-97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25367873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Immunol Res. 2017 Apr;5(4):286-291</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28373217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2015 Jun 10;33(17):1974-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25605845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2018 Jun 10;36(17):1714-1768</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melanoma Res. 2013 Feb;23(1):47-54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23262440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Invest New Drugs. 2013 Aug;31(4):1071-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23408334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2019 Feb 18;7(1):47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30777137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2009 Sep 1;15(17):5591-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19671877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2019 Mar 21;380(12):1116-1127</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30779529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asia Pac J Clin Oncol. 2017 Oct;13(5):e284-e290</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27981760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2019 Oct 20;37(30):2738-2745</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31163011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA Oncol. 2016 Feb;2(2):234-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26633184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2018 Oct 1;36(28):2872-2878</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30125216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2018 Apr 05;378(14):1277-1290</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29562145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Invest. 2020 Jan 2;130(1):51-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31895048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2019 Feb 11;7(1):41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30744698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inflamm Bowel Dis. 2018 Jul 12;24(8):1695-1705</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29718308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2009 Nov 19;361(21):2066-78</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19923578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA Oncol. 2018 Dec 1;4(12):1721-1728</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncologist. 2018 Sep;23(9):991-997</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29853659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Commun. 2016 Feb 02;7:10391</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26837003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2016 Nov 10;375(19):1845-1855</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27717298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912-3917</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29581255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ACG Case Rep J. 2017 Apr 12;4:e57</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28459081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Med. 2018 Dec;24(12):1804-1808</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30420754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2018 Mar 10;36(8):773-779</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29355075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2015 May 21;372(21):2006-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25891304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncoimmunology. 2017 Jul 5;6(10):e1344805</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29123955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2014 Sep 26;345(6204):1623-1627</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25213377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Annu Rev Immunol. 2016 May 20;34:539-73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26927206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2018 May 31;378(22):2093-2104</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29658845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AJR Am J Roentgenol. 2013 May;200(5):W468-74</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23718569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2018 Jan 1;29(1):250-255</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29045547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case Rep Gastrointest Med. 2018 May 31;2018:3406437</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29955400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Front Immunol. 2017 Nov 15;8:1547</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29230210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BMJ Case Rep. 2016 Aug 18;2016:</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27539137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2017 Nov 21;5(1):95</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29162153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2017 Oct 5;377(14):1345-1356</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28889792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2018 Jan 11;378(2):158-168</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ESMO Open. 2018 Jan 13;3(1):e000278</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Surg Pathol. 2017 Jan;41(1):134-137</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27792061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ther Adv Med Oncol. 2019 Feb 19;11:1758835919830826</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30815041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semin Arthritis Rheum. 2017 Oct;47(2):149-156</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28284845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Commun. 2017 Dec 22;8(1):2256</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29273790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Mol Life Sci. 2006 Jan;63(1):60-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16314919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Immunol Immunother. 2017 May;66(5):581-592</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdom Radiol (NY). 2016 Feb;41(2):207-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26867901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Hepatol. 2018 Jun;68(6):1181-1190</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29427729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2011 Jun 30;364(26):2517-26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21639810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Exp Med. 2013 Aug 26;210(9):1695-710</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23897981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2018 Jan 5;359(6371):91-97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29097494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Cancer. 2017 Aug;81:203-205</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28641200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncoimmunology. 2018 Oct 31;8(1):e1524695</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30546965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melanoma Res. 2018 Dec;28(6):645-647</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30256271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case Rep Oncol. 2019 Feb 8;12(1):164-170</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31043955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Histopathology. 2020 Jan;76(2):233-243</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31361907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2019 Nov 7;7(1):292</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31699151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2017 Dec 1;35(34):3851-3858</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28678668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Immunol Res. 2018 Dec;6(12):1453-1458</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30275274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2019 Mar 1;25(5):1557-1563</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30409824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case Rep Oncol. 2018 Aug 17;11(2):549-556</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30186138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2015 Dec 15;21(24):5642-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26672088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Med. 2019 Sep;8(11):4986-4999</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31286682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28881921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Immunother Cancer. 2019 Aug 22;7(1):226</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31439050</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32162824</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1549-490X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>The oncologist</Title>
          <ISOAbbreviation>Oncologist</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>197</StartPage>
          <EndPage>202</EndPage>
          <MedlinePgn>197-202</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2018-0304</ELocationID>
        <Abstract>
          <AbstractText>As the use of immune checkpoint inhibitors for several different malignancies becomes more mainstream, their side-effect profile raises new challenges. In 2011, the Food and Drug Administration approved the first checkpoint inhibitor for the treatment of advanced melanoma, and since then, checkpoint inhibitors have demonstrated efficacy in many other tumor types. Given the frequent use of immune checkpoint inhibitors in a wide range of cancers today, the diagnosis and management of their immune-mediated toxicities need special attention. One of the most common is immune-mediated colitis. Workup and management of immune-mediated colitis can be challenging and is the purpose of this review. KEY POINTS: Rate of immune mediated colitis differ from different kind of immune checkpoint inhibitor treatment. To work up immune-mediated colitis, tests to rule out infectious etiologies of diarrhea, colonoscopy and abdominal image will help to differentiate immune mediated colitis from colitis from other etiology. Patients with mild colitis can be managed with supportive therapies alone, but more severe cases may require immunomodulators such as steroid. Refractory cases may require tumor necrosis factor (TNF) inhibitors, such as infliximab in addition to steroid treatment.</AbstractText>
          <CopyrightInformation>&#xa9; AlphaMed Press 2019.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Bhavana Pendurthi</ForeName>
            <Initials>BP</Initials>
            <AffiliationInfo>
              <Affiliation>Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marshall</LastName>
            <ForeName>John L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Aiwu Ruth</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>09</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Oncologist</MedlineTA>
        <NlmUniqueID>9607837</NlmUniqueID>
        <ISSNLinking>1083-7159</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B72HH48FLU</RegistryNumber>
          <NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Disclosures of potential conflicts of interest may be found at the end of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32162824</ArticleId>
        <ArticleId IdType="pmc">PMC7066712</ArticleId>
        <ArticleId IdType="doi">10.1634/theoncologist.2018-0304</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015;27:450&#x2013;461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4400238</ArticleId>
            <ArticleId IdType="pubmed">25858804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krummel MF, Allison JP. CD28 and CTLA&#x2010;4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459&#x2013;465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2192127</ArticleId>
            <ArticleId IdType="pubmed">7543139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walunas TL, Bakker CY, Bluestone JA. CTLA&#x2010;4 ligation blocks CD28&#x2010;dependent T cell activation [published erratum appears in J Exp Med 1996;184:301]. J Exp Med 1996;183:2541&#x2013;2550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2192609</ArticleId>
            <ArticleId IdType="pubmed">8676075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walunas TL, Lenschow DJ, Bakker CY et al. CTLA&#x2010;4 can function as a negative regulator of T cell activation. Immunity 1994;1:405&#x2013;413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7882171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lacroix M. Targeted Therapies in Cancer. Hauppauge, NY: Nova Sciences Publishers, 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>Takahashi T, Tagami T, Yamazaki S et al. Immunologic self&#x2010;tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte&#x2010;associated antigen 4. J Exp Med 2000;192:303&#x2013;310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2193248</ArticleId>
            <ArticleId IdType="pubmed">10899917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francisco LM, Sage PT, Sharpe AH. The PD&#x2010;1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219&#x2013;242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2919275</ArticleId>
            <ArticleId IdType="pubmed">20636820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maughan BL, Bailey E, Gill DM et al. Incidence of immune&#x2010;related adverse events with program death receptor&#x2010;1 and program death receptor&#x2010;1 ligand&#x2010;directed therapies in genitourinary cancers. Front Oncol 2017;7:56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5377000</ArticleId>
            <ArticleId IdType="pubmed">28421161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marin&#x2010;Acevedo JA, Harris DM, Burton MC. Immunotherapy&#x2010;induced colitis: An emerging problem for the hospitalist. J Hosp Med 2018;13:413&#x2013;418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29419822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V, Chaudhary N, Garg M et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017;8:49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5296331</ArticleId>
            <ArticleId IdType="pubmed">28228726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman CF, Proverbs&#x2010;Singh TA, Postow MA. Treatment of the immune&#x2010;related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol 2016;2:1346&#x2013;1353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27367787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi F, O'Day S, McDermott D et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711&#x2013;723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double&#x2010;blind, multicentre, phase 2, dose&#x2010;ranging study. Lancet Oncol 2010;11:155&#x2013;164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20004617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eggermont AM, Chiarion&#x2010;Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high&#x2010;risk stage III melanoma (EORTC 18071): A randomised, double&#x2010;blind, phase 3 trial. Lancet Oncol 2015;16:522&#x2013;530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25840693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chiarion&#x2010;Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sznol M, Ferrucci PF, Hogg D et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 2017; 35:3815&#x2013;3822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28915085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammers HJ, Plimack ER, Infante JR et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 Study. J Clin Oncol 2017;35:3851&#x2013;3858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7587408</ArticleId>
            <ArticleId IdType="pubmed">28678668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tirumani SH, Ramaiya NH, Keraliya A et al. Radiographic profiling of immune&#x2010;related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2015;3:1185&#x2013;1192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4596761</ArticleId>
            <ArticleId IdType="pubmed">26100356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minor DR, Chin K, Kashani&#x2010;Sabet M. Infliximab in the treatment of anti&#x2010;CTLA4 antibody (ipilimumab) induced immune&#x2010;related colitis. Cancer Biother Radiopharm 2009;24:321&#x2013;325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19538054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai S, Nakamura S, Matsumoto T. Nivolumab&#x2010;induced colitis treated by infliximab. Clin Gastroenterol Hepatol 2017;15:e80&#x2013;e81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27664866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S et al. Immune checkpoint inhibition&#x2010;related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018;3:e000278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5786923</ArticleId>
            <ArticleId IdType="pubmed">29387476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini A. Immune&#x2010;mediated adverse events associated with ipilimumab ctla&#x2010;4 blockade therapy: The underlying mechanisms and clinical management. Scientifica (Cairo) 2013;2013:857519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3820355</ArticleId>
            <ArticleId IdType="pubmed">24278787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Read S, Malmstr&#xf6;m V, Powrie F. Cytotoxic T lymphocyte&#x2010;associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295&#x2013;302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2193261</ArticleId>
            <ArticleId IdType="pubmed">10899916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutzac C, Adam J, Soularue E et al. Colon immune&#x2010;related adverse events: Anti&#x2010;CTLA&#x2010;4 and anti&#x2010;PD&#x2010;1 blockade induce distinct immunopathological entities. J Crohns Colitis 2017;11:1238&#x2013;1246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28967957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T&#x2010;lymphocyte&#x2010;associated antigen 4. J Clin Oncol 2006;24:2283&#x2013;2289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2140223</ArticleId>
            <ArticleId IdType="pubmed">16710025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guthery SL, Heubi JE, Filipovich A. Enteral metronidazole for the prevention of graft versus host disease in pediatric marrow transplant recipients: Results of a pilot study. Bone Marrow Transplant 2004;33:1235&#x2013;1239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15077127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA. Managing immune checkpoint&#x2010;blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015:76&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25993145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010;10:308&#x2013;315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20172761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merrill SP, Reynolds P, Kalra A et al. Early administration of infliximab for severe ipilimumab&#x2010;related diarrhea in a critically ill patient. Ann Pharmacother 2014;48:806&#x2013;810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24651165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawlor G, Moss AC. Cause for controversy? Infliximab in the treatment of ulcerative colitis: An update. Clin Exp Gastroenterol 2009;2:149&#x2013;161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3108644</ArticleId>
            <ArticleId IdType="pubmed">21694839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito H. IL&#x2010;6 and Crohn's disease. Curr Drug Targets Inflamm Allergy 2003;2:125&#x2013;130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito H. Novel therapy for Crohn's disease targeting IL&#x2010;6 signalling. Expert Opin Ther Targets. 2004;8:287&#x2013;294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15268624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stroud CR, Hegde A, Cherry C et al. Tocilizumab for the management of immune mediated adverse events secondary to PD&#x2010;1 blockade. J Oncol Pharm Pract 2019;25:551&#x2013;557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29207939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergqvist V, Hertervig E, Gedeon P et al. Vedolizumab treatment for immune checkpoint inhibitor&#x2010;induced enterocolitis. Cancer Immunol Immunother 2017;66:581&#x2013;592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5406433</ArticleId>
            <ArticleId IdType="pubmed">28204866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber J, Thompson JA, Hamid O et al. A randomized, double&#x2010;blind, placebo&#x2010;controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591&#x2013;5598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19671877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Felice KM, Gupta A, Rakshit S et al. Ipilimumab&#x2010;induced colitis in patients with metastatic melanoma. Melanoma Res 2015;25:321&#x2013;327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25933207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C et al. Cancer immunotherapy with anti&#x2010;CTLA&#x2010;4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016;10:395&#x2013;401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4946758</ArticleId>
            <ArticleId IdType="pubmed">26783344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prieux&#x2010;Klotz C, Dior M, Damotte D et al. Immune checkpoint inhibitor&#x2010;induced colitis: Diagnosis and management. Target Oncol 2017;12:301&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28540478</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32130969</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1558-4488</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Seminars in nephrology</Title>
          <ISOAbbreviation>Semin Nephrol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>76</StartPage>
          <EndPage>85</EndPage>
          <MedlinePgn>76-85</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semnephrol.2019.12.009</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0270-9295(19)30119-6</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors have quickly become a critical component to the management of advanced renal cell carcinoma. These therapies have been approved for patients who are treatment-naive and who have progressed on antiangiogenesis agents. Combinations of immune checkpoint inhibitors with antiangiogenesis agents show significant response rates and prolong survival. Adverse events associated with the use of checkpoint inhibition present unique challenges in the management of patients, and careful considerations are needed when checkpoint inhibitors are combined with antiangiogenesis agents. Nevertheless, the improvement in overall survival associated with these agents indicates that they will remain a vital component of kidney cancer treatment.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Parikh</LastName>
            <ForeName>Mamta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA. Electronic address: mbparikh@ucdavis.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bajwa</LastName>
            <ForeName>Poornima</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K12 CA138464</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA093373</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Semin Nephrol</MedlineTA>
        <NlmUniqueID>8110298</NlmUniqueID>
        <ISSNLinking>0270-9295</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
          <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>52CMI0WC3Y</RegistryNumber>
          <NameOfSubstance UI="C000594389">atezolizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>C9LVQ0YUXG</RegistryNumber>
          <NameOfSubstance UI="D000077784">Axitinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DPT0O3T46P</RegistryNumber>
          <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>KXG2PJ551I</RegistryNumber>
          <NameOfSubstance UI="C000609138">avelumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000309" MajorTopicYN="N">Adrenal Insufficiency</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077784" MajorTopicYN="N">Axitinib</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005076" MajorTopicYN="N">Exanthema</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019693" MajorTopicYN="N">Hepatitis, Autoimmune</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072659" MajorTopicYN="N">Hypophysitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009393" MajorTopicYN="N">Nephritis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011537" MajorTopicYN="N">Pruritus</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">checkpoint inhibition</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
        <Keyword MajorTopicYN="N">kidney cancer</Keyword>
        <Keyword MajorTopicYN="N">renal cell carcinoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32130969</ArticleId>
        <ArticleId IdType="mid">NIHMS1568959</ArticleId>
        <ArticleId IdType="pmc">PMC7164329</ArticleId>
        <ArticleId IdType="doi">10.1016/j.semnephrol.2019.12.009</ArticleId>
        <ArticleId IdType="pii">S0270-9295(19)30119-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Oliver RTD, Miller RM, Mehta A, Barnett MJ. A Phase II study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol Biother 1988; 1: 14&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3267368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliver RTD, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha interferon as treatment for metastatic renal cell carcinoma. Br J Urol. 1989; 63: 128&#x2013;131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2702395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol. 1992; 148: 1247&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1404646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11773181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg SA, Yang JC, White DE, Steinberg SM. Duration of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Annals of surgery 1998; 228: 307&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1191483</ArticleId>
            <ArticleId IdType="pubmed">9742914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant inteleukin-2 therapy. J Clin Oncol. 1995; 13: 688&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7884429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med. 2001; 345: 1711&#x2013;2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11759660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev Cancer. 2012; 12: 252&#x2013;264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10581077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H, Strome SE, Salomao DR, Tamua H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793&#x2013;800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12091876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003; 81: 281&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12721664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Research 2006; 66: 3381&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16585157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5719487</ArticleId>
            <ArticleId IdType="pubmed">26406148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDermott DF, Lee JL, Szczylik C, Donskov F, Malik J, Alekseev BY, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427. J Clin Oncol 2018; 36: s4500 (abstract).</Citation>
        </Reference>
        <Reference>
          <Citation>Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122&#x2013;133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5698004</ArticleId>
            <ArticleId IdType="pubmed">23724867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 study. J Clin Oncol 2017; 35: 3851&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7587408</ArticleId>
            <ArticleId IdType="pubmed">28678668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378: 1277&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5972549</ArticleId>
            <ArticleId IdType="pubmed">29562145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016; 7: 12624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5013615</ArticleId>
            <ArticleId IdType="pubmed">27571927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018; 24: 749&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6721896</ArticleId>
            <ArticleId IdType="pubmed">29867230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion 151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393: 2404&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31079938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chowdhury S, McDermott DF, Voss MH, Hawkins RE, Aimone P, Voi M, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2017; 35: s4506 (abstract).</Citation>
        </Reference>
        <Reference>
          <Citation>Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018; 6: 109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6196426</ArticleId>
            <ArticleId IdType="pubmed">30348216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 2011; 378: 1931&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22056247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised Phase 3 trial. Lancet Oncol. 2013; 14: 552&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23598172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase Ib trial. Lancet Oncol 2018; 19: 451&#x2013;460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29530667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer RJ, Penkov K, Haanen J, Rini BI, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1103&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6716603</ArticleId>
            <ArticleId IdType="pubmed">30779531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018; 19: 405&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6860026</ArticleId>
            <ArticleId IdType="pubmed">29439857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380: 1116&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30779529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nadal RM, Mortazavi A, Stein M, Pal SK, Davarpanah NN, Parnes HL, et al. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. J Clin Oncol 2018; 36: s515 (abstract).</Citation>
        </Reference>
        <Reference>
          <Citation>Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs- Part A: Renal, Penile, and Testicular Tumours. Eur Urol 2016; 70: 120&#x2013;3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26935559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JL, Ziobro M, Gafanov R, Matveev VB, Suarez C, Donskov F, et al. KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear renal cell carcinoma (NCC-RCC) J Clin Oncol 2019; 37: s4569 (abstract)</Citation>
        </Reference>
        <Reference>
          <Citation>Vogelzang NJ, McFarlane JJ, Kochenderfer MD, Molina AM, Arrowsmith E, Bauer TM, et al. Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the Phase IIIb/IV CheckMate 374 study. J Clin Oncol 2019; 37: s562 (abstract)</Citation>
        </Reference>
        <Reference>
          <Citation>McKay RR, McGregor BA, Gray K, Steinharter JA, Walsh MK, Braun DA, et al. Results of a Phase II Study of Atezolizumab and Bevacizumab in Non-Clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma with Sarcomatoid Differentiation. J Clin Oncol 2019; 37: s548 (abstract)</Citation>
        </Reference>
        <Reference>
          <Citation>Mouallem NE, Smith SC, Paul AK. Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urologic Oncology: Seminars and Original Investigations. 2018; 36: 265&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29306556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKay RR, Bosse D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, et al. The Clinical Activity of PD-1/PD-L1 inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunol Res 2018; 6: 758&#x2013;765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6712567</ArticleId>
            <ArticleId IdType="pubmed">29748390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12724780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32: 666&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12402038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375: 1749&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5247797</ArticleId>
            <ArticleId IdType="pubmed">27806233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osario JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small cell lung cancer. Ann Oncol 2017; 28: 583&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834017</ArticleId>
            <ArticleId IdType="pubmed">27998967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad Sci 2015; 112: 7061&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4460486</ArticleId>
            <ArticleId IdType="pubmed">26038559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Posto MA, Sidlow MD, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018; 378: 158&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SK, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151: 1206&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5061067</ArticleId>
            <ArticleId IdType="pubmed">26222619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26501224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, et al. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol 2019; JCO1900318 (epub)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31116675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, et al. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunol Res 2018; 6: 402&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29437040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sury K, Perazella MA. The nephrotoxicity of new immunotherapies. Expert Rev Clin Pharmacol 2019; 12: 513&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31035801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E, et al. Renal toxicities associated with pembrolizumab. Clin Kidney J 2019; 12: 81&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6366307</ArticleId>
            <ArticleId IdType="pubmed">30746132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bevacizumab FDA package insert.</Citation>
        </Reference>
        <Reference>
          <Citation>Axitinib FDA package insert.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32028372</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1537-4513</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunotherapy (Hagerstown, Md. : 1997)</Title>
          <ISOAbbreviation>J Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Complete Recovery of Immune Checkpoint Inhibitor-induced Colitis by Diverting Loop Ileostomy.</ArticleTitle>
        <Pagination>
          <StartPage>145</StartPage>
          <EndPage>148</EndPage>
          <MedlinePgn>145-148</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/CJI.0000000000000309</ELocationID>
        <Abstract>
          <AbstractText>Checkpoint inhibitor-induced side effects such as diarrhea and colitis occur in up to 30% of patients. We present a case of recurrent episodes of checkpoint inhibitor-induced colitis and subsequent Fournier gangrene that resolved after ileostomy formation. Once the Fournier gangrene and colitis had resolved, the ileostomy was reversed. However, within only 4 days, another serious flare-up of colitis occurred, necessitating emergent re-formation of the ileostomy. Expertise in the management of side effects of immune checkpoint inhibitor therapy is currently limited. Although most side effects are mild to moderate and transient, a minority of patients suffer from life-threatening complications, such as colitis. The creation of an ileostomy might be a valid treatment option in severe or recurrent colitis due to immune checkpoint inhibitor therapy. Intestinal diversion surgery may be useful if conservative treatment has failed, similar to other forms of immune-mediated intestinal inflammation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Horisberger</LastName>
            <ForeName>Karoline</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Transplantation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Portenkirchner</LastName>
            <ForeName>Carmen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Transplantation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rickenbacher</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Transplantation.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Biedermann</LastName>
            <ForeName>Luc</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Clinic of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gubler</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Clinic of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turina</LastName>
            <ForeName>Matthias</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Transplantation.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Immunother</MedlineTA>
        <NlmUniqueID>9706083</NlmUniqueID>
        <ISSNLinking>1524-9557</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName>
          <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020685" MajorTopicYN="N">Colonoscopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007081" MajorTopicYN="Y">Ileostomy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019990" MajorTopicYN="N">Perioperative Care</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32028372</ArticleId>
        <ArticleId IdType="doi">10.1097/CJI.0000000000000309</ArticleId>
        <ArticleId IdType="pii">00002371-202005000-00005</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Heinzerling L, de Toni E, Schett G, et al. Checkpoint inhibitors. Dtsch Arztebl Int. 2019;116:119&#x2013;126.</Citation>
        </Reference>
        <Reference>
          <Citation>Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018;472:125&#x2013;133.</Citation>
        </Reference>
        <Reference>
          <Citation>Prieux-Klotz C, Dior M, Damotte D, et al. Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017;12:301&#x2013;308.</Citation>
        </Reference>
        <Reference>
          <Citation>Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119:1675&#x2013;1682.</Citation>
        </Reference>
        <Reference>
          <Citation>Hodi FS, O&#x2019;Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711&#x2013;723.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6:e1344805.</Citation>
        </Reference>
        <Reference>
          <Citation>Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4:560&#x2013;575.</Citation>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10:395&#x2013;401.</Citation>
        </Reference>
        <Reference>
          <Citation>Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med. 2016;4:272.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Wang X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7:93.</Citation>
        </Reference>
        <Reference>
          <Citation>Hillock NT, Heard S, Kichenadasse G, et al. Infliximab for ipilimumab-induced colitis: a series of 13 patients. Asia Pac J Clin Oncol. 2017;13:e284&#x2013;e290.</Citation>
        </Reference>
        <Reference>
          <Citation>Elias AW, Kasi PM, Stauffer JA, et al. The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a retrospective study. Front Oncol. 2017;7:121.</Citation>
        </Reference>
        <Reference>
          <Citation>Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559&#x2013;574.</Citation>
        </Reference>
        <Reference>
          <Citation>Russell TA, Dawes AJ, Graham DS, et al. Rescue diverting loop ileostomy: an alternative to emergent colectomy in the setting of severe acute refractory IBD-colitis. Dis Colon Rectum. 2018;61:214&#x2013;220.</Citation>
        </Reference>
        <Reference>
          <Citation>Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19.</Citation>
        </Reference>
        <Reference>
          <Citation>Chang K, Svabek C, Vazquez-Guillamet C, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014;18:R3.</Citation>
        </Reference>
        <Reference>
          <Citation>Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785&#x2013;792.</Citation>
        </Reference>
        <Reference>
          <Citation>Dilling P, Walczak J, Pikiel P, et al. Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab&#x2014;case report. Pol Przegl Chir. 2014;86:94&#x2013;96.</Citation>
        </Reference>
        <Reference>
          <Citation>Shah R, Witt D, Asif T, et al. Ipilimumab as a cause of severe pan-colitis and colonic perforation. Cureus. 2017;9:e1182.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohn I, Rives JD. Antibiotic protection of colon anastomoses. Ann Surg. 1955;141:707&#x2013;717.</Citation>
        </Reference>
        <Reference>
          <Citation>Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn&#x2019;s disease in the neoterminal ileum. Lancet. 1991;338:771&#x2013;774.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">31864555</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1556-1380</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title>
          <ISOAbbreviation>J Thorac Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.</ArticleTitle>
        <Pagination>
          <StartPage>e15</StartPage>
          <EndPage>e20</EndPage>
          <MedlinePgn>e15-e20</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtho.2019.07.026</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1556-0864(19)30656-2</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>van Turenhout</LastName>
            <ForeName>Sietze T</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: sietzevanturenhout@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berghuis</LastName>
            <ForeName>Marieke</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Snaebjornsson</LastName>
            <ForeName>Petur</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilgenhof</LastName>
            <ForeName>Sofie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burgers</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pulmonology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haanen</LastName>
            <ForeName>John B A G</ForeName>
            <Initials>JBAG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Dieren</LastName>
            <ForeName>Jolanda M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Thorac Oncol</MedlineTA>
        <NlmUniqueID>101274235</NlmUniqueID>
        <ISSNLinking>1556-0864</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013256">Steroids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31864555</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jtho.2019.07.026</ArticleId>
        <ArticleId IdType="pii">S1556-0864(19)30656-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">31754740</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2366-0058</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Abdominal radiology (New York)</Title>
          <ISOAbbreviation>Abdom Radiol (NY)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.</ArticleTitle>
        <Pagination>
          <StartPage>3028</StartPage>
          <EndPage>3035</EndPage>
          <MedlinePgn>3028-3035</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00261-019-02334-3</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">To determine the frequency, imaging, and clinical manifestations of immune checkpoint inhibitor (ICI)-related colitis in cancer patients on monotherapy or combination therapy.</AbstractText>
          <AbstractText Label="METHODS">The electronic medical records of&#xa0;1044 cancer patients who received ICIs were retrospectively reviewed to identify 48 patients who had a clinical diagnosis of immune-related colitis. Imaging studies were reviewed to identify patients with imaging manifestations of colitis. Demographic data, type of ICIs, symptoms, presence of other immune-related adverse events (irAEs), and management were recorded.</AbstractText>
          <AbstractText Label="RESULTS">There was imaging evidence of immune-related colitis in 34 patients (24 men; median age: 63.5&#xa0;years). The median time to onset of colitis was 75&#xa0;days (IQR 25-75, 49.5-216&#xa0;days) in patients receiving monotherapy (group 1) and 78&#xa0;days (IQR 25-75, 44.3-99.5&#xa0;days) in patients undergoing combination therapy (group 2) following start of ICI. Symptoms included diarrhea (91.1% [31 of 34]), nausea/vomiting (52.9% [18 of 34]), and abdominal pain (52.9% [18 of 34]). The most common imaging findings were bowel wall thickening (97% [33 of 34]) and fluid-filled colon (82.3% [28 of 34]). Colitis was diffuse in 21 of 34 (61.8%) patients. Imaging manifestations did not differ between the two groups (p&#x2009;&gt;&#x2009;0.05). Steroids and antibiotics were used to treat colitis in 29 of 34 (85.2%) and 13 of 34 (38.2%) patients, respectively. No patients in group 1 experienced concurrent irAEs, but 5 of 18 (27.8%) of patients in group 2 had other irAEs (p&#x2009;=&#x2009;0.046).</AbstractText>
          <AbstractText Label="CONCLUSION">Immune-related colitis occurred in 3.3% of patients receiving ICIs with bowel wall thickening, fluid-filled colon and pancolitis being the most common imaging manifestations. Imaging manifestations did not differ between patients receiving monotherapy or combination therapy. However, concurrent irAEs were significantly observed in patients undergoing combination therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shieh</LastName>
            <ForeName>Alice C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guler</LastName>
            <ForeName>Ezgi</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-8028-0350</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA. gulerezgi@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pfau</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Radzinsky</LastName>
            <ForeName>Ethan</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Daniel A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoimes</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramaiya</LastName>
            <ForeName>Nikhil H</ForeName>
            <Initials>NH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tirumani</LastName>
            <ForeName>Sree Harsha</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Abdom Radiol (NY)</MedlineTA>
        <NlmUniqueID>101674571</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="Y">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adverse drug event</Keyword>
        <Keyword MajorTopicYN="N">Colitis</Keyword>
        <Keyword MajorTopicYN="N">Diagnostic imaging</Keyword>
        <Keyword MajorTopicYN="N">Neoplasms</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31754740</ArticleId>
        <ArticleId IdType="doi">10.1007/s00261-019-02334-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s00261-019-02334-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Press Announcements&#x2009;&gt;&#x2009;FDA approves new treatment for a type of late-stage skin cancer. https://web.archive.org/web/20110327063147/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm1193237.htm . Published March 27, 2011. Accessed June 2, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al (2017) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 377:1345-1356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1709684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M (2015) Radiographic Profiling of Immune-related Adverse Events in Advanced Melanoma Patients Treated With Ipilimumab. Cancer Immunol Res 3:1185-1192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puzanov I, Diab A, Abdallah K, et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0300-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, Ibrahim N (2013) Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 200:W468-474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/AJR.12.9751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mekki A, Dercle L, Lichtenstein P, et al (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91-104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.03.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ, et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283-2289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.04.5716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber J, Thompson JA, Hamid O, et al (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591-5598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-1024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO&#xa0;Clinical Practice Guidelines for diagnosis, treatment and follow up.&#xa0;Ann Oncol 28(suppl 4):iv119-iv142.</Citation>
        </Reference>
        <Reference>
          <Citation>Sosa A, Cadena EL, Olive CS, Karachaliou N, Rosell R (2018) Clinical assessment of immune-related adverse events.&#xa0;Ther Adv Med Oncol 10:1758835918764628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758835918764628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2:1346-1353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.1051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, De Felice KM, Loftus EV Jr, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42:406-417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.13281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Neuer M, Marmarelis ME, Jangi SR, et al (2017) Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. Cancer Immunol Res 5:286-291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB (2017) Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 6:e1344805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1344805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horn L, Spigel DR, Vokes EE, et al (2017) Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small- Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35:3924-3933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.74.3062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessandrino F, Sahu S, Nishino M, et al (2019) Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol (NY) 44:1917-1927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00261-019-01935-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.&#xa0;N. Engl. J. Med&#xa0;373:1270-1271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irwin DE, Davis B, Bell JA, Galaznik A, Garcia-Ribas I (2018) Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy. J Comp Eff Res 8:81-90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/cer-2018-0072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy HG, Schneider BJ, Tai AW (2018) Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. Clin Transl Gastroenterol 9:180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41424-018-0049-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S, Khanal S, Zhang H (2019) Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag 15:211-221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/TCRM.S193338</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31609734</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1531-7056</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in gastroenterology</Title>
          <ISOAbbreviation>Curr Opin Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.</ArticleTitle>
        <Pagination>
          <StartPage>25</StartPage>
          <EndPage>32</EndPage>
          <MedlinePgn>25-32</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MOG.0000000000000593</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW">Diarrhea and colitis are among the most commonly encountered immune-mediated adverse events among patients receiving antiprogrammed cell death protein/ligand-1 (PD-1/L1) as well as anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies. With growing indications and widespread use of immune checkpoint inhibitors, it is imperative to summarize the current body of evidence concerning the incidence, pathogenesis, risk factors, diagnostic challenges, and treatment options currently available for the management of immune-mediated diarrhea and colitis. Additionally, with emerging evidence analyzing the resumption of immune checkpoint inhibitors, it is pivotal to summarize our current understanding and future challenges.</AbstractText>
          <AbstractText Label="RECENT FINDINGS">Immune-mediated diarrhea and colitis can potentially be a viable surrogate marker for improved survival as it is validated further in large-scale studies. Early endoscopic evaluation can aid in the identification of patients at risk of developing steroid refractory immune-mediated colitis, and hence can be chosen to receive early add-on therapy with infliximab, vedolizumab or fecal microbiota transplantation, an emerging treatment option for immune-mediated diarrhea and colitis. Resuming immune checkpoint inhibitors carries a manageable risk of recurrent diarrhea and colitis, with most cases being mild and effectively managed with immunosuppressive therapy.</AbstractText>
          <AbstractText Label="SUMMARY">As our understanding of immune-mediated diarrhea and colitis grows, it is likely that this clinicopathologic entity will represent more than just an adverse event. With a growing number of treatment options, the management algorithms for immune-mediated diarrhea/colitis are likely to evolve in the future.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abu-Sbeih</LastName>
            <ForeName>Hamzah</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri Department of Internal Medicine, Saint Joseph Hospital, Chicago, Illinois Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ali</LastName>
            <ForeName>Faisal S</ForeName>
            <Initials>FS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yinghong</ForeName>
            <Initials>Y</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Curr Opin Gastroenterol</MedlineTA>
        <NlmUniqueID>8506887</NlmUniqueID>
        <ISSNLinking>0267-1379</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31609734</ArticleId>
        <ArticleId IdType="doi">10.1097/MOG.0000000000000593</ArticleId>
        <ArticleId IdType="pii">00001574-202001000-00007</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 2018; 62:29&#x2013;39.</Citation>
        </Reference>
        <Reference>
          <Citation>Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33:1974&#x2013;1982.</Citation>
        </Reference>
        <Reference>
          <Citation>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378:158&#x2013;168.</Citation>
        </Reference>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252&#x2013;264.</Citation>
        </Reference>
        <Reference>
          <Citation>Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohn's Colitis 2016; 10:395&#x2013;401.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 2018; 24:1695&#x2013;1705.</Citation>
        </Reference>
        <Reference>
          <Citation>Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018; 3:e000278doi: 10.1136/esmoopen-2017-000278.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdel-Wahab N, Yu RK, Diab A, et al. Genetic determinants of adverse events in cancer patients receiving immune checkpoint inhibitors. J Clin Oncol 2019; 37: (15_Suppl): 2586&#x2013;12586.</Citation>
        </Reference>
        <Reference>
          <Citation>Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018; 360:k793.</Citation>
        </Reference>
        <Reference>
          <Citation>Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16:563&#x2013;580.</Citation>
        </Reference>
        <Reference>
          <Citation>Ali F, Hussain MR, Deep A, et al. Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: a meta-analysis of clinical trials. J Clin Oncol 2019; 37: (15_Suppl): e14117&#x2013;e114117.</Citation>
        </Reference>
        <Reference>
          <Citation>Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44:51&#x2013;60.</Citation>
        </Reference>
        <Reference>
          <Citation>Soularue E, Lepage P, Colombel JF, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018; 67:2056&#x2013;2067.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol 2018; 4:1721&#x2013;1728.</Citation>
        </Reference>
        <Reference>
          <Citation>Horvat TZ, Adel NG, Dang T-O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33:3193&#x2013;3198.</Citation>
        </Reference>
        <Reference>
          <Citation>Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283&#x2013;2289.</Citation>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K, et al. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother 2018; 41:101&#x2013;108.</Citation>
        </Reference>
        <Reference>
          <Citation>Ascierto PA, Vecchio M Del, Robert C, et al. Ipilimumab 10&#x200a;mg/kg versus ipilimumab 3&#x200a;mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017; 18:611&#x2013;622.</Citation>
        </Reference>
        <Reference>
          <Citation>Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 2017; 28:2377&#x2013;2385.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology 2017; 6:e1344805.</Citation>
        </Reference>
        <Reference>
          <Citation>Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017; 28:1368&#x2013;1379.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 2018; 6:37.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Qiao W, et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother 2019; 68:553&#x2013;561.</Citation>
        </Reference>
        <Reference>
          <Citation>Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol 2015; 1:1340&#x2013;1341.</Citation>
        </Reference>
        <Reference>
          <Citation>Suresh K, Psoter KJ, Voong KR, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol 2019; 14:494&#x2013;502.</Citation>
        </Reference>
        <Reference>
          <Citation>Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep 2017; 5:59.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Luo W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018; 6:95doi: 10.1186/s40425-018-0411-1.</Citation>
        </Reference>
        <Reference>
          <Citation>Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10:11.</Citation>
        </Reference>
        <Reference>
          <Citation>Chatzikonstantinou M, Konstantopoulos P, Stergiopoulos S, et al. Calprotectin as a diagnostic tool for inflammatory bowel diseases. Biomed Rep 2016; 5:403&#x2013;407.</Citation>
        </Reference>
        <Reference>
          <Citation>Abej E, El-Matary W, Singh H, Bernstein CN. The utility of fecal calprotectin in the real-world clinical care of patients with inflammatory bowel disease. Can J Gastroenterol Hepatol 2016; 2016:6Article ID 2483261.</Citation>
        </Reference>
        <Reference>
          <Citation>Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor&#x2013;induced colitis: a multicenter study. J Immunother Cancer 2018; 6:142.</Citation>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36:1714&#x2013;1768.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson JA, Schneider BJ, Andrews S, et al. NCCN Guidelines Version 2.2019 Management of Immunotherapy-Related Toxicities NCCN Guidelines Panel Disclosures NCCN wishes to acknowledge the contributions of ASCO in supporting advisory committees for the development of these NCCN Guidelines. Continue [Internet]. J Natl Compr Canc Netw 2019;17:255&#x2013;289.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 2018; 24:1804&#x2013;1808.</Citation>
        </Reference>
        <Reference>
          <Citation>Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018; 29:250&#x2013;255.</Citation>
        </Reference>
        <Reference>
          <Citation>Niki M, Nakaya A, Kurata T, et al. Immune checkpoint inhibitor re-challenge in patients with advanced nonsmall cell lung cancer. Oncotarget 2018; 9:32298&#x2013;32304.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujita K, Uchida N, Kanai O, et al. Retreatment with pembrolizumab in advanced nonsmall cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol 2018; 81:1105&#x2013;1109.</Citation>
        </Reference>
        <Reference>
          <Citation>Hakozaki T, Okuma Y, Kashima J. Re-challenging immune checkpoint inhibitor in a patient with advanced nonsmall cell lung cancer: a case report. BMC Cancer 2018; 18:302.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31595568</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1443-1661</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society</Title>
          <ISOAbbreviation>Dig Endosc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.</ArticleTitle>
        <Pagination>
          <StartPage>616</StartPage>
          <EndPage>620</EndPage>
          <MedlinePgn>616-620</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/den.13555</ELocationID>
        <Abstract>
          <AbstractText>We reviewed the records of patients with immune checkpoint inhibitor (ICI)-induced diarrhea during 2015 to 2019. ICI included nivolumab and ipilimumab. There were 11 patients with ICI-induced diarrhea aged 46-81 years (median, 63 years). On colonoscopy, four patients appeared normal, whereas loss of vascularity, erythema, granularity, erosions or ulcerations apparently mimicking ulcerative colitis were found in seven patients. Those seven patients had acute inflammation, cryptitis, crypt abscess and apoptosis, suggestive of ICI-induced colitis. Five of the seven patients were treated with prednisolone, two of whom were resistant to prednisolone and required infliximab. In contrast, none of the four patients without ICI-induced colitis required further treatment. Our observations suggest that diversity exists in the clinical, endoscopic and histological severity of patients with ICI-induced diarrhea. Colonoscopy together with biopsy is inevitable for the diagnosis of ICI-induced colitis, which requires intensive treatment.</AbstractText>
          <CopyrightInformation>&#xa9; 2019 Japan Gastroenterological Endoscopy Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yanai</LastName>
            <ForeName>Shunichi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Shotaro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawasaki</LastName>
            <ForeName>Keisuke</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-2645-4417</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toya</LastName>
            <ForeName>Yosuke</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akasaka</LastName>
            <ForeName>Risaburo</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oizumi</LastName>
            <ForeName>Tomofumi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishida</LastName>
            <ForeName>Kazuyuki</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Diagnostic Pathology, Department of Pathology, School of Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sugai</LastName>
            <ForeName>Tamotsu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Diagnostic Pathology, Department of Pathology, School of Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumoto</LastName>
            <ForeName>Takayuki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Dig Endosc</MedlineTA>
        <NlmUniqueID>9101419</NlmUniqueID>
        <ISSNLinking>0915-5635</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074324" MajorTopicYN="N">Ipilimumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">colitis</Keyword>
        <Keyword MajorTopicYN="N">diarrhea</Keyword>
        <Keyword MajorTopicYN="N">immune-related adverse event</Keyword>
        <Keyword MajorTopicYN="N">ipilimumab</Keyword>
        <Keyword MajorTopicYN="N">nivolumab</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31595568</ArticleId>
        <ArticleId IdType="doi">10.1111/den.13555</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014; 32: 1020-30.</Citation>
        </Reference>
        <Reference>
          <Citation>Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015; 372: 320-30.</Citation>
        </Reference>
        <Reference>
          <Citation>Yanai S, Nakamura S, Matsumoto T. Nivolumab-induced colitis treated by infliximab. Clin. Gastroenterol. Hepatol. 2017; 15: e80-1.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamauchi R, Araki T, Mitsuyama K et al. The characteristics of nivolumab-induced colitis: An evaluation of three cases and a literature review. BMC Gastroenterol. 2018; 18: 135.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am. J. Surg. Pathol. 2017; 41: 643-54.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 2017; 6: e1344805.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Abu-Sbeih H, Mao E et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm. Bowel. Dis. 2018; 24: 1695-705.</Citation>
        </Reference>
        <Reference>
          <Citation>Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: Pathologists&#x2019; perspective. J. Clin. Pathol. 2018; 71: 665-71.</Citation>
        </Reference>
        <Reference>
          <Citation>Tandon P, Bourassa-Blanchette S, Bishay K et al. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: A systematic review and meta-analysis. J. Immunother. 2018; 41: 101-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Wright AP, Piper MS, Bishu S et al. Systematic review and case series: Flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment. Pharmacol. Ther. 2019; 49: 1474-83.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
